assay_id,relationship_type,description,variant_id,assay_organism,assay_type,src_assay_id,bao_format,doc_id,assay_test_type,assay_tax_id,confidence_score,curated_by,src_id,chembl_id,cell_id,tissue_id
7524,N,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618647,,2113.0
7525,N,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618648,,2113.0
7526,N,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618649,,2113.0
7527,N,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618650,,2107.0
7528,N,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618651,,2107.0
7529,N,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL876497,,2107.0
7530,N,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618652,,2048.0
7531,N,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618653,,2048.0
7532,N,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618654,,2048.0
7533,N,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,,Rattus norvegicus,A,,BAO_0000218,6351,,10116.0,1,Intermediate,1,CHEMBL618655,,
7534,N,Compound was tested for solubility in water,,Rattus norvegicus,A,,BAO_0000218,1465,,10116.0,1,Intermediate,1,CHEMBL618656,,
7535,U,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),,,P,,BAO_0000100,5182,,,0,Intermediate,1,CHEMBL618657,,
7536,N,Solubility was determined,,Rattus norvegicus,A,,BAO_0000218,17847,,10116.0,1,Intermediate,1,CHEMBL618658,,
7537,N,solubility in water (ug/mL) at 37 degree C.,,Rattus norvegicus,A,,BAO_0000218,15339,,10116.0,1,Intermediate,1,CHEMBL618659,,
7538,N,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,,Rattus norvegicus,A,,BAO_0000218,5202,,10116.0,1,Intermediate,1,CHEMBL618660,,
7539,N,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,,Rattus norvegicus,A,,BAO_0000218,1088,,10116.0,1,Intermediate,1,CHEMBL618661,,
7540,N,Half life in rats,,Rattus norvegicus,A,,BAO_0000218,3169,,10116.0,1,Intermediate,1,CHEMBL873807,,
7541,N,Half life in Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5353,,10116.0,1,Intermediate,1,CHEMBL618662,,
7542,N,Half life period after 3 mg/kg iv administration,,Rattus norvegicus,A,,BAO_0000218,2864,In vivo,10116.0,1,Intermediate,1,CHEMBL618663,,
7543,N,Half life period after 3 mg/kg iv administration in rat,,Rattus norvegicus,A,,BAO_0000218,2864,In vivo,10116.0,1,Intermediate,1,CHEMBL618664,,
7544,N,Half life period after 3 mg/kg iv administration in the rat,,Rattus norvegicus,A,,BAO_0000218,2864,In vivo,10116.0,1,Intermediate,1,CHEMBL618665,,
7545,N,Half life period in female Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,6362,,10116.0,1,Intermediate,1,CHEMBL876498,,
7546,N,Half life period in rat,,Rattus norvegicus,A,,BAO_0000218,6249,,10116.0,1,Intermediate,1,CHEMBL618666,,
7547,N,Half-life in rats was determined,,Rattus norvegicus,A,,BAO_0000218,3169,,10116.0,1,Intermediate,1,CHEMBL620440,,
7548,N,Half-life in rats with metabolic oxidation,,Rattus norvegicus,A,,BAO_0000218,3169,,10116.0,1,Intermediate,1,CHEMBL620441,,
7549,N,Half-life in rats,,Rattus norvegicus,A,,BAO_0000218,3169,,10116.0,1,Intermediate,1,CHEMBL620442,,
7550,N,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,Rattus norvegicus,A,,BAO_0000218,17260,In vivo,10116.0,1,Intermediate,1,CHEMBL620443,,
7551,N,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,Rattus norvegicus,A,,BAO_0000218,17260,In vivo,10116.0,1,Intermediate,1,CHEMBL620444,,
7552,N,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,Rattus norvegicus,A,,BAO_0000218,17260,In vivo,10116.0,1,Intermediate,1,CHEMBL620445,,
7553,N,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,Rattus norvegicus,A,,BAO_0000218,17260,In vivo,10116.0,1,Intermediate,1,CHEMBL620446,,
7554,N,Biological half-life measured in plasma of rat,,Rattus norvegicus,A,,BAO_0000218,2879,,10116.0,1,Intermediate,1,CHEMBL620447,,1969.0
7555,N,Biological half-life measured in plasma of rat; 22-25,,Rattus norvegicus,A,,BAO_0000218,2879,,10116.0,1,Intermediate,1,CHEMBL621129,,1969.0
7556,N,Biological half-life measured in plasma of rat; 9-16,,Rattus norvegicus,A,,BAO_0000218,2879,,10116.0,1,Intermediate,1,CHEMBL621130,,1969.0
7557,N,Compound was evaluated for its half life when administered intravenously in rat,,Rattus norvegicus,A,,BAO_0000218,3184,In vivo,10116.0,1,Intermediate,1,CHEMBL873808,,
7558,N,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,,Rattus norvegicus,A,,BAO_0000218,4891,In vivo,10116.0,1,Intermediate,1,CHEMBL876598,,
7559,N,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,429,In vivo,10116.0,1,Intermediate,1,CHEMBL621131,,
7560,N,Half life (T1/2) after oral administration in rat,,Rattus norvegicus,A,,BAO_0000218,5656,In vivo,10116.0,1,Intermediate,1,CHEMBL621132,,
7561,N,Half life of compound after iv administration of 20 mg/kg dose in rat,,Rattus norvegicus,A,,BAO_0000218,4413,In vivo,10116.0,1,Intermediate,1,CHEMBL621133,,
7562,N,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,3598,In vivo,10116.0,1,Expert,1,CHEMBL621312,,
7563,N,Half life of compound was determined in rat,,Rattus norvegicus,A,,BAO_0000218,17267,,10116.0,1,Intermediate,1,CHEMBL621313,,
7564,N,Half life of compound was determined in rat blood,,Rattus norvegicus,A,,BAO_0000218,4727,,10116.0,1,Intermediate,1,CHEMBL621314,,178.0
7565,N,Half life at 1 mg/kg was determined in rat,,Rattus norvegicus,A,,BAO_0000218,17651,In vivo,10116.0,1,Intermediate,1,CHEMBL621315,,
7566,N,Half life at 10 mg/kg was determined in rat,,Rattus norvegicus,A,,BAO_0000218,17651,In vivo,10116.0,1,Intermediate,1,CHEMBL621316,,
7567,N,Half life in rats,,Rattus norvegicus,A,,BAO_0000218,401,,10116.0,1,Intermediate,1,CHEMBL621317,,
7568,N,Half life in rats in hours,,Rattus norvegicus,A,,BAO_0000218,4942,,10116.0,1,Intermediate,1,CHEMBL621318,,
7569,N,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,Rattus norvegicus,A,,BAO_0000218,17735,In vivo,10116.0,1,Intermediate,1,CHEMBL621319,,
7570,N,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,6056,In vivo,10116.0,1,Intermediate,1,CHEMBL621377,,
7571,N,Half life was determined,,Rattus norvegicus,A,,BAO_0000218,5213,,10116.0,1,Intermediate,1,CHEMBL621378,,
7572,N,Half life after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,6616,In vivo,10116.0,1,Intermediate,1,CHEMBL876599,,
7573,N,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5937,In vivo,10116.0,1,Intermediate,1,CHEMBL621379,,
7574,N,Half life in rat plasma,,Rattus norvegicus,A,,BAO_0000218,5819,,10116.0,1,Intermediate,1,CHEMBL621380,,1969.0
7575,N,Half life in rat plasma; Not detected,,Rattus norvegicus,A,,BAO_0000218,5819,,10116.0,1,Intermediate,1,CHEMBL621381,,1969.0
7576,N,Half life in rats,,Rattus norvegicus,A,,BAO_0000218,6803,,10116.0,1,Intermediate,1,CHEMBL618515,,
7577,N,Half life period of compound was determined after peroral administration,,Rattus norvegicus,A,,BAO_0000218,17804,In vivo,10116.0,1,Intermediate,1,CHEMBL618516,,
7578,N,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,,Rattus norvegicus,A,,BAO_0000218,17804,In vivo,10116.0,1,Intermediate,1,CHEMBL618517,,
7579,N,Half life period in rat,,Rattus norvegicus,A,,BAO_0000218,5948,,10116.0,1,Intermediate,1,CHEMBL618518,,
7580,N,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,Rattus norvegicus,A,,BAO_0000218,1916,In vivo,10116.0,1,Intermediate,1,CHEMBL618519,,
7581,N,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,Rattus norvegicus,A,,BAO_0000218,1916,In vivo,10116.0,1,Intermediate,1,CHEMBL618698,,
7582,N,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,,Rattus norvegicus,A,,BAO_0000218,1916,In vivo,10116.0,1,Intermediate,1,CHEMBL618862,,
7583,N,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,4890,In vivo,10116.0,1,Intermediate,1,CHEMBL618863,,
7584,N,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,,Rattus norvegicus,A,,BAO_0000218,17764,In vivo,10116.0,1,Intermediate,1,CHEMBL618864,,
7585,N,Half life time in rat the dose of 2 mg/kg,,Rattus norvegicus,A,,BAO_0000218,4727,In vivo,10116.0,1,Intermediate,1,CHEMBL618865,,
7586,N,Half-life 24 hr after 10 mg/kg iv administration in rats,,Rattus norvegicus,A,,BAO_0000218,17509,In vivo,10116.0,1,Intermediate,1,CHEMBL618866,,
7587,N,Half-life 24 hr after 2 mg/kg iv administration in rats,,Rattus norvegicus,A,,BAO_0000218,17509,In vivo,10116.0,1,Intermediate,1,CHEMBL618867,,
7588,N,Half-life consistent with the observed metabolic steady state in rats,,Rattus norvegicus,A,,BAO_0000218,6597,,10116.0,1,Intermediate,1,CHEMBL875828,,
7589,N,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,Rattus norvegicus,A,,BAO_0000218,17735,In vivo,10116.0,1,Intermediate,1,CHEMBL618868,,
7590,N,Half-life for oxidative metabolic stability was determined using male human,,Rattus norvegicus,A,,BAO_0000218,6597,,10116.0,1,Intermediate,1,CHEMBL618869,,
7591,N,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",,Rattus norvegicus,A,,BAO_0000218,17670,In vivo,10116.0,1,Intermediate,1,CHEMBL618870,,
7592,N,Half-life in rat plasma,,Rattus norvegicus,A,,BAO_0000218,1696,,10116.0,1,Intermediate,1,CHEMBL618871,,1969.0
7593,N,Half-life in rat plasma was determined,,Rattus norvegicus,A,,BAO_0000218,1742,,10116.0,1,Intermediate,1,CHEMBL618872,,1969.0
7594,N,Half-life in rats was determined,,Rattus norvegicus,A,,BAO_0000218,17800,,10116.0,1,Intermediate,1,CHEMBL873816,,
7595,U,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,,,A,,BAO_0000218,12923,,,0,Autocuration,1,CHEMBL618873,,
7596,U,Area under curve after oral dose of 0.1 mg//kg,,,A,,BAO_0000019,11954,,,0,Autocuration,1,CHEMBL621602,,
7597,U,Area under curve after oral dose of 0.3 mg/kg,,,A,,BAO_0000218,11954,,,0,Autocuration,1,CHEMBL621603,,
7598,U,Area under curve after oral dose of 1 mg/kg,,,A,,BAO_0000218,11954,,,0,Autocuration,1,CHEMBL621604,,
7599,U,Area under curve after oral dose of 10 mg/kg,,,A,,BAO_0000218,11954,,,0,Autocuration,1,CHEMBL621605,,
7600,U,Area under curve after oral dose of 23.4 mg/kg,,,A,,BAO_0000218,11954,,,0,Autocuration,1,CHEMBL621606,,
7601,U,Area under curve after oral dose of 3 mg/kg,,,A,,BAO_0000218,11954,,,0,Autocuration,1,CHEMBL621607,,
7602,U,Area under curve after oral dose of 3.87 mg/kg,,,A,,BAO_0000218,11954,,,0,Autocuration,1,CHEMBL621608,,
7603,U,Area under curve was determined,,,A,,BAO_0000019,5237,,,0,Autocuration,1,CHEMBL621609,,
7604,U,Area under curve at a dose of 10 mg/kg,,,A,,BAO_0000218,4026,,,0,Autocuration,1,CHEMBL621610,,
7605,N,Area under curve was determined; ND=No data,,Rattus norvegicus,A,,BAO_0000218,5237,,10116.0,1,Intermediate,1,CHEMBL621611,,
7606,N,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,Rattus norvegicus,A,,BAO_0000218,14793,,10116.0,1,Intermediate,1,CHEMBL621612,,
7607,N,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,Rattus norvegicus,A,,BAO_0000218,14793,,10116.0,1,Intermediate,1,CHEMBL622308,,
7608,N,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,Rattus norvegicus,A,,BAO_0000218,14793,,10116.0,1,Intermediate,1,CHEMBL622309,,
7609,N,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,,Rattus norvegicus,A,,BAO_0000218,14793,,10116.0,1,Intermediate,1,CHEMBL622310,,
7610,N,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,Rattus norvegicus,A,,BAO_0000218,14793,,10116.0,1,Intermediate,1,CHEMBL622311,,
7611,N,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,,Rattus norvegicus,A,,BAO_0000218,14793,,10116.0,1,Intermediate,1,CHEMBL622312,,
7612,N,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,Rattus norvegicus,A,,BAO_0000218,14793,,10116.0,1,Intermediate,1,CHEMBL622931,,
7613,N,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,,Rattus norvegicus,A,,BAO_0000218,14793,,10116.0,1,Intermediate,1,CHEMBL622932,,
7614,N,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,Rattus norvegicus,A,,BAO_0000218,14793,,10116.0,1,Intermediate,1,CHEMBL622736,,1969.0
7615,N,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,Rattus norvegicus,A,,BAO_0000218,14793,,10116.0,1,Intermediate,1,CHEMBL622737,,1969.0
7616,N,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,Rattus norvegicus,A,,BAO_0000218,14793,,10116.0,1,Intermediate,1,CHEMBL622738,,1969.0
7617,N,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,,Rattus norvegicus,A,,BAO_0000218,14793,,10116.0,1,Intermediate,1,CHEMBL622739,,1969.0
7618,N,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,Rattus norvegicus,A,,BAO_0000218,14793,,10116.0,1,Intermediate,1,CHEMBL622740,,1969.0
7619,N,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,,Rattus norvegicus,A,,BAO_0000218,14793,,10116.0,1,Intermediate,1,CHEMBL622741,,1969.0
7620,N,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,Rattus norvegicus,A,,BAO_0000218,14793,,10116.0,1,Intermediate,1,CHEMBL622742,,1969.0
7621,N,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,,Rattus norvegicus,A,,BAO_0000218,14793,,10116.0,1,Intermediate,1,CHEMBL622743,,1969.0
7622,N,AUC in mice,,Mus musculus,A,,BAO_0000218,11637,,10090.0,1,Intermediate,1,CHEMBL622744,,1969.0
7623,U,Area under curve was measured from the graph obtained from concentration Vs time,,,A,,BAO_0000019,11149,,,0,Autocuration,1,CHEMBL624134,,
7624,U,Area under curve value of compound per hour after oral administration,,,A,,BAO_0000019,10016,,,0,Autocuration,1,CHEMBL624135,,
7625,N,Area under curve was determined after oral administration in rats,,Rattus norvegicus,A,,BAO_0000218,17796,,10116.0,1,Intermediate,1,CHEMBL624136,,
7626,N,Area under curve was determined after oral administration in rats; No data,,Rattus norvegicus,A,,BAO_0000218,17796,,10116.0,1,Intermediate,1,CHEMBL624137,,
7627,N,Area under curve was determined after oral administration in rats;No data,,Rattus norvegicus,A,,BAO_0000218,17796,,10116.0,1,Intermediate,1,CHEMBL624320,,
7628,N,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,Canis lupus familiaris,A,,BAO_0000218,12923,,9615.0,1,Intermediate,1,CHEMBL624321,,
7629,N,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,15372,,10116.0,1,Intermediate,1,CHEMBL624322,,
7630,N,Area under curve was determined for the compound after iv dose of 5.06 in rats,,Rattus norvegicus,A,,BAO_0000218,15372,,10116.0,1,Intermediate,1,CHEMBL624323,,
7631,N,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,15372,,10116.0,1,Intermediate,1,CHEMBL624324,,
7632,N,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,15372,,10116.0,1,Intermediate,1,CHEMBL624325,,
7633,N,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,15372,,10116.0,1,Intermediate,1,CHEMBL624326,,
7634,N,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,15372,,10116.0,1,Intermediate,1,CHEMBL624327,,
7635,N,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,15372,,10116.0,1,Intermediate,1,CHEMBL624328,,
7636,N,Area under curve was determined in Dogs after peroral administration,,Canis lupus familiaris,A,,BAO_0000218,14169,,9615.0,1,Intermediate,1,CHEMBL627848,,
7637,N,Area under curve was determined in Rats after peroral administration,,Rattus norvegicus,A,,BAO_0000218,14169,,10116.0,1,Intermediate,1,CHEMBL627849,,
7638,N,Area under curve was determined in carotid blood of rat when administered intradermally,,Rattus norvegicus,A,,BAO_0000218,14258,,10116.0,1,Intermediate,1,CHEMBL627850,,
7639,N,Area under curve was determined in portal blood of rat when administered intradermally,,Rattus norvegicus,A,,BAO_0000218,14258,,10116.0,1,Intermediate,1,CHEMBL627851,,
7640,N,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,Mus musculus,A,,BAO_0000218,15011,,10090.0,1,Intermediate,1,CHEMBL627852,,
7641,N,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,Mus musculus,A,,BAO_0000218,15011,,10090.0,1,Intermediate,1,CHEMBL627853,,
7642,N,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,Mus musculus,A,,BAO_0000218,15011,,10090.0,1,Intermediate,1,CHEMBL627854,,
7643,N,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,Mus musculus,A,,BAO_0000218,15011,,10090.0,1,Intermediate,1,CHEMBL627855,,
7644,N,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),,Mus musculus,A,,BAO_0000218,15011,,10090.0,1,Intermediate,1,CHEMBL627856,,
7645,N,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,Mus musculus,A,,BAO_0000218,15011,,10090.0,1,Intermediate,1,CHEMBL875339,,
7646,N,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),,Mus musculus,A,,BAO_0000218,15011,,10090.0,1,Intermediate,1,CHEMBL627857,,
7647,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL627858,,2106.0
7648,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627859,,178.0
7649,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627860,,955.0
7650,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627019,,948.0
7651,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627020,,2107.0
7652,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627021,,2048.0
7653,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627022,,2385.0
7654,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627023,,
7655,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627024,,2106.0
7656,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627025,,2046.0
7657,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627026,,2113.0
7658,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627027,,178.0
7659,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627028,,955.0
7660,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627029,,948.0
7661,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627030,,2113.0
7662,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627031,,2107.0
7663,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627032,,2048.0
7664,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627033,,2385.0
7665,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627034,,
7666,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627035,,2106.0
7667,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627036,,2046.0
7668,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL875340,,178.0
7669,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627037,,948.0
7670,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627038,,2113.0
7671,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627039,,2107.0
7672,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL627040,,2385.0
7673,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL624663,,2106.0
7674,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL625963,,2046.0
7675,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL876799,,955.0
7676,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL626133,,2048.0
7677,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL626134,,
7678,N,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6295,,10116.0,1,Intermediate,1,CHEMBL626135,,
7679,N,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6296,,10116.0,1,Intermediate,1,CHEMBL626136,,
7680,N,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,,Rattus norvegicus,A,,BAO_0000218,6296,,10116.0,1,Intermediate,1,CHEMBL626137,,
7681,N,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6295,,10116.0,1,Intermediate,1,CHEMBL626138,,
7682,N,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6296,,10116.0,1,Intermediate,1,CHEMBL626139,,
7683,N,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,Rattus norvegicus,A,,BAO_0000218,17260,In vivo,10116.0,1,Intermediate,1,CHEMBL626140,,
7684,N,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,Rattus norvegicus,A,,BAO_0000218,17260,In vivo,10116.0,1,Intermediate,1,CHEMBL626141,,
7685,N,C24h in rat p.o. at 20 mg/kg concentration,,Rattus norvegicus,A,,BAO_0000218,17686,,10116.0,1,Intermediate,1,CHEMBL626142,,
7686,N,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627930,,2385.0
7687,N,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627931,,2385.0
7688,N,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627932,,2385.0
7689,N,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627933,,2106.0
7690,N,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627934,,2106.0
7691,N,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627935,,2106.0
7692,N,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627936,,178.0
7693,N,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627937,,178.0
7694,N,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627938,,178.0
7695,N,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627939,,178.0
7696,N,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627940,,178.0
7697,N,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627941,,178.0
7698,N,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL876800,,178.0
7699,N,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627942,,178.0
7700,N,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627943,,178.0
7701,N,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627944,,178.0
7702,N,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627945,,178.0
7703,N,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL628584,,178.0
7704,N,Biodistribution in rat blood in the presence of GdDTPA at 15 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL628585,,178.0
7705,N,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL628586,,178.0
7706,N,Biodistribution in rat blood in the presence of GdDTPA at 30 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL628587,,178.0
7707,N,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL628588,,178.0
7708,N,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL628589,,178.0
7709,N,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL625304,,178.0
7710,N,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL625305,,178.0
7711,N,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL625306,,178.0
7712,N,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL625307,,178.0
7713,N,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL625308,,178.0
7714,N,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627740,,178.0
7715,N,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627741,,178.0
7716,N,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627742,,178.0
7717,N,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627743,,178.0
7718,N,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627744,,178.0
7719,N,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627745,,10000001.0
7720,N,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627746,,10000001.0
7721,N,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627747,,10000001.0
7722,N,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL876810,,10000001.0
7723,N,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627748,,10000001.0
7724,N,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627749,,10000001.0
7725,N,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL627750,,10000001.0
7726,N,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618728,,10000001.0
7727,N,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618729,,10000001.0
7728,N,Biodistribution in rat bone in the presence of GdDTPA at 15 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618730,,10000001.0
7729,N,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618731,,10000001.0
7730,N,Biodistribution in rat bone in the presence of GdDTPA at 30 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618732,,10000001.0
7731,N,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618733,,10000001.0
7732,N,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618734,,10000001.0
7733,N,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618735,,10000001.0
7734,N,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL876602,,10000001.0
7735,N,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618736,,10000001.0
7736,N,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618737,,10000001.0
7737,N,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618738,,10000001.0
7738,N,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618739,,10000001.0
7739,N,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618740,,10000001.0
7740,N,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618741,,10000001.0
7741,N,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618742,,10000001.0
7742,N,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL618743,,10000001.0
7743,N,Half-life from rat plasma at a single oral dose of 25 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17752,In vivo,10116.0,1,Intermediate,1,CHEMBL618744,,1969.0
7744,N,Half-life in male rat,,Rattus norvegicus,A,,BAO_0000218,5610,,10116.0,1,Intermediate,1,CHEMBL618745,,
7745,N,Half-life in rat after peroral administration at 10 mg/kg concentration,,Rattus norvegicus,A,,BAO_0000218,5939,In vivo,10116.0,1,Intermediate,1,CHEMBL620479,,
7746,N,Half-life in rat after peroral administration at 5 mg/kg concentration,,Rattus norvegicus,A,,BAO_0000218,5939,In vivo,10116.0,1,Intermediate,1,CHEMBL620480,,
7747,N,Half-life in rat at a dose of 3 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17771,In vivo,10116.0,1,Intermediate,1,CHEMBL620481,,
7748,N,Half-life was evaluated in rats,,Rattus norvegicus,A,,BAO_0000218,1974,,10116.0,1,Intermediate,1,CHEMBL620482,,
7749,N,Half-life was measured in rat,,Rattus norvegicus,A,,BAO_0000218,4239,,10116.0,1,Intermediate,1,CHEMBL876603,,
7750,N,Half-life period for the compound was determined in rats at 50 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,6681,In vivo,10116.0,1,Intermediate,1,CHEMBL620483,,
7751,N,Half-life period in rats after intravenous administration at 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17752,In vivo,10116.0,1,Intermediate,1,CHEMBL620484,,
7752,N,Half-life period in rat at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6046,In vivo,10116.0,1,Intermediate,1,CHEMBL620485,,
7753,N,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,6685,In vivo,10116.0,1,Intermediate,1,CHEMBL620486,,
7754,N,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",,Rattus norvegicus,A,,BAO_0000218,6685,In vivo,10116.0,1,Intermediate,1,CHEMBL620487,,
7755,N,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",,Rattus norvegicus,A,,BAO_0000218,6685,In vivo,10116.0,1,Intermediate,1,CHEMBL620488,,
7756,N,Half-life time in rat the dose of 2 mg/kg,,Rattus norvegicus,A,,BAO_0000218,4727,In vivo,10116.0,1,Intermediate,1,CHEMBL620489,,
7757,N,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,,Rattus norvegicus,A,,BAO_0000218,1088,In vivo,10116.0,1,Intermediate,1,CHEMBL620490,,
7758,N,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5610,In vivo,10116.0,1,Intermediate,1,CHEMBL620491,,
7759,N,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,Rattus norvegicus,A,,BAO_0000218,3032,In vivo,10116.0,1,Intermediate,1,CHEMBL876604,,1969.0
7760,N,Oral half life was determined,,Rattus norvegicus,A,,BAO_0000218,5199,In vivo,10116.0,1,Intermediate,1,CHEMBL620492,,
7761,N,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",,Rattus norvegicus,A,,BAO_0000218,14941,In vivo,10116.0,1,Intermediate,1,CHEMBL620493,,
7762,N,Pharmacokinetic property (t1/2) in rat,,Rattus norvegicus,A,,BAO_0000218,4408,In vivo,10116.0,1,Intermediate,1,CHEMBL620494,,
7763,N,Plasma elimination half-life was determined,,Rattus norvegicus,A,,BAO_0000218,2552,,10116.0,1,Intermediate,1,CHEMBL620495,,1969.0
7764,N,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,Rattus norvegicus,A,,BAO_0000218,5199,In vivo,10116.0,1,Intermediate,1,CHEMBL620496,,1969.0
7765,N,Plasma half life was observed after intravenous administration in rat,,Rattus norvegicus,A,,BAO_0000218,15662,In vivo,10116.0,1,Intermediate,1,CHEMBL620497,,1969.0
7766,N,Plasma half-life was determined,,Rattus norvegicus,A,,BAO_0000218,1465,,10116.0,1,Intermediate,1,CHEMBL620498,,1969.0
7767,N,Plasma half-life following oral administration in Fisher rats,,Rattus norvegicus,A,,BAO_0000218,1446,In vivo,10116.0,1,Intermediate,1,CHEMBL620499,,1969.0
7768,N,Plasma half-life in rat,,Rattus norvegicus,A,,BAO_0000218,6824,,10116.0,1,Intermediate,1,CHEMBL620500,,1969.0
7769,N,Plasmatic Half-life after intravenous administration to rat,,Rattus norvegicus,A,,BAO_0000218,17533,In vivo,10116.0,1,Intermediate,1,CHEMBL873809,,1969.0
7770,N,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,Rattus norvegicus,A,,BAO_0000218,5979,In vivo,10116.0,1,Intermediate,1,CHEMBL620501,,
7771,N,Terminal half life after intravenous administration (1 mg/kg) in rat,,Rattus norvegicus,A,,BAO_0000218,4689,In vivo,10116.0,1,Intermediate,1,CHEMBL620502,,
7772,N,Terminal half life in Rat at a oral dose of 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,4689,In vivo,10116.0,1,Intermediate,1,CHEMBL620503,,
7773,N,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,Rattus norvegicus,A,,BAO_0000218,2463,In vivo,10116.0,1,Intermediate,1,CHEMBL620504,,
7774,N,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,4883,In vivo,10116.0,1,Intermediate,1,CHEMBL876605,,
7775,N,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,4883,In vivo,10116.0,1,Intermediate,1,CHEMBL620505,,
7776,N,plasma half life was observed after intravenous administration in rat,,Rattus norvegicus,A,,BAO_0000218,15662,In vivo,10116.0,1,Intermediate,1,CHEMBL873811,,1969.0
7777,N,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,3598,In vivo,10116.0,1,Expert,1,CHEMBL624016,,
7778,N,Half life of compound determined in rat,,Rattus norvegicus,A,,BAO_0000218,4576,,10116.0,1,Intermediate,1,CHEMBL624017,,
7779,N,Mean residence time determined in rat,,Rattus norvegicus,A,,BAO_0000218,4576,,10116.0,1,Intermediate,1,CHEMBL624018,,
7780,N,Plasma half life determined in rat,,Rattus norvegicus,A,,BAO_0000218,4576,,10116.0,1,Intermediate,1,CHEMBL624019,,
7781,N,Compound was evaluated for Tmax in brain after intravenous administration in male rats,,Rattus norvegicus,A,,BAO_0000218,4910,In vivo,10116.0,1,Intermediate,1,CHEMBL624020,,955.0
7782,N,Compound was evaluated for pharmacokinetic parameter maximum time period,,Rattus norvegicus,A,,BAO_0000218,4891,In vivo,10116.0,1,Intermediate,1,CHEMBL624201,,
7783,N,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,429,In vivo,10116.0,1,Intermediate,1,CHEMBL872528,,
7784,N,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL624202,,
7785,N,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL624203,,
7786,N,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL624350,,
7787,N,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL621320,,
7788,N,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,Rattus norvegicus,A,,BAO_0000218,17582,In vivo,10116.0,1,Intermediate,1,CHEMBL621321,,
7789,N,Maximum time (Tmax) required to reach Cmax in rats,,Rattus norvegicus,A,,BAO_0000218,4026,,10116.0,1,Intermediate,1,CHEMBL621322,,
7790,N,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,4890,In vivo,10116.0,1,Intermediate,1,CHEMBL621323,,
7791,N,Maximum time of clearance of compound in rats after peroral administration,,Rattus norvegicus,A,,BAO_0000218,6571,In vivo,10116.0,1,Intermediate,1,CHEMBL621324,,
7792,N,Maximum time at the dose of 2 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,4727,,10116.0,1,Intermediate,1,CHEMBL621325,,
7793,N,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17651,In vivo,10116.0,1,Intermediate,1,CHEMBL875837,,1969.0
7794,N,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17651,In vivo,10116.0,1,Intermediate,1,CHEMBL621326,,1969.0
7795,N,Tmax in Guinea pig (PO dose),,Rattus norvegicus,A,,BAO_0000218,14465,In vivo,10116.0,1,Intermediate,1,CHEMBL621327,,
7796,N,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",,Rattus norvegicus,A,,BAO_0000218,14941,In vivo,10116.0,1,Intermediate,1,CHEMBL621328,,
7797,N,Pharmacokinetic parameter (Tmax) in rat,,Rattus norvegicus,A,,BAO_0000218,5960,In vivo,10116.0,1,Intermediate,1,CHEMBL621329,,
7798,N,Pharmacokinetic parameter (Tmax) was estimated,,Rattus norvegicus,A,,BAO_0000218,5022,In vivo,10116.0,1,Intermediate,1,CHEMBL621330,,
7799,N,Pharmacokinetic property (Tmax) in rat,,Rattus norvegicus,A,,BAO_0000218,4408,In vivo,10116.0,1,Intermediate,1,CHEMBL621331,,
7800,N,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,Rattus norvegicus,A,,BAO_0000218,5983,In vivo,10116.0,1,Intermediate,1,CHEMBL621332,,
7801,N,T max in Rat at a oral dose of 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,4689,In vivo,10116.0,1,Intermediate,1,CHEMBL621333,,
7802,N,T max was determined at 10 mg/kg po dose in rats,,Rattus norvegicus,A,,BAO_0000218,2792,In vivo,10116.0,1,Intermediate,1,CHEMBL621334,,
7803,N,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),,Mus musculus,A,,BAO_0000218,15011,,10090.0,1,Intermediate,1,CHEMBL621335,,
7804,N,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,,Canis lupus familiaris,A,,BAO_0000218,14180,,9615.0,1,Intermediate,1,CHEMBL621336,,
7805,N,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,,Rattus norvegicus,A,,BAO_0000218,14180,,10116.0,1,Intermediate,1,CHEMBL621337,,
7806,N,Area under curve was measured after i.v. administration into Beagle dog.,,Canis lupus familiaris,A,,BAO_0000218,14599,,9615.0,1,Intermediate,1,CHEMBL621338,,
7807,N,Area under curve was measured after iv administration into Beagle dog,,Canis lupus familiaris,A,,BAO_0000218,14599,,9615.0,1,Intermediate,1,CHEMBL875838,,
7808,N,Area under curve was measured after po administration into Beagle dog,,Canis lupus familiaris,A,,BAO_0000218,14599,,9615.0,1,Intermediate,1,CHEMBL621339,,
7809,N,Area under curve was measured after po administration into Beagle dog.,,Canis lupus familiaris,A,,BAO_0000218,14599,,9615.0,1,Intermediate,1,CHEMBL621340,,
7810,U,Area under curve was measured at peroral dose of 3 mg/kg,,,A,,BAO_0000218,15675,,,0,Autocuration,1,CHEMBL621341,,
7811,U,Area under curve was measured by using concentration Vs time,,,A,,BAO_0000019,12706,,,0,Autocuration,1,CHEMBL621342,,
7812,U,Area under curve was measured by using concentration Vs time; not tested,,,A,,BAO_0000019,12706,,,0,Autocuration,1,CHEMBL621343,,
7813,N,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),,Mus musculus,A,,BAO_0000218,9750,,10090.0,1,Intermediate,1,CHEMBL621344,,
7814,N,Area under curve(AUC) was measured in mice after oral administration.,,Mus musculus,A,,BAO_0000218,9750,,10090.0,1,Intermediate,1,CHEMBL621345,,
7815,U,Area under curve(AUC) value of the compound,,,A,,BAO_0000019,14691,,,0,Autocuration,1,CHEMBL621346,,
7816,U,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,,,A,,BAO_0000218,14691,,,0,Autocuration,1,CHEMBL621347,,
7817,N,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,,Canis lupus familiaris,A,,BAO_0000218,14691,,9615.0,1,Intermediate,1,CHEMBL621348,,
7818,U,Area under curve(carotid artery) was determined by the availability in blood,,,A,,BAO_0000019,2939,,,0,Autocuration,1,CHEMBL621349,,178.0
7819,U,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,,,A,,BAO_0000019,2939,,,0,Autocuration,1,CHEMBL621350,,178.0
7820,U,Area under curve(carotid artery) was determined by the availability in blood; No data,,,A,,BAO_0000019,2939,,,0,Autocuration,1,CHEMBL875839,,178.0
7821,U,Area under curve(portal vein) was determined by the availability in blood,,,A,,BAO_0000019,2939,,,0,Autocuration,1,CHEMBL620211,,178.0
7822,U,Area under curve(portal vein) was determined by the availability in blood; ND means no data,,,A,,BAO_0000019,2939,,,0,Autocuration,1,CHEMBL620212,,178.0
7823,U,Area under curve(portal vein) was determined by the availability in blood; No data,,,A,,BAO_0000019,2939,,,0,Autocuration,1,CHEMBL620213,,178.0
7824,N,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,Macaca mulatta,A,,BAO_0000218,9552,,9544.0,1,Intermediate,1,CHEMBL620214,,1969.0
7825,N,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,Macaca mulatta,A,,BAO_0000218,9552,,9544.0,1,Intermediate,1,CHEMBL620215,,1969.0
7826,N,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,,Macaca mulatta,A,,BAO_0000218,9552,,9544.0,1,Intermediate,1,CHEMBL620216,,1969.0
7827,N,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",,Canis lupus familiaris,A,,BAO_0000218,9552,,9615.0,1,Intermediate,1,CHEMBL620888,,1969.0
7828,N,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",,Canis lupus familiaris,A,,BAO_0000218,9552,,9615.0,1,Intermediate,1,CHEMBL620889,,1969.0
7829,U,Area under plasma concentration vs time curve observed in rats for 0-3 h,,,A,,BAO_0000019,9552,,,0,Autocuration,1,CHEMBL620890,,1969.0
7830,N,Area under plasma time curve determined in male rat,,Rattus norvegicus,A,,BAO_0000218,11911,,10116.0,1,Intermediate,1,CHEMBL620891,,1969.0
7831,U,Area under the MAP curve measured over 5 min.,,,A,,BAO_0000019,16618,,,0,Autocuration,1,CHEMBL620892,,
7832,N,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,,Mus musculus,A,,BAO_0000218,14387,,10090.0,1,Intermediate,1,CHEMBL621079,,
7833,N,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,,Mus musculus,A,,BAO_0000218,14387,,10090.0,1,Intermediate,1,CHEMBL621080,,
7834,N,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,,Canis lupus familiaris,A,,BAO_0000218,12836,,9615.0,1,Intermediate,1,CHEMBL621081,,
7835,N,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,,Cricetinae,A,,BAO_0000218,12836,,10026.0,1,Intermediate,1,CHEMBL621082,,
7836,N,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,,Rattus norvegicus,A,,BAO_0000218,12836,,10116.0,1,Intermediate,1,CHEMBL621083,,
7837,N,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,,Canis lupus familiaris,A,,BAO_0000218,14339,,9615.0,1,Intermediate,1,CHEMBL621084,,
7838,N,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,,Canis lupus familiaris,A,,BAO_0000218,14339,,9615.0,1,Intermediate,1,CHEMBL621085,,
7839,N,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,,Canis lupus familiaris,A,,BAO_0000218,14339,,9615.0,1,Intermediate,1,CHEMBL621086,,
7840,N,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,Canis lupus familiaris,A,,BAO_0000218,10524,,9615.0,1,Intermediate,1,CHEMBL621087,,
7841,N,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),,Canis lupus familiaris,A,,BAO_0000218,9994,,9615.0,1,Intermediate,1,CHEMBL622607,,
7842,N,Serum AUC in marmosets (IV dose),,Canis lupus familiaris,A,,BAO_0000218,11325,,9615.0,1,Intermediate,1,CHEMBL622608,,
7843,U,Area under the curve after intravenous administration at a dose of 10 umol/kg,,,A,,BAO_0000019,12536,,,0,Autocuration,1,CHEMBL624481,,
7844,U,Area under the curve after intravenous administration at a dose of 2 umol/kg,,,A,,BAO_0000019,12536,,,0,Autocuration,1,CHEMBL624482,,
7845,U,Area under the curve after intravenous administration at a dose of 4 umol/kg,,,A,,BAO_0000019,12536,,,0,Autocuration,1,CHEMBL624483,,
7846,U,Area under the curve after intravenous administration at a dose of 40 umol/kg,,,A,,BAO_0000019,12536,,,0,Autocuration,1,CHEMBL624484,,
7847,U,Area under the curve after intravenous administration at a dose of 5 umol/kg,,,A,,BAO_0000019,12536,,,0,Autocuration,1,CHEMBL624485,,
7848,N,Area under the curve for fumarate salt was evaluated in F344 Rats.,,Rattus norvegicus,A,,BAO_0000218,15556,,10116.0,1,Intermediate,1,CHEMBL624486,,
7849,U,Area under the curve for the compound was calculated.,,,A,,BAO_0000019,2809,,,0,Autocuration,1,CHEMBL624487,,
7850,U,Area under the curve in concentration/ time,,,A,,BAO_0000019,9511,,,0,Autocuration,1,CHEMBL624488,,
7851,N,Area under the curve administered intraintestinal in rats.,,Rattus norvegicus,A,,BAO_0000218,12818,,10116.0,1,Intermediate,1,CHEMBL624489,,
7852,N,Area under the curve administered intravenously in rats.,,Rattus norvegicus,A,,BAO_0000218,12818,,10116.0,1,Intermediate,1,CHEMBL625184,,
7853,U,Area under the curve during intravenous administration,,,A,,BAO_0000019,15118,,,0,Autocuration,1,CHEMBL625185,,
7854,U,Area under the curve during intravenous administration; Not determined,,,A,,BAO_0000019,15118,,,0,Autocuration,1,CHEMBL875954,,
7855,U,Area under the curve during systemic administration,,,A,,BAO_0000019,15118,,,0,Autocuration,1,CHEMBL625186,,
7856,U,Area under the curve during systemic administration; Not determined,,,A,,BAO_0000019,15118,,,0,Autocuration,1,CHEMBL625187,,
7857,U,Area under the curve was calculated for the compound.,,,A,,BAO_0000019,2632,,,0,Autocuration,1,CHEMBL625188,,
7858,N,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,,Canis lupus familiaris,A,,BAO_0000218,14346,,9615.0,1,Intermediate,1,CHEMBL625189,,
7859,N,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,,Canis lupus familiaris,A,,BAO_0000218,14346,,9615.0,1,Intermediate,1,CHEMBL625190,,
7860,N,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,,Rattus norvegicus,A,,BAO_0000218,14346,,10116.0,1,Intermediate,1,CHEMBL621733,,
7861,N,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,,Rattus norvegicus,A,,BAO_0000218,14346,,10116.0,1,Intermediate,1,CHEMBL621734,,
7862,N,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,,Rattus norvegicus,A,,BAO_0000218,11149,,10116.0,1,Intermediate,1,CHEMBL621735,,
7863,N,Clearance of the drug was measured in the plasma of rat; No data,,Rattus norvegicus,A,,BAO_0000218,17796,,10116.0,1,Intermediate,1,CHEMBL621736,,1969.0
7864,N,The pharmacokinetic parameter plasma clearance in vivo in rats,,Rattus norvegicus,A,,BAO_0000218,5247,,10116.0,1,Intermediate,1,CHEMBL621737,,1969.0
7865,N,Plasma clearance at the dose of 2 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,4727,,10116.0,1,Intermediate,1,CHEMBL621738,,
7866,N,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,Rattus norvegicus,A,,BAO_0000218,5654,In vivo,10116.0,1,Intermediate,1,CHEMBL622806,,
7867,N,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,Rattus norvegicus,A,,BAO_0000218,5654,In vivo,10116.0,1,Intermediate,1,CHEMBL623519,,
7868,N,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,Rattus norvegicus,A,,BAO_0000218,17260,In vivo,10116.0,1,Intermediate,1,CHEMBL623520,,
7869,N,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,,Rattus norvegicus,A,,BAO_0000218,17065,In vivo,10116.0,1,Intermediate,1,CHEMBL623521,,
7870,N,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17671,In vivo,10116.0,1,Intermediate,1,CHEMBL623522,,
7871,N,Clearance rate in rat,,Rattus norvegicus,A,,BAO_0000218,6672,In vivo,10116.0,1,Intermediate,1,CHEMBL623523,,
7872,N,Clearance rate in rat,,Rattus norvegicus,A,,BAO_0000218,6673,In vivo,10116.0,1,Intermediate,1,CHEMBL623690,,
7873,N,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL623691,,
7874,N,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL623692,,
7875,N,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL623693,,
7876,N,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL623694,,
7877,N,Clearance of compound after iv administration of 20 mg/kg dose in rat,,Rattus norvegicus,A,,BAO_0000218,4413,In vivo,10116.0,1,Intermediate,1,CHEMBL623695,,
7878,N,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,,Rattus norvegicus,A,,BAO_0000218,2661,In vivo,10116.0,1,Intermediate,1,CHEMBL623696,,
7879,N,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,,Rattus norvegicus,A,,BAO_0000218,2661,In vivo,10116.0,1,Intermediate,1,CHEMBL623697,,
7880,U,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,Macaca mulatta,A,,BAO_0000218,5005,In vivo,9544.0,0,Intermediate,1,CHEMBL623698,,1969.0
7881,U,Compound was tested for its plasma clearance rate in Sprague Dawley rats,,Rattus norvegicus,A,,BAO_0000218,5005,In vivo,10116.0,0,Intermediate,1,CHEMBL623699,,1969.0
7882,N,Mean (%CV) PK parameters for CL(mL/min/kg).,,Rattus norvegicus,A,,BAO_0000218,15765,In vivo,10116.0,1,Intermediate,1,CHEMBL623700,,
7883,N,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,,Rattus norvegicus,A,,BAO_0000218,3747,In vivo,10116.0,1,Intermediate,1,CHEMBL623701,,
7884,N,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,,Rattus norvegicus,A,,BAO_0000218,16366,In vivo,10116.0,1,Intermediate,1,CHEMBL623702,,1969.0
7885,N,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,,Rattus norvegicus,A,,BAO_0000218,4199,In vivo,10116.0,1,Intermediate,1,CHEMBL623703,,
7886,N,Plasma clearance in rat was determined,,Rattus norvegicus,A,,BAO_0000218,17267,In vivo,10116.0,1,Intermediate,1,CHEMBL623704,,
7887,N,Plasma clearance in rat after administration of 2 mg/kg iv,,Rattus norvegicus,A,,BAO_0000218,6535,In vivo,10116.0,1,Intermediate,1,CHEMBL623705,,
7888,N,Plasma clearance in rat after administration of 2 mg/kg iv,,Rattus norvegicus,A,,BAO_0000218,6535,In vivo,10116.0,1,Intermediate,1,CHEMBL623706,,
7889,N,Plasma clearance was determined,,Rattus norvegicus,A,,BAO_0000218,5041,In vivo,10116.0,1,Intermediate,1,CHEMBL623707,,
7890,N,Plasma clearance in rat,,Rattus norvegicus,A,,BAO_0000218,5960,In vivo,10116.0,1,Intermediate,1,CHEMBL623708,,
7891,N,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5937,In vivo,10116.0,1,Intermediate,1,CHEMBL623709,,
7892,N,Plasma clearance in rat by iv administration,,Rattus norvegicus,A,,BAO_0000218,5871,In vivo,10116.0,1,Intermediate,1,CHEMBL623710,,
7893,N,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5874,In vivo,10116.0,1,Intermediate,1,CHEMBL623711,,
7894,N,Plasma clearance in rat p.o.,,Rattus norvegicus,A,,BAO_0000218,6504,In vivo,10116.0,1,Intermediate,1,CHEMBL623712,,
7895,N,Plasma clearance in rats,,Rattus norvegicus,A,,BAO_0000218,6803,In vivo,10116.0,1,Intermediate,1,CHEMBL623713,,
7896,N,Plasma clearance was determined; ND denotes no data,,Rattus norvegicus,A,,BAO_0000218,5041,In vivo,10116.0,1,Intermediate,1,CHEMBL623714,,
7897,N,Plasma clearance was determined; ND denotes not determined,,Rattus norvegicus,A,,BAO_0000218,5041,In vivo,10116.0,1,Intermediate,1,CHEMBL623715,,
7898,N,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,Rattus norvegicus,A,,BAO_0000218,1916,In vivo,10116.0,1,Intermediate,1,CHEMBL623716,,
7899,N,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,Rattus norvegicus,A,,BAO_0000218,5199,In vivo,10116.0,1,Intermediate,1,CHEMBL622980,,
7900,N,Plasma administration to rats,,Rattus norvegicus,A,,BAO_0000218,16367,In vivo,10116.0,1,Intermediate,1,CHEMBL622981,,
7901,N,Plasma clearance of the compound in female Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,6362,In vivo,10116.0,1,Intermediate,1,CHEMBL622982,,
7902,N,Plasma clearance was observed after intravenous administration in rat,,Rattus norvegicus,A,,BAO_0000218,15662,In vivo,10116.0,1,Intermediate,1,CHEMBL622983,,
7903,N,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,,Rattus norvegicus,A,,BAO_0000218,6215,In vivo,10116.0,1,Intermediate,1,CHEMBL622984,,
7904,N,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,,Rattus norvegicus,A,,BAO_0000218,1466,In vivo,10116.0,1,Intermediate,1,CHEMBL622985,,
7905,N,plasma clearance was observed after intravenous administration in rat,,Rattus norvegicus,A,,BAO_0000218,15662,In vivo,10116.0,1,Intermediate,1,CHEMBL623631,,1969.0
7906,N,In vivo CL/F determined,,Rattus norvegicus,A,,BAO_0000218,4723,In vivo,10116.0,1,Intermediate,1,CHEMBL623632,,
7907,N,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,,Rattus norvegicus,A,,BAO_0000218,2792,In vivo,10116.0,1,Intermediate,1,CHEMBL623633,,1969.0
7908,N,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,,Rattus norvegicus,A,,BAO_0000218,2792,In vivo,10116.0,1,Intermediate,1,CHEMBL623634,,1969.0
7909,N,Compound was tested for the lower blood clearance in rat,,Rattus norvegicus,A,,BAO_0000218,5213,In vivo,10116.0,1,Intermediate,1,CHEMBL623635,,
7910,N,Evaluated for the low clearance in rat (in vivo),,Rattus norvegicus,A,,BAO_0000218,4687,In vivo,10116.0,1,Intermediate,1,CHEMBL621195,,
7911,N,Pharmacokinetic property (CLb)of the compound was determined in rat,,Rattus norvegicus,A,,BAO_0000218,3371,In vivo,10116.0,1,Intermediate,1,CHEMBL621196,,
7912,N,Rapid clearance after intravenous administration in rat was determined,,Rattus norvegicus,A,,BAO_0000218,4690,In vivo,10116.0,1,Intermediate,1,CHEMBL875287,,
7913,N,Clearance measured in rat,,Rattus norvegicus,A,,BAO_0000218,5702,In vivo,10116.0,1,Intermediate,1,CHEMBL621197,,
7914,N,Compound was evaluated for plasma clearance in rat,,Rattus norvegicus,A,,BAO_0000218,740,In vivo,10116.0,1,Intermediate,1,CHEMBL621198,,1969.0
7915,N,Low plasma clearance was calculated in rat,,Rattus norvegicus,A,,BAO_0000218,4853,In vivo,10116.0,1,Intermediate,1,CHEMBL621199,,1969.0
7916,N,Pharmacokinetic property (Clp) in rat,,Rattus norvegicus,A,,BAO_0000218,5789,In vivo,10116.0,1,Intermediate,1,CHEMBL621200,,
7917,N,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,,Rattus norvegicus,A,,BAO_0000218,4527,In vivo,10116.0,1,Intermediate,1,CHEMBL621201,,
7918,N,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,,Rattus norvegicus,A,,BAO_0000218,4527,In vivo,10116.0,1,Intermediate,1,CHEMBL621202,,
7919,N,Plasma clearance after IV dosing at 0.5 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,6518,In vivo,10116.0,1,Intermediate,1,CHEMBL621203,,
7920,N,Plasma clearance after IV dosing at 1 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,6518,In vivo,10116.0,1,Intermediate,1,CHEMBL621204,,
7921,N,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621205,,948.0
7922,N,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621206,,948.0
7923,N,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621207,,948.0
7924,N,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621208,,948.0
7925,N,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621209,,948.0
7926,N,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL876484,,948.0
7927,N,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621210,,948.0
7928,N,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621211,,948.0
7929,N,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621212,,948.0
7930,N,Biodistribution in rat heart in the presence of GdDTPA at 15 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621213,,948.0
7931,N,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621214,,948.0
7932,N,Biodistribution in rat heart in the presence of GdDTPA at 30 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621215,,948.0
7933,N,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621216,,948.0
7934,N,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621217,,948.0
7935,N,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621218,,948.0
7936,N,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621219,,948.0
7937,N,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621220,,948.0
7938,N,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621221,,948.0
7939,N,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621222,,948.0
7940,N,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621223,,948.0
7941,N,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL876485,,948.0
7942,N,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621224,,948.0
7943,N,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621225,,948.0
7944,N,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621226,,948.0
7945,N,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621227,,2113.0
7946,N,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621228,,2113.0
7947,N,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621229,,2113.0
7948,N,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621230,,2113.0
7949,N,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621231,,2113.0
7950,N,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621232,,2113.0
7951,N,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621233,,2113.0
7952,N,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621234,,2113.0
7953,N,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621235,,2113.0
7954,N,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621236,,2113.0
7955,N,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621237,,2113.0
7956,N,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL876486,,2113.0
7957,N,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622436,,160.0
7958,N,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622437,,160.0
7959,N,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622438,,160.0
7960,N,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622439,,2107.0
7961,N,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622440,,2107.0
7962,N,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622441,,2107.0
7963,N,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622442,,2107.0
7964,N,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622443,,2107.0
7965,N,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622444,,2107.0
7966,N,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622445,,2107.0
7967,N,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622446,,2107.0
7968,N,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622447,,2107.0
7969,N,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622448,,2107.0
7970,N,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622449,,2107.0
7971,N,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622450,,2107.0
7972,N,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622451,,2107.0
7973,N,Biodistribution in rat liver in the presence of GdDTPA at 15 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622452,,2107.0
7974,N,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622453,,2107.0
7975,N,Biodistribution in rat liver in the presence of GdDTPA at 30 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622454,,2107.0
7976,N,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL622455,,2107.0
7977,N,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL876024,,2107.0
7978,N,T max was determined at 3 mg/kg po dose in rats,,Rattus norvegicus,A,,BAO_0000218,2792,In vivo,10116.0,1,Intermediate,1,CHEMBL622456,,
7979,N,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,15078,In vivo,10116.0,1,Intermediate,1,CHEMBL622457,,
7980,N,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,15078,In vivo,10116.0,1,Intermediate,1,CHEMBL622458,,
7981,N,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,,Rattus norvegicus,A,,BAO_0000218,15022,,10116.0,1,Intermediate,1,CHEMBL622459,,
7982,N,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,,Rattus norvegicus,A,,BAO_0000218,15022,,10116.0,1,Intermediate,1,CHEMBL873343,,
7983,N,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,,Rattus norvegicus,A,,BAO_0000218,15022,,10116.0,1,Intermediate,1,CHEMBL622460,,
7984,N,Time for maximum plasma concentration determined in rat,,Rattus norvegicus,A,,BAO_0000218,4576,,10116.0,1,Intermediate,1,CHEMBL622461,,1969.0
7985,N,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,6681,In vivo,10116.0,1,Intermediate,1,CHEMBL622462,,1969.0
7986,N,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,,Rattus norvegicus,A,,BAO_0000218,16365,In vivo,10116.0,1,Intermediate,1,CHEMBL622463,,
7987,N,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,,Rattus norvegicus,A,,BAO_0000218,16365,In vivo,10116.0,1,Intermediate,1,CHEMBL622464,,
7988,N,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,,Rattus norvegicus,A,,BAO_0000218,16365,In vivo,10116.0,1,Intermediate,1,CHEMBL622465,,
7989,N,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,,Rattus norvegicus,A,,BAO_0000218,16365,In vivo,10116.0,1,Intermediate,1,CHEMBL622466,,
7990,N,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,,Rattus norvegicus,A,,BAO_0000218,16365,In vivo,10116.0,1,Intermediate,1,CHEMBL622467,,
7991,N,Time of maximum plasma concentration in rat,,Rattus norvegicus,A,,BAO_0000218,6824,,10116.0,1,Intermediate,1,CHEMBL622468,,1969.0
7992,N,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,6685,,10116.0,1,Intermediate,1,CHEMBL876025,,1969.0
7993,N,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,Rattus norvegicus,A,,BAO_0000218,6685,,10116.0,1,Intermediate,1,CHEMBL622469,,1969.0
7994,N,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,Rattus norvegicus,A,,BAO_0000218,6685,,10116.0,1,Intermediate,1,CHEMBL622470,,1969.0
7995,N,Time required to reach maximum concentration (Cmax) after oral administration in rat,,Rattus norvegicus,A,,BAO_0000218,15662,In vivo,10116.0,1,Intermediate,1,CHEMBL622471,,
7996,N,Time required to reach maximum concentration in rat plasma,,Rattus norvegicus,A,,BAO_0000218,1742,,10116.0,1,Intermediate,1,CHEMBL622472,,1969.0
7997,N,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,Rattus norvegicus,A,,BAO_0000218,2774,In vivo,10116.0,1,Intermediate,1,CHEMBL622473,,1969.0
7998,N,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,5199,In vivo,10116.0,1,Intermediate,1,CHEMBL624282,,1969.0
7999,N,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,12873,In vivo,10116.0,1,Intermediate,1,CHEMBL624283,,1969.0
8000,N,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,12873,In vivo,10116.0,1,Intermediate,1,CHEMBL624284,,1969.0
8001,N,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,Rattus norvegicus,A,,BAO_0000218,1916,In vivo,10116.0,1,Intermediate,1,CHEMBL624285,,1969.0
8002,N,Time to reach Cmax after oral administration to rats,,Rattus norvegicus,A,,BAO_0000218,16367,In vivo,10116.0,1,Intermediate,1,CHEMBL624286,,
8003,N,Time to reach Cmax when a dose of 1 mg/kg is administered orally,,Rattus norvegicus,A,,BAO_0000218,16366,In vivo,10116.0,1,Intermediate,1,CHEMBL624287,,
8004,N,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,,Rattus norvegicus,A,,BAO_0000218,216,,10116.0,1,Intermediate,1,CHEMBL624288,,
8005,N,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,,Rattus norvegicus,A,,BAO_0000218,6410,In vivo,10116.0,1,Intermediate,1,CHEMBL624289,,1969.0
8006,N,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6410,In vivo,10116.0,1,Intermediate,1,CHEMBL873344,,1969.0
8007,N,Tmax after peroral administration (10 mg/kg) was determined in rat,,Rattus norvegicus,A,,BAO_0000218,6215,In vivo,10116.0,1,Intermediate,1,CHEMBL619623,,
8008,N,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,3598,In vivo,10116.0,1,Expert,1,CHEMBL621399,,
8009,N,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,,Rattus norvegicus,A,,BAO_0000218,4527,In vivo,10116.0,1,Intermediate,1,CHEMBL621400,,
8010,N,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",,Rattus norvegicus,A,,BAO_0000218,17670,In vivo,10116.0,1,Intermediate,1,CHEMBL621401,,
8011,N,Tmax was determined,,Rattus norvegicus,A,,BAO_0000218,1465,,10116.0,1,Intermediate,1,CHEMBL621402,,
8012,N,Tmax was determined,,Rattus norvegicus,A,,BAO_0000218,2552,,10116.0,1,Intermediate,1,CHEMBL621403,,
8013,N,Tmax after oral administration in rat,,Rattus norvegicus,A,,BAO_0000218,5656,In vivo,10116.0,1,Intermediate,1,CHEMBL621121,,
8014,N,Tmax after peroral administration in rats at 2.4 uM/kg,,Rattus norvegicus,A,,BAO_0000218,17764,In vivo,10116.0,1,Intermediate,1,CHEMBL872525,,
8015,N,Tmax in male rat,,Rattus norvegicus,A,,BAO_0000218,5610,,10116.0,1,Intermediate,1,CHEMBL621122,,
8016,N,Tmax in rat at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6046,In vivo,10116.0,1,Intermediate,1,CHEMBL621123,,
8017,N,Tmax in rat by po administration at a dose of 40 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5874,In vivo,10116.0,1,Intermediate,1,CHEMBL621124,,
8018,N,Tmax in rats,,Rattus norvegicus,A,,BAO_0000218,17596,,10116.0,1,Intermediate,1,CHEMBL621125,,
8019,N,Tmax was measured in rats after peroral administration at 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17804,In vivo,10116.0,1,Intermediate,1,CHEMBL621126,,
8020,N,Tmax value after oral dose at a dose of 10 mg/kg in rats.,,Rattus norvegicus,A,,BAO_0000218,1908,In vivo,10116.0,1,Intermediate,1,CHEMBL621127,,
8021,N,Tmax value after administration of 20 mg/Kg oral dose in rat,,Rattus norvegicus,A,,BAO_0000218,2959,In vivo,10116.0,1,Intermediate,1,CHEMBL621128,,
8022,N,Tmax value at a dose of 10 mg/kg in male SD rats,,Rattus norvegicus,A,,BAO_0000218,6757,In vivo,10116.0,1,Intermediate,1,CHEMBL618263,,
8023,N,Tmax value at a dose of 100 mg/kg in male SD rats,,Rattus norvegicus,A,,BAO_0000218,6757,In vivo,10116.0,1,Intermediate,1,CHEMBL618264,,
8024,N,Tmax value at a dose of 50 mg/kg in male SD rats,,Rattus norvegicus,A,,BAO_0000218,6757,In vivo,10116.0,1,Intermediate,1,CHEMBL618265,,
8025,N,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,Rattus norvegicus,A,,BAO_0000218,4186,In vivo,10116.0,1,Intermediate,1,CHEMBL618266,,1969.0
8026,N,time required to reach maximum concentration (Cmax) after oral administration in rat,,Rattus norvegicus,A,,BAO_0000218,15662,In vivo,10116.0,1,Intermediate,1,CHEMBL618267,,
8027,N,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),,Rattus norvegicus,A,,BAO_0000218,429,,10116.0,1,Intermediate,1,CHEMBL618450,,1088.0
8028,N,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),,Rattus norvegicus,A,,BAO_0000218,429,,10116.0,1,Intermediate,1,CHEMBL618451,,1088.0
8029,N,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,Rattus norvegicus,A,,BAO_0000218,5546,,10116.0,1,Intermediate,1,CHEMBL618452,,
8030,N,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,,Rattus norvegicus,A,,BAO_0000218,3173,,10116.0,1,Intermediate,1,CHEMBL618453,,1088.0
8031,N,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,,Rattus norvegicus,A,,BAO_0000218,3173,,10116.0,1,Intermediate,1,CHEMBL618454,,1088.0
8032,N,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,,Rattus norvegicus,A,,BAO_0000218,3173,,10116.0,1,Intermediate,1,CHEMBL618455,,1088.0
8033,N,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,,Rattus norvegicus,A,,BAO_0000218,4257,In vivo,10116.0,1,Intermediate,1,CHEMBL618456,,
8034,N,Compound distribution in rat tissues was determined,,Rattus norvegicus,A,,BAO_0000218,6011,In vivo,10116.0,1,Intermediate,1,CHEMBL618457,,
8035,N,Volume of distribution was evaluated in rat,,Rattus norvegicus,A,,BAO_0000218,5472,In vivo,10116.0,1,Intermediate,1,CHEMBL618458,,
8036,N,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,,Rattus norvegicus,A,,BAO_0000218,14346,,10116.0,1,Intermediate,1,CHEMBL618459,,
8037,N,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,,Rattus norvegicus,A,,BAO_0000218,14346,,10116.0,1,Intermediate,1,CHEMBL876733,,
8038,N,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,,Canis lupus familiaris,A,,BAO_0000218,14346,,9615.0,1,Intermediate,1,CHEMBL618460,,
8039,N,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,,Rattus norvegicus,A,,BAO_0000218,14346,,10116.0,1,Intermediate,1,CHEMBL618461,,
8040,U,Area under the curve was determined after oral administration (300 uM/Kg),,,A,,BAO_0000019,15469,,,0,Autocuration,1,CHEMBL618462,,
8041,N,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,,Rattus norvegicus,A,,BAO_0000218,14346,,10116.0,1,Intermediate,1,CHEMBL618463,,
8042,N,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,,Rattus norvegicus,A,,BAO_0000218,14346,,10116.0,1,Intermediate,1,CHEMBL618464,,
8043,N,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,,Rattus norvegicus,A,,BAO_0000218,14346,,10116.0,1,Intermediate,1,CHEMBL618465,,
8044,N,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,,Rattus norvegicus,A,,BAO_0000218,14346,,10116.0,1,Intermediate,1,CHEMBL618466,,
8045,N,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,,Rattus norvegicus,A,,BAO_0000218,14346,,10116.0,1,Intermediate,1,CHEMBL618467,,
8046,N,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,15372,,10116.0,1,Intermediate,1,CHEMBL618468,,
8047,N,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,,Canis lupus familiaris,A,,BAO_0000218,12935,,9615.0,1,Intermediate,1,CHEMBL618469,,1969.0
8048,N,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,,Canis lupus familiaris,A,,BAO_0000218,12935,,9615.0,1,Intermediate,1,CHEMBL618470,,1969.0
8049,U,Plasma drug AUC in rat (PO dose),,,A,,BAO_0000218,14813,,,0,Autocuration,1,CHEMBL618471,,
8050,N,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,,Mus musculus,A,,BAO_0000218,15792,,10090.0,1,Intermediate,1,CHEMBL618472,,
8051,U,Area under was determined at a dose of 30 mg/kg,,,A,,BAO_0000218,3579,,,0,Autocuration,1,CHEMBL618473,,
8052,N,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,,Mustela putorius furo,A,,BAO_0000218,12487,,9669.0,1,Intermediate,1,CHEMBL621699,,
8053,N,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,,Rattus norvegicus,A,,BAO_0000218,12487,,10116.0,1,Intermediate,1,CHEMBL621700,,
8054,N,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,,Rattus norvegicus,A,,BAO_0000218,12487,,10116.0,1,Intermediate,1,CHEMBL621701,,
8055,N,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,,Mustela putorius furo,A,,BAO_0000218,12487,,9669.0,1,Intermediate,1,CHEMBL621702,,
8056,N,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,,Canis lupus familiaris,A,,BAO_0000218,12487,,9615.0,1,Intermediate,1,CHEMBL621703,,
8057,N,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,,Canis lupus familiaris,A,,BAO_0000218,12487,,9615.0,1,Intermediate,1,CHEMBL621704,,
8058,N,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",,Rattus norvegicus,A,,BAO_0000218,12902,,10116.0,1,Intermediate,1,CHEMBL624259,,
8059,N,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",,Rattus norvegicus,A,,BAO_0000218,12902,,10116.0,1,Intermediate,1,CHEMBL624260,,
8060,N,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",,Rattus norvegicus,A,,BAO_0000218,12902,,10116.0,1,Intermediate,1,CHEMBL624430,,
8061,N,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",,Rattus norvegicus,A,,BAO_0000218,12902,,10116.0,1,Intermediate,1,CHEMBL624431,,
8062,N,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",,Rattus norvegicus,A,,BAO_0000218,12902,,10116.0,1,Intermediate,1,CHEMBL624432,,
8063,N,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",,Rattus norvegicus,A,,BAO_0000218,12902,,10116.0,1,Intermediate,1,CHEMBL624433,,
8064,N,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",,Rattus norvegicus,A,,BAO_0000218,12902,,10116.0,1,Intermediate,1,CHEMBL624434,,
8065,N,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",,Rattus norvegicus,A,,BAO_0000218,12902,,10116.0,1,Intermediate,1,CHEMBL624435,,
8066,N,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,,Mus musculus,A,,BAO_0000218,12745,,10090.0,1,Intermediate,1,CHEMBL618570,,
8067,N,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,Mus musculus,A,,BAO_0000218,12745,,10090.0,1,Intermediate,1,CHEMBL618571,,
8068,N,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,,Mus musculus,A,,BAO_0000218,12745,,10090.0,1,Intermediate,1,CHEMBL618572,,
8069,N,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,Mus musculus,A,,BAO_0000218,12745,,10090.0,1,Intermediate,1,CHEMBL618573,,
8070,N,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,,Mus musculus,A,,BAO_0000218,12745,,10090.0,1,Intermediate,1,CHEMBL619267,,
8071,N,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,Mus musculus,A,,BAO_0000218,12745,,10090.0,1,Intermediate,1,CHEMBL619431,,
8072,N,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,,Mus musculus,A,,BAO_0000218,12745,,10090.0,1,Intermediate,1,CHEMBL619432,,
8073,N,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,Mus musculus,A,,BAO_0000218,12745,,10090.0,1,Intermediate,1,CHEMBL619433,,
8074,U,AUC in mice after oral dose (50 mg/kg),,,A,,BAO_0000218,13298,,,0,Autocuration,1,CHEMBL619434,,1969.0
8075,N,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,,Mus musculus,A,,BAO_0000218,12226,,10090.0,1,Intermediate,1,CHEMBL619435,,1977.0
8076,U,AUC (0-4 hr) ug/ml/h,,,A,,BAO_0000019,12634,,,0,Autocuration,1,CHEMBL619436,,1969.0
8077,N,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,,Rattus norvegicus,A,,BAO_0000218,14810,,10116.0,1,Intermediate,1,CHEMBL619437,,
8078,U,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,,,A,,BAO_0000218,13889,,,0,Autocuration,1,CHEMBL619438,,
8079,N,Compound was evaluated for Area under curve in mice,,Mus musculus,A,,BAO_0000218,10018,,10090.0,1,Intermediate,1,CHEMBL619439,,
8080,N,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,Rattus norvegicus,A,,BAO_0000218,8758,,10116.0,1,Intermediate,1,CHEMBL619440,,
8081,U,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,,F,,BAO_0000218,8758,,,0,Autocuration,1,CHEMBL619441,,
8082,N,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,Rattus norvegicus,A,,BAO_0000218,8758,,10116.0,1,Intermediate,1,CHEMBL619442,,
8083,U,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,,,A,,BAO_0000019,2249,,,0,Autocuration,1,CHEMBL875156,,
8084,U,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,,,A,,BAO_0000019,2249,,,0,Autocuration,1,CHEMBL619443,,
8085,U,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,,,A,,BAO_0000019,2249,,,0,Autocuration,1,CHEMBL619444,,
8086,U,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,,,A,,BAO_0000019,2249,,,0,Autocuration,1,CHEMBL623464,,
8087,N,Compound was evaluated for area under curve when administered through oral route in mouse,,Mus musculus,A,,BAO_0000218,15115,,10090.0,1,Intermediate,1,CHEMBL623465,,
8088,N,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,,Rattus norvegicus,A,,BAO_0000218,6518,In vivo,10116.0,1,Intermediate,1,CHEMBL623466,,
8089,N,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,,Rattus norvegicus,A,,BAO_0000218,6518,In vivo,10116.0,1,Intermediate,1,CHEMBL623467,,
8090,N,Plasma clearance in rat,,Rattus norvegicus,A,,BAO_0000218,6249,In vivo,10116.0,1,Intermediate,1,CHEMBL623468,,
8091,N,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,Rattus norvegicus,A,,BAO_0000218,2463,In vivo,10116.0,1,Intermediate,1,CHEMBL622660,,
8092,N,Plasma clearance rate in Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,4969,In vivo,10116.0,1,Intermediate,1,CHEMBL622661,,
8093,N,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,,Rattus norvegicus,F,,BAO_0000218,17720,In vivo,10116.0,1,Intermediate,1,CHEMBL622662,,
8094,N,Pharmacokinetic property (total body clearance) in rat,,Rattus norvegicus,A,,BAO_0000218,3457,In vivo,10116.0,1,Intermediate,1,CHEMBL622663,,
8095,N,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,,Rattus norvegicus,A,,BAO_0000218,5983,In vivo,10116.0,1,Intermediate,1,CHEMBL622664,,
8096,N,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6295,,10116.0,1,Intermediate,1,CHEMBL622665,,
8097,N,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6296,,10116.0,1,Intermediate,1,CHEMBL622666,,
8098,N,Cl in rat i.v. at 2 mg/kg concentration,,Rattus norvegicus,A,,BAO_0000218,17686,In vivo,10116.0,1,Intermediate,1,CHEMBL621615,,
8099,N,Clearance of compound after intravenous administration in rats at 24 uM/kg,,Rattus norvegicus,A,,BAO_0000218,17764,In vivo,10116.0,1,Intermediate,1,CHEMBL621616,,
8100,N,Clearance was determined,,Rattus norvegicus,A,,BAO_0000218,5503,In vivo,10116.0,1,Intermediate,1,CHEMBL621617,,
8101,N,Clearance by intravenous administration of 3.4 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,4368,In vivo,10116.0,1,Intermediate,1,CHEMBL621618,,
8102,N,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6005,In vivo,10116.0,1,Intermediate,1,CHEMBL621619,,
8103,N,Clearance rate after i.v. administration in rats,,Rattus norvegicus,A,,BAO_0000218,5031,In vivo,10116.0,1,Intermediate,1,CHEMBL621620,,
8104,N,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,4890,In vivo,10116.0,1,Intermediate,1,CHEMBL621786,,
8105,N,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,Rattus norvegicus,A,,BAO_0000218,5182,In vivo,10116.0,1,Intermediate,1,CHEMBL621787,,
8106,N,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,,Rattus norvegicus,A,,BAO_0000218,5979,In vivo,10116.0,1,Intermediate,1,CHEMBL621788,,
8107,N,Clearance (Cl) after oral administration in rat,,Rattus norvegicus,A,,BAO_0000218,5656,In vivo,10116.0,1,Intermediate,1,CHEMBL621789,,
8108,N,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17804,In vivo,10116.0,1,Intermediate,1,CHEMBL621790,,
8109,N,Compound was tested for plasma clearance in rat,,Rattus norvegicus,A,,BAO_0000218,4839,In vivo,10116.0,1,Intermediate,1,CHEMBL621791,,1969.0
8110,N,In vitro microsome metabolism clearance in rat was determined,,Rattus norvegicus,A,,BAO_0000218,5041,In vitro,10116.0,1,Intermediate,1,CHEMBL621792,,
8111,N,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,,Rattus norvegicus,A,,BAO_0000218,5041,In vitro,10116.0,1,Intermediate,1,CHEMBL621793,,
8112,N,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL621794,,
8113,N,In vivo plasma clearance was determined,,Rattus norvegicus,A,,BAO_0000218,5496,In vivo,10116.0,1,Intermediate,1,CHEMBL621795,,1969.0
8114,N,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,,Rattus norvegicus,A,,BAO_0000218,5739,In vivo,10116.0,1,Intermediate,1,CHEMBL621796,,
8115,N,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,,Rattus norvegicus,A,,BAO_0000218,5676,In vivo,10116.0,1,Intermediate,1,CHEMBL621797,401.0,2107.0
8116,N,Pharmacokinetic property (Plasma clearance) was measured in rat,,Rattus norvegicus,A,,BAO_0000218,4239,In vivo,10116.0,1,Intermediate,1,CHEMBL621798,,
8117,N,Pharmacokinetic property (clearance) in rat i.v.,,Rattus norvegicus,A,,BAO_0000218,5676,In vivo,10116.0,1,Intermediate,1,CHEMBL621799,,
8118,N,"Plasma Clearance was evaluated in rats, iv",,Rattus norvegicus,A,,BAO_0000218,1918,In vivo,10116.0,1,Intermediate,1,CHEMBL621800,,
8119,N,Plasma clearance (in vivo) in rats was determined,,Rattus norvegicus,A,,BAO_0000218,17800,In vivo,10116.0,1,Intermediate,1,CHEMBL621801,,
8120,N,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,6056,In vivo,10116.0,1,Intermediate,1,CHEMBL621802,,
8121,N,Plasma clearance was determined,,Rattus norvegicus,A,,BAO_0000218,5496,In vivo,10116.0,1,Intermediate,1,CHEMBL618596,,
8122,N,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,,Rattus norvegicus,A,,BAO_0000218,5939,In vivo,10116.0,1,Intermediate,1,CHEMBL618597,,
8123,N,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,,Rattus norvegicus,A,,BAO_0000218,5939,In vivo,10116.0,1,Intermediate,1,CHEMBL618598,,
8124,N,Plasma clearance in rats,,Rattus norvegicus,A,,BAO_0000218,17752,In vivo,10116.0,1,Intermediate,1,CHEMBL618599,,
8125,N,Plasma clearance rate determined in rat,,Rattus norvegicus,A,,BAO_0000218,4576,In vivo,10116.0,1,Intermediate,1,CHEMBL618600,,
8126,N,Plasma clearance was determined in rat,,Rattus norvegicus,A,,BAO_0000218,6011,In vivo,10116.0,1,Intermediate,1,CHEMBL618601,,
8127,N,Plasma clearance was determined,,Rattus norvegicus,A,,BAO_0000218,5510,In vivo,10116.0,1,Intermediate,1,CHEMBL618602,,
8128,N,Plasma clearance value in rat,,Rattus norvegicus,A,,BAO_0000218,5948,In vivo,10116.0,1,Intermediate,1,CHEMBL618603,,
8129,N,Clearance rate constant using isolated perfused rat liver (IPRL) assay,,Rattus norvegicus,A,,BAO_0000218,6125,Ex vivo,10116.0,1,Intermediate,1,CHEMBL618604,,2107.0
8130,N,Clearance in rat,,Rattus norvegicus,A,,BAO_0000218,4839,In vivo,10116.0,1,Intermediate,1,CHEMBL618605,,
8131,N,Total body clearance in rat i.v. at 2 mg/kg concentration,,Rattus norvegicus,A,,BAO_0000218,17686,In vivo,10116.0,1,Intermediate,1,CHEMBL618606,,
8132,N,Clearance of compound in rats after intravenous administration,,Rattus norvegicus,A,,BAO_0000218,6571,In vivo,10116.0,1,Intermediate,1,CHEMBL618607,,
8133,N,Clearance after iv administration to rats,,Rattus norvegicus,A,,BAO_0000218,3364,In vivo,10116.0,1,Intermediate,1,CHEMBL618608,,
8134,N,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,13569,In vivo,10116.0,1,Intermediate,1,CHEMBL618609,,
8135,N,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,13569,In vivo,10116.0,1,Intermediate,1,CHEMBL618610,,
8136,N,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,13569,In vivo,10116.0,1,Intermediate,1,CHEMBL618611,,
8137,N,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,13569,In vivo,10116.0,1,Intermediate,1,CHEMBL618612,,
8138,N,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,13569,In vivo,10116.0,1,Intermediate,1,CHEMBL618613,,
8139,N,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,13569,In vivo,10116.0,1,Intermediate,1,CHEMBL621076,,
8140,N,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,13569,In vivo,10116.0,1,Intermediate,1,CHEMBL621077,,
8141,N,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",,Rattus norvegicus,A,,BAO_0000218,17670,In vivo,10116.0,1,Intermediate,1,CHEMBL621078,,
8142,N,Clearance in rat,,Rattus norvegicus,A,,BAO_0000218,5970,In vivo,10116.0,1,Intermediate,1,CHEMBL621251,,
8143,N,Clearance in rat after oral administration at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6495,In vivo,10116.0,1,Intermediate,1,CHEMBL621252,,
8144,N,Clearance in rat.,,Rattus norvegicus,A,,BAO_0000218,4590,In vivo,10116.0,1,Intermediate,1,CHEMBL621253,,
8145,N,Clearance rate following an oral dose of 20 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,6193,In vivo,10116.0,1,Intermediate,1,CHEMBL621254,,
8146,N,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,,Rattus norvegicus,A,,BAO_0000218,2832,In vivo,10116.0,1,Intermediate,1,CHEMBL621255,,
8147,N,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,,Rattus norvegicus,A,,BAO_0000218,1052,In vivo,10116.0,1,Intermediate,1,CHEMBL621256,,1969.0
8148,N,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621257,,2107.0
8149,N,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621258,,2107.0
8150,N,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621259,,2107.0
8151,N,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621260,,2107.0
8152,N,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL876494,,2107.0
8153,N,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621261,,2107.0
8154,N,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621262,,2107.0
8155,N,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621263,,2107.0
8156,N,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621264,,2107.0
8157,N,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621265,,2385.0
8158,N,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621266,,2385.0
8159,N,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621267,,2385.0
8160,N,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621268,,2385.0
8161,N,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621269,,2385.0
8162,N,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621270,,2385.0
8163,N,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621271,,2385.0
8164,N,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621272,,2385.0
8165,N,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621273,,2385.0
8166,N,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621274,,2385.0
8167,N,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL876495,,2385.0
8168,N,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621275,,2385.0
8169,N,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621276,,2385.0
8170,N,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621277,,2385.0
8171,N,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621278,,160.0
8172,N,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621279,,160.0
8173,N,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621280,,160.0
8174,N,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621281,,2106.0
8175,N,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621282,,2106.0
8176,N,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621283,,2106.0
8177,N,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621284,,2106.0
8178,N,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621285,,2106.0
8179,N,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621286,,2106.0
8180,N,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL623220,,2106.0
8181,N,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL623221,,2106.0
8182,N,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL876029,,2106.0
8183,N,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL623222,,945.0
8184,N,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL623223,,945.0
8185,N,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,,Rattus norvegicus,A,,BAO_0000218,9866,In vivo,10116.0,1,Intermediate,1,CHEMBL621445,,945.0
8186,N,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL621446,,178.0
8187,N,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL621447,,178.0
8188,N,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL619681,,178.0
8189,N,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL619682,,178.0
8190,N,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL619683,,178.0
8191,N,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL619684,,955.0
8192,N,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL619685,,955.0
8193,N,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL619686,,955.0
8194,N,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL619687,,955.0
8195,N,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL619688,,955.0
8196,N,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL619689,,948.0
8197,N,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL619690,,948.0
8198,N,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL619691,,948.0
8199,N,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6062,In vivo,10116.0,1,Intermediate,1,CHEMBL619692,,
8200,N,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,3598,,10116.0,1,Expert,1,CHEMBL619693,,
8201,N,Vc value after IV dose at a dose of 5 mg/kg in rats.,,Rattus norvegicus,A,,BAO_0000218,1908,In vivo,10116.0,1,Intermediate,1,CHEMBL619694,,
8202,N,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,,Rattus norvegicus,A,,BAO_0000218,17596,In vivo,10116.0,1,Intermediate,1,CHEMBL619695,,
8203,N,Compound was evaluated for pharmacokinetic parameter volume of distribution,,Rattus norvegicus,A,,BAO_0000218,4891,In vivo,10116.0,1,Intermediate,1,CHEMBL619696,,
8204,N,Compound was evaluated for volume of distribution in rat,,Rattus norvegicus,A,,BAO_0000218,740,In vivo,10116.0,1,Intermediate,1,CHEMBL619697,,
8205,N,Steady state volume distribution was determined; steady state(ss),,Rattus norvegicus,A,,BAO_0000218,16366,In vivo,10116.0,1,Intermediate,1,CHEMBL619698,,
8206,N,Steady state volume of distribution after iv administration to rats,,Rattus norvegicus,A,,BAO_0000218,3364,In vivo,10116.0,1,Intermediate,1,CHEMBL619699,,
8207,N,Steady state volume of distribution dosing at 3 mg/kg iv,,Rattus norvegicus,A,,BAO_0000218,2552,In vivo,10116.0,1,Intermediate,1,CHEMBL619700,,
8208,N,The compound was evaluated for volume of distribution in rat,,Rattus norvegicus,A,,BAO_0000218,406,In vivo,10116.0,1,Intermediate,1,CHEMBL619701,,
8209,N,The compound was tested for volume of distribution in rat,,Rattus norvegicus,A,,BAO_0000218,12500,In vivo,10116.0,1,Intermediate,1,CHEMBL619702,,
8210,N,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,,Rattus norvegicus,A,,BAO_0000218,12500,In vivo,10116.0,1,Intermediate,1,CHEMBL620335,,
8211,N,Volume distribution (VD) after oral administration in rat,,Rattus norvegicus,A,,BAO_0000218,5656,In vivo,10116.0,1,Intermediate,1,CHEMBL620336,,
8212,N,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17671,In vivo,10116.0,1,Intermediate,1,CHEMBL620337,,
8213,N,Volume distribution in rat,,Rattus norvegicus,A,,BAO_0000218,1094,In vivo,10116.0,1,Intermediate,1,CHEMBL620520,,
8214,N,Volume distribution in rat,,Rattus norvegicus,A,,BAO_0000218,5833,In vivo,10116.0,1,Intermediate,1,CHEMBL620521,,
8215,N,Volume distribution in rat after peroral administration at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5939,In vivo,10116.0,1,Intermediate,1,CHEMBL875825,,
8216,N,Volume distribution in rat after peroral administration at 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5939,In vivo,10116.0,1,Intermediate,1,CHEMBL620522,,
8217,N,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6005,In vivo,10116.0,1,Intermediate,1,CHEMBL620523,,
8218,N,Volume of distribution in rat.,,Rattus norvegicus,A,,BAO_0000218,1696,In vivo,10116.0,1,Intermediate,1,CHEMBL620524,,
8219,N,Volume of distribution in rat,,Rattus norvegicus,A,,BAO_0000218,6672,In vivo,10116.0,1,Intermediate,1,CHEMBL620525,,
8220,N,Volume of distribution in rat,,Rattus norvegicus,A,,BAO_0000218,6673,In vivo,10116.0,1,Intermediate,1,CHEMBL620526,,
8221,N,Volume of distribution in rat by iv administration,,Rattus norvegicus,A,,BAO_0000218,5871,In vivo,10116.0,1,Intermediate,1,CHEMBL620527,,
8222,N,Volume of distribution in rats,,Rattus norvegicus,A,,BAO_0000218,6803,In vivo,10116.0,1,Intermediate,1,CHEMBL620528,,
8223,N,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,Rattus norvegicus,A,,BAO_0000218,5199,In vivo,10116.0,1,Intermediate,1,CHEMBL620529,,
8224,N,Volume distribution at the dose of 2 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,4727,,10116.0,1,Intermediate,1,CHEMBL620530,,
8225,N,Steady state volume of distribution was determined,,Rattus norvegicus,A,,BAO_0000218,16367,In vivo,10116.0,1,Intermediate,1,CHEMBL620531,,
8226,U,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,Macaca mulatta,A,,BAO_0000218,5005,In vivo,9544.0,0,Intermediate,1,CHEMBL620532,,
8227,U,Compound was tested for its plasma volume distribution in Sprague Dawley rats,,Rattus norvegicus,A,,BAO_0000218,5005,In vivo,10116.0,0,Intermediate,1,CHEMBL620533,,
8228,U,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,,Rattus norvegicus,A,,BAO_0000218,5005,In vivo,10116.0,0,Intermediate,1,CHEMBL620534,,
8229,N,Mean (%CV) PK parameters for Vdss(mL/kg).,,Rattus norvegicus,A,,BAO_0000218,15765,In vivo,10116.0,1,Intermediate,1,CHEMBL620535,,
8230,N,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,,Rattus norvegicus,A,,BAO_0000218,2792,In vivo,10116.0,1,Intermediate,1,CHEMBL875826,,
8231,N,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,,Rattus norvegicus,A,,BAO_0000218,2792,In vivo,10116.0,1,Intermediate,1,CHEMBL620536,,
8232,N,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5334,In vivo,10116.0,1,Intermediate,1,CHEMBL620537,,
8233,N,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,,Rattus norvegicus,A,,BAO_0000218,5334,In vivo,10116.0,1,Intermediate,1,CHEMBL618526,,
8234,N,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,,Rattus norvegicus,A,,BAO_0000218,5739,In vivo,10116.0,1,Intermediate,1,CHEMBL618527,,
8235,N,Pharmacokinetic property (Vdss) in rat,,Rattus norvegicus,A,,BAO_0000218,5789,In vivo,10116.0,1,Intermediate,1,CHEMBL618528,,
8236,N,Pharmacokinetic property (vdss) was measured in rat,,Rattus norvegicus,A,,BAO_0000218,4239,In vivo,10116.0,1,Intermediate,1,CHEMBL618529,,
8237,N,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,4709,In vivo,10116.0,1,Intermediate,1,CHEMBL618530,,
8238,N,Volume of distribution in rat,,Rattus norvegicus,A,,BAO_0000218,6642,In vivo,10116.0,1,Intermediate,1,CHEMBL618531,,
8239,N,The pharmacokinetic parameter volume of distribution in vivo in rats,,Rattus norvegicus,A,,BAO_0000218,5247,In vivo,10116.0,1,Intermediate,1,CHEMBL618532,,
8240,N,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,,Rattus norvegicus,F,,BAO_0000218,17720,In vivo,10116.0,1,Intermediate,1,CHEMBL618533,,
8241,N,Vdss in rat i.v. at 2 mg/kg concentration,,Rattus norvegicus,A,,BAO_0000218,17686,In vivo,10116.0,1,Intermediate,1,CHEMBL618534,,
8242,N,Volume distribution after intravenous administration (1 mg/kg) in rat,,Rattus norvegicus,A,,BAO_0000218,4689,In vivo,10116.0,1,Intermediate,1,CHEMBL618535,,
8243,N,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,Rattus norvegicus,A,,BAO_0000218,5654,In vivo,10116.0,1,Intermediate,1,CHEMBL618536,,
8244,N,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,Rattus norvegicus,A,,BAO_0000218,5654,In vivo,10116.0,1,Intermediate,1,CHEMBL618537,,
8245,N,Volume distribution at a dose of 10 uM/kg in rat was determined,,Rattus norvegicus,A,,BAO_0000218,4527,In vivo,10116.0,1,Intermediate,1,CHEMBL618538,,
8246,N,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,Rattus norvegicus,A,,BAO_0000218,4521,In vivo,10116.0,1,Intermediate,1,CHEMBL618539,,
8247,N,Volume distribution was calculated in rat,,Rattus norvegicus,A,,BAO_0000218,6057,In vivo,10116.0,1,Intermediate,1,CHEMBL618540,,
8248,N,Volume distribution was determined,,Rattus norvegicus,A,,BAO_0000218,5510,In vivo,10116.0,1,Intermediate,1,CHEMBL618541,,
8249,N,Volume of distribution after intravenous administration was evaluated in rat,,Rattus norvegicus,A,,BAO_0000218,2938,In vivo,10116.0,1,Intermediate,1,CHEMBL618542,,
8250,N,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Rattus norvegicus,A,,BAO_0000218,6679,In vivo,10116.0,1,Intermediate,1,CHEMBL622544,,
8251,N,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",,Rattus norvegicus,A,,BAO_0000218,6685,In vivo,10116.0,1,Intermediate,1,CHEMBL622545,,
8252,N,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,Rattus norvegicus,A,,BAO_0000218,6685,In vivo,10116.0,1,Intermediate,1,CHEMBL622546,,
8253,N,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",,Rattus norvegicus,A,,BAO_0000218,6685,In vivo,10116.0,1,Intermediate,1,CHEMBL622547,,
8254,N,Volume of distribution in steady state was determined in rat,,Rattus norvegicus,A,,BAO_0000218,5145,In vivo,10116.0,1,Intermediate,1,CHEMBL622548,,
8255,N,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,,Rattus norvegicus,A,,BAO_0000218,6467,In vivo,10116.0,1,Intermediate,1,CHEMBL622549,,
8256,N,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,Rattus norvegicus,A,,BAO_0000218,6467,In vivo,10116.0,1,Intermediate,1,CHEMBL622550,,
8257,N,Compound was evaluated for area under curve when administered through oral route to mouse,,Mus musculus,A,,BAO_0000218,15115,,10090.0,1,Intermediate,1,CHEMBL622551,,
8258,N,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,Rattus norvegicus,A,,BAO_0000218,8758,,10116.0,1,Intermediate,1,CHEMBL622552,,
8259,N,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,Rattus norvegicus,A,,BAO_0000218,8758,,10116.0,1,Intermediate,1,CHEMBL622553,,
8260,U,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,,,F,,BAO_0000218,8267,In vivo,,0,Autocuration,1,CHEMBL622554,,
8261,N,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,,Canis lupus familiaris,A,,BAO_0000218,8267,,9615.0,1,Intermediate,1,CHEMBL622555,,
8262,N,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,Mus musculus,A,,BAO_0000218,14239,,10090.0,1,Intermediate,1,CHEMBL622556,,
8263,N,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,Mus musculus,A,,BAO_0000218,14239,,10090.0,1,Intermediate,1,CHEMBL622557,,
8264,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,,Mus musculus,A,,BAO_0000218,10754,,10090.0,1,Intermediate,1,CHEMBL622558,,178.0
8265,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,,Mus musculus,A,,BAO_0000218,10754,,10090.0,1,Intermediate,1,CHEMBL622559,,178.0
8266,N,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,,Canis lupus familiaris,A,,BAO_0000218,10754,,9615.0,1,Intermediate,1,CHEMBL622560,,
8267,N,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,,Rattus norvegicus,A,,BAO_0000218,14681,,10116.0,1,Intermediate,1,CHEMBL622561,,
8268,N,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,,Rattus norvegicus,A,,BAO_0000218,14681,,10116.0,1,Intermediate,1,CHEMBL622562,,
8269,N,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,Rattus norvegicus,A,,BAO_0000218,14681,,10116.0,1,Intermediate,1,CHEMBL622563,,
8270,U,Concentration of compound in Central nervous system,,,A,,BAO_0000019,13118,,,0,Autocuration,1,CHEMBL622564,,
8271,U,Concentration of compound in Central nervous system; Not detectable,,,A,,BAO_0000019,13118,,,0,Autocuration,1,CHEMBL622565,,
8272,N,"Concentration of diester in the blood, following oral administration in mice",,Mus musculus,A,,BAO_0000218,13318,,10090.0,1,Intermediate,1,CHEMBL622566,,
8273,N,"Concentration of monoester in the blood, following oral administration in mice",,Mus musculus,A,,BAO_0000218,13318,,10090.0,1,Intermediate,1,CHEMBL624515,,
8274,N,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,,Mus musculus,A,,BAO_0000218,13318,,10090.0,1,Intermediate,1,CHEMBL624516,,
8275,U,Evaluated for Pharmacokinetic property: Area under the curve,,,A,,BAO_0000019,15692,,,0,Autocuration,1,CHEMBL624517,,
8276,N,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,,Mus musculus,A,,BAO_0000218,14839,,10090.0,1,Intermediate,1,CHEMBL624518,,
8277,N,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,,Macaca fascicularis,A,,BAO_0000218,14839,,9541.0,1,Intermediate,1,CHEMBL624519,,
8278,N,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,,Macaca fascicularis,A,,BAO_0000218,14839,,9541.0,1,Intermediate,1,CHEMBL624520,,
8279,N,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,,Macaca fascicularis,A,,BAO_0000218,14839,,9541.0,1,Intermediate,1,CHEMBL624521,,
8280,N,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,,Macaca fascicularis,A,,BAO_0000218,14839,,9541.0,1,Intermediate,1,CHEMBL624522,,
8281,N,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,,Macaca fascicularis,A,,BAO_0000218,14839,,9541.0,1,Intermediate,1,CHEMBL624523,,
8282,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,Macaca fascicularis,A,,BAO_0000218,14839,,9541.0,1,Intermediate,1,CHEMBL624409,,
8283,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",,Macaca fascicularis,A,,BAO_0000218,14839,,9541.0,1,Intermediate,1,CHEMBL624410,,
8284,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,Macaca fascicularis,A,,BAO_0000218,14839,,9541.0,1,Intermediate,1,CHEMBL624411,,
8285,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",,Macaca fascicularis,A,,BAO_0000218,14839,,9541.0,1,Intermediate,1,CHEMBL623531,,
8286,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",,Macaca fascicularis,A,,BAO_0000218,14839,,9541.0,1,Intermediate,1,CHEMBL623532,,
8287,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",,Macaca fascicularis,A,,BAO_0000218,14839,,9541.0,1,Intermediate,1,CHEMBL623533,,
8288,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,Macaca fascicularis,A,,BAO_0000218,14839,,9541.0,1,Intermediate,1,CHEMBL623534,,
8289,N,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,,Mus musculus,A,,BAO_0000218,14839,,10090.0,1,Intermediate,1,CHEMBL623535,,
8290,N,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,,Mus musculus,A,,BAO_0000218,14839,,10090.0,1,Intermediate,1,CHEMBL623536,,
8291,N,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,,Mus musculus,A,,BAO_0000218,14839,,10090.0,1,Intermediate,1,CHEMBL623537,,
8292,N,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,,Mus musculus,A,,BAO_0000218,14839,,10090.0,1,Intermediate,1,CHEMBL623538,,
8293,N,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,,Mus musculus,A,,BAO_0000218,14839,,10090.0,1,Intermediate,1,CHEMBL623539,,
8294,N,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,,Mus musculus,A,,BAO_0000218,14839,,10090.0,1,Intermediate,1,CHEMBL623540,,
8295,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",,Mus musculus,A,,BAO_0000218,14839,,10090.0,1,Intermediate,1,CHEMBL623541,,
8296,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",,Mus musculus,A,,BAO_0000218,14839,,10090.0,1,Intermediate,1,CHEMBL623542,,
8297,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",,Mus musculus,A,,BAO_0000218,14839,,10090.0,1,Intermediate,1,CHEMBL623543,,
8298,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",,Mus musculus,A,,BAO_0000218,14839,,10090.0,1,Intermediate,1,CHEMBL623544,,
8299,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",,Mus musculus,A,,BAO_0000218,14839,,10090.0,1,Intermediate,1,CHEMBL623545,,
8300,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",,Mus musculus,A,,BAO_0000218,14839,,10090.0,1,Intermediate,1,CHEMBL623546,,
8301,N,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,5408,In vivo,10116.0,1,Intermediate,1,CHEMBL623547,,1969.0
8302,N,High i.v. clearance in Dawley rats,,Rattus norvegicus,A,,BAO_0000218,6827,In vivo,10116.0,1,Intermediate,1,CHEMBL623548,,
8303,N,In vitro clearance in rat liver microsomes,,Rattus norvegicus,A,,BAO_0000218,17538,In vitro,10116.0,1,Intermediate,1,CHEMBL623549,,2107.0
8304,N,Intrinsic clearance in rat liver microsomes was determined,,Rattus norvegicus,A,,BAO_0000218,6331,In vitro,10116.0,1,Intermediate,1,CHEMBL623550,,2107.0
8305,N,Intrinsic clearance in rat hepatocytes was determined,,Rattus norvegicus,A,,BAO_0000218,5948,In vitro,10116.0,1,Intermediate,1,CHEMBL875276,401.0,2107.0
8306,N,Plasma Clearance was determined,,Rattus norvegicus,A,,BAO_0000218,4026,In vivo,10116.0,1,Intermediate,1,CHEMBL621872,,
8307,N,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,,Rattus norvegicus,A,,BAO_0000218,6647,In vivo,10116.0,1,Intermediate,1,CHEMBL621873,,
8308,N,Plasma clearance in rat.,,Rattus norvegicus,A,,BAO_0000218,1696,In vivo,10116.0,1,Intermediate,1,CHEMBL621874,,
8309,N,Plasma clearance in rats,,Rattus norvegicus,A,,BAO_0000218,6597,In vivo,10116.0,1,Intermediate,1,CHEMBL621875,,
8310,N,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,,Rattus norvegicus,A,,BAO_0000218,347,In vivo,10116.0,1,Intermediate,1,CHEMBL621876,,
8311,N,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,,Rattus norvegicus,A,,BAO_0000218,16423,In vivo,10116.0,1,Intermediate,1,CHEMBL621877,,
8312,N,Plasma clearance was measured in rat,,Rattus norvegicus,A,,BAO_0000218,2879,In vivo,10116.0,1,Intermediate,1,CHEMBL621878,,
8313,N,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,Rattus norvegicus,A,,BAO_0000218,4883,In vivo,10116.0,1,Intermediate,1,CHEMBL621879,,
8314,N,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",,Rattus norvegicus,A,,BAO_0000218,5328,In vivo,10116.0,1,Intermediate,1,CHEMBL621880,,1969.0
8315,N,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5160,In vivo,10116.0,1,Intermediate,1,CHEMBL621881,,
8316,N,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,Rattus norvegicus,A,,BAO_0000218,17582,In vivo,10116.0,1,Intermediate,1,CHEMBL621882,,
8317,N,Total clearance at 1 mg/kg was determined in rat,,Rattus norvegicus,A,,BAO_0000218,17651,In vivo,10116.0,1,Intermediate,1,CHEMBL875283,,
8318,N,Total clearance at 10 mg/kg was determined in rat,,Rattus norvegicus,A,,BAO_0000218,17651,In vivo,10116.0,1,Intermediate,1,CHEMBL621883,,
8319,N,Clearance in rat,,Rattus norvegicus,A,,BAO_0000218,6596,In vivo,10116.0,1,Intermediate,1,CHEMBL621884,,
8320,N,Plasma clearance rate determined in rats,,Rattus norvegicus,A,,BAO_0000218,4796,In vivo,10116.0,1,Intermediate,1,CHEMBL621885,,
8321,N,Clearance of compound in rat was evaluated,,Rattus norvegicus,A,,BAO_0000218,6850,In vivo,10116.0,1,Intermediate,1,CHEMBL621886,,
8322,N,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,,Rattus norvegicus,A,,BAO_0000218,5932,In vivo,10116.0,1,Intermediate,1,CHEMBL621887,,1969.0
8323,N,Pharmacokinetic property (blood clearance) in rat,,Rattus norvegicus,A,,BAO_0000218,3371,In vivo,10116.0,1,Intermediate,1,CHEMBL621888,,
8324,N,Plasma clearance in rat,,Rattus norvegicus,A,,BAO_0000218,2083,In vivo,10116.0,1,Intermediate,1,CHEMBL621889,,
8325,N,Plasma clearance in rats,,Rattus norvegicus,A,,BAO_0000218,4942,In vivo,10116.0,1,Intermediate,1,CHEMBL621890,,
8326,N,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,,Rattus norvegicus,A,,BAO_0000218,6838,In vitro,10116.0,1,Intermediate,1,CHEMBL621891,,2107.0
8327,N,Clearance in Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5353,In vivo,10116.0,1,Intermediate,1,CHEMBL621892,,
8328,N,Clearance rat,,Rattus norvegicus,A,,BAO_0000218,6641,In vivo,10116.0,1,Intermediate,1,CHEMBL621893,,
8329,N,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),,Rattus norvegicus,A,,BAO_0000218,6641,In vivo,10116.0,1,Intermediate,1,CHEMBL621894,,
8330,N,Clearance rat; Not determined,,Rattus norvegicus,A,,BAO_0000218,6641,In vivo,10116.0,1,Intermediate,1,CHEMBL621895,,
8331,N,Clearance rate was determined in rat at a dose of 1 mpk i.v.,,Rattus norvegicus,A,,BAO_0000218,6444,In vivo,10116.0,1,Intermediate,1,CHEMBL875284,,
8332,N,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,Rattus norvegicus,A,,BAO_0000218,6444,In vivo,10116.0,1,Intermediate,1,CHEMBL618699,,
8333,N,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,Rattus norvegicus,A,,BAO_0000218,6444,In vivo,10116.0,1,Intermediate,1,CHEMBL618700,,
8334,N,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,6211,In vivo,10116.0,1,Intermediate,1,CHEMBL618701,,
8335,N,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,Rattus norvegicus,A,,BAO_0000218,12873,In vivo,10116.0,1,Intermediate,1,CHEMBL876600,,1969.0
8336,N,Clearance of compound in rat after 1 mg/kg i.v. administration,,Rattus norvegicus,A,,BAO_0000218,6570,In vivo,10116.0,1,Intermediate,1,CHEMBL618702,,
8337,N,Compound was evaluated for Hepatic clearance in rat,,Rattus norvegicus,A,,BAO_0000218,3341,In vivo,10116.0,1,Intermediate,1,CHEMBL618703,,
8338,N,In vivo clearance after 5 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,4891,In vivo,10116.0,1,Intermediate,1,CHEMBL618704,,
8339,N,Compound was tested for plasma clearance in rats,,Rattus norvegicus,A,,BAO_0000218,1094,In vivo,10116.0,1,Intermediate,1,CHEMBL618705,,1969.0
8340,N,Hepatic clearance after intravenous administration was evaluated in rat,,Rattus norvegicus,A,,BAO_0000218,2938,In vivo,10116.0,1,Intermediate,1,CHEMBL618706,,
8341,N,Lower clearance in rat (i.v.) at 0.5 mpk,,Rattus norvegicus,A,,BAO_0000218,17853,In vivo,10116.0,1,Intermediate,1,CHEMBL618707,,
8342,N,Pharmacokinetic parameter expressed as plasma clearance in rat,,Rattus norvegicus,A,,BAO_0000218,6049,In vivo,10116.0,1,Intermediate,1,CHEMBL618708,,1969.0
8343,N,Pharmacokinetic property (Clp) in rat,,Rattus norvegicus,A,,BAO_0000218,5789,In vivo,10116.0,1,Intermediate,1,CHEMBL618709,,
8344,N,Plasma clearance in Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,4514,In vivo,10116.0,1,Intermediate,1,CHEMBL618710,,
8345,N,Plasma clearance (Clp) in rat,,Rattus norvegicus,A,,BAO_0000218,6448,In vivo,10116.0,1,Intermediate,1,CHEMBL618711,,
8346,N,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6062,In vivo,10116.0,1,Intermediate,1,CHEMBL618712,,
8347,N,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,,Rattus norvegicus,A,,BAO_0000218,5710,In vivo,10116.0,1,Intermediate,1,CHEMBL618713,,
8348,N,Plasma clearance after intravenous administration of 1 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,4709,In vivo,10116.0,1,Intermediate,1,CHEMBL618714,,
8349,N,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,Rattus norvegicus,A,,BAO_0000218,4521,In vivo,10116.0,1,Intermediate,1,CHEMBL618715,,
8350,N,Plasma clearance in rat was determined,,Rattus norvegicus,A,,BAO_0000218,1742,In vivo,10116.0,1,Intermediate,1,CHEMBL618716,,
8351,N,Plasma clearance measured in rat,,Rattus norvegicus,A,,BAO_0000218,6057,In vivo,10116.0,1,Intermediate,1,CHEMBL876601,,
8352,N,Plasma clearance was calculated in rat,,Rattus norvegicus,A,,BAO_0000218,6057,In vivo,10116.0,1,Intermediate,1,CHEMBL618717,,
8353,N,Plasma clearance in rat,,Rattus norvegicus,A,,BAO_0000218,5145,In vivo,10116.0,1,Intermediate,1,CHEMBL618718,,
8354,N,Plasma clearance in rat,,Rattus norvegicus,A,,BAO_0000218,5833,In vivo,10116.0,1,Intermediate,1,CHEMBL618719,,
8355,N,Plasma clearance in rat,,Rattus norvegicus,A,,BAO_0000218,6453,In vivo,10116.0,1,Intermediate,1,CHEMBL618720,,
8356,N,Plasma clearance in rat,,Rattus norvegicus,A,,BAO_0000218,6640,In vivo,10116.0,1,Intermediate,1,CHEMBL618721,,
8357,N,Plasma clearance in rats,,Rattus norvegicus,A,,BAO_0000218,6305,In vivo,10116.0,1,Intermediate,1,CHEMBL621477,,
8358,N,Plasma clearance in rat,,Rattus norvegicus,A,,BAO_0000218,6642,In vivo,10116.0,1,Intermediate,1,CHEMBL621478,,
8359,N,Plasma clearance was evaluated in rat,,Rattus norvegicus,A,,BAO_0000218,5472,In vivo,10116.0,1,Intermediate,1,CHEMBL621479,,
8360,N,Plasma clearance was evaluated in rat; Not tested,,Rattus norvegicus,A,,BAO_0000218,5472,In vivo,10116.0,1,Intermediate,1,CHEMBL621480,,
8361,N,Plasma clearance rate was determined for the compound in rat,,Rattus norvegicus,A,,BAO_0000218,5144,In vivo,10116.0,1,Intermediate,1,CHEMBL621481,,
8362,N,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",,Rattus norvegicus,A,,BAO_0000218,6685,In vivo,10116.0,1,Intermediate,1,CHEMBL621482,,
8363,N,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,Rattus norvegicus,A,,BAO_0000218,6685,In vivo,10116.0,1,Intermediate,1,CHEMBL621483,,
8364,N,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",,Rattus norvegicus,A,,BAO_0000218,6685,In vivo,10116.0,1,Intermediate,1,CHEMBL621484,,
8365,N,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL621485,,948.0
8366,N,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL621486,,948.0
8367,N,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL621487,,160.0
8368,N,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL621488,,160.0
8369,N,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL621489,,160.0
8370,N,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL621490,,160.0
8371,N,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL621491,,160.0
8372,N,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL621492,,2113.0
8373,N,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL621493,,2113.0
8374,N,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL621494,,2113.0
8375,N,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL621495,,2113.0
8376,N,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL621496,,2113.0
8377,N,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL621497,,2107.0
8378,N,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL621498,,2107.0
8379,N,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL621499,,2107.0
8380,N,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL618634,,2107.0
8381,N,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL618635,,2107.0
8382,N,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL618636,,2048.0
8383,N,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL619737,,2048.0
8384,N,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL619738,,2048.0
8385,N,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL624329,,2048.0
8386,N,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL624330,,2048.0
8387,N,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL624331,,2385.0
8388,N,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL624332,,2385.0
8389,N,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL624333,,2385.0
8390,N,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL624334,,2385.0
8391,N,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL624335,,2385.0
8392,N,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL620016,,2106.0
8393,N,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL620169,,2106.0
8394,N,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL620170,,2106.0
8395,N,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL620171,,2106.0
8396,N,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL620172,,2106.0
8397,N,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL620173,,945.0
8398,N,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL620174,,945.0
8399,N,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL620175,,945.0
8400,N,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL620176,,945.0
8401,N,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,In vivo,10116.0,1,Intermediate,1,CHEMBL620177,,945.0
8402,N,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,,10116.0,1,Intermediate,1,CHEMBL620178,,2037.0
8403,N,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,,10116.0,1,Intermediate,1,CHEMBL620179,,2037.0
8404,N,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,,10116.0,1,Intermediate,1,CHEMBL620180,,
8405,N,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,,Rattus norvegicus,A,,BAO_0000218,6570,In vivo,10116.0,1,Intermediate,1,CHEMBL620181,,
8406,N,Volume of distribution of compound in rats after intravenous administration,,Rattus norvegicus,A,,BAO_0000218,6571,In vivo,10116.0,1,Intermediate,1,CHEMBL620182,,
8407,N,Volume of distribution in rat,,Rattus norvegicus,A,,BAO_0000218,6453,In vivo,10116.0,1,Intermediate,1,CHEMBL620183,,
8408,N,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,,Rattus norvegicus,A,,BAO_0000218,6444,In vivo,10116.0,1,Intermediate,1,CHEMBL620184,,
8409,N,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,Rattus norvegicus,A,,BAO_0000218,6444,In vivo,10116.0,1,Intermediate,1,CHEMBL620185,,
8410,N,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,Rattus norvegicus,A,,BAO_0000218,6444,In vivo,10116.0,1,Intermediate,1,CHEMBL620186,,
8411,N,Volume of distribution was determined in Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5353,In vivo,10116.0,1,Intermediate,1,CHEMBL620187,,
8412,N,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5334,In vivo,10116.0,1,Intermediate,1,CHEMBL620188,,
8413,N,Volume of distribution was reported in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5334,In vivo,10116.0,1,Intermediate,1,CHEMBL620189,,
8414,N,Volumes of distribution in rat after peroral administration,,Rattus norvegicus,A,,BAO_0000218,6641,In vivo,10116.0,1,Intermediate,1,CHEMBL620190,,
8415,N,Volumes of distribution in rat after po administration,,Rattus norvegicus,A,,BAO_0000218,6641,In vivo,10116.0,1,Intermediate,1,CHEMBL620191,,
8416,N,Volumes of distribution in rat after po administration; Not determined,,Rattus norvegicus,A,,BAO_0000218,6641,In vivo,10116.0,1,Intermediate,1,CHEMBL620192,,
8417,N,Pharmacokinetic property (Volume) in rat i.v.,,Rattus norvegicus,A,,BAO_0000218,5676,In vivo,10116.0,1,Intermediate,1,CHEMBL620193,,
8418,N,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,,Rattus norvegicus,A,,BAO_0000218,6410,In vivo,10116.0,1,Intermediate,1,CHEMBL620194,,
8419,N,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",,Rattus norvegicus,A,,BAO_0000218,17670,In vivo,10116.0,1,Intermediate,1,CHEMBL876730,,
8420,N,Volume distribution in rat after oral administration at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6495,In vivo,10116.0,1,Intermediate,1,CHEMBL620195,,
8421,N,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,5408,In vivo,10116.0,1,Intermediate,1,CHEMBL620196,,
8422,N,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,Rattus norvegicus,A,,BAO_0000218,4883,In vivo,10116.0,1,Intermediate,1,CHEMBL620197,,
8423,N,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,,Rattus norvegicus,A,,BAO_0000218,6647,In vivo,10116.0,1,Intermediate,1,CHEMBL620198,,
8424,N,Volume of distribution in rats,,Rattus norvegicus,A,,BAO_0000218,6495,In vivo,10116.0,1,Intermediate,1,CHEMBL620199,,
8425,N,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,,Rattus norvegicus,A,,BAO_0000218,2661,In vivo,10116.0,1,Intermediate,1,CHEMBL620200,,
8426,N,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,,Rattus norvegicus,A,,BAO_0000218,2661,In vivo,10116.0,1,Intermediate,1,CHEMBL620201,,
8427,N,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL620202,,
8428,N,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL620203,,
8429,N,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL620204,,
8430,N,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL620205,,
8431,N,Pharmacokinetic parameter (Vss) in rat,,Rattus norvegicus,A,,BAO_0000218,5960,In vivo,10116.0,1,Intermediate,1,CHEMBL624664,,
8432,N,Pharmacokinetic property (Volume) in rat i.v.,,Rattus norvegicus,A,,BAO_0000218,5676,In vivo,10116.0,1,Intermediate,1,CHEMBL624665,,
8433,N,Pharmacokinetic property (Vss) in rat,,Rattus norvegicus,A,,BAO_0000218,5948,,10116.0,1,Intermediate,1,CHEMBL624666,,
8434,N,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,Rattus norvegicus,A,,BAO_0000218,5979,In vivo,10116.0,1,Intermediate,1,CHEMBL624667,,
8435,N,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL624668,,
8436,N,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL624669,,
8437,N,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL624670,,
8438,N,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL624671,,
8439,N,Steady state volume distribution in rat,,Rattus norvegicus,A,,BAO_0000218,6448,In vivo,10116.0,1,Intermediate,1,CHEMBL624672,,
8440,N,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",,Rattus norvegicus,A,,BAO_0000218,12873,In vivo,10116.0,1,Intermediate,1,CHEMBL624673,,1969.0
8441,N,Steady state volume of distribution determined in rat,,Rattus norvegicus,A,,BAO_0000218,4576,In vivo,10116.0,1,Intermediate,1,CHEMBL624674,,
8442,N,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,Rattus norvegicus,A,,BAO_0000218,17582,In vivo,10116.0,1,Intermediate,1,CHEMBL624675,,
8443,N,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,,Rattus norvegicus,A,,BAO_0000218,1466,In vivo,10116.0,1,Intermediate,1,CHEMBL621728,,
8444,N,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,,Rattus norvegicus,A,,BAO_0000218,5182,,10116.0,1,Intermediate,1,CHEMBL621729,,
8445,N,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,,Rattus norvegicus,A,,BAO_0000218,5182,,10116.0,1,Intermediate,1,CHEMBL621730,,
8446,N,Volume distribution in rat after administration of 2 mg/kg iv,,Rattus norvegicus,A,,BAO_0000218,6535,In vivo,10116.0,1,Intermediate,1,CHEMBL621731,,
8447,N,Volume distribution in rat after administration of 2 mg/kg iv,,Rattus norvegicus,A,,BAO_0000218,6535,In vivo,10116.0,1,Intermediate,1,CHEMBL621732,,
8448,N,Volume in steady state distribution value was determined,,Rattus norvegicus,A,,BAO_0000218,5041,In vivo,10116.0,1,Intermediate,1,CHEMBL621908,,
8449,N,Volume in steady state distribution value was determined; ND denotes no data,,Rattus norvegicus,A,,BAO_0000218,5041,In vivo,10116.0,1,Intermediate,1,CHEMBL875347,,
8450,N,Volume in steady state distribution value was determined; ND denotes not determined,,Rattus norvegicus,A,,BAO_0000218,5041,In vivo,10116.0,1,Intermediate,1,CHEMBL621909,,
8451,N,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,,Rattus norvegicus,A,,BAO_0000218,17065,In vivo,10116.0,1,Intermediate,1,CHEMBL621910,,
8452,N,Volume of distribution at steady state was evaluated in rats,,Rattus norvegicus,A,,BAO_0000218,6597,In vivo,10116.0,1,Intermediate,1,CHEMBL621911,,
8453,N,Volume of distribution at steady state was observed after intravenous administration in rat,,Rattus norvegicus,A,,BAO_0000218,15662,In vivo,10116.0,1,Intermediate,1,CHEMBL621912,,
8454,N,Volume of distribution in steady state was determined in rat,,Rattus norvegicus,A,,BAO_0000218,6485,In vivo,10116.0,1,Intermediate,1,CHEMBL621913,,
8455,N,Volume of distribution in steady state was determined in rat,,Rattus norvegicus,A,,BAO_0000218,17655,In vivo,10116.0,1,Intermediate,1,CHEMBL621914,,
8456,N,Volume of distribution after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,6616,In vivo,10116.0,1,Intermediate,1,CHEMBL621915,,
8457,N,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,Rattus norvegicus,A,,BAO_0000218,1916,In vivo,10116.0,1,Intermediate,1,CHEMBL621916,,
8458,N,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL621917,,2107.0
8459,N,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL621918,,2107.0
8460,N,Biodistribution of compound (oxidized form) in spleen tissue,,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL621919,,2106.0
8461,N,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL621920,,2106.0
8462,N,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL621921,,2106.0
8463,N,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL622401,,2106.0
8464,N,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL875348,,2106.0
8465,N,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL622402,,2106.0
8466,N,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL622403,,178.0
8467,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL622404,,178.0
8468,N,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL622405,,955.0
8469,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL622406,,955.0
8470,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL622407,,955.0
8471,N,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL622408,,948.0
8472,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL622409,,948.0
8473,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL622410,,948.0
8474,N,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL622411,,2113.0
8475,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL627864,,2113.0
8476,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL627865,,2113.0
8477,N,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL627866,,2107.0
8478,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL627751,,2107.0
8479,N,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL627752,,2106.0
8480,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL627753,,2106.0
8481,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,Mus musculus,A,,BAO_0000218,16438,In vivo,10090.0,1,Intermediate,1,CHEMBL627754,,2106.0
8482,N,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,,Mus musculus,A,,BAO_0000218,12467,,10090.0,1,Intermediate,1,CHEMBL627755,,
8483,N,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL627756,,955.0
8484,N,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL627757,,955.0
8485,N,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL627758,,955.0
8486,N,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL627759,,955.0
8487,N,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL627760,,955.0
8488,N,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL627761,,955.0
8489,N,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL876811,,948.0
8490,N,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL627762,,948.0
8491,N,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL627763,,948.0
8492,N,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL627764,,948.0
8493,N,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL627765,,948.0
8494,N,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL627766,,948.0
8495,N,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL627767,,2113.0
8496,N,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL627768,,2113.0
8497,N,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL628422,,2113.0
8498,N,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL628423,,2113.0
8499,N,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5089,In vivo,10116.0,1,Intermediate,1,CHEMBL628424,,
8500,N,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5089,In vivo,10116.0,1,Intermediate,1,CHEMBL628425,,
8501,N,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,,Rattus norvegicus,A,,BAO_0000218,4257,In vivo,10116.0,1,Intermediate,1,CHEMBL628426,,
8502,N,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Rattus norvegicus,A,,BAO_0000218,6679,In vivo,10116.0,1,Intermediate,1,CHEMBL628427,,
8503,N,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,Rattus norvegicus,A,,BAO_0000218,5546,In vivo,10116.0,1,Intermediate,1,CHEMBL626938,,
8504,N,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,6141,In vivo,10116.0,1,Intermediate,1,CHEMBL626939,,
8505,N,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5334,In vivo,10116.0,1,Intermediate,1,CHEMBL626940,,
8506,N,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5334,In vivo,10116.0,1,Intermediate,1,CHEMBL626941,,
8507,N,Plasma clearance was reported in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5334,In vivo,10116.0,1,Intermediate,1,CHEMBL626942,,
8508,N,Plasma clearance after intravenous administration (1 mg/kg) in rat,,Rattus norvegicus,A,,BAO_0000218,4689,In vivo,10116.0,1,Intermediate,1,CHEMBL876812,,
8509,N,Plasma clearance of compound in rats was evaluated,,Rattus norvegicus,A,,BAO_0000218,6848,In vivo,10116.0,1,Intermediate,1,CHEMBL626943,,
8510,N,Plasma clearance of compound in rats was evaluated; ND indicates not determined,,Rattus norvegicus,A,,BAO_0000218,6848,In vivo,10116.0,1,Intermediate,1,CHEMBL626944,,
8511,N,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,,Rattus norvegicus,A,,BAO_0000218,6467,In vivo,10116.0,1,Intermediate,1,CHEMBL626945,,
8512,N,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,Rattus norvegicus,A,,BAO_0000218,6467,In vivo,10116.0,1,Intermediate,1,CHEMBL626946,,
8513,N,Plasma clearance rate in Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,4956,In vivo,10116.0,1,Intermediate,1,CHEMBL626856,,
8514,N,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),,Rattus norvegicus,A,,BAO_0000218,5529,In vivo,10116.0,1,Intermediate,1,CHEMBL626857,,
8515,N,The compound was evaluated for plasma clearance in rat,,Rattus norvegicus,A,,BAO_0000218,406,In vivo,10116.0,1,Intermediate,1,CHEMBL626858,,1969.0
8516,N,Total plasma clearance in rat,,Rattus norvegicus,A,,BAO_0000218,17655,In vivo,10116.0,1,Intermediate,1,CHEMBL627018,,1969.0
8517,N,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,,Rattus norvegicus,A,,BAO_0000218,3293,In vivo,10116.0,1,Intermediate,1,CHEMBL625331,,178.0
8518,N,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,,Rattus norvegicus,A,,BAO_0000218,4075,In vivo,10116.0,1,Intermediate,1,CHEMBL625332,,178.0
8519,N,C max was determined at 10 mg/kg po dose in rats,,Rattus norvegicus,A,,BAO_0000218,2792,In vivo,10116.0,1,Intermediate,1,CHEMBL877590,,
8520,N,C max was determined at 3 mg/kg po dose in rats,,Rattus norvegicus,A,,BAO_0000218,2792,In vivo,10116.0,1,Intermediate,1,CHEMBL625333,,
8521,N,Cmax after repeated oral dose of compound at 1 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,17594,In vivo,10116.0,1,Intermediate,1,CHEMBL625334,,
8522,N,Cmax after single intravenous bolus of 1 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,17594,In vivo,10116.0,1,Intermediate,1,CHEMBL625335,,
8523,N,Cmax of compound at 5 mg/kg after po administration was determined in rat,,Rattus norvegicus,A,,BAO_0000218,4762,In vivo,10116.0,1,Intermediate,1,CHEMBL625336,,
8524,N,Cmax 24 hr after 10 mg/kg oral administration in rats,,Rattus norvegicus,A,,BAO_0000218,17509,In vivo,10116.0,1,Intermediate,1,CHEMBL625337,,
8525,N,Cmax 24 hr after 2 mg/kg oral administration in rats,,Rattus norvegicus,A,,BAO_0000218,17509,In vivo,10116.0,1,Intermediate,1,CHEMBL625338,,
8526,N,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,,Rattus norvegicus,A,,BAO_0000218,1466,In vivo,10116.0,1,Intermediate,1,CHEMBL625339,,1969.0
8527,N,Cmax in rat after administration of 2 mg/kg iv,,Rattus norvegicus,A,,BAO_0000218,6535,In vivo,10116.0,1,Intermediate,1,CHEMBL625340,,
8528,N,Cmax in rat after administration of 2 mg/kg iv,,Rattus norvegicus,A,,BAO_0000218,6535,In vivo,10116.0,1,Intermediate,1,CHEMBL625341,,
8529,N,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,3169,In vivo,10116.0,1,Intermediate,1,CHEMBL622687,,
8530,N,Cmax wa determined in rat plasma at 30 mg/kg after po administration,,Rattus norvegicus,A,,BAO_0000218,6515,In vivo,10116.0,1,Intermediate,1,CHEMBL622688,,1969.0
8531,N,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,,Rattus norvegicus,A,,BAO_0000218,11149,In vivo,10116.0,1,Intermediate,1,CHEMBL622689,,178.0
8532,N,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,,Rattus norvegicus,A,,BAO_0000218,11149,In vivo,10116.0,1,Intermediate,1,CHEMBL620295,,178.0
8533,N,Cmax after 10 mg/kg oral administration in rat,,Rattus norvegicus,A,,BAO_0000218,17858,In vivo,10116.0,1,Intermediate,1,CHEMBL620296,,
8534,N,Cmax after IV dosing at 0.5 mg/kg in rat; no data,,Rattus norvegicus,A,,BAO_0000218,6518,In vivo,10116.0,1,Intermediate,1,CHEMBL620297,,
8535,N,Cmax after IV dosing at 1 mg/kg in rat; no data,,Rattus norvegicus,A,,BAO_0000218,6518,In vivo,10116.0,1,Intermediate,1,CHEMBL620298,,
8536,N,Cmax after oral administration at 20 mpk in rats,,Rattus norvegicus,A,,BAO_0000218,4426,In vivo,10116.0,1,Intermediate,1,CHEMBL620299,,
8537,N,Cmax after oral administration at 20 mpk in rats; Not performed.,,Rattus norvegicus,A,,BAO_0000218,4426,In vivo,10116.0,1,Intermediate,1,CHEMBL620300,,
8538,N,Cmax after oral administration at 20 mpk in rats d; Not performed.,,Rattus norvegicus,A,,BAO_0000218,4426,In vivo,10116.0,1,Intermediate,1,CHEMBL620301,,
8539,N,Cmax after oral administration in rat,,Rattus norvegicus,A,,BAO_0000218,5656,In vivo,10116.0,1,Intermediate,1,CHEMBL620302,,
8540,N,Cmax after oral administration at a dose of 2 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,6518,In vivo,10116.0,1,Intermediate,1,CHEMBL620303,,
8541,N,Cmax after oral administration at a dose of 4 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,6518,In vivo,10116.0,1,Intermediate,1,CHEMBL620304,,
8542,N,Cmax in rats after 20 mg/kg oral dose,,Rattus norvegicus,A,,BAO_0000218,6113,In vivo,10116.0,1,Intermediate,1,CHEMBL620305,,
8543,N,Cmax after peroral administration in rats at 2.4 uM/kg,,Rattus norvegicus,A,,BAO_0000218,17764,In vivo,10116.0,1,Intermediate,1,CHEMBL620306,,
8544,N,Cmax at the dose of 2 mg/Kg administered perorally in rats,,Rattus norvegicus,A,,BAO_0000218,4756,In vivo,10116.0,1,Intermediate,1,CHEMBL620307,,
8545,N,Cmax at the dose of 5 mg/Kg administered perorally in rats,,Rattus norvegicus,A,,BAO_0000218,4756,In vivo,10116.0,1,Intermediate,1,CHEMBL620308,,
8546,N,Cmax by administering at 20 mg/kg p.o. in rats,,Rattus norvegicus,A,,BAO_0000218,6402,In vivo,10116.0,1,Intermediate,1,CHEMBL620309,,
8547,N,Cmax in male rat,,Rattus norvegicus,A,,BAO_0000218,5610,In vivo,10116.0,1,Intermediate,1,CHEMBL620310,,
8548,N,Cmax in rat,,Rattus norvegicus,A,,BAO_0000218,5207,In vivo,10116.0,1,Intermediate,1,CHEMBL620311,,
8549,N,Cmax in rat,,Rattus norvegicus,A,,BAO_0000218,6011,In vivo,10116.0,1,Intermediate,1,CHEMBL620312,,
8550,N,Cmax in rat,,Rattus norvegicus,A,,BAO_0000218,6504,In vivo,10116.0,1,Intermediate,1,CHEMBL620313,,
8551,N,Cmax in rat at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6046,In vivo,10116.0,1,Intermediate,1,CHEMBL620314,,
8552,N,Cmax in rat at the dose of 1 mg/kg i.v.,,Rattus norvegicus,A,,BAO_0000218,6504,In vivo,10116.0,1,Intermediate,1,CHEMBL620315,,
8553,N,Cmax in rat by po administration at a dose of 40 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5874,In vivo,10116.0,1,Intermediate,1,CHEMBL620316,,
8554,N,Cmax in rat p.o. at 20 mg/kg concentration,,Rattus norvegicus,A,,BAO_0000218,17686,In vivo,10116.0,1,Intermediate,1,CHEMBL620317,,
8555,N,Cmax in rats,,Rattus norvegicus,A,,BAO_0000218,5836,In vivo,10116.0,1,Intermediate,1,CHEMBL620318,,
8556,N,Cmax in rats,,Rattus norvegicus,A,,BAO_0000218,17596,In vivo,10116.0,1,Intermediate,1,CHEMBL620319,,
8557,N,Cmax was evaluated after 20 uM/kg of peroral administration,,Rattus norvegicus,A,,BAO_0000218,16423,In vivo,10116.0,1,Intermediate,1,CHEMBL620320,,
8558,N,Cmax was measured in rats after peroral administration at 3 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17804,In vivo,10116.0,1,Intermediate,1,CHEMBL620321,,
8559,N,Cmax value after oral dose at a dose of 10 mg/kg in rats.,,Rattus norvegicus,A,,BAO_0000218,1908,In vivo,10116.0,1,Intermediate,1,CHEMBL620322,,
8560,N,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,,10116.0,1,Intermediate,1,CHEMBL620323,,
8561,N,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,,10116.0,1,Intermediate,1,CHEMBL620324,,1870.0
8562,N,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,,10116.0,1,Intermediate,1,CHEMBL620325,,1870.0
8563,N,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,,10116.0,1,Intermediate,1,CHEMBL620326,,10000000.0
8564,N,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,,10116.0,1,Intermediate,1,CHEMBL620327,,10000000.0
8565,N,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,,10116.0,1,Intermediate,1,CHEMBL620328,,
8566,N,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,,10116.0,1,Intermediate,1,CHEMBL620329,,
8567,N,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,,10116.0,1,Intermediate,1,CHEMBL620330,,1891.0
8568,N,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,,10116.0,1,Intermediate,1,CHEMBL875286,,1891.0
8569,N,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,,10116.0,1,Intermediate,1,CHEMBL620331,,
8570,N,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,,10116.0,1,Intermediate,1,CHEMBL620332,,
8571,N,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,,10116.0,1,Intermediate,1,CHEMBL620333,,2435.0
8572,N,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,A,,BAO_0000218,13950,,10116.0,1,Intermediate,1,CHEMBL620334,,2435.0
8573,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL621015,,178.0
8574,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL621016,,178.0
8575,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL621191,,178.0
8576,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL621192,,178.0
8577,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL621193,,178.0
8578,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL621194,,178.0
8579,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL624204,,178.0
8580,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL624205,,178.0
8581,N,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624206,,178.0
8582,N,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624207,,178.0
8583,N,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624208,,178.0
8584,N,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624209,,178.0
8585,N,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624210,,178.0
8586,N,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624211,,178.0
8587,N,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624212,,178.0
8588,N,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624213,,178.0
8589,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL876611,,178.0
8590,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL624214,,178.0
8591,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL624215,,178.0
8592,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624216,,178.0
8593,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624217,,178.0
8594,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624218,,178.0
8595,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624219,,178.0
8596,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624220,,178.0
8597,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624221,,178.0
8598,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL624222,,
8599,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL624223,,
8600,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL624224,,
8601,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL624225,,
8602,N,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,,Rattus norvegicus,A,,BAO_0000218,17764,In vivo,10116.0,1,Intermediate,1,CHEMBL622420,,
8603,N,Volume of steady state distribution after i.v. administration in rats,,Rattus norvegicus,A,,BAO_0000218,5031,In vivo,10116.0,1,Intermediate,1,CHEMBL622421,,
8604,N,Vss after intravenous administration (5.0 mg/kg) was determined in rat,,Rattus norvegicus,A,,BAO_0000218,6215,In vivo,10116.0,1,Intermediate,1,CHEMBL622422,,
8605,N,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17671,In vivo,10116.0,1,Intermediate,1,CHEMBL622423,,
8606,N,Vss was determined,,Rattus norvegicus,A,,BAO_0000218,17752,In vivo,10116.0,1,Intermediate,1,CHEMBL622424,,
8607,N,Vss in rat,,Rattus norvegicus,A,,BAO_0000218,6596,In vivo,10116.0,1,Intermediate,1,CHEMBL622425,,
8608,N,Vss was evaluated after 10 uM/kg of intra arterial administration,,Rattus norvegicus,A,,BAO_0000218,16423,In vivo,10116.0,1,Intermediate,1,CHEMBL876612,,
8609,N,volume of distribution at steady state was observed after intravenous administration in rat,,Rattus norvegicus,A,,BAO_0000218,15662,In vivo,10116.0,1,Intermediate,1,CHEMBL622426,,
8610,N,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6062,In vivo,10116.0,1,Intermediate,1,CHEMBL622427,,
8611,N,Pharmacokinetic (PK) parameter Vz in rat,,Rattus norvegicus,A,,BAO_0000218,5874,In vivo,10116.0,1,Intermediate,1,CHEMBL622428,,
8612,N,Volume distribution in rats,,Rattus norvegicus,A,,BAO_0000218,4942,In vivo,10116.0,1,Intermediate,1,CHEMBL622429,,
8613,N,Volume of distribution in rat; No data,,Rattus norvegicus,A,,BAO_0000218,17796,In vivo,10116.0,1,Intermediate,1,CHEMBL622430,,
8614,N,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,4890,In vivo,10116.0,1,Intermediate,1,CHEMBL622431,,
8615,N,% absorption predicted from in vitro rat ileum transport studies,,Rattus norvegicus,A,,BAO_0000218,15765,,10116.0,1,Intermediate,1,CHEMBL622432,,2116.0
8616,N,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,13569,In vivo,10116.0,1,Intermediate,1,CHEMBL622433,,
8617,N,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,13569,In vivo,10116.0,1,Intermediate,1,CHEMBL622434,,
8618,N,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,13569,In vivo,10116.0,1,Intermediate,1,CHEMBL622435,,
8619,N,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,13569,In vivo,10116.0,1,Intermediate,1,CHEMBL618748,,
8620,N,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,13569,In vivo,10116.0,1,Intermediate,1,CHEMBL618749,,
8621,N,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,13569,In vivo,10116.0,1,Intermediate,1,CHEMBL618750,,
8622,N,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,13569,In vivo,10116.0,1,Intermediate,1,CHEMBL618751,,
8623,N,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,13569,In vivo,10116.0,1,Intermediate,1,CHEMBL618752,,
8624,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,4576,In vivo,10116.0,1,Intermediate,1,CHEMBL618753,,
8625,N,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,,Rattus norvegicus,A,,BAO_0000218,750,In vivo,10116.0,1,Intermediate,1,CHEMBL618754,,1969.0
8626,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,750,In vivo,10116.0,1,Intermediate,1,CHEMBL618755,,
8627,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,4590,In vivo,10116.0,1,Intermediate,1,CHEMBL618756,,
8628,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,1716,In vivo,10116.0,1,Intermediate,1,CHEMBL618757,,
8629,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,1974,In vivo,10116.0,1,Intermediate,1,CHEMBL618758,,
8630,N,Oral bioavailability in rat (dose 30 mg/kg),,Rattus norvegicus,A,,BAO_0000218,4502,In vivo,10116.0,1,Intermediate,1,CHEMBL621088,,
8631,N,Pharmacokinetic property (cLogP) in rat,,Rattus norvegicus,A,,BAO_0000218,3371,,10116.0,1,Intermediate,1,CHEMBL621089,,
8632,N,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,,Rattus norvegicus,F,,BAO_0000218,9099,,10116.0,1,Intermediate,1,CHEMBL621090,,178.0
8633,N,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,,Rattus norvegicus,F,,BAO_0000218,9099,,10116.0,1,Intermediate,1,CHEMBL621091,,178.0
8634,N,Clearance in rat.,,Rattus norvegicus,A,,BAO_0000218,4590,In vivo,10116.0,1,Intermediate,1,CHEMBL876731,,
8635,N,Compound was evaluated for its clearance when administered intravenously in rat,,Rattus norvegicus,A,,BAO_0000218,3184,In vivo,10116.0,1,Intermediate,1,CHEMBL621092,,
8636,N,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,16456,In vivo,10116.0,1,Intermediate,1,CHEMBL621093,,
8637,N,Blood: Brain distribution ratio is determined in rat,,Rattus norvegicus,A,,BAO_0000218,4199,,10116.0,1,Intermediate,1,CHEMBL621094,,
8638,N,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,,Rattus norvegicus,A,,BAO_0000218,4199,,10116.0,1,Intermediate,1,CHEMBL621095,,
8639,N,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,,Rattus norvegicus,A,,BAO_0000218,4199,,10116.0,1,Intermediate,1,CHEMBL621096,,
8640,N,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL621097,,2113.0
8641,N,Percent dose excreted in 0-48 hours administered ip to male rat,,Rattus norvegicus,F,,BAO_0000218,7449,,10116.0,1,Intermediate,1,CHEMBL621098,,
8642,N,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL621099,,2037.0
8643,N,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL621100,,2037.0
8644,N,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL621101,,2037.0
8645,N,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL621102,,2037.0
8646,N,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL876732,,2037.0
8647,N,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL621103,,
8648,N,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL621104,,
8649,N,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL621105,,
8650,N,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL621106,,
8651,N,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL621107,,
8652,N,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL621108,,
8653,N,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL621109,,
8654,N,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL621110,,2113.0
8655,N,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL621111,,2113.0
8656,N,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL622541,,2107.0
8657,N,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL622542,,2107.0
8658,N,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL622543,,2107.0
8659,N,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL624412,,2107.0
8660,N,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL624413,,2107.0
8661,N,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL624414,,2107.0
8662,N,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL624415,,2048.0
8663,N,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL624416,,2048.0
8664,N,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL624417,,2048.0
8665,N,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL624418,,2048.0
8666,N,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL624419,,2048.0
8667,N,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL624420,,2048.0
8668,N,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL624421,,2385.0
8669,N,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL624422,,2385.0
8670,N,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL624423,,2385.0
8671,N,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL625123,,2385.0
8672,N,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL625124,,2385.0
8673,N,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL625125,,2385.0
8674,N,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL625126,,14.0
8675,N,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL626947,,14.0
8676,N,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL626948,,14.0
8677,N,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL626949,,14.0
8678,N,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL626950,,14.0
8679,N,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL626951,,14.0
8680,N,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL626952,,2106.0
8681,N,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL626953,,2106.0
8682,N,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL626954,,2106.0
8683,N,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL626955,,2106.0
8684,N,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL626956,,2106.0
8685,N,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL626957,,2106.0
8686,N,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL626958,,178.0
8687,N,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL626959,,178.0
8688,N,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL626960,,178.0
8689,N,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL626961,,178.0
8690,N,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL627589,,178.0
8691,N,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),,Mus musculus,A,,BAO_0000218,17208,In vivo,10090.0,1,Intermediate,1,CHEMBL627590,,178.0
8692,N,Time taken for EC90 was determined when tested in mouse,,Mus musculus,A,,BAO_0000218,3132,,10090.0,1,Intermediate,1,CHEMBL627591,,
8693,N,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,,Mus musculus,A,,BAO_0000218,3132,,10090.0,1,Intermediate,1,CHEMBL627592,,
8694,N,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,Mus musculus,A,,BAO_0000218,16597,In vivo,10090.0,1,Intermediate,1,CHEMBL627593,,
8695,N,Half life in mice,,Mus musculus,A,,BAO_0000218,5727,,10090.0,1,Intermediate,1,CHEMBL627594,,
8696,N,Half life period in mouse after 10 mg/Kg dose,,Mus musculus,A,,BAO_0000218,5302,In vivo,10090.0,1,Intermediate,1,CHEMBL876813,,
8697,N,Half life period in mouse after 10 mg/kg dose,,Mus musculus,A,,BAO_0000218,5302,In vivo,10090.0,1,Intermediate,1,CHEMBL627595,,
8698,N,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,Mus musculus,A,,BAO_0000218,6348,In vivo,10090.0,1,Intermediate,1,CHEMBL627596,,
8699,N,Cmax value at 5 mg/kg po was determined in rat,,Rattus norvegicus,A,,BAO_0000218,5964,In vivo,10116.0,1,Intermediate,1,CHEMBL627597,,
8700,N,Cmax value evaluated in rat,,Rattus norvegicus,A,,BAO_0000218,6078,In vivo,10116.0,1,Intermediate,1,CHEMBL627598,,
8701,N,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,,Rattus norvegicus,A,,BAO_0000218,5206,In vivo,10116.0,1,Intermediate,1,CHEMBL627599,,955.0
8702,N,Cmax value after administration of 20 mg/Kg oral dose in rat,,Rattus norvegicus,A,,BAO_0000218,2959,In vivo,10116.0,1,Intermediate,1,CHEMBL627600,,
8703,N,Cmax value at 1 mg/kg po in rat,,Rattus norvegicus,A,,BAO_0000218,5964,In vivo,10116.0,1,Intermediate,1,CHEMBL627601,,
8704,N,Cmax value at 5 mg/kg po in rat,,Rattus norvegicus,A,,BAO_0000218,5964,In vivo,10116.0,1,Intermediate,1,CHEMBL627776,,
8705,N,Cmax value at a dose of 10 mg/kg in male SD rats,,Rattus norvegicus,A,,BAO_0000218,6757,In vivo,10116.0,1,Intermediate,1,CHEMBL627777,,
8706,N,Cmax value at a dose of 100 mg/kg in male SD rats,,Rattus norvegicus,A,,BAO_0000218,6757,In vivo,10116.0,1,Intermediate,1,CHEMBL627778,,
8707,N,Cmax value at a dose of 50 mg/kg in male SD rats,,Rattus norvegicus,A,,BAO_0000218,6757,In vivo,10116.0,1,Intermediate,1,CHEMBL627779,,
8708,N,Cmax value in rats at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17617,In vivo,10116.0,1,Intermediate,1,CHEMBL876814,,
8709,N,Cmax value was evaluated in rats at a dose of 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,1445,In vivo,10116.0,1,Intermediate,1,CHEMBL627780,,
8710,N,Cmax value was determined after peroral administration of 20 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,6082,In vivo,10116.0,1,Intermediate,1,CHEMBL627781,,
8711,N,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,Rattus norvegicus,A,,BAO_0000218,1446,In vivo,10116.0,1,Intermediate,1,CHEMBL627782,,
8712,N,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,,Rattus norvegicus,A,,BAO_0000218,5407,In vivo,10116.0,1,Intermediate,1,CHEMBL627783,,1969.0
8713,N,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,,Rattus norvegicus,A,,BAO_0000218,2690,In vivo,10116.0,1,Intermediate,1,CHEMBL627784,,1969.0
8714,N,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,,Rattus norvegicus,A,,BAO_0000218,2661,In vivo,10116.0,1,Intermediate,1,CHEMBL627785,,
8715,N,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,,Rattus norvegicus,A,,BAO_0000218,2661,In vivo,10116.0,1,Intermediate,1,CHEMBL627786,,
8716,N,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,,Rattus norvegicus,A,,BAO_0000218,4891,In vivo,10116.0,1,Intermediate,1,CHEMBL627787,,1969.0
8717,N,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,,Rattus norvegicus,A,,BAO_0000218,2807,In vivo,10116.0,1,Intermediate,1,CHEMBL627788,,1969.0
8718,N,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,,Rattus norvegicus,A,,BAO_0000218,2807,In vivo,10116.0,1,Intermediate,1,CHEMBL626579,,1969.0
8719,N,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,,Rattus norvegicus,A,,BAO_0000218,2807,In vivo,10116.0,1,Intermediate,1,CHEMBL626580,,1969.0
8720,N,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,3634,In vivo,10116.0,1,Intermediate,1,CHEMBL876815,,
8721,N,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,,Rattus norvegicus,A,,BAO_0000218,1881,In vivo,10116.0,1,Intermediate,1,CHEMBL626581,,1969.0
8722,N,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,,Rattus norvegicus,A,,BAO_0000218,1881,In vivo,10116.0,1,Intermediate,1,CHEMBL626582,,1969.0
8723,N,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,429,In vivo,10116.0,1,Intermediate,1,CHEMBL626583,,
8724,N,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL626205,,
8725,N,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL626206,,
8726,N,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL626207,,
8727,N,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL623882,,
8728,N,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,,Rattus norvegicus,A,,BAO_0000218,17582,In vivo,10116.0,1,Intermediate,1,CHEMBL623883,,
8729,N,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,,Rattus norvegicus,A,,BAO_0000218,17582,In vivo,10116.0,1,Intermediate,1,CHEMBL623884,,
8730,N,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,Rattus norvegicus,A,,BAO_0000218,3032,In vivo,10116.0,1,Intermediate,1,CHEMBL623885,,1969.0
8731,N,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6295,In vivo,10116.0,1,Intermediate,1,CHEMBL623886,,1969.0
8732,N,Maximal concentration in rat was determined,,Rattus norvegicus,A,,BAO_0000218,6619,In vivo,10116.0,1,Intermediate,1,CHEMBL623887,,
8733,N,Maximal concentration after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,6616,In vivo,10116.0,1,Intermediate,1,CHEMBL623888,,
8734,N,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,3249,In vivo,10116.0,1,Intermediate,1,CHEMBL623889,,1969.0
8735,N,Maximal plasma concentration in rat after oral administration at 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17791,In vivo,10116.0,1,Intermediate,1,CHEMBL623890,,1969.0
8736,N,Cmax in rat plasma after oral dose (50 mg/Kg),,Rattus norvegicus,A,,BAO_0000218,17791,In vivo,10116.0,1,Intermediate,1,CHEMBL623891,,1969.0
8737,N,Maximal plasma concentration was determined.,,Rattus norvegicus,A,,BAO_0000218,1360,In vivo,10116.0,1,Intermediate,1,CHEMBL623892,,1969.0
8738,N,Maximal plasma drug concentration was determined,,Rattus norvegicus,A,,BAO_0000218,2552,In vivo,10116.0,1,Intermediate,1,CHEMBL623893,,1969.0
8739,N,Maximal concentration in rats after peroral administration,,Rattus norvegicus,A,,BAO_0000218,6571,In vivo,10116.0,1,Intermediate,1,CHEMBL877616,,
8740,N,Maximum concentration in rat after 2 mg/kg peroral administration,,Rattus norvegicus,A,,BAO_0000218,6570,In vivo,10116.0,1,Intermediate,1,CHEMBL623894,,
8741,N,Maximum concentration in rat plasma after 5 mg/kg oral gavage,,Rattus norvegicus,A,,BAO_0000218,6567,In vivo,10116.0,1,Intermediate,1,CHEMBL623895,,1969.0
8742,N,Maximum concentration of compound in rat was evaluated.,,Rattus norvegicus,A,,BAO_0000218,3031,In vivo,10116.0,1,Intermediate,1,CHEMBL623896,,
8743,N,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,3436,In vivo,10116.0,1,Intermediate,1,CHEMBL623897,,
8744,N,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,3436,In vivo,10116.0,1,Intermediate,1,CHEMBL623898,,
8745,N,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,,Rattus norvegicus,A,,BAO_0000218,2083,In vivo,10116.0,1,Intermediate,1,CHEMBL623899,,
8746,N,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,3436,In vivo,10116.0,1,Intermediate,1,CHEMBL623900,,
8747,N,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,,Rattus norvegicus,A,,BAO_0000218,4527,In vivo,10116.0,1,Intermediate,1,CHEMBL623901,,
8748,N,Maximum concentration was evaluated in rats,,Rattus norvegicus,A,,BAO_0000218,1974,In vivo,10116.0,1,Intermediate,1,CHEMBL623902,,
8749,N,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,,Rattus norvegicus,A,,BAO_0000218,3307,In vivo,10116.0,1,Intermediate,1,CHEMBL623903,,1359.0
8750,N,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,,Rattus norvegicus,A,,BAO_0000218,3307,In vivo,10116.0,1,Intermediate,1,CHEMBL623904,,1969.0
8751,N,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,Rattus norvegicus,A,,BAO_0000218,1916,In vivo,10116.0,1,Intermediate,1,CHEMBL877617,,1969.0
8752,N,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,1500,In vivo,10116.0,1,Intermediate,1,CHEMBL623905,,
8753,N,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,1500,In vivo,10116.0,1,Intermediate,1,CHEMBL623906,,
8754,N,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,Rattus norvegicus,A,,BAO_0000218,4186,In vivo,10116.0,1,Intermediate,1,CHEMBL623907,,1969.0
8755,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL623908,,
8756,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL623909,,
8757,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL623910,,
8758,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL623911,,
8759,N,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623912,,
8760,N,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624616,,
8761,N,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624617,,
8762,N,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624618,,
8763,N,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624619,,
8764,N,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624794,,
8765,N,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624795,,
8766,N,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623921,,
8767,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL623922,,
8768,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL623923,,
8769,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL623924,,
8770,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623925,,
8771,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623926,,
8772,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623927,,
8773,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623928,,
8774,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623929,,
8775,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623930,,
8776,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL623931,,955.0
8777,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622165,,955.0
8778,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL621249,,955.0
8779,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL621250,,955.0
8780,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL621448,,955.0
8781,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL621449,,955.0
8782,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL621450,,955.0
8783,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL621451,,955.0
8784,N,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL621452,,955.0
8785,N,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL621453,,955.0
8786,N,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL621454,,955.0
8787,N,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL621455,,955.0
8788,N,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL621456,,955.0
8789,N,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL625145,,955.0
8790,N,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL875847,,955.0
8791,N,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL625146,,955.0
8792,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL625147,,955.0
8793,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL625148,,955.0
8794,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL625149,,955.0
8795,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL625150,,955.0
8796,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL625151,,955.0
8797,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL625152,,955.0
8798,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL625153,,955.0
8799,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL625154,,955.0
8800,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL625155,,955.0
8801,N,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL625156,,
8802,N,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL624354,,
8803,N,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL624355,,10000000.0
8804,N,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL624356,,10000000.0
8805,N,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL624357,,10000000.0
8806,N,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL624358,,10000000.0
8807,N,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL624359,,2435.0
8808,N,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL624360,,2435.0
8809,N,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL624361,,2435.0
8810,N,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL624362,,2435.0
8811,N,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL624363,,2435.0
8812,N,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL624364,,178.0
8813,N,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL624365,,178.0
8814,N,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL624366,,178.0
8815,N,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL624367,,178.0
8816,N,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL624368,,955.0
8817,N,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL624369,,955.0
8818,N,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL624370,,955.0
8819,N,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL625069,,955.0
8820,N,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL625070,,955.0
8821,N,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL626051,,948.0
8822,N,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL626052,,948.0
8823,N,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL626053,,948.0
8824,N,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL626054,,948.0
8825,N,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL626055,,948.0
8826,N,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL626056,,2113.0
8827,N,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL626057,,2113.0
8828,N,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL625193,,2113.0
8829,N,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL625194,,2113.0
8830,N,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL625195,,2107.0
8831,N,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL625196,,2107.0
8832,N,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL625197,,2107.0
8833,N,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL625198,,2107.0
8834,N,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL627929,,2107.0
8835,N,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL627074,,2048.0
8836,N,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL627075,,2048.0
8837,N,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL627076,,2048.0
8838,N,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL627077,,2048.0
8839,N,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL627078,,2048.0
8840,N,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL627079,,2385.0
8841,N,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,,Mus musculus,A,,BAO_0000218,4573,In vivo,10090.0,1,Intermediate,1,CHEMBL873824,,
8842,N,Half life in mouse plasma was determined at dose 25 mg/kg,,Mus musculus,A,,BAO_0000218,3132,In vivo,10090.0,1,Intermediate,1,CHEMBL627080,,1969.0
8843,N,Half life was determined,,Mus musculus,A,,BAO_0000218,17718,,10090.0,1,Intermediate,1,CHEMBL627081,,
8844,N,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,Mus musculus,A,,BAO_0000218,17728,In vivo,10090.0,1,Intermediate,1,CHEMBL627082,,
8845,N,Half-life in male mice after 1 mg/kg intravenous dose,,Mus musculus,A,,BAO_0000218,5961,In vivo,10090.0,1,Intermediate,1,CHEMBL627083,,
8847,N,Half life in mice plasma,,Mus musculus,A,,BAO_0000218,17731,,10090.0,1,Intermediate,1,CHEMBL627085,,1969.0
8848,N,Half life in mouse,,Mus musculus,A,,BAO_0000218,17592,,10090.0,1,Intermediate,1,CHEMBL627086,,
8849,N,Half life in mouse plasma at dose 25 mg/kg,,Mus musculus,A,,BAO_0000218,3132,In vivo,10090.0,1,Intermediate,1,CHEMBL627087,,1969.0
8850,N,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,,Mus musculus,A,,BAO_0000218,17729,In vivo,10090.0,1,Intermediate,1,CHEMBL627088,,
8851,N,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,,Mus musculus,A,,BAO_0000218,17729,In vivo,10090.0,1,Intermediate,1,CHEMBL627089,,
8852,N,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,,Mus musculus,A,,BAO_0000218,17729,In vivo,10090.0,1,Intermediate,1,CHEMBL627090,,
8853,N,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,Mus musculus,A,,BAO_0000218,3277,In vivo,10090.0,1,Intermediate,1,CHEMBL627091,,
8854,N,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",,Mus musculus,A,,BAO_0000218,3760,In vivo,10090.0,1,Intermediate,1,CHEMBL627092,,
8855,N,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",,Mus musculus,A,,BAO_0000218,3760,In vivo,10090.0,1,Intermediate,1,CHEMBL876785,,
8856,N,Half-life by iv administration in mouse,,Mus musculus,A,,BAO_0000218,2862,In vivo,10090.0,1,Intermediate,1,CHEMBL627093,,
8857,N,Half-life by oral administration in mouse,,Mus musculus,A,,BAO_0000218,2862,In vivo,10090.0,1,Intermediate,1,CHEMBL627094,,
8858,N,Half-life in mice,,Mus musculus,A,,BAO_0000218,5980,,10090.0,1,Intermediate,1,CHEMBL627095,,
8859,N,Half-life using mouse brain homogenate,,Mus musculus,A,,BAO_0000218,6159,,10090.0,1,Intermediate,1,CHEMBL627096,,955.0
8860,N,Half-life was measured in mice,,Mus musculus,A,,BAO_0000218,6254,,10090.0,1,Intermediate,1,CHEMBL627097,,
8861,N,Half-life was measured in mouse after an iv dose of 1 mg/kg,,Mus musculus,A,,BAO_0000218,6062,In vivo,10090.0,1,Intermediate,1,CHEMBL627098,,
8862,N,Half-life period was determined in mouse blood,,Mus musculus,A,,BAO_0000218,1574,,10090.0,1,Intermediate,1,CHEMBL627099,,178.0
8863,N,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",,Mus musculus,A,,BAO_0000218,56,,10090.0,1,Intermediate,1,CHEMBL627100,,955.0
8864,N,Plasma half life in mouse,,Mus musculus,A,,BAO_0000218,993,,10090.0,1,Intermediate,1,CHEMBL627101,,1969.0
8865,N,Stability of the peptide in the presence of mouse serum,,Mus musculus,A,,BAO_0000218,6652,,10090.0,1,Intermediate,1,CHEMBL627102,,
8866,N,Terminal half life of compound was determined in mouse,,Mus musculus,A,,BAO_0000218,17852,,10090.0,1,Intermediate,1,CHEMBL627103,,
8867,N,Terminal half life was evaluated in mice after intravenous administration,,Mus musculus,A,,BAO_0000218,2675,In vivo,10090.0,1,Intermediate,1,CHEMBL627104,,
8868,N,Terminal half life was evaluated in mice after oral administration,,Mus musculus,A,,BAO_0000218,2675,In vivo,10090.0,1,Intermediate,1,CHEMBL627105,,
8869,N,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,,Mus musculus,A,,BAO_0000218,499,,10090.0,1,Intermediate,1,CHEMBL876786,,
8870,N,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,,Mus musculus,A,,BAO_0000218,499,,10090.0,1,Intermediate,1,CHEMBL873825,,
8871,N,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,,Mus musculus,A,,BAO_0000218,499,,10090.0,1,Intermediate,1,CHEMBL627106,,
8872,N,half life period is evaluated by administering intravenously at 25 mg/kg in mice,,Mus musculus,A,,BAO_0000218,14239,In vivo,10090.0,1,Intermediate,1,CHEMBL626336,,
8873,N,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",,Mus musculus,A,,BAO_0000218,5506,In vivo,10090.0,1,Intermediate,1,CHEMBL877462,,
8874,N,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",,Mus musculus,A,,BAO_0000218,5506,In vivo,10090.0,1,Intermediate,1,CHEMBL626337,,
8875,N,Half life after intraperitoneal administration of 100 mg/kg in mice,,Mus musculus,A,,BAO_0000218,17734,,10090.0,1,Intermediate,1,CHEMBL626338,,
8876,N,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,,Mus musculus,A,,BAO_0000218,17728,In vivo,10090.0,1,Intermediate,1,CHEMBL626339,,
8877,N,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,Mus musculus,A,,BAO_0000218,17728,In vivo,10090.0,1,Intermediate,1,CHEMBL626340,,
8878,N,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,,Mus musculus,A,,BAO_0000218,17728,In vivo,10090.0,1,Intermediate,1,CHEMBL625377,,
8879,N,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,,Mus musculus,A,,BAO_0000218,17728,In vivo,10090.0,1,Intermediate,1,CHEMBL625378,,
8880,N,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,,Mus musculus,A,,BAO_0000218,17728,In vivo,10090.0,1,Intermediate,1,CHEMBL625379,,
8881,U,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),,Sus scrofa,A,,BAO_0000251,14294,,9823.0,0,Autocuration,1,CHEMBL625380,,
8882,U,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),,Sus scrofa,A,,BAO_0000251,14294,,9823.0,0,Autocuration,1,CHEMBL625381,,
8883,U,Stability to porcine renal DHP-I,,Sus scrofa,A,,BAO_0000019,6056,,9823.0,0,Autocuration,1,CHEMBL625382,,
8884,U,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,,Sus scrofa,A,,BAO_0000218,1317,In vivo,9823.0,0,Autocuration,1,CHEMBL873828,,
8885,U,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,,Sus scrofa,A,,BAO_0000218,1317,In vivo,9823.0,0,Autocuration,1,CHEMBL625383,,
8886,U,Half-life of the parent prodrug in porcine esterase solution,,Sus scrofa,A,,BAO_0000019,5229,,9823.0,0,Autocuration,1,CHEMBL625384,,
8887,U,"First order rate constant, k was determined in in pig liver Esterase",,Sus scrofa,A,,BAO_0000019,4231,,9823.0,0,Autocuration,1,CHEMBL625385,,
8888,U,Half life of the in pig liver Esterase,,Sus scrofa,A,,BAO_0000221,4231,,9823.0,0,Autocuration,1,CHEMBL625386,,2107.0
8889,U,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,,Sus scrofa,A,,BAO_0000221,5318,,9823.0,0,Autocuration,1,CHEMBL623571,,2107.0
8890,U,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,,Sus scrofa,A,,BAO_0000221,5318,,9823.0,0,Autocuration,1,CHEMBL623572,,2107.0
8891,U,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,,Sus scrofa,A,,BAO_0000221,5318,,9823.0,0,Autocuration,1,CHEMBL623573,,2107.0
8892,U,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,,Sus scrofa,A,,BAO_0000221,3305,,9823.0,0,Autocuration,1,CHEMBL623574,,2107.0
8893,U,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,,Sus scrofa,A,,BAO_0000221,3305,,9823.0,0,Autocuration,1,CHEMBL623575,,2107.0
8894,U,Half-life in the presence of pig liver esterase(PLE) was evaluated.,,Sus scrofa,A,,BAO_0000221,2842,,9823.0,0,Autocuration,1,CHEMBL623749,,2107.0
8895,U,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,,Sus scrofa,A,,BAO_0000221,2842,,9823.0,0,Autocuration,1,CHEMBL623750,,2107.0
8896,U,Half-life in vitro in pig liver,,Sus scrofa,A,,BAO_0000221,889,In vitro,9823.0,0,Autocuration,1,CHEMBL623751,,2107.0
8897,U,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,,Sus scrofa,A,,BAO_0000221,1904,,9823.0,0,Autocuration,1,CHEMBL623752,,2107.0
8898,N,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,Rattus norvegicus,A,,BAO_0000218,4186,In vivo,10116.0,1,Intermediate,1,CHEMBL623753,,1969.0
8899,N,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,Rattus norvegicus,A,,BAO_0000218,2774,In vivo,10116.0,1,Intermediate,1,CHEMBL623754,,1969.0
8900,N,Maximum concentration in rat plasma was determined,,Rattus norvegicus,A,,BAO_0000218,1742,In vivo,10116.0,1,Intermediate,1,CHEMBL623755,,1969.0
8901,N,Maximum concentration in rats,,Rattus norvegicus,A,,BAO_0000218,3169,In vivo,10116.0,1,Intermediate,1,CHEMBL623756,,
8902,N,Maximum concentration in rats at 1-2 hours,,Rattus norvegicus,A,,BAO_0000218,3169,In vivo,10116.0,1,Intermediate,1,CHEMBL623757,,
8903,N,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,,Rattus norvegicus,A,,BAO_0000218,2081,In vivo,10116.0,1,Intermediate,1,CHEMBL623758,,
8904,N,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,,Rattus norvegicus,A,,BAO_0000218,3307,In vivo,10116.0,1,Intermediate,1,CHEMBL623759,,955.0
8905,N,Maximum concentration at the dose of 2 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,4727,In vivo,10116.0,1,Intermediate,1,CHEMBL623760,,
8906,N,Maximum concentration was evaluated in rats,,Rattus norvegicus,A,,BAO_0000218,6597,In vivo,10116.0,1,Intermediate,1,CHEMBL623761,,
8907,N,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,,Rattus norvegicus,A,,BAO_0000218,16365,In vivo,10116.0,1,Intermediate,1,CHEMBL623762,,1969.0
8908,N,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,,Rattus norvegicus,A,,BAO_0000218,16365,In vivo,10116.0,1,Intermediate,1,CHEMBL877594,,1969.0
8909,N,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,,Rattus norvegicus,A,,BAO_0000218,16365,In vivo,10116.0,1,Intermediate,1,CHEMBL623763,,1969.0
8910,N,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,,Rattus norvegicus,A,,BAO_0000218,16365,In vivo,10116.0,1,Intermediate,1,CHEMBL623764,,1969.0
8911,N,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,,Rattus norvegicus,A,,BAO_0000218,16365,In vivo,10116.0,1,Intermediate,1,CHEMBL623765,,1969.0
8912,N,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,,Rattus norvegicus,A,,BAO_0000218,2591,In vivo,10116.0,1,Intermediate,1,CHEMBL623766,,178.0
8913,N,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,,Rattus norvegicus,A,,BAO_0000218,2591,In vivo,10116.0,1,Intermediate,1,CHEMBL623767,,178.0
8914,N,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,,Rattus norvegicus,A,,BAO_0000218,2591,In vivo,10116.0,1,Intermediate,1,CHEMBL623768,,178.0
8915,N,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL623769,,1969.0
8916,N,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL623770,,1969.0
8917,N,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL623771,,1969.0
8918,N,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL623772,,1969.0
8919,N,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL623773,,1969.0
8920,N,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL623774,,1969.0
8921,N,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL623775,,1969.0
8922,N,Cmax in rat (PO dose),,Rattus norvegicus,A,,BAO_0000218,14465,In vivo,10116.0,1,Intermediate,1,CHEMBL623776,,
8923,N,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,A,,BAO_0000218,4723,In vivo,10116.0,1,Intermediate,1,CHEMBL622191,,1969.0
8924,N,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,A,,BAO_0000218,4723,In vivo,10116.0,1,Intermediate,1,CHEMBL622192,,1969.0
8925,N,Maximum plasma concentration determined in rat,,Rattus norvegicus,A,,BAO_0000218,4576,In vivo,10116.0,1,Intermediate,1,CHEMBL622193,,1969.0
8926,N,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,12873,In vivo,10116.0,1,Intermediate,1,CHEMBL622194,,1969.0
8927,N,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,12873,In vivo,10116.0,1,Intermediate,1,CHEMBL622195,,1969.0
8928,N,Maximum plasma concentration in rat,,Rattus norvegicus,A,,BAO_0000218,6824,In vivo,10116.0,1,Intermediate,1,CHEMBL622196,,1969.0
8929,N,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,,Rattus norvegicus,A,,BAO_0000218,17065,In vivo,10116.0,1,Intermediate,1,CHEMBL622197,,1969.0
8930,N,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,,Rattus norvegicus,A,,BAO_0000218,2932,In vivo,10116.0,1,Intermediate,1,CHEMBL622198,,1969.0
8931,N,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,,Rattus norvegicus,A,,BAO_0000218,2932,In vivo,10116.0,1,Intermediate,1,CHEMBL622199,,1969.0
8932,N,Maximum plasma concentration of compound was measured in rat,,Rattus norvegicus,A,,BAO_0000218,2879,In vivo,10116.0,1,Intermediate,1,CHEMBL622200,,1969.0
8933,N,Maximum plasma concentration after 20 mg/kg oral administration in rat,,Rattus norvegicus,A,,BAO_0000218,2864,In vivo,10116.0,1,Intermediate,1,CHEMBL622201,,1969.0
8934,N,Maximum plasma concentration after oral administration to rats,,Rattus norvegicus,A,,BAO_0000218,16367,In vivo,10116.0,1,Intermediate,1,CHEMBL623990,,1969.0
8935,N,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,Rattus norvegicus,A,,BAO_0000218,17717,In vivo,10116.0,1,Intermediate,1,CHEMBL623991,,1969.0
8936,N,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",,Rattus norvegicus,A,,BAO_0000218,17717,In vivo,10116.0,1,Intermediate,1,CHEMBL623992,,1969.0
8937,N,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,Rattus norvegicus,A,,BAO_0000218,17717,In vivo,10116.0,1,Intermediate,1,CHEMBL623993,,1969.0
8938,N,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,,Rattus norvegicus,A,,BAO_0000218,17717,In vivo,10116.0,1,Intermediate,1,CHEMBL623994,,1969.0
8939,N,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,,Rattus norvegicus,F,,BAO_0000218,17720,In vivo,10116.0,1,Intermediate,1,CHEMBL623995,,1969.0
8940,N,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,,Rattus norvegicus,F,,BAO_0000218,17720,In vivo,10116.0,1,Intermediate,1,CHEMBL623996,,1969.0
8941,N,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,,Rattus norvegicus,F,,BAO_0000218,17720,In vivo,10116.0,1,Intermediate,1,CHEMBL623997,,1969.0
8942,N,Maximum plasma concentration dosed orally in rats,,Rattus norvegicus,A,,BAO_0000218,4516,In vivo,10116.0,1,Intermediate,1,CHEMBL623998,,1969.0
8943,N,Maximum plasma concentration dosed orally in rats after 6 hours,,Rattus norvegicus,A,,BAO_0000218,4516,In vivo,10116.0,1,Intermediate,1,CHEMBL623999,,1969.0
8944,N,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,,Rattus norvegicus,A,,BAO_0000218,4516,In vivo,10116.0,1,Intermediate,1,CHEMBL624000,,1969.0
8945,N,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,5199,In vivo,10116.0,1,Intermediate,1,CHEMBL624001,,1969.0
8946,N,Maximum plasma concentration in rat after po administration,,Rattus norvegicus,A,,BAO_0000218,17538,In vivo,10116.0,1,Intermediate,1,CHEMBL624002,,1969.0
8947,N,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,6685,In vivo,10116.0,1,Intermediate,1,CHEMBL624003,,1969.0
8948,N,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",,Rattus norvegicus,A,,BAO_0000218,6685,In vivo,10116.0,1,Intermediate,1,CHEMBL624004,,1969.0
8949,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL624005,,948.0
8950,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL624006,,948.0
8951,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL624007,,948.0
8952,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL624008,,948.0
8953,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL624009,,948.0
8954,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL874387,,948.0
8955,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL624010,,948.0
8956,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL624011,,948.0
8957,N,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624012,,948.0
8958,N,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624013,,948.0
8959,N,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624736,,948.0
8960,N,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624737,,948.0
8961,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL624738,,948.0
8962,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL624739,,948.0
8963,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL624740,,948.0
8964,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624896,,948.0
8965,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624897,,948.0
8966,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624108,,948.0
8967,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624109,,948.0
8968,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624110,,948.0
8969,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624111,,948.0
8970,N,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624112,,948.0
8971,N,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL624113,,948.0
8972,N,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL619709,,948.0
8973,N,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL619710,,948.0
8974,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL619711,,2113.0
8975,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL619712,,2113.0
8976,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL619713,,2113.0
8977,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL619714,,2113.0
8978,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL619715,,2113.0
8979,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL619716,,2113.0
8980,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL619717,,2113.0
8981,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL619718,,2113.0
8982,N,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL619719,,2113.0
8983,N,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL875329,,2113.0
8984,N,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL619720,,2113.0
8985,N,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL619721,,2113.0
8986,N,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL619722,,2113.0
8987,N,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL619723,,2113.0
8988,N,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL619724,,2113.0
8989,N,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL619725,,2113.0
8990,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL619726,,2113.0
8991,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL619727,,2113.0
8992,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL619728,,2113.0
8993,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL619729,,2113.0
8994,N,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL619730,,2385.0
8995,N,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL619731,,2385.0
8996,N,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL619732,,2385.0
8997,N,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL619733,,2385.0
8998,N,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL619734,,2385.0
8999,N,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL619735,,14.0
9000,N,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL875330,,14.0
9001,N,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL628465,,14.0
9002,N,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL628466,,14.0
9003,N,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL628467,,14.0
9004,N,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL628468,,2106.0
9005,N,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL628469,,2106.0
9006,N,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL628470,,2106.0
9007,N,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL628471,,2106.0
9008,N,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL628472,,2106.0
9009,N,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL625191,,2046.0
9010,N,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL625192,,2046.0
9011,N,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL875337,,2046.0
9012,N,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL626341,,2046.0
9013,N,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL626342,,2046.0
9014,N,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,A,,BAO_0000218,11977,In vivo,10116.0,1,Intermediate,1,CHEMBL621943,,2107.0
9015,N,Half life in rats,,Rattus norvegicus,A,,BAO_0000218,3748,,10116.0,1,Intermediate,1,CHEMBL621944,,
9016,N,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,,Rattus norvegicus,A,,BAO_0000218,15765,,10116.0,1,Intermediate,1,CHEMBL621945,,
9017,N,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),,Rattus norvegicus,A,,BAO_0000218,4871,,10116.0,1,Intermediate,1,CHEMBL621946,,
9018,N,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,,Rattus norvegicus,A,,BAO_0000218,4871,,10116.0,1,Intermediate,1,CHEMBL621947,,
9019,N,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),,Rattus norvegicus,A,,BAO_0000218,4872,,10116.0,1,Intermediate,1,CHEMBL621948,,
9020,N,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,,Rattus norvegicus,A,,BAO_0000218,4872,,10116.0,1,Intermediate,1,CHEMBL621949,,
9021,N,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),,Rattus norvegicus,A,,BAO_0000218,5413,,10116.0,1,Intermediate,1,CHEMBL621950,,
9022,N,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,,Rattus norvegicus,A,,BAO_0000218,5413,,10116.0,1,Intermediate,1,CHEMBL621951,,
9023,N,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,,Rattus norvegicus,A,,BAO_0000218,15272,In vivo,10116.0,1,Intermediate,1,CHEMBL621952,,178.0
9024,N,Stability (%) in rat liver microsomes,,Rattus norvegicus,A,,BAO_0000218,4689,,10116.0,1,Intermediate,1,CHEMBL621953,,2107.0
9025,N,Area under curve was calculated after intravenous administration,,Rattus norvegicus,A,,BAO_0000218,6057,,10116.0,1,Intermediate,1,CHEMBL621954,,
9026,N,Area under the curve was calculated after iv administration in rat,,Rattus norvegicus,A,,BAO_0000218,6057,,10116.0,1,Intermediate,1,CHEMBL621955,,
9027,N,Area under the curve was calculated in rat after peroral administration,,Rattus norvegicus,A,,BAO_0000218,6057,,10116.0,1,Intermediate,1,CHEMBL621956,,
9028,N,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,6211,,10116.0,1,Intermediate,1,CHEMBL621957,,
9029,N,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,5710,,10116.0,1,Intermediate,1,CHEMBL621958,,
9030,N,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,5710,,10116.0,1,Intermediate,1,CHEMBL621959,,
9031,N,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,,Rattus norvegicus,A,,BAO_0000218,17853,,10116.0,1,Intermediate,1,CHEMBL621960,,
9032,N,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,,Rattus norvegicus,A,,BAO_0000218,17853,,10116.0,1,Intermediate,1,CHEMBL621961,,
9033,N,p value of the compound,,Rattus norvegicus,A,,BAO_0000218,15765,,10116.0,1,Intermediate,1,CHEMBL621962,,
9034,N,p value of the compound,,Rattus norvegicus,F,,BAO_0000218,15765,,10116.0,1,Intermediate,1,CHEMBL876787,,
9035,N,p value of the compound,,Rattus norvegicus,A,,BAO_0000218,15765,,10116.0,1,Intermediate,1,CHEMBL621963,,
9036,N,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,Rattus norvegicus,A,,BAO_0000218,6175,,10116.0,1,Intermediate,1,CHEMBL622637,,945.0
9037,N,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,Rattus norvegicus,A,,BAO_0000218,6175,,10116.0,1,Intermediate,1,CHEMBL622638,,945.0
9038,N,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,Rattus norvegicus,A,,BAO_0000218,6175,,10116.0,1,Intermediate,1,CHEMBL626561,,945.0
9039,U,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),,Oryctolagus cuniculus,F,,BAO_0000019,7991,,9986.0,0,Autocuration,1,CHEMBL626562,,
9040,U,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),,Oryctolagus cuniculus,A,,BAO_0000218,429,,9986.0,0,Autocuration,1,CHEMBL626563,,
9041,U,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),,Oryctolagus cuniculus,A,,BAO_0000218,429,,9986.0,0,Autocuration,1,CHEMBL626564,,
9042,U,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,Oryctolagus cuniculus,A,,BAO_0000218,6253,In vivo,9986.0,0,Autocuration,1,CHEMBL626565,,
9043,U,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,Oryctolagus cuniculus,A,,BAO_0000218,6253,In vivo,9986.0,0,Autocuration,1,CHEMBL626566,,
9044,U,Clearance rate in rabbits,,Oryctolagus cuniculus,A,,BAO_0000218,3615,In vivo,9986.0,0,Autocuration,1,CHEMBL626567,,
9045,U,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,Oryctolagus cuniculus,A,,BAO_0000218,4059,In vivo,9986.0,0,Autocuration,1,CHEMBL626568,,
9046,U,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,Oryctolagus cuniculus,A,,BAO_0000218,5124,In vivo,9986.0,0,Autocuration,1,CHEMBL626569,,
9047,U,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,Oryctolagus cuniculus,A,,BAO_0000218,5124,In vivo,9986.0,0,Autocuration,1,CHEMBL626570,,
9048,U,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,Oryctolagus cuniculus,A,,BAO_0000218,5124,In vivo,9986.0,0,Autocuration,1,CHEMBL626571,,
9049,U,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,,Oryctolagus cuniculus,A,,BAO_0000218,429,In vivo,9986.0,0,Autocuration,1,CHEMBL626572,,
9050,U,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,Oryctolagus cuniculus,A,,BAO_0000218,4059,In vivo,9986.0,0,Autocuration,1,CHEMBL626573,,1969.0
9051,U,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,,Oryctolagus cuniculus,A,,BAO_0000251,9659,,9986.0,0,Autocuration,1,CHEMBL626574,,2107.0
9052,U,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,,Oryctolagus cuniculus,A,,BAO_0000251,9659,,9986.0,0,Autocuration,1,CHEMBL626575,,2107.0
9053,U,Dose at which bioavailability of intravenously administered compound was tested in rabbit,,Oryctolagus cuniculus,A,,BAO_0000218,3639,,9986.0,0,Autocuration,1,CHEMBL626576,,
9054,U,Dose at which bioavailability of perorally administered compound was tested in rabbit,,Oryctolagus cuniculus,A,,BAO_0000218,3639,,9986.0,0,Autocuration,1,CHEMBL626577,,
9055,U,The compound was tested for its bioavailability in rabbit (by oral dosage).,,Oryctolagus cuniculus,A,,BAO_0000218,3639,In vivo,9986.0,0,Autocuration,1,CHEMBL626578,,
9056,U,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,Oryctolagus cuniculus,A,,BAO_0000218,5124,In vivo,9986.0,0,Autocuration,1,CHEMBL625263,,
9057,U,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,Oryctolagus cuniculus,A,,BAO_0000218,5124,In vivo,9986.0,0,Autocuration,1,CHEMBL625264,,
9058,U,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,Oryctolagus cuniculus,A,,BAO_0000218,5124,In vivo,9986.0,0,Autocuration,1,CHEMBL625265,,
9059,U,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),,Oryctolagus cuniculus,A,,BAO_0000251,14294,,9986.0,0,Autocuration,1,CHEMBL625266,,
9060,U,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),,Oryctolagus cuniculus,A,,BAO_0000251,14294,,9986.0,0,Autocuration,1,CHEMBL876796,,
9061,U,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,,Oryctolagus cuniculus,A,,BAO_0000218,429,In vivo,9986.0,0,Autocuration,1,CHEMBL625267,,
9062,U,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,Oryctolagus cuniculus,A,,BAO_0000218,5124,In vivo,9986.0,0,Autocuration,1,CHEMBL625268,,1969.0
9063,U,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,Oryctolagus cuniculus,A,,BAO_0000218,5124,In vivo,9986.0,0,Autocuration,1,CHEMBL625269,,1969.0
9064,U,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,Oryctolagus cuniculus,A,,BAO_0000218,5124,In vivo,9986.0,0,Autocuration,1,CHEMBL624689,,1969.0
9065,U,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,,Oryctolagus cuniculus,A,,BAO_0000218,429,In vivo,9986.0,0,Autocuration,1,CHEMBL624690,,
9066,U,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),,Oryctolagus cuniculus,A,,BAO_0000218,429,,9986.0,0,Autocuration,1,CHEMBL624691,,1088.0
9067,U,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),,Oryctolagus cuniculus,A,,BAO_0000218,429,,9986.0,0,Autocuration,1,CHEMBL624692,,1088.0
9068,U,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,,Oryctolagus cuniculus,A,,BAO_0000218,4059,In vivo,9986.0,0,Autocuration,1,CHEMBL624693,,
9069,U,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,Oryctolagus cuniculus,A,,BAO_0000218,4137,In vivo,9986.0,0,Autocuration,1,CHEMBL624694,,
9070,U,In vitro Biological half-life in crude homogenate of rabbit renal cortex,,Oryctolagus cuniculus,A,,BAO_0000221,11672,In vitro,9986.0,0,Autocuration,1,CHEMBL877596,,
9071,U,Time within which only 10% of the drug was degraded,,Oryctolagus cuniculus,A,,BAO_0000019,12886,,9986.0,0,Autocuration,1,CHEMBL624695,,
9072,U,Half life period in rabbit liver homogenate,,Oryctolagus cuniculus,A,,BAO_0000221,3853,,9986.0,0,Autocuration,1,CHEMBL624696,,2107.0
9073,U,Half life value in rabbits,,Oryctolagus cuniculus,A,,BAO_0000019,3615,,9986.0,0,Autocuration,1,CHEMBL624697,,
9074,U,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,Oryctolagus cuniculus,A,,BAO_0000218,6253,In vivo,9986.0,0,Autocuration,1,CHEMBL624698,,178.0
9075,U,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,Oryctolagus cuniculus,A,,BAO_0000218,6253,In vivo,9986.0,0,Autocuration,1,CHEMBL624699,,178.0
9076,U,Half-life period in rabbits following intravenous administration at 2 mg/kg,,Oryctolagus cuniculus,A,,BAO_0000218,6077,In vivo,9986.0,0,Autocuration,1,CHEMBL624700,,
9077,N,AUC 0-8 hr value in rats at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17617,,10116.0,1,Intermediate,1,CHEMBL622903,,1969.0
9078,N,AUC after administration at 2000 mg/kg/day in rats,,Rattus norvegicus,A,,BAO_0000218,17594,,10116.0,1,Intermediate,1,CHEMBL622904,,1969.0
9079,N,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,,Rattus norvegicus,A,,BAO_0000218,6149,,10116.0,1,Intermediate,1,CHEMBL622905,,1969.0
9080,N,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,Rattus norvegicus,A,,BAO_0000218,17260,,10116.0,1,Intermediate,1,CHEMBL622906,,1969.0
9081,N,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,Rattus norvegicus,A,,BAO_0000218,17260,,10116.0,1,Intermediate,1,CHEMBL622907,,1969.0
9082,N,AUC in rat after oral administration at 10.5 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,6644,,10116.0,1,Intermediate,1,CHEMBL622908,,1969.0
9083,N,AUC in rat after oral administration at 11.2 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,6644,,10116.0,1,Intermediate,1,CHEMBL622909,,1969.0
9084,N,AUC in rat after oral administration at 9.7 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,6644,,10116.0,1,Intermediate,1,CHEMBL622910,,1969.0
9085,N,AUC in rat brain after oral administration at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6495,,10116.0,1,Intermediate,1,CHEMBL622911,,955.0
9086,N,AUC in rat p.o.,,Rattus norvegicus,A,,BAO_0000218,6504,,10116.0,1,Intermediate,1,CHEMBL622912,,1969.0
9087,N,AUC in rat p.o. at 20 mg/kg concentration,,Rattus norvegicus,A,,BAO_0000218,17686,,10116.0,1,Intermediate,1,CHEMBL622913,,1969.0
9088,N,AUC in rat plasma after oral administration at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6495,,10116.0,1,Intermediate,1,CHEMBL622914,,1969.0
9089,N,AUC in rats,,Rattus norvegicus,A,,BAO_0000218,216,,10116.0,1,Intermediate,1,CHEMBL622915,,1969.0
9090,N,AUC value after IV dose at a dose of 5 mg/kg in rats.,,Rattus norvegicus,A,,BAO_0000218,1908,,10116.0,1,Intermediate,1,CHEMBL622916,,1969.0
9091,N,AUC value after oral dose at a dose of 10 mg/kg in rats.,,Rattus norvegicus,A,,BAO_0000218,1908,,10116.0,1,Intermediate,1,CHEMBL622917,,1969.0
9092,N,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,Rattus norvegicus,A,,BAO_0000218,6685,In vivo,10116.0,1,Intermediate,1,CHEMBL622918,,1969.0
9093,N,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,,Rattus norvegicus,A,,BAO_0000218,216,In vivo,10116.0,1,Intermediate,1,CHEMBL622919,,1969.0
9094,N,Maximum plasma concentration was evaluated in rat,,Rattus norvegicus,A,,BAO_0000218,6049,In vivo,10116.0,1,Intermediate,1,CHEMBL622920,,1969.0
9095,N,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,Rattus norvegicus,A,,BAO_0000218,2463,In vivo,10116.0,1,Intermediate,1,CHEMBL622921,,1969.0
9096,N,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,Rattus norvegicus,A,,BAO_0000218,6679,In vivo,10116.0,1,Intermediate,1,CHEMBL622922,,1969.0
9097,N,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,6681,In vivo,10116.0,1,Intermediate,1,CHEMBL622923,,1969.0
9098,N,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,4890,In vivo,10116.0,1,Intermediate,1,CHEMBL877604,,1969.0
9099,N,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6410,In vivo,10116.0,1,Intermediate,1,CHEMBL622924,,1969.0
9100,N,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6410,In vivo,10116.0,1,Intermediate,1,CHEMBL622925,,1969.0
9101,N,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,,Rattus norvegicus,A,,BAO_0000218,16366,In vivo,10116.0,1,Intermediate,1,CHEMBL622926,,1969.0
9102,N,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6227,In vivo,10116.0,1,Intermediate,1,CHEMBL623625,,1969.0
9103,N,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,3598,In vivo,10116.0,1,Expert,1,CHEMBL623626,,1969.0
9104,N,Maximum plasma drug concentration was determined,,Rattus norvegicus,A,,BAO_0000218,1465,In vivo,10116.0,1,Intermediate,1,CHEMBL623627,,1969.0
9105,N,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,4368,In vivo,10116.0,1,Intermediate,1,CHEMBL623628,,
9106,N,Mean peak plasma concentration was observed after intravenous administration in rat,,Rattus norvegicus,A,,BAO_0000218,15662,In vivo,10116.0,1,Intermediate,1,CHEMBL623629,,1969.0
9107,N,Mean peak plasma concentration was observed after oral administration in rat,,Rattus norvegicus,A,,BAO_0000218,15662,In vivo,10116.0,1,Intermediate,1,CHEMBL623630,,1969.0
9108,N,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,5355,In vivo,10116.0,1,Intermediate,1,CHEMBL623804,,
9109,N,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,5355,In vivo,10116.0,1,Intermediate,1,CHEMBL623805,,
9110,N,Peak oral plasma concentration was determined in rats by oral administration,,Rattus norvegicus,A,,BAO_0000218,1567,In vivo,10116.0,1,Intermediate,1,CHEMBL623806,,1969.0
9111,N,Peak plasma concentration (Cmax) was determined,,Rattus norvegicus,A,,BAO_0000218,4026,In vivo,10116.0,1,Intermediate,1,CHEMBL623807,,1969.0
9112,N,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,6193,In vivo,10116.0,1,Intermediate,1,CHEMBL623808,,1969.0
9113,N,Peak plasma concentration (Cmax) in rats,,Rattus norvegicus,A,,BAO_0000218,4026,In vivo,10116.0,1,Intermediate,1,CHEMBL623809,,1969.0
9114,N,Peak plasma concentration at 1 mg/kg peroral administration,,Rattus norvegicus,A,,BAO_0000218,6485,In vivo,10116.0,1,Intermediate,1,CHEMBL623810,,1969.0
9115,N,Peak plasma concentration in rat,,Rattus norvegicus,A,,BAO_0000218,17655,In vivo,10116.0,1,Intermediate,1,CHEMBL623811,,1969.0
9116,N,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",,Rattus norvegicus,A,,BAO_0000218,14941,In vivo,10116.0,1,Intermediate,1,CHEMBL623812,,1969.0
9117,N,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5394,In vivo,10116.0,1,Intermediate,1,CHEMBL877605,,
9118,N,Pharmacokinetic property (Cmax) in rat,,Rattus norvegicus,A,,BAO_0000218,4408,In vivo,10116.0,1,Intermediate,1,CHEMBL623813,,
9119,N,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,Rattus norvegicus,A,,BAO_0000218,5983,In vivo,10116.0,1,Intermediate,1,CHEMBL623814,,
9120,N,Cmax in rat after 3mg/kg oral dose,,Rattus norvegicus,A,,BAO_0000218,4878,In vivo,10116.0,1,Intermediate,1,CHEMBL623815,,
9121,N,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,,Rattus norvegicus,A,,BAO_0000218,5862,In vivo,10116.0,1,Intermediate,1,CHEMBL623816,,
9122,N,Cmax in rats after 20 mg/kg oral dose,,Rattus norvegicus,A,,BAO_0000218,4517,In vivo,10116.0,1,Intermediate,1,CHEMBL623145,,
9123,N,Cmax in rat plasma after 30mg/kg oral dose,,Rattus norvegicus,A,,BAO_0000218,5932,In vivo,10116.0,1,Intermediate,1,CHEMBL623146,,1969.0
9124,N,Plasma concentration after oral administration of 100 mg/kg to rats,,Rattus norvegicus,A,,BAO_0000218,5436,In vivo,10116.0,1,Intermediate,1,CHEMBL623147,,1969.0
9125,N,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,Rattus norvegicus,A,,BAO_0000218,4910,In vivo,10116.0,1,Intermediate,1,CHEMBL623042,,955.0
9126,N,Tested for the Cmax in rat at 10 mg/kg per orally,,Rattus norvegicus,A,,BAO_0000218,4950,In vivo,10116.0,1,Intermediate,1,CHEMBL623043,,
9127,N,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,15078,In vivo,10116.0,1,Intermediate,1,CHEMBL623044,,
9128,N,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,15078,In vivo,10116.0,1,Intermediate,1,CHEMBL623045,,
9129,N,Bioavailability as oral Cmax in rats at 30 mins,,Rattus norvegicus,A,,BAO_0000218,3360,In vivo,10116.0,1,Intermediate,1,CHEMBL623046,,
9130,N,Bioavailability as oral Cmax in rats at 6hr,,Rattus norvegicus,A,,BAO_0000218,3360,In vivo,10116.0,1,Intermediate,1,CHEMBL623226,,
9131,N,The maximum concentration of compound was measured at the dose of 100 umol/kg,,Rattus norvegicus,A,,BAO_0000218,15022,In vivo,10116.0,1,Intermediate,1,CHEMBL623227,,
9132,N,The maximum concentration of compound was measured at the dose of 300 umol/kg,,Rattus norvegicus,A,,BAO_0000218,15022,In vivo,10116.0,1,Intermediate,1,CHEMBL623228,,
9133,N,The maximum concentration of compound was measured at the dose of 30 umol/kg,,Rattus norvegicus,A,,BAO_0000218,15022,In vivo,10116.0,1,Intermediate,1,CHEMBL623229,,
9134,N,The maximum plasma levels for the compounds were determined by LC-MS.,,Rattus norvegicus,A,,BAO_0000218,5160,In vivo,10116.0,1,Intermediate,1,CHEMBL623230,,1969.0
9135,N,mean peak plasma concentration was observed after intravenous administration in rat,,Rattus norvegicus,A,,BAO_0000218,15662,In vivo,10116.0,1,Intermediate,1,CHEMBL623231,,1969.0
9136,N,mean peak plasma concentration was observed after oral administration in rat,,Rattus norvegicus,A,,BAO_0000218,15662,In vivo,10116.0,1,Intermediate,1,CHEMBL623232,,1969.0
9137,N,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,4709,,10116.0,1,Intermediate,1,CHEMBL623233,,
9138,N,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,,Rattus norvegicus,A,,BAO_0000218,3535,,10116.0,1,Intermediate,1,CHEMBL623234,,
9139,N,Concentration in plasma (portal) following oral dose in rats at 1 hr,,Rattus norvegicus,A,,BAO_0000218,3535,,10116.0,1,Intermediate,1,CHEMBL623235,,
9140,N,Concentration in plasma (portal) following oral dose in rats at 2 hr,,Rattus norvegicus,A,,BAO_0000218,3535,,10116.0,1,Intermediate,1,CHEMBL623236,,
9141,N,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,,Rattus norvegicus,A,,BAO_0000218,3535,,10116.0,1,Intermediate,1,CHEMBL623237,,
9142,N,Concentration in plasma (systemic) following oral dose in rats at 1 hr,,Rattus norvegicus,A,,BAO_0000218,3535,,10116.0,1,Intermediate,1,CHEMBL623238,,
9143,N,Concentration in plasma (systemic) following oral dose in rats at 2 hr,,Rattus norvegicus,A,,BAO_0000218,3535,,10116.0,1,Intermediate,1,CHEMBL623239,,
9144,U,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,,Rattus norvegicus,A,,BAO_0000218,5005,In vivo,10116.0,0,Intermediate,1,CHEMBL623240,,1969.0
9145,N,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",,Rattus norvegicus,A,,BAO_0000218,6326,,10116.0,1,Intermediate,1,CHEMBL623241,,1898.0
9146,N,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",,Rattus norvegicus,A,,BAO_0000218,6326,,10116.0,1,Intermediate,1,CHEMBL623242,,1898.0
9147,N,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",,Rattus norvegicus,A,,BAO_0000218,6326,,10116.0,1,Intermediate,1,CHEMBL874394,,
9148,N,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",,Rattus norvegicus,A,,BAO_0000218,6326,,10116.0,1,Intermediate,1,CHEMBL623243,,
9149,N,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17411,,10116.0,1,Intermediate,1,CHEMBL623244,,
9150,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623245,,2113.0
9151,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623246,,2113.0
9152,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623247,,2113.0
9153,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623248,,2113.0
9154,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623249,,2113.0
9155,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL625072,,2107.0
9156,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL625073,,2107.0
9157,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL625074,,2107.0
9158,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL625075,,2107.0
9159,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL625076,,2107.0
9160,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL625077,,2107.0
9161,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL625078,,2107.0
9162,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL874395,,2107.0
9163,N,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL625079,,2107.0
9164,N,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL625080,,2107.0
9165,N,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL625081,,2107.0
9166,N,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL625082,,2107.0
9167,N,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL625083,,2107.0
9168,N,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL625084,,2107.0
9169,N,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL625085,,2107.0
9170,N,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL625086,,2107.0
9171,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL625087,,2107.0
9172,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL625088,,2107.0
9173,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622205,,2107.0
9174,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622206,,2107.0
9175,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622207,,2107.0
9176,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622366,,2107.0
9177,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622367,,2107.0
9178,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL875331,,2107.0
9179,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622368,,2107.0
9180,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622369,,2048.0
9181,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622370,,2048.0
9182,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622371,,2048.0
9183,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622372,,2048.0
9184,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622373,,2048.0
9185,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622374,,2048.0
9186,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622375,,2048.0
9187,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622376,,2048.0
9188,N,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622377,,2048.0
9189,N,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622378,,2048.0
9190,N,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622379,,2048.0
9191,N,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622380,,2048.0
9192,N,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622381,,2048.0
9193,N,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622382,,2048.0
9194,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622383,,2048.0
9195,N,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,Rattus norvegicus,A,,BAO_0000218,6175,,10116.0,1,Intermediate,1,CHEMBL875332,,945.0
9196,N,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,Rattus norvegicus,A,,BAO_0000218,6175,,10116.0,1,Intermediate,1,CHEMBL622384,,945.0
9197,N,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,Rattus norvegicus,A,,BAO_0000218,6175,,10116.0,1,Intermediate,1,CHEMBL622385,,945.0
9198,N,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,Rattus norvegicus,A,,BAO_0000218,6175,,10116.0,1,Intermediate,1,CHEMBL622386,,945.0
9199,N,The compound was tested for the plasma binding in rat,,Rattus norvegicus,A,,BAO_0000218,10839,,10116.0,1,Intermediate,1,CHEMBL622387,,
9200,N,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",,Rattus norvegicus,A,,BAO_0000218,16459,,10116.0,1,Intermediate,1,CHEMBL622388,,
9201,N,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",,Rattus norvegicus,A,,BAO_0000218,16459,,10116.0,1,Intermediate,1,CHEMBL622389,,
9202,N,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",,Rattus norvegicus,A,,BAO_0000218,16459,,10116.0,1,Intermediate,1,CHEMBL622390,,
9203,N,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),,Rattus norvegicus,A,,BAO_0000218,16459,,10116.0,1,Intermediate,1,CHEMBL622391,,
9204,N,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),,Rattus norvegicus,A,,BAO_0000218,16459,,10116.0,1,Intermediate,1,CHEMBL622392,,
9205,N,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),,Rattus norvegicus,A,,BAO_0000218,16459,,10116.0,1,Intermediate,1,CHEMBL622393,,
9206,N,Plasma level at 2 hr after administration of the compound,,Rattus norvegicus,A,,BAO_0000218,3278,,10116.0,1,Intermediate,1,CHEMBL622394,,
9207,N,plasma level at 2 hr after administration of the compound,,Rattus norvegicus,A,,BAO_0000218,3278,,10116.0,1,Intermediate,1,CHEMBL622395,,
9208,N,Stability in rat serum measured as % recovery at 1 min,,Rattus norvegicus,A,,BAO_0000218,4684,,10116.0,1,Intermediate,1,CHEMBL622396,,1977.0
9209,N,Stability in rat serum measured as % recovery at 10 min,,Rattus norvegicus,A,,BAO_0000218,4684,,10116.0,1,Intermediate,1,CHEMBL624894,,1977.0
9210,N,Stability in rat serum measured as % recovery at 10 mins,,Rattus norvegicus,A,,BAO_0000218,4684,,10116.0,1,Intermediate,1,CHEMBL624895,,1977.0
9211,N,Stability in rat serum measured as % recovery at 2 hr,,Rattus norvegicus,A,,BAO_0000218,4684,,10116.0,1,Intermediate,1,CHEMBL624058,,1977.0
9212,N,Stability in rat serum measured as % recovery at 3 min,,Rattus norvegicus,A,,BAO_0000218,4684,,10116.0,1,Intermediate,1,CHEMBL624059,,1977.0
9213,N,Stability in rat serum measured as % recovery at 3 mins,,Rattus norvegicus,A,,BAO_0000218,4684,,10116.0,1,Intermediate,1,CHEMBL624060,,1977.0
9214,N,Stability in rat serum measured as % recovery at 5 min,,Rattus norvegicus,A,,BAO_0000218,4684,,10116.0,1,Intermediate,1,CHEMBL624061,,1977.0
9215,N,Stability in rat serum measured as % recovery at 5 mins,,Rattus norvegicus,A,,BAO_0000218,4684,,10116.0,1,Intermediate,1,CHEMBL624062,,1977.0
9216,N,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,16456,In vivo,10116.0,1,Intermediate,1,CHEMBL624063,,
9217,N,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,16456,In vivo,10116.0,1,Intermediate,1,CHEMBL624064,,
9218,N,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,,Rattus norvegicus,A,,BAO_0000218,723,,10116.0,1,Intermediate,1,CHEMBL624065,,1969.0
9219,N,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,,Rattus norvegicus,A,,BAO_0000218,723,,10116.0,1,Intermediate,1,CHEMBL624066,,1969.0
9220,N,Half life tested in mature male rat at a dose of 30 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5160,In vivo,10116.0,1,Intermediate,1,CHEMBL877490,,
9221,N,Half life after intravenous administration of 1 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,4709,In vivo,10116.0,1,Intermediate,1,CHEMBL874442,,
9222,N,Half life period after administration (30 mg/kg) in rat,,Rattus norvegicus,A,,BAO_0000218,5633,In vivo,10116.0,1,Intermediate,1,CHEMBL626890,,
9223,N,Half life period in rat after 5 mg/Kg dose,,Rattus norvegicus,A,,BAO_0000218,5302,In vivo,10116.0,1,Intermediate,1,CHEMBL626891,,
9224,N,Half life period in rat after 5 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,5302,In vivo,10116.0,1,Intermediate,1,CHEMBL626892,,
9225,N,Half life period was determined,,Rattus norvegicus,A,,BAO_0000218,17791,,10116.0,1,Intermediate,1,CHEMBL626893,,
9226,N,Half life period was evaluated in rat,,Rattus norvegicus,A,,BAO_0000218,17791,,10116.0,1,Intermediate,1,CHEMBL626894,,
9227,N,Half life period was evaluated in rat; 0.5-1.0,,Rattus norvegicus,A,,BAO_0000218,17791,,10116.0,1,Intermediate,1,CHEMBL626895,,
9228,N,Half life period was evaluated in rat; 5.9-7.5,,Rattus norvegicus,A,,BAO_0000218,17791,,10116.0,1,Intermediate,1,CHEMBL626896,,
9229,N,Half-life in rat plasma,,Rattus norvegicus,A,,BAO_0000218,14512,,10116.0,1,Intermediate,1,CHEMBL626897,,1969.0
9230,N,Half-life time in rat was determined,,Rattus norvegicus,A,,BAO_0000218,6230,,10116.0,1,Intermediate,1,CHEMBL626898,,
9231,N,Terminal half-life after iv administration to rats,,Rattus norvegicus,A,,BAO_0000218,3364,In vivo,10116.0,1,Intermediate,1,CHEMBL626899,,
9232,N,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,,Rattus norvegicus,A,,BAO_0000218,6874,In vivo,10116.0,1,Intermediate,1,CHEMBL626900,,
9233,N,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,,Rattus norvegicus,A,,BAO_0000218,857,,10116.0,1,Intermediate,1,CHEMBL626901,,
9234,N,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),,Rattus norvegicus,A,,BAO_0000218,858,In vivo,10116.0,1,Intermediate,1,CHEMBL626902,,
9235,N,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),,Rattus norvegicus,A,,BAO_0000218,858,In vivo,10116.0,1,Intermediate,1,CHEMBL626903,,
9236,N,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,5355,In vivo,10116.0,1,Intermediate,1,CHEMBL874443,,
9237,N,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,5355,In vivo,10116.0,1,Intermediate,1,CHEMBL626904,,
9238,N,Half life in rats,,Rattus norvegicus,A,,BAO_0000218,6305,,10116.0,1,Intermediate,1,CHEMBL626905,,
9239,N,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,,Rattus norvegicus,A,,BAO_0000218,13501,In vivo,10116.0,1,Intermediate,1,CHEMBL873830,,1969.0
9240,N,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,17594,In vivo,10116.0,1,Intermediate,1,CHEMBL626906,,
9241,N,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,Rattus norvegicus,A,,BAO_0000218,4186,In vivo,10116.0,1,Intermediate,1,CHEMBL631076,,1969.0
9242,N,Biological half-life was measured in plasma of rats,,Rattus norvegicus,A,,BAO_0000218,2932,,10116.0,1,Intermediate,1,CHEMBL631077,,1969.0
9243,N,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,,Rattus norvegicus,A,,BAO_0000218,17065,In vivo,10116.0,1,Intermediate,1,CHEMBL631078,,
9244,N,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,,Rattus norvegicus,A,,BAO_0000218,15765,In vivo,10116.0,1,Intermediate,1,CHEMBL631079,,
9245,N,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,,Rattus norvegicus,A,,BAO_0000218,2713,In vivo,10116.0,1,Intermediate,1,CHEMBL631080,,
9246,N,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,,Rattus norvegicus,A,,BAO_0000218,2661,In vivo,10116.0,1,Intermediate,1,CHEMBL631081,,
9247,N,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,,Rattus norvegicus,A,,BAO_0000218,2661,In vivo,10116.0,1,Intermediate,1,CHEMBL631239,,
9248,N,Compound was evaluated for plasma half life in rat,,Rattus norvegicus,A,,BAO_0000218,740,,10116.0,1,Intermediate,1,CHEMBL631240,,1969.0
9249,N,AUC value at a dose of 5 mg/kg (p.o.) in rats,,Rattus norvegicus,A,,BAO_0000218,6597,,10116.0,1,Intermediate,1,CHEMBL631241,,1969.0
9250,N,AUC value after administration of 20 mg/Kg oral dose in rat,,Rattus norvegicus,A,,BAO_0000218,2959,,10116.0,1,Intermediate,1,CHEMBL631242,,1969.0
9251,N,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,17594,,10116.0,1,Intermediate,1,CHEMBL631243,,1969.0
9252,N,AUC0-96 after administration at 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17596,,10116.0,1,Intermediate,1,CHEMBL874444,,1969.0
9253,N,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,17594,,10116.0,1,Intermediate,1,CHEMBL631244,,1969.0
9254,N,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",,Rattus norvegicus,A,,BAO_0000218,3293,,10116.0,1,Intermediate,1,CHEMBL631245,,
9255,N,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,,Rattus norvegicus,A,,BAO_0000218,6757,,10116.0,1,Intermediate,1,CHEMBL627162,,
9256,N,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,,Rattus norvegicus,A,,BAO_0000218,6757,,10116.0,1,Intermediate,1,CHEMBL627163,,
9257,N,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,,Rattus norvegicus,A,,BAO_0000218,6757,,10116.0,1,Intermediate,1,CHEMBL627164,,
9258,N,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,,Rattus norvegicus,A,,BAO_0000218,5979,,10116.0,1,Intermediate,1,CHEMBL627165,,2113.0
9259,N,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,,Rattus norvegicus,A,,BAO_0000218,5979,,10116.0,1,Intermediate,1,CHEMBL627166,,
9260,N,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,,Rattus norvegicus,A,,BAO_0000218,5979,,10116.0,1,Intermediate,1,CHEMBL627167,,
9261,N,Area under curve (AUC) at a dose of 30 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,4026,,10116.0,1,Intermediate,1,CHEMBL627822,,
9262,N,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,5355,,10116.0,1,Intermediate,1,CHEMBL627823,,
9263,N,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,5355,,10116.0,1,Intermediate,1,CHEMBL627824,,
9264,N,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,5355,,10116.0,1,Intermediate,1,CHEMBL627825,,
9265,N,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,,Rattus norvegicus,A,,BAO_0000218,5633,,10116.0,1,Intermediate,1,CHEMBL627826,,
9266,N,Area under curve (Pharmacokinetic property) was determined,,Rattus norvegicus,A,,BAO_0000218,1716,,10116.0,1,Intermediate,1,CHEMBL627827,,
9267,N,Area under curve (Pharmacokinetic property) of the compound; Not determined,,Rattus norvegicus,A,,BAO_0000218,1716,,10116.0,1,Intermediate,1,CHEMBL627828,,
9268,N,Area under curve after intravenous administration (1 mg/kg) in rat,,Rattus norvegicus,A,,BAO_0000218,4689,,10116.0,1,Intermediate,1,CHEMBL627829,,
9269,N,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,,Rattus norvegicus,A,,BAO_0000218,4527,,10116.0,1,Intermediate,1,CHEMBL627830,,
9270,N,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,,Rattus norvegicus,A,,BAO_0000218,4527,,10116.0,1,Intermediate,1,CHEMBL627831,,
9271,N,Area under curve in male SD rats was observed after oral administration in rat,,Rattus norvegicus,A,,BAO_0000218,15662,,10116.0,1,Intermediate,1,CHEMBL627832,,
9272,N,Area under curve of compound after iv administration of 20 mg/kg dose in rat,,Rattus norvegicus,A,,BAO_0000218,4413,,10116.0,1,Intermediate,1,CHEMBL627833,,
9273,N,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,3598,,10116.0,1,Expert,1,CHEMBL627834,,
9274,N,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,3598,,10116.0,1,Expert,1,CHEMBL628004,,
9275,N,Area under curve at 5 mg/kg po was determined in rat,,Rattus norvegicus,A,,BAO_0000218,5964,,10116.0,1,Intermediate,1,CHEMBL628005,,
9276,N,Area under curve in Rat at a oral dose of 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,4689,,10116.0,1,Intermediate,1,CHEMBL628006,,
9277,N,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,Rattus norvegicus,A,,BAO_0000218,4186,,10116.0,1,Intermediate,1,CHEMBL628007,,
9278,N,Area under curve was determined,,Rattus norvegicus,A,,BAO_0000218,5510,,10116.0,1,Intermediate,1,CHEMBL625676,,
9279,N,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,,Rattus norvegicus,A,,BAO_0000218,17858,,10116.0,1,Intermediate,1,CHEMBL631309,,
9280,N,Area under curve after intravenous administration at 3 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17804,,10116.0,1,Intermediate,1,CHEMBL631310,,
9281,N,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,,Rattus norvegicus,A,,BAO_0000218,6106,,10116.0,1,Intermediate,1,CHEMBL631311,,
9282,N,Area under curve at 4 hr in rat,,Rattus norvegicus,A,,BAO_0000218,5964,,10116.0,1,Intermediate,1,CHEMBL631312,,
9283,N,Area under curve at a dose of 30 mg/kg,,Rattus norvegicus,A,,BAO_0000218,4026,,10116.0,1,Intermediate,1,CHEMBL631313,,
9284,N,Area under curve at the dose of 2 mg/Kg administered perorally in rats,,Rattus norvegicus,A,,BAO_0000218,4756,,10116.0,1,Intermediate,1,CHEMBL631314,,
9285,N,Area under curve at the dose of 5 mg/Kg administered perorally in rats,,Rattus norvegicus,A,,BAO_0000218,4756,,10116.0,1,Intermediate,1,CHEMBL631315,,
9286,N,Area under curve for a 2-mpk po dose in SD rats,,Rattus norvegicus,A,,BAO_0000218,5862,,10116.0,1,Intermediate,1,CHEMBL631316,,
9287,N,Area under curve in SD rats,,Rattus norvegicus,A,,BAO_0000218,5862,,10116.0,1,Intermediate,1,CHEMBL631317,,
9288,N,Area under curve in rat after oral administration at 13 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,6644,,10116.0,1,Intermediate,1,CHEMBL874471,,
9289,N,Area under curve in rat by po administration at 0-24 hr,,Rattus norvegicus,A,,BAO_0000218,5871,,10116.0,1,Intermediate,1,CHEMBL631318,,
9290,N,Area under curve in rat plasma,,Rattus norvegicus,A,,BAO_0000218,5919,,10116.0,1,Intermediate,1,CHEMBL631319,,1969.0
9291,N,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5939,,10116.0,1,Intermediate,1,CHEMBL631320,,
9292,N,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5939,,10116.0,1,Intermediate,1,CHEMBL631321,,
9293,N,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,,Rattus norvegicus,A,,BAO_0000218,10,,10116.0,1,Intermediate,1,CHEMBL631322,,
9294,N,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,,Rattus norvegicus,A,,BAO_0000218,11149,,10116.0,1,Intermediate,1,CHEMBL631323,,
9295,N,Area under curve value in rat at a dose of 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5302,,10116.0,1,Intermediate,1,CHEMBL631324,,
9296,N,Area under curve was determined after oral administration in rats,,Rattus norvegicus,A,,BAO_0000218,17796,,10116.0,1,Intermediate,1,CHEMBL631325,,
9297,N,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,4890,,10116.0,1,Intermediate,1,CHEMBL631326,,
9298,N,Area under curve was determined after peroral administration in rat,,Rattus norvegicus,A,,BAO_0000218,6011,,10116.0,1,Intermediate,1,CHEMBL631327,,
9299,N,Area under curve was determined at a dose 30 mpk administered orally.,,Rattus norvegicus,A,,BAO_0000218,5375,,10116.0,1,Intermediate,1,CHEMBL631328,,
9300,N,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,,Rattus norvegicus,A,,BAO_0000218,17764,,10116.0,1,Intermediate,1,CHEMBL631329,,
9301,N,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,4368,,10116.0,1,Intermediate,1,CHEMBL627217,,
9302,N,Area under curve was determined in male rat,,Rattus norvegicus,A,,BAO_0000218,5610,,10116.0,1,Intermediate,1,CHEMBL626352,,
9303,N,Area under curve was determined in rat after PO administration,,Rattus norvegicus,A,,BAO_0000218,5833,,10116.0,1,Intermediate,1,CHEMBL626353,,
9304,N,Area under curve was determined in rat after a 3 mg/kg of oral dose,,Rattus norvegicus,A,,BAO_0000218,4257,,10116.0,1,Intermediate,1,CHEMBL626354,,
9305,N,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5937,,10116.0,1,Intermediate,1,CHEMBL626355,,
9306,N,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5932,,10116.0,1,Intermediate,1,CHEMBL626356,,
9307,N,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,,Rattus norvegicus,A,,BAO_0000218,5932,,10116.0,1,Intermediate,1,CHEMBL626357,,
9308,N,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17411,,10116.0,1,Intermediate,1,CHEMBL626358,,
9309,N,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17411,,10116.0,1,Intermediate,1,CHEMBL626359,,
9310,N,Peak plasma concentration in rat at a dose of 3 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17771,,10116.0,1,Intermediate,1,CHEMBL626360,,1969.0
9311,N,Plasma concentration at 2 hr in rats was evaluated.,,Rattus norvegicus,A,,BAO_0000218,1628,,10116.0,1,Intermediate,1,CHEMBL626361,,
9312,N,Plasma concentration at 2 hr in rats was evaluated; Not available,,Rattus norvegicus,A,,BAO_0000218,1628,,10116.0,1,Intermediate,1,CHEMBL626362,,
9313,N,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17411,,10116.0,1,Intermediate,1,CHEMBL626363,,
9314,N,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,Rattus norvegicus,A,,BAO_0000218,4910,,10116.0,1,Intermediate,1,CHEMBL626970,,
9315,N,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,,Rattus norvegicus,A,,BAO_0000218,4910,,10116.0,1,Intermediate,1,CHEMBL626971,,
9316,N,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,Rattus norvegicus,A,,BAO_0000218,4910,,10116.0,1,Intermediate,1,CHEMBL626972,,1969.0
9317,N,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,,Rattus norvegicus,A,,BAO_0000218,4910,,10116.0,1,Intermediate,1,CHEMBL626973,,1969.0
9318,N,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,Rattus norvegicus,A,,BAO_0000218,4910,,10116.0,1,Intermediate,1,CHEMBL626974,,1969.0
9319,N,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,,Rattus norvegicus,A,,BAO_0000218,4910,,10116.0,1,Intermediate,1,CHEMBL874592,,1969.0
9320,N,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,,Rattus norvegicus,A,,BAO_0000218,5510,,10116.0,1,Intermediate,1,CHEMBL626975,,
9321,N,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,,Rattus norvegicus,A,,BAO_0000218,5510,,10116.0,1,Intermediate,1,CHEMBL626976,,
9322,N,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,,Rattus norvegicus,A,,BAO_0000218,5510,,10116.0,1,Intermediate,1,CHEMBL626977,,
9323,N,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,,Rattus norvegicus,A,,BAO_0000218,5510,,10116.0,1,Intermediate,1,CHEMBL626978,,
9324,N,PK study was carried to determine the relative absorption ranking in rat.,,Rattus norvegicus,A,,BAO_0000218,16427,,10116.0,1,Intermediate,1,CHEMBL626979,,
9325,N,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,4689,In vivo,10116.0,1,Intermediate,1,CHEMBL626980,,1969.0
9326,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL626981,,178.0
9327,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL626982,,178.0
9328,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL626983,,178.0
9329,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622522,,178.0
9330,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622523,,178.0
9331,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622524,,178.0
9332,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622525,,955.0
9333,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622526,,955.0
9334,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL619849,,955.0
9335,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL619850,,955.0
9336,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL623864,,955.0
9337,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL623865,,955.0
9338,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL623866,,948.0
9339,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL623867,,948.0
9340,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL877615,,948.0
9341,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL623868,,948.0
9342,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL623869,,948.0
9343,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL623870,,948.0
9344,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL623871,,2048.0
9345,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL623872,,2048.0
9346,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622129,,2048.0
9347,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622130,,2048.0
9348,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622131,,2048.0
9349,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622132,,2048.0
9350,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622133,,2048.0
9351,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622134,,2048.0
9352,N,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622135,,2048.0
9353,N,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622136,,2048.0
9354,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622137,,2385.0
9355,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622138,,2385.0
9356,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL623017,,2385.0
9357,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL623018,,2385.0
9358,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL623019,,2385.0
9359,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL623020,,2385.0
9360,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL623021,,2385.0
9361,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL623022,,2385.0
9362,N,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623023,,2385.0
9363,N,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623024,,2385.0
9364,N,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623025,,2385.0
9365,N,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL620545,,2385.0
9366,N,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL620546,,2385.0
9367,N,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL620547,,2385.0
9368,N,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL620548,,2385.0
9369,N,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL620549,,2385.0
9370,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL620550,,2385.0
9371,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL620551,,2385.0
9372,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL620552,,2385.0
9373,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL620553,,2385.0
9374,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL620554,,2385.0
9375,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL875845,,2385.0
9376,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL620555,,2385.0
9377,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL620556,,2385.0
9378,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL620557,,2385.0
9379,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL620558,,
9380,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL620559,,
9381,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622939,,
9382,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622940,,
9383,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622941,,
9384,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622942,,
9385,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622943,,
9386,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622944,,
9387,N,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622945,,
9388,N,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622946,,
9389,N,Compound was evaluated for terminal half life in rat,,Rattus norvegicus,A,,BAO_0000218,3341,,10116.0,1,Intermediate,1,CHEMBL622947,,
9390,N,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,,Rattus norvegicus,A,,BAO_0000218,3634,In vivo,10116.0,1,Intermediate,1,CHEMBL622948,,1969.0
9391,N,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,,Rattus norvegicus,A,,BAO_0000218,3634,In vivo,10116.0,1,Intermediate,1,CHEMBL622949,,1969.0
9392,N,Compound was tested for its half life in rat,,Rattus norvegicus,A,,BAO_0000218,4839,,10116.0,1,Intermediate,1,CHEMBL622950,,
9393,U,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,Macaca mulatta,A,,BAO_0000218,5005,In vivo,9544.0,0,Intermediate,1,CHEMBL622951,,1969.0
9394,U,Compound was tested for its plasma half life in Sprague Dawley rats,,Rattus norvegicus,A,,BAO_0000366,5005,,10116.0,0,Intermediate,1,CHEMBL622952,,1969.0
9395,U,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,,Rattus norvegicus,A,,BAO_0000366,5005,,10116.0,0,Intermediate,1,CHEMBL622953,,1969.0
9396,N,Compound was tested for plasma half-life period in rat,,Rattus norvegicus,A,,BAO_0000218,1094,,10116.0,1,Intermediate,1,CHEMBL873818,,1969.0
9397,N,Elimination half life after i.v. administration of compound in rats,,Rattus norvegicus,A,,BAO_0000218,5031,In vivo,10116.0,1,Intermediate,1,CHEMBL622954,,
9398,N,Elimination half-life after IV dosing at 0.5 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,6518,In vivo,10116.0,1,Intermediate,1,CHEMBL622955,,
9399,N,Elimination half-life after IV dosing at 1 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,6518,In vivo,10116.0,1,Intermediate,1,CHEMBL875229,,
9400,N,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,6518,In vivo,10116.0,1,Intermediate,1,CHEMBL622956,,
9401,N,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,6518,In vivo,10116.0,1,Intermediate,1,CHEMBL622957,,
9402,N,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,Rattus norvegicus,A,,BAO_0000218,5408,In vivo,10116.0,1,Intermediate,1,CHEMBL622958,,955.0
9403,N,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,Rattus norvegicus,A,,BAO_0000218,5408,In vivo,10116.0,1,Intermediate,1,CHEMBL622959,,1969.0
9404,N,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,Rattus norvegicus,A,,BAO_0000218,5408,In vivo,10116.0,1,Intermediate,1,CHEMBL622960,,955.0
9405,N,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,Rattus norvegicus,A,,BAO_0000218,5408,In vivo,10116.0,1,Intermediate,1,CHEMBL622961,,1969.0
9406,N,Evaluated for the half life in rat (in vivo),,Rattus norvegicus,A,,BAO_0000218,4687,In vivo,10116.0,1,Intermediate,1,CHEMBL622962,,
9407,N,Hafl life in rat,,Rattus norvegicus,A,,BAO_0000218,6640,,10116.0,1,Intermediate,1,CHEMBL622963,,
9408,N,Hafl life rat,,Rattus norvegicus,A,,BAO_0000218,6640,,10116.0,1,Intermediate,1,CHEMBL622964,,
9409,N,Hafl life rat,,Rattus norvegicus,A,,BAO_0000218,6641,,10116.0,1,Intermediate,1,CHEMBL622965,,
9410,N,Hafl life rat; Not determined,,Rattus norvegicus,A,,BAO_0000218,6640,,10116.0,1,Intermediate,1,CHEMBL622966,,
9411,N,Hafl life rat; Not determined,,Rattus norvegicus,A,,BAO_0000218,6641,,10116.0,1,Intermediate,1,CHEMBL622967,,
9412,N,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17411,In vivo,10116.0,1,Intermediate,1,CHEMBL622968,,2113.0
9413,N,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17411,In vivo,10116.0,1,Intermediate,1,CHEMBL622969,,2107.0
9414,N,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17411,In vivo,10116.0,1,Intermediate,1,CHEMBL875327,,2048.0
9415,N,Half life in rat after 1 mg/kg i.v. administration,,Rattus norvegicus,A,,BAO_0000218,6570,In vivo,10116.0,1,Intermediate,1,CHEMBL628638,,
9416,N,Half life in rat after 2 mg/kg peroral administration,,Rattus norvegicus,A,,BAO_0000218,6570,In vivo,10116.0,1,Intermediate,1,CHEMBL628639,,
9417,N,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17411,In vivo,10116.0,1,Intermediate,1,CHEMBL625840,,
9418,N,Half life of 10 mg/kg oral dose determined in rats,,Rattus norvegicus,A,,BAO_0000218,4722,In vivo,10116.0,1,Intermediate,1,CHEMBL625841,,
9419,N,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL625842,,
9420,N,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL625843,,
9421,N,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL625844,,
9422,N,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL873822,,
9423,N,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL625845,,
9424,N,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL627059,,
9425,N,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL627060,,
9426,N,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL627061,,
9427,N,Half life of compound at 5 mg/kg after po administration was determined in rat,,Rattus norvegicus,A,,BAO_0000218,4762,In vivo,10116.0,1,Intermediate,1,CHEMBL627709,,
9428,N,Half life of compound determined after intravenous administration to rat,,Rattus norvegicus,A,,BAO_0000218,5327,In vivo,10116.0,1,Intermediate,1,CHEMBL627710,,
9429,N,Half life of compound was determined in rat,,Rattus norvegicus,A,,BAO_0000218,4847,,10116.0,1,Intermediate,1,CHEMBL627711,,
9430,N,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,Rattus norvegicus,A,,BAO_0000218,17720,In vivo,10116.0,1,Intermediate,1,CHEMBL627712,,1969.0
9431,N,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,A,,BAO_0000218,4723,In vivo,10116.0,1,Intermediate,1,CHEMBL627713,,
9432,N,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,A,,BAO_0000218,4723,In vivo,10116.0,1,Intermediate,1,CHEMBL627714,,
9433,U,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,Macaca fascicularis,A,,BAO_0000218,4256,In vivo,9541.0,0,Intermediate,1,CHEMBL627889,,
9434,U,Half life determined in rat by intravenous administration,,Rattus norvegicus,A,,BAO_0000218,4256,In vivo,10116.0,0,Intermediate,1,CHEMBL627890,,
9435,N,Half life determined in rats after iv administration,,Rattus norvegicus,A,,BAO_0000218,4722,In vivo,10116.0,1,Intermediate,1,CHEMBL627891,,
9436,N,Half life in rat plasma after administration of 2 mg/kg iv,,Rattus norvegicus,A,,BAO_0000218,6535,In vivo,10116.0,1,Intermediate,1,CHEMBL627892,,1969.0
9437,N,Half life in rat plasma after administration of 2 mg/kg iv,,Rattus norvegicus,A,,BAO_0000218,6535,In vivo,10116.0,1,Intermediate,1,CHEMBL627893,,1969.0
9438,N,Half life in rat plasma was determined,,Rattus norvegicus,A,,BAO_0000218,1435,,10116.0,1,Intermediate,1,CHEMBL627894,,1969.0
9439,N,Half life in rat plasma was determined; NA means not applicable,,Rattus norvegicus,A,,BAO_0000218,1435,,10116.0,1,Intermediate,1,CHEMBL627895,,1969.0
9440,N,Half life in rat was tested,,Rattus norvegicus,A,,BAO_0000218,5206,,10116.0,1,Intermediate,1,CHEMBL627896,,
9441,N,Half life measured in rat plasma,,Rattus norvegicus,A,,BAO_0000218,6080,,10116.0,1,Intermediate,1,CHEMBL627897,,1969.0
9442,N,Half life recorded in rats,,Rattus norvegicus,A,,BAO_0000218,4449,,10116.0,1,Intermediate,1,CHEMBL627898,,
9443,N,Half life was calculated,,Rattus norvegicus,A,,BAO_0000218,6057,,10116.0,1,Intermediate,1,CHEMBL627899,,
9444,N,Half life was calculated in rat,,Rattus norvegicus,A,,BAO_0000218,6057,,10116.0,1,Intermediate,1,CHEMBL873823,,
9445,N,Half life was determined,,Rattus norvegicus,A,,BAO_0000218,3747,,10116.0,1,Intermediate,1,CHEMBL627900,,
9446,N,Half life after 10 mg/kg oral administration in rat,,Rattus norvegicus,A,,BAO_0000218,17858,In vivo,10116.0,1,Intermediate,1,CHEMBL627901,,
9447,N,Half life after administering orally a dose of 10 mg/kg to a fasting rat,,Rattus norvegicus,A,,BAO_0000218,16365,In vivo,10116.0,1,Intermediate,1,CHEMBL627902,,
9448,N,Half life after administering orally a dose of 30 mg/kg,,Rattus norvegicus,A,,BAO_0000218,16365,In vivo,10116.0,1,Intermediate,1,CHEMBL627903,,
9449,N,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,,Rattus norvegicus,A,,BAO_0000218,5031,,10116.0,1,Intermediate,1,CHEMBL627904,,
9450,N,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,,Rattus norvegicus,A,,BAO_0000218,4722,,10116.0,1,Intermediate,1,CHEMBL627905,,
9451,N,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,6078,,10116.0,1,Intermediate,1,CHEMBL627906,,
9452,N,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,6078,,10116.0,1,Intermediate,1,CHEMBL627907,,
9453,N,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6078,,10116.0,1,Intermediate,1,CHEMBL876783,,
9454,N,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,,Rattus norvegicus,A,,BAO_0000218,6078,,10116.0,1,Intermediate,1,CHEMBL627908,,
9455,N,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,,Rattus norvegicus,A,,BAO_0000218,17065,,10116.0,1,Intermediate,1,CHEMBL627909,,
9456,N,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,,Rattus norvegicus,A,,BAO_0000218,1353,,10116.0,1,Intermediate,1,CHEMBL627910,,
9457,N,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),,Rattus norvegicus,A,,BAO_0000218,1353,,10116.0,1,Intermediate,1,CHEMBL627911,,
9458,N,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),,Rattus norvegicus,A,,BAO_0000218,1353,,10116.0,1,Intermediate,1,CHEMBL627912,,
9459,N,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),,Rattus norvegicus,A,,BAO_0000218,1353,,10116.0,1,Intermediate,1,CHEMBL627913,,
9460,N,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),,Rattus norvegicus,A,,BAO_0000218,1353,,10116.0,1,Intermediate,1,CHEMBL627914,,
9461,N,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,,Rattus norvegicus,A,,BAO_0000218,16423,,10116.0,1,Intermediate,1,CHEMBL627915,,
9462,N,Area under the curve was evaluated after 20 uM/kg of peroral administration,,Rattus norvegicus,A,,BAO_0000218,16423,,10116.0,1,Intermediate,1,CHEMBL627916,,
9463,N,Area under the curve was measured in rat after an iv dose of 1 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6062,,10116.0,1,Intermediate,1,CHEMBL627917,,
9464,N,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,6056,,10116.0,1,Intermediate,1,CHEMBL627918,,
9465,N,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,,Rattus norvegicus,A,,BAO_0000218,5182,,10116.0,1,Intermediate,1,CHEMBL627919,,
9466,N,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6410,,10116.0,1,Intermediate,1,CHEMBL627920,,
9467,N,Area under the curve was evaluated at an oral dose of 30 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6410,,10116.0,1,Intermediate,1,CHEMBL627921,,
9468,N,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,A,,BAO_0000218,4723,,10116.0,1,Intermediate,1,CHEMBL627922,,
9469,N,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,A,,BAO_0000218,4723,,10116.0,1,Intermediate,1,CHEMBL876784,,
9470,N,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,A,,BAO_0000218,4723,,10116.0,1,Intermediate,1,CHEMBL627923,,
9471,N,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,A,,BAO_0000218,4723,,10116.0,1,Intermediate,1,CHEMBL626208,,
9472,N,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,A,,BAO_0000218,4723,,10116.0,1,Intermediate,1,CHEMBL626209,,
9473,N,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,A,,BAO_0000218,4723,,10116.0,1,Intermediate,1,CHEMBL626210,,
9474,N,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,Rattus norvegicus,A,,BAO_0000218,2463,,10116.0,1,Intermediate,1,CHEMBL627994,,1969.0
9475,N,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,4709,,10116.0,1,Intermediate,1,CHEMBL627995,,
9476,N,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,,Rattus norvegicus,A,,BAO_0000218,4075,,10116.0,1,Intermediate,1,CHEMBL627996,,
9477,N,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,,Rattus norvegicus,A,,BAO_0000218,5394,,10116.0,1,Intermediate,1,CHEMBL627997,,
9478,N,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,,Rattus norvegicus,A,,BAO_0000218,2661,,10116.0,1,Intermediate,1,CHEMBL627998,,
9479,N,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,,Rattus norvegicus,A,,BAO_0000218,2661,,10116.0,1,Intermediate,1,CHEMBL628640,,
9480,N,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,,Rattus norvegicus,A,,BAO_0000218,2661,,10116.0,1,Intermediate,1,CHEMBL628641,,
9481,N,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,,Rattus norvegicus,A,,BAO_0000218,2661,,10116.0,1,Intermediate,1,CHEMBL628642,,
9482,N,Compound was evaluated for area under the curve expressed as (h*ug/ml),,Rattus norvegicus,A,,BAO_0000218,17791,,10116.0,1,Intermediate,1,CHEMBL628643,,
9483,N,Compound was tested for area under curve in rat,,Rattus norvegicus,A,,BAO_0000218,2591,,10116.0,1,Intermediate,1,CHEMBL628644,,
9484,N,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,,Rattus norvegicus,A,,BAO_0000218,6567,,10116.0,1,Intermediate,1,CHEMBL628645,,
9485,N,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,6211,,10116.0,1,Intermediate,1,CHEMBL628646,,
9486,N,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),,Rattus norvegicus,A,,BAO_0000218,5529,,10116.0,1,Intermediate,1,CHEMBL628647,,
9487,N,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,Rattus norvegicus,A,,BAO_0000218,5408,,10116.0,1,Intermediate,1,CHEMBL628648,,
9488,N,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,Rattus norvegicus,A,,BAO_0000218,5408,,10116.0,1,Intermediate,1,CHEMBL625358,,
9489,N,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,Rattus norvegicus,A,,BAO_0000218,5408,,10116.0,1,Intermediate,1,CHEMBL625359,,
9490,N,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,Rattus norvegicus,A,,BAO_0000218,5408,,10116.0,1,Intermediate,1,CHEMBL625360,,
9491,N,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),,Rattus norvegicus,A,,BAO_0000218,429,,10116.0,1,Intermediate,1,CHEMBL625361,,
9492,N,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),,Rattus norvegicus,A,,BAO_0000218,429,,10116.0,1,Intermediate,1,CHEMBL625362,,
9493,N,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),,Rattus norvegicus,A,,BAO_0000218,429,,10116.0,1,Intermediate,1,CHEMBL625363,,
9494,N,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,Rattus norvegicus,A,,BAO_0000218,4796,,10116.0,1,Intermediate,1,CHEMBL625364,,
9495,N,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,,10116.0,1,Intermediate,1,CHEMBL625365,,
9496,N,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,,10116.0,1,Intermediate,1,CHEMBL625366,,
9497,N,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,,10116.0,1,Intermediate,1,CHEMBL625367,,
9498,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL625368,,2113.0
9499,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL625369,,2113.0
9500,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL625370,,2113.0
9501,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL625371,,2113.0
9502,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL625372,,2113.0
9503,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL625373,,2113.0
9504,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL625374,,2107.0
9505,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL877593,,2107.0
9506,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL625375,,2107.0
9507,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL625376,,2107.0
9508,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL621973,,2107.0
9509,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL621974,,2107.0
9510,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL621975,,2048.0
9511,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622166,,2048.0
9512,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622167,,2048.0
9513,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622168,,2048.0
9514,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622169,,2048.0
9515,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622170,,2048.0
9516,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622171,,2046.0
9517,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622172,,2046.0
9518,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622173,,2046.0
9519,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622174,,2046.0
9520,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622175,,2046.0
9521,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622176,,2046.0
9522,N,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622177,,2046.0
9523,N,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622178,,2046.0
9524,N,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622179,,2046.0
9525,N,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622180,,2046.0
9526,N,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622181,,
9527,N,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622182,,
9528,N,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622183,,
9529,N,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622184,,
9530,N,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622185,,
9531,N,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622186,,
9532,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622187,,
9533,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL625002,,
9534,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622090,,
9535,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622091,,
9536,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622092,,
9537,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622093,,
9538,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622094,,
9539,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622095,,
9540,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622264,,
9541,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622265,,2106.0
9542,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622266,,2106.0
9543,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622267,,2106.0
9544,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622268,,2106.0
9545,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622269,,2106.0
9546,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL625071,,2106.0
9547,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL621621,,2106.0
9548,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL621622,,2106.0
9549,N,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL621623,,2106.0
9550,N,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL621624,,2106.0
9551,N,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL621625,,2106.0
9552,N,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL621626,,2106.0
9553,N,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL621627,,2106.0
9554,N,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL621628,,2106.0
9555,N,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL875328,,2106.0
9556,N,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL621629,,2106.0
9557,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL621630,,2106.0
9558,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL621631,,2106.0
9559,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL621632,,2106.0
9560,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL621633,,2106.0
9561,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL621634,,2106.0
9562,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL621635,,2106.0
9563,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL621636,,2106.0
9564,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL621637,,2106.0
9565,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL621638,,2106.0
9566,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL618883,,
9567,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL618884,,
9568,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL628627,,
9569,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL628628,,
9570,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL628629,,
9571,N,Half life after administering orally a dose of 3 mg/kg,,Rattus norvegicus,A,,BAO_0000218,16365,In vivo,10116.0,1,Intermediate,1,CHEMBL628630,,
9572,N,Half life after administering orally a dose of 3 mg/kg to a fasting rat,,Rattus norvegicus,A,,BAO_0000218,16365,In vivo,10116.0,1,Intermediate,1,CHEMBL628631,,
9573,N,Half life after administering intravenously a dose of 1 mg/kg,,Rattus norvegicus,A,,BAO_0000218,16365,In vivo,10116.0,1,Intermediate,1,CHEMBL628632,,
9574,N,Half life after oral dosing in rats,,Rattus norvegicus,A,,BAO_0000218,526,In vivo,10116.0,1,Intermediate,1,CHEMBL628633,,
9575,N,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,,Rattus norvegicus,A,,BAO_0000218,16365,In vivo,10116.0,1,Intermediate,1,CHEMBL628634,,
9576,N,Half life by intravenous administration of 3.4 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,4368,In vivo,10116.0,1,Intermediate,1,CHEMBL627789,,
9577,N,Half life in rat,,Rattus norvegicus,A,,BAO_0000218,3371,,10116.0,1,Intermediate,1,CHEMBL627790,,
9578,N,Half life in rat,,Rattus norvegicus,A,,BAO_0000218,6448,,10116.0,1,Intermediate,1,CHEMBL627791,,
9579,N,Half life in rat,,Rattus norvegicus,A,,BAO_0000218,6453,,10116.0,1,Intermediate,1,CHEMBL627792,,
9580,N,Half life in rat after intravenous administration of the compound,,Rattus norvegicus,A,,BAO_0000218,4353,In vivo,10116.0,1,Intermediate,1,CHEMBL627793,,
9581,N,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,,Rattus norvegicus,A,,BAO_0000218,4353,In vivo,10116.0,1,Intermediate,1,CHEMBL627794,,1969.0
9582,N,Half life in rat after po administration of the compound,,Rattus norvegicus,A,,BAO_0000218,4353,In vivo,10116.0,1,Intermediate,1,CHEMBL627795,,
9583,N,Half life in rat after po administration of the compound; ND means Not determined,,Rattus norvegicus,A,,BAO_0000218,4353,In vivo,10116.0,1,Intermediate,1,CHEMBL627796,,
9584,N,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,,Rattus norvegicus,A,,BAO_0000218,4353,In vivo,10116.0,1,Intermediate,1,CHEMBL875335,,1969.0
9585,N,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,,Rattus norvegicus,A,,BAO_0000218,4353,In vivo,10116.0,1,Intermediate,1,CHEMBL627797,,1969.0
9586,N,Half life in rat i.v.,,Rattus norvegicus,A,,BAO_0000218,5789,In vivo,10116.0,1,Intermediate,1,CHEMBL627798,,
9587,N,Half life in rat i.v. at 2 mg/kg concentration,,Rattus norvegicus,A,,BAO_0000218,17686,In vivo,10116.0,1,Intermediate,1,CHEMBL627799,,
9588,N,Half life in rats,,Rattus norvegicus,A,,BAO_0000218,6495,,10116.0,1,Intermediate,1,CHEMBL627800,,
9589,N,Half life in rats after intravenous administration,,Rattus norvegicus,A,,BAO_0000218,484,In vivo,10116.0,1,Intermediate,1,CHEMBL627801,,
9590,N,Half life in rats at the dose of 1.0 mpk by i.v. administration,,Rattus norvegicus,A,,BAO_0000218,6467,In vivo,10116.0,1,Intermediate,1,CHEMBL627802,,
9591,N,Half life in rat,,Rattus norvegicus,A,,BAO_0000218,6642,,10116.0,1,Expert,1,CHEMBL627803,,
9592,N,Half life was evaluated after intravenous administration to rats,,Rattus norvegicus,A,,BAO_0000218,16367,In vivo,10116.0,1,Intermediate,1,CHEMBL873820,,
9593,N,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),,Rattus norvegicus,A,,BAO_0000218,1369,,10116.0,1,Intermediate,1,CHEMBL627804,,
9594,N,Half life was evaluated in rat,,Rattus norvegicus,A,,BAO_0000218,5472,,10116.0,1,Intermediate,1,CHEMBL627805,,
9595,N,Half life was evaluated in rat,,Rattus norvegicus,A,,BAO_0000218,6049,,10116.0,1,Intermediate,1,CHEMBL627806,,
9596,N,Half life was evaluated in rat; Not tested,,Rattus norvegicus,A,,BAO_0000218,5472,,10116.0,1,Intermediate,1,CHEMBL627107,,
9597,N,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,,Rattus norvegicus,A,,BAO_0000218,16366,In vivo,10116.0,1,Intermediate,1,CHEMBL627108,,
9598,N,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,,Rattus norvegicus,A,,BAO_0000218,11149,In vivo,10116.0,1,Intermediate,1,CHEMBL627109,,
9599,N,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,,Rattus norvegicus,A,,BAO_0000218,11149,In vivo,10116.0,1,Intermediate,1,CHEMBL627110,,178.0
9600,U,Half life was measured in monkey at dose of 10 mg/kg by po administration,,Primates,A,,BAO_0000218,2891,In vivo,9443.0,0,Intermediate,1,CHEMBL627111,,
9601,U,Half life was measured in monkey at dose of 10 mg/kg by po administration,,Primates,A,,BAO_0000218,2891,In vivo,9443.0,0,Intermediate,1,CHEMBL627112,,
9602,U,Half life was measured in rat at dose of 30 mg/kg by iv administration,,Rattus norvegicus,A,,BAO_0000218,2891,In vivo,10116.0,0,Intermediate,1,CHEMBL627113,,
9603,U,Half life was measured in rat at dose of 30 mg/kg by po administration,,Rattus norvegicus,A,,BAO_0000218,2891,In vivo,10116.0,0,Intermediate,1,CHEMBL627114,,
9604,N,Half life (t1/2) was determined,,Rattus norvegicus,A,,BAO_0000218,4026,,10116.0,1,Intermediate,1,CHEMBL627115,,
9605,N,Half life period at a dose of 10 uM/kg in rat was determined,,Rattus norvegicus,A,,BAO_0000218,4527,,10116.0,1,Intermediate,1,CHEMBL627116,,
9606,N,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,,Rattus norvegicus,A,,BAO_0000218,4527,In vivo,10116.0,1,Intermediate,1,CHEMBL627117,,
9607,N,Half life period was determined,,Rattus norvegicus,A,,BAO_0000218,5503,,10116.0,1,Intermediate,1,CHEMBL627118,,
9608,N,Half life period after intravenous administration at 20 mpk in rats,,Rattus norvegicus,A,,BAO_0000218,4426,In vivo,10116.0,1,Intermediate,1,CHEMBL627119,,
9609,N,Half life period after intravenous administration at 20 mpk in rats; Not performed.,,Rattus norvegicus,A,,BAO_0000218,4426,In vivo,10116.0,1,Intermediate,1,CHEMBL627120,,
9610,N,Half life period after intravenous administration in rat,,Rattus norvegicus,A,,BAO_0000218,6109,In vivo,10116.0,1,Intermediate,1,CHEMBL626922,,
9611,N,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,Rattus norvegicus,A,,BAO_0000218,5654,In vivo,10116.0,1,Intermediate,1,CHEMBL626923,,
9612,N,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,Rattus norvegicus,A,,BAO_0000218,5654,In vivo,10116.0,1,Intermediate,1,CHEMBL626924,,
9613,N,Half life period in 80% rat plasma at 37 degree Centigrade,,Rattus norvegicus,A,,BAO_0000218,4755,,10116.0,1,Intermediate,1,CHEMBL626925,,1969.0
9614,N,Half life period in SD rats,,Rattus norvegicus,A,,BAO_0000218,5862,,10116.0,1,Intermediate,1,CHEMBL626926,,
9615,N,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),,Rattus norvegicus,A,,BAO_0000218,1515,,10116.0,1,Intermediate,1,CHEMBL626927,,1969.0
9616,N,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),,Rattus norvegicus,A,,BAO_0000218,1515,,10116.0,1,Intermediate,1,CHEMBL626928,,1969.0
9617,N,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,Rattus norvegicus,A,,BAO_0000218,1515,,10116.0,1,Intermediate,1,CHEMBL626929,,1969.0
9618,N,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,Rattus norvegicus,A,,BAO_0000218,1515,,10116.0,1,Intermediate,1,CHEMBL626930,,1969.0
9619,N,Half life period in rat,,Rattus norvegicus,A,,BAO_0000218,5960,,10116.0,1,Intermediate,1,CHEMBL626931,,
9620,N,Half life period in rat,,Rattus norvegicus,A,,BAO_0000218,6103,,10116.0,1,Intermediate,1,CHEMBL626932,,
9621,N,Half life period in rat,,Rattus norvegicus,A,,BAO_0000218,6317,,10116.0,1,Intermediate,1,CHEMBL626933,,
9622,N,Half life period in rat after oral administration at 10.5 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,6644,In vivo,10116.0,1,Intermediate,1,CHEMBL873826,,
9623,N,Half life period in rat after oral administration at 11.2 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,6644,In vivo,10116.0,1,Intermediate,1,CHEMBL626934,,
9624,N,Half life period in rat after oral administration at 13 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,6644,In vivo,10116.0,1,Intermediate,1,CHEMBL626935,,
9625,N,Half life period in rat after oral administration at 9.7 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,6644,In vivo,10116.0,1,Intermediate,1,CHEMBL626936,,
9626,N,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,,10116.0,1,Intermediate,1,CHEMBL626937,,
9627,N,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6295,,10116.0,1,Intermediate,1,CHEMBL625906,,
9628,N,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6296,,10116.0,1,Intermediate,1,CHEMBL625907,,
9629,N,PK study was carried to determine AUC (area under curve) value in rat,,Rattus norvegicus,A,,BAO_0000218,16427,,10116.0,1,Intermediate,1,CHEMBL625908,,
9630,N,Pharmacokinetic parameter AUC after intravenous administration to rats,,Rattus norvegicus,A,,BAO_0000218,16367,,10116.0,1,Intermediate,1,CHEMBL625909,,
9631,N,Pharmacokinetic parameter AUC after oral administration to rats,,Rattus norvegicus,A,,BAO_0000218,16367,,10116.0,1,Intermediate,1,CHEMBL625910,,
9632,N,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,,Rattus norvegicus,A,,BAO_0000218,16365,,10116.0,1,Intermediate,1,CHEMBL625911,,
9633,N,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,,Rattus norvegicus,A,,BAO_0000218,16365,,10116.0,1,Intermediate,1,CHEMBL625912,,
9634,N,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,,Rattus norvegicus,A,,BAO_0000218,16365,,10116.0,1,Intermediate,1,CHEMBL626538,,
9635,N,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,,Rattus norvegicus,A,,BAO_0000218,16365,,10116.0,1,Intermediate,1,CHEMBL876794,,
9636,N,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,,Rattus norvegicus,A,,BAO_0000218,16365,,10116.0,1,Intermediate,1,CHEMBL626539,,
9637,N,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,,Rattus norvegicus,A,,BAO_0000218,16365,,10116.0,1,Intermediate,1,CHEMBL626540,,
9638,N,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5394,,10116.0,1,Intermediate,1,CHEMBL626541,,
9639,N,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5394,,10116.0,1,Intermediate,1,CHEMBL626542,,
9640,N,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,,Rattus norvegicus,A,,BAO_0000218,2792,,10116.0,1,Intermediate,1,CHEMBL626543,,
9641,N,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,,Rattus norvegicus,A,,BAO_0000218,2792,,10116.0,1,Intermediate,1,CHEMBL626544,,
9642,N,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,,Rattus norvegicus,A,,BAO_0000218,2792,,10116.0,1,Intermediate,1,CHEMBL626545,,
9643,N,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,,Rattus norvegicus,A,,BAO_0000218,2792,,10116.0,1,Intermediate,1,CHEMBL626546,,
9644,N,Pharmacokinetic parameter area under curve was reported,,Rattus norvegicus,A,,BAO_0000218,5334,,10116.0,1,Intermediate,1,CHEMBL626547,,
9645,N,Pharmacokinetic property (AUC) in rat,,Rattus norvegicus,A,,BAO_0000218,4408,,10116.0,1,Intermediate,1,CHEMBL626548,,
9646,N,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,,Rattus norvegicus,A,,BAO_0000218,5983,,10116.0,1,Intermediate,1,CHEMBL626549,,
9647,N,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,,Rattus norvegicus,A,,BAO_0000218,4397,,10116.0,1,Intermediate,1,CHEMBL626550,,
9648,N,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,,Rattus norvegicus,A,,BAO_0000218,4397,,10116.0,1,Intermediate,1,CHEMBL626551,,
9649,N,Pharmacokinetic property was determined,,Rattus norvegicus,A,,BAO_0000218,5491,,10116.0,1,Intermediate,1,CHEMBL623777,,
9650,N,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5491,,10116.0,1,Intermediate,1,CHEMBL623778,,
9651,N,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,,Rattus norvegicus,A,,BAO_0000218,5491,,10116.0,1,Intermediate,1,CHEMBL623779,,
9652,N,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,Rattus norvegicus,A,,BAO_0000218,4199,,10116.0,1,Intermediate,1,CHEMBL623780,,1969.0
9653,N,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,,Rattus norvegicus,A,,BAO_0000218,4199,,10116.0,1,Intermediate,1,CHEMBL622015,,1969.0
9654,N,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,,Rattus norvegicus,A,,BAO_0000218,4199,,10116.0,1,Intermediate,1,CHEMBL622016,,1969.0
9655,N,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",,Rattus norvegicus,A,,BAO_0000218,5173,,10116.0,1,Intermediate,1,CHEMBL622017,,
9656,N,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",,Rattus norvegicus,A,,BAO_0000218,5173,,10116.0,1,Intermediate,1,CHEMBL622018,,
9657,N,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",,Rattus norvegicus,A,,BAO_0000218,5173,,10116.0,1,Intermediate,1,CHEMBL622019,,
9658,N,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",,Rattus norvegicus,A,,BAO_0000218,5173,,10116.0,1,Intermediate,1,CHEMBL622020,,
9659,N,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,,Rattus norvegicus,A,,BAO_0000218,16366,,10116.0,1,Intermediate,1,CHEMBL622021,,
9660,N,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,,Rattus norvegicus,A,,BAO_0000218,16366,,10116.0,1,Intermediate,1,CHEMBL622022,,
9661,N,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,,Rattus norvegicus,A,,BAO_0000218,5327,,10116.0,1,Intermediate,1,CHEMBL622023,,
9662,N,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,6681,,10116.0,1,Intermediate,1,CHEMBL622024,,
9663,N,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),,Rattus norvegicus,A,,BAO_0000218,12873,,10116.0,1,Intermediate,1,CHEMBL622693,,
9664,N,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),,Rattus norvegicus,A,,BAO_0000218,12873,,10116.0,1,Intermediate,1,CHEMBL622694,,
9665,N,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,6685,,10116.0,1,Intermediate,1,CHEMBL622695,,
9666,N,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,Rattus norvegicus,A,,BAO_0000218,6685,,10116.0,1,Intermediate,1,CHEMBL622696,,
9667,N,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",,Rattus norvegicus,A,,BAO_0000218,6685,,10116.0,1,Intermediate,1,CHEMBL622697,,
9668,N,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",,Rattus norvegicus,A,,BAO_0000218,6619,,10116.0,1,Intermediate,1,CHEMBL622874,,
9669,N,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",,Rattus norvegicus,A,,BAO_0000218,6619,,10116.0,1,Intermediate,1,CHEMBL622875,,
9670,N,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,Rattus norvegicus,A,,BAO_0000218,10363,,10116.0,1,Intermediate,1,CHEMBL622876,,
9671,N,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,Rattus norvegicus,A,,BAO_0000218,4796,,10116.0,1,Intermediate,1,CHEMBL622877,,
9672,N,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,Rattus norvegicus,A,,BAO_0000218,4910,,10116.0,1,Intermediate,1,CHEMBL622878,,
9673,N,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,,Rattus norvegicus,A,,BAO_0000218,4910,,10116.0,1,Intermediate,1,CHEMBL622879,,1969.0
9674,N,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,,Rattus norvegicus,A,,BAO_0000218,4839,,10116.0,1,Intermediate,1,CHEMBL877602,,
9675,N,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,15078,,10116.0,1,Intermediate,1,CHEMBL622880,,
9676,N,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,15078,,10116.0,1,Intermediate,1,CHEMBL622881,,
9677,N,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,15078,,10116.0,1,Intermediate,1,CHEMBL622882,,
9678,N,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,15078,,10116.0,1,Intermediate,1,CHEMBL622883,,
9679,N,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622884,,2046.0
9680,N,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",,Rattus norvegicus,A,,BAO_0000218,11450,,10116.0,1,Intermediate,1,CHEMBL622885,,2046.0
9681,N,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,Rattus norvegicus,A,,BAO_0000218,8151,,10116.0,1,Intermediate,1,CHEMBL622886,,
9682,N,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,8151,,10116.0,1,Intermediate,1,CHEMBL622887,,
9683,N,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,8151,,10116.0,1,Intermediate,1,CHEMBL622888,,1088.0
9684,N,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622889,,178.0
9685,N,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622890,,178.0
9686,N,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622891,,178.0
9687,N,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL877603,,178.0
9688,N,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622892,,955.0
9689,N,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622893,,955.0
9690,N,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622894,,955.0
9691,N,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622895,,955.0
9692,N,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622896,,955.0
9693,N,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622897,,948.0
9694,N,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622898,,948.0
9695,N,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622899,,948.0
9696,N,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622900,,2113.0
9697,N,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL624114,,2113.0
9698,N,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL624115,,2113.0
9699,N,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL624116,,2113.0
9700,N,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL624117,,2107.0
9701,N,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL624118,,2107.0
9702,N,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL624119,,2107.0
9703,N,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL624120,,2107.0
9704,N,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL624121,,2048.0
9705,N,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL624122,,2048.0
9706,N,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL624123,,2048.0
9707,N,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL624124,,2048.0
9708,N,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL624125,,2385.0
9709,N,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL624126,,2385.0
9710,N,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL624127,,2385.0
9711,N,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL624128,,2385.0
9712,N,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL624129,,14.0
9713,N,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL624130,,14.0
9714,N,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622340,,14.0
9715,N,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622341,,14.0
9716,N,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622342,,160.0
9717,N,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622343,,160.0
9718,N,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622344,,160.0
9719,N,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622345,,160.0
9720,N,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622346,,2106.0
9721,N,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622347,,2106.0
9722,N,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622348,,2106.0
9723,N,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622349,,2106.0
9724,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622350,,
9725,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622351,,
9726,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622352,,
9727,N,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622353,,
9728,N,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622354,,
9729,N,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622355,,
9730,N,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622356,,
9731,N,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622357,,
9732,N,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622358,,
9733,N,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL622359,,
9734,N,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL874393,,
9735,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622872,,
9736,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL622873,,
9737,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL623047,,
9738,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623048,,
9739,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623049,,
9740,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623050,,
9741,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623051,,
9742,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL623052,,
9743,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL626343,,
9744,N,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL626344,,
9745,N,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL626345,,
9746,N,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL626346,,
9747,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL626347,,
9748,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL626348,,
9749,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,Rattus norvegicus,A,,BAO_0000218,16434,,10116.0,1,Intermediate,1,CHEMBL626349,,
9750,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,Rattus norvegicus,F,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL626350,,
9751,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL626351,,
9752,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL627650,,
9753,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,Rattus norvegicus,F,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL627651,,
9754,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL627652,,
9755,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,Rattus norvegicus,A,,BAO_0000218,16435,,10116.0,1,Intermediate,1,CHEMBL627653,,
9756,N,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL627654,,
9757,N,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL627835,,
9758,N,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL627836,,
9759,N,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL627837,,
9760,N,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL627838,,
9761,N,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL875338,,
9762,N,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL627839,,
9763,N,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL627840,,
9764,N,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL627841,,
9765,N,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL627842,,
9766,N,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL627843,,
9767,N,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL627844,,
9768,N,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL627845,,
9769,N,Half life period in rat by iv administration at a dose of 3 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5874,In vivo,10116.0,1,Intermediate,1,CHEMBL627846,,
9770,N,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),,Rattus norvegicus,A,,BAO_0000218,1515,,10116.0,1,Intermediate,1,CHEMBL627847,,1969.0
9771,N,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),,Rattus norvegicus,A,,BAO_0000218,1515,,10116.0,1,Intermediate,1,CHEMBL873821,,1969.0
9772,N,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,Rattus norvegicus,A,,BAO_0000218,1515,,10116.0,1,Intermediate,1,CHEMBL626079,,1969.0
9773,N,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,Rattus norvegicus,A,,BAO_0000218,1515,,10116.0,1,Intermediate,1,CHEMBL626080,,1969.0
9774,N,Half life period was evaluated in rat plasma,,Rattus norvegicus,A,,BAO_0000218,5491,,10116.0,1,Intermediate,1,CHEMBL626081,,1969.0
9775,N,Half life period was evaluated in rat plasma; Not tested,,Rattus norvegicus,A,,BAO_0000218,5491,,10116.0,1,Intermediate,1,CHEMBL875344,,1969.0
9776,N,Half life period was evaluated in rats,,Rattus norvegicus,A,,BAO_0000218,1918,,10116.0,1,Intermediate,1,CHEMBL626082,,
9777,N,"Half life period was evaluated in rats, iv",,Rattus norvegicus,A,,BAO_0000218,1918,In vivo,10116.0,1,Intermediate,1,CHEMBL626250,,
9778,N,Half life period after intravenous administration at 5 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,6113,In vivo,10116.0,1,Intermediate,1,CHEMBL626251,,
9779,N,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,Rattus norvegicus,A,,BAO_0000218,5546,In vivo,10116.0,1,Intermediate,1,CHEMBL626252,,
9780,N,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5553,In vivo,10116.0,1,Intermediate,1,CHEMBL626253,,
9781,N,Half life stability of compound was evaluated in rat plasma,,Rattus norvegicus,A,,BAO_0000218,4188,,10116.0,1,Intermediate,1,CHEMBL626254,,1969.0
9782,N,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,,Rattus norvegicus,A,,BAO_0000218,6215,In vivo,10116.0,1,Intermediate,1,CHEMBL626255,,
9783,N,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,6141,In vivo,10116.0,1,Intermediate,1,CHEMBL626256,,
9784,N,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,Rattus norvegicus,A,,BAO_0000218,5182,In vivo,10116.0,1,Intermediate,1,CHEMBL626257,,
9785,N,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,,Rattus norvegicus,A,,BAO_0000218,5182,In vivo,10116.0,1,Intermediate,1,CHEMBL626258,,
9786,N,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,,Rattus norvegicus,A,,BAO_0000218,5710,In vivo,10116.0,1,Intermediate,1,CHEMBL626259,,
9787,N,Half in rat i.v.,,Rattus norvegicus,A,,BAO_0000218,5789,In vivo,10116.0,1,Intermediate,1,CHEMBL626260,,
9788,N,Half period in rat after intravenous administration,,Rattus norvegicus,A,,BAO_0000218,6011,In vivo,10116.0,1,Intermediate,1,CHEMBL875345,,
9789,N,Half-life after repeated oral dose of compound at 1 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,17594,In vivo,10116.0,1,Intermediate,1,CHEMBL626261,,
9790,N,Half-life measured in in vitro Cathepsin B assay in rat liver,,Rattus norvegicus,A,,BAO_0000218,12357,In vitro,10116.0,1,Intermediate,1,CHEMBL626262,,2107.0
9791,N,Half-life of compound was determined in rats,,Rattus norvegicus,A,,BAO_0000218,5210,,10116.0,1,Intermediate,1,CHEMBL626263,,
9792,N,Half-life at 10 mg/kg in rat upon intravenous administration,,Rattus norvegicus,A,,BAO_0000218,17596,In vivo,10116.0,1,Intermediate,1,CHEMBL625270,,
9793,N,Half-life determined in rat,,Rattus norvegicus,A,,BAO_0000218,6672,,10116.0,1,Intermediate,1,CHEMBL625271,,
9794,N,Half-life determined in rat,,Rattus norvegicus,A,,BAO_0000218,6673,,10116.0,1,Intermediate,1,CHEMBL625272,,
9795,N,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,,Rattus norvegicus,A,,BAO_0000218,4910,In vivo,10116.0,1,Intermediate,1,CHEMBL625273,,955.0
9796,N,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",,Rattus norvegicus,A,,BAO_0000218,3741,,10116.0,1,Intermediate,1,CHEMBL625274,,1969.0
9797,N,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17671,In vivo,10116.0,1,Intermediate,1,CHEMBL625275,,
9798,N,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,,Rattus norvegicus,A,,BAO_0000218,4910,In vivo,10116.0,1,Intermediate,1,CHEMBL625276,,1969.0
9799,N,Half-life in rat plasma,,Rattus norvegicus,A,,BAO_0000218,17537,,10116.0,1,Intermediate,1,CHEMBL625277,,1969.0
9800,N,Half-life in rat plasma was determined,,Rattus norvegicus,A,,BAO_0000218,4965,,10116.0,1,Intermediate,1,CHEMBL625278,,1969.0
9801,N,Half-life in rat plasma; Not tested,,Rattus norvegicus,A,,BAO_0000218,17537,,10116.0,1,Intermediate,1,CHEMBL625279,,1969.0
9802,N,Half-life in rat serum,,Rattus norvegicus,A,,BAO_0000218,6124,,10116.0,1,Intermediate,1,CHEMBL625280,,1977.0
9803,N,Half-life in rat serum; na is not available,,Rattus norvegicus,A,,BAO_0000218,6124,,10116.0,1,Intermediate,1,CHEMBL876797,,1977.0
9804,N,Half-life was calculated in rat,,Rattus norvegicus,A,,BAO_0000218,6078,,10116.0,1,Intermediate,1,CHEMBL625281,,
9805,N,Half-life was calculated in rat plasma,,Rattus norvegicus,A,,BAO_0000218,17668,,10116.0,1,Intermediate,1,CHEMBL873827,,1969.0
9806,N,Half-life was determined,,Rattus norvegicus,A,,BAO_0000218,3185,,10116.0,1,Intermediate,1,CHEMBL625282,,
9807,N,Half-life was determined,,Rattus norvegicus,A,,BAO_0000218,4883,,10116.0,1,Intermediate,1,CHEMBL625283,,
9808,N,Half-life after administration of 20 mg/Kg oral dose in rat,,Rattus norvegicus,A,,BAO_0000218,2959,In vivo,10116.0,1,Intermediate,1,CHEMBL625284,,
9809,N,Half-life after administration of 3.2 mg/kg intravenously in male rat,,Rattus norvegicus,A,,BAO_0000218,4029,In vivo,10116.0,1,Intermediate,1,CHEMBL625285,,
9810,N,Half-life after intravenous administration in female rat,,Rattus norvegicus,A,,BAO_0000218,4029,In vivo,10116.0,1,Intermediate,1,CHEMBL625286,,
9811,N,Half-life after intravenous administration in male rat,,Rattus norvegicus,A,,BAO_0000218,4029,In vivo,10116.0,1,Intermediate,1,CHEMBL625287,,
9812,N,Half-life after intravenous dose in rat,,Rattus norvegicus,A,,BAO_0000218,6180,In vivo,10116.0,1,Intermediate,1,CHEMBL625288,,
9813,N,Half-life in a rat liver homogenate preparation,,Rattus norvegicus,A,,BAO_0000218,1557,,10116.0,1,Intermediate,1,CHEMBL625289,,2107.0
9814,N,Half-life in plasma of rat,,Rattus norvegicus,A,,BAO_0000218,12500,,10116.0,1,Intermediate,1,CHEMBL625290,,1969.0
9815,N,Half-life in plasma of rat at dose of 3-10 mgkg,,Rattus norvegicus,A,,BAO_0000218,12500,,10116.0,1,Intermediate,1,CHEMBL876798,,1969.0
9816,N,Half-life in rat,,Rattus norvegicus,A,,BAO_0000218,5064,,10116.0,1,Intermediate,1,CHEMBL625291,,
9817,N,Half-life in rat,,Rattus norvegicus,A,,BAO_0000218,5145,,10116.0,1,Intermediate,1,CHEMBL625292,,
9818,N,Half-life in rat,,Rattus norvegicus,A,,BAO_0000218,5147,,10116.0,1,Intermediate,1,CHEMBL625293,,
9819,N,Half-life in rat,,Rattus norvegicus,A,,BAO_0000218,5833,,10116.0,1,Intermediate,1,CHEMBL622832,,
9820,N,Half-life in rat,,Rattus norvegicus,A,,BAO_0000218,6596,,10116.0,1,Intermediate,1,CHEMBL622833,,
9821,N,Half-life in rat,,Rattus norvegicus,A,,BAO_0000218,17655,,10116.0,1,Intermediate,1,CHEMBL622834,,
9822,N,Half-life in rat after oral administration at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6495,In vivo,10116.0,1,Intermediate,1,CHEMBL622835,,
9823,N,Half-life in rat after po administration at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17538,In vivo,10116.0,1,Intermediate,1,CHEMBL622836,,
9824,N,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,,Rattus norvegicus,A,,BAO_0000218,17538,In vivo,10116.0,1,Intermediate,1,CHEMBL622837,,
9825,N,Half-life in rat at 3 mg/kg dose administered intravenously,,Rattus norvegicus,A,,BAO_0000218,10,In vivo,10116.0,1,Intermediate,1,CHEMBL622838,,
9826,N,Half-life in rat brain homogenate,,Rattus norvegicus,A,,BAO_0000218,17669,,10116.0,1,Intermediate,1,CHEMBL622839,,955.0
9827,N,Half-life in rat plasma,,Rattus norvegicus,A,,BAO_0000218,17065,,10116.0,1,Intermediate,1,CHEMBL622840,,1969.0
9828,N,Half-life in rats,,Rattus norvegicus,A,,BAO_0000218,4333,,10116.0,1,Intermediate,1,CHEMBL622841,,
9829,N,Half-life in Dawley rats,,Rattus norvegicus,A,,BAO_0000218,6827,,10116.0,1,Intermediate,1,CHEMBL622842,,
9830,N,Half-life in vitro in rat plasma,,Rattus norvegicus,A,,BAO_0000218,889,In vitro,10116.0,1,Intermediate,1,CHEMBL622843,,1969.0
9831,N,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,,Rattus norvegicus,A,,BAO_0000218,889,In vitro,10116.0,1,Intermediate,1,CHEMBL622844,,1969.0
9832,N,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",,Rattus norvegicus,A,,BAO_0000218,3747,,10116.0,1,Intermediate,1,CHEMBL622845,,
9833,N,The area under the curve of compound was measured at the dose of 100 umol/kg,,Rattus norvegicus,A,,BAO_0000218,15022,,10116.0,1,Intermediate,1,CHEMBL622846,,
9834,N,The area under the curve of compound was measured at the dose of 300 umol/kg,,Rattus norvegicus,A,,BAO_0000218,15022,,10116.0,1,Intermediate,1,CHEMBL622847,,
9835,N,The area under the curve of compound was measured at the dose of 30 umol/kg,,Rattus norvegicus,A,,BAO_0000218,15022,,10116.0,1,Intermediate,1,CHEMBL622848,,
9836,N,Bioavailability as oral AUC in rats,,Rattus norvegicus,A,,BAO_0000218,3360,In vivo,10116.0,1,Intermediate,1,CHEMBL622849,,
9837,N,The plasma concentration versus time curve (AUC) was determined,,Rattus norvegicus,A,,BAO_0000218,5334,,10116.0,1,Intermediate,1,CHEMBL622850,,1969.0
9838,N,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17411,,10116.0,1,Intermediate,1,CHEMBL876807,,
9839,N,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17411,,10116.0,1,Intermediate,1,CHEMBL622851,,
9840,N,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17411,,10116.0,1,Intermediate,1,CHEMBL622852,,
9841,N,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,,Rattus norvegicus,A,,BAO_0000218,6570,,10116.0,1,Intermediate,1,CHEMBL622853,,
9842,N,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,,Rattus norvegicus,A,,BAO_0000218,6570,,10116.0,1,Intermediate,1,CHEMBL622854,,
9843,N,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17411,,10116.0,1,Intermediate,1,CHEMBL622855,,
9844,N,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",,Rattus norvegicus,A,,BAO_0000218,14941,,10116.0,1,Intermediate,1,CHEMBL622856,,1969.0
9845,N,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",,Rattus norvegicus,A,,BAO_0000218,14941,,10116.0,1,Intermediate,1,CHEMBL622857,,1969.0
9846,N,AUC in rat after po administration at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17538,,10116.0,1,Intermediate,1,CHEMBL622858,,1969.0
9847,N,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17752,,10116.0,1,Intermediate,1,CHEMBL622859,,1969.0
9848,N,Area under curve value 24 hr after 10 mg/kg iv administration in rats,,Rattus norvegicus,A,,BAO_0000218,17509,,10116.0,1,Intermediate,1,CHEMBL622860,,
9849,N,Area under curve value 24 hr after 10 mg/kg oral administration in rats,,Rattus norvegicus,A,,BAO_0000218,17509,,10116.0,1,Intermediate,1,CHEMBL622861,,
9850,N,Area under curve value 24 hr after 2 mg/kg iv administration in rats,,Rattus norvegicus,A,,BAO_0000218,17509,,10116.0,1,Intermediate,1,CHEMBL622862,,
9851,N,Area under curve value 24 hr after 2 mg/kg oral administration in rats,,Rattus norvegicus,A,,BAO_0000218,17509,,10116.0,1,Intermediate,1,CHEMBL622863,,
9852,N,Area under curve value 6 hr after po administration in rat,,Rattus norvegicus,A,,BAO_0000218,17509,,10116.0,1,Intermediate,1,CHEMBL623817,,
9853,N,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,Rattus norvegicus,A,,BAO_0000218,17717,,10116.0,1,Intermediate,1,CHEMBL623818,,
9854,N,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",,Rattus norvegicus,A,,BAO_0000218,17717,,10116.0,1,Intermediate,1,CHEMBL623819,,
9855,N,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,Rattus norvegicus,A,,BAO_0000218,17717,,10116.0,1,Intermediate,1,CHEMBL623820,,
9856,N,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,,Rattus norvegicus,A,,BAO_0000218,17717,,10116.0,1,Intermediate,1,CHEMBL623821,,
9857,N,AUC normalized for dose (AUCN) in rat,,Rattus norvegicus,A,,BAO_0000218,6642,,10116.0,1,Intermediate,1,CHEMBL623822,,1969.0
9858,N,Area under curve in rat after p.o. administration,,Rattus norvegicus,A,,BAO_0000218,6640,,10116.0,1,Intermediate,1,CHEMBL623823,,
9859,N,Area under curve in rat after p.o. administration,,Rattus norvegicus,A,,BAO_0000218,6641,,10116.0,1,Intermediate,1,CHEMBL623824,,
9860,N,Area under curve in rat after p.o. administration; Not determined,,Rattus norvegicus,A,,BAO_0000218,6641,,10116.0,1,Intermediate,1,CHEMBL623825,,
9861,N,Area under curve in rat after peroral administration,,Rattus norvegicus,A,,BAO_0000218,6641,,10116.0,1,Intermediate,1,CHEMBL622070,,
9862,N,Area under curve (carotid artery) value of the compound,,Rattus norvegicus,A,,BAO_0000218,3603,,10116.0,1,Intermediate,1,CHEMBL622071,,
9863,N,Bioavailability expressed as the area under curve of rat carotid artery,,Rattus norvegicus,A,,BAO_0000218,3550,,10116.0,1,Intermediate,1,CHEMBL622072,,
9864,N,Area under curve in male SD rats was observed after intravenous administration in rat,,Rattus norvegicus,A,,BAO_0000218,15662,,10116.0,1,Intermediate,1,CHEMBL622073,,
9865,N,Area under curve of the compound was determined,,Rattus norvegicus,A,,BAO_0000218,17720,,10116.0,1,Intermediate,1,CHEMBL622074,,
9866,N,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,,Rattus norvegicus,A,,BAO_0000218,5407,,10116.0,1,Intermediate,1,CHEMBL622075,,
9867,N,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17752,,10116.0,1,Intermediate,1,CHEMBL622076,,1969.0
9868,N,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17752,,10116.0,1,Intermediate,1,CHEMBL622077,,1969.0
9869,N,Area under curve (portal vein) value of the compound,,Rattus norvegicus,A,,BAO_0000218,3603,,10116.0,1,Intermediate,1,CHEMBL622078,,
9870,N,Bioavailability expressed as the area under curve of rat portal vein,,Rattus norvegicus,A,,BAO_0000218,3550,,10116.0,1,Intermediate,1,CHEMBL622079,,
9871,N,Area Under plasma concentration time curve in rat upon peroral administration,,Rattus norvegicus,A,,BAO_0000218,17655,,10116.0,1,Intermediate,1,CHEMBL622080,,1969.0
9872,N,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,17582,,10116.0,1,Intermediate,1,CHEMBL877612,,
9873,N,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,17582,,10116.0,1,Intermediate,1,CHEMBL622081,,
9874,N,Compound was evaluated for oral bioavailability in rats,,Rattus norvegicus,A,,BAO_0000218,17791,,10116.0,1,Intermediate,1,CHEMBL622082,,
9875,N,Compound was evaluated for oral bioavailability in rats after iv administration,,Rattus norvegicus,A,,BAO_0000218,17791,,10116.0,1,Intermediate,1,CHEMBL622083,,
9876,N,Compound was evaluated for oral bioavailability in rats; 30-80,,Rattus norvegicus,A,,BAO_0000218,17791,,10116.0,1,Intermediate,1,CHEMBL622084,,
9877,N,Compound was evaluated for oral bioavailability in rats; 50-60,,Rattus norvegicus,A,,BAO_0000218,17791,,10116.0,1,Intermediate,1,CHEMBL622085,,
9878,N,Compound was evaluated for oral bioavailability in rats; no data,,Rattus norvegicus,A,,BAO_0000218,17791,,10116.0,1,Intermediate,1,CHEMBL622086,,
9879,N,Compound was evaluated for oral bioavailability in rats; peptide,,Rattus norvegicus,A,,BAO_0000218,17791,,10116.0,1,Intermediate,1,CHEMBL622087,,
9880,N,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL622088,,178.0
9881,N,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL622089,,178.0
9882,N,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL623685,,178.0
9883,N,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL623686,,178.0
9884,N,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL623687,,945.0
9885,N,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL623688,,945.0
9886,N,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL623689,,945.0
9887,N,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622485,,945.0
9888,N,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622486,,2046.0
9889,N,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL877613,,2046.0
9890,N,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622487,,2046.0
9891,N,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622488,,2046.0
9892,N,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,In vivo,10116.0,1,Intermediate,1,CHEMBL622489,,948.0
9893,N,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,Rattus norvegicus,A,,BAO_0000218,6899,,10116.0,1,Intermediate,1,CHEMBL622490,,1088.0
9894,N,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,Rattus norvegicus,A,,BAO_0000218,6899,,10116.0,1,Intermediate,1,CHEMBL622491,,1088.0
9895,N,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,,Rattus norvegicus,A,,BAO_0000218,6899,,10116.0,1,Intermediate,1,CHEMBL622492,,2107.0
9896,N,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,Rattus norvegicus,A,,BAO_0000218,6899,,10116.0,1,Intermediate,1,CHEMBL622493,,1088.0
9897,N,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,Rattus norvegicus,A,,BAO_0000218,6899,,10116.0,1,Intermediate,1,CHEMBL622494,,1088.0
9898,N,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,Rattus norvegicus,A,,BAO_0000218,8677,,10116.0,1,Intermediate,1,CHEMBL622495,,2385.0
9899,N,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,,Rattus norvegicus,A,,BAO_0000218,6899,,10116.0,1,Intermediate,1,CHEMBL622496,,
9900,N,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,Rattus norvegicus,A,,BAO_0000218,6899,,10116.0,1,Intermediate,1,CHEMBL622497,,1088.0
9901,N,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,,Rattus norvegicus,A,,BAO_0000218,2189,,10116.0,1,Intermediate,1,CHEMBL622498,,
9902,N,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,,Rattus norvegicus,A,,BAO_0000218,2189,,10116.0,1,Intermediate,1,CHEMBL624918,,1088.0
9903,N,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,,Rattus norvegicus,A,,BAO_0000218,2189,,10116.0,1,Intermediate,1,CHEMBL624919,,1088.0
9904,N,Biodistribution of compound in rat blood after 5 min of administration,,Rattus norvegicus,A,,BAO_0000218,10839,In vivo,10116.0,1,Intermediate,1,CHEMBL624920,,178.0
9905,N,Biodistribution of compound in rat blood after 5 min of administration.,,Rattus norvegicus,A,,BAO_0000218,10839,In vivo,10116.0,1,Intermediate,1,CHEMBL624921,,178.0
9906,N,Biodistribution of compound in rat brain after 5 min of administration,,Rattus norvegicus,A,,BAO_0000218,10839,In vivo,10116.0,1,Intermediate,1,CHEMBL624922,,955.0
9907,N,Biodistribution of compound in rat heart after 5 min of administration,,Rattus norvegicus,A,,BAO_0000218,10839,In vivo,10116.0,1,Intermediate,1,CHEMBL624923,,948.0
9908,N,Biodistribution of compound in rat heart after 5 min of administration.,,Rattus norvegicus,A,,BAO_0000218,10839,In vivo,10116.0,1,Intermediate,1,CHEMBL624924,,948.0
9909,N,Biodistribution of compound in rat kidney after 5 min of administration,,Rattus norvegicus,A,,BAO_0000218,10839,In vivo,10116.0,1,Intermediate,1,CHEMBL624925,,2113.0
9910,N,Biodistribution of compound in rat kidney after 5 min of administration.,,Rattus norvegicus,A,,BAO_0000218,10839,In vivo,10116.0,1,Intermediate,1,CHEMBL624926,,2113.0
9911,N,Biodistribution of compound in rat liver after 5 min of administration,,Rattus norvegicus,A,,BAO_0000218,10839,In vivo,10116.0,1,Intermediate,1,CHEMBL624927,,2107.0
9912,N,Biodistribution of compound in rat liver after 5 min of administration.,,Rattus norvegicus,A,,BAO_0000218,10839,In vivo,10116.0,1,Intermediate,1,CHEMBL874402,,2107.0
9913,N,Biodistribution of compound in rat lung after 5 min of administration,,Rattus norvegicus,A,,BAO_0000218,10839,In vivo,10116.0,1,Intermediate,1,CHEMBL624928,,2048.0
9914,N,Biodistribution of compound in rat lung after 5 min of administration.,,Rattus norvegicus,A,,BAO_0000218,10839,In vivo,10116.0,1,Intermediate,1,CHEMBL624929,,2048.0
9915,N,Biodistribution of compound in rat muscle after 5 min of administration,,Rattus norvegicus,A,,BAO_0000218,10839,In vivo,10116.0,1,Intermediate,1,CHEMBL624930,,2385.0
9916,N,Biodistribution of compound in rat muscle after 5 min of administration.,,Rattus norvegicus,A,,BAO_0000218,10839,In vivo,10116.0,1,Intermediate,1,CHEMBL624931,,2385.0
9917,N,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,Rattus norvegicus,A,,BAO_0000218,4043,,10116.0,1,Intermediate,1,CHEMBL624932,,948.0
9918,N,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,Rattus norvegicus,A,,BAO_0000218,4043,,10116.0,1,Intermediate,1,CHEMBL624933,,948.0
9919,N,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,Rattus norvegicus,A,,BAO_0000218,4043,,10116.0,1,Intermediate,1,CHEMBL624934,,2107.0
9920,N,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,Rattus norvegicus,A,,BAO_0000218,4043,,10116.0,1,Intermediate,1,CHEMBL624935,,2107.0
9921,N,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,Rattus norvegicus,A,,BAO_0000218,4043,,10116.0,1,Intermediate,1,CHEMBL624936,,
9922,N,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,Rattus norvegicus,A,,BAO_0000218,4043,,10116.0,1,Intermediate,1,CHEMBL624937,,
9923,N,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,Rattus norvegicus,A,,BAO_0000218,4043,,10116.0,1,Intermediate,1,CHEMBL624938,,2106.0
9924,N,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,Rattus norvegicus,A,,BAO_0000218,4043,,10116.0,1,Intermediate,1,CHEMBL624939,,2106.0
9925,N,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,Rattus norvegicus,A,,BAO_0000218,4043,,10116.0,1,Intermediate,1,CHEMBL624940,,
9926,N,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,Rattus norvegicus,A,,BAO_0000218,4043,,10116.0,1,Intermediate,1,CHEMBL874403,,
9927,N,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,,Rattus norvegicus,A,,BAO_0000218,1446,,10116.0,1,Intermediate,1,CHEMBL624941,,
9928,N,Dose required to lower urine osmolality to 300 mOsm/kg in rat,,Rattus norvegicus,A,,BAO_0000218,9971,,10116.0,1,Intermediate,1,CHEMBL624942,,1088.0
9929,N,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,,Rattus norvegicus,A,,BAO_0000218,9971,,10116.0,1,Intermediate,1,CHEMBL624943,,1088.0
9930,N,% Bioavailability after 1 day of the drug administration in rats,,Rattus norvegicus,A,,BAO_0000218,5765,In vivo,10116.0,1,Intermediate,1,CHEMBL624944,,
9931,N,% Bioavailability after 4 day of the drug administration in rats,,Rattus norvegicus,A,,BAO_0000218,5765,In vivo,10116.0,1,Intermediate,1,CHEMBL624945,,
9932,N,Absolute bioavailability was evaluated in rat,,Rattus norvegicus,A,,BAO_0000218,4257,In vivo,10116.0,1,Intermediate,1,CHEMBL624946,,
9933,N,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL624947,,
9934,N,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL624948,,
9935,N,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL624949,,
9936,N,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL622025,,2113.0
9937,N,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL622026,,2113.0
9938,N,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL622027,,2113.0
9939,N,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL622028,,2113.0
9940,N,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL622029,,2107.0
9941,N,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL622208,,2107.0
9942,N,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL622209,,2107.0
9943,N,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL622210,,2107.0
9944,N,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL622211,,
9945,N,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL622212,,
9946,N,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL622213,,
9947,N,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL874404,,
9948,N,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL620452,,2385.0
9949,N,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL620453,,2385.0
9950,N,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL620454,,2385.0
9951,N,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL624067,,2385.0
9952,N,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL624068,,
9953,N,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL624069,,992.0
9954,N,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL624070,,992.0
9955,N,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL624071,,992.0
9956,N,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL624072,,995.0
9957,N,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL624073,,995.0
9958,N,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL624788,,995.0
9959,N,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL624789,,995.0
9960,N,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL624790,,
9961,N,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL624791,,
9962,N,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL624792,,
9963,N,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL624793,,
9964,N,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL877491,,2385.0
9965,N,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL624957,,2385.0
9966,N,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL624958,,2385.0
9967,N,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,,Rattus norvegicus,A,,BAO_0000218,13091,,10116.0,1,Intermediate,1,CHEMBL624959,,2385.0
9968,N,Dissociation constant was determined,,Rattus norvegicus,A,,BAO_0000218,11977,,10116.0,1,Intermediate,1,CHEMBL624960,,
9969,N,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",,Rattus norvegicus,A,,BAO_0000218,14941,,10116.0,1,Intermediate,1,CHEMBL624961,,
9970,N,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,15078,,10116.0,1,Intermediate,1,CHEMBL624962,,
9971,N,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,15078,,10116.0,1,Intermediate,1,CHEMBL624963,,
9972,N,Observed rate constant in 80% rat plasma at 37 degree Centigrade,,Rattus norvegicus,A,,BAO_0000218,4755,,10116.0,1,Intermediate,1,CHEMBL624964,,
9973,N,LogP value was evaluated in the in situ rat gut perfusion assay,,Rattus norvegicus,A,,BAO_0000218,589,,10116.0,1,Intermediate,1,CHEMBL624965,,
9974,N,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,Rattus norvegicus,A,,BAO_0000218,17582,In vivo,10116.0,1,Intermediate,1,CHEMBL624966,,
9975,N,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,,Rattus norvegicus,A,,BAO_0000218,5031,In vivo,10116.0,1,Intermediate,1,CHEMBL624967,,
9976,N,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,,Rattus norvegicus,A,,BAO_0000218,17764,In vivo,10116.0,1,Intermediate,1,CHEMBL624968,,
9977,N,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,,Rattus norvegicus,A,,BAO_0000218,17720,,10116.0,1,Intermediate,1,CHEMBL624969,,
9978,N,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,,Rattus norvegicus,F,,BAO_0000218,2862,,10116.0,1,Expert,1,CHEMBL624970,,
9979,N,Half-life was evaluated after 10 uM/kg of intra arterial administration,,Rattus norvegicus,A,,BAO_0000218,16423,,10116.0,1,Intermediate,1,CHEMBL624971,,
9980,N,Half-life was evaluated after 20 uM/kg of peroral administration,,Rattus norvegicus,A,,BAO_0000218,16423,In vivo,10116.0,1,Intermediate,1,CHEMBL624972,,
9981,N,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6005,In vivo,10116.0,1,Intermediate,1,CHEMBL624973,,
9982,N,Half-life was evaluated in plasma of rat,,Rattus norvegicus,A,,BAO_0000218,2938,,10116.0,1,Intermediate,1,CHEMBL624974,,1969.0
9983,N,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6410,In vivo,10116.0,1,Intermediate,1,CHEMBL624975,,
9984,N,Half-life was evaluated in rats at an oral dose of 30 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6410,In vivo,10116.0,1,Intermediate,1,CHEMBL877492,,
9985,N,Half-life was measured in rat after an iv dose of 1 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6062,In vivo,10116.0,1,Intermediate,1,CHEMBL624976,,
9986,N,Half-life period of compound in rats after peroral administration,,Rattus norvegicus,A,,BAO_0000218,6571,In vivo,10116.0,1,Intermediate,1,CHEMBL624977,,
9987,N,Half-life period of compound was measured in rat plasma.,,Rattus norvegicus,A,,BAO_0000218,3136,,10116.0,1,Intermediate,1,CHEMBL626848,,1969.0
9988,N,Half-life period of compound was measured in rat plasma; ND is not determined,,Rattus norvegicus,A,,BAO_0000218,3136,,10116.0,1,Intermediate,1,CHEMBL626849,,1969.0
9989,N,Half-life period of compound was measured in rat plasma; not determined,,Rattus norvegicus,A,,BAO_0000218,3136,,10116.0,1,Intermediate,1,CHEMBL626850,,1969.0
9990,N,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,Rattus norvegicus,A,,BAO_0000218,4521,In vivo,10116.0,1,Intermediate,1,CHEMBL626851,,
9991,N,Half-life period in rat by iv administration,,Rattus norvegicus,A,,BAO_0000218,5871,In vivo,10116.0,1,Intermediate,1,CHEMBL626852,,
9992,N,Half-life period in rats following intravenous administration at 2 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6077,In vivo,10116.0,1,Intermediate,1,CHEMBL626853,,
9993,N,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Rattus norvegicus,A,,BAO_0000218,6679,In vivo,10116.0,1,Intermediate,1,CHEMBL626854,,
9994,N,Half-life period was determined for the compound in rat,,Rattus norvegicus,A,,BAO_0000218,5144,,10116.0,1,Intermediate,1,CHEMBL627486,,
9995,N,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",,Rattus norvegicus,A,,BAO_0000218,4498,In vivo,10116.0,1,Intermediate,1,CHEMBL627487,,
9996,N,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",,Rattus norvegicus,A,,BAO_0000218,4498,In vivo,10116.0,1,Intermediate,1,CHEMBL627488,,
9997,N,Half-life value after IV dose at a dose of 5 mg/kg in rats.,,Rattus norvegicus,A,,BAO_0000218,1908,In vivo,10116.0,1,Intermediate,1,CHEMBL627489,,
9998,N,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,6211,In vivo,10116.0,1,Intermediate,1,CHEMBL627490,,
9999,N,Half-life was determined in rat after intravenous administration (0.5 mg/kg),,Rattus norvegicus,A,,BAO_0000218,5529,In vivo,10116.0,1,Intermediate,1,CHEMBL873829,,
10000,N,Half-life was determined in rat at a dose of 1 mpk i.v.,,Rattus norvegicus,A,,BAO_0000218,6444,In vivo,10116.0,1,Intermediate,1,CHEMBL627655,,
10001,N,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,Rattus norvegicus,A,,BAO_0000218,6444,In vivo,10116.0,1,Intermediate,1,CHEMBL625994,,
10002,N,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,Rattus norvegicus,A,,BAO_0000218,6444,In vivo,10116.0,1,Intermediate,1,CHEMBL625995,,
10003,N,Half-life in rat,,Rattus norvegicus,A,,BAO_0000218,5207,,10116.0,1,Intermediate,1,CHEMBL625996,,
10004,N,In vitro half life in rat plasma,,Rattus norvegicus,A,,BAO_0000218,530,In vitro,10116.0,1,Intermediate,1,CHEMBL625850,,1969.0
10005,N,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",,Rattus norvegicus,A,,BAO_0000218,1116,In vitro,10116.0,1,Intermediate,1,CHEMBL625851,,1969.0
10006,N,In vitro half life in rat,,Rattus norvegicus,A,,BAO_0000218,3219,In vitro,10116.0,1,Intermediate,1,CHEMBL625852,,
10007,N,In vivo half life period after intravenous administration in rat,,Rattus norvegicus,A,,BAO_0000218,6109,In vivo,10116.0,1,Intermediate,1,CHEMBL625853,,
10008,N,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,Rattus norvegicus,A,,BAO_0000218,17582,In vivo,10116.0,1,Intermediate,1,CHEMBL625854,,
10009,N,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,Rattus norvegicus,A,,BAO_0000218,17582,In vivo,10116.0,1,Intermediate,1,CHEMBL874450,,
10010,N,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL625855,,
10011,N,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL625856,,
10012,N,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL625857,,
10013,N,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL873831,,
10014,N,Longer half-life in rat (i.v.) at 0.5 mpk,,Rattus norvegicus,A,,BAO_0000218,17853,In vivo,10116.0,1,Intermediate,1,CHEMBL625858,,
10015,N,Longer half-life in rat (p.o.) at 2.0 mpk,,Rattus norvegicus,A,,BAO_0000218,17853,In vivo,10116.0,1,Intermediate,1,CHEMBL625859,,
10016,N,Pharmacokinetic property (half life) in rat,,Rattus norvegicus,A,,BAO_0000218,3457,,10116.0,1,Intermediate,1,CHEMBL625860,,
10017,N,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,,Rattus norvegicus,A,,BAO_0000218,2792,In vivo,10116.0,1,Intermediate,1,CHEMBL625861,,
10018,N,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,,Rattus norvegicus,A,,BAO_0000218,2792,In vivo,10116.0,1,Intermediate,1,CHEMBL625862,,
10019,N,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,,Rattus norvegicus,A,,BAO_0000218,2792,In vivo,10116.0,1,Intermediate,1,CHEMBL625863,,
10020,N,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,,Rattus norvegicus,A,,BAO_0000218,2792,In vivo,10116.0,1,Intermediate,1,CHEMBL625864,,
10021,N,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,,Rattus norvegicus,A,,BAO_0000218,5739,In vivo,10116.0,1,Intermediate,1,CHEMBL625865,,
10022,N,Pharmacokinetic half time was determined intravenously in rats.,,Rattus norvegicus,A,,BAO_0000218,15765,In vivo,10116.0,1,Intermediate,1,CHEMBL625866,,
10023,N,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,,Rattus norvegicus,A,,BAO_0000218,6567,In vivo,10116.0,1,Intermediate,1,CHEMBL625867,,1969.0
10024,N,Plasma half life of hydrolysis of the compound,,Rattus norvegicus,A,,BAO_0000218,2448,,10116.0,1,Intermediate,1,CHEMBL625868,,1969.0
10025,N,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5423,In vivo,10116.0,1,Intermediate,1,CHEMBL625869,,1969.0
10026,N,Plasma half life period was calculated in rat,,Rattus norvegicus,A,,BAO_0000218,4853,,10116.0,1,Intermediate,1,CHEMBL874451,,1969.0
10027,N,Plasma half-life in Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,4514,,10116.0,1,Intermediate,1,CHEMBL625870,,1969.0
10028,N,Plasma half-life in Sprague-Dawley rats; Not determined,,Rattus norvegicus,A,,BAO_0000218,4514,,10116.0,1,Intermediate,1,CHEMBL625871,,1969.0
10029,N,Plasma half-life in rats,,Rattus norvegicus,A,,BAO_0000218,1500,,10116.0,1,Intermediate,1,CHEMBL625872,,1969.0
10030,N,Plasma half-life in rats; <MQL,,Rattus norvegicus,A,,BAO_0000218,1500,,10116.0,1,Intermediate,1,CHEMBL625873,,1969.0
10031,N,Plasma half-life period (0-8 h) was determined,,Rattus norvegicus,A,,BAO_0000218,5334,,10116.0,1,Intermediate,1,CHEMBL625874,,1969.0
10032,N,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5334,,10116.0,1,Intermediate,1,CHEMBL625875,,1969.0
10033,N,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5334,In vivo,10116.0,1,Intermediate,1,CHEMBL625876,,1969.0
10034,N,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5334,In vivo,10116.0,1,Intermediate,1,CHEMBL631258,,1969.0
10035,N,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,,Rattus norvegicus,A,,BAO_0000218,4956,,10116.0,1,Intermediate,1,CHEMBL631259,,1969.0
10036,N,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,,Rattus norvegicus,A,,BAO_0000218,4956,,10116.0,1,Intermediate,1,CHEMBL631260,,1969.0
10037,N,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL631261,,178.0
10038,N,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL631262,,178.0
10039,N,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL631263,,178.0
10040,N,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL631264,,
10041,N,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL631265,,
10042,N,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL631266,,
10043,N,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL631267,,
10044,N,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL631268,,
10045,N,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL631269,,
10046,N,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL631270,,
10047,N,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL631271,,948.0
10048,N,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL631272,,948.0
10049,N,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL631273,,948.0
10050,N,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL631274,,948.0
10051,N,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL631275,,948.0
10052,N,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626984,,948.0
10053,N,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626985,,948.0
10054,N,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626986,,2107.0
10055,N,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626987,,2107.0
10056,N,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626988,,2107.0
10057,N,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626989,,2107.0
10058,N,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626990,,2107.0
10059,N,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626991,,2107.0
10060,N,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626992,,2107.0
10061,N,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626993,,2048.0
10062,N,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL874593,,2048.0
10063,N,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626994,,2048.0
10064,N,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626995,,2048.0
10065,N,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626190,,2048.0
10066,N,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626191,,2048.0
10067,N,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626364,,2048.0
10068,N,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626365,,2046.0
10069,N,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626366,,2046.0
10070,N,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626367,,2046.0
10071,N,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626368,,2046.0
10072,N,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626369,,2046.0
10073,N,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626370,,2046.0
10074,N,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",,Rattus norvegicus,A,,BAO_0000218,4498,In vivo,10116.0,1,Intermediate,1,CHEMBL626371,,
10075,N,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",,Rattus norvegicus,A,,BAO_0000218,4498,In vivo,10116.0,1,Intermediate,1,CHEMBL626372,,
10076,N,Bioavailability after a dose of 10 mg/kg p.o.,,Rattus norvegicus,A,,BAO_0000218,3603,In vivo,10116.0,1,Intermediate,1,CHEMBL626373,,
10077,N,Bioavailability after peroral administration (10 mg/kg) was determined in rat,,Rattus norvegicus,A,,BAO_0000218,6215,In vivo,10116.0,1,Intermediate,1,CHEMBL626374,,
10078,N,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,,Rattus norvegicus,A,,BAO_0000218,5710,In vivo,10116.0,1,Intermediate,1,CHEMBL626375,,
10079,N,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),,Rattus norvegicus,A,,BAO_0000218,5710,In vivo,10116.0,1,Intermediate,1,CHEMBL626376,,
10080,N,Bioavailability in rat po was determined,,Rattus norvegicus,A,,BAO_0000218,5676,In vivo,10116.0,1,Intermediate,1,CHEMBL626377,,
10081,N,Bioavailability of compound at 10 mg/kg in rat after oral administration,,Rattus norvegicus,A,,BAO_0000218,17667,In vivo,10116.0,1,Intermediate,1,CHEMBL626378,,
10082,N,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,17667,In vivo,10116.0,1,Intermediate,1,CHEMBL626379,,
10083,N,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,6848,In vivo,10116.0,1,Intermediate,1,CHEMBL626380,,
10084,N,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,6848,In vivo,10116.0,1,Intermediate,1,CHEMBL626381,,
10085,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,17267,In vivo,10116.0,1,Intermediate,1,CHEMBL626382,,
10086,N,Bioavailability in rat (Sprague-Dawley) (female),,Rattus norvegicus,A,,BAO_0000218,6362,In vivo,10116.0,1,Intermediate,1,CHEMBL626383,,
10087,N,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17671,In vivo,10116.0,1,Intermediate,1,CHEMBL874652,,
10088,N,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),,Rattus norvegicus,A,,BAO_0000218,17671,In vivo,10116.0,1,Intermediate,1,CHEMBL626384,,
10089,N,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,,Rattus norvegicus,A,,BAO_0000218,4333,In vivo,10116.0,1,Intermediate,1,CHEMBL626385,,
10090,N,Bioavailability in rat at an oral dose of 2 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6077,In vivo,10116.0,1,Intermediate,1,CHEMBL626386,,
10091,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,3278,In vivo,10116.0,1,Intermediate,1,CHEMBL626387,,
10092,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,5964,In vivo,10116.0,1,Intermediate,1,CHEMBL626388,,
10093,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,4884,In vivo,10116.0,1,Intermediate,1,CHEMBL626389,,
10094,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,4905,In vivo,10116.0,1,Intermediate,1,CHEMBL626390,,
10095,N,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,,Rattus norvegicus,A,,BAO_0000218,4884,In vivo,10116.0,1,Intermediate,1,CHEMBL626391,,
10096,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6850,In vivo,10116.0,1,Intermediate,1,CHEMBL626392,,
10097,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,2864,In vivo,10116.0,1,Intermediate,1,CHEMBL626393,,
10098,N,Bioavailability was determined in rat,,Rattus norvegicus,A,,BAO_0000218,5780,In vivo,10116.0,1,Intermediate,1,CHEMBL623026,,
10099,N,Bioavailability,,Rattus norvegicus,A,,BAO_0000218,1465,In vivo,10116.0,1,Intermediate,1,CHEMBL623027,,
10100,N,Bioavailability,,Rattus norvegicus,A,,BAO_0000218,5199,In vivo,10116.0,1,Intermediate,1,CHEMBL623028,,
10101,N,Bioavailability in rat after 1 day dosing,,Rattus norvegicus,A,,BAO_0000218,5765,In vivo,10116.0,1,Intermediate,1,CHEMBL623029,,
10102,N,Bioavailability in rat after 4 day dosing,,Rattus norvegicus,A,,BAO_0000218,5765,In vivo,10116.0,1,Intermediate,1,CHEMBL623030,,
10103,N,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,,Rattus norvegicus,A,,BAO_0000218,6518,In vivo,10116.0,1,Intermediate,1,CHEMBL623031,,
10104,N,Bioavailability after IV dosing at 1 mg/kg in rat; no data,,Rattus norvegicus,A,,BAO_0000218,6518,In vivo,10116.0,1,Intermediate,1,CHEMBL623032,,
10105,N,Bioavailability after oral administration at a dose of 2 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,6518,In vivo,10116.0,1,Intermediate,1,CHEMBL623033,,
10106,N,Bioavailability after oral administration at a dose of 4 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,6518,In vivo,10116.0,1,Intermediate,1,CHEMBL623034,,
10107,N,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,,Rattus norvegicus,A,,BAO_0000218,2083,In vivo,10116.0,1,Intermediate,1,CHEMBL623035,,
10108,N,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,Rattus norvegicus,A,,BAO_0000218,17260,In vivo,10116.0,1,Intermediate,1,CHEMBL623036,,
10109,N,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,4956,In vivo,10116.0,1,Intermediate,1,CHEMBL623037,,
10110,N,Bioavailability by intravenous administration of 3.4 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,4368,In vivo,10116.0,1,Intermediate,1,CHEMBL623038,,
10111,N,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17752,In vivo,10116.0,1,Intermediate,1,CHEMBL874385,,1969.0
10112,N,Bioavailability in rat (Fisher) (fasted),,Rattus norvegicus,A,,BAO_0000218,1446,In vivo,10116.0,1,Intermediate,1,CHEMBL623039,,
10113,U,Bioavailability in monkey after po administration of 10 mg/kg dose,,Primates,A,,BAO_0000218,2891,In vivo,9443.0,0,Intermediate,1,CHEMBL623040,,
10114,U,Oral bioavailability in monkey (dose 10 mg/kg),,Primates,A,,BAO_0000218,2891,In vivo,9443.0,0,Intermediate,1,CHEMBL623041,,
10115,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6672,In vivo,10116.0,1,Intermediate,1,CHEMBL623741,,
10116,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6673,In vivo,10116.0,1,Intermediate,1,CHEMBL623742,,
10117,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,17655,In vivo,10116.0,1,Intermediate,1,CHEMBL623743,,
10118,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,17796,In vivo,10116.0,1,Intermediate,1,CHEMBL623744,,
10119,N,Bioavailability in rat (dose 2.0 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,17853,In vivo,10116.0,1,Intermediate,1,CHEMBL623745,,
10120,N,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),,Rattus norvegicus,A,,BAO_0000218,4521,In vivo,10116.0,1,Intermediate,1,CHEMBL623746,,
10121,N,Oral bioavailability in rat (dose 5 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,4940,In vivo,10116.0,1,Intermediate,1,CHEMBL623747,,
10122,U,Bioavailability in rat after po administration of 30 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,2891,In vivo,10116.0,0,Intermediate,1,CHEMBL623748,,
10123,U,Bioavailability in rat after po administration of 30 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,2891,In vivo,10116.0,0,Intermediate,1,CHEMBL623916,,
10124,N,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,Rattus norvegicus,A,,BAO_0000218,4521,In vivo,10116.0,1,Intermediate,1,CHEMBL623917,,
10125,N,Bioavailability in rat (dose 2 mg/kg i.v.),,Rattus norvegicus,A,,BAO_0000218,17686,In vivo,10116.0,1,Intermediate,1,CHEMBL623918,,
10126,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,17796,In vivo,10116.0,1,Intermediate,1,CHEMBL874386,,
10127,N,Bioavailability in rat; Only traces detected in rat plasma,,Rattus norvegicus,A,,BAO_0000218,17796,In vivo,10116.0,1,Intermediate,1,CHEMBL623919,,1969.0
10128,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,5064,In vivo,10116.0,1,Intermediate,1,CHEMBL623920,,
10129,N,Bioavailability upon oral administration of compound,,Rattus norvegicus,A,,BAO_0000218,5147,In vivo,10116.0,1,Intermediate,1,CHEMBL623148,,
10130,N,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),,Rattus norvegicus,A,,BAO_0000218,1916,In vivo,10116.0,1,Intermediate,1,CHEMBL623149,,
10131,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6049,In vivo,10116.0,1,Intermediate,1,CHEMBL623150,,
10132,N,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",,Rattus norvegicus,A,,BAO_0000218,1445,In vivo,10116.0,1,Intermediate,1,CHEMBL623151,,
10133,N,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",,Rattus norvegicus,A,,BAO_0000218,1445,In vivo,10116.0,1,Intermediate,1,CHEMBL623152,,
10134,N,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,,Rattus norvegicus,F,,BAO_0000218,2862,,10116.0,1,Expert,1,CHEMBL623153,,
10135,N,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,,Rattus norvegicus,F,,BAO_0000218,2862,,10116.0,1,Expert,1,CHEMBL623154,,
10136,N,In vitro and metabolic stability was determined,,Rattus norvegicus,A,,BAO_0000218,4194,,10116.0,1,Intermediate,1,CHEMBL623155,,
10137,N,In vitro metabolic stability in rat hepatocytes,,Rattus norvegicus,A,,BAO_0000218,4194,,10116.0,1,Intermediate,1,CHEMBL623156,,
10138,N,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,,Rattus norvegicus,A,,BAO_0000218,5486,,10116.0,1,Intermediate,1,CHEMBL623157,,
10139,N,Metabolic rate for compound was observed in rat hepatocytes,,Rattus norvegicus,A,,BAO_0000218,17582,In vitro,10116.0,1,Intermediate,1,CHEMBL623158,401.0,2107.0
10140,N,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,,Rattus norvegicus,A,,BAO_0000218,5600,,10116.0,1,Intermediate,1,CHEMBL623159,,
10141,N,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),,Rattus norvegicus,A,,BAO_0000218,14294,,10116.0,1,Intermediate,1,CHEMBL874390,,
10142,N,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),,Rattus norvegicus,A,,BAO_0000218,14294,,10116.0,1,Intermediate,1,CHEMBL623160,,
10143,N,Metabolism of compound in rat S9 microsomes; Trace,,Rattus norvegicus,A,,BAO_0000218,14294,,10116.0,1,Intermediate,1,CHEMBL623161,,
10144,N,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,,Rattus norvegicus,A,,BAO_0000218,17847,,10116.0,1,Intermediate,1,CHEMBL623162,,
10145,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL623163,,
10146,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL623164,,
10147,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL623165,,
10148,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL623166,,
10149,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL624983,,
10150,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL624984,,
10151,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL624985,,
10152,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL622970,,
10153,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL622971,,
10154,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL622972,,
10155,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL622973,,
10156,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL622974,,
10157,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL622975,,
10158,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL622976,,
10159,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL622977,,
10160,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL624351,,
10161,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL624352,,
10162,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL624353,,
10163,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL622397,,
10164,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL622398,,
10165,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL622399,,
10166,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL622400,,
10167,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL628428,,
10168,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL628590,,
10169,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL628591,,
10170,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL628592,,
10171,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL628593,,
10172,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL875333,,
10173,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL628594,,
10174,N,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,,Rattus norvegicus,A,,BAO_0000218,4969,,10116.0,1,Intermediate,1,CHEMBL628595,,1969.0
10175,N,Stability in rat plasma was determined,,Rattus norvegicus,A,,BAO_0000218,6737,,10116.0,1,Intermediate,1,CHEMBL628596,,1969.0
10176,N,Stability in rat plasma was determined; ND= no data,,Rattus norvegicus,A,,BAO_0000218,6737,,10116.0,1,Intermediate,1,CHEMBL628597,,1969.0
10177,N,Tested for plasma half life period in rat (0-8 hr),,Rattus norvegicus,A,,BAO_0000218,5089,,10116.0,1,Intermediate,1,CHEMBL628598,,1969.0
10178,N,Tested for plasma half life period in rat (0-8 hr); Not determined,,Rattus norvegicus,A,,BAO_0000218,5089,,10116.0,1,Intermediate,1,CHEMBL628599,,1969.0
10179,N,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,,Rattus norvegicus,A,,BAO_0000218,1466,In vivo,10116.0,1,Intermediate,1,CHEMBL628600,,
10180,N,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,,Rattus norvegicus,A,,BAO_0000218,1466,In vivo,10116.0,1,Intermediate,1,CHEMBL628601,,
10181,N,Tested for the half life in rat,,Rattus norvegicus,A,,BAO_0000218,4950,,10116.0,1,Intermediate,1,CHEMBL628602,,
10182,N,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,,Rattus norvegicus,A,,BAO_0000218,2412,In vitro,10116.0,1,Intermediate,1,CHEMBL628603,,
10183,N,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,,Rattus norvegicus,A,,BAO_0000218,2412,In vitro,10116.0,1,Intermediate,1,CHEMBL628604,,
10184,N,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,,Rattus norvegicus,A,,BAO_0000218,2412,In vitro,10116.0,1,Intermediate,1,CHEMBL628605,,
10185,N,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,,Rattus norvegicus,A,,BAO_0000218,2412,In vitro,10116.0,1,Intermediate,1,CHEMBL628606,,
10186,N,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,,Rattus norvegicus,A,,BAO_0000218,2412,In vitro,10116.0,1,Intermediate,1,CHEMBL628607,,
10187,N,The biological half life the compound was measured at the dose of 100 umol/kg,,Rattus norvegicus,A,,BAO_0000218,15022,,10116.0,1,Intermediate,1,CHEMBL628608,,
10188,N,The biological half life the compound was measured at the dose of 30 umol/kg,,Rattus norvegicus,A,,BAO_0000218,15022,,10116.0,1,Intermediate,1,CHEMBL628609,,
10189,N,The compound was evaluated for plasma half life period in rat,,Rattus norvegicus,A,,BAO_0000218,406,,10116.0,1,Intermediate,1,CHEMBL628610,,1969.0
10190,N,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,15078,In vivo,10116.0,1,Intermediate,1,CHEMBL873819,,
10191,N,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,15078,In vivo,10116.0,1,Intermediate,1,CHEMBL628611,,
10192,N,The pharmacokinetic parameter half-life period in vivo in rats,,Rattus norvegicus,A,,BAO_0000218,5247,In vivo,10116.0,1,Intermediate,1,CHEMBL628612,,
10193,N,"The pharmacokinetic property, Half-life was determined",,Rattus norvegicus,A,,BAO_0000218,5041,In vivo,10116.0,1,Intermediate,1,CHEMBL628613,,
10194,N,"The pharmacokinetic property, Half-life in rat in vivo",,Rattus norvegicus,A,,BAO_0000218,5041,In vivo,10116.0,1,Intermediate,1,CHEMBL628614,,
10195,N,"The pharmacokinetic property, Half-life was determined; ND denotes no data",,Rattus norvegicus,A,,BAO_0000218,5041,In vivo,10116.0,1,Intermediate,1,CHEMBL628615,,
10196,N,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",,Rattus norvegicus,A,,BAO_0000218,5041,In vivo,10116.0,1,Intermediate,1,CHEMBL628616,,
10197,N,The plasma half life period in rats,,Rattus norvegicus,A,,BAO_0000218,3918,,10116.0,1,Intermediate,1,CHEMBL627924,,1969.0
10198,N,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,,Rattus norvegicus,A,,BAO_0000218,2906,,10116.0,1,Intermediate,1,CHEMBL627925,,2107.0
10199,N,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,Rattus norvegicus,A,,BAO_0000218,6467,In vivo,10116.0,1,Intermediate,1,CHEMBL627926,,
10200,N,t1/2 (apparent elimination)of the compound was determined,,Rattus norvegicus,A,,BAO_0000218,5510,,10116.0,1,Intermediate,1,CHEMBL627927,,
10201,N,t1/2 value in rat,,Rattus norvegicus,A,,BAO_0000218,3788,,10116.0,1,Intermediate,1,CHEMBL627928,,
10202,N,Half life in rat,,Rattus norvegicus,A,,BAO_0000218,17796,,10116.0,1,Intermediate,1,CHEMBL627539,,
10203,N,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,Rattus norvegicus,A,,BAO_0000218,12873,In vivo,10116.0,1,Intermediate,1,CHEMBL876790,,1969.0
10204,N,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,,Rattus norvegicus,A,,BAO_0000218,5983,In vivo,10116.0,1,Intermediate,1,CHEMBL858186,,
10205,N,Half-life period in fasted rats,,Rattus norvegicus,A,,BAO_0000218,15765,,10116.0,1,Intermediate,1,CHEMBL627540,,
10206,N,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,,Rattus norvegicus,A,,BAO_0000218,2661,In vivo,10116.0,1,Intermediate,1,CHEMBL627541,,
10207,N,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,,Rattus norvegicus,A,,BAO_0000218,2661,In vivo,10116.0,1,Intermediate,1,CHEMBL627715,,
10208,N,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,429,In vivo,10116.0,1,Intermediate,1,CHEMBL627716,,
10209,N,Maximum time required to achieve Cmax was determined in rat,,Rattus norvegicus,A,,BAO_0000218,17655,,10116.0,1,Intermediate,1,CHEMBL627717,,
10210,N,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,Rattus norvegicus,A,,BAO_0000218,17717,In vivo,10116.0,1,Intermediate,1,CHEMBL627718,,
10211,N,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,Rattus norvegicus,A,,BAO_0000218,17717,In vivo,10116.0,1,Intermediate,1,CHEMBL627719,,
10212,N,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,,Rattus norvegicus,A,,BAO_0000218,17717,In vivo,10116.0,1,Intermediate,1,CHEMBL627720,,
10213,N,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,,Rattus norvegicus,A,,BAO_0000218,6570,In vivo,10116.0,1,Intermediate,1,CHEMBL627721,,
10214,N,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,,Rattus norvegicus,A,,BAO_0000218,6570,In vivo,10116.0,1,Intermediate,1,CHEMBL627722,,
10215,N,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL627723,,
10216,N,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL626058,,
10217,N,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL626059,,
10218,N,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL626060,,
10219,N,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,,Rattus norvegicus,A,,BAO_0000218,17720,In vivo,10116.0,1,Intermediate,1,CHEMBL626061,,1969.0
10220,N,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,A,,BAO_0000218,4723,In vivo,10116.0,1,Intermediate,1,CHEMBL876791,,
10221,N,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,A,,BAO_0000218,4723,In vivo,10116.0,1,Intermediate,1,CHEMBL626062,,
10222,N,Tmax at the dose of 2 mg/Kg administered perorally in rats,,Rattus norvegicus,A,,BAO_0000218,4756,In vivo,10116.0,1,Intermediate,1,CHEMBL626063,,
10223,N,Tmax at the dose of 5 mg/Kg administered perorally in rats,,Rattus norvegicus,A,,BAO_0000218,4756,In vivo,10116.0,1,Intermediate,1,CHEMBL626064,,
10224,N,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,,Rattus norvegicus,A,,BAO_0000218,17720,In vivo,10116.0,1,Intermediate,1,CHEMBL626065,,1969.0
10225,N,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,,Rattus norvegicus,A,,BAO_0000218,17720,In vivo,10116.0,1,Intermediate,1,CHEMBL626066,,1969.0
10226,N,tmax upon peroral administration of 10.0 mg/Kg dose in rat,,Rattus norvegicus,A,,BAO_0000218,1466,In vivo,10116.0,1,Intermediate,1,CHEMBL626067,,
10227,N,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,,Rattus norvegicus,F,,BAO_0000218,7449,,10116.0,1,Intermediate,1,CHEMBL626068,,
10228,N,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,,Rattus norvegicus,F,,BAO_0000218,7449,,10116.0,1,Intermediate,1,CHEMBL626069,,
10229,N,Percent total excretion of 3-methoxyacetaminophen glucuronide,,Rattus norvegicus,F,,BAO_0000218,7449,,10116.0,1,Intermediate,1,CHEMBL626070,,
10230,N,Percent total excretion of N-methoxyacetaminophen glucuronide,,Rattus norvegicus,F,,BAO_0000218,7449,,10116.0,1,Intermediate,1,CHEMBL626071,,
10231,N,Percent total excretion of N-methoxyacetaminophen sulfate,,Rattus norvegicus,F,,BAO_0000218,7449,,10116.0,1,Intermediate,1,CHEMBL626072,,
10232,N,Percent total excretion of acetaminophen,,Rattus norvegicus,F,,BAO_0000218,7449,,10116.0,1,Intermediate,1,CHEMBL626073,,
10233,N,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",,Rattus norvegicus,A,,BAO_0000218,7768,,10116.0,1,Intermediate,1,CHEMBL626741,,2046.0
10234,N,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",,Rattus norvegicus,A,,BAO_0000218,17655,,10116.0,1,Intermediate,1,CHEMBL626742,,
10235,N,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,,Rattus norvegicus,A,,BAO_0000218,17735,,10116.0,1,Intermediate,1,CHEMBL626743,,
10236,N,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,Rattus norvegicus,A,,BAO_0000218,5960,,10116.0,1,Intermediate,1,CHEMBL876792,,
10237,N,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,Rattus norvegicus,A,,BAO_0000218,17735,,10116.0,1,Intermediate,1,CHEMBL626744,,
10238,N,Compound was tested for antidiuretic activity in rats,,Rattus norvegicus,A,,BAO_0000218,7116,,10116.0,1,Intermediate,1,CHEMBL626745,,
10239,N,AUC in rat after 3mg/kg oral dose,,Rattus norvegicus,A,,BAO_0000218,4878,In vivo,10116.0,1,Intermediate,1,CHEMBL626746,,1969.0
10240,N,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5939,,10116.0,1,Intermediate,1,CHEMBL626747,,
10241,N,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5939,,10116.0,1,Intermediate,1,CHEMBL626748,,
10242,N,Bioavailability administered orally at a dose of 10 mg/kg to rats,,Rattus norvegicus,A,,BAO_0000218,16367,,10116.0,1,Intermediate,1,CHEMBL626749,,
10243,N,Oral Bioavailability was determined,,Rattus norvegicus,A,,BAO_0000218,16366,,10116.0,1,Intermediate,1,CHEMBL626750,,
10244,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,4426,,10116.0,1,Intermediate,1,CHEMBL626751,,
10245,N,Oral bioavailability in rat; Not performed.,,Rattus norvegicus,A,,BAO_0000218,4426,,10116.0,1,Intermediate,1,CHEMBL626913,,
10246,N,Bioavailability,,Rattus norvegicus,A,,BAO_0000218,5041,,10116.0,1,Intermediate,1,CHEMBL626914,,
10247,N,Bioavailability was determined; ND denotes no data,,Rattus norvegicus,A,,BAO_0000218,5041,,10116.0,1,Intermediate,1,CHEMBL626915,,
10248,N,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,1500,,10116.0,1,Intermediate,1,CHEMBL626916,,
10249,N,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,1500,,10116.0,1,Intermediate,1,CHEMBL626917,,
10250,N,Binding towards rat plasma protein at 10 uM,,Rattus norvegicus,A,,BAO_0000218,17409,,10116.0,1,Intermediate,1,CHEMBL626918,,
10251,N,Binding towards rat plasma protein at 100 uM,,Rattus norvegicus,A,,BAO_0000218,17409,,10116.0,1,Intermediate,1,CHEMBL626919,,
10252,N,Bioavailability in rat (dose 20 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,2959,In vivo,10116.0,1,Intermediate,1,CHEMBL626920,,
10253,N,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,,Rattus norvegicus,A,,BAO_0000218,13501,In vivo,10116.0,1,Intermediate,1,CHEMBL621976,,
10254,N,Bioavailability in rat after 5 mg/kg oral gavage,,Rattus norvegicus,A,,BAO_0000218,6567,In vivo,10116.0,1,Intermediate,1,CHEMBL877599,,
10255,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6571,In vivo,10116.0,1,Intermediate,1,CHEMBL621977,,
10256,N,Bioavailability in rat (dose 1 mg/kg i.v.),,Rattus norvegicus,A,,BAO_0000218,6715,In vivo,10116.0,1,Intermediate,1,CHEMBL621978,,
10257,N,Bioavailability in rat (dose 3 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,6715,In vivo,10116.0,1,Intermediate,1,CHEMBL621979,,
10258,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,2932,In vivo,10116.0,1,Intermediate,1,CHEMBL621980,,
10259,N,Bioavailability of the compound in rats after administration of 30 mg/kg,,Rattus norvegicus,A,,BAO_0000218,4171,In vivo,10116.0,1,Intermediate,1,CHEMBL621981,,
10260,N,Bioavailability after administration of 10 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,17509,In vivo,10116.0,1,Intermediate,1,CHEMBL621982,,
10261,N,Bioavailability after administration of 2 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,17509,In vivo,10116.0,1,Intermediate,1,CHEMBL882953,,
10262,N,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,,Rattus norvegicus,A,,BAO_0000218,4527,In vivo,10116.0,1,Intermediate,1,CHEMBL621983,,
10263,N,Bioavailability in dogs was determined; high,,Rattus norvegicus,A,,BAO_0000218,4026,In vivo,10116.0,1,Intermediate,1,CHEMBL621984,,
10264,N,Bioavailability in monkey after intravenous administration at 1 mpk,,Rattus norvegicus,A,,BAO_0000218,6659,In vivo,10116.0,1,Intermediate,1,CHEMBL621985,,
10265,N,Bioavailability in monkey after peroral administration at 10 mpk,,Rattus norvegicus,A,,BAO_0000218,6659,In vivo,10116.0,1,Intermediate,1,CHEMBL621986,,
10266,N,Bioavailability in rat after intravenous administration at 1 mpk,,Rattus norvegicus,A,,BAO_0000218,6659,In vivo,10116.0,1,Intermediate,1,CHEMBL621987,,
10267,N,Bioavailability in rat after intravenous administration at 2 mpk,,Rattus norvegicus,F,,BAO_0000218,6659,In vivo,10116.0,1,Intermediate,1,CHEMBL877600,,
10268,N,Bioavailability in rat after peroral administration at 30 mpk,,Rattus norvegicus,A,,BAO_0000218,6659,In vivo,10116.0,1,Intermediate,1,CHEMBL621988,,
10269,N,Bioavailability in rat after peroral administration at at 100 mpk,,Rattus norvegicus,F,,BAO_0000218,6659,In vivo,10116.0,1,Intermediate,1,CHEMBL621989,,
10270,N,Bioavailability in rats was evaluated,,Rattus norvegicus,A,,BAO_0000218,6597,In vivo,10116.0,1,Intermediate,1,CHEMBL621990,,
10271,N,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,,Rattus norvegicus,A,,BAO_0000218,1202,In vivo,10116.0,1,Intermediate,1,CHEMBL621991,,
10272,N,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,,Rattus norvegicus,A,,BAO_0000218,1202,In vivo,10116.0,1,Intermediate,1,CHEMBL621992,,
10273,N,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,,Rattus norvegicus,A,,BAO_0000218,1202,In vivo,10116.0,1,Intermediate,1,CHEMBL621993,,
10274,N,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,,Rattus norvegicus,A,,BAO_0000218,1202,In vivo,10116.0,1,Intermediate,1,CHEMBL621994,,
10275,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,5207,In vivo,10116.0,1,Intermediate,1,CHEMBL621995,,
10276,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,5970,In vivo,10116.0,1,Intermediate,1,CHEMBL621996,,
10277,N,Oral bioavailability in rat (dose 10 mg/kg),,Rattus norvegicus,A,,BAO_0000218,17538,In vivo,10116.0,1,Intermediate,1,CHEMBL621997,,
10278,N,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,,Rattus norvegicus,A,,BAO_0000218,17538,In vivo,10116.0,1,Intermediate,1,CHEMBL621998,,
10279,N,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,,Rattus norvegicus,A,,BAO_0000218,1466,In vivo,10116.0,1,Intermediate,1,CHEMBL621999,,
10280,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,2879,In vivo,10116.0,1,Intermediate,1,CHEMBL622000,,
10281,N,Bioavailability was measured in rat after oral administration; 2-4,,Rattus norvegicus,A,,BAO_0000218,2879,In vivo,10116.0,1,Intermediate,1,CHEMBL622001,,
10282,N,Bioavailability was measured in rat after oral administration; 3-7,,Rattus norvegicus,A,,BAO_0000218,2879,In vivo,10116.0,1,Intermediate,1,CHEMBL622002,,
10283,N,Bioavailability in rat (intraduodenal administration),,Rattus norvegicus,A,,BAO_0000218,3777,In vivo,10116.0,1,Intermediate,1,CHEMBL622003,,
10284,N,Bioavailability in rat (intraduodenal administration),,Rattus norvegicus,A,,BAO_0000218,3777,In vivo,10116.0,1,Intermediate,1,CHEMBL877601,,
10285,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,3777,In vivo,10116.0,1,Intermediate,1,CHEMBL624871,,
10286,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,3777,In vivo,10116.0,1,Intermediate,1,CHEMBL622004,,
10287,N,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,5423,In vivo,10116.0,1,Intermediate,1,CHEMBL882954,,
10288,N,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,,Rattus norvegicus,A,,BAO_0000218,16365,In vivo,10116.0,1,Intermediate,1,CHEMBL622005,,
10289,N,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,,Rattus norvegicus,A,,BAO_0000218,16365,In vivo,10116.0,1,Intermediate,1,CHEMBL622006,,
10290,N,Bioavailability was measured in rat,,Rattus norvegicus,A,,BAO_0000218,4239,In vivo,10116.0,1,Intermediate,1,CHEMBL622007,,
10291,N,Bioavailability was reported,,Rattus norvegicus,A,,BAO_0000218,5438,In vivo,10116.0,1,Intermediate,1,CHEMBL622008,,
10292,N,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,Rattus norvegicus,A,,BAO_0000218,5334,In vivo,10116.0,1,Intermediate,1,CHEMBL622009,,
10293,N,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,Rattus norvegicus,A,,BAO_0000218,5334,In vivo,10116.0,1,Intermediate,1,CHEMBL622010,,
10294,N,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,Rattus norvegicus,A,,BAO_0000218,4199,In vivo,10116.0,1,Intermediate,1,CHEMBL622011,,
10295,N,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),,Rattus norvegicus,A,,BAO_0000218,4199,In vivo,10116.0,1,Intermediate,1,CHEMBL622012,,
10296,N,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),,Rattus norvegicus,A,,BAO_0000218,4199,In vivo,10116.0,1,Intermediate,1,CHEMBL622013,,
10297,N,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,4890,In vivo,10116.0,1,Intermediate,1,CHEMBL622014,,
10298,N,Bioavailability was determined at 3 mg/kg po dose in rats,,Rattus norvegicus,A,,BAO_0000218,2792,In vivo,10116.0,1,Intermediate,1,CHEMBL624749,,
10299,N,Oral bioavailability in rat (dose 2 mg/kg),,Rattus norvegicus,A,,BAO_0000218,5529,In vivo,10116.0,1,Intermediate,1,CHEMBL624750,,
10300,N,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,6685,In vivo,10116.0,1,Intermediate,1,CHEMBL624751,,
10301,N,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,Rattus norvegicus,A,,BAO_0000218,6685,In vivo,10116.0,1,Intermediate,1,CHEMBL624752,,
10302,N,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,Rattus norvegicus,A,,BAO_0000218,6685,In vivo,10116.0,1,Intermediate,1,CHEMBL624753,,
10303,N,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6005,In vivo,10116.0,1,Intermediate,1,CHEMBL624754,,
10304,N,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,Rattus norvegicus,A,,BAO_0000218,6410,In vivo,10116.0,1,Intermediate,1,CHEMBL624755,,
10305,N,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6410,In vivo,10116.0,1,Intermediate,1,CHEMBL624756,,
10306,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6103,In vivo,10116.0,1,Intermediate,1,CHEMBL624757,,
10307,N,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,Rattus norvegicus,A,,BAO_0000218,6410,In vivo,10116.0,1,Intermediate,1,CHEMBL624758,,
10308,N,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6410,In vivo,10116.0,1,Intermediate,1,CHEMBL622270,,
10309,N,Bioavailability in rat (Sprague-Dawley),,Rattus norvegicus,A,,BAO_0000218,5353,In vivo,10116.0,1,Intermediate,1,CHEMBL622271,,
10310,N,Bioavailability in rat at the dose of 2 mg/kg,,Rattus norvegicus,A,,BAO_0000218,4727,In vivo,10116.0,1,Intermediate,1,CHEMBL622272,,
10311,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,17804,In vivo,10116.0,1,Intermediate,1,CHEMBL622273,,
10312,N,Bioavailability in rat (cannulated) (dose 2 mg/kg),,Rattus norvegicus,A,,BAO_0000218,5809,In vivo,10116.0,1,Intermediate,1,CHEMBL622274,,
10313,N,Bioavailability value of compound in rats was determined after peroral administration,,Rattus norvegicus,A,,BAO_0000218,17804,In vivo,10116.0,1,Intermediate,1,CHEMBL622275,,
10314,N,Oral bioavailability in rat (dose 20 mg/kg),,Rattus norvegicus,A,,BAO_0000218,3634,In vivo,10116.0,1,Intermediate,1,CHEMBL622276,,
10315,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,3341,In vivo,10116.0,1,Intermediate,1,CHEMBL622277,,
10316,N,Oral bioavailability in rat (dose 5 mg/kg),,Rattus norvegicus,A,,BAO_0000218,2690,In vivo,10116.0,1,Intermediate,1,CHEMBL622278,,
10317,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,3184,In vivo,10116.0,1,Intermediate,1,CHEMBL622279,,
10318,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,740,In vivo,10116.0,1,Intermediate,1,CHEMBL622280,,
10319,N,Compound was evaluated for oral bioavailability in rats; 15-27 %,,Rattus norvegicus,A,,BAO_0000218,1806,In vivo,10116.0,1,Intermediate,1,CHEMBL624083,,
10320,N,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,,Rattus norvegicus,A,,BAO_0000218,4891,In vivo,10116.0,1,Intermediate,1,CHEMBL624084,,
10321,N,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),,Rattus norvegicus,A,,BAO_0000218,3634,In vivo,10116.0,1,Intermediate,1,CHEMBL624085,,
10322,N,Compound was tested for bioavailability in rats,,Rattus norvegicus,A,,BAO_0000218,64,In vivo,10116.0,1,Intermediate,1,CHEMBL624086,,
10323,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,4839,In vivo,10116.0,1,Intermediate,1,CHEMBL624087,,
10324,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,1094,In vivo,10116.0,1,Intermediate,1,CHEMBL624088,,
10325,U,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,,Macaca mulatta,A,,BAO_0000218,5005,In vivo,9544.0,0,Intermediate,1,CHEMBL624089,,
10326,U,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,5005,In vivo,10116.0,0,Intermediate,1,CHEMBL624090,,
10327,N,Evaluated for the bioavailability in rat (in vivo),,Rattus norvegicus,A,,BAO_0000218,4687,In vivo,10116.0,1,Intermediate,1,CHEMBL624091,,
10328,N,F value of compound in rats was determined after peroral administration,,Rattus norvegicus,A,,BAO_0000218,17804,In vivo,10116.0,1,Intermediate,1,CHEMBL624092,,
10329,N,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL624093,,
10330,N,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL624094,,
10331,N,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL624095,,
10332,N,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5974,In vivo,10116.0,1,Intermediate,1,CHEMBL624096,,
10333,N,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",,Rattus norvegicus,A,,BAO_0000218,1088,In vivo,10116.0,1,Intermediate,1,CHEMBL624097,,
10334,N,Maximum fall in carotid flow in rat,,Rattus norvegicus,A,,BAO_0000218,1742,In vivo,10116.0,1,Intermediate,1,CHEMBL624098,,
10335,N,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,,Rattus norvegicus,A,,BAO_0000218,4689,In vivo,10116.0,1,Intermediate,1,CHEMBL874392,,
10336,N,Oral bioavailability in rat (dose 5 mg/kg),,Rattus norvegicus,A,,BAO_0000218,2463,In vivo,10116.0,1,Intermediate,1,CHEMBL624099,,
10337,N,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,Rattus norvegicus,A,,BAO_0000218,5654,In vivo,10116.0,1,Intermediate,1,CHEMBL624100,,
10338,N,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,Rattus norvegicus,A,,BAO_0000218,5654,In vivo,10116.0,1,Intermediate,1,CHEMBL624101,,
10339,N,Oral bioavailability in rat (male Wistar),,Rattus norvegicus,A,,BAO_0000218,6874,In vivo,10116.0,1,Intermediate,1,CHEMBL624102,,
10340,N,Oral bioavailability after administration (30 mg/kg) in rat; good,,Rattus norvegicus,A,,BAO_0000218,5633,In vivo,10116.0,1,Intermediate,1,CHEMBL624103,,
10341,N,Oral bioavailability at the dose of 2 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,5496,In vivo,10116.0,1,Intermediate,1,CHEMBL624104,,
10342,N,Oral bioavailability determined in rats,,Rattus norvegicus,A,,BAO_0000218,2358,In vivo,10116.0,1,Intermediate,1,CHEMBL624105,,
10343,N,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,16456,In vivo,10116.0,1,Intermediate,1,CHEMBL624106,,
10344,N,Oral bioavailability in rat (dose single 10 mg/kg),,Rattus norvegicus,A,,BAO_0000218,5302,In vivo,10116.0,1,Intermediate,1,CHEMBL624107,,
10345,N,Oral bioavailability in rat (dose single 10 mg/kg),,Rattus norvegicus,A,,BAO_0000218,5302,In vivo,10116.0,1,Intermediate,1,CHEMBL623943,,
10346,N,Oral bioavailability in rat (dose 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5302,In vivo,10116.0,1,Intermediate,1,CHEMBL623944,,
10347,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL623945,,
10348,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL623946,,
10349,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL623947,,
10350,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL623948,,
10351,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL623949,,
10352,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL623950,,
10353,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL874398,,
10354,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL623951,,
10355,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL623952,,
10356,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL623953,,
10357,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL623954,,
10358,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL623955,,
10359,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL623956,,
10360,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL627807,,
10361,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL627808,,
10362,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL627809,,
10363,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL627810,,
10364,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL627811,,
10365,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL627812,,
10366,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL627813,,
10367,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL627814,,
10368,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL875336,,
10369,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL627815,,
10370,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL627816,,
10371,N,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL627817,,
10372,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL627818,,
10373,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL627819,,
10374,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL627820,,
10375,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL627821,,
10376,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL628464,,
10377,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL626239,,
10378,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL626240,,
10379,N,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL626241,,
10380,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL626242,,
10381,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL626243,,
10382,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL626244,,
10383,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL626907,,
10384,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL626908,,
10385,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL626909,,
10386,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL626910,,
10387,N,Percent total excretion of acetaminophen cysteine conjugate,,Rattus norvegicus,F,,BAO_0000218,7449,,10116.0,1,Intermediate,1,CHEMBL875342,,
10388,N,Percent total excretion of acetaminophen glucuronide,,Rattus norvegicus,F,,BAO_0000218,7449,,10116.0,1,Intermediate,1,CHEMBL626911,,
10389,N,Percent total excretion of acetaminophen sulfate,,Rattus norvegicus,F,,BAO_0000218,7449,,10116.0,1,Intermediate,1,CHEMBL626912,,
10390,N,Percent total excretion of acetaminophen-mercapturic acid,,Rattus norvegicus,F,,BAO_0000218,7449,,10116.0,1,Intermediate,1,CHEMBL627065,,
10391,N,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,,Rattus norvegicus,A,,BAO_0000218,3172,,10116.0,1,Intermediate,1,CHEMBL627066,,1088.0
10392,N,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,16456,In vivo,10116.0,1,Intermediate,1,CHEMBL627067,,
10393,U,Biodistribution of compound in rat muscle after 5 min of administration,,ratrat,A,,BAO_0000218,10839,In vivo,8656.0,0,Autocuration,1,CHEMBL627068,,2385.0
10394,U,Biodistribution of compound in rat muscle after 5 min of administration.,,ratrat,A,,BAO_0000218,10839,In vivo,8656.0,0,Autocuration,1,CHEMBL627069,,2385.0
10395,U,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,Ovis aries,A,,BAO_0000218,5334,In vivo,9940.0,0,Autocuration,1,CHEMBL627070,,
10396,U,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,Ovis aries,A,,BAO_0000218,5334,In vivo,9940.0,0,Autocuration,1,CHEMBL627071,,
10397,U,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,Ovis aries,A,,BAO_0000218,5334,In vivo,9940.0,0,Autocuration,1,CHEMBL627072,,
10398,U,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,Ovis aries,A,,BAO_0000218,5334,In vivo,9940.0,0,Autocuration,1,CHEMBL627073,,
10399,U,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,Ovis aries,A,,BAO_0000218,5334,In vivo,9940.0,0,Autocuration,1,CHEMBL625387,,
10400,U,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,Ovis aries,A,,BAO_0000218,5334,In vivo,9940.0,0,Autocuration,1,CHEMBL625388,,
10401,U,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,Ovis aries,A,,BAO_0000218,5334,In vivo,9940.0,0,Autocuration,1,CHEMBL625389,,1969.0
10402,U,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,Ovis aries,A,,BAO_0000218,5334,In vivo,9940.0,0,Autocuration,1,CHEMBL875343,,1969.0
10403,N,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),,Serpentes,A,,BAO_0000218,1735,,8570.0,1,Intermediate,1,CHEMBL876795,,
10404,N,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,,Serpentes,A,,BAO_0000218,1469,,8570.0,1,Intermediate,1,CHEMBL626552,,
10405,N,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,,Serpentes,A,,BAO_0000218,1336,,8570.0,1,Intermediate,1,CHEMBL626553,,
10406,U,The human biological plasma half life of the compound,,Homo sapiens,A,,BAO_0000366,12403,,9606.0,0,Autocuration,1,CHEMBL626554,,1969.0
10407,N,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,8151,,10116.0,1,Intermediate,1,CHEMBL626555,,1088.0
10408,N,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,,Rattus norvegicus,A,,BAO_0000218,8004,,10116.0,1,Intermediate,1,CHEMBL626556,,
10409,N,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,,Rattus norvegicus,A,,BAO_0000218,8004,,10116.0,1,Intermediate,1,CHEMBL626557,,
10410,N,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,,Rattus norvegicus,A,,BAO_0000218,8004,,10116.0,1,Intermediate,1,CHEMBL626558,,
10411,N,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,,Rattus norvegicus,A,,BAO_0000218,8004,,10116.0,1,Intermediate,1,CHEMBL626559,,
10412,N,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,,Rattus norvegicus,A,,BAO_0000218,8004,,10116.0,1,Intermediate,1,CHEMBL626560,,
10413,N,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,,Rattus norvegicus,A,,BAO_0000218,8004,,10116.0,1,Intermediate,1,CHEMBL876803,,
10414,N,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,,Rattus norvegicus,A,,BAO_0000218,8004,,10116.0,1,Intermediate,1,CHEMBL627964,,
10415,N,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,,Rattus norvegicus,A,,BAO_0000218,8004,,10116.0,1,Intermediate,1,CHEMBL627965,,
10416,N,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,,Rattus norvegicus,A,,BAO_0000218,8004,,10116.0,1,Intermediate,1,CHEMBL627966,,
10417,N,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,,Rattus norvegicus,A,,BAO_0000218,8004,,10116.0,1,Intermediate,1,CHEMBL627967,,
10418,N,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,,Rattus norvegicus,A,,BAO_0000218,8004,,10116.0,1,Intermediate,1,CHEMBL627968,,
10419,N,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,,Rattus norvegicus,A,,BAO_0000218,8004,,10116.0,1,Intermediate,1,CHEMBL627969,,
10420,N,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,,Rattus norvegicus,A,,BAO_0000218,8004,,10116.0,1,Intermediate,1,CHEMBL627970,,
10421,N,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,,Rattus norvegicus,A,,BAO_0000218,8004,,10116.0,1,Intermediate,1,CHEMBL627971,,178.0
10422,N,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,,Rattus norvegicus,A,,BAO_0000218,8004,,10116.0,1,Intermediate,1,CHEMBL627972,,178.0
10423,D,Dissociation constant against binding to human cyclophilin A,,Homo sapiens,B,,BAO_0000357,15917,,9606.0,9,Expert,1,CHEMBL856029,,
10424,H,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,,Bos taurus,B,,BAO_0000019,12396,,9913.0,8,Expert,1,CHEMBL627973,,
10425,U,-Log C was determined by performing the electroshock minimum test,,,A,,BAO_0000019,7065,,,0,Autocuration,1,CHEMBL627974,,
10426,U,-Log C was determined by performing the foot shock test,,,A,,BAO_0000019,7065,,,0,Autocuration,1,CHEMBL627975,,
10427,U,-Log C was determined by performing the incl screen test,,,A,,BAO_0000019,7065,,,0,Autocuration,1,CHEMBL627976,,
10428,U,-Log C was determined by performing the maximum electroshock test,,,A,,BAO_0000019,7065,,,0,Autocuration,1,CHEMBL627977,,
10429,U,-Log C was determined by performing the pentylenetetrazole test,,,A,,BAO_0000019,7065,,,0,Autocuration,1,CHEMBL627978,,
10430,U,Tested for experimental arotinoid inhibitory dose,,,A,,BAO_0000019,12415,,,0,Autocuration,1,CHEMBL627979,,
10431,U,Negative log transformed activity,,,A,,BAO_0000019,10256,,,0,Autocuration,1,CHEMBL876804,,
10432,U,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",,,A,,BAO_0000019,7991,,,0,Autocuration,1,CHEMBL627980,,
10433,N,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,,Cavia porcellus,A,,BAO_0000218,14342,,10141.0,1,Intermediate,1,CHEMBL627981,,
10434,N,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,,Cavia porcellus,A,,BAO_0000218,14342,,10141.0,1,Intermediate,1,CHEMBL627982,,
10435,N,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,,Cavia porcellus,A,,BAO_0000218,14342,,10141.0,1,Intermediate,1,CHEMBL627983,,
10436,N,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,,Cavia porcellus,A,,BAO_0000218,14342,,10141.0,1,Intermediate,1,CHEMBL627984,,2116.0
10437,U,Solubility in water was determined; values expressed as -log,,,P,,BAO_0000100,6047,,,0,Autocuration,1,CHEMBL627985,,
10438,U,Ratio of Kcat to that of Km was determined,,,A,,BAO_0000019,17269,,,0,Autocuration,1,CHEMBL627986,,
10439,U,Observed first order rate constant,,,A,,BAO_0000019,10026,,,0,Autocuration,1,CHEMBL627987,,
10440,U,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,,,A,,BAO_0000019,14583,,,0,Autocuration,1,CHEMBL627988,,
10441,N,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,,Rattus norvegicus,A,,BAO_0000218,2661,In vivo,10116.0,1,Intermediate,1,CHEMBL627989,,
10442,N,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,,Rattus norvegicus,A,,BAO_0000218,2661,In vivo,10116.0,1,Intermediate,1,CHEMBL627990,,
10443,N,Oral Bioavailability after administration of 10 mg/kg in male rat,,Rattus norvegicus,A,,BAO_0000218,4029,In vivo,10116.0,1,Intermediate,1,CHEMBL876805,,
10444,N,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,17735,In vivo,10116.0,1,Intermediate,1,CHEMBL627991,,
10445,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,4576,In vivo,10116.0,1,Intermediate,1,CHEMBL627992,,
10446,N,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,,Rattus norvegicus,A,,BAO_0000218,17582,In vivo,10116.0,1,Intermediate,1,CHEMBL627993,,
10447,N,Oral bioavailability at 1 mg/kg was determined in rat,,Rattus norvegicus,A,,BAO_0000218,17651,In vivo,10116.0,1,Intermediate,1,CHEMBL622817,,
10448,N,Oral bioavailability at 10 mg/kg was determined in rat,,Rattus norvegicus,A,,BAO_0000218,17651,In vivo,10116.0,1,Intermediate,1,CHEMBL622818,,
10449,N,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",,Rattus norvegicus,A,,BAO_0000218,17670,In vivo,10116.0,1,Intermediate,1,CHEMBL622819,,
10450,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,5045,In vivo,10116.0,1,Intermediate,1,CHEMBL872267,,
10451,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,1696,In vivo,10116.0,1,Intermediate,1,CHEMBL622820,,
10452,N,Oral bioavailability after intravenous administration in rats at 24 uM/kg,,Rattus norvegicus,A,,BAO_0000218,17764,In vivo,10116.0,1,Intermediate,1,CHEMBL622821,,
10453,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6448,In vivo,10116.0,1,Intermediate,1,CHEMBL622822,,
10454,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6596,In vivo,10116.0,1,Intermediate,1,CHEMBL622823,,
10455,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,17547,In vivo,10116.0,1,Intermediate,1,CHEMBL622824,,
10456,N,Oral bioavailability in rat at a dose of 3 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17771,In vivo,10116.0,1,Intermediate,1,CHEMBL622825,,
10457,N,Oral bioavailability in rat after oral administration at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6495,In vivo,10116.0,1,Intermediate,1,CHEMBL622901,,
10458,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,4558,In vivo,10116.0,1,Intermediate,1,CHEMBL622902,,
10459,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,17596,In vivo,10116.0,1,Intermediate,1,CHEMBL621844,,
10460,N,Oral bioavailability in Dawley rats,,Rattus norvegicus,A,,BAO_0000218,6827,In vivo,10116.0,1,Intermediate,1,CHEMBL621845,,
10461,N,Oral bioavailability,,Rattus norvegicus,A,,BAO_0000218,4026,In vivo,10116.0,1,Intermediate,1,CHEMBL621846,,
10462,N,Oral bioavailability in rat (dose 30 mg/kg),,Rattus norvegicus,A,,BAO_0000218,10,In vivo,10116.0,1,Intermediate,1,CHEMBL621847,,
10463,N,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,Rattus norvegicus,A,,BAO_0000218,17717,In vivo,10116.0,1,Intermediate,1,CHEMBL877609,,
10464,N,Bioavailability in rat (dose 3 mg/kg i.v.),,Rattus norvegicus,A,,BAO_0000218,17717,In vivo,10116.0,1,Intermediate,1,CHEMBL621848,,
10465,N,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,Rattus norvegicus,A,,BAO_0000218,17717,In vivo,10116.0,1,Intermediate,1,CHEMBL621849,,
10466,N,Oral bioavailability in rat (dose 60 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,17717,In vivo,10116.0,1,Intermediate,1,CHEMBL622030,,
10467,N,Percent oral bioavailability determined in rats,,Rattus norvegicus,A,,BAO_0000218,4796,In vivo,10116.0,1,Intermediate,1,CHEMBL622031,,
10468,N,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,Rattus norvegicus,A,,BAO_0000218,4883,In vivo,10116.0,1,Intermediate,1,CHEMBL622032,,
10469,N,The compound was evaluated for bioavailability in rats; 32-51,,Rattus norvegicus,A,,BAO_0000218,2137,In vivo,10116.0,1,Intermediate,1,CHEMBL622033,,
10470,N,Bioavailability in rat (dose 20 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,2959,In vivo,10116.0,1,Intermediate,1,CHEMBL622034,,
10471,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,1361,In vivo,10116.0,1,Intermediate,1,CHEMBL622035,,
10472,N,Bioavailability percent in rat at the dose of 2 mg/kg,,Rattus norvegicus,A,,BAO_0000218,4727,In vivo,10116.0,1,Intermediate,1,CHEMBL882966,,
10473,N,Bioavailability was evaluated after 20 uM/kg of peroral administration,,Rattus norvegicus,A,,BAO_0000218,16423,In vivo,10116.0,1,Intermediate,1,CHEMBL622036,,
10474,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,5206,In vivo,10116.0,1,Intermediate,1,CHEMBL622037,,
10475,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6448,In vivo,10116.0,1,Intermediate,1,CHEMBL622038,,
10476,N,Bioavailability in rats,,Rattus norvegicus,A,,BAO_0000218,17723,In vivo,10116.0,1,Intermediate,1,CHEMBL622039,,
10477,N,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622040,,178.0
10478,N,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622041,,178.0
10479,N,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622042,,178.0
10480,N,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622043,,178.0
10481,N,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622044,,178.0
10482,N,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622045,,10000001.0
10483,N,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622046,,10000001.0
10484,N,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622047,,10000001.0
10485,N,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL877610,,10000001.0
10486,N,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622048,,955.0
10487,N,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622049,,955.0
10488,N,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622050,,955.0
10489,N,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622051,,955.0
10490,N,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622052,,
10491,N,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622053,,
10492,N,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622054,,
10493,N,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622055,,
10494,N,Oral bioavailability in rats was determined; High,,Rattus norvegicus,A,,BAO_0000218,5237,In vivo,10116.0,1,Intermediate,1,CHEMBL622056,,
10495,N,Oral bioavailability in the rat was determined,,Rattus norvegicus,A,,BAO_0000218,5503,In vivo,10116.0,1,Intermediate,1,CHEMBL622057,,
10496,N,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,,Rattus norvegicus,A,,BAO_0000218,15765,In vivo,10116.0,1,Intermediate,1,CHEMBL628008,,
10497,N,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),,Rattus norvegicus,A,,BAO_0000218,15660,In vivo,10116.0,1,Intermediate,1,CHEMBL622058,,
10498,N,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL622059,,
10499,N,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL622060,,
10500,N,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL622061,,
10501,N,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,A,,BAO_0000218,5978,In vivo,10116.0,1,Intermediate,1,CHEMBL622062,,
10502,N,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,,Rattus norvegicus,A,,BAO_0000218,5656,In vivo,10116.0,1,Intermediate,1,CHEMBL622063,,
10503,N,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,3598,In vivo,10116.0,1,Expert,1,CHEMBL877611,,
10504,N,Oral bioavailability of compound in Sprague Dawley rats,,Rattus norvegicus,A,,BAO_0000218,4216,In vivo,10116.0,1,Intermediate,1,CHEMBL622064,,
10505,N,Oral bioavailability of compound in rat,,Rattus norvegicus,A,,BAO_0000218,17839,In vivo,10116.0,1,Intermediate,1,CHEMBL622065,,
10506,N,Oral bioavailability in rat (dose 2 mg/kg),,Rattus norvegicus,A,,BAO_0000218,6570,In vivo,10116.0,1,Intermediate,1,CHEMBL622066,,
10507,N,Oral bioavailability of compound in rat was determined,,Rattus norvegicus,A,,BAO_0000218,5334,In vivo,10116.0,1,Intermediate,1,CHEMBL622067,,
10508,N,Oral bioavailability of compound in rats,,Rattus norvegicus,A,,BAO_0000218,6886,In vivo,10116.0,1,Intermediate,1,CHEMBL622068,,
10509,N,Oral bioavailability of compound was determined in rats,,Rattus norvegicus,A,,BAO_0000218,5210,In vivo,10116.0,1,Intermediate,1,CHEMBL622069,,
10510,N,Oral bioavailability at a dose of 30 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,4170,In vivo,10116.0,1,Intermediate,1,CHEMBL624796,,
10511,N,Oral bioavailability in rat (dose 10 mg/kg),,Rattus norvegicus,A,,BAO_0000218,6028,In vivo,10116.0,1,Intermediate,1,CHEMBL624797,,
10512,N,Oral bioavailability in rat (dose 10 mg/kg),,Rattus norvegicus,A,,BAO_0000218,6028,In vivo,10116.0,1,Intermediate,1,CHEMBL623053,,
10513,N,Oral bioavailability evaluated in rat,,Rattus norvegicus,A,,BAO_0000218,6078,In vivo,10116.0,1,Intermediate,1,CHEMBL623054,,
10514,N,Oral bioavailability in fasted rat,,Rattus norvegicus,A,,BAO_0000218,6168,In vivo,10116.0,1,Intermediate,1,CHEMBL623055,,
10515,N,Oral bioavailability in fed rat,,Rattus norvegicus,A,,BAO_0000218,6168,In vivo,10116.0,1,Intermediate,1,CHEMBL623056,,
10516,N,Oral bioavailability in rat (mature male) (dose 30 mg/kg),,Rattus norvegicus,A,,BAO_0000218,5160,In vivo,10116.0,1,Intermediate,1,CHEMBL623057,,
10517,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6057,In vivo,10116.0,1,Intermediate,1,CHEMBL623058,,
10518,N,Oral bioavailability in rat (dose 10 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,6535,In vivo,10116.0,1,Intermediate,1,CHEMBL623059,,
10519,N,Oral bioavailability in rat after administration of 10 mg/kg po,,Rattus norvegicus,A,,BAO_0000218,6535,In vivo,10116.0,1,Intermediate,1,CHEMBL623060,,
10520,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,4194,In vivo,10116.0,1,Intermediate,1,CHEMBL623061,,
10521,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6230,In vivo,10116.0,1,Intermediate,1,CHEMBL623062,,
10522,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6619,In vivo,10116.0,1,Intermediate,1,CHEMBL623063,,
10523,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,17607,In vivo,10116.0,1,Intermediate,1,CHEMBL623064,,
10524,N,Oral bioavailability in ratrs,,Rattus norvegicus,A,,BAO_0000218,4942,In vivo,10116.0,1,Intermediate,1,CHEMBL623065,,
10525,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,4942,In vivo,10116.0,1,Intermediate,1,CHEMBL623066,,
10526,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6646,In vivo,10116.0,1,Intermediate,1,CHEMBL623067,,
10527,N,Oral bioavailability in rats was determined; High,,Rattus norvegicus,A,,BAO_0000218,5237,In vivo,10116.0,1,Intermediate,1,CHEMBL623068,,
10528,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6646,In vivo,10116.0,1,Intermediate,1,CHEMBL623069,,
10529,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,4449,In vivo,10116.0,1,Intermediate,1,CHEMBL623070,,
10530,N,Oral bioavailability was calculated in rat,,Rattus norvegicus,A,,BAO_0000218,6057,In vivo,10116.0,1,Intermediate,1,CHEMBL623071,,
10531,N,Oral bioavailability,,Rattus norvegicus,A,,BAO_0000218,2552,In vivo,10116.0,1,Intermediate,1,CHEMBL623072,,
10532,N,Oral bioavailability,,Rattus norvegicus,A,,BAO_0000218,5496,In vivo,10116.0,1,Intermediate,1,CHEMBL623073,,
10533,N,Oral bioavailability,,Rattus norvegicus,A,,BAO_0000218,6484,In vivo,10116.0,1,Intermediate,1,CHEMBL623074,,
10534,N,Oral bioavailability,,Rattus norvegicus,A,,BAO_0000218,6485,In vivo,10116.0,1,Intermediate,1,CHEMBL623075,,
10535,N,Oral bioavailability after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,6616,In vivo,10116.0,1,Intermediate,1,CHEMBL623076,,
10536,N,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,Rattus norvegicus,A,,BAO_0000218,4969,In vivo,10116.0,1,Intermediate,1,CHEMBL623077,,
10537,N,Oral bioavailability in rat (Sprague-Dawley),,Rattus norvegicus,A,,BAO_0000218,5862,In vivo,10116.0,1,Intermediate,1,CHEMBL623078,,
10538,N,Oral bioavailability in Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,4514,In vivo,10116.0,1,Intermediate,1,CHEMBL623079,,
10539,N,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,Rattus norvegicus,A,,BAO_0000218,4514,In vivo,10116.0,1,Intermediate,1,CHEMBL623080,,
10540,N,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,Rattus norvegicus,A,,BAO_0000218,4514,In vivo,10116.0,1,Intermediate,1,CHEMBL623081,,
10541,N,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,,Rattus norvegicus,A,,BAO_0000218,5546,In vivo,10116.0,1,Intermediate,1,CHEMBL623082,,
10542,N,Oral bioavailability in fasted rat,,Rattus norvegicus,A,,BAO_0000218,6168,In vivo,10116.0,1,Intermediate,1,CHEMBL874400,,
10543,N,Oral bioavailability in fed rat,,Rattus norvegicus,A,,BAO_0000218,6168,In vivo,10116.0,1,Intermediate,1,CHEMBL623083,,
10544,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,3624,In vivo,10116.0,1,Intermediate,1,CHEMBL623084,,
10545,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,5213,In vivo,10116.0,1,Intermediate,1,CHEMBL623085,,
10546,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,5496,In vivo,10116.0,1,Intermediate,1,CHEMBL623086,,
10547,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,5553,In vivo,10116.0,1,Intermediate,1,CHEMBL623087,,
10548,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,5833,In vivo,10116.0,1,Intermediate,1,CHEMBL623088,,
10549,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,5836,In vivo,10116.0,1,Intermediate,1,CHEMBL623089,,
10550,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,5865,In vivo,10116.0,1,Intermediate,1,CHEMBL623090,,
10551,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,5960,In vivo,10116.0,1,Intermediate,1,CHEMBL623091,,
10552,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6249,In vivo,10116.0,1,Intermediate,1,CHEMBL623092,,
10553,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6448,In vivo,10116.0,1,Intermediate,1,CHEMBL623093,,
10554,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6453,In vivo,10116.0,1,Intermediate,1,CHEMBL874401,,
10555,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6640,In vivo,10116.0,1,Intermediate,1,CHEMBL623094,,
10556,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,17607,In vivo,10116.0,1,Intermediate,1,CHEMBL623095,,
10557,N,Oral bioavailability in rat after peroral administration at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5939,In vivo,10116.0,1,Intermediate,1,CHEMBL623096,,
10558,N,Oral bioavailability in rat after peroral administration at 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5939,In vivo,10116.0,1,Intermediate,1,CHEMBL624913,,
10559,N,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,6281,In vivo,10116.0,1,Intermediate,1,CHEMBL624914,,
10560,N,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5874,In vivo,10116.0,1,Intermediate,1,CHEMBL624915,,
10561,N,Oral bioavailability in rat; Not measured,,Rattus norvegicus,A,,BAO_0000218,5213,In vivo,10116.0,1,Intermediate,1,CHEMBL624916,,
10562,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,4964,In vivo,10116.0,1,Intermediate,1,CHEMBL624917,,
10563,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,,Rattus norvegicus,A,,BAO_0000218,11020,,10116.0,1,Intermediate,1,CHEMBL625157,,
10564,N,In vitro metabolic potential in rat liver microsomes,,Rattus norvegicus,A,,BAO_0000218,6251,,10116.0,1,Intermediate,1,CHEMBL625158,,2107.0
10565,N,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",,Rattus norvegicus,A,,BAO_0000218,1568,In vivo,10116.0,1,Intermediate,1,CHEMBL625159,,
10566,N,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",,Rattus norvegicus,A,,BAO_0000218,3032,In vivo,10116.0,1,Intermediate,1,CHEMBL625160,,
10567,N,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,,Rattus norvegicus,A,,BAO_0000218,3748,In vivo,10116.0,1,Intermediate,1,CHEMBL625161,,
10568,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,401,In vivo,10116.0,1,Intermediate,1,CHEMBL625162,,
10569,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6512,In vivo,10116.0,1,Intermediate,1,CHEMBL625163,,
10570,N,Oral bioavailability in rats at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17617,In vivo,10116.0,1,Intermediate,1,CHEMBL625164,,
10571,N,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Rattus norvegicus,A,,BAO_0000218,6679,In vivo,10116.0,1,Intermediate,1,CHEMBL625165,,
10572,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6742,In vivo,10116.0,1,Intermediate,1,CHEMBL625166,,
10573,N,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,,Rattus norvegicus,A,,BAO_0000218,589,,10116.0,1,Intermediate,1,CHEMBL625167,,
10574,N,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,,Rattus norvegicus,A,,BAO_0000218,589,,10116.0,1,Intermediate,1,CHEMBL625168,,
10575,N,Plasma clearance of the compound,,Rattus norvegicus,A,,BAO_0000218,3185,In vivo,10116.0,1,Intermediate,1,CHEMBL625169,,
10576,N,Plasma clearance at 10 mg/kg in rat upon intravenous administration,,Rattus norvegicus,A,,BAO_0000218,17596,In vivo,10116.0,1,Intermediate,1,CHEMBL626264,,
10577,N,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,,Rattus norvegicus,A,,BAO_0000218,2713,In vivo,10116.0,1,Intermediate,1,CHEMBL626265,,
10578,N,The compound was tested for plasma clearance in rat,,Rattus norvegicus,A,,BAO_0000218,12500,In vivo,10116.0,1,Intermediate,1,CHEMBL626266,,1969.0
10579,N,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,,Rattus norvegicus,A,,BAO_0000218,12500,In vivo,10116.0,1,Intermediate,1,CHEMBL626267,,1969.0
10580,N,Plasma concentration upon oral administration of 1 mg/Kg in rats,,Rattus norvegicus,A,,BAO_0000218,2713,,10116.0,1,Intermediate,1,CHEMBL626268,,
10581,N,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,,Rattus norvegicus,A,,BAO_0000218,1446,,10116.0,1,Intermediate,1,CHEMBL626269,,
10582,N,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,,Rattus norvegicus,A,,BAO_0000218,6227,,10116.0,1,Intermediate,1,CHEMBL626270,,
10583,N,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,4709,,10116.0,1,Intermediate,1,CHEMBL626271,,
10584,N,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",,Rattus norvegicus,A,,BAO_0000218,5510,,10116.0,1,Intermediate,1,CHEMBL626272,,
10585,N,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,Rattus norvegicus,A,,BAO_0000218,5510,,10116.0,1,Intermediate,1,CHEMBL626273,,
10586,N,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,Rattus norvegicus,A,,BAO_0000218,5510,,10116.0,1,Intermediate,1,CHEMBL875346,,
10587,N,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",,Rattus norvegicus,A,,BAO_0000218,5510,,10116.0,1,Intermediate,1,CHEMBL626274,,
10588,N,Compound was tested for protein binding in rat plasma,,Rattus norvegicus,A,,BAO_0000218,4514,,10116.0,1,Intermediate,1,CHEMBL626275,,
10589,N,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,,Rattus norvegicus,A,,BAO_0000218,2713,,10116.0,1,Intermediate,1,CHEMBL624646,,
10590,N,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,,Rattus norvegicus,A,,BAO_0000218,2713,,10116.0,1,Intermediate,1,CHEMBL624647,,
10591,N,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,,Rattus norvegicus,A,,BAO_0000218,5340,,10116.0,1,Intermediate,1,CHEMBL624648,,2107.0
10592,N,Area under curve ratio was determined (po/iv) in rat,,Rattus norvegicus,A,,BAO_0000218,12058,,10116.0,1,Intermediate,1,CHEMBL624649,,
10593,N,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,,10116.0,1,Intermediate,1,CHEMBL624650,,
10594,N,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,,10116.0,1,Intermediate,1,CHEMBL624651,,
10595,N,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,,10116.0,1,Intermediate,1,CHEMBL624652,,
10596,N,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6495,,10116.0,1,Intermediate,1,CHEMBL624653,,
10597,N,Ratio of AUCbrain to AUCplasma,,Rattus norvegicus,A,,BAO_0000218,6078,,10116.0,1,Intermediate,1,CHEMBL624654,,
10598,N,Ratio of brain to plasma,,Rattus norvegicus,A,,BAO_0000218,5656,,10116.0,1,Intermediate,1,CHEMBL624655,,
10599,N,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,,Rattus norvegicus,A,,BAO_0000218,4910,,10116.0,1,Intermediate,1,CHEMBL624656,,
10600,N,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,Rattus norvegicus,A,,BAO_0000218,4910,,10116.0,1,Intermediate,1,CHEMBL624657,,
10601,N,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,Rattus norvegicus,A,,BAO_0000218,4910,,10116.0,1,Intermediate,1,CHEMBL624658,,
10602,N,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL624659,,
10603,N,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL624660,,
10604,N,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,,Rattus norvegicus,A,,BAO_0000218,10130,,10116.0,1,Intermediate,1,CHEMBL624661,,
10605,N,Steady state brain :blood ratio was determined,,Rattus norvegicus,A,,BAO_0000218,5213,,10116.0,1,Intermediate,1,CHEMBL624662,,
10606,N,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,Rattus norvegicus,A,,BAO_0000218,4910,,10116.0,1,Intermediate,1,CHEMBL625199,,
10607,N,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,Rattus norvegicus,A,,BAO_0000218,4910,,10116.0,1,Intermediate,1,CHEMBL625200,,
10608,N,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,,Rattus norvegicus,A,,BAO_0000218,4910,,10116.0,1,Intermediate,1,CHEMBL625201,,
10609,N,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,Rattus norvegicus,A,,BAO_0000218,4910,,10116.0,1,Intermediate,1,CHEMBL625202,,
10610,N,Percentage recovery after 3h incubation with rat hapatocytes was determined,,Rattus norvegicus,A,,BAO_0000218,2083,,10116.0,1,Intermediate,1,CHEMBL625203,,
10611,N,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,,Rattus norvegicus,A,,BAO_0000218,2082,,10116.0,1,Intermediate,1,CHEMBL625204,,
10612,N,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,,Rattus norvegicus,A,,BAO_0000218,2082,,10116.0,1,Intermediate,1,CHEMBL625205,,
10613,N,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,6351,,10116.0,1,Intermediate,1,CHEMBL625206,,
10614,U,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",,,A,,BAO_0000019,14583,,,0,Autocuration,1,CHEMBL625207,,
10615,U,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,,,A,,BAO_0000019,14583,,,0,Autocuration,1,CHEMBL625208,,
10616,N,In vivo absorption in Caco-2 cell line monolayers was determined,,Homo sapiens,A,,BAO_0000218,4608,,9606.0,1,Intermediate,1,CHEMBL625209,495.0,
10617,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,13668,,,0,Autocuration,1,CHEMBL625210,,
10618,N,Area under curve was determine after peroral administration at 10 mpk in Rat,,Rattus norvegicus,A,,BAO_0000218,5669,,10116.0,1,Intermediate,1,CHEMBL625211,,
10619,N,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,Macaca mulatta,A,,BAO_0000218,5669,,9544.0,1,Intermediate,1,CHEMBL625212,,
10620,N,Area under curve was determine after peroral administration at 160 mpk in Rat,,Rattus norvegicus,A,,BAO_0000218,5669,,10116.0,1,Intermediate,1,CHEMBL625213,,
10621,N,Area under curve was determine after peroral administration at 20 mpk in Rat,,Rattus norvegicus,A,,BAO_0000218,5669,,10116.0,1,Intermediate,1,CHEMBL625214,,
10622,N,Area under curve was determine after peroral administration at 50 mpk in Rat,,Rattus norvegicus,A,,BAO_0000218,5669,,10116.0,1,Intermediate,1,CHEMBL874542,,
10623,U,Calculated partition coefficient (clogP) (AlogP),,,P,,BAO_0000100,6472,,,0,Autocuration,1,CHEMBL625215,,
10624,U,Activated partial thromboplastin time measured,,,A,,BAO_0000019,15106,,,0,Autocuration,1,CHEMBL625216,,
10625,U,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),,,P,,BAO_0000100,15207,,,0,Autocuration,1,CHEMBL625217,,
10626,U,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),,,P,,BAO_0000100,15207,,,0,Autocuration,1,CHEMBL625218,,
10627,N,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,,Canis lupus familiaris,A,,BAO_0000218,13941,,9615.0,1,Intermediate,1,CHEMBL622864,,1969.0
10628,N,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,,Rattus norvegicus,A,,BAO_0000218,13941,,10116.0,1,Intermediate,1,CHEMBL622865,,1969.0
10629,N,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,,Rattus norvegicus,A,,BAO_0000218,13941,,10116.0,1,Intermediate,1,CHEMBL622866,,1969.0
10630,N,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,,Canis lupus familiaris,A,,BAO_0000218,13941,,9615.0,1,Intermediate,1,CHEMBL622867,,1969.0
10631,N,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,,Cavia porcellus,A,,BAO_0000218,15240,,10141.0,1,Intermediate,1,CHEMBL876808,,1969.0
10632,U,AUC in brain,,,A,,BAO_0000019,10655,,,0,Autocuration,1,CHEMBL627725,,955.0
10633,U,AUC in serum,,,A,,BAO_0000019,10655,,,0,Autocuration,1,CHEMBL627726,,1977.0
10634,U,AUC was determined,,,A,,BAO_0000019,6504,,,0,Autocuration,1,CHEMBL627727,,1969.0
10635,U,AUC of the compound.,,,A,,BAO_0000019,10615,,,0,Autocuration,1,CHEMBL627728,,1969.0
10636,U,AUC value (0-4 hr),,,A,,BAO_0000019,10353,,,0,Autocuration,1,CHEMBL627729,,1969.0
10637,U,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",,,A,,BAO_0000019,14907,,,0,Autocuration,1,CHEMBL627730,,1969.0
10638,U,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,,,A,,BAO_0000019,14907,,,0,Autocuration,1,CHEMBL627731,,1969.0
10639,U,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",,,A,,BAO_0000019,14907,,,0,Autocuration,1,CHEMBL627732,,1969.0
10640,U,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",,,A,,BAO_0000019,14907,,,0,Autocuration,1,CHEMBL627733,,1969.0
10641,N,AUC(area under curve) was determined after intravenous administration in rats,,Rattus norvegicus,A,,BAO_0000218,16359,,10116.0,1,Intermediate,1,CHEMBL627734,,1969.0
10642,N,AUC(area under curve) was determined after oral administration in rats,,Rattus norvegicus,A,,BAO_0000218,16359,,10116.0,1,Intermediate,1,CHEMBL627735,,1969.0
10643,N,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,,Cavia porcellus,A,,BAO_0000218,15240,,10141.0,1,Intermediate,1,CHEMBL627736,,1969.0
10644,N,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,,Rattus norvegicus,A,,BAO_0000218,15240,,10116.0,1,Intermediate,1,CHEMBL876809,,1969.0
10645,U,Area Under Curve after oral dosing of 100 uM/Kg,,,A,,BAO_0000019,15469,,,0,Autocuration,1,CHEMBL627737,,
10646,U,Area Under Curve after oral dosing of 30 uM/Kg,,,A,,BAO_0000019,15469,,,0,Autocuration,1,CHEMBL627738,,
10647,U,Area Under Curve was measured by ploting the graph between concentration verses time,,,A,,BAO_0000019,13520,,,0,Autocuration,1,CHEMBL627739,,
10648,N,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,,Canis lupus familiaris,A,,BAO_0000218,17025,,9615.0,1,Intermediate,1,CHEMBL626143,,
10649,U,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,,Simiiformes,A,,BAO_0000218,17025,,314293.0,0,Autocuration,1,CHEMBL626144,,
10650,N,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,,Oryctolagus cuniculus,A,,BAO_0000218,17025,,9986.0,1,Intermediate,1,CHEMBL626145,,
10651,N,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,,Rattus norvegicus,A,,BAO_0000218,17025,,10116.0,1,Intermediate,1,CHEMBL626146,,
10652,N,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,,Rattus norvegicus,A,,BAO_0000218,12032,,10116.0,1,Intermediate,1,CHEMBL626147,,178.0
10653,U,Area under curve (AUC) was determined,,,A,,BAO_0000019,10291,,,0,Autocuration,1,CHEMBL626148,,
10654,U,Area under curve (AUC) following ip administration at 1 mg/kg,,,A,,BAO_0000218,5767,,,0,Autocuration,1,CHEMBL626149,,
10655,U,Area under curve (AUC) was determined; ND is Not determined,,,A,,BAO_0000019,1434,,,0,Autocuration,1,CHEMBL626150,,
10656,N,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,,Canis lupus familiaris,A,,BAO_0000218,14925,,9615.0,1,Intermediate,1,CHEMBL626151,,
10657,N,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,,Canis lupus familiaris,A,,BAO_0000218,14925,,9615.0,1,Intermediate,1,CHEMBL626152,,
10658,N,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,,Canis lupus familiaris,A,,BAO_0000218,14925,,9615.0,1,Intermediate,1,CHEMBL626153,,
10659,U,Area under curve (AUR) was determined,,,A,,BAO_0000019,1434,,,0,Autocuration,1,CHEMBL626154,,
10660,U,Area under curve at 1 uM/dg administered intravenously,,,A,,BAO_0000019,11883,,,0,Autocuration,1,CHEMBL626155,,
10661,U,Area under curve at 10 uM/dg administered perorally,,,A,,BAO_0000019,11883,,,0,Autocuration,1,CHEMBL626156,,
10662,U,Area under curve at 2 uM/dg administered intravenously,,,A,,BAO_0000019,11883,,,0,Autocuration,1,CHEMBL626157,,
10663,U,Area under curve at 20 uM/dg administered perorally,,,A,,BAO_0000019,11883,,,0,Autocuration,1,CHEMBL626158,,
10664,N,Area under curve at a peroral dose of 3 mg/kg in dog,,Canis lupus familiaris,A,,BAO_0000218,15233,,9615.0,1,Intermediate,1,CHEMBL626159,,
10665,N,Area under curve at a peroral dose of 3 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,15233,,10116.0,1,Intermediate,1,CHEMBL626160,,
10666,N,Area under curve at an iv dose of 1 mg/kg in dog,,Canis lupus familiaris,A,,BAO_0000218,15233,,9615.0,1,Intermediate,1,CHEMBL626161,,
10667,N,Area under curve at an iv dose of 1 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,15233,,10116.0,1,Intermediate,1,CHEMBL626162,,
10668,U,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,,,A,,BAO_0000019,12978,,,0,Autocuration,1,CHEMBL626163,,
10669,U,Area under curve gives the effective duration for the angiotensin II antagonist effect.,,,A,,BAO_0000019,12978,,,0,Autocuration,1,CHEMBL626164,,
10670,N,Area under curve measured as conc vs time after intravenous administration to mice.,,Mus musculus,A,,BAO_0000218,11355,,10090.0,1,Intermediate,1,CHEMBL626165,,
10671,N,Area under curve measured as conc vs time after peroral administration to mice.,,Mus musculus,A,,BAO_0000218,11355,,10090.0,1,Intermediate,1,CHEMBL626166,,
10672,N,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,Canis lupus familiaris,A,,BAO_0000218,12923,,9615.0,1,Intermediate,1,CHEMBL626167,,
10673,N,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,,Canis lupus familiaris,A,,BAO_0000218,12923,,9615.0,1,Intermediate,1,CHEMBL626168,,
10674,N,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,,Canis lupus familiaris,A,,BAO_0000218,12923,,9615.0,1,Intermediate,1,CHEMBL877463,,
10675,N,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,,Canis lupus familiaris,A,,BAO_0000218,12923,,9615.0,1,Intermediate,1,CHEMBL626169,,
10676,N,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL626170,,948.0
10677,N,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL626171,,948.0
10678,N,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL626172,,948.0
10679,N,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL626173,,948.0
10680,N,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL626174,,2113.0
10681,N,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL626175,,2113.0
10682,N,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL626176,,2113.0
10683,N,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL626177,,2113.0
10684,N,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622499,,2113.0
10685,N,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622500,,2107.0
10686,N,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622501,,2107.0
10687,N,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622502,,2107.0
10688,N,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL622503,,2107.0
10689,N,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL877614,,2107.0
10690,N,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL624839,,2048.0
10691,N,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL624840,,2048.0
10692,N,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL624841,,2048.0
10693,N,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL624842,,2048.0
10694,N,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL624843,,2385.0
10695,N,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL624844,,2385.0
10696,N,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL624845,,2385.0
10697,N,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,,Rattus norvegicus,A,,BAO_0000218,17738,In vivo,10116.0,1,Intermediate,1,CHEMBL621904,,2385.0
10698,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL621905,,178.0
10699,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL874382,,178.0
10700,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL621906,,178.0
10701,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL621907,,955.0
10702,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622096,,955.0
10703,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622097,,955.0
10704,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622098,,948.0
10705,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622099,,948.0
10706,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622100,,948.0
10707,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622101,,2113.0
10708,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622102,,2113.0
10709,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622103,,2113.0
10710,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622104,,2107.0
10711,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622105,,2107.0
10712,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622106,,2107.0
10713,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622107,,2048.0
10714,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622108,,2048.0
10715,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622109,,2048.0
10716,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622110,,2385.0
10717,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622111,,2385.0
10718,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL874383,,2385.0
10719,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622112,,14.0
10720,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622113,,14.0
10721,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622114,,14.0
10722,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622115,,2106.0
10723,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,,Rattus norvegicus,A,,BAO_0000218,11195,In vivo,10116.0,1,Intermediate,1,CHEMBL622116,,2106.0
10724,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6193,In vivo,10116.0,1,Intermediate,1,CHEMBL622117,,
10725,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6803,In vivo,10116.0,1,Intermediate,1,CHEMBL622118,,
10726,N,Oral bioavailability in rats at 6 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6647,In vivo,10116.0,1,Intermediate,1,CHEMBL622119,,
10727,N,Oral bioavailability in rat (dose 6 mg/kg),,Rattus norvegicus,A,,BAO_0000218,6647,In vivo,10116.0,1,Intermediate,1,CHEMBL622120,,
10728,N,Oral bioavailability in rats at 6 mg/kg dose; Not tested,,Rattus norvegicus,A,,BAO_0000218,6647,In vivo,10116.0,1,Intermediate,1,CHEMBL622121,,
10729,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6640,In vivo,10116.0,1,Intermediate,1,CHEMBL622122,,
10730,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6641,In vivo,10116.0,1,Intermediate,1,CHEMBL622123,,
10731,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6641,In vivo,10116.0,1,Intermediate,1,CHEMBL622124,,
10732,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6642,In vivo,10116.0,1,Intermediate,1,CHEMBL622125,,
10733,N,Oral bioavailability,,Rattus norvegicus,A,,BAO_0000218,5472,In vivo,10116.0,1,Intermediate,1,CHEMBL622126,,
10734,N,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,Rattus norvegicus,A,,BAO_0000218,6141,In vivo,10116.0,1,Intermediate,1,CHEMBL620455,,
10735,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,4390,In vivo,10116.0,1,Intermediate,1,CHEMBL620456,,
10736,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,5472,In vivo,10116.0,1,Intermediate,1,CHEMBL620457,,
10737,N,Oral bioavailability was evaluated; Not tested,,Rattus norvegicus,A,,BAO_0000218,5472,In vivo,10116.0,1,Intermediate,1,CHEMBL620458,,
10738,N,Oral bioavailability,,Rattus norvegicus,A,,BAO_0000218,5438,In vivo,10116.0,1,Intermediate,1,CHEMBL620459,,
10739,N,Oral bioavailability in rat by oral dosing,,Rattus norvegicus,A,,BAO_0000218,4883,In vivo,10116.0,1,Intermediate,1,CHEMBL620460,,
10740,N,Oral bioavailability in rat (dose 10 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,1908,In vivo,10116.0,1,Intermediate,1,CHEMBL620461,,
10741,N,Oral bioavailability in rat (Sprague-Dawley),,Rattus norvegicus,A,,BAO_0000218,4853,In vivo,10116.0,1,Intermediate,1,CHEMBL620462,,
10742,N,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,Rattus norvegicus,A,,BAO_0000218,4853,In vivo,10116.0,1,Intermediate,1,CHEMBL620463,,
10743,N,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,Rattus norvegicus,A,,BAO_0000218,4853,In vivo,10116.0,1,Intermediate,1,CHEMBL620464,,
10744,N,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,Rattus norvegicus,A,,BAO_0000218,4853,In vivo,10116.0,1,Intermediate,1,CHEMBL620465,,
10745,N,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,4853,In vivo,10116.0,1,Intermediate,1,CHEMBL620466,,
10746,N,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,,Rattus norvegicus,A,,BAO_0000218,4853,In vivo,10116.0,1,Intermediate,1,CHEMBL620467,,
10747,N,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,,Rattus norvegicus,A,,BAO_0000218,4853,In vivo,10116.0,1,Intermediate,1,CHEMBL620468,,
10748,N,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,,Rattus norvegicus,A,,BAO_0000218,12873,In vivo,10116.0,1,Intermediate,1,CHEMBL620469,,
10749,N,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,,Rattus norvegicus,A,,BAO_0000218,12873,In vivo,10116.0,1,Intermediate,1,CHEMBL620470,,
10750,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,3169,In vivo,10116.0,1,Intermediate,1,CHEMBL620471,,
10751,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6305,In vivo,10116.0,1,Intermediate,1,CHEMBL620472,,
10752,N,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,,Rattus norvegicus,A,,BAO_0000218,4762,In vivo,10116.0,1,Intermediate,1,CHEMBL620473,,
10753,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,17847,In vivo,10116.0,1,Intermediate,1,CHEMBL620474,,
10754,N,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),,Rattus norvegicus,A,,BAO_0000218,6211,In vivo,10116.0,1,Intermediate,1,CHEMBL620475,,
10755,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6011,In vivo,10116.0,1,Intermediate,1,CHEMBL620476,,
10756,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,6317,In vivo,10116.0,1,Intermediate,1,CHEMBL620477,,
10757,N,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,6644,In vivo,10116.0,1,Intermediate,1,CHEMBL620478,,
10758,N,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,6644,In vivo,10116.0,1,Intermediate,1,CHEMBL618768,,
10759,N,Oral bioavailability in rat after oral administration at 13 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,6644,In vivo,10116.0,1,Intermediate,1,CHEMBL618769,,
10760,N,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,6644,In vivo,10116.0,1,Intermediate,1,CHEMBL618770,,
10761,N,Oral bioavailability (dose 20 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,6113,In vivo,10116.0,1,Intermediate,1,CHEMBL618771,,
10762,N,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5937,In vivo,10116.0,1,Intermediate,1,CHEMBL618772,,
10763,N,Oral bioavailability in rat at 10 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,5711,In vivo,10116.0,1,Intermediate,1,CHEMBL618773,,
10764,N,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,Rattus norvegicus,A,,BAO_0000218,17717,In vivo,10116.0,1,Intermediate,1,CHEMBL875842,,
10765,N,Bioavailability in rat (dose 3 mg/kg i.v.),,Rattus norvegicus,A,,BAO_0000218,17717,In vivo,10116.0,1,Intermediate,1,CHEMBL618774,,
10766,N,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,Rattus norvegicus,A,,BAO_0000218,17717,In vivo,10116.0,1,Intermediate,1,CHEMBL618775,,
10767,N,Oral bioavailability in rat (dose 60 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,17717,In vivo,10116.0,1,Intermediate,1,CHEMBL618776,,
10768,N,Percent bioavailability (F) in rats after iv administration,,Rattus norvegicus,A,,BAO_0000218,4722,In vivo,10116.0,1,Intermediate,1,CHEMBL618777,,
10769,N,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,4722,In vivo,10116.0,1,Intermediate,1,CHEMBL618778,,
10770,N,Bioavailability in rat (dose 5 uM/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,4353,In vivo,10116.0,1,Intermediate,1,CHEMBL618779,,
10771,N,Oral bioavailability,,Rattus norvegicus,A,,BAO_0000218,15662,In vivo,10116.0,1,Intermediate,1,CHEMBL618780,,
10772,N,Bioavailability in rat (dose 2 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,4756,In vivo,10116.0,1,Intermediate,1,CHEMBL618781,,
10773,N,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,,Rattus norvegicus,A,,BAO_0000218,4756,In vivo,10116.0,1,Intermediate,1,CHEMBL618782,,
10774,N,Oral bioavailability in rat (dose 20 mg/kg),,Rattus norvegicus,A,,BAO_0000218,3436,In vivo,10116.0,1,Intermediate,1,CHEMBL618783,,
10775,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,17800,In vivo,10116.0,1,Intermediate,1,CHEMBL618784,,
10776,N,Percent oral bioavailability evaluated in rat,,Rattus norvegicus,A,,BAO_0000218,15762,In vivo,10116.0,1,Intermediate,1,CHEMBL618785,,
10777,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,5089,In vivo,10116.0,1,Intermediate,1,CHEMBL618786,,
10778,N,Percent oral bioavailability in rat; Not determined,,Rattus norvegicus,A,,BAO_0000218,5089,In vivo,10116.0,1,Intermediate,1,CHEMBL618787,,
10779,N,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,3185,In vivo,10116.0,1,Intermediate,1,CHEMBL618788,,
10780,N,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,5145,In vivo,10116.0,1,Intermediate,1,CHEMBL618789,,
10781,N,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),,Rattus norvegicus,A,,BAO_0000218,3457,In vivo,10116.0,1,Intermediate,1,CHEMBL618790,,
10782,N,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),,Rattus norvegicus,A,,BAO_0000218,3457,In vivo,10116.0,1,Intermediate,1,CHEMBL618791,,
10783,N,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,,Rattus norvegicus,A,,BAO_0000218,5983,In vivo,10116.0,1,Intermediate,1,CHEMBL875843,,
10784,N,Oral bioavailability in rat (dose 20 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,5739,In vivo,10116.0,1,Intermediate,1,CHEMBL618792,,
10785,N,Cmax at a dose of 30 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,3579,In vivo,10116.0,1,Intermediate,1,CHEMBL623395,,
10786,U,Cmax in monkeys at a dose of 1 mg/kg,,Simiiformes,A,,BAO_0000218,17788,In vivo,314293.0,0,Autocuration,1,CHEMBL623396,,
10787,N,Cmax in rat,,Rattus norvegicus,A,,BAO_0000218,14956,In vivo,10116.0,1,Intermediate,1,CHEMBL623397,,
10788,N,Cmax in rats at a dose of 1 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17788,In vivo,10116.0,1,Intermediate,1,CHEMBL623398,,
10789,N,Cmax was measured in mice after an oral dose of 50 mg/kg.,,Mus musculus,A,,BAO_0000218,9750,In vivo,10090.0,1,Intermediate,1,CHEMBL623399,,
10790,U,"Cmax value at a dose of 12.7 uM/kg, po",,,A,,BAO_0000218,12767,In vivo,,0,Autocuration,1,CHEMBL623400,,
10791,U,"Cmax value at a dose of 6.3 uM/kg, iv",,,A,,BAO_0000218,12767,In vivo,,0,Autocuration,1,CHEMBL623401,,
10792,U,"Cmax value at a dose of 7.1 uM/kg, iv",,,A,,BAO_0000218,12767,In vivo,,0,Autocuration,1,CHEMBL623402,,
10793,U,Cmax value of compound was determined after 1 hr,,,A,,BAO_0000218,12703,In vivo,,0,Autocuration,1,CHEMBL623403,,
10794,U,Cmax value of the compound,,,A,,BAO_0000218,15778,In vivo,,0,Autocuration,1,CHEMBL623404,,
10795,N,Cmax value administered intraintestinal in rats.,,Rattus norvegicus,A,,BAO_0000218,12818,In vivo,10116.0,1,Intermediate,1,CHEMBL625997,,
10796,N,Cmax value administered perorally was determined in rat; Not determined,,Rattus norvegicus,A,,BAO_0000218,14964,In vivo,10116.0,1,Intermediate,1,CHEMBL625998,,
10797,U,Cmax value at the dose of 2.3 mg/kg,,,A,,BAO_0000218,15808,In vivo,,0,Autocuration,1,CHEMBL625999,,
10798,U,Cmax value at the dose of 5 mg/kg,,,A,,BAO_0000218,15808,In vivo,,0,Autocuration,1,CHEMBL626000,,
10799,U,Cmax value in the period of 8 hr after dosing. ,,,A,,BAO_0000218,15778,In vivo,,0,Autocuration,1,CHEMBL626001,,
10800,U,Cmax value at a oral dose of 20 mg/kg; Not tested,,,A,,BAO_0000218,3715,In vivo,,0,Autocuration,1,CHEMBL626002,,
10801,U,Cmax value at a oral dose of 20 mg/kg,,,A,,BAO_0000218,3715,In vivo,,0,Autocuration,1,CHEMBL626003,,
10802,N,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,Rattus norvegicus,A,,BAO_0000218,1446,In vivo,10116.0,1,Intermediate,1,CHEMBL626004,,
10803,N,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,,Cavia porcellus,A,,BAO_0000218,15240,In vivo,10141.0,1,Intermediate,1,CHEMBL626005,,
10804,N,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,,Rattus norvegicus,A,,BAO_0000218,15240,In vivo,10116.0,1,Intermediate,1,CHEMBL626006,,
10805,N,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,,Rattus norvegicus,A,,BAO_0000218,14810,In vivo,10116.0,1,Intermediate,1,CHEMBL626007,,1969.0
10806,N,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,Mus musculus,A,,BAO_0000218,14239,In vivo,10090.0,1,Intermediate,1,CHEMBL626008,,1969.0
10807,N,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,,Canis lupus familiaris,A,,BAO_0000218,12555,In vivo,9615.0,1,Intermediate,1,CHEMBL626009,,2107.0
10808,N,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,,Canis lupus familiaris,A,,BAO_0000218,10754,In vivo,9615.0,1,Intermediate,1,CHEMBL626010,,
10809,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,,Mus musculus,A,,BAO_0000218,10754,In vivo,10090.0,1,Intermediate,1,CHEMBL626011,,178.0
10810,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,,Mus musculus,A,,BAO_0000218,10754,In vivo,10090.0,1,Intermediate,1,CHEMBL626012,,178.0
10811,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,,Mus musculus,A,,BAO_0000218,10754,In vivo,10090.0,1,Intermediate,1,CHEMBL626013,,178.0
10812,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,,Mus musculus,A,,BAO_0000218,10754,In vivo,10090.0,1,Intermediate,1,CHEMBL626014,,178.0
10813,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,,Mus musculus,A,,BAO_0000218,10754,In vivo,10090.0,1,Intermediate,1,CHEMBL877496,,178.0
10814,N,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,,Canis lupus familiaris,F,,BAO_0000218,14600,In vivo,9615.0,1,Intermediate,1,CHEMBL626015,,
10815,N,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,,Canis lupus familiaris,F,,BAO_0000218,14600,In vivo,9615.0,1,Intermediate,1,CHEMBL626016,,
10816,N,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,,Canis lupus familiaris,F,,BAO_0000218,14600,In vivo,9615.0,1,Intermediate,1,CHEMBL626017,,
10817,N,Bioavailability as maximal plasma concentration in dogs,,Canis lupus familiaris,A,,BAO_0000218,13543,In vivo,9615.0,1,Intermediate,1,CHEMBL626018,,1969.0
10818,N,Bioavailability as maximal plasma concentration in dogs,,Canis lupus familiaris,A,,BAO_0000218,13543,In vivo,9615.0,1,Intermediate,1,CHEMBL626692,,1969.0
10819,N,Bioavailability as maximal plasma concentration in rats,,Rattus norvegicus,A,,BAO_0000218,13543,In vivo,10116.0,1,Intermediate,1,CHEMBL626693,,1969.0
10820,U,Bioavailability as maximal plasma concentration in rats,,Rattus norvegicus,A,,BAO_0000218,13543,In vivo,10116.0,0,Autocuration,1,CHEMBL626694,,1969.0
10821,N,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,Canis lupus familiaris,A,,BAO_0000218,14600,In vivo,9615.0,1,Intermediate,1,CHEMBL626695,,178.0
10822,N,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,Canis lupus familiaris,A,,BAO_0000218,14600,In vivo,9615.0,1,Intermediate,1,CHEMBL626696,,178.0
10823,N,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,Canis lupus familiaris,A,,BAO_0000218,14600,In vivo,9615.0,1,Intermediate,1,CHEMBL626697,,178.0
10824,N,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,,Canis lupus familiaris,A,,BAO_0000218,14600,In vivo,9615.0,1,Intermediate,1,CHEMBL626859,,178.0
10825,N,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,Canis lupus familiaris,A,,BAO_0000218,14600,In vivo,9615.0,1,Intermediate,1,CHEMBL626860,,178.0
10826,N,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,Canis lupus familiaris,A,,BAO_0000218,14600,In vivo,9615.0,1,Intermediate,1,CHEMBL626861,,178.0
10827,N,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,Rattus norvegicus,A,,BAO_0000218,14681,In vivo,10116.0,1,Intermediate,1,CHEMBL626296,,
10828,U,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,,,A,,BAO_0000218,15905,In vivo,,0,Autocuration,1,CHEMBL626297,,
10829,U,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,,,A,,BAO_0000218,15905,In vivo,,0,Autocuration,1,CHEMBL626298,,1969.0
10830,N,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",,Rattus norvegicus,A,,BAO_0000218,13304,In vivo,10116.0,1,Intermediate,1,CHEMBL626299,,1969.0
10831,N,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,,Rattus norvegicus,A,,BAO_0000218,15137,In vivo,10116.0,1,Intermediate,1,CHEMBL626300,,1969.0
10832,N,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,,Rattus norvegicus,A,,BAO_0000218,15137,In vivo,10116.0,1,Intermediate,1,CHEMBL626301,,1969.0
10833,N,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,,Rattus norvegicus,A,,BAO_0000218,15137,In vivo,10116.0,1,Intermediate,1,CHEMBL626962,,1969.0
10834,N,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,,Rattus norvegicus,A,,BAO_0000218,15137,In vivo,10116.0,1,Intermediate,1,CHEMBL626963,,1969.0
10835,N,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,,Rattus norvegicus,A,,BAO_0000218,15137,In vivo,10116.0,1,Intermediate,1,CHEMBL626964,,1969.0
10836,N,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,,Macaca fascicularis,A,,BAO_0000218,14839,In vivo,9541.0,1,Intermediate,1,CHEMBL626965,,1969.0
10837,N,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,Mus musculus,A,,BAO_0000218,14839,In vivo,10090.0,1,Intermediate,1,CHEMBL626966,,1969.0
10838,N,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,Mus musculus,A,,BAO_0000218,14839,In vivo,10090.0,1,Intermediate,1,CHEMBL626967,,1969.0
10839,N,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,,Macaca fascicularis,A,,BAO_0000218,14839,In vivo,9541.0,1,Intermediate,1,CHEMBL626968,,1969.0
10840,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL626969,,948.0
10841,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL627126,,948.0
10842,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631276,,948.0
10843,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631277,,948.0
10844,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631278,,948.0
10845,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL874457,,948.0
10846,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631279,,948.0
10847,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631280,,948.0
10848,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631281,,948.0
10849,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631968,,948.0
10850,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631969,,948.0
10851,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631970,,948.0
10852,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631971,,948.0
10853,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631972,,948.0
10854,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL630435,,948.0
10855,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL630436,,948.0
10856,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL630437,,948.0
10857,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL630438,,948.0
10858,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL630439,,948.0
10859,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL630440,,2113.0
10860,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL630441,,2113.0
10861,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL630442,,2113.0
10862,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL625234,,2113.0
10863,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL625235,,2113.0
10864,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL625236,,2113.0
10865,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL625237,,2113.0
10866,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL626125,,2113.0
10867,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL626126,,2113.0
10868,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL626127,,2113.0
10869,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL626128,,2113.0
10870,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL626129,,2113.0
10871,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL626130,,2113.0
10872,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL626131,,2113.0
10873,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL626132,,2113.0
10874,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL626752,,2113.0
10875,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL626753,,2113.0
10876,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL626754,,2113.0
10877,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL626755,,2113.0
10878,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL626756,,2107.0
10879,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL626757,,2107.0
10880,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL626758,,2107.0
10881,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL626759,,2107.0
10882,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL626760,,2107.0
10883,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL626394,,
10884,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL626395,,
10885,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL626396,,
10886,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL626397,,
10887,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL626398,,
10888,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL626399,,
10889,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL874653,,
10890,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL626400,,
10891,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL626401,,
10892,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL626402,,
10893,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL626403,,
10894,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL626404,,
10895,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL626405,,
10896,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL625529,,
10897,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL625530,,
10898,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL625531,,
10899,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL625532,,
10900,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL625533,,
10901,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL875474,,
10902,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL625534,,
10903,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL625535,,
10904,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL625536,,
10905,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL625537,,
10906,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL625538,,
10907,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL625539,,
10908,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL625540,,
10909,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL625541,,
10910,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL625542,,
10911,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL625543,,
10912,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL625544,,
10913,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL625545,,
10914,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL625546,,
10915,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL625547,,
10916,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL625548,,
10917,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL625549,,
10918,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL625550,,
10919,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL625551,,
10920,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL875475,,
10921,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL625552,,
10922,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL625553,,
10923,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL625554,,
10924,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL625555,,
10925,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL625556,,
10926,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624986,,
10927,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624987,,
10928,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624988,,
10929,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL624989,,1637.0
10930,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL624990,,1637.0
10931,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL874391,,1637.0
10932,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL624991,,1637.0
10933,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL624992,,1637.0
10934,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL624993,,1637.0
10935,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL624994,,1637.0
10936,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL624995,,1637.0
10937,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL624996,,1637.0
10938,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL624997,,1637.0
10939,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL624998,,1637.0
10940,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL624999,,1637.0
10941,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL882955,,1637.0
10942,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625000,,1637.0
10943,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625001,,1637.0
10944,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625089,,1637.0
10945,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625090,,1637.0
10946,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625091,,1637.0
10947,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625092,,1637.0
10948,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625093,,1637.0
10949,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625094,,1637.0
10950,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625095,,1637.0
10951,N,Compound was evaluated for its bioavailability in the dogs,,Canis lupus familiaris,A,,BAO_0000218,2249,In vivo,9615.0,1,Intermediate,1,CHEMBL625096,,
10952,N,Compound was evaluated for its bioavailability in the rats,,Rattus norvegicus,A,,BAO_0000218,2249,In vivo,10116.0,1,Intermediate,1,CHEMBL625097,,
10953,U,Compound was evaluated for oral bioavailability,,,A,,BAO_0000218,17515,In vivo,,0,Autocuration,1,CHEMBL882956,,
10954,N,Compound was evaluated for percentage of Oral bioavailability in rats,,Rattus norvegicus,A,,BAO_0000218,14541,In vivo,10116.0,1,Intermediate,1,CHEMBL625098,,
10955,U,Bioavailability in guinea pig,,Cavia porcellus,A,,BAO_0000218,12797,In vivo,10141.0,0,Autocuration,1,CHEMBL625099,,
10956,N,Compound was evaluated for the oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,12797,In vivo,10116.0,1,Intermediate,1,CHEMBL625100,,
10957,N,Compound was evaluated for the oral bioavailability in dog,,Canis lupus familiaris,A,,BAO_0000218,12797,In vivo,9615.0,1,Intermediate,1,CHEMBL625101,,
10958,N,Compound was evaluated for the oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,12797,In vivo,10116.0,1,Intermediate,1,CHEMBL874396,,
10959,U,Bioavailability in dog (dosed i.v.),,Canis lupus familiaris,F,,BAO_0000218,11727,In vivo,9615.0,0,Autocuration,1,CHEMBL625102,,
10960,N,Compound was tested for in vivo bioavailability in dog,,Canis lupus familiaris,A,,BAO_0000218,13249,In vivo,9615.0,1,Intermediate,1,CHEMBL625103,,
10961,N,Compound was tested for in vivo bioavailability in hamsters,,Cricetinae,A,,BAO_0000218,13249,In vivo,10026.0,1,Intermediate,1,CHEMBL625104,,
10962,U,Compound was tested for in vivo bioavailability in monkey,,Simiiformes,A,,BAO_0000218,13249,In vivo,314293.0,0,Autocuration,1,CHEMBL625105,,
10963,N,Compound was tested for in vivo bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,13249,In vivo,10116.0,1,Intermediate,1,CHEMBL625106,,
10964,U,Oral bioavailability in mouse,,Mus musculus,A,,BAO_0000218,9552,In vivo,10090.0,0,Autocuration,1,CHEMBL625107,,
10965,N,Compound was tested for percent of oral bioavailability in mice; 56-74,,Mus musculus,A,,BAO_0000218,9552,In vivo,10090.0,1,Intermediate,1,CHEMBL625108,,
10966,U,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),,Mus musculus,A,,BAO_0000218,14839,In vivo,10090.0,0,Autocuration,1,CHEMBL625109,,
10967,U,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),,Macaca fascicularis,A,,BAO_0000218,14839,In vivo,9541.0,0,Autocuration,1,CHEMBL625110,,
10968,U,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),,Macaca fascicularis,A,,BAO_0000218,14839,In vivo,9541.0,0,Autocuration,1,CHEMBL625111,,
10969,N,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),,Mus musculus,A,,BAO_0000218,14839,In vivo,10090.0,1,Intermediate,1,CHEMBL625112,,
10970,N,Oral bioavailability in nude mice,,Mus musculus,A,,BAO_0000218,14839,In vivo,10090.0,1,Intermediate,1,CHEMBL875334,,
10971,U,Bioavailability in monkey (i.d. dosing),,Primates,A,,BAO_0000218,11219,In vivo,9443.0,0,Autocuration,1,CHEMBL628617,,
10972,U,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,9552,In vivo,10116.0,0,Autocuration,1,CHEMBL628618,,
10973,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,,,A,,BAO_0000218,11732,In vivo,,0,Autocuration,1,CHEMBL628619,,
10974,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,,,A,,BAO_0000218,11732,In vivo,,0,Autocuration,1,CHEMBL628620,,
10975,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,Macaca fascicularis,A,,BAO_0000218,14839,In vivo,9541.0,1,Intermediate,1,CHEMBL628621,,
10976,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,Macaca fascicularis,A,,BAO_0000218,14839,In vivo,9541.0,1,Intermediate,1,CHEMBL628622,,
10977,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,Macaca fascicularis,A,,BAO_0000218,14839,In vivo,9541.0,1,Intermediate,1,CHEMBL628623,,
10978,N,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,,Macaca fascicularis,A,,BAO_0000218,14839,In vivo,9541.0,1,Intermediate,1,CHEMBL628624,,1969.0
10979,N,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,Mus musculus,A,,BAO_0000218,14839,In vivo,10090.0,1,Intermediate,1,CHEMBL628625,,1969.0
10980,N,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,,Macaca fascicularis,A,,BAO_0000218,14839,In vivo,9541.0,1,Intermediate,1,CHEMBL628626,,1969.0
10981,N,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,Mus musculus,A,,BAO_0000218,14839,In vivo,10090.0,1,Intermediate,1,CHEMBL627041,,1969.0
10982,N,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,Mus musculus,A,,BAO_0000218,14839,In vivo,10090.0,1,Intermediate,1,CHEMBL627042,,1969.0
10983,N,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,Mus musculus,A,,BAO_0000218,14839,In vivo,10090.0,1,Intermediate,1,CHEMBL627043,,1969.0
10984,U,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,,,A,,BAO_0000218,13932,In vivo,,0,Autocuration,1,CHEMBL627044,,1969.0
10985,N,Cmax in mouse plasma,,Mus musculus,A,,BAO_0000218,11637,In vivo,10090.0,1,Intermediate,1,CHEMBL627045,,1969.0
10986,U,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,,,A,,BAO_0000218,11637,In vivo,,0,Autocuration,1,CHEMBL627046,,1969.0
10987,N,Maximal plasma concentration in rat,,Rattus norvegicus,A,,BAO_0000218,13960,In vivo,10116.0,1,Intermediate,1,CHEMBL627047,,1969.0
10988,N,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,,Rattus norvegicus,A,,BAO_0000218,15905,In vivo,10116.0,1,Intermediate,1,CHEMBL627048,,1969.0
10989,N,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,14062,In vivo,10116.0,1,Intermediate,1,CHEMBL627049,,
10990,N,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,14062,In vivo,10116.0,1,Intermediate,1,CHEMBL627050,,
10991,N,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,14062,In vivo,10116.0,1,Intermediate,1,CHEMBL627051,,
10992,N,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,14062,In vivo,10116.0,1,Intermediate,1,CHEMBL627052,,
10993,N,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,14062,In vivo,10116.0,1,Intermediate,1,CHEMBL627053,,
10994,N,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,14062,In vivo,10116.0,1,Intermediate,1,CHEMBL627054,,
10995,N,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,Mus musculus,A,,BAO_0000218,15011,In vivo,10090.0,1,Intermediate,1,CHEMBL627055,,
10996,N,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,Mus musculus,A,,BAO_0000218,15011,In vivo,10090.0,1,Intermediate,1,CHEMBL627056,,
10997,N,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,Mus musculus,A,,BAO_0000218,15011,In vivo,10090.0,1,Intermediate,1,CHEMBL627057,,
10998,N,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,Mus musculus,A,,BAO_0000218,15011,In vivo,10090.0,1,Intermediate,1,CHEMBL627058,,
10999,N,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,Mus musculus,A,,BAO_0000218,15011,In vivo,10090.0,1,Intermediate,1,CHEMBL626211,,
11000,U,Maximum Concentration of the compound.,,,A,,BAO_0000218,10291,In vivo,,0,Autocuration,1,CHEMBL626212,,
11001,N,Maximum Concentration was measured after iv administration into Beagle dog,,Canis lupus familiaris,A,,BAO_0000218,14599,In vivo,9615.0,1,Intermediate,1,CHEMBL626213,,
11002,N,Maximum Concentration was measured after iv administration into Beagle dog.,,Canis lupus familiaris,A,,BAO_0000218,14599,In vivo,9615.0,1,Intermediate,1,CHEMBL626214,,
11003,N,Maximum Concentration was measured after po administration into Beagle dog,,Canis lupus familiaris,A,,BAO_0000218,14599,In vivo,9615.0,1,Intermediate,1,CHEMBL626215,,
11004,N,Maximum Concentration was measured after po administration into Beagle dog.,,Canis lupus familiaris,A,,BAO_0000218,14599,In vivo,9615.0,1,Intermediate,1,CHEMBL626216,,
11005,U,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,,,A,,BAO_0000218,12767,In vivo,,0,Autocuration,1,CHEMBL626217,,178.0
11006,U,Maximum blood level reached after an iv dose of 12.2 uM/kg,,,A,,BAO_0000218,12767,In vivo,,0,Autocuration,1,CHEMBL626218,,178.0
11007,U,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,,,A,,BAO_0000218,12767,In vivo,,0,Autocuration,1,CHEMBL626219,,178.0
11008,U,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,,,A,,BAO_0000218,12767,In vivo,,0,Autocuration,1,CHEMBL626220,,178.0
11009,U,Maximum blood level reached after an oral dose of 5.0 mg/kg,,,A,,BAO_0000218,12767,In vivo,,0,Autocuration,1,CHEMBL626221,,178.0
11010,U,Maximum blood level reached at dose of 10.6 uM/kg orally,,,A,,BAO_0000218,12767,In vivo,,0,Autocuration,1,CHEMBL626222,,178.0
11011,N,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,,Cavia porcellus,A,,BAO_0000218,14706,In vivo,10141.0,1,Intermediate,1,CHEMBL626223,,
11012,N,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,,Cavia porcellus,A,,BAO_0000218,14706,In vivo,10141.0,1,Intermediate,1,CHEMBL626224,,
11013,N,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,14793,In vivo,10116.0,1,Intermediate,1,CHEMBL626225,,955.0
11014,N,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,14793,In vivo,10116.0,1,Intermediate,1,CHEMBL626226,,955.0
11015,N,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,,Rattus norvegicus,A,,BAO_0000218,14793,In vivo,10116.0,1,Intermediate,1,CHEMBL626227,,955.0
11016,N,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,14793,In vivo,10116.0,1,Intermediate,1,CHEMBL626228,,955.0
11017,N,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,14793,In vivo,10116.0,1,Intermediate,1,CHEMBL626229,,
11018,N,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,14793,In vivo,10116.0,1,Intermediate,1,CHEMBL626921,,
11019,N,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,,Rattus norvegicus,A,,BAO_0000218,14793,In vivo,10116.0,1,Intermediate,1,CHEMBL876793,,
11020,N,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,14793,In vivo,10116.0,1,Intermediate,1,CHEMBL625309,,
11021,N,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,Bacillus subtilis,A,,BAO_0000218,10524,In vivo,1423.0,1,Intermediate,1,CHEMBL625310,,
11022,U,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,,Simiiformes,A,,BAO_0000218,11871,In vivo,314293.0,0,Autocuration,1,CHEMBL625311,,
11023,N,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,11871,In vivo,10116.0,1,Intermediate,1,CHEMBL625312,,
11024,U,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,,,A,,BAO_0000218,3437,In vivo,,0,Autocuration,1,CHEMBL625313,,
11025,N,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,,Mus musculus,A,,BAO_0000218,12038,In vivo,10090.0,1,Intermediate,1,CHEMBL625314,,
11026,N,Maximum concentration in male rats after iv administration of 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,12038,In vivo,10116.0,1,Intermediate,1,CHEMBL625315,,
11027,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL625316,,2107.0
11028,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL625317,,2107.0
11029,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL625318,,2107.0
11030,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL625319,,2107.0
11031,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL625320,,2107.0
11032,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL625321,,2107.0
11033,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL625322,,2107.0
11034,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL876801,,2107.0
11035,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL625323,,2107.0
11036,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL625324,,2107.0
11037,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL625325,,2107.0
11038,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL625326,,2107.0
11039,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL625327,,2107.0
11040,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL625328,,2107.0
11041,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL625329,,2048.0
11042,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL625330,,2048.0
11043,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL627774,,2048.0
11044,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL627775,,2048.0
11045,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL627949,,2048.0
11046,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL627950,,2048.0
11047,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL627951,,2048.0
11048,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL627952,,2048.0
11049,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL627953,,2048.0
11050,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL627954,,2048.0
11051,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL627955,,2048.0
11052,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL627956,,2048.0
11053,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL876802,,2048.0
11054,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL627957,,2048.0
11055,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL627958,,2048.0
11056,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL627959,,2048.0
11057,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL627960,,2048.0
11058,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL627961,,2048.0
11059,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL627962,,2048.0
11060,N,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL627963,,
11061,N,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL624759,,
11062,N,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL624760,,
11063,N,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL624761,,
11064,N,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL877607,,
11065,N,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL624762,,2107.0
11066,N,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL624763,,2107.0
11067,N,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL624764,,2107.0
11068,N,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL624765,,2107.0
11069,N,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL624766,,2107.0
11070,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624767,,
11071,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624768,,
11072,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624769,,
11073,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624770,,
11074,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624771,,
11075,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624772,,
11076,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL624773,,
11077,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL624774,,
11078,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL624775,,
11079,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL624776,,
11080,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL624777,,
11081,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL624778,,
11082,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL624779,,
11083,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL624780,,
11084,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL624781,,
11085,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL877608,,
11086,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL624782,,
11087,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL624783,,
11088,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL624784,,
11089,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL624785,,
11090,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL624786,,
11091,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL624787,,
11092,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL628676,,
11093,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL621842,,
11094,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL621843,,
11095,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL623873,,
11096,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL623874,,
11097,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL623875,,
11098,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL623876,,
11099,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL623877,,
11100,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL623878,,
11101,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL623879,,
11102,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL623880,,
11103,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL623881,,
11104,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL623957,,
11105,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL623958,,
11106,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL623959,,
11107,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL623960,,
11108,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL623961,,
11109,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL623962,,
11110,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624676,,
11111,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624677,,
11112,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624678,,
11113,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624679,,
11114,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624680,,
11115,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,,,A,,BAO_0000218,11732,In vivo,,0,Autocuration,1,CHEMBL624849,,
11116,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,,,A,,BAO_0000218,11732,In vivo,,0,Autocuration,1,CHEMBL624850,,
11117,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,,,A,,BAO_0000218,11732,In vivo,,0,Autocuration,1,CHEMBL874399,,
11118,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,,,A,,BAO_0000218,11732,In vivo,,0,Autocuration,1,CHEMBL624851,,
11119,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,,,A,,BAO_0000218,11732,In vivo,,0,Autocuration,1,CHEMBL624852,,
11120,U,Oral bioavailability in rat (dose 10 mg/kg),,Rattus norvegicus,A,,BAO_0000218,13359,In vivo,10116.0,0,Autocuration,1,CHEMBL624853,,
11121,U,Oral bioavailability in rat (Sprague-Dawley),,Rattus norvegicus,A,,BAO_0000218,16618,In vivo,10116.0,0,Autocuration,1,CHEMBL624854,,
11122,U,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,13960,In vivo,10116.0,0,Autocuration,1,CHEMBL624855,,
11123,U,Oral bioavailability in rats was determined in vivo,,Rattus norvegicus,A,,BAO_0000218,13917,In vivo,10116.0,0,Autocuration,1,CHEMBL624856,,
11124,U,Oral bioavailability in dog,,Canis lupus familiaris,A,,BAO_0000218,14266,In vivo,9615.0,0,Autocuration,1,CHEMBL882957,,
11125,U,Oral bioavailability of compound in monkey,,Simiiformes,A,,BAO_0000218,12359,In vivo,314293.0,0,Autocuration,1,CHEMBL624857,,
11126,N,Oral bioavailability of compound in rat,,Rattus norvegicus,A,,BAO_0000218,12359,In vivo,10116.0,1,Intermediate,1,CHEMBL622202,,
11127,U,Bioavailability in rat of PMEA prodrug,,Rattus norvegicus,A,,BAO_0000218,12359,In vivo,10116.0,0,Autocuration,1,CHEMBL622203,,
11128,N,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,,Rattus norvegicus,A,,BAO_0000218,12359,In vivo,10116.0,1,Intermediate,1,CHEMBL625522,,
11129,U,Serum conc at 3 hours following 25 mg/kg dose,,Macaca mulatta,A,,BAO_0000218,10791,In vivo,9544.0,0,Autocuration,1,CHEMBL622868,,
11130,U,Urine conc 0-5 hours following 25 mg/kg dose,,Macaca mulatta,A,,BAO_0000218,10791,In vivo,9544.0,0,Autocuration,1,CHEMBL622869,,1088.0
11131,U,Urine conc 0-24 hours following 25 mg/kg dose,,Macaca mulatta,A,,BAO_0000218,10791,In vivo,9544.0,0,Autocuration,1,CHEMBL622870,,1088.0
11132,U,Oral bioavailability in African green monkeys; 20-25,,Chlorocebus aethiops,A,,BAO_0000218,138,In vivo,9534.0,0,Autocuration,1,CHEMBL622871,,
11133,N,Oral bioavailability in cynomolgus monkey.,,Macaca fascicularis,A,,BAO_0000218,14521,In vivo,9541.0,1,Intermediate,1,CHEMBL620560,,
11134,U,Oral bioavailability in dog,,Canis lupus familiaris,A,,BAO_0000218,13953,In vivo,9615.0,0,Autocuration,1,CHEMBL620561,,
11135,N,Oral bioavailability in dog at 10 mg/kg oral dose,,Canis lupus familiaris,A,,BAO_0000218,12836,In vivo,9615.0,1,Intermediate,1,CHEMBL620562,,
11136,N,Oral bioavailability in hamster at 10 mg/kg oral dose,,Cricetinae,A,,BAO_0000218,12836,In vivo,10026.0,1,Intermediate,1,CHEMBL620563,,
11137,N,Oral bioavailability in rat at 10 mg/kg oral dose,,Rattus norvegicus,A,,BAO_0000218,12836,In vivo,10116.0,1,Intermediate,1,CHEMBL620564,,
11138,U,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,14521,In vivo,10116.0,0,Autocuration,1,CHEMBL872265,,
11139,U,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,13953,In vivo,10116.0,0,Autocuration,1,CHEMBL620565,,
11140,U,Oral bioavailability,,Eutheria,A,,BAO_0000218,6799,In vivo,9347.0,0,Autocuration,1,CHEMBL620566,,
11141,U,Oral bioavailability was determined; range 49-102%,,,A,,BAO_0000218,11311,In vivo,,0,Autocuration,1,CHEMBL620567,,
11142,N,Oral bioavailability was determined in dogs,,Canis lupus familiaris,A,,BAO_0000218,4013,In vivo,9615.0,1,Intermediate,1,CHEMBL620568,,
11143,U,Oral bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,4013,In vivo,10116.0,0,Autocuration,1,CHEMBL620569,,
11144,U,Oral bioavailability,,Eutheria,A,,BAO_0000218,17591,In vivo,9347.0,0,Autocuration,1,CHEMBL620570,,
11145,U,Oral bioavailability was determined; Not orally available,,,A,,BAO_0000218,17591,In vivo,,0,Autocuration,1,CHEMBL620571,,
11146,N,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),,Mus musculus,A,,BAO_0000218,15011,In vivo,10090.0,1,Intermediate,1,CHEMBL620572,,
11147,U,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),,Mus musculus,A,,BAO_0000218,15011,In vivo,10090.0,0,Autocuration,1,CHEMBL620573,,
11148,U,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,,Mus musculus,A,,BAO_0000218,15011,In vivo,10090.0,0,Autocuration,1,CHEMBL620574,,
11149,U,Oral bioavailability in Rhesus monkey,,Macaca mulatta,A,,BAO_0000218,9552,In vivo,9544.0,0,Autocuration,1,CHEMBL620575,,
11150,U,Oral bioavailability in dog (female mongrel),,Canis lupus familiaris,A,,BAO_0000218,9552,In vivo,9615.0,0,Autocuration,1,CHEMBL620576,,
11151,U,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,,,A,,BAO_0000218,3639,In vivo,,0,Autocuration,1,CHEMBL875846,,
11152,U,Oral bioavailability in dog,,Canis lupus familiaris,A,,BAO_0000218,13397,In vivo,9615.0,0,Autocuration,1,CHEMBL620577,,
11153,U,Percentage Bioavailability was evaluated.,,,A,,BAO_0000218,3031,In vivo,,0,Autocuration,1,CHEMBL620578,,
11154,U,Bioavailability in rat administered i.d.,,Rattus norvegicus,A,,BAO_0000218,12818,In vivo,10116.0,0,Autocuration,1,CHEMBL620579,,
11155,U,Bioavailability,,Eutheria,A,,BAO_0000218,4847,In vivo,9347.0,0,Autocuration,1,CHEMBL621248,,
11156,U,Bioavailability in dog (male Beagle) i.v. administration,,Canis lupus familiaris,A,,BAO_0000218,12421,In vivo,9615.0,0,Autocuration,1,CHEMBL625390,,
11157,U,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",,Rattus norvegicus,A,,BAO_0000218,11966,In vivo,10116.0,0,Autocuration,1,CHEMBL625391,,
11158,U,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),,Primates,A,,BAO_0000218,11218,In vivo,9443.0,0,Autocuration,1,CHEMBL872266,,
11159,U,Oral bioavailability in rat (Sprague-Dawley) (male),,Rattus norvegicus,A,,BAO_0000218,13129,In vivo,10116.0,0,Autocuration,1,CHEMBL625392,,
11160,N,The oral bioavailability was measured on rats after oral administration,,Rattus norvegicus,A,,BAO_0000218,12350,In vivo,10116.0,1,Intermediate,1,CHEMBL625393,,
11161,N,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,2231,In vivo,10116.0,1,Intermediate,1,CHEMBL625394,,
11162,N,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,Macaca mulatta,A,,BAO_0000218,2231,In vivo,9544.0,1,Intermediate,1,CHEMBL625395,,
11163,U,Bioavailability in rat (dose 10 mg/kg i.d.),,Rattus norvegicus,A,,BAO_0000218,12187,In vivo,10116.0,0,Autocuration,1,CHEMBL625396,,
11164,U,Bioavailability in dog (male Beagle) i.v. administration,,Canis lupus familiaris,A,,BAO_0000218,12421,In vivo,9615.0,0,Autocuration,1,CHEMBL625397,,
11165,N,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL625398,,
11166,N,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL625399,,178.0
11167,N,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL626074,,2037.0
11168,N,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL626075,,
11169,N,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,2231,In vivo,10116.0,1,Intermediate,1,CHEMBL626076,,1969.0
11170,N,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,Macaca mulatta,A,,BAO_0000218,2231,In vivo,9544.0,1,Intermediate,1,CHEMBL626077,,1969.0
11171,N,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),,Rattus norvegicus,A,,BAO_0000218,12178,In vivo,10116.0,1,Intermediate,1,CHEMBL626078,,178.0
11172,U,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),,,A,,BAO_0000218,12178,In vivo,,0,Autocuration,1,CHEMBL625846,,178.0
11173,U,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),,,A,,BAO_0000218,12178,In vivo,,0,Autocuration,1,CHEMBL625847,,178.0
11174,N,Maximum concentration observed in rats at an oral dose of 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,15633,In vivo,10116.0,1,Expert,1,CHEMBL625848,,
11175,N,Maximum concentration of compound in plasma administered orally to rats,,Rattus norvegicus,A,,BAO_0000218,14258,In vivo,10116.0,1,Intermediate,1,CHEMBL625849,,1969.0
11176,N,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",,Canis lupus familiaris,A,,BAO_0000218,14224,In vivo,9615.0,1,Intermediate,1,CHEMBL626023,,1969.0
11177,N,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",,Canis lupus familiaris,A,,BAO_0000218,14224,In vivo,9615.0,1,Intermediate,1,CHEMBL626024,,1969.0
11178,N,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",,Canis lupus familiaris,A,,BAO_0000218,14224,In vivo,9615.0,1,Intermediate,1,CHEMBL626025,,1969.0
11179,U,Maximum concentration after 10 mg/kg by oral administration,,,A,,BAO_0000218,5566,In vivo,,0,Autocuration,1,CHEMBL626026,,
11180,U,Maximum concentration at a dose of 1.5 mg/kg,,,A,,BAO_0000218,16935,In vivo,,0,Autocuration,1,CHEMBL626027,,
11181,U,Maximum concentration at a dose of 2.0 mg/kg,,,A,,BAO_0000218,16935,In vivo,,0,Autocuration,1,CHEMBL626028,,
11182,N,Maximum concentration in dog plasma,,Canis lupus familiaris,A,,BAO_0000218,14224,In vivo,9615.0,1,Intermediate,1,CHEMBL626029,,1969.0
11183,U,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,,,A,,BAO_0000218,12536,In vivo,,0,Autocuration,1,CHEMBL626030,,1969.0
11184,U,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,,,A,,BAO_0000218,12536,In vivo,,0,Autocuration,1,CHEMBL626031,,1969.0
11185,U,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,,,A,,BAO_0000218,12536,In vivo,,0,Autocuration,1,CHEMBL626032,,1969.0
11186,U,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,,,A,,BAO_0000218,12536,In vivo,,0,Autocuration,1,CHEMBL626033,,1969.0
11187,U,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,,,A,,BAO_0000218,12536,In vivo,,0,Autocuration,1,CHEMBL626034,,1969.0
11188,N,Maximum concentration in plasma after oral administration in dog (25 mg/kg),,Canis lupus familiaris,A,,BAO_0000218,9994,In vivo,9615.0,1,Intermediate,1,CHEMBL626035,,1969.0
11189,U,Maximum concentration in plasma at Tmax,,,A,,BAO_0000218,1434,In vivo,,0,Autocuration,1,CHEMBL626036,,1969.0
11190,N,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,,Canis lupus familiaris,A,,BAO_0000218,12836,In vivo,9615.0,1,Expert,1,CHEMBL626037,,1969.0
11191,N,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,,Cricetinae,A,,BAO_0000218,12836,In vivo,10026.0,1,Intermediate,1,CHEMBL626038,,1969.0
11192,N,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,,Rattus norvegicus,A,,BAO_0000218,12836,In vivo,10116.0,1,Intermediate,1,CHEMBL626039,,1969.0
11193,N,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,12545,In vivo,10116.0,1,Intermediate,1,CHEMBL626040,,1969.0
11194,N,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,,Oryctolagus cuniculus,A,,BAO_0000218,13856,In vivo,9986.0,1,Intermediate,1,CHEMBL626041,,1969.0
11195,U,Maximum concentration was calculated,,,A,,BAO_0000218,3550,In vivo,,0,Autocuration,1,CHEMBL626042,,
11196,U,Maximum concentration was calculated.,,,A,,BAO_0000218,2632,In vivo,,0,Autocuration,1,CHEMBL626043,,
11197,U,Maximum concentration at a peroral dose of 10 mg/kg,,,A,,BAO_0000218,5566,In vivo,,0,Autocuration,1,CHEMBL626044,,
11198,U,Maximum concentration of the drug at 10 uM/dg administered perorally,,,A,,BAO_0000218,11883,In vivo,,0,Autocuration,1,CHEMBL626045,,
11199,U,Maximum concentration of the drug at 2 uM/dg administered intravenously,,,A,,BAO_0000218,11883,In vivo,,0,Autocuration,1,CHEMBL626046,,
11200,N,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",,Canis lupus familiaris,A,,BAO_0000218,14122,In vivo,9615.0,1,Intermediate,1,CHEMBL626047,,1969.0
11201,N,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",,Cricetinae,A,,BAO_0000218,14122,In vivo,10026.0,1,Intermediate,1,CHEMBL626048,,1969.0
11202,N,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",,Rattus norvegicus,A,,BAO_0000218,14122,In vivo,10116.0,1,Intermediate,1,CHEMBL626049,,1969.0
11203,N,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,,Rattus norvegicus,A,,BAO_0000218,12542,In vivo,10116.0,1,Intermediate,1,CHEMBL626050,,1969.0
11204,N,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,,Canis lupus familiaris,A,,BAO_0000218,12542,In vivo,9615.0,1,Intermediate,1,CHEMBL874541,,1969.0
11205,N,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,,Cricetinae,A,,BAO_0000218,12542,In vivo,10026.0,1,Intermediate,1,CHEMBL622826,,1969.0
11206,N,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,,Cricetinae,A,,BAO_0000218,12542,In vivo,10026.0,1,Intermediate,1,CHEMBL622827,,1969.0
11207,N,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,,Rattus norvegicus,A,,BAO_0000218,12542,In vivo,10116.0,1,Intermediate,1,CHEMBL622828,,1969.0
11208,N,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,,Rattus norvegicus,A,,BAO_0000218,14080,In vivo,10116.0,1,Intermediate,1,CHEMBL622829,,1969.0
11209,N,Maximum concentration reached following intravenous administration in male rat,,Rattus norvegicus,A,,BAO_0000218,11911,In vivo,10116.0,1,Intermediate,1,CHEMBL876806,,
11210,N,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,,Canis lupus familiaris,A,,BAO_0000218,13204,In vivo,9615.0,1,Intermediate,1,CHEMBL622830,,
11211,N,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,,Rattus norvegicus,A,,BAO_0000218,13204,In vivo,10116.0,1,Intermediate,1,CHEMBL622831,,
11212,N,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,,Canis lupus familiaris,A,,BAO_0000218,14346,In vivo,9615.0,1,Intermediate,1,CHEMBL626794,,
11213,N,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,,Rattus norvegicus,A,,BAO_0000218,14346,In vivo,10116.0,1,Intermediate,1,CHEMBL626795,,
11214,N,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,,Rattus norvegicus,A,,BAO_0000218,14346,In vivo,10116.0,1,Intermediate,1,CHEMBL626796,,
11215,N,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,,Rattus norvegicus,A,,BAO_0000218,14346,In vivo,10116.0,1,Intermediate,1,CHEMBL626797,,
11216,N,Maximum drug concentration is determined after oral dosing in rats.,,Rattus norvegicus,A,,BAO_0000218,14127,In vivo,10116.0,1,Intermediate,1,CHEMBL626798,,
11217,N,Maximum observed concentration in oral (5 mg/kg) fasted dogs,,Canis lupus familiaris,A,,BAO_0000218,14339,In vivo,9615.0,1,Intermediate,1,CHEMBL626799,,
11218,N,Maximum observed concentration in oral (5 mg/kg) fed dogs,,Canis lupus familiaris,A,,BAO_0000218,14339,In vivo,9615.0,1,Intermediate,1,CHEMBL626800,,
11219,U,Maximum plasma concentration,,,A,,BAO_0000218,13494,In vivo,,0,Autocuration,1,CHEMBL626801,,1969.0
11220,N,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,,Rattus norvegicus,A,,BAO_0000218,14925,In vivo,10116.0,1,Intermediate,1,CHEMBL876816,,1969.0
11221,N,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,14474,In vivo,10116.0,1,Intermediate,1,CHEMBL626802,,1969.0
11222,N,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,,Canis lupus familiaris,A,,BAO_0000218,14474,In vivo,9615.0,1,Intermediate,1,CHEMBL626803,,1969.0
11223,U,Maximum plasma concentration following oral administration of 30 umol/kg,,,A,,BAO_0000218,13917,In vivo,,0,Autocuration,1,CHEMBL626804,,1969.0
11224,N,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL626805,,1969.0
11225,N,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL626309,,1969.0
11226,N,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL626310,,1969.0
11227,N,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL626311,,1969.0
11228,N,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL626312,,1969.0
11229,N,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL626313,,995.0
11230,N,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL626314,,995.0
11231,N,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL626315,,995.0
11232,N,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL626316,,995.0
11233,N,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,Rattus norvegicus,A,,BAO_0000218,9796,,10116.0,1,Intermediate,1,CHEMBL626317,,995.0
11234,N,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),,Rattus norvegicus,A,,BAO_0000218,8363,,10116.0,1,Intermediate,1,CHEMBL626318,,
11235,N,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),,Rattus norvegicus,A,,BAO_0000218,8363,,10116.0,1,Intermediate,1,CHEMBL626319,,
11236,N,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),,Rattus norvegicus,A,,BAO_0000218,8363,,10116.0,1,Intermediate,1,CHEMBL626320,,
11237,N,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),,Rattus norvegicus,A,,BAO_0000218,8363,,10116.0,1,Intermediate,1,CHEMBL875053,,
11238,N,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),,Rattus norvegicus,A,,BAO_0000218,8363,,10116.0,1,Intermediate,1,CHEMBL626321,,
11239,N,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),,Rattus norvegicus,A,,BAO_0000218,8363,,10116.0,1,Intermediate,1,CHEMBL626322,,
11240,N,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),,Rattus norvegicus,A,,BAO_0000218,8363,,10116.0,1,Intermediate,1,CHEMBL626323,,
11241,N,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),,Rattus norvegicus,A,,BAO_0000218,8363,,10116.0,1,Intermediate,1,CHEMBL626324,,
11242,N,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),,Rattus norvegicus,A,,BAO_0000218,8363,,10116.0,1,Intermediate,1,CHEMBL626325,,
11243,N,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),,Rattus norvegicus,A,,BAO_0000218,8363,,10116.0,1,Intermediate,1,CHEMBL626326,,
11244,N,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),,Rattus norvegicus,A,,BAO_0000218,8363,,10116.0,1,Intermediate,1,CHEMBL626327,,
11245,N,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),,Rattus norvegicus,A,,BAO_0000218,8363,,10116.0,1,Intermediate,1,CHEMBL626328,,
11246,N,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL626329,,178.0
11247,N,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL626330,,178.0
11248,N,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL626331,,178.0
11249,N,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL626332,,178.0
11250,N,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL626333,,178.0
11251,N,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL626334,,178.0
11252,N,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL626335,,178.0
11253,N,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624798,,178.0
11254,N,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624799,,955.0
11255,N,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624800,,955.0
11256,N,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624801,,955.0
11257,N,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624802,,955.0
11258,N,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624803,,955.0
11259,N,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624804,,955.0
11260,N,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624805,,955.0
11261,N,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624806,,955.0
11262,N,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624807,,
11263,N,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624808,,
11264,N,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624809,,
11265,N,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624810,,
11266,N,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL877618,,
11267,N,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624811,,
11268,N,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624812,,
11269,N,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624813,,
11270,N,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624814,,
11271,N,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624815,,
11272,N,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624816,,
11273,N,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624817,,
11274,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624818,,
11275,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624819,,
11276,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624820,,
11277,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624821,,
11278,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624822,,
11279,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624823,,
11280,N,Observed diffusion coefficient in organic solvent for Escherichia coli,,Escherichia coli,A,,BAO_0000218,15599,,562.0,1,Intermediate,1,CHEMBL624824,,
11281,N,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,Rattus norvegicus,A,,BAO_0000218,9614,,10116.0,1,Intermediate,1,CHEMBL624825,,178.0
11282,N,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,Rattus norvegicus,A,,BAO_0000218,9614,,10116.0,1,Intermediate,1,CHEMBL624826,,178.0
11283,N,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,Rattus norvegicus,A,,BAO_0000218,9614,,10116.0,1,Intermediate,1,CHEMBL876817,,2081.0
11284,N,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,Rattus norvegicus,A,,BAO_0000218,9614,,10116.0,1,Intermediate,1,CHEMBL624827,,2081.0
11285,N,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,Rattus norvegicus,A,,BAO_0000218,9614,,10116.0,1,Intermediate,1,CHEMBL624828,,
11286,N,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,Rattus norvegicus,A,,BAO_0000218,9614,,10116.0,1,Intermediate,1,CHEMBL624829,,
11287,N,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,Rattus norvegicus,A,,BAO_0000218,9614,,10116.0,1,Intermediate,1,CHEMBL624830,,2107.0
11288,N,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,Rattus norvegicus,A,,BAO_0000218,9614,,10116.0,1,Intermediate,1,CHEMBL624831,,2107.0
11289,N,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,Rattus norvegicus,A,,BAO_0000218,9614,,10116.0,1,Intermediate,1,CHEMBL624832,,2081.0
11290,N,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,Rattus norvegicus,A,,BAO_0000218,9614,,10116.0,1,Intermediate,1,CHEMBL624833,,2081.0
11291,N,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,Rattus norvegicus,A,,BAO_0000218,9614,,10116.0,1,Intermediate,1,CHEMBL624834,,
11292,N,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,Rattus norvegicus,A,,BAO_0000218,9614,,10116.0,1,Intermediate,1,CHEMBL624835,,
11293,N,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,Rattus norvegicus,A,,BAO_0000218,9614,,10116.0,1,Intermediate,1,CHEMBL624836,,2106.0
11294,N,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,Rattus norvegicus,A,,BAO_0000218,9614,,10116.0,1,Intermediate,1,CHEMBL624837,,2106.0
11295,N,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,,Rattus norvegicus,A,,BAO_0000218,9071,,10116.0,1,Intermediate,1,CHEMBL624838,,178.0
11296,N,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,,Rattus norvegicus,A,,BAO_0000218,9071,,10116.0,1,Intermediate,1,CHEMBL622188,,178.0
11297,N,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,,Rattus norvegicus,A,,BAO_0000218,9071,,10116.0,1,Intermediate,1,CHEMBL622189,,948.0
11298,N,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,,Rattus norvegicus,A,,BAO_0000218,9071,,10116.0,1,Intermediate,1,CHEMBL622190,,948.0
11299,N,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,,Rattus norvegicus,A,,BAO_0000218,9071,,10116.0,1,Intermediate,1,CHEMBL625170,,948.0
11300,N,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,Rattus norvegicus,A,,BAO_0000218,9071,,10116.0,1,Intermediate,1,CHEMBL625171,,2113.0
11301,N,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,Rattus norvegicus,A,,BAO_0000218,9071,,10116.0,1,Intermediate,1,CHEMBL625172,,2113.0
11302,N,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,,Rattus norvegicus,A,,BAO_0000218,9071,,10116.0,1,Intermediate,1,CHEMBL625173,,2113.0
11303,N,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,,Rattus norvegicus,A,,BAO_0000218,9071,,10116.0,1,Intermediate,1,CHEMBL625174,,2107.0
11304,N,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,,Rattus norvegicus,A,,BAO_0000218,9071,,10116.0,1,Intermediate,1,CHEMBL625175,,2107.0
11305,N,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,,Rattus norvegicus,A,,BAO_0000218,9071,,10116.0,1,Intermediate,1,CHEMBL625176,,2107.0
11306,N,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,Rattus norvegicus,A,,BAO_0000218,9071,,10116.0,1,Intermediate,1,CHEMBL625177,,2048.0
11307,N,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,,Rattus norvegicus,A,,BAO_0000218,9071,,10116.0,1,Intermediate,1,CHEMBL625178,,2048.0
11308,N,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,,Rattus norvegicus,A,,BAO_0000218,9071,,10116.0,1,Intermediate,1,CHEMBL625179,,2048.0
11309,N,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,Rattus norvegicus,A,,BAO_0000218,9071,,10116.0,1,Intermediate,1,CHEMBL625180,,2048.0
11310,U,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",,,A,,BAO_0000218,10677,,,0,Autocuration,1,CHEMBL625181,,
11311,N,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,,Mus musculus,A,,BAO_0000218,9750,,10090.0,1,Intermediate,1,CHEMBL625182,,1088.0
11312,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL625183,,
11313,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL875848,,
11314,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL622260,,
11315,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL622261,,
11316,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL622262,,
11317,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL622263,,2113.0
11318,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL622418,,2113.0
11319,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL622419,,2107.0
11320,N,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL623388,,
11321,N,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL623389,,2107.0
11322,N,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL623390,,
11323,N,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL623391,,
11324,N,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL623392,,178.0
11325,N,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL623393,,2037.0
11326,N,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL623394,,
11327,N,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL618885,,
11328,N,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL618886,,2107.0
11329,N,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL618887,,
11330,N,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL619535,,
11331,N,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL619536,,178.0
11332,N,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL619537,,2037.0
11333,N,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL619705,,
11334,N,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL619706,,
11335,N,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL619707,,2107.0
11336,N,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL619708,,
11337,N,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL625219,,
11338,N,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL625220,,178.0
11339,N,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL625221,,2037.0
11340,N,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL625222,,
11341,N,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL625223,,
11342,N,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL625224,,2107.0
11343,N,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,A,,BAO_0000218,13256,In vivo,10090.0,1,Intermediate,1,CHEMBL625225,,
11344,N,Biodistribution in Rat blood after 24 hours of iv administration,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL625226,,178.0
11345,N,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL625227,,178.0
11346,N,Biodistribution in Rat blood after 30 minutes of iv administration,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL625228,,178.0
11347,N,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL875354,,178.0
11348,N,Biodistribution in Rat blood after 5 minutes of iv administration,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL625229,,178.0
11349,N,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL625230,,178.0
11350,N,Biodistribution in Rat heart after 24 hours of iv administration,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL625231,,948.0
11351,N,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL625900,,948.0
11352,N,Biodistribution in Rat heart after 30 minutes of iv administration,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL625901,,948.0
11353,N,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL625902,,948.0
11354,N,Biodistribution in Rat heart after 5 minutes of iv administration,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL625903,,948.0
11355,N,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL625904,,948.0
11356,N,Biodistribution in Rat liver after 24 hours of iv administration,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL625905,,2107.0
11357,N,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL627861,,2107.0
11358,N,Biodistribution in Rat liver after 30 minutes of iv administration,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL627862,,2107.0
11359,N,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL627863,,2107.0
11360,N,Biodistribution in Rat liver after 30 minutes of iv administration,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL627769,,2107.0
11361,N,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,Canis lupus familiaris,A,,BAO_0000218,13249,In vivo,9615.0,1,Intermediate,1,CHEMBL627770,,1969.0
11362,N,Cmax in cynomolgus monkey (PO dose),,Macaca fascicularis,A,,BAO_0000218,13622,In vivo,9541.0,1,Intermediate,1,CHEMBL627771,,
11363,N,Cmax in rat (PO dose),,Rattus norvegicus,A,,BAO_0000218,13622,In vivo,10116.0,1,Intermediate,1,CHEMBL627772,,
11364,N,Cmax in rat (PO dose),,Rattus norvegicus,A,,BAO_0000218,13622,In vivo,10116.0,1,Intermediate,1,CHEMBL627773,,
11365,N,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,13494,In vivo,10116.0,1,Intermediate,1,CHEMBL621922,,1969.0
11366,N,Cmax in rat plasma after oral dose (10 mg/kg),,Rattus norvegicus,A,,BAO_0000218,12170,In vivo,10116.0,1,Intermediate,1,CHEMBL621923,,1969.0
11367,U,Cmax in plasma after oral dose (10 mg/kg),,,A,,BAO_0000218,12170,In vivo,,0,Autocuration,1,CHEMBL621924,,1969.0
11368,N,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,,Canis lupus familiaris,A,,BAO_0000218,17025,In vivo,9615.0,1,Intermediate,1,CHEMBL621925,,1969.0
11369,U,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,,Simiiformes,A,,BAO_0000218,17025,In vivo,314293.0,0,Autocuration,1,CHEMBL621926,,1969.0
11370,N,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,,Oryctolagus cuniculus,A,,BAO_0000218,17025,In vivo,9986.0,1,Intermediate,1,CHEMBL621927,,1969.0
11371,N,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,,Rattus norvegicus,A,,BAO_0000218,17025,In vivo,10116.0,1,Intermediate,1,CHEMBL621928,,1969.0
11372,N,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,,Rattus norvegicus,A,,BAO_0000218,14187,In vivo,10116.0,1,Intermediate,1,CHEMBL621929,,1969.0
11373,N,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,,Mus musculus,A,,BAO_0000218,14816,In vivo,10090.0,1,Intermediate,1,CHEMBL621930,,1969.0
11374,N,Maximum plasma concentration after oral dosing in rat,,Rattus norvegicus,A,,BAO_0000218,17820,In vivo,10116.0,1,Intermediate,1,CHEMBL621931,,1969.0
11375,U,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,,A,,BAO_0000218,14380,In vivo,,0,Autocuration,1,CHEMBL621932,,1969.0
11376,U,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,,A,,BAO_0000218,14380,In vivo,,0,Autocuration,1,CHEMBL621933,,1969.0
11377,N,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,,Canis lupus familiaris,A,,BAO_0000218,14691,In vivo,9615.0,1,Intermediate,1,CHEMBL621934,,1969.0
11378,N,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,,Canis lupus familiaris,A,,BAO_0000218,14691,In vivo,9615.0,1,Intermediate,1,CHEMBL621935,,1969.0
11379,N,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,,Rattus norvegicus,A,,BAO_0000218,13375,In vivo,10116.0,1,Intermediate,1,CHEMBL621936,,1969.0
11380,U,Maximum plasma concentration was determined,,,A,,BAO_0000218,6236,In vivo,,0,Autocuration,1,CHEMBL621937,,1969.0
11381,U,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,A,,BAO_0000218,14380,In vivo,,0,Autocuration,1,CHEMBL621938,,1969.0
11382,U,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,A,,BAO_0000218,14380,In vivo,,0,Autocuration,1,CHEMBL621939,,1969.0
11383,U,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,,,A,,BAO_0000218,14380,In vivo,,0,Autocuration,1,CHEMBL621940,,1969.0
11384,U,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,,,A,,BAO_0000218,14380,In vivo,,0,Autocuration,1,CHEMBL621941,,1969.0
11385,U,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,,A,,BAO_0000218,14380,In vivo,,0,Autocuration,1,CHEMBL621942,,1969.0
11386,U,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,,A,,BAO_0000218,14380,In vivo,,0,Autocuration,1,CHEMBL626178,,1969.0
11387,U,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,,,A,,BAO_0000218,14380,In vivo,,0,Autocuration,1,CHEMBL626179,,1969.0
11388,U,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,,,A,,BAO_0000218,14380,In vivo,,0,Autocuration,1,CHEMBL626180,,1969.0
11389,N,Plasma Cmax in rat (PO dose),,Rattus norvegicus,A,,BAO_0000218,13622,In vivo,10116.0,1,Intermediate,1,CHEMBL626181,,1969.0
11390,N,Maximum serum concentration after po dose of 5.22 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,15372,In vivo,10116.0,1,Intermediate,1,CHEMBL626182,,
11391,N,Maximum serum concentration after po dose of 5.46 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,15372,In vivo,10116.0,1,Intermediate,1,CHEMBL626183,,
11392,N,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,15372,In vivo,10116.0,1,Intermediate,1,CHEMBL626184,,
11393,N,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,15372,In vivo,10116.0,1,Intermediate,1,CHEMBL626185,,
11394,N,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,,Canis lupus familiaris,A,,BAO_0000218,14925,In vivo,9615.0,1,Intermediate,1,CHEMBL626186,,1969.0
11395,N,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,,Canis lupus familiaris,A,,BAO_0000218,14925,In vivo,9615.0,1,Intermediate,1,CHEMBL877589,,1969.0
11396,U,Maximum concentration of the drug at 1 uM/dg administered intravenously,,,A,,BAO_0000218,11883,In vivo,,0,Autocuration,1,CHEMBL626187,,
11397,U,Maximum concentration of the drug at 20 uM/dg administered perorally,,,A,,BAO_0000218,11883,In vivo,,0,Autocuration,1,CHEMBL626188,,
11398,U,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,,,A,,BAO_0000218,13391,In vivo,,0,Autocuration,1,CHEMBL626189,,
11399,U,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,,A,,BAO_0000218,13391,In vivo,,0,Autocuration,1,CHEMBL626855,,178.0
11400,U,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,,A,,BAO_0000218,13391,In vivo,,0,Autocuration,1,CHEMBL623781,,178.0
11401,U,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,,A,,BAO_0000218,13391,In vivo,,0,Autocuration,1,CHEMBL623782,,178.0
11402,N,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,16360,In vivo,10116.0,1,Intermediate,1,CHEMBL623783,,1969.0
11403,N,Cmax in dog plasma after 1mg/kg oral dose,,Canis lupus familiaris,A,,BAO_0000218,3673,In vivo,9615.0,1,Intermediate,1,CHEMBL623784,,1969.0
11404,N,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,,Canis lupus familiaris,A,,BAO_0000218,14431,In vivo,9615.0,1,Intermediate,1,CHEMBL623785,,1969.0
11405,N,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,,Rattus norvegicus,A,,BAO_0000218,14431,In vivo,10116.0,1,Intermediate,1,CHEMBL623786,,1969.0
11406,N,Oral maximum concentration in rat,,Rattus norvegicus,A,,BAO_0000218,14964,In vivo,10116.0,1,Intermediate,1,CHEMBL623787,,
11407,N,Oral maximum concentration in rat,,Rattus norvegicus,A,,BAO_0000218,14964,In vivo,10116.0,1,Intermediate,1,CHEMBL623788,,
11408,N,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,,Mus musculus,A,,BAO_0000218,14209,In vivo,10090.0,1,Intermediate,1,CHEMBL623789,,1969.0
11409,N,Peak concentration in blood after intravenous administration to mice,,Mus musculus,A,,BAO_0000218,11355,In vivo,10090.0,1,Intermediate,1,CHEMBL623790,,178.0
11410,N,Peak concentration in blood after peroral administration to mice,,Mus musculus,A,,BAO_0000218,11355,In vivo,10090.0,1,Intermediate,1,CHEMBL623791,,178.0
11411,N,Peak concentration in rat plasma was determined,,Rattus norvegicus,A,,BAO_0000218,11966,In vivo,10116.0,1,Intermediate,1,CHEMBL623792,,1969.0
11412,U,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,,Simiiformes,A,,BAO_0000218,8918,In vivo,314293.0,0,Autocuration,1,CHEMBL623793,,1969.0
11413,N,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,,Mus musculus,A,,BAO_0000218,8918,In vivo,10090.0,1,Intermediate,1,CHEMBL623794,,1969.0
11414,N,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,,Rattus norvegicus,A,,BAO_0000218,8918,In vivo,10116.0,1,Intermediate,1,CHEMBL623795,,1969.0
11415,N,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL623796,,
11416,N,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL623797,,
11417,N,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL623798,,
11418,N,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL623799,,
11419,N,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624490,,160.0
11420,N,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624491,,160.0
11421,N,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624492,,160.0
11422,N,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624493,,160.0
11423,N,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL877595,,160.0
11424,N,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624494,,160.0
11425,N,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624495,,160.0
11426,N,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624681,,160.0
11427,N,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624682,,
11428,N,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624683,,
11429,N,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624684,,
11430,N,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624685,,
11431,N,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624686,,
11432,N,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624687,,
11433,N,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624688,,
11434,N,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL627161,,
11435,N,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL622127,,
11436,N,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL622128,,
11437,N,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL874384,,
11438,N,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624898,,
11439,N,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624899,,
11440,N,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624900,,
11441,N,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624901,,
11442,N,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624902,,
11443,N,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624903,,
11444,N,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624904,,
11445,N,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624905,,
11446,N,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624906,,
11447,N,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624907,,
11448,N,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624908,,
11449,N,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624909,,
11450,N,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624910,,
11451,N,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624911,,2385.0
11452,N,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL874388,,2385.0
11453,N,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL624912,,2385.0
11454,N,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL622930,,2385.0
11455,N,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL623121,,2385.0
11456,N,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL623122,,2385.0
11457,N,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL623123,,2385.0
11458,N,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL623124,,2385.0
11459,N,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL623125,,
11460,N,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL623126,,
11461,N,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL623127,,
11462,N,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL623128,,
11463,N,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL623129,,
11464,N,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL623130,,
11465,N,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL623131,,
11466,N,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL623132,,
11467,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL623133,,2107.0
11468,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL623134,,
11469,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL874389,,
11470,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL623135,,
11471,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL623136,,
11472,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL623137,,
11473,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL623138,,
11474,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL623139,,2113.0
11475,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL623140,,2113.0
11476,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL623141,,2107.0
11477,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL623142,,2107.0
11478,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL623143,,
11479,N,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,,Mus musculus,A,,BAO_0000218,14571,,10090.0,1,Intermediate,1,CHEMBL623144,,1088.0
11480,N,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,,Rattus norvegicus,A,,BAO_0000218,14571,,10116.0,1,Intermediate,1,CHEMBL623405,,1088.0
11481,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL624074,,
11482,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL624075,,
11483,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL624076,,
11484,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL624077,,
11485,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL624078,,
11486,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL624079,,2113.0
11487,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL624261,,2113.0
11488,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL624262,,
11489,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL624263,,
11490,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL624264,,
11491,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL624265,,
11492,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL624266,,
11493,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL624267,,
11494,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL624268,,
11495,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL875227,,
11496,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL624269,,2113.0
11497,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL624270,,2113.0
11498,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL624271,,
11499,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL624272,,
11500,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,Rattus norvegicus,A,,BAO_0000218,8319,,10116.0,1,Intermediate,1,CHEMBL624273,,
11501,N,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,12064,,10116.0,1,Intermediate,1,CHEMBL624274,,1088.0
11502,N,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,12064,,10116.0,1,Intermediate,1,CHEMBL624275,,1088.0
11503,N,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,12064,,10116.0,1,Intermediate,1,CHEMBL624276,,1088.0
11504,N,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,,Rattus norvegicus,A,,BAO_0000218,12038,,10116.0,1,Intermediate,1,CHEMBL624277,,1088.0
11505,U,% dose converted to 2-amino-5-chlorophenyl sulfate,,,A,,BAO_0000019,14314,,,0,Autocuration,1,CHEMBL624278,,
11506,U,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),,,A,,BAO_0000019,14314,,,0,Autocuration,1,CHEMBL624279,,
11507,N,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL624280,,1988.0
11508,N,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL624281,,1988.0
11509,N,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL622933,,1988.0
11510,N,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL622934,,1988.0
11511,N,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL622935,,2107.0
11512,N,Biodistribution in Rat liver after 5 minutes of iv administration,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL622936,,2107.0
11513,N,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL875228,,2107.0
11514,N,Biodistribution in Rat lung after 24 hours of iv administration,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL622937,,2048.0
11515,N,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL622938,,2048.0
11516,N,Biodistribution in Rat lung after 30 minutes of iv administration,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL619736,,2048.0
11517,N,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL625117,,2048.0
11518,N,Biodistribution in Rat lung after 5 minutes of iv administration,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL625118,,2048.0
11519,N,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,,Rattus norvegicus,A,,BAO_0000218,8829,In vivo,10116.0,1,Intermediate,1,CHEMBL625119,,2048.0
11520,N,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",,Rattus norvegicus,A,,BAO_0000218,14972,In vivo,10116.0,1,Intermediate,1,CHEMBL625120,,2037.0
11521,N,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",,Rattus norvegicus,A,,BAO_0000218,14972,In vivo,10116.0,1,Intermediate,1,CHEMBL625121,,
11522,N,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",,Rattus norvegicus,A,,BAO_0000218,14972,In vivo,10116.0,1,Intermediate,1,CHEMBL625122,,10000006.0
11523,N,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL622204,,178.0
11524,N,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL877503,,178.0
11525,N,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL627127,,178.0
11526,U,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,A,,BAO_0000218,14608,In vivo,,0,Autocuration,1,CHEMBL627128,,10000000.0
11527,U,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,A,,BAO_0000218,14608,In vivo,,0,Autocuration,1,CHEMBL627129,,10000000.0
11528,U,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,A,,BAO_0000218,14608,In vivo,,0,Autocuration,1,CHEMBL627130,,10000000.0
11529,N,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL627131,,955.0
11530,N,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL627132,,955.0
11531,N,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL627133,,955.0
11532,N,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL627134,,2037.0
11533,N,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL627135,,2037.0
11534,N,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL627136,,2037.0
11535,N,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL628435,,
11536,N,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL628436,,
11537,N,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL628437,,
11538,N,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL628438,,948.0
11539,N,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL628439,,948.0
11540,N,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL628440,,948.0
11541,N,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL628441,,10000000.0
11542,N,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL628442,,10000000.0
11543,N,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL628443,,10000000.0
11544,N,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL628444,,2113.0
11545,N,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL628445,,2113.0
11546,N,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL877504,,2113.0
11547,N,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL628446,,2107.0
11548,N,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL626874,,2107.0
11549,N,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL626875,,2107.0
11550,N,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL626876,,2048.0
11551,N,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL626877,,2048.0
11552,N,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL626878,,2048.0
11553,N,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL626879,,2385.0
11554,U,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,,Simiiformes,A,,BAO_0000218,8918,In vivo,314293.0,0,Autocuration,1,CHEMBL626880,,1969.0
11555,N,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,,Mus musculus,A,,BAO_0000218,8918,In vivo,10090.0,1,Intermediate,1,CHEMBL626881,,1969.0
11556,N,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,,Rattus norvegicus,A,,BAO_0000218,8918,In vivo,10116.0,1,Intermediate,1,CHEMBL626882,,1969.0
11557,N,Peak plasma concentration was measured in dogs,,Canis lupus familiaris,A,,BAO_0000218,14470,In vivo,9615.0,1,Intermediate,1,CHEMBL626883,,1969.0
11558,N,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,Rattus norvegicus,A,,BAO_0000218,14393,In vivo,10116.0,1,Intermediate,1,CHEMBL626884,,
11559,N,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,Rattus norvegicus,A,,BAO_0000218,14886,In vivo,10116.0,1,Intermediate,1,CHEMBL626885,,
11560,N,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,Rattus norvegicus,A,,BAO_0000218,14886,In vivo,10116.0,1,Intermediate,1,CHEMBL626886,,
11561,N,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,Rattus norvegicus,A,,BAO_0000218,14886,In vivo,10116.0,1,Intermediate,1,CHEMBL626887,,
11562,N,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,Rattus norvegicus,A,,BAO_0000218,14393,In vivo,10116.0,1,Intermediate,1,CHEMBL626888,,
11563,N,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,,Canis lupus familiaris,A,,BAO_0000218,13465,In vivo,9615.0,1,Intermediate,1,CHEMBL626889,,
11564,U,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,,Simiiformes,A,,BAO_0000218,13465,In vivo,314293.0,0,Autocuration,1,CHEMBL626761,,
11565,N,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,,Canis lupus familiaris,A,,BAO_0000218,13465,In vivo,9615.0,1,Intermediate,1,CHEMBL626762,,
11566,N,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,,Canis lupus familiaris,A,,BAO_0000218,13465,In vivo,9615.0,1,Intermediate,1,CHEMBL626763,,
11567,N,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,,Rattus norvegicus,A,,BAO_0000218,13465,In vivo,10116.0,1,Intermediate,1,CHEMBL626764,,
11568,N,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,,Rattus norvegicus,A,,BAO_0000218,13465,In vivo,10116.0,1,Intermediate,1,CHEMBL626765,,
11569,N,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,,Canis lupus familiaris,A,,BAO_0000218,13465,In vivo,9615.0,1,Intermediate,1,CHEMBL626766,,
11570,N,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,,Rattus norvegicus,A,,BAO_0000218,13465,In vivo,10116.0,1,Intermediate,1,CHEMBL626767,,
11571,N,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,,Rattus norvegicus,A,,BAO_0000218,13465,In vivo,10116.0,1,Intermediate,1,CHEMBL626768,,
11572,N,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,,Canis lupus familiaris,A,,BAO_0000218,13465,In vivo,9615.0,1,Intermediate,1,CHEMBL626769,,
11573,N,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,,Canis lupus familiaris,A,,BAO_0000218,13465,In vivo,9615.0,1,Intermediate,1,CHEMBL874463,,
11574,U,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,,Simiiformes,A,,BAO_0000218,13465,In vivo,314293.0,0,Autocuration,1,CHEMBL626770,,
11575,U,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,,Simiiformes,A,,BAO_0000218,13465,In vivo,314293.0,0,Autocuration,1,CHEMBL626771,,
11576,N,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,,Rattus norvegicus,A,,BAO_0000218,13465,In vivo,10116.0,1,Intermediate,1,CHEMBL626772,,
11577,N,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,Macaca fascicularis,A,,BAO_0000218,14731,In vivo,9541.0,1,Intermediate,1,CHEMBL626773,,
11578,N,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,,Mus musculus,A,,BAO_0000218,14731,In vivo,10090.0,1,Intermediate,1,CHEMBL626774,,
11579,N,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,,Canis lupus familiaris,A,,BAO_0000218,13376,In vivo,9615.0,1,Intermediate,1,CHEMBL626775,,
11580,N,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,,Canis lupus familiaris,A,,BAO_0000218,13376,In vivo,9615.0,1,Intermediate,1,CHEMBL626776,,
11581,N,Maximum concentration (Cmax) in rat when administered orally,,Rattus norvegicus,A,,BAO_0000218,14443,In vivo,10116.0,1,Intermediate,1,CHEMBL626777,,
11582,U,Maximal concentration in monkey plasma after 25 mg/kg oral dose,,Simiiformes,A,,BAO_0000218,13465,In vivo,314293.0,0,Autocuration,1,CHEMBL626778,,1969.0
11583,U,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",,Rattus norvegicus,A,,BAO_0000218,16359,In vivo,10116.0,0,Autocuration,1,CHEMBL626779,,
11584,U,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",,Rattus norvegicus,A,,BAO_0000218,16359,In vivo,10116.0,0,Autocuration,1,CHEMBL626780,,
11585,U,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,,,A,,BAO_0000218,15618,In vivo,,0,Autocuration,1,CHEMBL626781,,1969.0
11586,N,Pharmacokinetic profile Cmax was evaluated in rats,,Rattus norvegicus,A,,BAO_0000218,14554,In vivo,10116.0,1,Intermediate,1,CHEMBL632164,,
11587,N,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),,Canis lupus familiaris,A,,BAO_0000218,11537,In vivo,9615.0,1,Intermediate,1,CHEMBL632165,,
11588,N,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),,Mus musculus,A,,BAO_0000218,11537,In vivo,10090.0,1,Intermediate,1,CHEMBL632166,,
11589,N,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),,Canis lupus familiaris,A,,BAO_0000218,11537,In vivo,9615.0,1,Intermediate,1,CHEMBL632167,,
11590,N,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),,Mus musculus,A,,BAO_0000218,11537,In vivo,10090.0,1,Intermediate,1,CHEMBL632168,,
11591,U,Cmax in rat plasma,,Rattus norvegicus,A,,BAO_0000218,2021,In vivo,10116.0,0,Autocuration,1,CHEMBL632169,,1969.0
11592,N,Cmax in dog plasma after 30mg/kg oral dose,,Canis lupus familiaris,A,,BAO_0000218,5932,In vivo,9615.0,1,Intermediate,1,CHEMBL632170,,1969.0
11593,N,Cmax in rat plasma after 30mg/kg oral dose,,Rattus norvegicus,A,,BAO_0000218,5932,In vivo,10116.0,1,Intermediate,1,CHEMBL632171,,1969.0
11594,N,Plasma level in rats at 30 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17320,In vivo,10116.0,1,Intermediate,1,CHEMBL632172,,1969.0
11595,N,Tested for maximum plasma concentration in mice,,Mus musculus,A,,BAO_0000218,15831,In vivo,10090.0,1,Intermediate,1,CHEMBL632173,,1969.0
11596,N,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,15078,In vivo,10116.0,1,Intermediate,1,CHEMBL632174,,
11597,N,The Cmax values in female wistar rats.,,Rattus norvegicus,A,,BAO_0000218,14941,In vivo,10116.0,1,Intermediate,1,CHEMBL632175,,
11598,N,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,,Canis lupus familiaris,A,,BAO_0000218,15343,In vivo,9615.0,1,Intermediate,1,CHEMBL632176,,1969.0
11599,N,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,15343,In vivo,10116.0,1,Intermediate,1,CHEMBL632177,,1969.0
11600,N,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,,Rattus norvegicus,A,,BAO_0000218,14856,In vivo,10116.0,1,Intermediate,1,CHEMBL632178,,1969.0
11601,N,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,,Rattus norvegicus,A,,BAO_0000218,13129,In vivo,10116.0,1,Intermediate,1,CHEMBL632179,,
11602,N,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,,Rattus norvegicus,A,,BAO_0000218,13098,In vivo,10116.0,1,Intermediate,1,CHEMBL632180,,178.0
11603,N,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,,Rattus norvegicus,A,,BAO_0000218,13098,In vivo,10116.0,1,Intermediate,1,CHEMBL632181,,178.0
11604,N,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,,Rattus norvegicus,A,,BAO_0000218,13098,In vivo,10116.0,1,Intermediate,1,CHEMBL632182,,178.0
11605,U,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,,Mus musculus,A,,BAO_0000218,15478,In vivo,10090.0,0,Autocuration,1,CHEMBL632183,,178.0
11606,N,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,,Canis lupus familiaris,A,,BAO_0000218,15341,In vivo,9615.0,1,Intermediate,1,CHEMBL632184,,
11607,N,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,,Rattus norvegicus,A,,BAO_0000218,15341,In vivo,10116.0,1,Intermediate,1,CHEMBL874470,,
11608,N,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL631302,,
11609,N,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL631303,,
11610,N,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL631304,,
11611,N,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL631305,,
11612,N,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL631306,,
11613,N,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL631307,,
11614,N,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL631308,,
11615,N,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL625557,,
11616,N,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL625558,,2106.0
11617,N,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL625559,,2106.0
11618,N,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL625560,,2106.0
11619,N,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL625561,,2106.0
11620,N,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL625562,,2106.0
11621,N,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL875320,,2106.0
11622,N,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL625563,,2106.0
11623,N,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL625564,,2106.0
11624,N,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL625565,,995.0
11625,N,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL625566,,995.0
11626,N,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL625567,,995.0
11627,N,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL625568,,995.0
11628,N,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL628217,,995.0
11629,N,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL628218,,995.0
11630,N,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL628219,,995.0
11631,N,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,A,,BAO_0000218,8684,,10116.0,1,Intermediate,1,CHEMBL628220,,995.0
11632,U,Distribution in the blood after 120 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628221,,
11633,U,Distribution in the blood after 15 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628222,,
11634,U,Distribution in the blood after 30 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628223,,
11635,U,Distribution in the blood after 5 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628224,,
11636,U,Distribution in the blood after 60 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628225,,
11637,U,Distribution in the blood after 90 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628226,,
11638,U,Distribution in the bone after 120 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628227,,
11639,U,Distribution in the bone after 15 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL875481,,
11640,U,Distribution in the bone after 30 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628228,,
11641,U,Distribution in the bone after 5 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628229,,
11642,U,Distribution in the bone after 60 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628230,,
11643,U,Distribution in the bone after 90 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628231,,
11644,U,Distribution in the heart after 120 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628232,,
11645,U,Distribution in the heart after 15 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628233,,
11646,U,Distribution in the heart after 30 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628234,,
11647,U,Distribution in the heart after 5 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628235,,
11648,U,Distribution in the heart after 60 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628236,,
11649,U,Distribution in the heart after 90 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628237,,
11650,U,Distribution in the kidneys after 120 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628238,,
11651,U,Distribution in the kidneys after 15 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628239,,
11652,U,Distribution in the kidneys after 30 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628240,,
11653,U,Distribution in the kidneys after 5 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628241,,
11654,U,Distribution in the kidneys after 60 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628242,,
11655,U,Distribution in the kidneys after 90 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL875482,,
11656,U,Distribution in the liver after 120 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628243,,
11657,U,Distribution in the liver after 15 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628244,,
11658,U,Distribution in the liver after 30 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628245,,
11659,U,Distribution in the liver after 5 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628246,,
11660,U,Distribution in the liver after 60 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628247,,
11661,U,Distribution in the liver after 90 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628248,,
11662,U,Distribution in the lung after 120 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628249,,
11663,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",,Mus musculus,A,,BAO_0000218,14839,,10090.0,1,Intermediate,1,CHEMBL625452,,
11664,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",,Mus musculus,A,,BAO_0000218,14839,,10090.0,1,Intermediate,1,CHEMBL625453,,
11665,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",,Mus musculus,A,,BAO_0000218,14839,,10090.0,1,Intermediate,1,CHEMBL625454,,
11666,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",,Mus musculus,A,,BAO_0000218,14839,,10090.0,1,Intermediate,1,CHEMBL623844,,
11667,N,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,,Rattus norvegicus,A,,BAO_0000218,12178,,10116.0,1,Intermediate,1,CHEMBL623845,,
11668,N,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,,Rattus norvegicus,A,,BAO_0000218,12178,,10116.0,1,Intermediate,1,CHEMBL623846,,
11669,U,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,,,A,,BAO_0000218,12178,,,0,Autocuration,1,CHEMBL623847,,
11670,N,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,Macaca fascicularis,A,,BAO_0000218,12186,,9541.0,1,Intermediate,1,CHEMBL623848,,
11671,N,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,Macaca fascicularis,A,,BAO_0000218,12186,,9541.0,1,Intermediate,1,CHEMBL623849,,
11672,N,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,Macaca fascicularis,A,,BAO_0000218,12186,,9541.0,1,Intermediate,1,CHEMBL623850,,
11673,N,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,Macaca fascicularis,A,,BAO_0000218,12186,,9541.0,1,Intermediate,1,CHEMBL623851,,
11674,U,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,Simiiformes,A,,BAO_0000218,12187,,314293.0,0,Autocuration,1,CHEMBL623852,,
11675,N,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,Mustela putorius furo,A,,BAO_0000218,12187,,9669.0,1,Intermediate,1,CHEMBL624551,,
11676,N,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,Mustela putorius furo,A,,BAO_0000218,12187,,9669.0,1,Intermediate,1,CHEMBL624552,,
11677,U,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,Simiiformes,A,,BAO_0000218,12187,,314293.0,0,Autocuration,1,CHEMBL624553,,
11678,U,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,,Simiiformes,A,,BAO_0000218,12187,,314293.0,0,Autocuration,1,CHEMBL624554,,
11679,N,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,12187,,10116.0,1,Intermediate,1,CHEMBL624555,,
11680,N,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,Rattus norvegicus,A,,BAO_0000218,12187,,10116.0,1,Intermediate,1,CHEMBL624741,,
11681,N,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",,Canis lupus familiaris,A,,BAO_0000218,14122,,9615.0,1,Intermediate,1,CHEMBL624742,,
11682,N,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",,Cricetinae,A,,BAO_0000218,14122,,10026.0,1,Intermediate,1,CHEMBL624743,,
11683,N,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",,Rattus norvegicus,A,,BAO_0000218,14122,,10116.0,1,Intermediate,1,CHEMBL877606,,
11684,U,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,,,A,,BAO_0000218,13391,,,0,Autocuration,1,CHEMBL624744,,
11685,U,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,,A,,BAO_0000218,13391,,,0,Autocuration,1,CHEMBL624745,,178.0
11686,U,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,,A,,BAO_0000218,13391,,,0,Autocuration,1,CHEMBL624746,,178.0
11687,U,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,,A,,BAO_0000218,13391,,,0,Autocuration,1,CHEMBL624747,,178.0
11688,U,Oral absorption expressed as Area under curve was determined,,,A,,BAO_0000019,16360,,,0,Autocuration,1,CHEMBL624748,,
11689,N,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,,Canis lupus familiaris,A,,BAO_0000218,3673,,9615.0,1,Intermediate,1,CHEMBL622504,,
11690,N,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",,Canis lupus familiaris,A,,BAO_0000218,14122,,9615.0,1,Intermediate,1,CHEMBL622505,,
11691,N,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,Cricetinae,A,,BAO_0000218,14122,,10026.0,1,Intermediate,1,CHEMBL622506,,
11692,N,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,Cricetinae,A,,BAO_0000218,14122,,10026.0,1,Intermediate,1,CHEMBL622507,,
11693,N,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",,Rattus norvegicus,A,,BAO_0000218,14122,,10116.0,1,Intermediate,1,CHEMBL622508,,
11694,U,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,,,A,,BAO_0000019,13889,,,0,Autocuration,1,CHEMBL622509,,
11695,N,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,Rattus norvegicus,A,,BAO_0000218,14393,,10116.0,1,Intermediate,1,CHEMBL622510,,
11696,N,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),,Rattus norvegicus,A,,BAO_0000218,17279,,10116.0,1,Intermediate,1,CHEMBL622511,,
11697,N,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,Macaca fascicularis,A,,BAO_0000218,14548,,9541.0,1,Intermediate,1,CHEMBL622512,,
11698,N,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,Macaca fascicularis,A,,BAO_0000218,14548,,9541.0,1,Intermediate,1,CHEMBL622513,,
11699,N,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,,Macaca fascicularis,A,,BAO_0000218,14548,,9541.0,1,Intermediate,1,CHEMBL622514,,
11700,N,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,Canis lupus familiaris,A,,BAO_0000218,14548,,9615.0,1,Intermediate,1,CHEMBL622515,,
11701,N,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,,Canis lupus familiaris,A,,BAO_0000218,14548,,9615.0,1,Intermediate,1,CHEMBL622516,,
11702,N,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,Rattus norvegicus,A,,BAO_0000218,14548,,10116.0,1,Intermediate,1,CHEMBL622517,,
11703,N,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,,Rattus norvegicus,A,,BAO_0000218,14548,,10116.0,1,Intermediate,1,CHEMBL622518,,
11704,N,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,,Rattus norvegicus,A,,BAO_0000218,14548,,10116.0,1,Intermediate,1,CHEMBL622519,,
11705,N,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL622520,,2385.0
11706,N,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL622521,,2385.0
11707,N,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,,Mus musculus,A,,BAO_0000218,14608,In vivo,10090.0,1,Intermediate,1,CHEMBL625113,,14.0
11708,N,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL625114,,14.0
11709,N,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL874397,,14.0
11710,N,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL625115,,2106.0
11711,N,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL625116,,2106.0
11712,N,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL623932,,2106.0
11713,N,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL623933,,2435.0
11714,N,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL623934,,2435.0
11715,N,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL623935,,2435.0
11716,N,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL623936,,2046.0
11717,N,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL623937,,2046.0
11718,N,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,,Rattus norvegicus,A,,BAO_0000218,14608,In vivo,10116.0,1,Intermediate,1,CHEMBL623938,,2046.0
11719,N,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL623939,,
11720,N,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL623940,,
11721,N,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL623941,,
11722,N,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL627216,,
11723,N,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL623942,,
11724,N,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618793,,955.0
11725,N,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618794,,955.0
11726,N,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618795,,955.0
11727,N,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618796,,
11728,N,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618797,,
11729,N,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618798,,2113.0
11730,N,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618799,,2113.0
11731,N,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618800,,2113.0
11732,N,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618801,,2113.0
11733,N,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618802,,2113.0
11734,N,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618803,,2113.0
11735,N,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618804,,2107.0
11736,N,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618805,,2107.0
11737,N,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618806,,2107.0
11738,N,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618807,,2107.0
11739,N,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618808,,2107.0
11740,N,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618809,,2107.0
11741,N,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618810,,2385.0
11742,N,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618811,,2385.0
11743,N,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL875844,,2385.0
11744,N,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618812,,2385.0
11745,N,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618813,,2385.0
11746,N,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618814,,
11747,N,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618815,,
11748,N,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618816,,
11749,N,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL618817,,
11750,N,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL620544,,
11751,N,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,,Rattus norvegicus,A,,BAO_0000218,15341,In vivo,10116.0,1,Intermediate,1,CHEMBL626230,,
11752,N,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,,Rattus norvegicus,A,,BAO_0000218,15341,In vivo,10116.0,1,Intermediate,1,CHEMBL626231,,
11753,N,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,,Rattus norvegicus,A,,BAO_0000218,15341,In vivo,10116.0,1,Intermediate,1,CHEMBL626232,,
11754,N,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,,Canis lupus familiaris,A,,BAO_0000218,14906,In vivo,9615.0,1,Intermediate,1,CHEMBL626233,,1969.0
11755,N,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,,Rattus norvegicus,A,,BAO_0000218,14906,In vivo,10116.0,1,Intermediate,1,CHEMBL626234,,1969.0
11756,N,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,,Rattus norvegicus,A,,BAO_0000218,14906,In vivo,10116.0,1,Intermediate,1,CHEMBL875341,,1969.0
11757,N,The maximum plasma concentration (100 mg/kg) administered orally in human,,Homo sapiens,A,,BAO_0000218,14215,In vivo,9606.0,1,Intermediate,1,CHEMBL626235,,1969.0
11758,U,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,,Callithrix,A,,BAO_0000218,14215,In vivo,9481.0,0,Autocuration,1,CHEMBL626236,,1969.0
11759,U,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,,Simiiformes,A,,BAO_0000218,14215,In vivo,314293.0,0,Autocuration,1,CHEMBL626237,,1969.0
11760,N,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,,Canis lupus familiaris,A,,BAO_0000218,14215,In vivo,9615.0,1,Intermediate,1,CHEMBL626238,,1969.0
11761,N,The maximum plasma concentration (200 mg/kg) administered orally in human,,Homo sapiens,A,,BAO_0000218,14215,In vivo,9606.0,1,Intermediate,1,CHEMBL622412,,1969.0
11762,N,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,,Rattus norvegicus,A,,BAO_0000218,14215,In vivo,10116.0,1,Intermediate,1,CHEMBL623114,,1969.0
11763,U,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,,Callithrix,A,,BAO_0000218,14215,In vivo,9481.0,0,Autocuration,1,CHEMBL623115,,1969.0
11764,U,The maximum plasma concentration (25 mg/kg) administered orally in monkey,,Simiiformes,A,,BAO_0000218,14215,In vivo,314293.0,0,Autocuration,1,CHEMBL623116,,1969.0
11765,U,The maximum plasma concentration (30 mg/kg) administered orally in dog,,Canis lupus familiaris,A,,BAO_0000218,14215,In vivo,9615.0,0,Autocuration,1,CHEMBL623117,,1969.0
11766,N,The maximum plasma concentration (400 mg/kg) administered orally in human,,Homo sapiens,A,,BAO_0000218,14215,In vivo,9606.0,1,Intermediate,1,CHEMBL623118,,1969.0
11767,N,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,,Rattus norvegicus,A,,BAO_0000218,14215,In vivo,10116.0,1,Intermediate,1,CHEMBL623119,,1969.0
11768,N,The maximum plasma concentration (50 mg/kg) administered orally in rat,,Rattus norvegicus,A,,BAO_0000218,14215,In vivo,10116.0,1,Intermediate,1,CHEMBL623120,,1969.0
11769,N,The maximum plasma concentration (800 mg/kg) administered orally in human,,Homo sapiens,A,,BAO_0000218,14215,In vivo,9606.0,1,Intermediate,1,CHEMBL623286,,1969.0
11770,N,The maximum plasma concentration was measured on rats,,Rattus norvegicus,A,,BAO_0000218,14067,In vivo,10116.0,1,Intermediate,1,CHEMBL623287,,1969.0
11771,N,The maximum plasma concentration was measured on rats after oral administration,,Rattus norvegicus,A,,BAO_0000218,12350,In vivo,10116.0,1,Intermediate,1,CHEMBL623288,,1969.0
11772,N,Plasma drug Cmax in rat (PO dose),,Rattus norvegicus,A,,BAO_0000218,14813,In vivo,10116.0,1,Intermediate,1,CHEMBL623289,,1969.0
11773,U,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,,,A,,BAO_0000218,12536,In vivo,,0,Autocuration,1,CHEMBL623290,,
11774,N,maximum Plasma concentration in Dog was determined after Peroral administration,,Canis lupus familiaris,A,,BAO_0000218,14169,In vivo,9615.0,1,Intermediate,1,CHEMBL623291,,1969.0
11775,N,maximum Plasma concentration in Rats was determined after Peroral administration,,Rattus norvegicus,A,,BAO_0000218,14169,In vivo,10116.0,1,Intermediate,1,CHEMBL623292,,1969.0
11776,N,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,Canis lupus familiaris,A,,BAO_0000218,15604,In vivo,9615.0,1,Intermediate,1,CHEMBL623293,,1969.0
11777,U,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,Simiiformes,A,,BAO_0000218,15604,In vivo,314293.0,0,Autocuration,1,CHEMBL623294,,1969.0
11778,N,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,Rattus norvegicus,A,,BAO_0000218,15604,In vivo,10116.0,1,Intermediate,1,CHEMBL623295,,1969.0
11779,N,maximum concentration was measured when administered through oral route in mice,,Mus musculus,A,,BAO_0000218,14387,In vivo,10090.0,1,Intermediate,1,CHEMBL623296,,
11780,N,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,,Mus musculus,A,,BAO_0000218,15115,,10090.0,1,Intermediate,1,CHEMBL875349,,
11781,U,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,,Simiiformes,A,,BAO_0000019,15115,,314293.0,0,Autocuration,1,CHEMBL623297,,
11782,U,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,,Simiiformes,A,,BAO_0000019,15115,,314293.0,0,Autocuration,1,CHEMBL623298,,
11783,U,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,,Simiiformes,A,,BAO_0000019,15115,,314293.0,0,Autocuration,1,CHEMBL623299,,
11784,N,Pharmacokinetic parameter was evaluated in rats,,Rattus norvegicus,A,,BAO_0000218,16359,,10116.0,1,Intermediate,1,CHEMBL623300,,
11785,N,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,Mus musculus,A,,BAO_0000218,12829,,10090.0,1,Intermediate,1,CHEMBL623301,,
11786,N,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,,Mus musculus,A,,BAO_0000218,12829,,10090.0,1,Intermediate,1,CHEMBL623302,,
11787,N,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,Mus musculus,A,,BAO_0000218,12829,,10090.0,1,Intermediate,1,CHEMBL623303,,
11788,N,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,,Mus musculus,A,,BAO_0000218,12829,,10090.0,1,Intermediate,1,CHEMBL623304,,
11789,N,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,,Mus musculus,A,,BAO_0000218,12829,,10090.0,1,Intermediate,1,CHEMBL623305,,
11790,N,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,,Rattus norvegicus,A,,BAO_0000218,15137,,10116.0,1,Intermediate,1,CHEMBL623306,,1969.0
11791,N,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,,Rattus norvegicus,A,,BAO_0000218,15137,,10116.0,1,Intermediate,1,CHEMBL623307,,1969.0
11792,N,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,,Rattus norvegicus,A,,BAO_0000218,15137,,10116.0,1,Intermediate,1,CHEMBL623308,,1969.0
11793,N,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,,Mus musculus,A,,BAO_0000218,15137,,10090.0,1,Intermediate,1,CHEMBL623309,,1969.0
11794,N,Plasma Concentration after 120 min of oral administration to mice,,Mus musculus,A,,BAO_0000218,13509,,10090.0,1,Intermediate,1,CHEMBL623310,,
11795,N,Plasma Concentration after 30 min of oral administration to mice,,Mus musculus,A,,BAO_0000218,13509,,10090.0,1,Intermediate,1,CHEMBL623311,,
11796,N,Plasma Concentration after 60 min of oral administration to mice,,Macaca fascicularis,A,,BAO_0000218,13509,,9541.0,1,Intermediate,1,CHEMBL623312,,
11797,N,Plasma Concentration after 60 min of oral administration to mice; Not determined,,Mus musculus,A,,BAO_0000218,13509,,10090.0,1,Intermediate,1,CHEMBL875350,,
11798,N,Plasma Concentration after 90 min of oral administration to mice,,Mus musculus,A,,BAO_0000218,13509,,10090.0,1,Intermediate,1,CHEMBL628635,,
11799,N,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,12064,,10116.0,1,Intermediate,1,CHEMBL628636,,
11800,N,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,12064,,10116.0,1,Intermediate,1,CHEMBL628637,,
11801,N,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,,Rattus norvegicus,A,,BAO_0000218,12064,,10116.0,1,Intermediate,1,CHEMBL628058,,
11802,N,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,,Rattus norvegicus,A,,BAO_0000218,10677,,10116.0,1,Intermediate,1,CHEMBL628059,,
11803,N,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,,Rattus norvegicus,A,,BAO_0000218,10677,,10116.0,1,Intermediate,1,CHEMBL628060,,
11804,U,Distribution in the lung after 15 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628061,,
11805,U,Distribution in the lung after 30 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628062,,
11806,U,Distribution in the lung after 5 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628063,,
11807,U,Distribution in the lung after 60 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628064,,
11808,U,Distribution in the lung after 90 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628065,,
11809,U,Distribution in the muscle after 120 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628066,,2385.0
11810,U,Distribution in the muscle after 15 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628067,,2385.0
11811,N,Distribution in the muscle after 30 min of intravenous administration,,Mus musculus,A,,BAO_0000218,8926,,10090.0,1,Intermediate,1,CHEMBL874646,,2385.0
11812,U,Distribution in the muscle after 5 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628068,,2385.0
11813,U,Distribution in the muscle after 60 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628069,,2385.0
11814,U,Distribution in the muscle after 90 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628070,,2385.0
11815,U,Distribution in the spleen after 120 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628071,,2106.0
11816,U,Distribution in the spleen after 15 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628072,,2106.0
11817,U,Distribution in the spleen after 30 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628073,,2106.0
11818,U,Distribution in the spleen after 5 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628074,,2106.0
11819,U,Distribution in the spleen after 60 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628075,,2106.0
11820,U,Distribution in the spleen after 90 min of intravenous administration,,,A,,BAO_0000019,8926,,,0,Autocuration,1,CHEMBL628076,,2106.0
11821,N,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,,Rattus norvegicus,A,,BAO_0000218,7570,,10116.0,1,Intermediate,1,CHEMBL628077,,1235.0
11822,N,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,,Rattus norvegicus,A,,BAO_0000218,7570,,10116.0,1,Intermediate,1,CHEMBL628078,,178.0
11823,N,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,,Rattus norvegicus,A,,BAO_0000218,7570,,10116.0,1,Intermediate,1,CHEMBL628079,,2107.0
11824,N,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,,Rattus norvegicus,A,,BAO_0000218,7570,,10116.0,1,Intermediate,1,CHEMBL628080,,992.0
11825,N,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,,Rattus norvegicus,A,,BAO_0000218,7570,,10116.0,1,Intermediate,1,CHEMBL628081,,2046.0
11826,N,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,,Rattus norvegicus,A,,BAO_0000218,7570,,10116.0,1,Intermediate,1,CHEMBL628082,,1235.0
11827,N,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,,Rattus norvegicus,A,,BAO_0000218,7570,,10116.0,1,Intermediate,1,CHEMBL874647,,178.0
11828,N,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,,Rattus norvegicus,A,,BAO_0000218,7570,,10116.0,1,Intermediate,1,CHEMBL626406,,2107.0
11829,N,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,,Rattus norvegicus,A,,BAO_0000218,7570,,10116.0,1,Intermediate,1,CHEMBL626407,,992.0
11830,N,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,,Rattus norvegicus,A,,BAO_0000218,7570,,10116.0,1,Intermediate,1,CHEMBL626408,,2046.0
11831,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626409,,178.0
11832,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626410,,178.0
11833,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626411,,178.0
11834,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626412,,178.0
11835,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626413,,178.0
11836,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626414,,178.0
11837,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626415,,178.0
11838,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626416,,178.0
11839,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627062,,178.0
11840,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627063,,178.0
11841,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627064,,178.0
11842,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627227,,178.0
11843,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627228,,178.0
11844,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627229,,178.0
11845,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL625792,,178.0
11846,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL625793,,178.0
11847,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL625794,,178.0
11848,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL625795,,178.0
11849,N,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,,Mus musculus,A,,BAO_0000218,13792,,10090.0,1,Intermediate,1,CHEMBL625796,,
11850,N,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,,Canis lupus familiaris,A,,BAO_0000218,13376,,9615.0,1,Intermediate,1,CHEMBL625797,,
11851,N,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,,Canis lupus familiaris,A,,BAO_0000218,13376,,9615.0,1,Intermediate,1,CHEMBL625798,,
11852,U,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,A,,BAO_0000218,14380,,,0,Autocuration,1,CHEMBL875613,,
11853,U,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,A,,BAO_0000218,14380,,,0,Autocuration,1,CHEMBL625799,,
11854,U,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,,,A,,BAO_0000218,14380,,,0,Autocuration,1,CHEMBL625800,,
11855,U,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,,A,,BAO_0000218,14380,,,0,Autocuration,1,CHEMBL625801,,
11856,U,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,,A,,BAO_0000218,14380,,,0,Autocuration,1,CHEMBL625802,,
11857,U,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,,A,,BAO_0000218,14380,,,0,Autocuration,1,CHEMBL625803,,
11858,U,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,,,A,,BAO_0000019,14380,,,0,Autocuration,1,CHEMBL625804,,
11859,U,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,,,A,,BAO_0000218,14380,,,0,Autocuration,1,CHEMBL622530,,
11860,N,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL622531,,
11861,N,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL622532,,
11862,N,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL623176,,
11863,N,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL623177,,
11864,N,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL623178,,
11865,N,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL623179,,
11866,N,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL623180,,
11867,N,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL623181,,
11868,N,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL624131,,
11869,N,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL624132,,
11870,N,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL624133,,
11871,N,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL624846,,
11872,N,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL624847,,
11873,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL624848,,
11874,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL625012,,
11875,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL625013,,
11876,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL625014,,
11877,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL625015,,
11878,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL625016,,
11879,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL625017,,
11880,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL625018,,
11881,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL625019,,
11882,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL625020,,
11883,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL625021,,
11884,N,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,Rattus norvegicus,A,,BAO_0000218,14393,,10116.0,1,Intermediate,1,CHEMBL625022,,
11885,N,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,,Mus musculus,A,,BAO_0000218,14731,,10090.0,1,Intermediate,1,CHEMBL625023,,
11886,N,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,,Macaca fascicularis,A,,BAO_0000218,14731,,9541.0,1,Intermediate,1,CHEMBL625024,,
11887,N,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,Macaca fascicularis,A,,BAO_0000218,14731,,9541.0,1,Intermediate,1,CHEMBL627626,,
11888,U,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,,A,,BAO_0000218,13758,,,0,Autocuration,1,CHEMBL627627,,955.0
11889,U,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,,,A,,BAO_0000218,13758,,,0,Autocuration,1,CHEMBL627628,,1977.0
11890,U,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,,A,,BAO_0000218,13758,,,0,Autocuration,1,CHEMBL627629,,955.0
11891,U,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,,,A,,BAO_0000218,13758,,,0,Autocuration,1,CHEMBL627630,,1977.0
11892,U,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),,,A,,BAO_0000019,16359,,,0,Autocuration,1,CHEMBL627631,,
11893,U,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),,,A,,BAO_0000218,16359,,,0,Autocuration,1,CHEMBL629515,,
11894,N,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL629516,,2106.0
11895,N,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL629517,,2106.0
11896,N,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL629518,,2106.0
11897,N,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL877499,,
11898,N,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL629519,,
11899,N,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL629520,,
11900,N,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,Mus musculus,A,,BAO_0000218,15383,,10090.0,1,Intermediate,1,CHEMBL629521,,
11901,N,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),,Mus musculus,A,,BAO_0000218,14439,,10090.0,1,Intermediate,1,CHEMBL629522,,
11902,N,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),,Mus musculus,A,,BAO_0000218,14439,,10090.0,1,Intermediate,1,CHEMBL629523,,
11903,N,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),,Mus musculus,A,,BAO_0000218,14439,,10090.0,1,Intermediate,1,CHEMBL629524,,
11904,N,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),,Mus musculus,A,,BAO_0000218,14439,,10090.0,1,Intermediate,1,CHEMBL629525,,
11905,N,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),,Mus musculus,A,,BAO_0000218,14439,,10090.0,1,Intermediate,1,CHEMBL629526,,
11906,N,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),,Mus musculus,A,,BAO_0000218,14439,,10090.0,1,Intermediate,1,CHEMBL629527,,
11907,N,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),,Mus musculus,A,,BAO_0000218,14439,,10090.0,1,Intermediate,1,CHEMBL629528,,
11908,N,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),,Mus musculus,A,,BAO_0000218,14439,,10090.0,1,Intermediate,1,CHEMBL629529,,
11909,N,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),,Mus musculus,A,,BAO_0000218,14439,,10090.0,1,Intermediate,1,CHEMBL629530,,
11910,N,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),,Mus musculus,A,,BAO_0000218,14439,,10090.0,1,Intermediate,1,CHEMBL629531,,
11911,N,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),,Mus musculus,A,,BAO_0000218,14439,,10090.0,1,Intermediate,1,CHEMBL628656,,
11912,N,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),,Mus musculus,A,,BAO_0000218,14439,,10090.0,1,Intermediate,1,CHEMBL628657,,
11913,N,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL628658,,
11914,N,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL628659,,
11915,N,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL877500,,
11916,N,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL628660,,
11917,N,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL628661,,
11918,N,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL628662,,
11919,N,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL628663,,
11920,N,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL628664,,
11921,N,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL628665,,178.0
11922,N,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL628666,,178.0
11923,N,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL628667,,178.0
11924,N,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL628668,,178.0
11925,N,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL628669,,178.0
11926,N,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL628670,,178.0
11927,N,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL628671,,178.0
11928,N,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL628672,,10000001.0
11929,N,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL630300,,10000001.0
11930,N,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL629787,,10000001.0
11931,N,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL629788,,10000001.0
11932,N,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL629789,,955.0
11933,N,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL629790,,955.0
11934,N,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL629791,,955.0
11935,N,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL629792,,955.0
11936,N,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL629793,,955.0
11937,N,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL629794,,955.0
11938,N,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,,Rattus norvegicus,A,,BAO_0000218,10677,,10116.0,1,Intermediate,1,CHEMBL874459,,
11939,N,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,,Rattus norvegicus,A,,BAO_0000218,10677,,10116.0,1,Intermediate,1,CHEMBL629795,,
11940,N,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,,Rattus norvegicus,A,,BAO_0000218,10677,,10116.0,1,Intermediate,1,CHEMBL629796,,
11941,N,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,,Rattus norvegicus,A,,BAO_0000218,10677,,10116.0,1,Intermediate,1,CHEMBL629797,,
11942,N,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,,Rattus norvegicus,A,,BAO_0000218,10677,,10116.0,1,Intermediate,1,CHEMBL629798,,
11943,N,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL629799,,2369.0
11944,N,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL629800,,2369.0
11945,N,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL629801,,2369.0
11946,N,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL629802,,2369.0
11947,N,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL629803,,2369.0
11948,N,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL629804,,178.0
11949,N,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL629805,,178.0
11950,N,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL629806,,178.0
11951,N,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL629807,,178.0
11952,N,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL629808,,178.0
11953,N,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL629809,,955.0
11954,N,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL629810,,955.0
11955,N,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL629811,,955.0
11956,N,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL629812,,955.0
11957,N,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL629813,,955.0
11958,N,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL874460,,955.0
11959,N,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL629814,,
11960,N,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL629815,,
11961,N,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL629816,,
11962,N,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL629817,,
11963,N,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL626643,,2113.0
11964,N,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL626644,,2113.0
11965,N,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL626806,,2113.0
11966,N,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL626807,,2113.0
11967,N,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627261,,2107.0
11968,N,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627262,,2107.0
11969,N,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627263,,2107.0
11970,N,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627264,,2107.0
11971,N,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627265,,2048.0
11972,N,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627266,,2048.0
11973,N,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627267,,2048.0
11974,N,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627268,,2048.0
11975,N,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627269,,2385.0
11976,N,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627270,,2385.0
11977,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627271,,
11978,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627946,,
11979,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL875472,,
11980,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627947,,
11981,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627948,,
11982,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628113,,
11983,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628114,,
11984,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628115,,
11985,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628116,,
11986,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628117,,
11987,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628118,,
11988,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628119,,
11989,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628120,,
11990,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628121,,
11991,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628122,,
11992,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627297,,
11993,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627298,,
11994,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627299,,
11995,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627300,,
11996,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627301,,
11997,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627302,,
11998,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627303,,
11999,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627304,,
12000,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627305,,
12001,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627306,,
12002,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL623982,,
12003,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL623983,,
12004,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL623984,,
12005,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL623985,,
12006,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL623986,,
12007,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL623987,,
12008,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL623988,,
12009,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL623989,,
12010,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL622215,,
12011,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL622216,,
12012,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL877481,,
12013,U,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),,,A,,BAO_0000218,16359,,,0,Autocuration,1,CHEMBL622217,,
12014,N,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,Mus musculus,A,,BAO_0000218,13701,,10090.0,1,Intermediate,1,CHEMBL622218,,
12015,N,Pharmacokinetic profile AUC was evaluated in rats,,Rattus norvegicus,A,,BAO_0000218,14554,,10116.0,1,Intermediate,1,CHEMBL622219,,
12016,U,Pharmacokinetic property (Area under curve),,,A,,BAO_0000019,6241,,,0,Autocuration,1,CHEMBL622220,,
12017,N,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",,Canis lupus familiaris,A,,BAO_0000218,11537,,9615.0,1,Intermediate,1,CHEMBL622221,,
12018,N,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",,Mus musculus,A,,BAO_0000218,11537,,10090.0,1,Intermediate,1,CHEMBL622222,,
12019,N,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",,Canis lupus familiaris,A,,BAO_0000218,11537,,9615.0,1,Intermediate,1,CHEMBL622223,,
12020,N,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",,Mus musculus,A,,BAO_0000218,11537,,10090.0,1,Intermediate,1,CHEMBL622224,,
12021,U,Plasma concentration (AUC) was determined,,,A,,BAO_0000019,13118,,,0,Autocuration,1,CHEMBL622225,,
12022,U,Plasma concentration (AUC) was determined; Not detectable,,,A,,BAO_0000019,13118,,,0,Autocuration,1,CHEMBL622226,,
12023,N,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),,Cavia porcellus,A,,BAO_0000218,9562,,10141.0,1,Intermediate,1,CHEMBL624154,,
12024,N,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,,Rattus norvegicus,A,,BAO_0000218,10363,,10116.0,1,Intermediate,1,CHEMBL624155,,
12025,N,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,Rattus norvegicus,A,,BAO_0000218,10363,,10116.0,1,Intermediate,1,CHEMBL624156,,
12026,N,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,,Rattus norvegicus,A,,BAO_0000218,10363,,10116.0,1,Intermediate,1,CHEMBL624157,,
12027,N,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,10363,,10116.0,1,Intermediate,1,CHEMBL624158,,
12028,N,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,,Rattus norvegicus,A,,BAO_0000218,12504,,10116.0,1,Intermediate,1,CHEMBL624159,,
12029,N,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,,Rattus norvegicus,A,,BAO_0000218,12504,,10116.0,1,Intermediate,1,CHEMBL624160,,
12030,N,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,,Rattus norvegicus,A,,BAO_0000218,12504,,10116.0,1,Intermediate,1,CHEMBL624161,,
12031,N,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,,Rattus norvegicus,A,,BAO_0000218,12504,,10116.0,1,Intermediate,1,CHEMBL624162,,
12032,N,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,,Canis lupus familiaris,A,,BAO_0000218,13317,,9615.0,1,Intermediate,1,CHEMBL624163,,
12033,N,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,15078,,10116.0,1,Intermediate,1,CHEMBL624164,,
12034,N,The AUC(0-infinity) values in female wistar rats.,,Rattus norvegicus,A,,BAO_0000218,14941,,10116.0,1,Intermediate,1,CHEMBL624165,,
12035,N,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,15078,,10116.0,1,Intermediate,1,CHEMBL624166,,
12036,N,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",,Rattus norvegicus,A,,BAO_0000218,15078,,10116.0,1,Intermediate,1,CHEMBL624167,,
12037,N,The AUC(0-t)values in female wistar rats.,,Rattus norvegicus,A,,BAO_0000218,14941,,10116.0,1,Intermediate,1,CHEMBL624168,,
12038,N,The Area under the concentration time curve of compound was measured on rats,,Rattus norvegicus,A,,BAO_0000218,14067,,10116.0,1,Intermediate,1,CHEMBL624169,,
12039,N,The area under curve (100 mg/kg) administered orally in humans,,Homo sapiens,A,,BAO_0000218,14215,,9606.0,1,Intermediate,1,CHEMBL624170,,
12040,U,The area under curve (12.5 mg/kg) administered intravenously in marmoset,,Callithrix,A,,BAO_0000218,14215,,9481.0,0,Autocuration,1,CHEMBL624171,,
12041,U,The area under curve (12.5 mg/kg) administered intravenously in monkey,,Simiiformes,A,,BAO_0000218,14215,,314293.0,0,Autocuration,1,CHEMBL624172,,
12042,N,The area under curve (15 mg/kg) administered intravenously in dog,,Canis lupus familiaris,A,,BAO_0000218,14215,,9615.0,1,Intermediate,1,CHEMBL624173,,
12043,N,The area under curve (200 mg/kg) administered orally in humans,,Homo sapiens,A,,BAO_0000218,14215,,9606.0,1,Intermediate,1,CHEMBL877488,,
12044,N,The area under curve (25 mg/kg) administered intravenously in rat,,Rattus norvegicus,A,,BAO_0000218,14215,,10116.0,1,Intermediate,1,CHEMBL624174,,
12045,U,The area under curve (25 mg/kg) administered orally in marmoset,,Callithrix,A,,BAO_0000218,14215,,9481.0,0,Autocuration,1,CHEMBL624175,,
12046,U,The area under curve (25 mg/kg) administered orally in monkey,,Simiiformes,A,,BAO_0000218,14215,,314293.0,0,Autocuration,1,CHEMBL624176,,
12047,N,The area under curve (30 mg/kg) administered orally in dog,,Canis lupus familiaris,A,,BAO_0000218,14215,,9615.0,1,Intermediate,1,CHEMBL624177,,
12048,N,The area under curve (400 mg/kg) administered orally in humans,,Homo sapiens,A,,BAO_0000218,14215,,9606.0,1,Intermediate,1,CHEMBL624178,,
12049,N,The area under curve (50 mg/kg) administered orally in fasted rat,,Rattus norvegicus,A,,BAO_0000218,14215,,10116.0,1,Intermediate,1,CHEMBL624179,,
12050,N,The area under curve (50 mg/kg) administered orally in rat,,Rattus norvegicus,A,,BAO_0000218,14215,,10116.0,1,Intermediate,1,CHEMBL627689,,
12051,N,The area under curve (800 mg/kg) administered orally in humans,,Homo sapiens,A,,BAO_0000218,14215,,9606.0,1,Intermediate,1,CHEMBL627690,,
12052,U,The compound was evaluated for area under the curve,,,A,,BAO_0000019,11324,,,0,Autocuration,1,CHEMBL627691,,
12053,U,The compound was evaluated for area under the curve in marmosets,,Callithrix,A,,BAO_0000019,11324,,9481.0,0,Autocuration,1,CHEMBL627692,,
12054,U,The compound was evaluated for area under the curve in marmosets,,Callithrix,A,,BAO_0000019,11324,,9481.0,0,Autocuration,1,CHEMBL627693,,
12055,N,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,Rattus norvegicus,A,,BAO_0000218,13875,,10116.0,1,Intermediate,1,CHEMBL627694,,
12056,N,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,,Rattus norvegicus,A,,BAO_0000218,13875,,10116.0,1,Intermediate,1,CHEMBL627695,,
12057,U,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),,,A,,BAO_0000218,13875,,,0,Autocuration,1,CHEMBL627696,,
12058,N,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,Rattus norvegicus,A,,BAO_0000218,13875,,10116.0,1,Intermediate,1,CHEMBL627697,,
12059,N,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,Rattus norvegicus,A,,BAO_0000218,13875,,10116.0,1,Intermediate,1,CHEMBL627698,,
12060,N,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,,Rattus norvegicus,A,,BAO_0000218,13875,,10116.0,1,Intermediate,1,CHEMBL627699,,
12061,N,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,,Rattus norvegicus,A,,BAO_0000218,13807,,10116.0,1,Intermediate,1,CHEMBL627700,,
12062,N,Total drug exposure is determined after oral dosing in rats.,,Rattus norvegicus,A,,BAO_0000218,14127,,10116.0,1,Intermediate,1,CHEMBL627701,,
12063,U,Total drug exposure (5 mg/kg) when administered intravenously,,,A,,BAO_0000218,15116,,,0,Autocuration,1,CHEMBL627702,,
12064,U,Total drug exposure (5 mg/kg) when administered orally,,,A,,BAO_0000218,15116,,,0,Autocuration,1,CHEMBL627703,,
12065,U,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,Simiiformes,A,,BAO_0000218,15604,,314293.0,0,Autocuration,1,CHEMBL626873,,
12066,N,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,Rattus norvegicus,A,,BAO_0000218,15604,,10116.0,1,Intermediate,1,CHEMBL629583,,
12067,N,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,Canis lupus familiaris,A,,BAO_0000218,15604,,9615.0,1,Intermediate,1,CHEMBL629584,,
12068,N,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,Canis lupus familiaris,A,,BAO_0000218,15604,,9615.0,1,Intermediate,1,CHEMBL629585,,
12069,N,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL629586,,955.0
12070,N,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL629587,,955.0
12071,N,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL629588,,
12072,N,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL629589,,
12073,N,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL629590,,
12074,N,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL629591,,
12075,N,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL629592,,
12076,N,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL629593,,
12077,N,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL629594,,
12078,N,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL629595,,948.0
12079,N,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL630290,,948.0
12080,N,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627137,,948.0
12081,N,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627138,,948.0
12082,N,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627139,,948.0
12083,N,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627140,,948.0
12084,N,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627141,,948.0
12085,N,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627142,,2113.0
12086,N,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627143,,2113.0
12087,N,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL874449,,2113.0
12088,N,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627144,,2113.0
12089,N,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627145,,2113.0
12090,N,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627146,,2113.0
12091,N,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627147,,2113.0
12092,N,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627148,,2107.0
12093,N,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627149,,2048.0
12094,N,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL632160,,2048.0
12095,N,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL632161,,2048.0
12096,N,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL632162,,2048.0
12097,N,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL632163,,2048.0
12098,N,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL874469,,2048.0
12099,N,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627182,,2048.0
12100,N,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627183,,2385.0
12101,N,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627184,,2385.0
12102,N,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627185,,2385.0
12103,N,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627186,,2385.0
12104,N,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627187,,2385.0
12105,N,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627188,,2385.0
12106,N,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627189,,2385.0
12107,N,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627190,,
12108,N,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627191,,2107.0
12109,N,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627192,,2107.0
12110,N,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL627193,,2107.0
12111,N,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL874590,,2385.0
12112,N,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627194,,2385.0
12113,N,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627195,,2385.0
12114,N,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627196,,992.0
12115,N,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627197,,992.0
12116,N,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627198,,992.0
12117,N,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627199,,992.0
12118,N,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627200,,992.0
12119,N,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627201,,1969.0
12120,N,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627202,,1969.0
12121,N,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627203,,1969.0
12122,N,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627204,,1969.0
12123,N,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627205,,2106.0
12124,N,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627206,,2106.0
12125,N,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627207,,2106.0
12126,N,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627208,,2106.0
12127,N,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627209,,2046.0
12128,N,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627210,,2046.0
12129,N,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627211,,2046.0
12130,N,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627212,,2046.0
12131,N,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL627213,,995.0
12132,N,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL626599,,995.0
12133,N,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL626600,,995.0
12134,N,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,A,,BAO_0000218,10911,In vivo,10116.0,1,Intermediate,1,CHEMBL626601,,995.0
12135,U,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,,,A,,BAO_0000019,8081,,,0,Autocuration,1,CHEMBL627484,,
12136,N,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),,Macaca fascicularis,A,,BAO_0000218,17248,,9541.0,1,Intermediate,1,CHEMBL627485,,1969.0
12137,N,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,,Macaca fascicularis,A,,BAO_0000218,17248,,9541.0,1,Intermediate,1,CHEMBL628147,,1969.0
12138,N,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,,Macaca fascicularis,A,,BAO_0000218,17248,,9541.0,1,Intermediate,1,CHEMBL628148,,1969.0
12139,N,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),,Canis lupus familiaris,A,,BAO_0000218,17248,,9615.0,1,Intermediate,1,CHEMBL628149,,1969.0
12140,N,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,,Canis lupus familiaris,A,,BAO_0000218,17248,,9615.0,1,Intermediate,1,CHEMBL628150,,1969.0
12141,N,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,,Canis lupus familiaris,A,,BAO_0000218,17248,,9615.0,1,Intermediate,1,CHEMBL628318,,1969.0
12142,N,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,,Canis lupus familiaris,A,,BAO_0000218,17248,,9615.0,1,Intermediate,1,CHEMBL628319,,1969.0
12143,N,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,Canis lupus familiaris,A,,BAO_0000218,15592,,9615.0,1,Intermediate,1,CHEMBL875609,,
12144,U,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,,,A,,BAO_0000019,7040,,,0,Autocuration,1,CHEMBL628320,,
12145,U,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,,,A,,BAO_0000019,7040,,,0,Autocuration,1,CHEMBL628321,,
12146,U,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,,,A,,BAO_0000019,7040,,,0,Autocuration,1,CHEMBL628322,,
12147,U,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,,,A,,BAO_0000019,7040,,,0,Autocuration,1,CHEMBL628323,,
12148,U,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,,,A,,BAO_0000019,7040,,,0,Autocuration,1,CHEMBL628324,,
12149,U,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,,,A,,BAO_0000019,7040,,,0,Autocuration,1,CHEMBL628325,,
12150,U,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,,,A,,BAO_0000019,7040,,,0,Autocuration,1,CHEMBL628326,,
12151,N,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",,Canis lupus familiaris,A,,BAO_0000218,9614,,9615.0,1,Intermediate,1,CHEMBL628327,,1236.0
12152,N,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",,Canis lupus familiaris,A,,BAO_0000218,9614,,9615.0,1,Intermediate,1,CHEMBL628328,,1236.0
12153,N,"Concentration of compound in blood of dog 1, after administering intravenously",,Canis lupus familiaris,A,,BAO_0000218,9614,,9615.0,1,Intermediate,1,CHEMBL628329,,178.0
12154,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628330,,2107.0
12155,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628331,,2107.0
12156,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628332,,2107.0
12157,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628333,,2107.0
12158,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628334,,2107.0
12159,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628335,,2107.0
12160,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628336,,2107.0
12161,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628337,,2107.0
12162,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628338,,2107.0
12163,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL875610,,2107.0
12164,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628339,,2107.0
12165,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628340,,2107.0
12166,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL628341,,2107.0
12167,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL622214,,2107.0
12168,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL623167,,2107.0
12169,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL623168,,2107.0
12170,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL623169,,2107.0
12171,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL623170,,2107.0
12172,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627224,,2048.0
12173,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL875634,,2048.0
12174,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627225,,2048.0
12175,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627226,,2048.0
12176,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626083,,2048.0
12177,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626084,,2048.0
12178,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626085,,2048.0
12179,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626086,,2048.0
12180,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626087,,2048.0
12181,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626088,,2048.0
12182,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626089,,2048.0
12183,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626090,,2048.0
12184,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626091,,2048.0
12185,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626092,,2048.0
12186,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626093,,2048.0
12187,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626094,,2048.0
12188,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626095,,2048.0
12189,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626096,,2048.0
12190,U,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,Simiiformes,A,,BAO_0000218,15604,,314293.0,0,Autocuration,1,CHEMBL626097,,
12191,N,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,Rattus norvegicus,A,,BAO_0000218,15604,,10116.0,1,Intermediate,1,CHEMBL626098,,
12192,U,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,,,A,,BAO_0000218,1806,,,0,Autocuration,1,CHEMBL626099,,1969.0
12193,U,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,,,A,,BAO_0000218,1806,,,0,Autocuration,1,CHEMBL626100,,1969.0
12194,N,AUC 0-inf in dog,,Canis lupus familiaris,A,,BAO_0000218,17237,,9615.0,1,Intermediate,1,CHEMBL626101,,1969.0
12195,N,AUC 0-inf in guinea pig,,Cavia porcellus,A,,BAO_0000218,17237,,10141.0,1,Intermediate,1,CHEMBL626102,,1969.0
12196,N,AUC 0-t in dog,,Canis lupus familiaris,A,,BAO_0000218,17237,,9615.0,1,Intermediate,1,CHEMBL626103,,1969.0
12197,N,AUC 0-t in guinea pig,,Cavia porcellus,A,,BAO_0000218,17237,,10141.0,1,Intermediate,1,CHEMBL628391,,1969.0
12198,N,The compound was tested for brain to plasma partition in rat,,Rattus norvegicus,A,,BAO_0000218,15194,,10116.0,1,Intermediate,1,CHEMBL628392,,
12199,N,The compound was tested for brain to plasma partition in rat.,,Rattus norvegicus,A,,BAO_0000218,15194,,10116.0,1,Intermediate,1,CHEMBL628393,,
12200,U,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,,,A,,BAO_0000019,8787,,,0,Autocuration,1,CHEMBL628394,,178.0
12201,N,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,,Canis lupus familiaris,A,,BAO_0000218,17025,,9615.0,1,Intermediate,1,CHEMBL628395,,
12202,U,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,,Simiiformes,A,,BAO_0000218,17025,,314293.0,0,Autocuration,1,CHEMBL628396,,
12203,N,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,,Oryctolagus cuniculus,A,,BAO_0000218,17025,,9986.0,1,Intermediate,1,CHEMBL628397,,
12204,N,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,,Rattus norvegicus,A,,BAO_0000218,17025,,10116.0,1,Intermediate,1,CHEMBL628398,,
12205,N,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,,Macaca mulatta,A,,BAO_0000218,4236,,9544.0,1,Intermediate,1,CHEMBL628399,,
12206,N,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,,Canis lupus familiaris,A,,BAO_0000218,15343,,9615.0,1,Intermediate,1,CHEMBL628400,,
12207,N,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,15343,,10116.0,1,Intermediate,1,CHEMBL874907,,
12208,U,Area under curve of the compound was determined,,,A,,BAO_0000019,17720,,,0,Autocuration,1,CHEMBL628401,,
12209,U,AUC in monkeys at a dose of 1 mg/kg,,Simiiformes,A,,BAO_0000218,17788,,314293.0,0,Autocuration,1,CHEMBL628402,,1969.0
12210,N,AUC in rats at a dose of 1 mg/kg,,Rattus norvegicus,A,,BAO_0000218,17788,,10116.0,1,Intermediate,1,CHEMBL628403,,1969.0
12211,U,Compound was evaluated for the overall absorbance loss at pH of 2,,,A,,BAO_0000019,8778,,,0,Autocuration,1,CHEMBL628404,,
12212,U,Compound was evaluated for the overall absorbance loss at pH of 4,,,A,,BAO_0000019,8778,,,0,Autocuration,1,CHEMBL628405,,
12213,U,Compound was evaluated for the overall absorbance loss at pH of 7,,,A,,BAO_0000019,8778,,,0,Autocuration,1,CHEMBL628406,,
12214,N,Compound was evaluated for its absorption in the rats,,Rattus norvegicus,A,,BAO_0000218,2249,,10116.0,1,Intermediate,1,CHEMBL628407,,
12215,N,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,Rattus norvegicus,A,,BAO_0000218,8881,,10116.0,1,Intermediate,1,CHEMBL628408,,1088.0
12216,N,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,,Rattus norvegicus,A,,BAO_0000218,8881,,10116.0,1,Intermediate,1,CHEMBL629171,,1088.0
12217,N,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,Rattus norvegicus,A,,BAO_0000218,8881,,10116.0,1,Intermediate,1,CHEMBL629172,,1088.0
12218,N,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,,Rattus norvegicus,A,,BAO_0000218,8881,,10116.0,1,Intermediate,1,CHEMBL629173,,1088.0
12219,N,In vitro percent permeability into rat ileum,,Rattus norvegicus,A,,BAO_0000218,15286,,10116.0,1,Intermediate,1,CHEMBL629174,,
12220,N,In vitro percent permeability into rat ileum; Range is 10-17,,Rattus norvegicus,A,,BAO_0000218,15286,,10116.0,1,Intermediate,1,CHEMBL629175,,
12221,N,In vitro percent permeability into rat ileum; Range is 10-18,,Rattus norvegicus,A,,BAO_0000218,15286,,10116.0,1,Intermediate,1,CHEMBL629176,,
12222,N,In vitro percent permeability into rat ileum; Range is 10-19,,Rattus norvegicus,A,,BAO_0000218,15286,,10116.0,1,Intermediate,1,CHEMBL629177,,
12223,N,In vitro percent permeability into rat ileum; Range is 12-15,,Rattus norvegicus,A,,BAO_0000218,15286,,10116.0,1,Intermediate,1,CHEMBL629178,,
12224,N,In vitro percent permeability into rat ileum; Range is 13-19,,Rattus norvegicus,A,,BAO_0000218,15286,,10116.0,1,Intermediate,1,CHEMBL631869,,
12225,N,In vitro percent permeability into rat ileum; Range is 14-17,,Rattus norvegicus,A,,BAO_0000218,15286,,10116.0,1,Intermediate,1,CHEMBL631870,,
12226,N,In vitro percent permeability into rat ileum; Range is 15-18,,Rattus norvegicus,A,,BAO_0000218,15286,,10116.0,1,Intermediate,1,CHEMBL631871,,
12227,N,In vitro percent permeability into rat ileum; Range is 2-5,,Rattus norvegicus,A,,BAO_0000218,15286,,10116.0,1,Intermediate,1,CHEMBL631872,,
12228,U,In vitro percent permeability into rat ileum; Range is 23-42,,,A,,BAO_0000221,15286,,,0,Autocuration,1,CHEMBL875775,,2116.0
12229,N,In vitro percent permeability into rat ileum; Range is 28-36,,Rattus norvegicus,A,,BAO_0000218,15286,,10116.0,1,Intermediate,1,CHEMBL631873,,
12230,N,In vitro percent permeability into rat ileum; Range is 29-35,,Rattus norvegicus,A,,BAO_0000218,15286,,10116.0,1,Intermediate,1,CHEMBL631874,,
12231,N,In vitro percent permeability into rat ileum; Range is 46-66,,Rattus norvegicus,A,,BAO_0000218,15286,,10116.0,1,Intermediate,1,CHEMBL631875,,
12232,N,In vitro percent permeability into rat ileum; Range is 50-68,,Rattus norvegicus,A,,BAO_0000218,15286,,10116.0,1,Intermediate,1,CHEMBL631876,,
12233,N,In vitro percent permeability into rat ileum; Range is 78-81,,Rattus norvegicus,A,,BAO_0000218,15286,,10116.0,1,Intermediate,1,CHEMBL631877,,
12234,N,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,,Rattus norvegicus,A,,BAO_0000218,15286,,10116.0,1,Intermediate,1,CHEMBL631878,,
12235,N,In vitro percent permeability into rat ileum; nd indicates not detected,,Rattus norvegicus,A,,BAO_0000218,15286,,10116.0,1,Intermediate,1,CHEMBL631879,,
12236,N,In vitro percent permeability into rat ileum; nt indicates not detected,,Rattus norvegicus,A,,BAO_0000218,15286,,10116.0,1,Intermediate,1,CHEMBL631880,,
12237,N,In vitro percent permeability into rat ileum; nt indicates not tested,,Rattus norvegicus,A,,BAO_0000218,15286,,10116.0,1,Intermediate,1,CHEMBL631881,,
12238,N,Compound was tested for oral absorption in bile-duct cannulated rats,,Rattus norvegicus,A,,BAO_0000218,13770,,10116.0,1,Intermediate,1,CHEMBL631882,,
12239,N,Compound was tested for oral absorption in bile-duct cannulated rats.,,Rattus norvegicus,A,,BAO_0000218,13770,,10116.0,1,Intermediate,1,CHEMBL630749,,
12240,N,Oral absorption using Caco-2 cell monolayers.,,Homo sapiens,A,,BAO_0000218,5202,,9606.0,1,Intermediate,1,CHEMBL630750,,
12241,N,Percent of the drug absorbed after administration to humans was determined,,Homo sapiens,A,,BAO_0000218,14920,,9606.0,1,Intermediate,1,CHEMBL630253,,
12242,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL630254,,1969.0
12243,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL630255,,1969.0
12244,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL630256,,1969.0
12245,N,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL875781,,2107.0
12246,N,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL630257,,2107.0
12247,N,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",,Rattus norvegicus,A,,BAO_0000218,13751,In vivo,10116.0,1,Intermediate,1,CHEMBL630258,,2107.0
12248,N,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",,Rattus norvegicus,A,,BAO_0000218,15807,,10116.0,1,Intermediate,1,CHEMBL630259,,
12249,N,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",,Rattus norvegicus,A,,BAO_0000218,15807,,10116.0,1,Intermediate,1,CHEMBL630260,,2435.0
12250,N,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",,Rattus norvegicus,A,,BAO_0000218,15807,,10116.0,1,Intermediate,1,CHEMBL630261,,2435.0
12251,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630262,,
12252,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630263,,
12253,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630264,,
12254,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630265,,
12255,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630266,,
12256,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630267,,2113.0
12257,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630268,,2113.0
12258,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630269,,
12259,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630270,,
12260,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630141,,2048.0
12261,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630142,,2048.0
12262,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630143,,2385.0
12263,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630144,,2385.0
12264,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630145,,2367.0
12265,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630146,,2367.0
12266,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630147,,
12267,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630148,,
12268,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630149,,
12269,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630150,,2106.0
12270,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL630151,,2106.0
12271,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL632031,,2046.0
12272,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL632032,,2046.0
12273,N,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL632033,,
12274,N,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL632034,,
12275,N,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL632035,,2385.0
12276,N,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL632036,,
12277,N,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,,Rattus norvegicus,A,,BAO_0000218,14950,,10116.0,1,Intermediate,1,CHEMBL632037,,2046.0
12278,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL632038,,178.0
12279,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL632039,,178.0
12280,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL632040,,178.0
12281,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL632041,,178.0
12282,N,"Concentration of compound in blood of dog 2, after administering intravenously",,Canis lupus familiaris,A,,BAO_0000218,9614,,9615.0,1,Intermediate,1,CHEMBL632042,,178.0
12283,N,"Concentration of compound in left ventricle of dog 1, after administering intravenously",,Canis lupus familiaris,A,,BAO_0000218,9614,,9615.0,1,Intermediate,1,CHEMBL632043,,
12284,N,"Concentration of compound in left ventricle of dog 2, after administering intravenously",,Canis lupus familiaris,A,,BAO_0000218,9614,,9615.0,1,Intermediate,1,CHEMBL632044,,
12285,N,"Concentration of compound in liver of dog 1, after administering intravenously",,Canis lupus familiaris,A,,BAO_0000218,9614,,9615.0,1,Intermediate,1,CHEMBL632045,,2107.0
12286,N,"Concentration of compound in liver of dog 2, after administering intravenously",,Canis lupus familiaris,A,,BAO_0000218,9614,,9615.0,1,Intermediate,1,CHEMBL632046,,2107.0
12287,N,"Concentration of compound in lung of dog 1, after administering intravenously",,Canis lupus familiaris,A,,BAO_0000218,9614,,9615.0,1,Intermediate,1,CHEMBL632047,,2048.0
12288,N,"Concentration of compound in lung of dog 2, after administering intravenously",,Canis lupus familiaris,A,,BAO_0000218,9614,,9615.0,1,Intermediate,1,CHEMBL632048,,2048.0
12289,N,"Concentration of compound in muscle of dog 1, after administering intravenously",,Canis lupus familiaris,A,,BAO_0000218,9614,,9615.0,1,Intermediate,1,CHEMBL632049,,2385.0
12290,N,"Concentration of compound in muscle of dog 2, after administering intravenously",,Canis lupus familiaris,A,,BAO_0000218,9614,,9615.0,1,Intermediate,1,CHEMBL876418,,2385.0
12291,N,"Concentration of compound in spleen of dog 1,after administering intravenously",,Canis lupus familiaris,A,,BAO_0000218,9614,,9615.0,1,Intermediate,1,CHEMBL632050,,2106.0
12292,N,"Concentration of compound in spleen of dog 2, after administering intravenously",,Canis lupus familiaris,A,,BAO_0000218,9614,,9615.0,1,Intermediate,1,CHEMBL632051,,2106.0
12293,U,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,,,F,,BAO_0000218,10353,,,0,Autocuration,1,CHEMBL632052,,
12294,U,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,,,F,,BAO_0000218,10353,,,0,Autocuration,1,CHEMBL632053,,
12295,U,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,,A,,BAO_0000218,10353,,,0,Autocuration,1,CHEMBL632054,,
12296,U,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,,F,,BAO_0000218,10353,,,0,Autocuration,1,CHEMBL632055,,
12297,U,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,,,F,,BAO_0000218,10353,,,0,Autocuration,1,CHEMBL631181,,
12298,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL631182,,
12299,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL631183,,
12300,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL631184,,
12301,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL629774,,
12302,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL629775,,
12303,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL876549,,
12304,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628172,,
12305,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628173,,
12306,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628174,,
12307,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628175,,
12308,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628176,,
12309,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628177,,
12310,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628178,,
12311,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628179,,
12312,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628180,,
12313,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628181,,
12314,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628182,,
12315,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628183,,
12316,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628184,,
12317,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628185,,
12318,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL875617,,
12319,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628186,,
12320,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628187,,
12321,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628188,,
12322,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628189,,
12323,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628190,,
12324,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628191,,
12325,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL626513,,
12326,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626514,,2046.0
12327,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626515,,2046.0
12328,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626516,,2046.0
12329,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626517,,2046.0
12330,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626518,,2046.0
12331,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626519,,2046.0
12332,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626520,,2046.0
12333,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626521,,2046.0
12334,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626522,,2046.0
12335,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626523,,2046.0
12336,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626524,,2046.0
12337,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626688,,2046.0
12338,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626689,,2046.0
12339,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626690,,2046.0
12340,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL626691,,2046.0
12341,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL627319,,2046.0
12342,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL624052,,2046.0
12343,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",,Rattus norvegicus,A,,BAO_0000218,8608,,10116.0,1,Intermediate,1,CHEMBL624053,,2046.0
12344,N,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,Rattus norvegicus,A,,BAO_0000218,8085,,10116.0,1,Intermediate,1,CHEMBL624054,,
12345,N,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,Rattus norvegicus,A,,BAO_0000218,8085,,10116.0,1,Intermediate,1,CHEMBL624055,,
12346,N,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,Rattus norvegicus,A,,BAO_0000218,8085,,10116.0,1,Intermediate,1,CHEMBL624056,,
12347,N,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,Rattus norvegicus,A,,BAO_0000218,8085,,10116.0,1,Intermediate,1,CHEMBL624057,,995.0
12348,N,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,Rattus norvegicus,A,,BAO_0000218,8085,,10116.0,1,Intermediate,1,CHEMBL622281,,995.0
12349,N,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,Rattus norvegicus,A,,BAO_0000218,8085,,10116.0,1,Intermediate,1,CHEMBL622282,,995.0
12350,N,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,Rattus norvegicus,A,,BAO_0000218,8085,,10116.0,1,Intermediate,1,CHEMBL622283,,995.0
12351,N,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,Rattus norvegicus,A,,BAO_0000218,8085,,10116.0,1,Intermediate,1,CHEMBL622284,,995.0
12352,N,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,Rattus norvegicus,A,,BAO_0000218,8085,,10116.0,1,Intermediate,1,CHEMBL622285,,995.0
12353,N,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,Rattus norvegicus,A,,BAO_0000218,8085,,10116.0,1,Intermediate,1,CHEMBL622286,,995.0
12354,U,Distribution coefficient (D %) between octanol and buffer of pH 7.4,,,P,,BAO_0000100,7657,,,0,Autocuration,1,CHEMBL622287,,
12355,N,Partition coefficient (logD7.4),,Mus musculus,A,,BAO_0000218,8935,,10090.0,1,Intermediate,1,CHEMBL622288,,
12356,N,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,Mus musculus,A,,BAO_0000218,13792,,10090.0,1,Intermediate,1,CHEMBL622289,,
12357,N,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,Mus musculus,A,,BAO_0000218,13792,,10090.0,1,Intermediate,1,CHEMBL622290,,955.0
12358,N,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,Mus musculus,A,,BAO_0000218,13792,,10090.0,1,Intermediate,1,CHEMBL622291,,
12359,N,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,Mus musculus,A,,BAO_0000218,13792,,10090.0,1,Intermediate,1,CHEMBL622292,,955.0
12360,N,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,Mus musculus,A,,BAO_0000218,13792,,10090.0,1,Intermediate,1,CHEMBL622293,,
12361,N,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,Mus musculus,A,,BAO_0000218,13792,,10090.0,1,Intermediate,1,CHEMBL622294,,955.0
12362,N,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,Mus musculus,A,,BAO_0000218,13792,,10090.0,1,Intermediate,1,CHEMBL622295,,
12363,N,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,Rattus norvegicus,A,,BAO_0000218,13792,,10116.0,1,Intermediate,1,CHEMBL622296,,955.0
12364,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL874409,,1969.0
12365,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL622297,,1969.0
12366,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL622298,,1969.0
12367,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL622299,,1969.0
12368,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL622300,,1969.0
12369,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL622301,,1969.0
12370,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL622302,,1969.0
12371,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL622303,,1969.0
12372,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL622304,,1969.0
12373,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL622305,,1969.0
12374,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL622306,,1969.0
12375,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL626864,,1969.0
12376,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL626865,,1969.0
12377,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL626866,,1969.0
12378,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL626867,,1969.0
12379,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL626868,,1969.0
12380,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL626869,,1969.0
12381,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL626870,,1969.0
12382,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL626871,,1969.0
12383,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL626872,,1969.0
12384,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL632185,,1969.0
12385,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,,Rattus norvegicus,A,,BAO_0000218,14103,,10116.0,1,Intermediate,1,CHEMBL632186,,1969.0
12386,U,Amount of acetic acid produced by the compound,,,A,,BAO_0000019,12904,,,0,Autocuration,1,CHEMBL629310,,
12387,U,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,,,A,,BAO_0000019,12904,,,0,Autocuration,1,CHEMBL629311,,
12388,N,Log of (Cbrain/Cblood) in rats,,Rattus norvegicus,A,,BAO_0000218,9663,,10116.0,1,Intermediate,1,CHEMBL629312,,
12389,U,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),,,A,,BAO_0000221,7652,,,0,Autocuration,1,CHEMBL629313,,
12390,U,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,A,,BAO_0000221,7652,,,0,Autocuration,1,CHEMBL629314,,
12391,U,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),,,A,,BAO_0000221,7652,,,0,Autocuration,1,CHEMBL629315,,
12392,U,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),,,B,,BAO_0000219,7652,,,0,Autocuration,1,CHEMBL629316,,
12393,U,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,A,,BAO_0000221,7652,,,0,Autocuration,1,CHEMBL629317,,
12394,U,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),,,A,,BAO_0000019,7652,,,0,Autocuration,1,CHEMBL629318,,
12395,U,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),,,A,,BAO_0000019,7652,,,0,Autocuration,1,CHEMBL877497,,
12396,U,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),,,A,,BAO_0000019,7652,,,0,Autocuration,1,CHEMBL629319,,
12397,U,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,A,,BAO_0000019,7652,,,0,Autocuration,1,CHEMBL629320,,
12398,U,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),,,A,,BAO_0000019,7652,,,0,Autocuration,1,CHEMBL629496,,
12399,U,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),,,A,,BAO_0000019,7652,,,0,Autocuration,1,CHEMBL629497,,
12400,U,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),,,A,,BAO_0000019,7652,,,0,Autocuration,1,CHEMBL629498,,
12401,U,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),,,A,,BAO_0000019,7652,,,0,Autocuration,1,CHEMBL629499,,
12402,U,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),,,A,,BAO_0000019,7652,,,0,Autocuration,1,CHEMBL629500,,
12403,U,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),,,A,,BAO_0000019,7652,,,0,Autocuration,1,CHEMBL629501,,
12404,U,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),,,A,,BAO_0000019,7652,,,0,Autocuration,1,CHEMBL629502,,
12405,U,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,,,F,,BAO_0000218,8267,In vivo,,0,Autocuration,1,CHEMBL629503,,
12406,N,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,,Canis lupus familiaris,A,,BAO_0000218,8267,,9615.0,1,Intermediate,1,CHEMBL629504,,
12407,U,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,,,A,,BAO_0000019,14479,,,0,Autocuration,1,CHEMBL629505,,
12408,U,Compound was evaluated for total body clearance,,,A,,BAO_0000019,17515,,,0,Autocuration,1,CHEMBL629506,,
12409,U,Compound was evaluated for volume of distribution at steady state,,,A,,BAO_0000019,17515,,,0,Autocuration,1,CHEMBL629507,,
12410,U,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,,,A,,BAO_0000019,8142,,,0,Autocuration,1,CHEMBL877498,,
12411,U,Percentage of the diamine which is monoprotonated at pH 7.4,,,A,,BAO_0000019,14849,,,0,Autocuration,1,CHEMBL629508,,
12412,U,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,,,A,,BAO_0000019,7653,,,0,Autocuration,1,CHEMBL629509,,
12413,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL629510,,178.0
12414,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL629511,,178.0
12415,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL629512,,178.0
12416,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL629513,,178.0
12417,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL629514,,178.0
12418,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL628447,,178.0
12419,N,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL628448,,178.0
12420,N,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL628449,,178.0
12421,N,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL631119,,178.0
12422,N,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL631120,,178.0
12423,N,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL631121,,178.0
12424,N,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL874458,,178.0
12425,N,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL631122,,178.0
12426,N,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL631123,,178.0
12427,N,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL631124,,178.0
12428,N,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL631125,,178.0
12429,N,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL631290,,178.0
12430,N,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL631291,,178.0
12431,N,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL631292,,178.0
12432,N,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL631293,,178.0
12433,N,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL631294,,178.0
12434,N,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL631295,,178.0
12435,N,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL631296,,178.0
12436,N,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,Rattus norvegicus,A,,BAO_0000218,8631,,10116.0,1,Intermediate,1,CHEMBL631297,,178.0
12437,U,Maximum biodistribution (Bmax) was determined.,,,A,,BAO_0000218,10263,,,0,Autocuration,1,CHEMBL631298,,
12438,N,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,,Mus musculus,A,,BAO_0000218,12364,,10090.0,1,Intermediate,1,CHEMBL631299,,
12439,N,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,,Mus musculus,A,,BAO_0000218,12364,,10090.0,1,Intermediate,1,CHEMBL631300,,
12440,N,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,,Mus musculus,A,,BAO_0000218,12364,,10090.0,1,Intermediate,1,CHEMBL631301,,
12441,N,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,,Mus musculus,A,,BAO_0000218,12364,,10090.0,1,Intermediate,1,CHEMBL630291,,
12442,U,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL630292,,
12443,U,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL630293,,
12444,U,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL630294,,
12445,U,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL630295,,
12446,U,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL630296,,
12447,U,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL626782,,
12448,U,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL626783,,
12449,U,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL626784,,
12450,U,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL626785,,
12451,U,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL626786,,
12452,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL626787,,
12453,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL626788,,
12454,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL625927,,
12455,N,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL625928,,178.0
12456,N,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL625929,,178.0
12457,N,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL625930,,178.0
12458,N,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL625931,,178.0
12459,N,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627230,,178.0
12460,N,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627231,,178.0
12461,N,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627232,,178.0
12462,N,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627233,,178.0
12463,N,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL875470,,178.0
12464,N,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627234,,178.0
12465,N,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627235,,178.0
12466,N,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627236,,178.0
12467,N,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627237,,178.0
12468,N,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627238,,178.0
12469,N,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627239,,178.0
12470,N,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627240,,178.0
12471,N,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627241,,178.0
12472,N,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627242,,178.0
12473,N,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627243,,178.0
12474,N,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627244,,178.0
12475,N,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627245,,178.0
12476,N,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627246,,178.0
12477,N,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627247,,178.0
12478,N,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627248,,178.0
12479,N,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627249,,178.0
12480,N,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL625569,,178.0
12481,N,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL625570,,178.0
12482,N,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL625571,,178.0
12483,N,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL625572,,178.0
12484,N,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL625573,,178.0
12485,N,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL625574,,178.0
12486,N,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL626245,,178.0
12487,N,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL626246,,178.0
12488,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL626247,,
12489,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL626248,,
12490,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL626249,,
12491,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL626420,,
12492,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL626421,,
12493,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL626422,,
12494,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL626423,,
12495,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL626424,,
12496,N,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,,Canis lupus familiaris,A,,BAO_0000218,12023,,9615.0,1,Intermediate,1,CHEMBL626425,,
12497,N,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,,Rattus norvegicus,A,,BAO_0000218,12023,,10116.0,1,Intermediate,1,CHEMBL875476,,
12498,N,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,,Macaca fascicularis,A,,BAO_0000218,12023,,9541.0,1,Intermediate,1,CHEMBL626426,,
12499,U,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,,,P,,BAO_0000100,10580,,,0,Autocuration,1,CHEMBL626427,,
12500,U,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,,,P,,BAO_0000100,10580,,,0,Autocuration,1,CHEMBL626428,,
12501,U,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,,,A,,BAO_0000019,16032,,,0,Autocuration,1,CHEMBL626429,,
12502,U,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,,,A,,BAO_0000019,16032,,,0,Autocuration,1,CHEMBL625025,,1088.0
12503,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL625026,,178.0
12504,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL625027,,178.0
12505,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL874410,,178.0
12506,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL625028,,178.0
12507,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL625029,,178.0
12508,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL625030,,178.0
12509,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL625031,,178.0
12510,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL625032,,178.0
12511,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL625033,,178.0
12512,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL625034,,178.0
12513,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624872,,948.0
12514,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624873,,948.0
12515,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624874,,948.0
12516,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624875,,948.0
12517,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624876,,948.0
12518,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624877,,948.0
12519,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624878,,948.0
12520,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624879,,948.0
12521,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624880,,948.0
12522,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624881,,948.0
12523,N,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624882,,948.0
12524,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624883,,2113.0
12525,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624884,,2113.0
12526,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624885,,2113.0
12527,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624886,,2113.0
12528,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624887,,2113.0
12529,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624888,,2113.0
12530,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624889,,2113.0
12531,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624890,,2113.0
12532,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL621964,,2113.0
12533,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL621965,,2113.0
12534,N,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL621966,,2107.0
12535,N,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL621967,,2107.0
12536,N,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL622164,,2107.0
12537,U,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),,,A,,BAO_0000019,7653,,,0,Autocuration,1,CHEMBL623097,,
12538,U,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),,,A,,BAO_0000019,7653,,,0,Autocuration,1,CHEMBL623098,,
12539,U,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,,,A,,BAO_0000019,7653,,,0,Autocuration,1,CHEMBL623099,,
12540,U,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,,,A,,BAO_0000019,7653,,,0,Autocuration,1,CHEMBL623100,,
12541,N,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",,Rattus norvegicus,A,,BAO_0000218,9104,,10116.0,1,Intermediate,1,CHEMBL628673,,
12542,N,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",,Rattus norvegicus,A,,BAO_0000218,9104,,10116.0,1,Intermediate,1,CHEMBL628674,,
12543,N,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",,Rattus norvegicus,A,,BAO_0000218,9104,,10116.0,1,Intermediate,1,CHEMBL628675,,
12544,N,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",,Rattus norvegicus,A,,BAO_0000218,9104,,10116.0,1,Intermediate,1,CHEMBL627644,,
12545,N,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",,Rattus norvegicus,A,,BAO_0000218,9104,,10116.0,1,Intermediate,1,CHEMBL627645,,
12546,N,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",,Rattus norvegicus,A,,BAO_0000218,9104,,10116.0,1,Intermediate,1,CHEMBL627646,,
12547,N,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",,Rattus norvegicus,A,,BAO_0000218,9104,,10116.0,1,Intermediate,1,CHEMBL627647,,
12548,N,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",,Rattus norvegicus,A,,BAO_0000218,9104,,10116.0,1,Intermediate,1,CHEMBL627648,,
12549,N,Free level in rat plasma,,Rattus norvegicus,A,,BAO_0000218,12902,,10116.0,1,Intermediate,1,CHEMBL627649,,
12550,U,Level reaching in blood plasma of rat or human was determined,,,A,,BAO_0000019,6614,,,0,Autocuration,1,CHEMBL628313,,
12551,N,Log (Cbrain/Cblood) in rats,,Rattus norvegicus,A,,BAO_0000218,9663,,10116.0,1,Intermediate,1,CHEMBL628314,,
12552,U,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,,,A,,BAO_0000019,17658,,,0,Autocuration,1,CHEMBL628315,,
12553,U,Mean percentage of compound transport through membrane; expressed as membrane transport,,,A,,BAO_0000019,17658,,,0,Autocuration,1,CHEMBL628316,,
12554,U,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,,,A,,BAO_0000218,14314,,,0,Autocuration,1,CHEMBL628317,,
12555,U,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,,,A,,BAO_0000019,7385,,,0,Autocuration,1,CHEMBL628473,,
12556,U,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",,,A,,BAO_0000019,7385,,,0,Autocuration,1,CHEMBL628474,,
12557,U,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,,,A,,BAO_0000019,7385,,,0,Autocuration,1,CHEMBL628475,,
12558,U,Net water uptake by a carrier mediated transport (%cm) mechanism,,,A,,BAO_0000019,1329,,,0,Autocuration,1,CHEMBL628476,,
12559,U,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,Simiiformes,A,,BAO_0000218,12187,,314293.0,0,Autocuration,1,CHEMBL628477,,
12560,N,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,Mustela putorius furo,A,,BAO_0000218,12187,,9669.0,1,Intermediate,1,CHEMBL628478,,
12561,N,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,Mustela putorius furo,A,,BAO_0000218,12187,,9669.0,1,Intermediate,1,CHEMBL628479,,
12562,U,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,Simiiformes,A,,BAO_0000218,12187,,314293.0,0,Autocuration,1,CHEMBL628480,,
12563,U,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",,Simiiformes,A,,BAO_0000218,12187,,314293.0,0,Autocuration,1,CHEMBL628481,,
12564,N,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,12187,,10116.0,1,Intermediate,1,CHEMBL628482,,
12565,N,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,Rattus norvegicus,A,,BAO_0000218,12187,,10116.0,1,Intermediate,1,CHEMBL628483,,
12566,N,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,Rattus norvegicus,A,,BAO_0000218,9278,,10116.0,1,Intermediate,1,CHEMBL628484,,1969.0
12567,N,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,Rattus norvegicus,A,,BAO_0000218,9278,,10116.0,1,Intermediate,1,CHEMBL628485,,1969.0
12568,N,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",,Macaca fascicularis,A,,BAO_0000218,9278,,9541.0,1,Intermediate,1,CHEMBL628486,,1969.0
12569,N,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",,Homo sapiens,A,,BAO_0000218,9278,,9606.0,1,Intermediate,1,CHEMBL628487,,1969.0
12570,N,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,Rattus norvegicus,A,,BAO_0000218,9278,,10116.0,1,Intermediate,1,CHEMBL628488,,1969.0
12571,N,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,Rattus norvegicus,A,,BAO_0000218,9278,,10116.0,1,Intermediate,1,CHEMBL628489,,1969.0
12572,N,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,Rattus norvegicus,A,,BAO_0000218,9278,,10116.0,1,Intermediate,1,CHEMBL628490,,1969.0
12573,N,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,Macaca fascicularis,A,,BAO_0000218,12186,,9541.0,1,Intermediate,1,CHEMBL628491,,
12574,N,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,Macaca fascicularis,A,,BAO_0000218,12186,,9541.0,1,Intermediate,1,CHEMBL877507,,
12575,U,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,,A,,BAO_0000218,12186,,,0,Autocuration,1,CHEMBL628492,,
12576,U,% metabolized in monkey S-9 after 2 hours (10 ug/mL),,Simiiformes,A,,BAO_0000019,12041,,314293.0,0,Autocuration,1,CHEMBL628493,,
12577,U,% metabolized in monkey S-9 after 2 hours (1 ug/ml),,Simiiformes,A,,BAO_0000019,12041,,314293.0,0,Autocuration,1,CHEMBL628494,,
12578,U,% metabolized in monkey S-9 after 2 hours (10 ug/ml),,Simiiformes,A,,BAO_0000019,12041,,314293.0,0,Autocuration,1,CHEMBL628495,,
12579,N,Permeability in Caco-2 assay at 10E-6,,Homo sapiens,A,,BAO_0000218,6737,,9606.0,1,Intermediate,1,CHEMBL628496,,
12580,U,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,,A,,BAO_0000218,13758,,,0,Autocuration,1,CHEMBL628497,,955.0
12581,U,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,,A,,BAO_0000218,13758,,,0,Autocuration,1,CHEMBL628498,,955.0
12582,U,Plasma protein binding was determined,,,A,,BAO_0000019,5676,,,0,Autocuration,1,CHEMBL628499,,
12583,U,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL627656,,
12584,U,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL627657,,
12585,U,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL626808,,
12586,U,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL626809,,
12587,U,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL626810,,
12588,U,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL626811,,
12589,U,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL874465,,
12590,U,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL626812,,
12591,U,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL626813,,
12592,U,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,,,A,,BAO_0000218,14793,,,0,Autocuration,1,CHEMBL626814,,
12593,U,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,,,A,,BAO_0000019,14000,,,0,Autocuration,1,CHEMBL626815,,
12594,U,Partition coefficient (logP),,,A,,BAO_0000019,5948,,,0,Autocuration,1,CHEMBL628566,,
12595,U,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,P,,BAO_0000100,13824,,,0,Autocuration,1,CHEMBL628567,,
12596,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,10778,,,0,Autocuration,1,CHEMBL628568,,
12597,N,C max in dog,,Canis lupus familiaris,A,,BAO_0000218,17237,In vivo,9615.0,1,Intermediate,1,CHEMBL628569,,
12598,N,C max in guinea pig,,Cavia porcellus,A,,BAO_0000218,17237,In vivo,10141.0,1,Intermediate,1,CHEMBL628570,,
12599,U,C max value was evaluated,,,A,,BAO_0000218,2809,In vivo,,0,Autocuration,1,CHEMBL628571,,
12600,U,Cmax value after oral dose of 0.1 mg//kg,,,A,,BAO_0000218,11954,In vivo,,0,Autocuration,1,CHEMBL628572,,
12601,U,Cmax value after oral dose of 0.3 mg/kg,,,A,,BAO_0000218,11954,In vivo,,0,Autocuration,1,CHEMBL628573,,
12602,U,Cmax value after oral dose of 1 mg/kg,,,A,,BAO_0000218,11954,In vivo,,0,Autocuration,1,CHEMBL628574,,
12603,U,Cmax value after oral dose of 10 mg/kg,,,A,,BAO_0000218,11954,In vivo,,0,Autocuration,1,CHEMBL628575,,
12604,U,Cmax value after oral dose of 23.4 mg/kg,,,A,,BAO_0000218,11954,In vivo,,0,Autocuration,1,CHEMBL628576,,
12605,U,Cmax value after oral dose of 3 mg/kg,,,A,,BAO_0000218,11954,In vivo,,0,Autocuration,1,CHEMBL628577,,
12606,U,Cmax value after oral dose of 3.87 mg/kg,,,A,,BAO_0000218,11954,In vivo,,0,Autocuration,1,CHEMBL628578,,
12607,N,Cmax value in female Beagle dogs,,Canis lupus familiaris,A,,BAO_0000218,12768,In vivo,9615.0,1,Intermediate,1,CHEMBL874466,,
12608,N,Cmax value in male rats,,Rattus norvegicus,A,,BAO_0000218,12768,In vivo,10116.0,1,Intermediate,1,CHEMBL628579,,
12609,N,Cmax value in rat plasma when administered 20 mg/kg perorally,,Rattus norvegicus,A,,BAO_0000218,12780,In vivo,10116.0,1,Intermediate,1,CHEMBL628580,,1969.0
12610,N,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,Canis lupus familiaris,A,,BAO_0000218,15592,In vivo,9615.0,1,Intermediate,1,CHEMBL628581,,1969.0
12611,N,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,Canis lupus familiaris,A,,BAO_0000218,15592,In vivo,9615.0,1,Intermediate,1,CHEMBL628582,,1969.0
12612,N,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,,Canis lupus familiaris,A,,BAO_0000218,17025,,9615.0,1,Intermediate,1,CHEMBL628583,,
12613,U,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,,Simiiformes,A,,BAO_0000218,17025,,314293.0,0,Autocuration,1,CHEMBL625782,,
12614,N,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,,Oryctolagus cuniculus,A,,BAO_0000218,17025,,9986.0,1,Intermediate,1,CHEMBL625783,,
12615,N,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,,Rattus norvegicus,A,,BAO_0000218,17025,,10116.0,1,Intermediate,1,CHEMBL625784,,
12616,N,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,,Macaca mulatta,A,,BAO_0000218,4236,,9544.0,1,Intermediate,1,CHEMBL625785,,1969.0
12617,N,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,,Rattus norvegicus,A,,BAO_0000218,15791,,10116.0,1,Intermediate,1,CHEMBL625786,,
12618,U,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,,,A,,BAO_0000019,11149,,,0,Autocuration,1,CHEMBL874467,,
12619,N,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,Canis lupus familiaris,A,,BAO_0000218,15592,,9615.0,1,Intermediate,1,CHEMBL625787,,
12620,N,cytotoxicity against HIV protease enzyme.,,Human immunodeficiency virus,A,,BAO_0000218,15778,,12721.0,1,Intermediate,1,CHEMBL625964,,
12621,N,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,,Mus musculus,A,,BAO_0000218,12745,,10090.0,1,Intermediate,1,CHEMBL625965,,
12622,N,Apparent clearance in mice after oral administration of 100 mg/kg of dose,,Mus musculus,A,,BAO_0000218,12745,,10090.0,1,Intermediate,1,CHEMBL625966,,
12623,N,The plasma clearance in dog.,,Canis lupus familiaris,A,,BAO_0000218,13941,In vivo,9615.0,1,Intermediate,1,CHEMBL625967,,1969.0
12624,N,The plasma clearance in rat.,,Rattus norvegicus,A,,BAO_0000218,13941,In vivo,10116.0,1,Intermediate,1,CHEMBL625968,,1969.0
12625,N,Clearance from plasma in male Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,16449,In vivo,10116.0,1,Intermediate,1,CHEMBL625969,,1969.0
12626,N,Clearance from plasma in male cynomolgus monkeys,,Macaca fascicularis,A,,BAO_0000218,16449,In vivo,9541.0,1,Intermediate,1,CHEMBL625970,,1969.0
12627,N,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",,Canis lupus familiaris,A,,BAO_0000218,14224,In vivo,9615.0,1,Intermediate,1,CHEMBL625971,,1969.0
12628,N,Clearance of compound in dog plasma,,Canis lupus familiaris,A,,BAO_0000218,14224,In vivo,9615.0,1,Intermediate,1,CHEMBL625972,,1969.0
12629,N,Clearance of compound in human plasma,,Homo sapiens,A,,BAO_0000218,14224,In vivo,9606.0,1,Intermediate,1,CHEMBL625973,,1969.0
12630,N,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,,Canis lupus familiaris,A,,BAO_0000218,14317,In vivo,9615.0,1,Intermediate,1,CHEMBL625974,,
12631,N,Clearance of compound when administered intravenously as an individual dose to a single dog.,,Canis lupus familiaris,A,,BAO_0000218,14317,In vivo,9615.0,1,Intermediate,1,CHEMBL625975,,
12632,N,"Clearance (10 mg/kg, intravenously) in dog plasma",,Canis lupus familiaris,A,,BAO_0000218,14224,In vivo,9615.0,1,Intermediate,1,CHEMBL625976,,1969.0
12633,N,Clearance value in dog,,Canis lupus familiaris,A,,BAO_0000218,17237,In vivo,9615.0,1,Intermediate,1,CHEMBL625977,,
12634,N,Clearance value in guinea pig,,Cavia porcellus,A,,BAO_0000218,17237,In vivo,10141.0,1,Intermediate,1,CHEMBL625978,,
12635,N,Clearance values in rats after iv administration.,,Rattus norvegicus,A,,BAO_0000218,14187,In vivo,10116.0,1,Intermediate,1,CHEMBL874468,,
12636,U,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,,,A,,BAO_0000218,4806,In vivo,,0,Autocuration,1,CHEMBL625421,,1969.0
12637,N,In vivo clearance (5 mg/kg) was determined in rabbits,,Oryctolagus cuniculus,A,,BAO_0000218,15025,In vivo,9986.0,1,Intermediate,1,CHEMBL625422,,
12638,N,Plasma Clearance rate was determined for the compound in rats,,Rattus norvegicus,A,,BAO_0000218,13197,In vivo,10116.0,1,Intermediate,1,CHEMBL625423,,
12639,U,Plasma Clearance rate was determined for the compound in squirrel monkeys,,Saimiri,A,,BAO_0000218,13197,In vivo,9520.0,0,Autocuration,1,CHEMBL625424,,
12640,N,Plasma clearance in rat,,Rattus norvegicus,A,,BAO_0000218,13960,In vivo,10116.0,1,Intermediate,1,CHEMBL625425,,
12641,U,Plasma clearance of the compound,,,A,,BAO_0000218,17820,In vivo,,0,Autocuration,1,CHEMBL625426,,
12642,N,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,,Cavia porcellus,A,,BAO_0000218,14706,In vivo,10141.0,1,Intermediate,1,CHEMBL625427,,
12643,N,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,,Cavia porcellus,A,,BAO_0000218,14706,In vivo,10141.0,1,Intermediate,1,CHEMBL625428,,
12644,U,Plasma clearance was determined,,,A,,BAO_0000218,6504,In vivo,,0,Autocuration,1,CHEMBL625429,,
12645,N,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,,Canis lupus familiaris,A,,BAO_0000218,14925,In vivo,9615.0,1,Intermediate,1,CHEMBL625430,,
12646,N,Plasma clearance rate was determined for the compound in rats,,Rattus norvegicus,A,,BAO_0000218,13197,In vivo,10116.0,1,Intermediate,1,CHEMBL625431,,
12647,U,Plasma clearance rate was determined for the compound in squirrel monkeys,,Saimiri,A,,BAO_0000218,13197,In vivo,9520.0,0,Autocuration,1,CHEMBL627307,,
12648,U,Slow clearance (CL) was determined,,,A,,BAO_0000218,3437,In vivo,,0,Autocuration,1,CHEMBL627308,,
12649,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL627309,,
12650,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL627310,,
12651,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL627311,,
12652,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL627312,,
12653,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL627313,,
12654,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL627314,,
12655,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL627315,,
12656,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL627316,,
12657,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL627317,,
12658,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL627318,,
12659,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL627999,,
12660,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628000,,
12661,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628001,,
12662,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL628002,,
12663,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL625610,,
12664,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL625611,,
12665,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL625612,,
12666,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL625613,,
12667,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL875479,,
12668,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL625614,,
12669,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL625615,,
12670,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,,A,,BAO_0000218,9196,,,0,Autocuration,1,CHEMBL626302,,
12671,N,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL626303,,178.0
12672,N,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,Rattus norvegicus,A,,BAO_0000218,8374,,10116.0,1,Intermediate,1,CHEMBL627420,,178.0
12673,N,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,,Rattus norvegicus,A,,BAO_0000218,13477,,10116.0,1,Intermediate,1,CHEMBL627421,,
12674,N,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,,Rattus norvegicus,A,,BAO_0000218,13477,,10116.0,1,Intermediate,1,CHEMBL625695,,
12675,N,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,,Rattus norvegicus,A,,BAO_0000218,13477,,10116.0,1,Intermediate,1,CHEMBL625696,,
12676,N,Distribution of compound in mice brain was measured after 1 hr,,Mus musculus,A,,BAO_0000218,10009,,10090.0,1,Intermediate,1,CHEMBL875606,,955.0
12677,N,Distribution of compound in mice brain was measured after 24 hr r,,Mus musculus,A,,BAO_0000218,10009,,10090.0,1,Intermediate,1,CHEMBL625697,,955.0
12678,N,Distribution of compound in mice brain was measured after 2 hr,,Mus musculus,A,,BAO_0000218,10009,,10090.0,1,Intermediate,1,CHEMBL625698,,955.0
12679,N,Distribution of compound in mice brain was measured after 3 hr,,Mus musculus,A,,BAO_0000218,10009,,10090.0,1,Intermediate,1,CHEMBL625699,,955.0
12680,N,Distribution of compound in mice brain was measured after 6 hr,,Mus musculus,A,,BAO_0000218,10009,,10090.0,1,Intermediate,1,CHEMBL625700,,955.0
12681,N,Distribution of compound in mice liver was measured after 1 hr,,Mus musculus,A,,BAO_0000218,10009,,10090.0,1,Intermediate,1,CHEMBL625701,,
12682,N,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,,Mus musculus,A,,BAO_0000218,10009,,10090.0,1,Intermediate,1,CHEMBL625702,,
12683,N,Distribution of compound in mice liver was measured after 2 hr,,Mus musculus,A,,BAO_0000218,10009,,10090.0,1,Intermediate,1,CHEMBL625703,,
12684,N,Distribution of compound in mice liver was measured after 3 hr,,Mus musculus,A,,BAO_0000218,10009,,10090.0,1,Intermediate,1,CHEMBL625704,,
12685,N,Distribution of compound in mice liver was measured after 6 hr,,Mus musculus,A,,BAO_0000218,10009,,10090.0,1,Intermediate,1,CHEMBL625705,,
12686,N,Distribution in dog adrenal medulla 30 min after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL625706,,1236.0
12687,N,Distribution in dog adrenal medulla 72 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL625707,,1236.0
12688,N,Distribution in female dog Ovary 24 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL625708,,
12689,N,Distribution in female dog Ovary 72 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL625709,,
12690,N,Distribution in female dog adipose 24 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624180,,
12691,N,Distribution in female dog adipose 72 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624181,,
12692,N,Distribution in female dog adrenal cortex 72 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624182,,1235.0
12693,N,Distribution in female dog adrenal cortex 72 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624183,,1235.0
12694,N,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624184,,2107.0
12695,N,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL877489,,2107.0
12696,N,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624185,,2107.0
12697,N,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624186,,2107.0
12698,N,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624187,,2107.0
12699,N,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624188,,2107.0
12700,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624189,,2048.0
12701,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624190,,2048.0
12702,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624191,,2048.0
12703,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624192,,2048.0
12704,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624193,,2048.0
12705,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624194,,2048.0
12706,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624891,,2048.0
12707,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624892,,2048.0
12708,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL624893,,2048.0
12709,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL627632,,2048.0
12710,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL627633,,
12711,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL627634,,
12712,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL627635,,
12713,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL627636,,
12714,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626816,,
12715,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626817,,
12716,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626818,,
12717,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626819,,
12718,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626820,,
12719,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626821,,
12720,N,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626822,,2046.0
12721,N,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626823,,2046.0
12722,N,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626824,,2046.0
12723,N,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626825,,2046.0
12724,N,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626826,,2046.0
12725,N,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626827,,2046.0
12726,N,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626828,,2046.0
12727,N,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626829,,2046.0
12728,N,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626830,,2046.0
12729,N,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL627150,,
12730,N,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL627151,,
12731,N,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL627152,,
12732,N,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL627153,,
12733,U,Rate of acetate production by the compound was determined,,,A,,BAO_0000019,12904,,,0,Autocuration,1,CHEMBL627154,,
12734,U,Rate of acetate production by the compound was determined; Not determined,,,A,,BAO_0000019,12904,,,0,Autocuration,1,CHEMBL627155,,
12735,U,Rate of hydrolysis of nitrocefin by compound was evaluated in water,,,A,,BAO_0000019,3730,,,0,Autocuration,1,CHEMBL627156,,
12736,U,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,,,A,,BAO_0000019,3627,,,0,Autocuration,1,CHEMBL627157,,
12737,N,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,Oryctolagus cuniculus,A,,BAO_0000218,13799,,9986.0,1,Intermediate,1,CHEMBL627158,,
12738,N,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,Oryctolagus cuniculus,A,,BAO_0000218,13799,,9986.0,1,Intermediate,1,CHEMBL627159,,1969.0
12739,N,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,Mus musculus,A,,BAO_0000218,13799,,10090.0,1,Intermediate,1,CHEMBL627160,,
12740,N,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,Rattus norvegicus,A,,BAO_0000218,13799,,10116.0,1,Intermediate,1,CHEMBL628540,,
12741,N,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,Rattus norvegicus,A,,BAO_0000218,13799,,10116.0,1,Intermediate,1,CHEMBL628541,,1969.0
12742,N,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,Rattus norvegicus,A,,BAO_0000218,13799,,10116.0,1,Intermediate,1,CHEMBL628542,,1969.0
12743,U,Solubility after at a pH 1.2,,,P,,BAO_0000100,6629,,,0,Autocuration,1,CHEMBL628543,,
12744,U,Solubility after at pH 1.2,,,P,,BAO_0000100,6629,,,0,Autocuration,1,CHEMBL628544,,
12745,U,Solubility after injection of water,,,P,,BAO_0000100,6629,,,0,Autocuration,1,CHEMBL628545,,
12746,U,Statistical significance of IC 50 values; Expressed as R value,,,A,,BAO_0000019,14000,,,0,Autocuration,1,CHEMBL628546,,
12747,U,Systemic availability with respect to methyldopa was determined,,,A,,BAO_0000019,8267,,,0,Autocuration,1,CHEMBL874455,,
12748,N,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,,Rattus norvegicus,A,,BAO_0000218,13799,,10116.0,1,Intermediate,1,CHEMBL628547,,
12749,N,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,,Rattus norvegicus,A,,BAO_0000218,13799,,10116.0,1,Intermediate,1,CHEMBL628548,,1969.0
12750,N,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL628549,,1988.0
12751,N,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL628550,,1988.0
12752,N,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL628551,,1988.0
12753,N,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL628552,,1088.0
12754,N,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL628553,,1088.0
12755,N,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL628554,,1088.0
12756,N,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL628555,,1088.0
12757,N,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL628556,,1088.0
12758,N,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL628557,,2113.0
12759,N,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL628558,,1988.0
12760,N,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL628559,,1988.0
12761,N,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL628560,,1988.0
12762,N,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL874456,,1088.0
12763,N,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL628561,,1988.0
12764,N,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL628562,,1988.0
12765,N,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL628563,,1088.0
12766,N,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL628564,,1088.0
12767,N,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL628565,,1088.0
12768,N,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL631248,,1088.0
12769,N,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL631249,,1088.0
12770,N,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL627214,,2113.0
12771,N,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL874591,,1988.0
12772,N,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL627215,,1988.0
12773,N,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL625471,,1988.0
12774,N,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL625472,,
12775,N,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL625473,,
12776,N,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,,Canis lupus familiaris,A,,BAO_0000218,13317,In vivo,9615.0,1,Intermediate,1,CHEMBL625474,,
12777,N,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,,Canis lupus familiaris,A,,BAO_0000218,15341,In vivo,9615.0,1,Intermediate,1,CHEMBL625475,,
12778,N,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,,Rattus norvegicus,A,,BAO_0000218,15341,In vivo,10116.0,1,Intermediate,1,CHEMBL625476,,
12779,N,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,,Rattus norvegicus,A,,BAO_0000218,15341,In vivo,10116.0,1,Intermediate,1,CHEMBL625477,,
12780,N,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,,Rattus norvegicus,A,,BAO_0000218,15341,In vivo,10116.0,1,Intermediate,1,CHEMBL625478,,
12781,N,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,,Rattus norvegicus,A,,BAO_0000218,12801,In vitro,10116.0,1,Intermediate,1,CHEMBL625479,,
12782,N,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,,Rattus norvegicus,A,,BAO_0000218,12801,In vitro,10116.0,1,Intermediate,1,CHEMBL625480,,
12783,N,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,,Rattus norvegicus,A,,BAO_0000218,14856,In vivo,10116.0,1,Intermediate,1,CHEMBL625481,,1969.0
12784,N,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,14062,In vivo,10116.0,1,Intermediate,1,CHEMBL625482,,
12785,N,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,14062,In vivo,10116.0,1,Intermediate,1,CHEMBL625483,,
12786,N,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,14062,In vivo,10116.0,1,Intermediate,1,CHEMBL625484,,
12787,N,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,14062,In vivo,10116.0,1,Intermediate,1,CHEMBL625485,,
12788,N,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,,Canis lupus familiaris,A,,BAO_0000218,14346,In vivo,9615.0,1,Intermediate,1,CHEMBL625486,,1969.0
12789,N,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,,Rattus norvegicus,A,,BAO_0000218,14346,In vivo,10116.0,1,Intermediate,1,CHEMBL625487,,1969.0
12790,N,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,,Rattus norvegicus,A,,BAO_0000218,14346,In vivo,10116.0,1,Intermediate,1,CHEMBL625488,,1969.0
12791,N,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,,Rattus norvegicus,A,,BAO_0000218,14346,In vivo,10116.0,1,Intermediate,1,CHEMBL625489,,1969.0
12792,N,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,,Rattus norvegicus,A,,BAO_0000218,14346,In vivo,10116.0,1,Intermediate,1,CHEMBL625490,,1969.0
12793,N,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,,Canis lupus familiaris,A,,BAO_0000218,14346,In vivo,9615.0,1,Intermediate,1,CHEMBL625491,,1969.0
12794,N,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,,Rattus norvegicus,A,,BAO_0000218,14346,In vivo,10116.0,1,Intermediate,1,CHEMBL625492,,1969.0
12795,N,plasma clearance in human,,Homo sapiens,A,,BAO_0000218,15711,In vivo,9606.0,1,Intermediate,1,CHEMBL625493,,1969.0
12796,N,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,Rattus norvegicus,A,,BAO_0000218,14886,In vivo,10116.0,1,Intermediate,1,CHEMBL625494,,
12797,N,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,Rattus norvegicus,A,,BAO_0000218,14886,In vivo,10116.0,1,Intermediate,1,CHEMBL625495,,
12798,N,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,Rattus norvegicus,A,,BAO_0000218,14886,In vivo,10116.0,1,Intermediate,1,CHEMBL625496,,
12799,U,1-Octanol/water partition coefficient measured at 7.4,,,P,,BAO_0000100,4115,,,0,Autocuration,1,CHEMBL625497,,
12800,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,13733,,,0,Autocuration,1,CHEMBL625498,,
12801,U,Partition coefficient (logP),,,A,,BAO_0000019,12102,,,0,Autocuration,1,CHEMBL625499,,
12802,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,12676,,,0,Autocuration,1,CHEMBL625500,,
12803,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,13733,,,0,Autocuration,1,CHEMBL625501,,
12804,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,13740,,,0,Autocuration,1,CHEMBL625502,,
12805,U,Calculated partition coefficient (clogP) (relative to BAY K 8644),,,P,,BAO_0000100,12766,,,0,Autocuration,1,CHEMBL625503,,
12806,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,2764,,,0,Autocuration,1,CHEMBL625504,,
12807,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,12355,,,0,Autocuration,1,CHEMBL625505,,
12808,U,Calculated partition coefficient of the compound,,,P,,BAO_0000100,11314,,,0,Autocuration,1,CHEMBL625506,,
12809,U,Partition coefficient (logP),,,A,,BAO_0000019,12706,,,0,Autocuration,1,CHEMBL625507,,
12810,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,12645,,,0,Autocuration,1,CHEMBL625508,,
12811,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,13668,,,0,Autocuration,1,CHEMBL625509,,
12812,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,12819,,,0,Autocuration,1,CHEMBL625510,,
12813,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,13668,,,0,Autocuration,1,CHEMBL883125,,
12814,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,13017,,,0,Autocuration,1,CHEMBL625511,,
12815,U,Partition coefficient of the compound,,,A,,BAO_0000019,2448,,,0,Autocuration,1,CHEMBL874650,,
12816,U,Partition coefficient of the compound,,,A,,BAO_0000019,11526,,,0,Autocuration,1,CHEMBL625512,,
12817,U,Partition coefficient of compound was determined,,,A,,BAO_0000019,12426,,,0,Autocuration,1,CHEMBL625513,,
12818,U,Partition coefficient was determined,,,A,,BAO_0000019,2448,,,0,Autocuration,1,CHEMBL625514,,
12819,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,12001,,,0,Autocuration,1,CHEMBL625515,,
12820,U,partition coefficient of compound was determined,,,P,,BAO_0000100,12426,,,0,Autocuration,1,CHEMBL625516,,
12821,N,The total body administered intravenously in dog,,Canis lupus familiaris,A,,BAO_0000218,13204,In vivo,9615.0,1,Intermediate,1,CHEMBL625517,,
12822,N,The total body administered intravenously in rats,,Rattus norvegicus,A,,BAO_0000218,13204,In vivo,10116.0,1,Intermediate,1,CHEMBL625518,,
12823,N,Time taken for the administration to female NIH mice weighing 25-30 g.,,Mus musculus,A,,BAO_0000218,13889,,10090.0,1,Intermediate,1,CHEMBL625519,,
12824,U,Time taken for the administration,,,A,,BAO_0000019,13889,,,0,Autocuration,1,CHEMBL625520,,
12825,N,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,,Canis lupus familiaris,A,,BAO_0000218,17025,In vivo,9615.0,1,Intermediate,1,CHEMBL874651,,
12826,U,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,,Simiiformes,A,,BAO_0000218,17025,In vivo,314293.0,0,Autocuration,1,CHEMBL625521,,
12827,N,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,,Oryctolagus cuniculus,A,,BAO_0000218,17025,In vivo,9986.0,1,Intermediate,1,CHEMBL623171,,
12828,N,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,,Rattus norvegicus,A,,BAO_0000218,17025,In vivo,10116.0,1,Intermediate,1,CHEMBL623853,,
12829,U,Plasma clearance for the compound was determined.,,,A,,BAO_0000019,15067,,,0,Autocuration,1,CHEMBL623854,,
12830,U,CLog P value of the compound,,,P,,BAO_0000100,3091,,,0,Autocuration,1,CHEMBL874405,,
12831,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,15592,,,0,Autocuration,1,CHEMBL623855,,
12832,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,14738,,,0,Autocuration,1,CHEMBL623856,,
12833,U,ClogP value of the compound; nd ='no data',,,P,,BAO_0000100,14738,,,0,Autocuration,1,CHEMBL623857,,
12834,U,ClogP value of the compound; nd ='not determined',,,P,,BAO_0000100,14738,,,0,Autocuration,1,CHEMBL623858,,
12835,U,CLog P was determined,,,P,,BAO_0000100,6076,,,0,Autocuration,1,CHEMBL623859,,
12836,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,17840,,,0,Autocuration,1,CHEMBL839829,,
12837,U,CLogP was calculated,,,A,,BAO_0000019,13589,,,0,Autocuration,1,CHEMBL623860,,
12838,U,CLogP value was determined,,,A,,BAO_0000019,17655,,,0,Autocuration,1,CHEMBL623861,,
12839,U,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,,,A,,BAO_0000019,5867,,,0,Autocuration,1,CHEMBL623862,,
12840,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,5867,,,0,Autocuration,1,CHEMBL874406,,
12841,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,10783,,,0,Autocuration,1,CHEMBL623863,,
12842,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,14849,,,0,Autocuration,1,CHEMBL624021,,
12843,N,Distribution in female dog adrenal medulla 24 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624022,,1236.0
12844,N,Distribution in female dog adrenal medulla 72 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624023,,1236.0
12845,N,Distribution in female dog bile 24 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624024,,
12846,N,Distribution in female dog bile 72 hr after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624025,,
12847,N,Distribution in female dog blood 24 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624026,,
12848,N,Distribution in female dog blood 72 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624027,,
12849,N,Distribution in female dog heart 24 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624028,,
12850,N,Distribution in female dog heart 72 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624029,,
12851,N,Distribution in female dog kidney 24 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624030,,
12852,N,Distribution in female dog kidney 72 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624031,,
12853,N,Distribution in female dog large intestine 24 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624032,,160.0
12854,N,Distribution in female dog large intestine 72 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL874407,,160.0
12855,N,Distribution in female dog liver 24 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624033,,
12856,N,Distribution in female dog liver 72 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624034,,
12857,N,Distribution in female dog lung 24 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624035,,
12858,N,Distribution in female dog lung 72 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624036,,
12859,N,Distribution in female dog muscle 24 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624037,,2385.0
12860,N,Distribution in female dog muscle 72 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624038,,2385.0
12861,N,Distribution in female dog pancreas 24 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624039,,
12862,N,Distribution in female dog pancreas 72 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624040,,
12863,N,Distribution in female dog small intestine 24 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624041,,160.0
12864,N,Distribution in female dog small intestine 72 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624042,,160.0
12865,N,Distribution in female dog spleen 24 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624043,,2106.0
12866,N,Distribution in female dog spleen 72 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624044,,2106.0
12867,N,Distribution in female dog stomach 24 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624045,,945.0
12868,N,Distribution in female dog stomach 72 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624046,,945.0
12869,N,Distribution in female dog thyroid 24 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624047,,2046.0
12870,N,Distribution in female dog thyroid 72 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624048,,2046.0
12871,N,Distribution in female dog urine 24 hours after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL874408,,1088.0
12872,N,Distribution in female dog urine 72 hr after administration.,,Canis lupus familiaris,A,,BAO_0000218,8170,,9615.0,1,Intermediate,1,CHEMBL624049,,1088.0
12873,U,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,,,A,,BAO_0000218,14283,,,0,Autocuration,1,CHEMBL624050,,1969.0
12874,U,Plasma concentration at 7 hr after intravenous dosing,,,A,,BAO_0000019,5623,,,0,Autocuration,1,CHEMBL624051,,
12875,N,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,,Rattus norvegicus,A,,BAO_0000218,13477,,10116.0,1,Intermediate,1,CHEMBL623278,,
12876,N,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,,Rattus norvegicus,A,,BAO_0000218,13477,,10116.0,1,Intermediate,1,CHEMBL623279,,
12877,N,Plasma concentration of 3 mg/kg iv after 1 hr in rats,,Rattus norvegicus,A,,BAO_0000218,13477,,10116.0,1,Intermediate,1,CHEMBL623280,,
12878,N,Plasma concentration of 3 mg/kg iv after 2 hr in rats,,Rattus norvegicus,A,,BAO_0000218,13477,,10116.0,1,Intermediate,1,CHEMBL623963,,
12879,N,Plasma concentration of 3 mg/kg iv after 4 hr in rats,,Rattus norvegicus,A,,BAO_0000218,13477,,10116.0,1,Intermediate,1,CHEMBL623964,,
12880,N,Plasma concentration of 3 mg/kg iv after 6 hr in rats,,Rattus norvegicus,A,,BAO_0000218,13477,,10116.0,1,Intermediate,1,CHEMBL623965,,
12881,N,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,,Rattus norvegicus,A,,BAO_0000218,13477,,10116.0,1,Intermediate,1,CHEMBL623966,,
12882,N,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,,Rattus norvegicus,A,,BAO_0000218,13477,,10116.0,1,Intermediate,1,CHEMBL874415,,
12883,N,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,,Rattus norvegicus,A,,BAO_0000218,13477,,10116.0,1,Intermediate,1,CHEMBL623967,,
12884,N,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,,Rattus norvegicus,A,,BAO_0000218,13477,,10116.0,1,Intermediate,1,CHEMBL623968,,
12885,N,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,,Rattus norvegicus,A,,BAO_0000218,13477,,10116.0,1,Intermediate,1,CHEMBL623969,,
12886,N,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,,Rattus norvegicus,A,,BAO_0000218,13477,,10116.0,1,Intermediate,1,CHEMBL628409,,
12887,N,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,,Rattus norvegicus,A,,BAO_0000218,13477,,10116.0,1,Intermediate,1,CHEMBL628410,,
12888,N,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,,Rattus norvegicus,A,,BAO_0000218,13477,,10116.0,1,Intermediate,1,CHEMBL628411,,
12889,N,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,,Rattus norvegicus,A,,BAO_0000218,13477,,10116.0,1,Intermediate,1,CHEMBL628412,,
12890,U,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,,,A,,BAO_0000019,12553,,,0,Autocuration,1,CHEMBL628413,,
12891,U,The concentration in plasmat; Not determined,,,A,,BAO_0000019,14548,,,0,Autocuration,1,CHEMBL628414,,1969.0
12892,N,Tissue level at 10 mg/kg/po in wistar rats in blood,,Rattus norvegicus,A,,BAO_0000218,14393,,10116.0,1,Intermediate,1,CHEMBL628415,,
12893,N,Tissue level at 10 mg/kg/po in wistar rats in brown fat,,Rattus norvegicus,A,,BAO_0000218,14393,,10116.0,1,Intermediate,1,CHEMBL628416,,
12894,N,Tissue level at 10 mg/kg/po in wistar rats in heart,,Rattus norvegicus,A,,BAO_0000218,14393,,10116.0,1,Intermediate,1,CHEMBL628417,,
12895,N,Tissue level at 10 mg/kg/po in wistar rats in liver,,Rattus norvegicus,A,,BAO_0000218,14393,,10116.0,1,Intermediate,1,CHEMBL874908,,2107.0
12896,N,Tissue level at 10 mg/kg/po in wistar rats in plasma,,Rattus norvegicus,A,,BAO_0000218,14393,,10116.0,1,Intermediate,1,CHEMBL628418,,
12897,N,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,,Rattus norvegicus,A,,BAO_0000218,14393,,10116.0,1,Intermediate,1,CHEMBL628419,,2385.0
12898,N,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,,Rattus norvegicus,A,,BAO_0000218,14393,,10116.0,1,Intermediate,1,CHEMBL628420,,
12899,U,Water solubility at 37 degree C.,,,A,,BAO_0000019,1629,,,0,Autocuration,1,CHEMBL628421,,
12900,U,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,,P,,BAO_0000100,8194,,,0,Autocuration,1,CHEMBL626726,,
12901,U,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,P,,BAO_0000100,8194,,,0,Autocuration,1,CHEMBL626727,,
12902,N,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626728,,178.0
12903,N,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626729,,178.0
12904,N,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626730,,178.0
12905,N,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626731,,178.0
12906,N,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626732,,178.0
12907,N,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626733,,948.0
12908,N,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626734,,948.0
12909,N,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626735,,948.0
12910,N,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL874909,,948.0
12911,N,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626736,,948.0
12912,N,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL626737,,2113.0
12913,N,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL630999,,2113.0
12914,N,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL631000,,2113.0
12915,N,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL631001,,2113.0
12916,N,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL631002,,2113.0
12917,N,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL631003,,2107.0
12918,N,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL631004,,2107.0
12919,N,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL631005,,2107.0
12920,N,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL631006,,2107.0
12921,N,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL631007,,2107.0
12922,N,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL631008,,2048.0
12923,N,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL631009,,2048.0
12924,N,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL631010,,2048.0
12925,N,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL631011,,2048.0
12926,N,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL631012,,2048.0
12927,N,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL630271,,2046.0
12928,N,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL630272,,2046.0
12929,N,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL630273,,2046.0
12930,N,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL630274,,2046.0
12931,N,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL630275,,2046.0
12932,N,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL875782,,
12933,N,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL630276,,
12934,N,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL630277,,
12935,N,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL630278,,
12936,N,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,,Rattus norvegicus,A,,BAO_0000218,8594,,10116.0,1,Intermediate,1,CHEMBL630279,,
12937,U,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,,,A,,BAO_0000019,8151,,,0,Autocuration,1,CHEMBL630280,,
12938,U,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,A,,BAO_0000019,8151,,,0,Autocuration,1,CHEMBL630281,,
12939,N,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL630282,,
12940,N,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL630283,,
12941,U,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),,,A,,BAO_0000019,5797,,,0,Autocuration,1,CHEMBL630284,,
12942,U,Alkylating activity was determined,,,A,,BAO_0000019,7849,,,0,Autocuration,1,CHEMBL630285,,
12943,U,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),,,A,,BAO_0000251,14220,,,0,Autocuration,1,CHEMBL630286,,
12944,N,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",,Oryctolagus cuniculus,A,,BAO_0000218,8650,,9986.0,1,Intermediate,1,CHEMBL630069,,
12945,N,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",,Oryctolagus cuniculus,A,,BAO_0000218,8650,,9986.0,1,Intermediate,1,CHEMBL630070,,
12946,N,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",,Oryctolagus cuniculus,A,,BAO_0000218,8650,,9986.0,1,Intermediate,1,CHEMBL630071,,
12947,N,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",,Oryctolagus cuniculus,A,,BAO_0000218,8650,,9986.0,1,Intermediate,1,CHEMBL630072,,
12948,N,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",,Oryctolagus cuniculus,A,,BAO_0000218,8650,,9986.0,1,Intermediate,1,CHEMBL875110,,
12949,N,Compound was tested for antidiuretic activity in rats,,Rattus norvegicus,A,,BAO_0000218,7116,,10116.0,1,Intermediate,1,CHEMBL630073,,
12950,U,Compound was tested for inactivation kinetic values,,,A,,BAO_0000019,14131,,,0,Autocuration,1,CHEMBL630074,,
12951,U,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,,,A,,BAO_0000218,7415,In vivo,,0,Autocuration,1,CHEMBL630075,,
12952,U,Dissociation rate calculated from the first-order equation using the t1/2 value,,,A,,BAO_0000019,13178,,,0,Autocuration,1,CHEMBL630076,,
12953,U,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,,,P,,BAO_0000100,8815,,,0,Autocuration,1,CHEMBL630077,,
12954,U,Aqueous solubility was measured,,,P,,BAO_0000100,1450,,,0,Autocuration,1,CHEMBL630078,,
12955,U,Aqueous solubility was measured at a pH 4,,,P,,BAO_0000100,1450,,,0,Autocuration,1,CHEMBL630079,,
12956,U,Aqueous solubility (pH 7),,,P,,BAO_0000100,1450,,,0,Autocuration,1,CHEMBL630080,,
12957,U,Aqueous solubility was measured at a pH 9,,,P,,BAO_0000100,1450,,,0,Autocuration,1,CHEMBL630081,,
12958,U,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",,,A,,BAO_0000019,12711,,,0,Autocuration,1,CHEMBL630082,,
12959,U,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,,A,,BAO_0000019,12711,,,0,Autocuration,1,CHEMBL630083,,
12960,U,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,,A,,BAO_0000019,12711,,,0,Autocuration,1,CHEMBL630084,,
12961,U,Aqueous solubility of the compound,,,P,,BAO_0000100,15032,,,0,Autocuration,1,CHEMBL629198,,
12962,U,Aqueous solubility at 37 degree Celsius at pH 7.38,,,P,,BAO_0000100,9964,,,0,Autocuration,1,CHEMBL629199,,
12963,U,Aqueous solubility in pH 7.4 phosphate buffer,,,P,,BAO_0000100,14962,,,0,Autocuration,1,CHEMBL629200,,
12964,N,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,,Canis lupus familiaris,A,,BAO_0000218,12487,,9615.0,1,Intermediate,1,CHEMBL629201,,
12965,N,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,,Canis lupus familiaris,A,,BAO_0000218,12487,,9615.0,1,Intermediate,1,CHEMBL629202,,
12966,N,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,,Homo sapiens,A,,BAO_0000218,10026,,9606.0,1,Intermediate,1,CHEMBL875111,,
12967,N,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,,Homo sapiens,A,,BAO_0000218,10026,,9606.0,1,Intermediate,1,CHEMBL629203,,
12968,N,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,,Homo sapiens,A,,BAO_0000218,10026,,9606.0,1,Intermediate,1,CHEMBL629204,,
12969,N,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,,Homo sapiens,A,,BAO_0000218,10026,,9606.0,1,Intermediate,1,CHEMBL629205,,
12970,N,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,,Homo sapiens,A,,BAO_0000218,10026,,9606.0,1,Intermediate,1,CHEMBL629206,,
12971,U,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,,,A,,BAO_0000019,10026,,,0,Autocuration,1,CHEMBL631185,,
12972,N,Compound was evaluated for the average bile flow rat in rats,,Rattus norvegicus,A,,BAO_0000218,7415,,10116.0,1,Intermediate,1,CHEMBL631186,,
12973,N,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,Oryctolagus cuniculus,A,,BAO_0000218,17025,,9986.0,1,Intermediate,1,CHEMBL631187,,
12974,N,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,Oryctolagus cuniculus,A,,BAO_0000218,17025,,9986.0,1,Intermediate,1,CHEMBL631188,,
12975,U,Average half life period was determined,,,A,,BAO_0000019,10184,,,0,Autocuration,1,CHEMBL876419,,
12976,U,Average half life period was determined,,,A,,BAO_0000019,10184,,,0,Autocuration,1,CHEMBL631189,,
12977,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL631190,,
12978,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL631191,,
12979,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL631192,,
12980,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL632400,,
12981,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL630564,,
12982,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL630565,,
12983,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL630566,,
12984,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL631229,,
12985,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL631230,,
12986,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,6030,,,0,Autocuration,1,CHEMBL876428,,
12987,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,6147,,,0,Autocuration,1,CHEMBL631231,,
12988,U,Calculated partition coefficient (clogP) (MacLogP),,,P,,BAO_0000100,14556,,,0,Autocuration,1,CHEMBL631232,,
12989,U,Hydrophilicity was determined,,,A,,BAO_0000019,768,,,0,Autocuration,1,CHEMBL631233,,
12990,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,14452,,,0,Autocuration,1,CHEMBL631234,,
12991,U,Increased absorption was determined,,,A,,BAO_0000019,5237,,,0,Autocuration,1,CHEMBL883126,,
12992,U,Lipophilicity value was evaluated,,,P,,BAO_0000100,14378,,,0,Autocuration,1,CHEMBL631235,,
12993,U,Log P value of the compound.,,,P,,BAO_0000100,14418,,,0,Autocuration,1,CHEMBL631236,,
12994,U,Partition coefficient of compound was determined,,,A,,BAO_0000019,5249,,,0,Autocuration,1,CHEMBL631237,,
12995,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,14621,,,0,Autocuration,1,CHEMBL631238,,
12996,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,12542,,,0,Autocuration,1,CHEMBL876429,,
12997,U,Partition coefficient was measured by medchem software; Not calculated,,,A,,BAO_0000019,12542,,,0,Autocuration,1,CHEMBL631414,,
12998,U,Partition coefficient was measured by octanol-water using standard shake-flask method,,,P,,BAO_0000100,12542,,,0,Autocuration,1,CHEMBL631415,,
12999,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,15462,,,0,Autocuration,1,CHEMBL631416,,
13000,U,Partition coefficient (logP),,,A,,BAO_0000019,14884,,,0,Autocuration,1,CHEMBL631417,,
13001,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,16526,,,0,Autocuration,1,CHEMBL631418,,
13002,U,The Octanol/Water partition coefficient CLogP,,,P,,BAO_0000100,13693,,,0,Autocuration,1,CHEMBL631419,,
13003,U,The pharmacokinetic parameter C Log p was reported,,,A,,BAO_0000019,13693,,,0,Autocuration,1,CHEMBL631420,,
13004,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,13779,,,0,Autocuration,1,CHEMBL631421,,
13005,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,14772,,,0,Autocuration,1,CHEMBL631422,,
13006,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,14393,,,0,Autocuration,1,CHEMBL631423,,
13007,N,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,14793,In vivo,10116.0,1,Intermediate,1,CHEMBL876430,,1969.0
13008,N,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,14793,In vivo,10116.0,1,Intermediate,1,CHEMBL631424,,1969.0
13009,N,Compound was administered intravenously in dog to evaluate plasma clearance values,,Canis lupus familiaris,A,,BAO_0000218,13744,In vivo,9615.0,1,Intermediate,1,CHEMBL631425,,1969.0
13010,U,Compound was administered intravenously in monkey to evaluate plasma clearance values,,Simiiformes,A,,BAO_0000218,13744,In vivo,314293.0,0,Autocuration,1,CHEMBL631426,,1969.0
13011,N,Compound was administered intravenously in mouse to evaluate plasma clearance values,,Mus musculus,A,,BAO_0000218,13744,In vivo,10090.0,1,Intermediate,1,CHEMBL631427,,1969.0
13012,N,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,,Canis lupus familiaris,A,,BAO_0000218,13207,In vivo,9615.0,1,Intermediate,1,CHEMBL631428,,1969.0
13013,N,Intrinsic clearance in Rhesus liver microsome,,Macaca mulatta,A,,BAO_0000218,5669,In vitro,9544.0,1,Intermediate,1,CHEMBL631429,,2107.0
13014,N,Intrinsic clearance in dog liver microsome,,Canis lupus familiaris,A,,BAO_0000218,5669,In vitro,9615.0,1,Intermediate,1,CHEMBL631430,,2107.0
13015,N,Intrinsic clearance in rat liver microsome,,Rattus norvegicus,A,,BAO_0000218,5669,In vitro,10116.0,1,Intermediate,1,CHEMBL631431,,2107.0
13016,N,Low plasma clearance was calculated in rhesus monkey,,Macaca mulatta,A,,BAO_0000218,4853,In vivo,9544.0,1,Intermediate,1,CHEMBL631432,,1969.0
13017,N,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,Canis lupus familiaris,A,,BAO_0000218,16452,In vivo,9615.0,1,Intermediate,1,CHEMBL631433,,
13018,U,Plasma clearance after intravenous dose of 0.3 mg/kg,,,A,,BAO_0000218,11954,In vivo,,0,Autocuration,1,CHEMBL631434,,
13019,U,Plasma clearance after intravenous dose of 1 mg/kg,,,A,,BAO_0000218,11954,In vivo,,0,Autocuration,1,CHEMBL631435,,
13020,U,Plasma clearance after intravenous dose of 3 mg/kg,,,A,,BAO_0000218,11954,In vivo,,0,Autocuration,1,CHEMBL631436,,
13021,U,Plasma clearance after intravenous dose of 3.87 mg/kg,,,A,,BAO_0000218,11954,In vivo,,0,Autocuration,1,CHEMBL631437,,
13022,N,Plasma clearance after peroral administration at 10 mpk in Rat,,Rattus norvegicus,A,,BAO_0000218,5669,In vivo,10116.0,1,Intermediate,1,CHEMBL631438,,
13023,N,Plasma clearance after peroral administration at 10 mpk in Rhesus,,Macaca mulatta,A,,BAO_0000218,5669,In vivo,9544.0,1,Intermediate,1,CHEMBL876431,,
13024,N,Plasma clearance after peroral administration at 10 mpk in dog,,Canis lupus familiaris,A,,BAO_0000218,5669,In vivo,9615.0,1,Intermediate,1,CHEMBL631439,,
13025,N,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,,Rattus norvegicus,A,,BAO_0000218,13662,In vivo,10116.0,1,Intermediate,1,CHEMBL631440,,
13026,U,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),,,A,,BAO_0000019,8272,,,0,Autocuration,1,CHEMBL631441,,
13027,U,Critical Micellar concentration was determined,,,A,,BAO_0000019,13410,,,0,Autocuration,1,CHEMBL631442,,
13028,U,Critical Micellar concentration of the compound. was determined,,,A,,BAO_0000019,13410,,,0,Autocuration,1,CHEMBL626525,,
13029,U,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,,,A,,BAO_0000019,12628,,,0,Autocuration,1,CHEMBL627168,,
13030,U,Critical micellar concentration was measured in water by the dye solubilization method,,,A,,BAO_0000019,9675,,,0,Autocuration,1,CHEMBL875618,,
13031,U,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,,,B,,BAO_0000019,12628,,,0,Autocuration,1,CHEMBL626612,,
13032,U,CMR value (relative to BAY K 8644),,,A,,BAO_0000019,12766,,,0,Autocuration,1,CHEMBL626613,,
13033,U,Carbamoylating activity was determined,,,A,,BAO_0000019,7849,,,0,Autocuration,1,CHEMBL626614,,
13034,U,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,,Simiiformes,A,,BAO_0000218,12187,,314293.0,0,Autocuration,1,CHEMBL626615,,
13035,U,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,,,A,,BAO_0000019,2040,,,0,Autocuration,1,CHEMBL626616,,
13036,U,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,,,A,,BAO_0000019,2040,,,0,Autocuration,1,CHEMBL626617,,
13037,N,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,,Canis lupus familiaris,A,,BAO_0000218,14180,In vivo,9615.0,1,Intermediate,1,CHEMBL626618,,1969.0
13038,N,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,,Rattus norvegicus,A,,BAO_0000218,14180,In vivo,10116.0,1,Intermediate,1,CHEMBL626619,,1969.0
13039,N,"Clearance rate at 0.46 mg/kg, iv, in dogs",,Canis lupus familiaris,A,,BAO_0000218,14474,In vivo,9615.0,1,Intermediate,1,CHEMBL626620,,
13040,N,"Clearance rate at 5.5 mg/kg, iv, in rat",,Rattus norvegicus,A,,BAO_0000218,14474,In vivo,10116.0,1,Intermediate,1,CHEMBL626621,,
13041,N,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,Macaca fascicularis,A,,BAO_0000218,14548,In vivo,9541.0,1,Intermediate,1,CHEMBL626622,,
13042,N,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,Macaca fascicularis,A,,BAO_0000218,14548,In vivo,9541.0,1,Intermediate,1,CHEMBL626623,,
13043,N,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,Canis lupus familiaris,A,,BAO_0000218,14548,In vivo,9615.0,1,Intermediate,1,CHEMBL626624,,
13044,N,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,Rattus norvegicus,A,,BAO_0000218,14548,In vivo,10116.0,1,Intermediate,1,CHEMBL626625,,
13045,N,Clearance rate constant using isolated perfused rat liver (IPRL) assay,,Rattus norvegicus,A,,BAO_0000218,6125,Ex vivo,10116.0,1,Intermediate,1,CHEMBL626626,,2107.0
13046,U,Tested for the total clearance of the compound,,,A,,BAO_0000218,6874,In vivo,,0,Autocuration,1,CHEMBL626627,,
13047,N,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,,Canis lupus familiaris,A,,BAO_0000218,15343,In vivo,9615.0,1,Intermediate,1,CHEMBL626628,,
13048,U,Total body clearance was determined,,,A,,BAO_0000218,6236,In vivo,,0,Autocuration,1,CHEMBL626629,,
13049,N,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL626630,,
13050,N,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL626631,,
13051,U,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,,P,,BAO_0000100,8194,,,0,Autocuration,1,CHEMBL626632,,
13052,U,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,P,,BAO_0000100,8194,,,0,Autocuration,1,CHEMBL626633,,
13053,U,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,,,P,,BAO_0000100,8194,,,0,Autocuration,1,CHEMBL626634,,
13054,U,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,,P,,BAO_0000100,8194,,,0,Autocuration,1,CHEMBL626635,,
13055,U,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,P,,BAO_0000100,8194,,,0,Autocuration,1,CHEMBL626636,,
13056,U,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,,P,,BAO_0000100,8194,,,0,Autocuration,1,CHEMBL626637,,
13057,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),,Pneumocystis carinii,A,,BAO_0000218,13273,,4754.0,1,Intermediate,1,CHEMBL626638,,
13058,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,,Pneumocystis carinii,A,,BAO_0000218,13273,,4754.0,1,Intermediate,1,CHEMBL626639,,
13059,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,,Pneumocystis carinii,A,,BAO_0000218,13273,,4754.0,1,Intermediate,1,CHEMBL626640,,
13060,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,,Pneumocystis carinii,A,,BAO_0000218,13273,,4754.0,1,Intermediate,1,CHEMBL626641,,
13061,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,,Pneumocystis carinii,A,,BAO_0000218,13273,,4754.0,1,Intermediate,1,CHEMBL627272,,
13062,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,,Pneumocystis carinii,A,,BAO_0000218,13273,,4754.0,1,Intermediate,1,CHEMBL627273,,
13063,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),,Pneumocystis carinii,A,,BAO_0000218,13273,,4754.0,1,Intermediate,1,CHEMBL627441,,
13064,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),,Pneumocystis carinii,A,,BAO_0000218,13273,,4754.0,1,Intermediate,1,CHEMBL628355,,
13065,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),,Pneumocystis carinii,A,,BAO_0000218,13273,,4754.0,1,Intermediate,1,CHEMBL628356,,
13066,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),,Pneumocystis carinii,A,,BAO_0000218,13273,,4754.0,1,Intermediate,1,CHEMBL628357,,
13067,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),,Pneumocystis carinii,A,,BAO_0000218,13273,,4754.0,1,Intermediate,1,CHEMBL628358,,
13068,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),,Pneumocystis carinii,A,,BAO_0000218,13273,,4754.0,1,Intermediate,1,CHEMBL622307,,
13069,U,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,,,A,,BAO_0000019,13118,,,0,Autocuration,1,CHEMBL622527,,
13070,U,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,,,A,,BAO_0000019,13118,,,0,Autocuration,1,CHEMBL622528,,
13071,U,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,,,A,,BAO_0000019,13118,,,0,Autocuration,1,CHEMBL622529,,
13072,U,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,,,A,,BAO_0000019,13118,,,0,Autocuration,1,CHEMBL622992,,
13073,U,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,,,A,,BAO_0000019,13118,,,0,Autocuration,1,CHEMBL622993,,
13074,U,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,,,A,,BAO_0000019,13118,,,0,Autocuration,1,CHEMBL622994,,
13075,N,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",,Rattus norvegicus,A,,BAO_0000218,10633,,10116.0,1,Intermediate,1,CHEMBL622995,,
13076,N,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",,Rattus norvegicus,A,,BAO_0000218,10633,,10116.0,1,Intermediate,1,CHEMBL622996,,
13077,N,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",,Rattus norvegicus,A,,BAO_0000218,10633,,10116.0,1,Intermediate,1,CHEMBL622997,,
13078,N,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",,Rattus norvegicus,A,,BAO_0000218,10633,,10116.0,1,Intermediate,1,CHEMBL622998,,
13079,U,Cp max following ip administration at 1 mg/kg,,,A,,BAO_0000218,5767,,,0,Autocuration,1,CHEMBL622999,,
13080,U,Maximum concentration in plasma was reported at 0.5 hour,,,A,,BAO_0000218,3302,In vivo,,0,Autocuration,1,CHEMBL623000,,1969.0
13081,U,Maximum concentration in plasma was reported at 2 hour,,,A,,BAO_0000218,3302,In vivo,,0,Autocuration,1,CHEMBL623001,,1969.0
13082,N,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,,Mus musculus,A,,BAO_0000218,12467,,10090.0,1,Intermediate,1,CHEMBL623002,,
13083,U,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),,,P,,BAO_0000100,11778,,,0,Autocuration,1,CHEMBL623003,,
13084,U,Steady state concentration was evaluated,,,A,,BAO_0000019,4321,,,0,Autocuration,1,CHEMBL623004,,
13085,U,Partition coefficient (logP),,,A,,BAO_0000019,14884,,,0,Autocuration,1,CHEMBL623005,,
13086,U,Partition coefficient (logD7.4),,,A,,BAO_0000019,15234,,,0,Autocuration,1,CHEMBL623006,,
13087,N,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL623007,,2107.0
13088,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL623008,,10000001.0
13089,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL876654,,2037.0
13090,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL623009,,
13091,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL623010,,
13092,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL623011,,948.0
13093,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL623012,,160.0
13094,U,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,,A,,BAO_0000019,8151,,,0,Autocuration,1,CHEMBL623013,,
13095,U,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,A,,BAO_0000019,8151,,,0,Autocuration,1,CHEMBL623014,,
13096,U,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,,,A,,BAO_0000019,8151,,,0,Autocuration,1,CHEMBL623015,,1088.0
13097,U,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,,A,,BAO_0000019,8151,,,0,Autocuration,1,CHEMBL623016,,1088.0
13098,U,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,,,A,,BAO_0000019,8151,,,0,Autocuration,1,CHEMBL624858,,1088.0
13099,N,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,,Rattus norvegicus,A,,BAO_0000218,8151,,10116.0,1,Intermediate,1,CHEMBL624859,,
13100,N,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,8151,,10116.0,1,Intermediate,1,CHEMBL624860,,
13101,N,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,Rattus norvegicus,A,,BAO_0000218,8151,,10116.0,1,Intermediate,1,CHEMBL624861,,
13102,N,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,Rattus norvegicus,A,,BAO_0000218,8151,,10116.0,1,Intermediate,1,CHEMBL624862,,
13103,N,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,,Rattus norvegicus,A,,BAO_0000218,8151,,10116.0,1,Intermediate,1,CHEMBL624863,,
13104,N,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,Rattus norvegicus,A,,BAO_0000218,8151,,10116.0,1,Intermediate,1,CHEMBL876655,,
13105,N,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624864,,
13106,N,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624865,,
13107,N,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624866,,
13108,N,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,,Canis lupus familiaris,F,,BAO_0000218,6996,,9615.0,1,Expert,1,CHEMBL624867,,
13109,N,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL624868,,
13110,N,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL628450,,
13111,N,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL628451,,
13112,N,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL628452,,
13113,N,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL628453,,
13114,N,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL628454,,
13115,N,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL628455,,
13116,N,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL628456,,
13117,N,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL628457,,
13118,N,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL877505,,
13119,N,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL628458,,
13120,N,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL628459,,
13121,N,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL628460,,
13122,N,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL628461,,
13123,U,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",,,B,,BAO_0000218,6996,,,0,Autocuration,1,CHEMBL628462,,
13124,N,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL628463,,
13125,N,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",,Rattus norvegicus,F,,BAO_0000218,6996,,10116.0,1,Expert,1,CHEMBL625666,,
13126,U,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,,B,,BAO_0000218,6996,,,0,Autocuration,1,CHEMBL625667,,
13127,N,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Expert,1,CHEMBL625668,,
13128,N,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL625669,,
13129,U,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,,,A,,BAO_0000019,7114,,,0,Autocuration,1,CHEMBL625670,,
13130,N,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,,Rattus norvegicus,A,,BAO_0000218,7114,,10116.0,1,Intermediate,1,CHEMBL625671,,
13131,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL625672,,
13132,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL625673,,
13133,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL625674,,
13134,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL625675,,
13135,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL627637,,
13136,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL627638,,
13137,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL627639,,
13138,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL627640,,
13139,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL627641,,
13140,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL627642,,
13141,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL877506,,
13142,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,Mus musculus,A,,BAO_0000218,8613,,10090.0,1,Intermediate,1,CHEMBL627275,,
13143,N,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",,Mustela putorius furo,A,,BAO_0000218,11219,,9669.0,1,Intermediate,1,CHEMBL627643,,
13144,N,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,Mustela putorius furo,A,,BAO_0000218,11219,,9669.0,1,Intermediate,1,CHEMBL631246,,
13145,N,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,Mustela putorius furo,A,,BAO_0000218,11219,,9669.0,1,Intermediate,1,CHEMBL631247,,
13146,N,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,Mustela putorius furo,A,,BAO_0000218,11219,,9669.0,1,Intermediate,1,CHEMBL629532,,
13147,N,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,,Mustela putorius furo,A,,BAO_0000218,11219,,9669.0,1,Intermediate,1,CHEMBL629533,,
13148,N,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,Mustela putorius furo,A,,BAO_0000218,11219,,9669.0,1,Intermediate,1,CHEMBL629534,,
13149,N,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,,Mustela putorius furo,A,,BAO_0000218,11219,,9669.0,1,Intermediate,1,CHEMBL629535,,
13150,U,Pharmacokinetic parameter :drug bound to plasma was reported,,,A,,BAO_0000019,14837,,,0,Autocuration,1,CHEMBL625932,,
13151,U,compound was evaluated for drug bound in plasma,,,A,,BAO_0000019,14837,,,0,Autocuration,1,CHEMBL625933,,
13152,N,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,,Rattus norvegicus,A,,BAO_0000218,15343,,10116.0,1,Intermediate,1,CHEMBL625934,,
13153,U,Bioavailability,,Eutheria,A,,BAO_0000218,13761,,9347.0,0,Autocuration,1,CHEMBL625935,,
13154,N,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,,Rattus norvegicus,A,,BAO_0000218,14810,,10116.0,1,Intermediate,1,CHEMBL625936,,
13155,N,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,,Rattus norvegicus,A,,BAO_0000218,14810,,10116.0,1,Intermediate,1,CHEMBL625937,,
13156,N,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,Canis lupus familiaris,A,,BAO_0000218,13249,,9615.0,1,Intermediate,1,CHEMBL625938,,
13157,N,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,,Rattus norvegicus,A,,BAO_0000218,9267,,10116.0,1,Intermediate,1,CHEMBL625939,,1970.0
13158,N,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,,Rattus norvegicus,A,,BAO_0000218,9267,,10116.0,1,Intermediate,1,CHEMBL625940,,1970.0
13159,N,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,,Rattus norvegicus,A,,BAO_0000218,9267,,10116.0,1,Intermediate,1,CHEMBL874464,,1970.0
13160,N,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,,Rattus norvegicus,A,,BAO_0000218,9267,,10116.0,1,Intermediate,1,CHEMBL625941,,1970.0
13161,N,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,,Rattus norvegicus,A,,BAO_0000218,9267,,10116.0,1,Intermediate,1,CHEMBL625942,,1970.0
13162,N,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,,Rattus norvegicus,A,,BAO_0000218,9267,,10116.0,1,Intermediate,1,CHEMBL625943,,1970.0
13163,N,In vitro protein binding in human serum at 5 ug/ml,,Homo sapiens,A,,BAO_0000218,15549,,9606.0,1,Intermediate,1,CHEMBL625944,,1977.0
13164,U,Serum protein binding ability was measured,,,A,,BAO_0000019,10929,,,0,Autocuration,1,CHEMBL625945,,
13165,U,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,,A,,BAO_0000019,15444,,,0,Autocuration,1,CHEMBL625946,,
13166,U,Oral bioavailability in dog,,Canis lupus familiaris,A,,BAO_0000218,12860,In vivo,9615.0,0,Autocuration,1,CHEMBL625947,,
13167,N,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,Rattus norvegicus,A,,BAO_0000218,12170,In vivo,10116.0,1,Intermediate,1,CHEMBL625948,,
13168,U,Absolute oral bioavailability at an iv dose of 14 mg/kg,,,A,,BAO_0000218,15173,In vivo,,0,Autocuration,1,CHEMBL625949,,
13169,U,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,,,A,,BAO_0000218,15173,In vivo,,0,Autocuration,1,CHEMBL625950,,
13170,U,Oral bioavailability (dose 15 mg/kg i.v.),,Eutheria,A,,BAO_0000218,15173,In vivo,9347.0,0,Autocuration,1,CHEMBL625951,,
13171,U,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,,,A,,BAO_0000218,15173,In vivo,,0,Autocuration,1,CHEMBL625952,,
13172,U,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,,,A,,BAO_0000218,15173,In vivo,,0,Autocuration,1,CHEMBL625953,,
13173,U,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,,,A,,BAO_0000218,15173,In vivo,,0,Autocuration,1,CHEMBL625954,,
13174,U,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,,,A,,BAO_0000218,15173,In vivo,,0,Autocuration,1,CHEMBL882959,,
13175,N,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,,Canis lupus familiaris,A,,BAO_0000218,11767,In vivo,9615.0,1,Intermediate,1,CHEMBL625955,,
13176,U,Bioavailability in ferret,,Mustela putorius furo,A,,BAO_0000218,11219,In vivo,9669.0,0,Autocuration,1,CHEMBL625956,,
13177,N,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,,Macaca fascicularis,A,,BAO_0000218,12186,In vivo,9541.0,1,Intermediate,1,CHEMBL625957,,
13178,N,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL625958,,
13179,N,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL625959,,
13180,N,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL626642,,
13181,N,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL631330,,
13182,N,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL631331,,
13183,N,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL631332,,
13184,N,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL631333,,
13185,N,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL632018,,
13186,N,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL632019,,
13187,N,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL632020,,
13188,N,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL632021,,
13189,N,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL632022,,
13190,N,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL632023,,
13191,N,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL632024,,
13192,N,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL874472,,
13193,N,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL632025,,
13194,N,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL632026,,
13195,N,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL632027,,
13196,N,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL632028,,
13197,N,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL626430,,
13198,N,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL626431,,
13199,N,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL626432,,
13200,N,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL626433,,
13201,N,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL626434,,
13202,N,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL627280,,
13203,N,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL627281,,
13204,N,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL627282,,
13205,U,Total body clearance was measured at given dose,,,A,,BAO_0000019,7199,,,0,Autocuration,1,CHEMBL627283,,
13206,U,Total body clearance was measured at given dose.,,,A,,BAO_0000218,7199,,,0,Autocuration,1,CHEMBL627284,,
13207,N,Metabolic clearance from the body in rat,,Rattus norvegicus,A,,BAO_0000218,7095,,10116.0,1,Intermediate,1,CHEMBL627285,,
13208,U,Renal clearance from the body,,,A,,BAO_0000218,7095,In vivo,,0,Autocuration,1,CHEMBL627286,,
13209,N,Renal clearance from the body in rat,,Rattus norvegicus,A,,BAO_0000218,7095,In vivo,10116.0,1,Intermediate,1,CHEMBL875477,,
13210,N,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,12528,In vivo,10116.0,1,Intermediate,1,CHEMBL627287,,
13211,N,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,,Canis lupus familiaris,A,,BAO_0000218,12528,In vivo,9615.0,1,Intermediate,1,CHEMBL627288,,
13212,N,Total clearance from the body in rat,,Rattus norvegicus,A,,BAO_0000218,7095,,10116.0,1,Intermediate,1,CHEMBL627289,,
13213,N,Clearance into cortex from rat plasma or PBS,,Rattus norvegicus,A,,BAO_0000218,14223,In vivo,10116.0,1,Intermediate,1,CHEMBL627290,,1969.0
13214,U,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,,,A,,BAO_0000218,13569,In vivo,,0,Autocuration,1,CHEMBL627291,,
13215,U,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,,,A,,BAO_0000218,13569,In vivo,,0,Autocuration,1,CHEMBL627292,,
13216,U,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,,,A,,BAO_0000218,13569,In vivo,,0,Autocuration,1,CHEMBL627293,,
13217,U,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,,A,,BAO_0000218,13569,In vivo,,0,Autocuration,1,CHEMBL627294,,
13218,U,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,,,A,,BAO_0000218,13569,In vivo,,0,Autocuration,1,CHEMBL875478,,
13219,U,Clearance was determined,,,A,,BAO_0000218,13979,In vivo,,0,Autocuration,1,CHEMBL627295,,
13220,N,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,,Mus musculus,A,,BAO_0000218,14315,In vivo,10090.0,1,Intermediate,1,CHEMBL627296,,
13221,N,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,,Oryctolagus cuniculus,A,,BAO_0000218,14315,In vivo,9986.0,1,Intermediate,1,CHEMBL626119,,
13222,N,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,,Rattus norvegicus,A,,BAO_0000218,14315,In vivo,10116.0,1,Intermediate,1,CHEMBL626120,,
13223,N,Clearance in rat after iv dose (100 ug/kg),,Rattus norvegicus,A,,BAO_0000218,12174,In vivo,10116.0,1,Intermediate,1,CHEMBL626121,,
13224,U,Clearance in guinea pig,,Cavia porcellus,A,,BAO_0000218,12797,In vivo,10141.0,0,Autocuration,1,CHEMBL626122,,
13225,N,Compound was evaluated for clearance in rat,,Rattus norvegicus,A,,BAO_0000218,12797,In vivo,10116.0,1,Intermediate,1,CHEMBL626123,,
13226,N,Compound was evaluated for the clearance in dog,,Canis lupus familiaris,A,,BAO_0000218,12797,In vivo,9615.0,1,Intermediate,1,CHEMBL623456,,
13227,N,Compound was evaluated for the clearance in rat,,Rattus norvegicus,A,,BAO_0000218,12797,In vivo,10116.0,1,Intermediate,1,CHEMBL623457,,
13228,N,Compound was tested in vivo for clearance after iv administration in the rat,,Rattus norvegicus,A,,BAO_0000218,11500,In vivo,10116.0,1,Intermediate,1,CHEMBL623458,,
13229,U,IV clearance determined at an iv dose of 14 mg/kg,,,A,,BAO_0000218,15173,In vivo,,0,Autocuration,1,CHEMBL623459,,
13230,U,IV clearance determined at an iv dose of 15.2 mg/kg,,,A,,BAO_0000218,15173,In vivo,,0,Autocuration,1,CHEMBL875484,,
13231,U,IV clearance determined at an iv dose of 15 mg/kg,,,A,,BAO_0000218,15173,In vivo,,0,Autocuration,1,CHEMBL623460,,
13232,U,IV clearance determined at an peroral dose of 30 mg/kg.,,,A,,BAO_0000218,15173,In vivo,,0,Autocuration,1,CHEMBL623461,,
13233,U,IV clearance determined at an peroral dose of 30.2 mg/kg.,,,A,,BAO_0000218,15173,In vivo,,0,Autocuration,1,CHEMBL623462,,
13234,U,IV clearance determined at an peroral dose of 30.3 mg/kg.,,,A,,BAO_0000218,15173,In vivo,,0,Autocuration,1,CHEMBL627386,,
13235,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL627387,,2113.0
13236,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL627388,,2107.0
13237,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL627389,,2048.0
13238,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL627390,,2385.0
13239,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL627391,,1969.0
13240,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL627392,,
13241,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL627393,,2106.0
13242,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL627394,,3126.0
13243,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL627395,,10000001.0
13244,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL875485,,2037.0
13245,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL627396,,
13246,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL627397,,
13247,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL627398,,948.0
13248,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL627399,,10000001.0
13249,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL627400,,2113.0
13250,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL627401,,2107.0
13251,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL627402,,2048.0
13252,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL627403,,2385.0
13253,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL627404,,1969.0
13254,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL623101,,
13255,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL877480,,2106.0
13256,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL623102,,3126.0
13257,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL623103,,10000001.0
13258,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL623104,,2037.0
13259,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL623105,,
13260,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL623106,,
13261,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL623107,,948.0
13262,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL623108,,160.0
13263,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL623109,,2113.0
13264,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL623110,,2107.0
13265,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL623111,,2048.0
13266,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL625060,,2385.0
13267,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL625061,,1969.0
13268,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL625062,,
13269,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL625063,,2106.0
13270,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL625064,,3126.0
13271,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL625065,,10000001.0
13272,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL625066,,2037.0
13273,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL625067,,
13274,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL625068,,
13275,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL622159,,948.0
13276,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL622160,,160.0
13277,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL622161,,2113.0
13278,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL622162,,2048.0
13279,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL622163,,2385.0
13280,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL622313,,1969.0
13281,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL622314,,
13282,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL622315,,2106.0
13283,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,,Rattus norvegicus,A,,BAO_0000218,14198,In vivo,10116.0,1,Intermediate,1,CHEMBL622316,,3126.0
13284,N,Normal diffusion coefficient in water for Escherichia coli,,Escherichia coli,A,,BAO_0000218,15599,,562.0,1,Intermediate,1,CHEMBL877486,,
13285,U,Average max percent decrease in RVR (renal vascular resistance) was determined,,,A,,BAO_0000019,8204,,,0,Autocuration,1,CHEMBL622317,,
13286,U,Average max percent decrease in RVR (renal vascular resistance) was determined.,,,A,,BAO_0000019,8204,,,0,Autocuration,1,CHEMBL622318,,
13287,U,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,,,A,,BAO_0000019,6154,,,0,Autocuration,1,CHEMBL622319,,
13288,U,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,,,A,,BAO_0000019,6154,,,0,Autocuration,1,CHEMBL622320,,
13289,U,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,,,A,,BAO_0000019,6154,,,0,Autocuration,1,CHEMBL622321,,
13290,U,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,,,A,,BAO_0000019,6154,,,0,Autocuration,1,CHEMBL622322,,
13291,U,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,,,A,,BAO_0000019,7114,,,0,Autocuration,1,CHEMBL622323,,
13292,N,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,,Rattus norvegicus,A,,BAO_0000218,7114,,10116.0,1,Intermediate,1,CHEMBL622324,,
13293,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL622325,,1088.0
13294,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL622326,,1088.0
13295,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL877487,,1088.0
13296,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL622327,,1088.0
13297,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL622328,,1088.0
13298,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL622329,,1088.0
13299,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL622330,,1088.0
13300,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL622331,,1088.0
13301,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL622332,,1088.0
13302,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL622333,,1088.0
13303,U,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,Simiiformes,A,,BAO_0000218,8133,,314293.0,0,Autocuration,1,CHEMBL627658,,1088.0
13304,U,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",,Simiiformes,A,,BAO_0000218,8133,,314293.0,0,Autocuration,1,CHEMBL630428,,1088.0
13305,U,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,Simiiformes,A,,BAO_0000218,8133,,314293.0,0,Autocuration,1,CHEMBL630429,,1088.0
13306,U,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",,Simiiformes,A,,BAO_0000218,8133,,314293.0,0,Autocuration,1,CHEMBL630430,,1088.0
13307,U,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",,Simiiformes,A,,BAO_0000218,8133,,314293.0,0,Autocuration,1,CHEMBL630431,,1088.0
13308,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL630432,,1088.0
13309,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL630433,,1088.0
13310,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL630434,,1088.0
13311,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL629372,,1088.0
13312,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL629553,,1088.0
13313,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL629554,,1088.0
13314,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL874447,,1088.0
13315,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL629555,,1088.0
13316,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL629556,,1088.0
13317,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL629557,,1088.0
13318,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL629558,,1088.0
13319,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL629559,,1088.0
13320,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL629560,,1088.0
13321,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL629561,,1088.0
13322,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL629562,,1088.0
13323,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL629563,,1088.0
13324,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL629564,,1088.0
13325,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL629565,,1088.0
13326,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL629566,,1088.0
13327,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL629567,,1088.0
13328,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL629568,,1088.0
13329,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL629569,,1088.0
13330,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL629570,,1088.0
13331,U,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,Simiiformes,A,,BAO_0000218,8133,,314293.0,0,Autocuration,1,CHEMBL629571,,1088.0
13332,U,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,Rattus norvegicus,A,,BAO_0000218,12170,In vivo,10116.0,0,Autocuration,1,CHEMBL629572,,
13333,U,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,Rattus norvegicus,A,,BAO_0000218,12170,In vivo,10116.0,0,Autocuration,1,CHEMBL629573,,
13334,U,Bioavailability (dose 20 mg/kg),,Eutheria,A,,BAO_0000218,4985,In vivo,9347.0,0,Autocuration,1,CHEMBL629574,,
13335,U,Bioavailability in dog,,Canis lupus familiaris,A,,BAO_0000218,15145,In vivo,9615.0,0,Autocuration,1,CHEMBL629575,,
13336,U,Bioavailability in rat (Sprague-Dawley) (male),,Rattus norvegicus,A,,BAO_0000218,14080,In vivo,10116.0,0,Autocuration,1,CHEMBL874448,,
13337,U,Bioavailability in monkey (dose 10 mg/kg i.d.),,Primates,A,,BAO_0000218,11219,In vivo,9443.0,0,Autocuration,1,CHEMBL629576,,
13338,U,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,15145,In vivo,10116.0,0,Autocuration,1,CHEMBL629577,,
13339,U,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,15145,In vivo,10116.0,0,Autocuration,1,CHEMBL629578,,
13340,U,Bioavailability in dog (dose 3.0 mg/kg p.o.),,Canis lupus familiaris,A,,BAO_0000218,1202,In vivo,9615.0,0,Autocuration,1,CHEMBL629579,,
13341,U,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,,Canis lupus familiaris,A,,BAO_0000218,1202,In vivo,9615.0,0,Autocuration,1,CHEMBL882958,,
13342,N,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,,Pan troglodytes,A,,BAO_0000218,1202,In vivo,9598.0,1,Intermediate,1,CHEMBL629580,,
13343,U,Bioavailability,,Eutheria,A,,BAO_0000218,4026,In vivo,9347.0,0,Autocuration,1,CHEMBL629581,,
13344,U,Bioavailability in squirrel monkey,,Saimiri,A,,BAO_0000218,1492,In vivo,9520.0,0,Autocuration,1,CHEMBL629582,,
13345,N,Bioavailability was evaluated in dog,,Canis lupus familiaris,A,,BAO_0000218,12793,In vivo,9615.0,1,Intermediate,1,CHEMBL628522,,
13346,N,Bioavailability was evaluated in hamster,,Cricetinae,A,,BAO_0000218,12793,In vivo,10026.0,1,Intermediate,1,CHEMBL625432,,
13347,U,Bioavailability in rat,,Rattus norvegicus,A,,BAO_0000218,12793,In vivo,10116.0,0,Autocuration,1,CHEMBL625433,,
13348,N,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,14793,In vivo,10116.0,1,Intermediate,1,CHEMBL625434,,1969.0
13349,N,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,,Rattus norvegicus,A,,BAO_0000218,14793,In vivo,10116.0,1,Intermediate,1,CHEMBL625435,,1969.0
13350,U,Bioavailability in rat (dose 10 mg/kg p.o.),,Rattus norvegicus,A,,BAO_0000218,14793,In vivo,10116.0,0,Autocuration,1,CHEMBL625436,,
13351,N,Bioavailability was measured in cynomolgus monkeys.,,Macaca fascicularis,A,,BAO_0000218,14731,In vivo,9541.0,1,Intermediate,1,CHEMBL874588,,
13352,N,Bioavailability was measured in nude mice.,,Mus musculus,A,,BAO_0000218,14731,In vivo,10090.0,1,Intermediate,1,CHEMBL625437,,
13353,U,Bioavailability in ferret (dose 10 mg/kg i.d.),,Mustela putorius furo,A,,BAO_0000218,12187,In vivo,9669.0,0,Autocuration,1,CHEMBL625438,,
13354,U,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),,Simiiformes,A,,BAO_0000218,12187,In vivo,314293.0,0,Autocuration,1,CHEMBL625439,,
13355,U,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",,Simiiformes,A,,BAO_0000218,12187,In vivo,314293.0,0,Autocuration,1,CHEMBL625440,,
13356,U,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),,Simiiformes,A,,BAO_0000218,12187,In vivo,314293.0,0,Autocuration,1,CHEMBL625441,,
13357,U,Bioavailability in rat (dose 10 mg/kg i.d.),,Rattus norvegicus,A,,BAO_0000218,12187,In vivo,10116.0,0,Autocuration,1,CHEMBL625442,,
13358,N,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,Rattus norvegicus,A,,BAO_0000218,12187,In vivo,10116.0,1,Intermediate,1,CHEMBL625443,,
13359,U,Bioavailability was determined; extremely poor,,,A,,BAO_0000218,17431,In vivo,,0,Autocuration,1,CHEMBL625444,,
13360,N,% bioavailability in mice after oral administration of prodrug,,Mus musculus,A,,BAO_0000218,13318,In vivo,10090.0,1,Intermediate,1,CHEMBL625445,,
13361,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625446,,
13362,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL882960,,
13363,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625447,,
13364,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625448,,
13365,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625449,,
13366,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL874589,,
13367,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625450,,
13368,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625451,,
13369,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL626584,,
13370,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL626585,,
13371,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL626586,,
13372,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL626587,,
13373,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL626588,,
13374,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL626589,,
13375,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL626590,,
13376,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL626591,,
13377,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL627181,,
13378,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628083,,
13379,U,IV clearance determined at an peroral dose of 15 mg/kg.,,,A,,BAO_0000218,15173,In vivo,,0,Autocuration,1,CHEMBL628084,,
13380,N,Mouse oral clearance was measured against Hymenolepiasis nana.,,Hymenolepis nana,F,,BAO_0000218,7732,In vivo,102285.0,1,Expert,1,CHEMBL628085,,
13381,N,Mouse oral clearance was measured against Nematospiroides dubius,,Heligmosomoides polygyrus,F,,BAO_0000218,7732,In vivo,6339.0,1,Expert,1,CHEMBL628086,,
13382,U,Mouse oral clearance was measured against N. dubius; NT is Not Tested,,,F,,BAO_0000218,7732,In vivo,,0,Autocuration,1,CHEMBL628087,,
13383,N,Mouse oral clearance was measured against N. nana; NT is Not Tested,,Mus musculus,A,,BAO_0000218,7732,In vivo,10090.0,1,Intermediate,1,CHEMBL628088,,
13384,U,Mouse oral clearance was measured against N. nana; NT is Not Tested,,,B,,BAO_0000218,7732,In vivo,,0,Autocuration,1,CHEMBL628089,,
13385,U,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,,,A,,BAO_0000218,8328,In vivo,,0,Autocuration,1,CHEMBL628090,,
13386,U,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,,,A,,BAO_0000218,8328,In vivo,,0,Autocuration,1,CHEMBL628091,,
13387,U,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,,,A,,BAO_0000218,8328,In vivo,,0,Autocuration,1,CHEMBL628092,,
13388,U,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,,,A,,BAO_0000218,8328,In vivo,,0,Autocuration,1,CHEMBL628093,,
13389,U,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,,,A,,BAO_0000218,8328,In vivo,,0,Autocuration,1,CHEMBL875607,,
13390,U,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,,,A,,BAO_0000218,8328,In vivo,,0,Autocuration,1,CHEMBL625710,,
13391,U,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,,,A,,BAO_0000218,8328,In vivo,,0,Autocuration,1,CHEMBL625711,,
13392,U,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,,,A,,BAO_0000218,8328,In vivo,,0,Autocuration,1,CHEMBL625712,,
13393,U,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,,,A,,BAO_0000218,8328,In vivo,,0,Autocuration,1,CHEMBL625713,,
13394,N,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,,Canis lupus familiaris,A,,BAO_0000218,13376,In vivo,9615.0,1,Intermediate,1,CHEMBL625714,,
13395,N,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,,Macaca mulatta,A,,BAO_0000218,13477,In vivo,9544.0,1,Intermediate,1,CHEMBL625715,,
13396,N,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,,Rattus norvegicus,A,,BAO_0000218,13477,In vivo,10116.0,1,Intermediate,1,CHEMBL625716,,
13397,N,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,,Rattus norvegicus,A,,BAO_0000218,13477,In vivo,10116.0,1,Intermediate,1,CHEMBL625717,,
13398,N,Plasma clearance was determined for the compound in rats,,Rattus norvegicus,A,,BAO_0000218,13313,In vivo,10116.0,1,Intermediate,1,CHEMBL625718,,
13399,N,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,,Rattus norvegicus,A,,BAO_0000218,12504,In vivo,10116.0,1,Intermediate,1,CHEMBL625719,,
13400,N,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,,Rattus norvegicus,A,,BAO_0000218,12504,In vivo,10116.0,1,Intermediate,1,CHEMBL625720,,
13401,N,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,,Rattus norvegicus,A,,BAO_0000218,12504,In vivo,10116.0,1,Intermediate,1,CHEMBL625721,,
13402,N,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,,Rattus norvegicus,A,,BAO_0000218,12504,In vivo,10116.0,1,Intermediate,1,CHEMBL625722,,
13403,N,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,,Rattus norvegicus,A,,BAO_0000218,13129,In vivo,10116.0,1,Intermediate,1,CHEMBL625723,,
13404,N,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,,Heligmosomoides polygyrus,A,,BAO_0000218,7732,In vivo,6339.0,1,Intermediate,1,CHEMBL625724,,
13405,N,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,,Heligmosomoides polygyrus,A,,BAO_0000218,7732,In vivo,6339.0,1,Intermediate,1,CHEMBL625725,,
13406,N,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,,Heligmosomoides polygyrus,A,,BAO_0000218,7732,In vivo,6339.0,1,Intermediate,1,CHEMBL625726,,
13407,N,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,,Heligmosomoides polygyrus,A,,BAO_0000218,7732,In vivo,6339.0,1,Intermediate,1,CHEMBL875608,,
13408,N,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,,Heligmosomoides polygyrus,A,,BAO_0000218,7732,In vivo,6339.0,1,Intermediate,1,CHEMBL625727,,
13409,U,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,,Rattus norvegicus,A,,BAO_0000218,9278,In vivo,10116.0,0,Autocuration,1,CHEMBL625728,,1088.0
13410,U,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,Rattus norvegicus,A,,BAO_0000218,9278,In vivo,10116.0,0,Autocuration,1,CHEMBL625729,,
13411,U,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,,Rattus norvegicus,A,,BAO_0000218,9278,In vivo,10116.0,0,Autocuration,1,CHEMBL625730,,
13412,U,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,Rattus norvegicus,A,,BAO_0000218,9278,In vivo,10116.0,0,Autocuration,1,CHEMBL625731,,1088.0
13413,U,Urinary clearance was determined in rat at 25 mg/kg os dosage,,Rattus norvegicus,A,,BAO_0000218,9278,In vivo,10116.0,0,Autocuration,1,CHEMBL626417,,1088.0
13414,N,Urinary clearance was determined at 100 mg/kg oral dosage in human,,Homo sapiens,A,,BAO_0000218,9278,In vivo,9606.0,1,Intermediate,1,CHEMBL626418,,1088.0
13415,N,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,,Canis lupus familiaris,A,,BAO_0000218,9278,In vivo,9615.0,1,Intermediate,1,CHEMBL626419,,1088.0
13416,N,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,Canis lupus familiaris,A,,BAO_0000218,5932,In vivo,9615.0,1,Intermediate,1,CHEMBL626592,,1969.0
13417,N,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,,Rattus norvegicus,A,,BAO_0000218,5932,In vivo,10116.0,1,Intermediate,1,CHEMBL626593,,1969.0
13418,N,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,Rattus norvegicus,A,,BAO_0000218,5182,In vivo,10116.0,1,Intermediate,1,CHEMBL626594,,
13419,N,Clearance rate in dogs,,Canis lupus familiaris,A,,BAO_0000218,10499,In vivo,9615.0,1,Intermediate,1,CHEMBL625035,,
13420,U,Compound was measured for intrinsic clearance,,,A,,BAO_0000019,6051,In vitro,,0,Autocuration,1,CHEMBL625036,,
13421,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,17508,,,0,Autocuration,1,CHEMBL625037,,
13422,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,6228,,,0,Autocuration,1,CHEMBL625038,,
13423,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,6231,,,0,Autocuration,1,CHEMBL625039,,
13424,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,17740,,,0,Autocuration,1,CHEMBL625040,,
13425,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,6495,,,0,Autocuration,1,CHEMBL625041,,
13426,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,2171,,,0,Autocuration,1,CHEMBL625042,,
13427,U,Partition coefficient of the compound,,,A,,BAO_0000019,3255,,,0,Autocuration,1,CHEMBL874411,,
13428,U,Permeability,,,A,,BAO_0000019,6821,,,0,Autocuration,1,CHEMBL625043,,
13429,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,2685,,,0,Autocuration,1,CHEMBL625044,,
13430,U,Partition coefficient (logD),,,A,,BAO_0000019,17584,,,0,Autocuration,1,CHEMBL625045,,
13431,U,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,P,,BAO_0000100,13824,,,0,Autocuration,1,CHEMBL625046,,
13432,U,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,P,,BAO_0000100,13824,,,0,Autocuration,1,CHEMBL625047,,
13433,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,16479,,,0,Autocuration,1,CHEMBL625048,,
13434,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,11997,,,0,Autocuration,1,CHEMBL625049,,
13435,U,Calculated logarithm of partition coefficient (P) was determined,,,P,,BAO_0000100,2988,,,0,Autocuration,1,CHEMBL625050,,
13436,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,931,,,0,Autocuration,1,CHEMBL625051,,
13437,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,4381,,,0,Autocuration,1,CHEMBL874412,,
13438,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,4397,,,0,Autocuration,1,CHEMBL625052,,
13439,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,5889,,,0,Autocuration,1,CHEMBL625053,,
13440,U,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,,,A,,BAO_0000019,6154,,,0,Autocuration,1,CHEMBL623250,,
13441,U,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,,,A,,BAO_0000019,6154,,,0,Autocuration,1,CHEMBL623251,,
13442,U,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,,,A,,BAO_0000019,6154,,,0,Autocuration,1,CHEMBL623252,,
13443,U,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,,,A,,BAO_0000019,6154,,,0,Autocuration,1,CHEMBL623253,,
13444,U,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,,,A,,BAO_0000019,6154,,,0,Autocuration,1,CHEMBL623254,,
13445,U,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,,,A,,BAO_0000019,6154,,,0,Autocuration,1,CHEMBL623255,,
13446,U,Percent degradation of compound at a pH of 1 over a 18 hr period,,,A,,BAO_0000019,6887,,,0,Autocuration,1,CHEMBL626831,,
13447,U,Percent degradation of compound at pH of 1 over an 18 hr period,,,A,,BAO_0000019,6887,,,0,Autocuration,1,CHEMBL877494,,
13448,U,Delta Logarithm of Partition Coefficient value was determined.,,,A,,BAO_0000019,14116,,,0,Autocuration,1,CHEMBL626832,,
13449,U,Delta logPoct-cyc,,,A,,BAO_0000019,11137,,,0,Autocuration,1,CHEMBL626833,,
13450,U,Lipophilicity estimated on reversed phase TLC,,,P,,BAO_0000100,7230,,,0,Autocuration,1,CHEMBL626834,,
13451,U,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,,,A,,BAO_0000019,15741,,,0,Autocuration,1,CHEMBL626835,,
13452,U,Delta logPoct-cyc,,,A,,BAO_0000019,9663,,,0,Autocuration,1,CHEMBL626836,,
13453,U,Change in logarithm of partition coefficient of the compound,,,P,,BAO_0000100,9663,,,0,Autocuration,1,CHEMBL626837,,
13454,U,Delta logD (pH 6.5),,,A,,BAO_0000019,13807,,,0,Autocuration,1,CHEMBL626838,,
13455,U,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",,,P,,BAO_0000100,13807,,,0,Autocuration,1,CHEMBL626839,,
13456,U,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,,,A,,BAO_0000019,17425,,,0,Autocuration,1,CHEMBL626840,,
13457,U,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),,,A,,BAO_0000019,12143,,,0,Autocuration,1,CHEMBL626841,,
13458,U,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,,,A,,BAO_0000219,12608,,,0,Autocuration,1,CHEMBL626842,,
13459,U,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,,,A,,BAO_0000219,12608,,,0,Autocuration,1,CHEMBL626843,,
13460,N,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,,Rattus norvegicus,A,,BAO_0000218,8649,,10116.0,1,Intermediate,1,CHEMBL626844,,
13461,N,Amount of deuterium retained was reported after normal workup in rats,,Rattus norvegicus,A,,BAO_0000218,8649,,10116.0,1,Intermediate,1,CHEMBL877495,,
13462,N,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,,Rattus norvegicus,A,,BAO_0000218,8649,,10116.0,1,Intermediate,1,CHEMBL626845,,
13463,N,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,,Rattus norvegicus,A,,BAO_0000218,8649,,10116.0,1,Intermediate,1,CHEMBL626846,,
13464,N,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,Rattus norvegicus,A,,BAO_0000218,8649,,10116.0,1,Intermediate,1,CHEMBL626847,,
13465,N,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,Rattus norvegicus,A,,BAO_0000218,8649,,10116.0,1,Intermediate,1,CHEMBL628677,,
13466,N,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,,Rattus norvegicus,A,,BAO_0000218,8649,,10116.0,1,Intermediate,1,CHEMBL628678,,
13467,U,Compound was subjected to electrochemical oxidation,,,A,,BAO_0000019,9659,,,0,Autocuration,1,CHEMBL628679,,
13468,U,Compound was subjected to photochemical oxidation,,,A,,BAO_0000019,9659,,,0,Autocuration,1,CHEMBL628680,,
13469,U,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,,,A,,BAO_0000019,9659,,,0,Autocuration,1,CHEMBL628681,,
13470,U,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,,,A,,BAO_0000019,9659,,,0,Autocuration,1,CHEMBL628682,,
13471,U,Oxidation of compound by methemoglobin in presence of hydroperoxide,,,A,,BAO_0000019,9659,,,0,Autocuration,1,CHEMBL628683,,
13472,N,Percent diffusion through fuzzy rat skin after 48 h of incubation,,Rattus norvegicus,A,,BAO_0000218,9607,,10116.0,1,Intermediate,1,CHEMBL628684,,
13473,U,Dissociation constant (pKa),,,P,,BAO_0000100,7057,,,0,Autocuration,1,CHEMBL877501,,
13474,U,Dissociation constant value of the compound; ND means not determined.,,,P,,BAO_0000100,7057,,,0,Autocuration,1,CHEMBL628685,,
13475,N,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,,Rattus norvegicus,A,,BAO_0000218,7911,,10116.0,1,Intermediate,1,CHEMBL628686,,178.0
13476,N,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,Rattus norvegicus,A,,BAO_0000218,7911,,10116.0,1,Intermediate,1,CHEMBL628687,,178.0
13477,N,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,,Rattus norvegicus,A,,BAO_0000218,7911,,10116.0,1,Intermediate,1,CHEMBL628688,,
13478,N,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,Rattus norvegicus,A,,BAO_0000218,7911,,10116.0,1,Intermediate,1,CHEMBL628689,,
13479,N,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,,Rattus norvegicus,A,,BAO_0000218,7911,,10116.0,1,Intermediate,1,CHEMBL628690,,2107.0
13480,N,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,Rattus norvegicus,A,,BAO_0000218,7911,,10116.0,1,Intermediate,1,CHEMBL629363,,2107.0
13481,N,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,,Rattus norvegicus,A,,BAO_0000218,7911,,10116.0,1,Intermediate,1,CHEMBL629364,,2106.0
13482,N,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,Rattus norvegicus,A,,BAO_0000218,7911,,10116.0,1,Intermediate,1,CHEMBL629365,,2106.0
13483,N,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,,Rattus norvegicus,A,,BAO_0000218,7911,,10116.0,1,Intermediate,1,CHEMBL629366,,
13484,N,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,,Rattus norvegicus,A,,BAO_0000218,7911,,10116.0,1,Intermediate,1,CHEMBL629367,,1088.0
13485,N,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,Rattus norvegicus,A,,BAO_0000218,7911,,10116.0,1,Intermediate,1,CHEMBL629368,,1988.0
13486,N,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,Rattus norvegicus,A,,BAO_0000218,7911,,10116.0,1,Intermediate,1,CHEMBL877502,,1088.0
13487,N,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,,Mus musculus,A,,BAO_0000218,13792,,10090.0,1,Intermediate,1,CHEMBL629369,,2037.0
13488,N,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,,Mus musculus,A,,BAO_0000218,13792,,10090.0,1,Intermediate,1,CHEMBL629370,,955.0
13489,U,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",,Simiiformes,A,,BAO_0000218,8133,,314293.0,0,Autocuration,1,CHEMBL629371,,1088.0
13490,U,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,Simiiformes,A,,BAO_0000218,8133,,314293.0,0,Autocuration,1,CHEMBL626276,,1088.0
13491,U,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,Simiiformes,A,,BAO_0000218,8133,,314293.0,0,Autocuration,1,CHEMBL626277,,1088.0
13492,U,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,Simiiformes,A,,BAO_0000218,8133,,314293.0,0,Autocuration,1,CHEMBL631250,,1088.0
13493,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL631251,,1088.0
13494,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL631252,,1088.0
13495,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL631253,,1088.0
13496,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL631254,,1088.0
13497,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL631255,,1088.0
13498,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL631256,,1088.0
13499,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL631257,,1088.0
13500,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL628009,,1088.0
13501,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL628010,,1088.0
13502,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL628011,,1088.0
13503,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL628012,,1088.0
13504,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL628013,,1088.0
13505,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL628014,,1088.0
13506,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL628015,,1088.0
13507,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL628016,,1088.0
13508,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL874461,,1088.0
13509,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL628017,,1088.0
13510,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL628018,,1088.0
13511,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL628019,,1088.0
13512,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL628020,,1088.0
13513,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL628021,,1088.0
13514,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL628022,,1088.0
13515,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,Canis lupus familiaris,A,,BAO_0000218,8133,,9615.0,1,Intermediate,1,CHEMBL628023,,1088.0
13516,U,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,Simiiformes,A,,BAO_0000218,8133,,314293.0,0,Autocuration,1,CHEMBL628024,,1088.0
13517,U,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",,Simiiformes,A,,BAO_0000218,8133,,314293.0,0,Autocuration,1,CHEMBL628025,,1088.0
13518,U,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,Simiiformes,A,,BAO_0000218,8133,,314293.0,0,Autocuration,1,CHEMBL628026,,1088.0
13519,U,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,Simiiformes,A,,BAO_0000218,8133,,314293.0,0,Autocuration,1,CHEMBL628027,,1088.0
13520,U,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,Simiiformes,A,,BAO_0000218,8133,,314293.0,0,Autocuration,1,CHEMBL628028,,1088.0
13521,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL628029,,1088.0
13522,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL628030,,1088.0
13523,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL628031,,1088.0
13524,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL628032,,1088.0
13525,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL628033,,1088.0
13526,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL628034,,1088.0
13527,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL628035,,1088.0
13528,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL628036,,1088.0
13529,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL874462,,1088.0
13530,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628037,,
13531,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628123,,
13532,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628124,,
13533,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628125,,
13534,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628126,,
13535,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628127,,
13536,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628128,,
13537,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628129,,
13538,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628130,,
13539,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628131,,
13540,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628132,,
13541,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628133,,
13542,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628134,,
13543,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628135,,
13544,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628136,,
13545,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628137,,
13546,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628138,,
13547,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628139,,
13548,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628140,,
13549,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628141,,
13550,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628142,,
13551,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628143,,
13552,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628144,,
13553,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628145,,
13554,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL628146,,
13555,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625355,,
13556,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625356,,
13557,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625357,,
13558,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625527,,
13559,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL875473,,
13560,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL625528,,
13561,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,,Rattus norvegicus,A,,BAO_0000218,9025,In vivo,10116.0,1,Intermediate,1,CHEMBL626304,,
13562,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,,Canis lupus familiaris,A,,BAO_0000218,9025,In vivo,9615.0,1,Intermediate,1,CHEMBL624138,,1637.0
13563,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,6448,,,0,Autocuration,1,CHEMBL624139,,
13564,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,17221,,,0,Autocuration,1,CHEMBL624140,,
13565,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,6545,,,0,Autocuration,1,CHEMBL624141,,
13566,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,577,,,0,Autocuration,1,CHEMBL624142,,
13567,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,6285,,,0,Autocuration,1,CHEMBL624143,,
13568,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,6500,,,0,Autocuration,1,CHEMBL624144,,
13569,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,6716,,,0,Autocuration,1,CHEMBL624145,,
13570,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,13658,,,0,Autocuration,1,CHEMBL624146,,
13571,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,6549,,,0,Autocuration,1,CHEMBL624147,,
13572,U,Calculated partition coefficient (clogP) (MacLogP),,,P,,BAO_0000100,14685,,,0,Autocuration,1,CHEMBL883123,,
13573,U,Partition coefficient (logP),,,A,,BAO_0000019,6893,,,0,Autocuration,1,CHEMBL624148,,
13574,U,Kinetic parameter was determined,,,A,,BAO_0000019,3687,,,0,Autocuration,1,CHEMBL874416,,
13575,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,4207,,,0,Autocuration,1,CHEMBL624149,,
13576,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,4626,,,0,Autocuration,1,CHEMBL624150,,
13577,U,Lipophilicity was determined,,,P,,BAO_0000100,1021,,,0,Autocuration,1,CHEMBL624151,,
13578,U,Lipophilicity was determined,,,P,,BAO_0000100,3777,,,0,Autocuration,1,CHEMBL624152,,
13579,U,Lipophilicity was determined,,,P,,BAO_0000100,17533,,,0,Autocuration,1,CHEMBL622139,,
13580,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,6524,,,0,Autocuration,1,CHEMBL622140,,
13581,U,Lipophilicity was determined,,,P,,BAO_0000100,17533,,,0,Autocuration,1,CHEMBL622141,,
13582,U,Lipophilicity in octanol-water,,,P,,BAO_0000100,6480,,,0,Autocuration,1,CHEMBL622142,,
13583,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,17606,,,0,Autocuration,1,CHEMBL622143,,
13584,U,Octanol-water partition coefficient was determined,,,P,,BAO_0000100,6863,,,0,Autocuration,1,CHEMBL622144,,
13585,U,Partition coefficient (logP),,,A,,BAO_0000019,1356,,,0,Autocuration,1,CHEMBL877473,,
13586,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,3326,,,0,Autocuration,1,CHEMBL622145,,
13587,U,Partition coefficient was determined; ND means not determined,,,A,,BAO_0000019,1356,,,0,Autocuration,1,CHEMBL622146,,
13588,U,Calculated partition coefficient (clogP),,,P,,BAO_0000100,12984,,,0,Autocuration,1,CHEMBL622147,,
13589,U,Partition coefficient of the compound,,,A,,BAO_0000019,17363,,,0,Autocuration,1,CHEMBL622148,,
13590,U,Permeability was determined,,,A,,BAO_0000019,6827,,,0,Autocuration,1,CHEMBL883124,,
13591,U,The compound was evaluated for the partition coefficient,,,P,,BAO_0000100,261,,,0,Autocuration,1,CHEMBL622149,,
13592,U,Partition coefficient (logP),,,A,,BAO_0000019,2685,,,0,Autocuration,1,CHEMBL622150,,
13593,U,The lipophilicity was reported,,,P,,BAO_0000100,414,,,0,Autocuration,1,CHEMBL622151,,
13594,U,logarithm of the octanol-water partition coefficient for the compound,,,P,,BAO_0000100,15769,,,0,Autocuration,1,CHEMBL622152,,
13595,U,Clogp value was determined,,,A,,BAO_0000019,17248,,,0,Autocuration,1,CHEMBL622153,,
13596,U,Clp at a dose of 1.5 mg/kg,,,A,,BAO_0000218,16935,In vivo,,0,Autocuration,1,CHEMBL877474,,
13597,U,Clp at a dose of 2.0 mg/kg,,,A,,BAO_0000218,16935,In vivo,,0,Autocuration,1,CHEMBL622154,,
13598,U,"Clp, plasma clearance at a dose of 10 mg/kg",,,A,,BAO_0000218,14832,In vivo,,0,Autocuration,1,CHEMBL622155,,1969.0
13599,U,"Clp, plasma clearance at a dose of 50 mg/kg",,,A,,BAO_0000218,14832,In vivo,,0,Autocuration,1,CHEMBL622156,,1969.0
13600,N,Compound was tested for plasma clearance in rat,,Rattus norvegicus,A,,BAO_0000218,2399,In vivo,10116.0,1,Intermediate,1,CHEMBL622157,,1969.0
13601,N,Compound was tested for plasma clearance in rat; Not determined,,Rattus norvegicus,A,,BAO_0000218,2399,In vivo,10116.0,1,Intermediate,1,CHEMBL622158,,1969.0
13602,N,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,6227,In vivo,10116.0,1,Intermediate,1,CHEMBL622807,,
13603,N,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,,Macaca mulatta,A,,BAO_0000218,6227,In vivo,9544.0,1,Intermediate,1,CHEMBL622808,,
13604,U,Plasma clearance by iv administration at a dose 0.003 ug/mL,,,A,,BAO_0000218,5623,In vivo,,0,Autocuration,1,CHEMBL622809,,
13605,U,Plasma clearance determined,,,A,,BAO_0000218,4854,In vivo,,0,Autocuration,1,CHEMBL622810,,
13606,N,Plasma clearance after iv administration at 3 mg/kg in hamster,,Cricetinae,A,,BAO_0000218,4493,In vivo,10026.0,1,Intermediate,1,CHEMBL876653,,
13607,N,Plasma clearance after iv administration at 4 mg/kg in hamster,,Cricetinae,A,,BAO_0000218,4493,In vivo,10026.0,1,Intermediate,1,CHEMBL622811,,
13608,N,Rate of clearance in rat was determined,,Rattus norvegicus,A,,BAO_0000218,14956,In vivo,10116.0,1,Intermediate,1,CHEMBL622986,,
13609,N,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,15372,In vivo,10116.0,1,Intermediate,1,CHEMBL622987,,1969.0
13610,N,Total plasma clearance after iv dose of 5.10 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,15372,In vivo,10116.0,1,Intermediate,1,CHEMBL622988,,1969.0
13611,N,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,15372,In vivo,10116.0,1,Intermediate,1,CHEMBL622989,,1969.0
13612,N,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,,Rattus norvegicus,A,,BAO_0000218,15372,In vivo,10116.0,1,Intermediate,1,CHEMBL622990,,1969.0
13613,U,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,Simiiformes,A,,BAO_0000218,15604,In vivo,314293.0,0,Autocuration,1,CHEMBL622991,,1969.0
13614,N,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,Rattus norvegicus,A,,BAO_0000218,15604,In vivo,10116.0,1,Intermediate,1,CHEMBL622227,,1969.0
13615,N,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,Canis lupus familiaris,A,,BAO_0000218,15604,In vivo,9615.0,1,Intermediate,1,CHEMBL622228,,1969.0
13616,N,Clpl value in rat,,Rattus norvegicus,A,,BAO_0000218,14964,In vivo,10116.0,1,Intermediate,1,CHEMBL622229,,
13617,N,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,,Cavia porcellus,A,,BAO_0000218,15240,In vivo,10141.0,1,Intermediate,1,CHEMBL622230,,
13618,N,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,16449,In vivo,10116.0,1,Intermediate,1,CHEMBL622231,,
13619,N,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,,Macaca fascicularis,A,,BAO_0000218,16449,In vivo,9541.0,1,Intermediate,1,CHEMBL622232,,
13620,U,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,,,A,,BAO_0000218,12902,In vivo,,0,Autocuration,1,CHEMBL622233,,
13621,U,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,,,A,,BAO_0000218,12902,In vivo,,0,Autocuration,1,CHEMBL622234,,
13622,U,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,,,A,,BAO_0000218,12902,In vivo,,0,Autocuration,1,CHEMBL622235,,
13623,U,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,,,A,,BAO_0000218,12902,In vivo,,0,Autocuration,1,CHEMBL622236,,
13624,U,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,,,A,,BAO_0000218,12902,In vivo,,0,Autocuration,1,CHEMBL622237,,
13625,U,Cmax in minutes at a po dose of 10.0(pmol/g/h).,,,A,,BAO_0000218,12902,In vivo,,0,Autocuration,1,CHEMBL877482,,
13626,U,Cmax in minutes at a po dose of 20.0(pmol/g/h).,,,A,,BAO_0000218,12902,In vivo,,0,Autocuration,1,CHEMBL622238,,
13627,U,Cmax in minutes at a po dose of 40.0(pmol/g/h).,,,A,,BAO_0000218,12902,In vivo,,0,Autocuration,1,CHEMBL622239,,
13628,U,Cmax was calculated as maximum concentration reached in the blood,,,A,,BAO_0000218,11149,In vivo,,0,Autocuration,1,CHEMBL622240,,178.0
13629,U,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,,,A,,BAO_0000218,11149,In vivo,,0,Autocuration,1,CHEMBL622241,,178.0
13630,N,Cmax was determine after peroral administration at 10 mpk in Rat,,Rattus norvegicus,A,,BAO_0000218,5669,In vivo,10116.0,1,Intermediate,1,CHEMBL631013,,
13631,N,Cmax was determine after peroral administration at 10 mpk in Rhesus,,Macaca mulatta,A,,BAO_0000218,5669,In vivo,9544.0,1,Intermediate,1,CHEMBL631014,,
13632,N,Cmax was determine after peroral administration at 10 mpk in dog,,Canis lupus familiaris,A,,BAO_0000218,5669,In vivo,9615.0,1,Intermediate,1,CHEMBL631015,,
13633,N,Cmax was determine after peroral administration at 160 mpk in Rat,,Rattus norvegicus,A,,BAO_0000218,5669,In vivo,10116.0,1,Intermediate,1,CHEMBL631016,,
13634,N,Cmax was determine after peroral administration at 20 mpk in Rat,,Rattus norvegicus,A,,BAO_0000218,5669,In vivo,10116.0,1,Intermediate,1,CHEMBL631017,,
13635,N,Cmax was determine after peroral administration at 50 mpk in Rat,,Rattus norvegicus,A,,BAO_0000218,5669,In vivo,10116.0,1,Intermediate,1,CHEMBL631018,,
13636,U,Cmax was determined,,,A,,BAO_0000218,4236,In vivo,,0,Autocuration,1,CHEMBL631019,,
13637,N,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,,Mus musculus,A,,BAO_0000218,13792,,10090.0,1,Intermediate,1,CHEMBL875761,,955.0
13638,N,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,,Mus musculus,A,,BAO_0000218,13792,,10090.0,1,Intermediate,1,CHEMBL631020,,955.0
13639,N,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,,Mus musculus,A,,BAO_0000218,13792,,10090.0,1,Intermediate,1,CHEMBL631669,,955.0
13640,N,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,,Mus musculus,A,,BAO_0000218,13792,,10090.0,1,Intermediate,1,CHEMBL631670,,955.0
13641,N,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,,Mus musculus,A,,BAO_0000218,13792,,10090.0,1,Intermediate,1,CHEMBL631671,,2435.0
13642,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631672,,178.0
13643,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631673,,178.0
13644,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631856,,178.0
13645,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631857,,178.0
13646,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631858,,178.0
13647,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631859,,178.0
13648,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631860,,178.0
13649,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631861,,178.0
13650,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631862,,178.0
13651,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631863,,178.0
13652,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631864,,178.0
13653,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631865,,178.0
13654,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL631866,,178.0
13655,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL629360,,178.0
13656,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL629361,,178.0
13657,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL629362,,178.0
13658,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL630740,,178.0
13659,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL630741,,178.0
13660,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL630742,,178.0
13661,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL630743,,
13662,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL630744,,
13663,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL630745,,
13664,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL630746,,
13665,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL630747,,
13666,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL630748,,
13667,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL632056,,
13668,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL632057,,
13669,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL632058,,
13670,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL632059,,
13671,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL632060,,
13672,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL632061,,
13673,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL629207,,
13674,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL629208,,
13675,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL629209,,
13676,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL629210,,
13677,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL629211,,
13678,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL629212,,
13679,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,,Rattus norvegicus,A,,BAO_0000218,8418,,10116.0,1,Intermediate,1,CHEMBL629213,,
13680,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL629214,,1088.0
13681,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL629215,,1088.0
13682,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",,Rattus norvegicus,A,,BAO_0000218,8133,,10116.0,1,Intermediate,1,CHEMBL635154,,1088.0
13683,N,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL629216,,
13684,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL629217,,
13685,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL629218,,
13686,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL629219,,
13687,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL629220,,
13688,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL629221,,
13689,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL631127,,
13690,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL631128,,
13691,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL631129,,
13692,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL631130,,
13693,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL631131,,
13694,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL631132,,
13695,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL631133,,
13696,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL631134,,
13697,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL875120,,
13698,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL631135,,
13699,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL631136,,
13700,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL631137,,
13701,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL631138,,
13702,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL631139,,
13703,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL631140,,
13704,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL631141,,
13705,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL631142,,
13706,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL631143,,
13707,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,A,,BAO_0000218,6996,,10116.0,1,Intermediate,1,CHEMBL631144,,
13708,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL631145,,
13709,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL631146,,
13710,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL631147,,
13711,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL631148,,
13712,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL631149,,
13713,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL631150,,
13714,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL631151,,
13715,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL631152,,
13716,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL631443,,
13717,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL631444,,
13718,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL631445,,
13719,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL631446,,
13720,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL631447,,
13721,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL631448,,
13722,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL631449,,
13723,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL631450,,
13724,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,Canis lupus familiaris,A,,BAO_0000218,6996,,9615.0,1,Intermediate,1,CHEMBL629724,,
13725,N,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,Mus musculus,A,,BAO_0000218,9716,In vivo,10090.0,1,Intermediate,1,CHEMBL629725,,14.0
13726,N,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,Mus musculus,A,,BAO_0000218,9716,In vivo,10090.0,1,Intermediate,1,CHEMBL629726,,14.0
13727,N,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,Mus musculus,A,,BAO_0000218,9716,In vivo,10090.0,1,Intermediate,1,CHEMBL629727,,2106.0
13728,N,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,Mus musculus,A,,BAO_0000218,9716,In vivo,10090.0,1,Intermediate,1,CHEMBL630404,,2106.0
13729,N,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,Mus musculus,A,,BAO_0000218,9716,In vivo,10090.0,1,Intermediate,1,CHEMBL630405,,2106.0
13730,N,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,Mus musculus,A,,BAO_0000218,9716,In vivo,10090.0,1,Intermediate,1,CHEMBL630406,,2106.0
13731,N,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,Mus musculus,A,,BAO_0000218,9716,In vivo,10090.0,1,Intermediate,1,CHEMBL630407,,945.0
13732,N,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,Mus musculus,A,,BAO_0000218,9716,In vivo,10090.0,1,Intermediate,1,CHEMBL630573,,945.0
13733,N,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,Mus musculus,A,,BAO_0000218,9716,In vivo,10090.0,1,Intermediate,1,CHEMBL630574,,945.0
13734,N,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,Mus musculus,A,,BAO_0000218,9716,In vivo,10090.0,1,Intermediate,1,CHEMBL630575,,945.0
13735,N,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,Mus musculus,A,,BAO_0000218,9716,In vivo,10090.0,1,Intermediate,1,CHEMBL630576,,
13736,N,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,Mus musculus,A,,BAO_0000218,9716,In vivo,10090.0,1,Intermediate,1,CHEMBL630577,,
13737,N,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,Mus musculus,A,,BAO_0000218,9716,In vivo,10090.0,1,Intermediate,1,CHEMBL630578,,
13738,N,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,Mus musculus,A,,BAO_0000218,9716,In vivo,10090.0,1,Intermediate,1,CHEMBL630579,,
13739,N,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),,Mus musculus,A,,BAO_0000218,12192,,10090.0,1,Intermediate,1,CHEMBL630580,,2113.0
13740,N,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,,Mus musculus,A,,BAO_0000218,12192,,10090.0,1,Intermediate,1,CHEMBL630581,,2113.0
13741,N,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),,Mus musculus,A,,BAO_0000218,12192,,10090.0,1,Intermediate,1,CHEMBL630582,,2113.0
13742,N,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,,Mus musculus,A,,BAO_0000218,12192,,10090.0,1,Intermediate,1,CHEMBL630583,,
13743,N,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),,Mus musculus,A,,BAO_0000218,12192,,10090.0,1,Intermediate,1,CHEMBL630584,,
13744,N,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,,Mus musculus,A,,BAO_0000218,12192,,10090.0,1,Intermediate,1,CHEMBL630585,,
13745,N,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),,Mus musculus,A,,BAO_0000218,12192,,10090.0,1,Intermediate,1,CHEMBL630586,,
13746,N,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,,Mus musculus,A,,BAO_0000218,12192,,10090.0,1,Intermediate,1,CHEMBL630587,,
13747,N,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),,Mus musculus,A,,BAO_0000218,12192,,10090.0,1,Intermediate,1,CHEMBL630588,,
13748,N,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,,Mus musculus,A,,BAO_0000218,12192,,10090.0,1,Intermediate,1,CHEMBL630589,,
13749,N,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),,Mus musculus,A,,BAO_0000218,12192,,10090.0,1,Intermediate,1,CHEMBL630590,,
13750,U,Removal of 238-Plutonium(IV) in feces at 24 h,,,A,,BAO_0000019,12192,,,0,Autocuration,1,CHEMBL630591,,1988.0
13751,U,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),,,A,,BAO_0000019,12192,,,0,Autocuration,1,CHEMBL630592,,1988.0
13752,U,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,,,A,,BAO_0000019,12192,,,0,Autocuration,1,CHEMBL630593,,
13753,U,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),,,A,,BAO_0000019,12192,,,0,Autocuration,1,CHEMBL630594,,
13754,U,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),,,A,,BAO_0000019,12192,,,0,Autocuration,1,CHEMBL630595,,1088.0
13755,U,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),,,A,,BAO_0000019,12192,,,0,Autocuration,1,CHEMBL630596,,1088.0
13756,U,Removal of 238-Plutonium(IV) in urine after 0-24 h,,,A,,BAO_0000019,12192,,,0,Autocuration,1,CHEMBL630597,,1088.0
13757,U,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),,,A,,BAO_0000019,12192,,,0,Autocuration,1,CHEMBL630598,,1088.0
13758,U,Removal of 238-Plutonium(IV) in urine after 0-4 h,,,A,,BAO_0000019,12192,,,0,Autocuration,1,CHEMBL630599,,1088.0
13759,U,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),,,A,,BAO_0000019,12192,,,0,Autocuration,1,CHEMBL630600,,1088.0
13760,U,Removal of 238-Plutonium(IV) in urine after 4-24 h,,,A,,BAO_0000019,12192,,,0,Autocuration,1,CHEMBL630601,,1088.0
13761,U,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),,,A,,BAO_0000019,12192,,,0,Autocuration,1,CHEMBL630602,,1088.0
13762,U,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),,,A,,BAO_0000019,12192,,,0,Autocuration,1,CHEMBL630603,,1088.0
13763,U,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),,,A,,BAO_0000019,12192,,,0,Autocuration,1,CHEMBL630604,,1088.0
13764,N,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL624869,,178.0
13765,N,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL624870,,178.0
13766,N,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL623189,,178.0
13767,N,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL623190,,178.0
13768,N,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL623191,,178.0
13769,N,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL623192,,
13770,N,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL623193,,
13771,N,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL623194,,
13772,N,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL623195,,
13773,N,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL623196,,
13774,N,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,,Rattus norvegicus,A,,BAO_0000218,11836,,10116.0,1,Intermediate,1,CHEMBL623197,,
13775,N,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,Rattus norvegicus,A,,BAO_0000218,11836,,10116.0,1,Intermediate,1,CHEMBL623198,,
13776,N,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,Rattus norvegicus,A,,BAO_0000218,11836,,10116.0,1,Intermediate,1,CHEMBL623199,,
13777,N,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,,Rattus norvegicus,A,,BAO_0000218,11836,,10116.0,1,Intermediate,1,CHEMBL623200,,2385.0
13778,N,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,,Rattus norvegicus,A,,BAO_0000218,11836,,10116.0,1,Intermediate,1,CHEMBL623201,,2385.0
13779,N,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,,Rattus norvegicus,A,,BAO_0000218,11836,,10116.0,1,Intermediate,1,CHEMBL623202,,2385.0
13780,N,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,,Rattus norvegicus,A,,BAO_0000218,11836,,10116.0,1,Intermediate,1,CHEMBL623203,,2385.0
13781,N,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,,Rattus norvegicus,A,,BAO_0000218,11836,,10116.0,1,Intermediate,1,CHEMBL623204,,2385.0
13782,N,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,,Rattus norvegicus,A,,BAO_0000218,11836,,10116.0,1,Intermediate,1,CHEMBL623205,,2385.0
13783,N,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,Rattus norvegicus,A,,BAO_0000218,11836,,10116.0,1,Intermediate,1,CHEMBL623206,,2385.0
13784,N,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,,Rattus norvegicus,A,,BAO_0000218,11836,,10116.0,1,Intermediate,1,CHEMBL623207,,2385.0
13785,N,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,,Rattus norvegicus,A,,BAO_0000218,11836,,10116.0,1,Intermediate,1,CHEMBL623208,,2385.0
13786,N,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,Rattus norvegicus,A,,BAO_0000218,11836,,10116.0,1,Intermediate,1,CHEMBL623209,,2385.0
13787,N,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,Rattus norvegicus,A,,BAO_0000218,11836,,10116.0,1,Intermediate,1,CHEMBL623210,,2385.0
13788,N,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,Rattus norvegicus,A,,BAO_0000218,11836,,10116.0,1,Intermediate,1,CHEMBL623211,,
13789,N,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,Rattus norvegicus,A,,BAO_0000218,11836,,10116.0,1,Intermediate,1,CHEMBL623212,,995.0
13790,U,Tested in vitro for intrinsic activity relative to quinpirole,,,A,,BAO_0000019,12640,,,0,Autocuration,1,CHEMBL623213,,
13791,U,"Relative ion enhancement, determined in pulsed ultrafiltration",,,A,,BAO_0000019,14218,,,0,Autocuration,1,CHEMBL623214,,
13792,U,% ionization at the pH 7.4 at 37 degree Centigrade,,,A,,BAO_0000019,11296,,,0,Autocuration,1,CHEMBL623215,,
13793,U,Percentage ionization was measured,,,A,,BAO_0000019,10929,,,0,Autocuration,1,CHEMBL623216,,
13794,N,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,,Bos taurus,A,,BAO_0000218,13841,,9913.0,1,Intermediate,1,CHEMBL623217,,
13795,U,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,,,A,,BAO_0000019,10431,,,0,Autocuration,1,CHEMBL623218,,
13796,U,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,,,A,,BAO_0000019,10431,,,0,Autocuration,1,CHEMBL623913,,
13797,U,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,,,A,,BAO_0000019,10431,,,0,Autocuration,1,CHEMBL623914,,
13798,U,Compound was evaluated for the partition coefficient in octanol/water,,,P,,BAO_0000100,8826,,,0,Autocuration,1,CHEMBL623915,,
13799,U,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),,,P,,BAO_0000100,8826,,,0,Autocuration,1,CHEMBL624080,,
13800,U,Equilibrium constant measured by the pulse radiolysis at pH 7,,,A,,BAO_0000019,9884,,,0,Autocuration,1,CHEMBL624081,,
13801,N,In vitro hydrolytic rate constant determined in human blood,,Homo sapiens,A,,BAO_0000218,9827,,9606.0,1,Intermediate,1,CHEMBL624082,,
13802,N,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,,Homo sapiens,A,,BAO_0000218,10009,,9606.0,1,Intermediate,1,CHEMBL625054,,
13803,U,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,,,A,,BAO_0000019,10009,,,0,Autocuration,1,CHEMBL877485,,
13804,N,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,,Mus musculus,A,,BAO_0000218,10009,,10090.0,1,Intermediate,1,CHEMBL625055,,
13805,N,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,,Mus musculus,A,,BAO_0000218,10009,,10090.0,1,Intermediate,1,CHEMBL625056,,
13806,N,In vitro oxidation of compound in presence of human plasma,,Homo sapiens,A,,BAO_0000218,10009,,9606.0,1,Intermediate,1,CHEMBL625057,,
13807,U,In vitro oxidation of compound in presence of hydrogen peroxide,,,A,,BAO_0000019,10009,,,0,Autocuration,1,CHEMBL625058,,
13808,N,In vitro oxidation of compound in presence of mouse brain homogenate,,Mus musculus,A,,BAO_0000218,10009,,10090.0,1,Intermediate,1,CHEMBL625059,,
13809,N,In vitro oxidation of compound in presence of mouse liver homogenate,,Mus musculus,A,,BAO_0000218,10009,,10090.0,1,Intermediate,1,CHEMBL629536,,
13810,N,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629537,,
13811,N,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629538,,
13812,N,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629539,,
13813,N,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL874445,,
13814,N,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629540,,
13815,N,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629541,,
13816,N,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629542,,
13817,N,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL630243,,
13818,N,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL630244,,
13819,N,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL630245,,
13820,N,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL630246,,
13821,N,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL630247,,
13822,N,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL630248,,
13823,N,Biodistribution in rat blood at 240 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630249,,178.0
13824,N,Biodistribution in rat blood at 30 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630250,,178.0
13825,N,Biodistribution in rat blood at 360 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630251,,178.0
13826,N,Biodistribution in rat blood at 3 hr after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630252,,178.0
13827,N,Biodistribution in rat blood at 60 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630408,,178.0
13828,N,Biodistribution in rat cerebellum at 120 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630409,,2037.0
13829,N,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL874446,,2037.0
13830,N,Biodistribution in rat cerebellum at 15 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630410,,2037.0
13831,N,Biodistribution in rat cerebellum at 240 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630411,,2037.0
13832,N,Biodistribution in rat cerebellum at 30 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630412,,2037.0
13833,N,Biodistribution in rat cerebellum at 360 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630413,,2037.0
13834,N,Biodistribution in rat cerebellum at 3 hr after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630414,,2037.0
13835,N,Biodistribution in rat cerebellum at 60 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630415,,2037.0
13836,N,Biodistribution in rat cortex at 120 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630416,,
13837,N,Biodistribution in rat cortex at 1440 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630417,,
13838,N,Biodistribution in rat cortex at 15 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630418,,
13839,N,Biodistribution in rat cortex at 240 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630419,,
13840,N,Biodistribution in rat cortex at 30 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630420,,
13841,N,Biodistribution in rat cortex at 360 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630421,,
13842,N,Biodistribution in rat cortex at 3 hr after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630422,,
13843,N,Biodistribution in rat cortex at 60 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630423,,
13844,N,Biodistribution in rat heart at 120 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630424,,948.0
13845,N,Biodistribution in rat heart at 15 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630425,,948.0
13846,N,Biodistribution in rat heart at 240 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL629462,,948.0
13847,N,Biodistribution in rat heart at 30 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630426,,948.0
13848,N,Biodistribution in rat heart at 360 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630427,,948.0
13849,N,Biodistribution in rat heart at 3 hr after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL625877,,948.0
13850,N,Biodistribution in rat heart at 60 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL625878,,948.0
13851,N,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL625879,,10000000.0
13852,N,Biodistribution in rat hippocampus at 240 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL625880,,10000000.0
13853,N,Biodistribution in rat hippocampus at 30 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL625881,,10000000.0
13854,N,Biodistribution in rat hippocampus at 360 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL625882,,10000000.0
13855,N,Biodistribution in rat hippocampus at 15 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL625883,,10000000.0
13856,N,Biodistribution in rat kidney at 120 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL625884,,2113.0
13857,N,Biodistribution in rat kidney at 1440 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL625885,,2113.0
13858,N,Biodistribution in rat kidney at 15 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628649,,2113.0
13859,N,Biodistribution in rat kidney at 240 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628650,,2113.0
13860,N,Biodistribution in rat kidney at 30 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628651,,2113.0
13861,N,Biodistribution in rat kidney at 360 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628652,,2113.0
13862,N,Biodistribution in rat kidney at 60 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628653,,2113.0
13863,N,Biodistribution in rat liver at 120 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628654,,2107.0
13864,N,Biodistribution in rat liver at 1440 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628655,,2107.0
13865,N,Biodistribution in rat liver at 15 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL625238,,2107.0
13866,N,Biodistribution in rat liver at 240 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL625239,,2107.0
13867,N,Biodistribution in rat liver at 30 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL625240,,2107.0
13868,N,Biodistribution in rat liver at 360 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL625241,,2107.0
13869,N,Biodistribution in rat liver at 60 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL625242,,2107.0
13870,N,Biodistribution in rat lung at 120 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL874587,,2048.0
13871,N,Biodistribution in rat lung at 1440 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL625405,,2048.0
13872,N,Biodistribution in rat lung at 15 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL625406,,2048.0
13873,N,Biodistribution in rat lung at 240 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL625407,,2048.0
13874,N,Biodistribution in rat lung at 30 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL625408,,2048.0
13875,N,Biodistribution in rat lung at 360 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL625409,,2048.0
13876,N,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,,Rattus norvegicus,A,,BAO_0000218,12361,,10116.0,1,Intermediate,1,CHEMBL625410,,1515.0
13877,N,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,,Rattus norvegicus,A,,BAO_0000218,12361,,10116.0,1,Intermediate,1,CHEMBL625411,,1515.0
13878,N,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,,Rattus norvegicus,A,,BAO_0000218,12361,,10116.0,1,Intermediate,1,CHEMBL625412,,1515.0
13879,N,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,,Rattus norvegicus,A,,BAO_0000218,12361,,10116.0,1,Intermediate,1,CHEMBL625413,,1515.0
13880,N,Percent of maximal contractile response to compound in rat thoracic aorta strips v,,Rattus norvegicus,A,,BAO_0000218,12361,,10116.0,1,Intermediate,1,CHEMBL625414,,1515.0
13881,N,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,,Rattus norvegicus,A,,BAO_0000218,12361,,10116.0,1,Intermediate,1,CHEMBL625415,,1515.0
13882,N,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,,Rattus norvegicus,A,,BAO_0000218,12361,,10116.0,1,Intermediate,1,CHEMBL625416,,1515.0
13883,N,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,,Rattus norvegicus,A,,BAO_0000218,12712,,10116.0,1,Intermediate,1,CHEMBL625417,,1088.0
13884,N,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,,Rattus norvegicus,A,,BAO_0000218,7415,,10116.0,1,Intermediate,1,CHEMBL625418,,1988.0
13885,N,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,,Rattus norvegicus,A,,BAO_0000218,7415,,10116.0,1,Intermediate,1,CHEMBL625419,,1088.0
13886,N,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,,Rattus norvegicus,A,,BAO_0000218,7415,,10116.0,1,Intermediate,1,CHEMBL625420,,
13887,N,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,,Rattus norvegicus,A,,BAO_0000218,7415,,10116.0,1,Intermediate,1,CHEMBL626996,,
13888,N,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",,Rattus norvegicus,A,,BAO_0000218,7415,,10116.0,1,Intermediate,1,CHEMBL626997,,1988.0
13889,N,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",,Rattus norvegicus,A,,BAO_0000218,7415,,10116.0,1,Intermediate,1,CHEMBL626998,,1088.0
13890,N,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",,Rattus norvegicus,A,,BAO_0000218,7415,,10116.0,1,Intermediate,1,CHEMBL626999,,
13891,N,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,,Mus musculus,A,,BAO_0000218,8050,,10090.0,1,Intermediate,1,CHEMBL627000,,
13892,N,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,,Mus musculus,A,,BAO_0000218,8050,,10090.0,1,Intermediate,1,CHEMBL627001,,
13893,N,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,,Mus musculus,A,,BAO_0000218,8050,,10090.0,1,Intermediate,1,CHEMBL627002,,
13894,N,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,,Mus musculus,A,,BAO_0000218,8050,,10090.0,1,Intermediate,1,CHEMBL627003,,
13895,N,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,,Mus musculus,A,,BAO_0000218,8050,,10090.0,1,Intermediate,1,CHEMBL627004,,1088.0
13896,N,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,,Mus musculus,A,,BAO_0000218,8050,,10090.0,1,Intermediate,1,CHEMBL627005,,1088.0
13897,N,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,,Mus musculus,A,,BAO_0000218,8050,,10090.0,1,Intermediate,1,CHEMBL874594,,1088.0
13898,N,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,,Mus musculus,A,,BAO_0000218,8050,,10090.0,1,Intermediate,1,CHEMBL627006,,1088.0
13899,N,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,,Mus musculus,A,,BAO_0000218,8050,,10090.0,1,Intermediate,1,CHEMBL627007,,1088.0
13900,N,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,,Mus musculus,A,,BAO_0000218,8050,,10090.0,1,Intermediate,1,CHEMBL627884,,1088.0
13901,N,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,,Mus musculus,A,,BAO_0000218,8050,,10090.0,1,Intermediate,1,CHEMBL627885,,1088.0
13902,N,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,,Mus musculus,A,,BAO_0000218,8050,,10090.0,1,Intermediate,1,CHEMBL627886,,1088.0
13903,N,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,,Mus musculus,A,,BAO_0000218,8050,,10090.0,1,Intermediate,1,CHEMBL627887,,1088.0
13904,N,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,,Mus musculus,A,,BAO_0000218,8050,,10090.0,1,Intermediate,1,CHEMBL627888,,1088.0
13905,N,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,,Mus musculus,A,,BAO_0000218,8050,,10090.0,1,Intermediate,1,CHEMBL628057,,1088.0
13906,N,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,,Mus musculus,A,,BAO_0000218,8050,,10090.0,1,Intermediate,1,CHEMBL627405,,1088.0
13907,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627406,,1088.0
13908,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627407,,1088.0
13909,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627408,,1088.0
13910,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627409,,1088.0
13911,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL875486,,1088.0
13912,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627410,,1088.0
13913,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627411,,1088.0
13914,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627412,,1088.0
13915,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627413,,1088.0
13916,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627414,,1088.0
13917,N,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627415,,1088.0
13918,N,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627416,,1088.0
13919,N,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627417,,1088.0
13920,N,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627418,,1088.0
13921,N,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627419,,1088.0
13922,N,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627320,,1088.0
13923,N,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627321,,1088.0
13924,N,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL627322,,2113.0
13925,N,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL627323,,2113.0
13926,N,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL627491,,2113.0
13927,N,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL627492,,2113.0
13928,N,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL627493,,2113.0
13929,N,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL627494,,2107.0
13930,N,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL627495,,2107.0
13931,N,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL627496,,2107.0
13932,N,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL627497,,2107.0
13933,N,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL627498,,2107.0
13934,N,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL627499,,2048.0
13935,N,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL627500,,2048.0
13936,N,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL627501,,2048.0
13937,N,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL625616,,2048.0
13938,N,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL625617,,2048.0
13939,N,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL625618,,2385.0
13940,N,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL625619,,2385.0
13941,N,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL625620,,2385.0
13942,N,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL625621,,2385.0
13943,N,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL625622,,2385.0
13944,N,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL625788,,2106.0
13945,N,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL625789,,2106.0
13946,N,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL625790,,2106.0
13947,N,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL625791,,2106.0
13948,N,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL622334,,2106.0
13949,N,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL622335,,2046.0
13950,N,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL622336,,2046.0
13951,N,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL622337,,2046.0
13952,N,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL622338,,2046.0
13953,N,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL622339,,2046.0
13954,N,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL624153,,
13955,N,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL628430,,
13956,N,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL628431,,
13957,N,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL628432,,
13958,N,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL628433,,
13959,N,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL628434,,2106.0
13960,N,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL626789,,2106.0
13961,N,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL626790,,2106.0
13962,N,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL626791,,2106.0
13963,N,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL626792,,2106.0
13964,N,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL626793,,2106.0
13965,N,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL627436,,
13966,N,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL627437,,
13967,N,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL627438,,
13968,N,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL627439,,
13969,N,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL627440,,
13970,N,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL627602,,
13971,N,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL627603,,
13972,N,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL627604,,
13973,N,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL627605,,
13974,N,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL627606,,
13975,N,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL627607,,
13976,N,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL627608,,
13977,N,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL627609,,
13978,N,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL627610,,
13979,N,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL627611,,
13980,N,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL627612,,
13981,U,Octanol:water partition coefficient is evaluated,,,P,,BAO_0000100,8362,,,0,Autocuration,1,CHEMBL627613,,
13982,U,Partition coefficient in 1-octanol/water system,,,P,,BAO_0000100,8257,,,0,Autocuration,1,CHEMBL627614,,
13983,U,Partition coefficient in 1-octanol/water system measured using radio active compounds,,,P,,BAO_0000100,8257,,,0,Autocuration,1,CHEMBL627615,,
13984,U,Partition coefficient in octanol/water system was determined,,,P,,BAO_0000100,9468,,,0,Autocuration,1,CHEMBL627616,,
13985,U,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,,,P,,BAO_0000100,9468,,,0,Autocuration,1,CHEMBL627617,,
13986,U,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,,,A,,BAO_0000019,10568,,,0,Autocuration,1,CHEMBL627618,,
13987,U,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",,,A,,BAO_0000019,10568,,,0,Autocuration,1,CHEMBL627619,,
13988,U,Pseudo-first-order rate constant of the compound,,,A,,BAO_0000019,15359,,,0,Autocuration,1,CHEMBL627620,,
13989,U,Pseudo-first-order rate constant with 1-min time point,,,A,,BAO_0000019,15359,,,0,Autocuration,1,CHEMBL627621,,
13990,U,Pseudo-first-order rate constant without 1-min time point,,,A,,BAO_0000019,15359,,,0,Autocuration,1,CHEMBL627622,,
13991,U,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,,,A,,BAO_0000019,10431,,,0,Autocuration,1,CHEMBL627623,,
13992,U,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,,,A,,BAO_0000019,10431,,,0,Autocuration,1,CHEMBL627624,,
13993,U,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,,,A,,BAO_0000019,10431,,,0,Autocuration,1,CHEMBL627625,,
13994,U,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,,,A,,BAO_0000019,15704,,,0,Autocuration,1,CHEMBL628523,,
13995,U,The alkaline hydrolysis second order rate constant(K OH) of the compound,,,A,,BAO_0000019,15287,,,0,Autocuration,1,CHEMBL628524,,
13996,U,The efflux rate constant of the compound,,,A,,BAO_0000019,7516,,,0,Autocuration,1,CHEMBL628525,,
13997,U,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,A,,BAO_0000019,12973,,,0,Autocuration,1,CHEMBL625732,,
13998,U,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,A,,BAO_0000019,12973,,,0,Autocuration,1,CHEMBL625733,,
13999,U,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,F,,BAO_0000019,12973,,,0,Autocuration,1,CHEMBL625734,,
14000,U,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,,,A,,BAO_0000019,12973,,,0,Autocuration,1,CHEMBL625913,,
14001,U,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,,,A,,BAO_0000019,8696,,,0,Autocuration,1,CHEMBL625914,,
14002,U,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,,,A,,BAO_0000019,15052,,,0,Autocuration,1,CHEMBL625915,,
14003,U,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,,,A,,BAO_0000019,15052,,,0,Autocuration,1,CHEMBL625916,,
14004,U,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),,,A,,BAO_0000019,10503,,,0,Autocuration,1,CHEMBL625917,,
14005,U,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL625918,,
14006,U,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL625919,,
14007,U,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL625920,,
14008,U,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL874453,,
14009,U,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL625921,,
14010,U,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,,,A,,BAO_0000019,10503,,,0,Autocuration,1,CHEMBL625922,,
14011,U,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL625923,,
14012,U,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL625924,,
14013,U,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL625925,,
14014,U,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL625926,,
14015,N,Biodistribution in rat lung at 60 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL627704,,2048.0
14016,N,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL627705,,
14017,N,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL627706,,
14018,N,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL627707,,
14019,N,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL627708,,
14020,N,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628361,,
14021,N,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628362,,
14022,N,Biodistribution in rat striatum at 120 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628363,,2435.0
14023,N,Biodistribution in rat striatum at 1440 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628364,,2435.0
14024,N,Biodistribution in rat striatum at 15 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628365,,2435.0
14025,N,Biodistribution in rat striatum at 240 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL874454,,2435.0
14026,N,Biodistribution in rat striatum at 30 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628531,,2435.0
14027,N,Biodistribution in rat striatum at 360 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628532,,2435.0
14028,N,Biodistribution in rat striatum at 3 hr after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628533,,2435.0
14029,N,Biodistribution in rat striatum at 60 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628534,,2435.0
14030,N,Biodistribution in rat thyroid at 120 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628535,,2046.0
14031,N,Biodistribution in rat thyroid at 1440 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628536,,2046.0
14032,N,Biodistribution in rat thyroid at 15 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628537,,2046.0
14033,N,Biodistribution in rat thyroid at 240 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628538,,2046.0
14034,N,Biodistribution in rat thyroid at 30 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628539,,2046.0
14035,N,Biodistribution in rat thyroid at 360 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630297,,2046.0
14036,N,Biodistribution in rat thyroid at 60 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630298,,2046.0
14037,N,Biodistribution in rest of brain of rat 120 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL630299,,955.0
14038,N,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628094,,955.0
14039,N,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628095,,955.0
14040,N,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL874648,,955.0
14041,N,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628096,,955.0
14042,N,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628097,,955.0
14043,N,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,,Rattus norvegicus,A,,BAO_0000218,13100,In vivo,10116.0,1,Intermediate,1,CHEMBL628098,,955.0
14044,U,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",,,A,,BAO_0000019,13331,,,0,Autocuration,1,CHEMBL628099,,
14045,U,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,,A,,BAO_0000019,13331,,,0,Autocuration,1,CHEMBL628100,,
14046,U,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),,,A,,BAO_0000019,13331,,,0,Autocuration,1,CHEMBL628101,,
14047,U,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",,,A,,BAO_0000019,13331,,,0,Autocuration,1,CHEMBL628102,,
14048,U,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",,,A,,BAO_0000019,13331,,,0,Autocuration,1,CHEMBL628103,,
14049,U,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,,A,,BAO_0000019,13331,,,0,Autocuration,1,CHEMBL628104,,
14050,U,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",,,A,,BAO_0000019,13331,,,0,Autocuration,1,CHEMBL628105,,
14051,U,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",,,A,,BAO_0000019,13331,,,0,Autocuration,1,CHEMBL628106,,
14052,N,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,Rattus norvegicus,A,,BAO_0000218,10086,,10116.0,1,Intermediate,1,CHEMBL628107,,1088.0
14053,U,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,,F,,BAO_0000218,10086,,,0,Autocuration,1,CHEMBL628108,,1088.0
14054,N,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,Rattus norvegicus,A,,BAO_0000218,10086,,10116.0,1,Intermediate,1,CHEMBL628109,,1088.0
14055,U,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,,F,,BAO_0000218,10086,,,0,Autocuration,1,CHEMBL625299,,1088.0
14056,N,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,,Rattus norvegicus,A,,BAO_0000218,10086,,10116.0,1,Intermediate,1,CHEMBL625300,,1088.0
14057,N,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,,Rattus norvegicus,A,,BAO_0000218,10086,,10116.0,1,Intermediate,1,CHEMBL625301,,1088.0
14058,N,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,,Rattus norvegicus,A,,BAO_0000218,10086,,10116.0,1,Intermediate,1,CHEMBL625302,,1088.0
14059,N,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,,Rattus norvegicus,A,,BAO_0000218,10086,,10116.0,1,Intermediate,1,CHEMBL874649,,1088.0
14060,N,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,,Rattus norvegicus,A,,BAO_0000218,13248,,10116.0,1,Intermediate,1,CHEMBL625303,,
14061,N,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,,Rattus norvegicus,A,,BAO_0000218,13248,,10116.0,1,Intermediate,1,CHEMBL625463,,
14062,N,In vitro metabolism in human liver microsomes,,Homo sapiens,A,,BAO_0000218,14527,,9606.0,1,Intermediate,1,CHEMBL625464,,2107.0
14063,N,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,,Homo sapiens,A,,BAO_0000218,3008,,9606.0,1,Intermediate,1,CHEMBL625465,,
14064,N,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL625466,,1088.0
14065,N,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL625467,,1088.0
14066,N,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL625468,,1088.0
14067,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL625469,,1088.0
14068,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL625470,,1088.0
14069,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL632418,,1088.0
14070,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL627250,,1088.0
14071,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL627251,,1088.0
14072,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL627252,,1088.0
14073,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL627253,,1088.0
14074,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL627254,,1088.0
14075,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL875471,,1088.0
14076,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL627255,,1088.0
14077,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL627256,,1088.0
14078,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL627257,,1088.0
14079,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL627258,,1088.0
14080,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL627259,,1088.0
14081,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL627260,,1088.0
14082,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623256,,1088.0
14083,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL874413,,1088.0
14084,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623257,,1088.0
14085,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623258,,1088.0
14086,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623259,,1088.0
14087,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623260,,1088.0
14088,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623261,,1088.0
14089,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623262,,1088.0
14090,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623263,,1088.0
14091,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623264,,1088.0
14092,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623265,,1088.0
14093,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623266,,1088.0
14094,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623267,,1088.0
14095,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623268,,1088.0
14096,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623269,,1088.0
14097,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623270,,1088.0
14098,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623271,,1088.0
14099,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623272,,1088.0
14100,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623273,,1088.0
14101,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623274,,1088.0
14102,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL874414,,1088.0
14103,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623275,,1088.0
14104,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL629150,,1088.0
14105,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623276,,1088.0
14106,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623277,,1088.0
14107,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623112,,1088.0
14108,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623113,,1088.0
14109,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623800,,1088.0
14110,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623801,,1088.0
14111,N,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL623802,,2106.0
14112,N,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL623803,,995.0
14113,N,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL623970,,995.0
14114,N,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL623971,,995.0
14115,N,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),,Rattus norvegicus,A,,BAO_0000218,14045,In vivo,10116.0,1,Intermediate,1,CHEMBL623972,,178.0
14116,N,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),,Rattus norvegicus,A,,BAO_0000218,14045,In vivo,10116.0,1,Intermediate,1,CHEMBL623973,,178.0
14117,N,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),,Rattus norvegicus,A,,BAO_0000218,14045,In vivo,10116.0,1,Intermediate,1,CHEMBL623974,,178.0
14118,N,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),,Rattus norvegicus,A,,BAO_0000218,14045,In vivo,10116.0,1,Intermediate,1,CHEMBL623975,,178.0
14119,N,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),,Rattus norvegicus,A,,BAO_0000218,14045,In vivo,10116.0,1,Intermediate,1,CHEMBL623976,,955.0
14120,N,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),,Rattus norvegicus,A,,BAO_0000218,14045,In vivo,10116.0,1,Intermediate,1,CHEMBL623977,,955.0
14121,N,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),,Rattus norvegicus,A,,BAO_0000218,14045,In vivo,10116.0,1,Intermediate,1,CHEMBL623978,,955.0
14122,N,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),,Rattus norvegicus,A,,BAO_0000218,14045,In vivo,10116.0,1,Intermediate,1,CHEMBL623979,,955.0
14123,N,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),,Rattus norvegicus,A,,BAO_0000218,14045,In vivo,10116.0,1,Intermediate,1,CHEMBL623980,,
14124,N,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),,Rattus norvegicus,A,,BAO_0000218,14045,In vivo,10116.0,1,Intermediate,1,CHEMBL623981,,
14125,N,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),,Rattus norvegicus,A,,BAO_0000218,14045,In vivo,10116.0,1,Intermediate,1,CHEMBL626278,,
14126,N,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),,Rattus norvegicus,A,,BAO_0000218,14045,In vivo,10116.0,1,Intermediate,1,CHEMBL626279,,
14127,N,Biodistribution in mice bladder plus excreted urine was determined,,Mus musculus,A,,BAO_0000218,14045,In vivo,10090.0,1,Intermediate,1,CHEMBL626280,,
14128,N,"Percentage biodistribution in mouse blood, 10 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL626281,,
14129,N,"Percentage biodistribution in mouse blood, 30 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL626282,,
14130,N,"Percentage biodistribution in mouse blood, 5 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL626283,,
14131,N,"Percentage biodistribution in mouse blood, 60 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL626284,,
14132,N,"Percentage biodistribution in mouse brain, 10 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL626285,,955.0
14133,N,"Percentage biodistribution in mouse brain, 30 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL626286,,955.0
14134,N,"Percentage biodistribution in mouse brain, 5 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL626287,,955.0
14135,N,"Percentage biodistribution in mouse brain, 60 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL626288,,955.0
14136,N,"Percentage biodistribution in mouse heart, 10 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL626289,,
14137,N,"Percentage biodistribution in mouse heart, 30 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL626290,,
14138,N,"Percentage biodistribution in mouse heart, 5 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL626291,,
14139,N,"Percentage biodistribution in mouse heart, 60 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL839888,,
14140,N,"Percentage biodistribution in mouse intestine, 10 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL626292,,160.0
14141,N,"Percentage biodistribution in mouse intestine, 30 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL626293,,160.0
14142,N,"Percentage biodistribution in mouse intestine, 5 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL626294,,160.0
14143,N,"Percentage biodistribution in mouse intestine, 60 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL626295,,160.0
14144,N,"Percentage biodistribution in mouse liver, 10 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL627659,,2107.0
14145,N,"Percentage biodistribution in mouse liver, 30 minutes of post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL627660,,2107.0
14146,N,"Percentage biodistribution in mouse liver, 5 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL627661,,2107.0
14147,N,Biodistribution in mice liver at 60 minutes of post injection,,Mus musculus,A,,BAO_0000218,14045,In vivo,10090.0,1,Intermediate,1,CHEMBL627662,,2107.0
14148,N,Biodistribution in mice lungs at 10 min of post injection,,Mus musculus,A,,BAO_0000218,14045,In vivo,10090.0,1,Intermediate,1,CHEMBL627663,,2048.0
14149,N,"Percentage biodistribution in mouse lung, 30 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL627664,,
14150,N,"Percentage biodistribution in mousee lung, 5 minutes post injection",,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL627665,,
14151,N,Biodistribution in mice lungs at 60 min of post injection,,Mus musculus,A,,BAO_0000218,14045,In vivo,10090.0,1,Intermediate,1,CHEMBL627666,,2048.0
14152,N,Percentage biodistribution in mouse spleen,,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL627667,,2106.0
14153,N,Percentage biodistribution in mouse stomach,,Mus musculus,A,,BAO_0000218,14045,,10090.0,1,Intermediate,1,CHEMBL627668,,945.0
14154,N,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,,Mus musculus,A,,BAO_0000218,11745,,10090.0,1,Intermediate,1,CHEMBL627669,,1088.0
14155,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627670,,1255.0
14156,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627671,,178.0
14157,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627672,,1474.0
14158,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627673,,
14159,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627674,,2113.0
14160,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627675,,2107.0
14161,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627676,,2048.0
14162,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627677,,2385.0
14163,U,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL627678,,
14164,N,Affinity for protein binding expressed as association constant in fresh rat serum,,Rattus norvegicus,A,,BAO_0000218,7095,,10116.0,1,Intermediate,1,CHEMBL627679,,1977.0
14165,U,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,,A,,BAO_0000019,12185,,,0,Autocuration,1,CHEMBL627680,,
14166,U,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,,A,,BAO_0000019,12185,,,0,Autocuration,1,CHEMBL627681,,
14167,U,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,,A,,BAO_0000019,12185,,,0,Autocuration,1,CHEMBL627682,,
14168,U,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,,A,,BAO_0000019,12185,,,0,Autocuration,1,CHEMBL627683,,
14169,U,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,,,A,,BAO_0000019,12686,,,0,Autocuration,1,CHEMBL627684,,
14170,U,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,,A,,BAO_0000019,12686,,,0,Autocuration,1,CHEMBL874441,,
14171,U,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,,,A,,BAO_0000019,12686,,,0,Autocuration,1,CHEMBL627685,,
14172,U,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,,A,,BAO_0000019,12686,,,0,Autocuration,1,CHEMBL627686,,
14173,U,Apparent rate constant Koff for inactivation of dTMP synthase.,,,A,,BAO_0000019,8057,,,0,Autocuration,1,CHEMBL627687,,
14174,U,The irreversible inhibitor activity by second order rate equation.,,,A,,BAO_0000019,15778,,,0,Autocuration,1,CHEMBL627688,,
14175,N,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,,Rattus norvegicus,A,,BAO_0000218,12375,,10116.0,1,Intermediate,1,CHEMBL628038,,
14176,N,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,,Rattus norvegicus,A,,BAO_0000218,12375,,10116.0,1,Intermediate,1,CHEMBL628039,,
14177,N,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,,Rattus norvegicus,A,,BAO_0000218,12375,,10116.0,1,Intermediate,1,CHEMBL628040,,
14178,U,Dissociation rate calculated from the first-order equation using t1/2 value,,,A,,BAO_0000019,13588,,,0,Autocuration,1,CHEMBL628041,,
14179,U,The compound was tested for Binding constant against DNA,,,A,,BAO_0000019,15039,,,0,Autocuration,1,CHEMBL630226,,
14180,U,First order rate constant for cyclization of the compound,,,A,,BAO_0000019,9500,,,0,Autocuration,1,CHEMBL628042,,
14181,U,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,,A,,BAO_0000019,10014,,,0,Autocuration,1,CHEMBL625232,,
14182,U,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,,A,,BAO_0000019,10014,,,0,Autocuration,1,CHEMBL625233,,
14183,U,Hydrolysis rate constant was determined,,,A,,BAO_0000019,568,,,0,Autocuration,1,CHEMBL625979,,
14184,U,Observed first order rate constant,,,A,,BAO_0000019,10026,,,0,Autocuration,1,CHEMBL625980,,
14185,U,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,A,,BAO_0000019,10281,,,0,Autocuration,1,CHEMBL625981,,
14186,U,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,A,,BAO_0000019,10281,,,0,Autocuration,1,CHEMBL625982,,
14187,U,Second-order rate constant for attack on PNPA at 25 degree Centigrade,,,A,,BAO_0000019,9680,,,0,Autocuration,1,CHEMBL625983,,
14188,U,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL625984,,
14189,U,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL625985,,
14190,U,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL625986,,
14191,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL625987,,
14192,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL625988,,
14193,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL625989,,
14194,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL625990,,
14195,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL625991,,
14196,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL625992,,
14197,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL625993,,
14198,U,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL631973,,
14199,U,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL632143,,
14200,U,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL632144,,
14201,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL632145,,
14202,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL632146,,
14203,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL632147,,
14204,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL632148,,
14205,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL632149,,
14206,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL632150,,
14207,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL632151,,
14208,N,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,,Homo sapiens,A,,BAO_0000218,3008,,9606.0,1,Intermediate,1,CHEMBL632152,,
14209,N,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,Homo sapiens,A,,BAO_0000218,4509,,9606.0,1,Intermediate,1,CHEMBL632153,,
14210,N,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,Homo sapiens,A,,BAO_0000218,4509,,9606.0,1,Intermediate,1,CHEMBL632154,,
14211,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL632155,,
14212,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL632156,,
14213,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL632157,,
14214,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL632158,,
14215,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL632159,,
14216,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL626305,,
14217,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL626306,,
14218,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL626307,,
14219,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL626308,,
14220,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL626479,,
14221,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,,Human herpesvirus 1,A,,BAO_0000218,8613,,10298.0,1,Intermediate,1,CHEMBL626480,,
14222,U,Calculated partition coefficient (clogP) (MlogP),,,P,,BAO_0000100,6021,,,0,Autocuration,1,CHEMBL626481,,
14223,U,Equipotent potent ratio relative to carbachol (nicotinic activity),,,A,,BAO_0000019,9348,,,0,Autocuration,1,CHEMBL626482,,
14224,N,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",,Canis lupus familiaris,A,,BAO_0000218,15592,,9615.0,1,Intermediate,1,CHEMBL626483,,
14225,N,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",,Canis lupus familiaris,A,,BAO_0000218,15592,,9615.0,1,Intermediate,1,CHEMBL626484,,
14226,U,Solubility at pH 7.4 in micro g/mL;NA denotes available,,,P,,BAO_0000100,15592,,,0,Autocuration,1,CHEMBL626485,,
14227,U,Solubility at pH 7.4 in micro g/mL;NA denotes not available,,,P,,BAO_0000100,15592,,,0,Autocuration,1,CHEMBL626486,,
14228,U,Solubility at pH 7.4 in ug/mL;NA denotes not available,,,P,,BAO_0000100,15592,,,0,Autocuration,1,CHEMBL626487,,
14229,N,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,Canis lupus familiaris,A,,BAO_0000218,15592,In vivo,9615.0,1,Intermediate,1,CHEMBL626488,,1969.0
14230,N,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,,Rattus norvegicus,A,,BAO_0000218,7095,,10116.0,1,Intermediate,1,CHEMBL626489,,1977.0
14231,U,Area under the MAP curve measured over 5 min; ND means Not determined,,,A,,BAO_0000019,16618,,,0,Autocuration,1,CHEMBL626490,,
14232,U,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,,,P,,BAO_0000100,16835,,,0,Autocuration,1,CHEMBL626491,,
14233,U,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,,,P,,BAO_0000100,15284,,,0,Autocuration,1,CHEMBL626492,,
14234,U,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,,,A,,BAO_0000019,15750,,,0,Autocuration,1,CHEMBL626493,,
14235,N,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,,Rattus norvegicus,A,,BAO_0000218,16618,In vivo,10116.0,1,Intermediate,1,CHEMBL626494,,
14236,U,Half life after oral tested,,,A,,BAO_0000218,16618,In vivo,,0,Autocuration,1,CHEMBL626495,,
14237,N,Half life was determined in plasma of rat; NT indicates not tested,,Rattus norvegicus,A,,BAO_0000218,15812,,10116.0,1,Intermediate,1,CHEMBL626496,,1969.0
14238,N,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,,Rattus norvegicus,A,,BAO_0000218,16618,In vivo,10116.0,1,Intermediate,1,CHEMBL626497,,
14239,U,Oral bioavailability after oral tested,,,A,,BAO_0000218,16618,In vivo,,0,Autocuration,1,CHEMBL626498,,
14240,N,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),,Rattus norvegicus,A,,BAO_0000218,13098,,10116.0,1,Intermediate,1,CHEMBL626499,,
14241,N,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),,Rattus norvegicus,A,,BAO_0000218,13098,,10116.0,1,Intermediate,1,CHEMBL626500,,
14242,N,half life was determined in plasma of rat; NT indicates not tested,,Rattus norvegicus,A,,BAO_0000218,15812,,10116.0,1,Intermediate,1,CHEMBL626501,,1969.0
14243,N,half life was determined in plasma of rat; NT means not tested,,Rattus norvegicus,A,,BAO_0000218,15812,,10116.0,1,Intermediate,1,CHEMBL626502,,1969.0
14244,N,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL626503,,
14245,N,Mean sodium excretion in rats (Control/Drug treatment value); inactive,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL626504,,
14246,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL626505,,
14247,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL626506,,
14248,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL626507,,
14249,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL626508,,
14250,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL626509,,
14251,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL875480,,
14252,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL626510,,
14253,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL626511,,
14254,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL626512,,
14255,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL628208,,
14256,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL628209,,
14257,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL628210,,
14258,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL628211,,
14259,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL628212,,
14260,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL628213,,
14261,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628214,,1088.0
14262,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628215,,1088.0
14263,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628216,,1088.0
14264,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626595,,1088.0
14265,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626596,,1088.0
14266,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626597,,1088.0
14267,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626598,,1088.0
14268,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL622242,,1088.0
14269,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL622243,,1088.0
14270,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL622244,,1088.0
14271,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL622245,,1088.0
14272,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL622246,,1088.0
14273,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL622247,,1088.0
14274,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL622248,,1088.0
14275,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL877483,,1088.0
14276,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL622249,,1088.0
14277,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL622250,,1088.0
14278,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL622251,,1088.0
14279,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL622252,,1088.0
14280,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL622253,,1088.0
14281,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL622254,,1088.0
14282,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL622255,,1088.0
14283,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL622256,,1088.0
14284,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL622257,,1088.0
14285,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL622258,,1088.0
14286,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL622259,,1088.0
14287,N,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL622927,,1088.0
14288,N,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL622928,,1088.0
14289,N,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL622929,,1088.0
14290,N,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL623182,,1088.0
14291,N,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL623183,,1088.0
14292,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623184,,1088.0
14293,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623185,,1088.0
14294,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL877484,,1088.0
14295,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL627274,,1088.0
14296,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623186,,1088.0
14297,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623187,,1088.0
14298,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL623188,,1088.0
14299,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628055,,1088.0
14300,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628056,,1088.0
14301,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628200,,1088.0
14302,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628201,,1088.0
14303,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628202,,1088.0
14304,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628203,,1088.0
14305,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628204,,1088.0
14306,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628205,,1088.0
14307,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628206,,1088.0
14308,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL628207,,2367.0
14309,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627220,,2367.0
14310,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627221,,2385.0
14311,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627222,,2367.0
14312,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627223,,
14313,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL632062,,2385.0
14314,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL632063,,2106.0
14315,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL632064,,1255.0
14316,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL632065,,178.0
14317,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL632066,,1474.0
14318,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL632067,,
14319,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629188,,2113.0
14320,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629189,,2107.0
14321,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629190,,2048.0
14322,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629191,,2385.0
14323,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629192,,2367.0
14324,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629193,,2385.0
14325,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629194,,2367.0
14326,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629195,,
14327,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629373,,2385.0
14328,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629374,,2106.0
14329,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629375,,2367.0
14330,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629376,,1255.0
14331,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629377,,178.0
14332,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629378,,1474.0
14333,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629379,,
14334,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629151,,2113.0
14335,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629152,,2107.0
14336,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629153,,2048.0
14337,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629154,,2385.0
14338,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629155,,2367.0
14339,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629156,,2367.0
14340,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629157,,2385.0
14341,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629158,,2367.0
14342,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629159,,
14343,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629160,,2385.0
14344,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629161,,2106.0
14345,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629162,,1255.0
14346,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629163,,178.0
14347,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629164,,1474.0
14348,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629165,,
14349,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629166,,2107.0
14350,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629167,,2048.0
14351,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL629168,,2385.0
14352,U,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,,,A,,BAO_0000019,2193,,,0,Autocuration,1,CHEMBL629169,,
14353,U,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,,,A,,BAO_0000019,2193,,,0,Autocuration,1,CHEMBL629170,,
14354,U,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,,,A,,BAO_0000019,2193,,,0,Autocuration,1,CHEMBL631153,,
14355,U,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,,,A,,BAO_0000019,2193,,,0,Autocuration,1,CHEMBL875121,,
14356,U,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,,,A,,BAO_0000019,2193,,,0,Autocuration,1,CHEMBL631154,,
14357,U,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,,,A,,BAO_0000019,2193,,,0,Autocuration,1,CHEMBL631155,,
14358,U,Hydrolysis rate constant was determined,,,A,,BAO_0000019,568,,,0,Autocuration,1,CHEMBL631156,,
14359,U,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",,,A,,BAO_0000019,9680,,,0,Autocuration,1,CHEMBL631157,,
14360,U,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,,A,,BAO_0000019,9680,,,0,Autocuration,1,CHEMBL631158,,
14361,U,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,,A,,BAO_0000019,9680,,,0,Autocuration,1,CHEMBL631159,,
14362,U,Observed second order rate constant,,,A,,BAO_0000019,10026,,,0,Autocuration,1,CHEMBL631160,,
14363,U,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,A,,BAO_0000019,10281,,,0,Autocuration,1,CHEMBL631161,,
14364,U,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,,A,,BAO_0000019,10014,,,0,Autocuration,1,CHEMBL631162,,
14365,U,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,,A,,BAO_0000019,10014,,,0,Autocuration,1,CHEMBL630313,,
14366,U,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,,A,,BAO_0000019,9680,,,0,Autocuration,1,CHEMBL630314,,
14367,U,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,,A,,BAO_0000019,9680,,,0,Autocuration,1,CHEMBL630315,,
14368,U,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL630316,,
14369,U,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL630986,,
14370,U,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL630987,,
14371,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL630988,,
14372,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL630989,,
14373,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL630990,,
14374,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL630991,,
14375,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL630992,,
14376,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL630993,,
14377,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,A,,BAO_0000019,13028,,,0,Autocuration,1,CHEMBL630994,,
14378,N,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,,Rattus norvegicus,A,,BAO_0000218,10014,,10116.0,1,Intermediate,1,CHEMBL630995,,
14379,U,Association constant for compound at 31 degree C was determined,,,A,,BAO_0000019,9962,,,0,Autocuration,1,CHEMBL629252,,
14380,U,Calculated antagonist equilibrium dissociation constant of the compound,,,A,,BAO_0000019,12029,,,0,Autocuration,1,CHEMBL629253,,
14381,U,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,,,A,,BAO_0000019,12029,,,0,Autocuration,1,CHEMBL629944,,
14382,N,Dissociation constants vs LTE4 on guinea pig trachea,,Cavia porcellus,A,,BAO_0000218,10583,,10141.0,1,Intermediate,1,CHEMBL629945,,3126.0
14383,U,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",,,A,,BAO_0000019,568,,,0,Autocuration,1,CHEMBL629946,,
14384,U,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",,,A,,BAO_0000019,568,,,0,Autocuration,1,CHEMBL629947,,
14385,U,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",,,A,,BAO_0000019,568,,,0,Autocuration,1,CHEMBL629948,,
14386,U,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",,,A,,BAO_0000019,568,,,0,Autocuration,1,CHEMBL856024,,
14387,U,Affinity constant KD value was derived from TMP,,,A,,BAO_0000019,7493,,,0,Autocuration,1,CHEMBL629949,,
14388,U,Apparent dissociation (binding) rate constant was evaluated,,,A,,BAO_0000019,8371,,,0,Autocuration,1,CHEMBL629950,,
14389,U,Dissociation constant (KD) of the compound,,,P,,BAO_0000100,13114,,,0,Autocuration,1,CHEMBL630127,,
14390,U,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,,,P,,BAO_0000100,15515,,,0,Autocuration,1,CHEMBL630128,,
14391,U,Dissociation constant from ESR titration experiments,,,P,,BAO_0000100,522,,,0,Autocuration,1,CHEMBL630129,,
14392,U,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,,,,BAO_0000019,13888,,,0,Autocuration,1,CHEMBL630130,,
14393,U,Dissociation constant was evaluated.,,,P,,BAO_0000100,2616,,,0,Autocuration,1,CHEMBL875234,,
14394,U,Dissociation constant was reported,,,P,,BAO_0000100,3798,,,0,Autocuration,1,CHEMBL630131,,
14395,N,Dissociation constant was determined in rat pituitary cells.,,Rattus norvegicus,A,,BAO_0000218,8731,,10116.0,1,Intermediate,1,CHEMBL630132,,
14396,U,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,,,A,,BAO_0000019,11892,,,0,Autocuration,1,CHEMBL630133,,
14397,U,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,,,A,,BAO_0000019,11892,,,0,Autocuration,1,CHEMBL630134,,
14398,U,Equilibrium dissociation constant of the compound,,,A,,BAO_0000019,2582,,,0,Autocuration,1,CHEMBL630135,,
14399,U,Equilibrium dissociation constant was determined,,,A,,BAO_0000019,11892,,,0,Autocuration,1,CHEMBL630136,,
14400,U,Kinetic constant KD was evaluated,,,A,,BAO_0000019,13396,,,0,Autocuration,1,CHEMBL630137,,
14401,U,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,,,A,,BAO_0000019,603,,,0,Autocuration,1,CHEMBL630138,,
14402,U,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,,,A,,BAO_0000019,15673,,,0,Autocuration,1,CHEMBL630139,,
14403,U,Rate constant for hydrolysis in aqueous acetone.,,,A,,BAO_0000019,10368,,,0,Autocuration,1,CHEMBL630140,,
14404,U,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,,,A,,BAO_0000019,14228,,,0,Autocuration,1,CHEMBL875235,,
14405,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL876439,,
14406,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL630605,,
14407,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL630606,,
14408,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL630607,,
14409,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL630608,,
14410,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL630609,,
14411,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL630610,,
14412,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL630611,,
14413,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629552,,
14414,N,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629733,,
14415,N,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629734,,
14416,N,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629735,,
14417,N,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629736,,
14418,N,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629737,,
14419,N,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629738,,
14420,N,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629739,,
14421,N,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629740,,
14422,N,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629741,,
14423,N,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629742,,
14424,N,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629743,,
14425,N,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629744,,
14426,N,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629745,,
14427,N,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629746,,
14428,N,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629747,,
14429,N,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629748,,
14430,N,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629749,,
14431,N,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629750,,
14432,N,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629751,,
14433,N,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629752,,
14434,N,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629753,,
14435,N,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629754,,
14436,N,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629755,,
14437,N,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629756,,
14438,N,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629757,,
14439,N,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629758,,
14440,N,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629759,,
14441,N,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL629760,,
14442,N,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,Rattus norvegicus,A,,BAO_0000218,11510,,10116.0,1,Intermediate,1,CHEMBL876443,,
14443,N,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,,Canis lupus familiaris,A,,BAO_0000218,8310,,9615.0,1,Intermediate,1,CHEMBL629761,,
14444,N,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,,Canis lupus familiaris,A,,BAO_0000218,8310,,9615.0,1,Intermediate,1,CHEMBL629762,,
14445,N,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,Mus musculus,A,,BAO_0000218,8310,,10090.0,1,Intermediate,1,CHEMBL629763,,
14446,N,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,Mus musculus,A,,BAO_0000218,8310,,10090.0,1,Intermediate,1,CHEMBL629764,,
14447,N,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,Mus musculus,A,,BAO_0000218,8310,,10090.0,1,Intermediate,1,CHEMBL629765,,
14448,N,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,,Mus musculus,A,,BAO_0000218,8310,,10090.0,1,Intermediate,1,CHEMBL629766,,
14449,N,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,Mus musculus,A,,BAO_0000218,8310,,10090.0,1,Intermediate,1,CHEMBL629767,,
14450,N,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,,Canis lupus familiaris,A,,BAO_0000218,8310,,9615.0,1,Intermediate,1,CHEMBL629768,,
14451,N,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,,Mus musculus,A,,BAO_0000218,8310,,10090.0,1,Intermediate,1,CHEMBL629769,,
14452,N,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,,Canis lupus familiaris,A,,BAO_0000218,8310,,9615.0,1,Intermediate,1,CHEMBL629770,,
14453,N,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,,Canis lupus familiaris,A,,BAO_0000218,8310,,9615.0,1,Intermediate,1,CHEMBL629771,,
14454,N,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,Mus musculus,A,,BAO_0000218,8310,,10090.0,1,Intermediate,1,CHEMBL629772,,
14455,N,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,Mus musculus,A,,BAO_0000218,8310,,10090.0,1,Intermediate,1,CHEMBL629773,,
14456,N,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,Mus musculus,A,,BAO_0000218,8310,,10090.0,1,Intermediate,1,CHEMBL625455,,
14457,N,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,,Mus musculus,A,,BAO_0000218,8310,,10090.0,1,Intermediate,1,CHEMBL625456,,
14458,N,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,,Mus musculus,A,,BAO_0000218,8310,,10090.0,1,Intermediate,1,CHEMBL625457,,
14459,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL625458,,1088.0
14460,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL625459,,1088.0
14461,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL875483,,1088.0
14462,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL634779,,1088.0
14463,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL625460,,1088.0
14464,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626117,,1088.0
14465,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626118,,1088.0
14466,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628342,,1088.0
14467,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628343,,1088.0
14468,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628344,,1088.0
14469,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628345,,1088.0
14470,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628346,,1088.0
14471,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628347,,1088.0
14472,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628348,,1088.0
14473,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628349,,1088.0
14474,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL875611,,1088.0
14475,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628350,,1088.0
14476,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628351,,1088.0
14477,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628352,,1088.0
14478,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628353,,1088.0
14479,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628354,,1088.0
14480,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626667,,1088.0
14481,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626668,,1088.0
14482,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626669,,1088.0
14483,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626670,,1088.0
14484,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626671,,1088.0
14485,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626672,,1088.0
14486,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626673,,1088.0
14487,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626674,,1088.0
14488,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626675,,1088.0
14489,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626676,,1088.0
14490,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626677,,1088.0
14491,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626678,,1088.0
14492,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626679,,1088.0
14493,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL875612,,1088.0
14494,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626680,,1088.0
14495,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626681,,1088.0
14496,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626682,,1088.0
14497,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626683,,1088.0
14498,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626684,,1088.0
14499,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626685,,1088.0
14500,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626686,,1088.0
14501,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626687,,1088.0
14502,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL624978,,1088.0
14503,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL624979,,1088.0
14504,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL624980,,1088.0
14505,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL624981,,1088.0
14506,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL624982,,1088.0
14507,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627564,,2367.0
14508,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627565,,2367.0
14509,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627566,,
14510,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627567,,2385.0
14511,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627568,,2106.0
14512,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627569,,2113.0
14513,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627570,,1255.0
14514,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627571,,178.0
14515,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627572,,1474.0
14516,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627573,,
14517,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627574,,2113.0
14518,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627575,,2107.0
14519,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627576,,2048.0
14520,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627577,,2385.0
14521,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627578,,2367.0
14522,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627579,,2367.0
14523,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627580,,2385.0
14524,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627581,,2367.0
14525,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627582,,
14526,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627583,,2385.0
14527,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627584,,2106.0
14528,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627585,,2367.0
14529,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,,,A,,BAO_0000218,13257,In vivo,,0,Autocuration,1,CHEMBL627586,,2385.0
14530,N,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL627587,,
14531,N,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL627588,,
14532,N,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL628250,,
14533,N,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL628251,,
14534,N,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL628252,,10000000.0
14535,N,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL628253,,10000000.0
14536,N,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL628254,,1898.0
14537,N,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL877493,,1898.0
14538,N,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL628255,,
14539,N,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL628256,,
14540,N,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL628257,,10000000.0
14541,N,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL628258,,1898.0
14542,N,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL628259,,
14543,N,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL628429,,
14544,N,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL626862,,10000000.0
14545,N,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL626863,,1898.0
14546,N,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL625886,,2037.0
14547,N,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL625887,,2037.0
14548,N,Biodistribution of the [11C]-radiolabeled compound in rat cortex,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL625888,,
14549,N,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL625889,,
14550,N,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL625890,,10000000.0
14551,N,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL625891,,10000000.0
14552,N,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL625892,,1898.0
14553,N,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL625893,,1898.0
14554,N,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL625894,,2037.0
14555,N,Biodistribution of the [18F]-radiolabeled compound in rat cortex,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL625895,,
14556,U,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,A,,BAO_0000019,12404,,,0,Autocuration,1,CHEMBL625896,,
14557,U,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",,,A,,BAO_0000019,568,,,0,Autocuration,1,CHEMBL625897,,
14558,U,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,,A,,BAO_0000019,568,,,0,Autocuration,1,CHEMBL625898,,
14559,U,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,,A,,BAO_0000019,568,,,0,Autocuration,1,CHEMBL625899,,
14560,U,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,A,,BAO_0000019,12404,,,0,Autocuration,1,CHEMBL626124,,
14561,N,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,,Escherichia coli,A,,BAO_0000218,7624,,562.0,1,Intermediate,1,CHEMBL628500,,
14562,N,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",,Rattus norvegicus,A,,BAO_0000218,7624,,10116.0,1,Intermediate,1,CHEMBL857856,,
14563,N,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",,Rattus norvegicus,A,,BAO_0000218,7624,,10116.0,1,Intermediate,1,CHEMBL628501,,
14564,U,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",,,A,,BAO_0000019,4643,,,0,Autocuration,1,CHEMBL628502,,
14565,U,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,,,A,,BAO_0000019,11532,,,0,Autocuration,1,CHEMBL628503,,
14566,U,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,,,A,,BAO_0000019,11018,,,0,Autocuration,1,CHEMBL628504,,
14567,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,,A,,BAO_0000019,2276,,,0,Autocuration,1,CHEMBL628505,,
14568,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",,,A,,BAO_0000019,2276,,,0,Autocuration,1,CHEMBL874452,,
14569,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",,,A,,BAO_0000019,2276,,,0,Autocuration,1,CHEMBL628506,,
14570,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,,A,,BAO_0000019,2276,,,0,Autocuration,1,CHEMBL628507,,
14571,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",,,A,,BAO_0000019,2276,,,0,Autocuration,1,CHEMBL628508,,
14572,U,Michaelis constant (KM) was evaluated,,,A,,BAO_0000019,8949,,,0,Autocuration,1,CHEMBL628509,,
14573,U,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,A,,BAO_0000019,12404,,,0,Autocuration,1,CHEMBL628510,,
14574,U,Substrate concentration for half maximal velocity was reported for rat hexokinase I,,,B,,BAO_0000019,7625,,,0,Autocuration,1,CHEMBL628511,,
14575,U,Substrate concentration for half maximal velocity was reported for rat hexokinase II,,,B,,BAO_0000019,7625,,,0,Autocuration,1,CHEMBL628512,,
14576,U,Substrate concentration for half maximal velocity was reported for rat hexokinase III,,,B,,BAO_0000019,7625,,,0,Autocuration,1,CHEMBL628513,,
14577,U,Substrate concentration for half maximal velocity was reported for yeast hexokinase,,,B,,BAO_0000019,7625,,,0,Autocuration,1,CHEMBL628514,,
14578,U,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,,,A,,BAO_0000019,12908,,,0,Autocuration,1,CHEMBL628515,,
14579,U,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,,,A,,BAO_0000019,10368,,,0,Autocuration,1,CHEMBL628516,,
14580,U,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,,A,,BAO_0000019,13108,,,0,Autocuration,1,CHEMBL628517,,
14581,U,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,,A,,BAO_0000019,13108,,,0,Autocuration,1,CHEMBL628518,,
14582,U,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,,,A,,BAO_0000019,15217,,,0,Autocuration,1,CHEMBL628519,,
14583,U,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,,,A,,BAO_0000019,15217,,,0,Autocuration,1,CHEMBL628520,,
14584,U,Binding constant was determined,,,A,,BAO_0000019,10933,,,0,Autocuration,1,CHEMBL628521,,
14585,U,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,,,A,,BAO_0000019,2363,,,0,Autocuration,1,CHEMBL630443,,
14586,U,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,,,A,,BAO_0000019,2363,,,0,Autocuration,1,CHEMBL630444,,
14587,U,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,,,A,,BAO_0000019,2276,,,0,Autocuration,1,CHEMBL857732,,
14588,U,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,,,P,,BAO_0000100,14915,,,0,Autocuration,1,CHEMBL630445,,
14589,U,Catalytic rate constant of the compound,,,A,,BAO_0000019,8847,,,0,Autocuration,1,CHEMBL630446,,
14590,U,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,,,B,,BAO_0000019,15357,,,0,Autocuration,1,CHEMBL630447,,
14591,U,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),,,A,,BAO_0000019,2869,,,0,Autocuration,1,CHEMBL630448,,
14592,U,Catalytic rate constant against phospholipase A2 was determined,,,A,,BAO_0000019,3484,,,0,Autocuration,1,CHEMBL630449,,
14593,U,"Compound was evaluated for catalytic constant, Kcat",,,A,,BAO_0000019,1373,,,0,Autocuration,1,CHEMBL630450,,
14594,U,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,,,A,,BAO_0000019,8142,,,0,Autocuration,1,CHEMBL630451,,
14595,U,Kcat calculated from 0.693/T1/2,,,A,,BAO_0000019,14131,,,0,Autocuration,1,CHEMBL630452,,
14596,U,Kcat was determined,,,A,,BAO_0000019,17269,,,0,Autocuration,1,CHEMBL630453,,
14597,U,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,,,A,,BAO_0000019,3485,,,0,Autocuration,1,CHEMBL630454,,
14598,U,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,,,A,,BAO_0000019,3485,,,0,Autocuration,1,CHEMBL630455,,
14599,U,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,,,A,,BAO_0000019,3485,,,0,Autocuration,1,CHEMBL631487,,
14600,U,Kcat value was determined,,,A,,BAO_0000019,5962,,,0,Autocuration,1,CHEMBL631488,,
14601,U,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,,,A,,BAO_0000019,3133,,,0,Autocuration,1,CHEMBL876440,,
14602,U,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,,,A,,BAO_0000019,3133,,,0,Autocuration,1,CHEMBL631489,,
14603,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,,A,,BAO_0000019,2276,,,0,Autocuration,1,CHEMBL857742,,
14604,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",,,A,,BAO_0000019,2276,,,0,Autocuration,1,CHEMBL631490,,
14605,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",,,A,,BAO_0000019,2276,,,0,Autocuration,1,CHEMBL631491,,
14606,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,,A,,BAO_0000019,2276,,,0,Autocuration,1,CHEMBL631492,,
14607,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",,,A,,BAO_0000019,2276,,,0,Autocuration,1,CHEMBL631493,,
14608,U,Kinetic parameter for rate of conversion to PABA was determined,,,A,,BAO_0000019,4892,,,0,Autocuration,1,CHEMBL631494,,
14609,U,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,,A,,BAO_0000019,3133,,,0,Autocuration,1,CHEMBL631495,,
14610,N,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL631496,,1988.0
14611,N,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL631497,,1088.0
14612,N,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL631498,,1088.0
14613,N,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL629776,,1088.0
14614,N,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL629777,,1088.0
14615,N,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL629778,,1088.0
14616,N,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL630456,,
14617,N,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL630457,,
14618,N,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL630458,,
14619,N,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL630459,,
14620,N,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL630460,,
14621,N,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL876550,,
14622,N,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL630461,,
14623,N,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL630462,,
14624,N,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL630463,,
14625,N,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL630464,,
14626,N,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL630465,,
14627,N,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL630466,,
14628,N,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL630467,,
14629,N,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL630633,,
14630,N,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL630634,,
14631,N,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL630635,,
14632,N,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL630636,,
14633,N,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,,Rattus norvegicus,A,,BAO_0000218,11488,,10116.0,1,Intermediate,1,CHEMBL630637,,
14634,N,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL630638,,1988.0
14635,N,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL630639,,1988.0
14636,N,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL630640,,1988.0
14637,N,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL876551,,1988.0
14638,N,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL630641,,1088.0
14639,N,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL630642,,1088.0
14640,N,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL630643,,1088.0
14641,N,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL630644,,1088.0
14642,N,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL630645,,1088.0
14643,N,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL625599,,1988.0
14644,N,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL625600,,1988.0
14645,N,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL625601,,1988.0
14646,N,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL625602,,1988.0
14647,N,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL627470,,1088.0
14648,N,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL627471,,1088.0
14649,N,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL627472,,1088.0
14650,N,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL627473,,1088.0
14651,N,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,Oryctolagus cuniculus,A,,BAO_0000218,7132,,9986.0,1,Intermediate,1,CHEMBL627474,,1088.0
14652,N,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,Rattus norvegicus,A,,BAO_0000218,13925,In vivo,10116.0,1,Intermediate,1,CHEMBL627475,,178.0
14653,N,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,Rattus norvegicus,A,,BAO_0000218,13925,In vivo,10116.0,1,Intermediate,1,CHEMBL627476,,178.0
14654,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627477,,1088.0
14655,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627478,,1088.0
14656,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627479,,1088.0
14657,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627480,,1088.0
14658,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627481,,1088.0
14659,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627482,,1088.0
14660,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL627483,,1088.0
14661,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL875636,,1088.0
14662,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL625764,,1088.0
14663,N,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL625765,,1088.0
14664,N,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL625766,,1088.0
14665,N,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL625767,,1088.0
14666,N,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL625768,,1088.0
14667,N,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL625769,,1088.0
14668,N,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL625770,,1088.0
14669,N,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL625771,,1088.0
14670,N,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL625772,,1088.0
14671,N,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,Canis lupus familiaris,A,,BAO_0000218,12582,,9615.0,1,Intermediate,1,CHEMBL625773,,1088.0
14672,N,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL625774,,1088.0
14673,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL625775,,1088.0
14674,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL625776,,1088.0
14675,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL625777,,1088.0
14676,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL625778,,1088.0
14677,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL625779,,1088.0
14678,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL625780,,1088.0
14679,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL625781,,1088.0
14680,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL875637,,1088.0
14681,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626473,,1088.0
14682,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626474,,1088.0
14683,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626475,,1088.0
14684,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626476,,1088.0
14685,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL634397,,1088.0
14686,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL626477,,1088.0
14687,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631069,,1088.0
14688,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631070,,1088.0
14689,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631071,,1088.0
14690,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631072,,1088.0
14691,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631073,,1088.0
14692,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631074,,1088.0
14693,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631075,,1088.0
14694,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631725,,1088.0
14695,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631726,,1088.0
14696,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631727,,1088.0
14697,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631728,,1088.0
14698,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631729,,1088.0
14699,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631730,,1088.0
14700,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631731,,1088.0
14701,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631910,,1088.0
14702,N,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL631911,,10000000.0
14703,N,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL631912,,1898.0
14704,N,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,,Rattus norvegicus,A,,BAO_0000218,15413,In vivo,10116.0,1,Intermediate,1,CHEMBL631913,,1898.0
14705,N,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631914,,178.0
14706,N,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631915,,178.0
14707,N,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL875778,,178.0
14708,N,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631916,,178.0
14709,N,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631917,,178.0
14710,N,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631918,,178.0
14711,N,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631919,,178.0
14712,N,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631920,,178.0
14713,N,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631921,,178.0
14714,N,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631922,,178.0
14715,N,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631923,,178.0
14716,N,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631924,,
14717,N,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630234,,
14718,N,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630235,,
14719,N,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630236,,
14720,N,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630237,,
14721,N,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630238,,
14722,N,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630239,,
14723,N,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630303,,
14724,N,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630304,,
14725,N,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630305,,
14726,N,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630306,,2113.0
14727,N,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630307,,2113.0
14728,N,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630308,,2113.0
14729,N,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630309,,2113.0
14730,N,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL629309,,2113.0
14731,N,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL629993,,2113.0
14732,N,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL629994,,2113.0
14733,N,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL629995,,2113.0
14734,N,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631993,,2113.0
14735,N,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631994,,2113.0
14736,N,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631995,,2113.0
14737,N,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631996,,2107.0
14738,N,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631997,,2107.0
14739,N,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631998,,2107.0
14740,N,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631999,,2107.0
14741,N,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL632000,,2107.0
14742,N,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL632001,,2107.0
14743,N,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL874424,,2107.0
14744,N,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL632002,,2107.0
14745,N,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL632003,,2107.0
14746,U,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,,A,,BAO_0000019,3133,,,0,Autocuration,1,CHEMBL632004,,
14747,U,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,,,A,,BAO_0000019,2742,,,0,Autocuration,1,CHEMBL632005,,
14748,U,Compound was tested for amidase rate in the presence of N62C screen enzyme,,,A,,BAO_0000019,2742,,,0,Autocuration,1,CHEMBL632006,,
14749,U,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,,,A,,BAO_0000019,2742,,,0,Autocuration,1,CHEMBL632007,,
14750,U,Compound was tested for amidase rate in the presence of S166C screen enzyme,,,A,,BAO_0000019,2742,,,0,Autocuration,1,CHEMBL632008,,
14751,U,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,,,A,,BAO_0000019,2742,,,0,Autocuration,1,CHEMBL632009,,
14752,U,Compound was tested for esterase rate in the presence of N62C screen enzyme,,,A,,BAO_0000019,2742,,,0,Autocuration,1,CHEMBL632010,,
14753,U,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,,,A,,BAO_0000019,2742,,,0,Autocuration,1,CHEMBL857750,,
14754,U,Compound was tested for esterase rate in the presence of S166C screen enzyme,,,A,,BAO_0000019,2742,,,0,Autocuration,1,CHEMBL632011,,
14755,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,A,,BAO_0000019,2276,,,0,Autocuration,1,CHEMBL632012,,
14756,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,A,,BAO_0000019,2276,,,0,Autocuration,1,CHEMBL632013,,
14757,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",,,A,,BAO_0000019,2276,,,0,Autocuration,1,CHEMBL632014,,
14758,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,A,,BAO_0000019,2276,,,0,Autocuration,1,CHEMBL629622,,
14759,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,A,,BAO_0000019,2276,,,0,Autocuration,1,CHEMBL629623,,
14760,U,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",,,A,,BAO_0000019,2276,,,0,Autocuration,1,CHEMBL629624,,
14761,U,Ratio of Kcat to that of Km was determined,,,A,,BAO_0000019,17269,,,0,Autocuration,1,CHEMBL629625,,
14762,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,,A,,BAO_0000019,2276,,,0,Autocuration,1,CHEMBL629626,,
14763,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,,A,,BAO_0000019,2276,,,0,Autocuration,1,CHEMBL629627,,
14764,U,"Compound was evaluated for constant, Kd",,,A,,BAO_0000019,15917,,,0,Autocuration,1,CHEMBL629628,,
14765,U,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,,,A,,BAO_0000019,10933,,,0,Autocuration,1,CHEMBL629629,,
14766,U,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,,,A,,BAO_0000019,10933,,,0,Autocuration,1,CHEMBL629630,,
14767,U,Dissociation Constant of compound determined,,,A,,BAO_0000019,14293,,,0,Autocuration,1,CHEMBL856030,,
14768,U,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,,,B,,BAO_0000019,6698,,,0,Autocuration,1,CHEMBL629631,,
14769,U,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,,,B,,BAO_0000019,6698,,,0,Autocuration,1,CHEMBL629632,,
14770,U,Dissociation constant of compound with Fructose was determined,,,P,,BAO_0000100,4318,,,0,Autocuration,1,CHEMBL629633,,
14771,U,Dissociation constant of compound with Fructose was determined; Not determined,,,P,,BAO_0000100,4318,,,0,Autocuration,1,CHEMBL629634,,
14772,U,Dissociation constant of compound with Lactulose was determined,,,P,,BAO_0000100,4318,,,0,Autocuration,1,CHEMBL629635,,
14773,U,Dissociation constant of compound with Lactulose was determined; Not determined,,,P,,BAO_0000100,4318,,,0,Autocuration,1,CHEMBL629636,,
14774,U,Dissociation constant of the Compound,,,P,,BAO_0000100,14959,,,0,Autocuration,1,CHEMBL629637,,
14775,U,Dissociation constant by non-linear regression analysis,,,P,,BAO_0000100,5913,,,0,Autocuration,1,CHEMBL629638,,
14776,U,Dissociation constant was determined,,,P,,BAO_0000100,14218,,,0,Autocuration,1,CHEMBL629639,,
14777,U,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,,,P,,BAO_0000100,10689,,,0,Autocuration,1,CHEMBL629640,,
14778,U,Dissociation constant was determined,,,P,,BAO_0000100,13925,,,0,Autocuration,1,CHEMBL629641,,
14779,U,Dissociation constant was determined,,,P,,BAO_0000100,16359,,,0,Autocuration,1,CHEMBL631344,,
14780,N,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,,Rattus norvegicus,A,,BAO_0000218,10944,,10116.0,1,Intermediate,1,CHEMBL631345,,2385.0
14781,U,The dissociation constant determined by fluorescence displacement assay,,,A,,BAO_0000019,11080,,,0,Autocuration,1,CHEMBL631346,,
14782,U,kd value surface plasmon resonance (SPR) method,,,A,,BAO_0000019,17805,,,0,Autocuration,1,CHEMBL631524,,
14783,N,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,,Rattus norvegicus,A,,BAO_0000218,10944,,10116.0,1,Intermediate,1,CHEMBL631525,,2385.0
14784,U,First dissociation constant of the binding of compound to V30M TTR,,,F,,BAO_0000019,16645,,,0,Autocuration,1,CHEMBL631526,,
14785,U,Second dissociation constant of the binding of compound to V30M TTR,,,F,,BAO_0000019,16645,,,0,Autocuration,1,CHEMBL631527,,
14786,U,"Compound was evaluated for equilibrium constant, Ke",,,A,,BAO_0000019,7793,,,0,Autocuration,1,CHEMBL631528,,
14787,U,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,,,A,,BAO_0000019,12199,,,0,Autocuration,1,CHEMBL631529,,1898.0
14788,U,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,,,A,,BAO_0000019,12199,,,0,Autocuration,1,CHEMBL631530,,1898.0
14789,U,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,,,A,,BAO_0000019,9680,,,0,Autocuration,1,CHEMBL631531,,
14790,U,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,,A,,BAO_0000019,9680,,,0,Autocuration,1,CHEMBL631532,,
14791,U,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,,,A,,BAO_0000019,9680,,,0,Autocuration,1,CHEMBL631533,,
14792,N,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,Mus musculus,A,,BAO_0000218,13758,,10090.0,1,Intermediate,1,CHEMBL876552,,
14793,N,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,Mus musculus,A,,BAO_0000218,13758,,10090.0,1,Intermediate,1,CHEMBL631534,,
14794,N,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,Mus musculus,A,,BAO_0000218,13758,,10090.0,1,Intermediate,1,CHEMBL631535,,
14795,N,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,Mus musculus,A,,BAO_0000218,13758,,10090.0,1,Intermediate,1,CHEMBL631536,,
14796,N,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,,Mus musculus,A,,BAO_0000218,13758,,10090.0,1,Intermediate,1,CHEMBL631537,,
14797,N,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,Mus musculus,A,,BAO_0000218,13758,,10090.0,1,Intermediate,1,CHEMBL631538,,
14798,N,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,,Mus musculus,A,,BAO_0000218,13758,,10090.0,1,Intermediate,1,CHEMBL631539,,
14799,N,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,Mus musculus,A,,BAO_0000218,13758,,10090.0,1,Intermediate,1,CHEMBL631540,,
14800,N,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,Rattus norvegicus,A,,BAO_0000218,14393,,10116.0,1,Intermediate,1,CHEMBL625637,,
14801,N,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,Rattus norvegicus,A,,BAO_0000218,14393,,10116.0,1,Intermediate,1,CHEMBL625638,,
14802,N,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,A,,BAO_0000218,15078,,10116.0,1,Intermediate,1,CHEMBL625639,,
14803,N,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,Rattus norvegicus,A,,BAO_0000218,13925,In vivo,10116.0,1,Intermediate,1,CHEMBL625640,,955.0
14804,N,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,Rattus norvegicus,A,,BAO_0000218,13925,In vivo,10116.0,1,Intermediate,1,CHEMBL625641,,955.0
14805,N,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,Rattus norvegicus,A,,BAO_0000218,13925,In vivo,10116.0,1,Intermediate,1,CHEMBL625642,,948.0
14806,N,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,Rattus norvegicus,A,,BAO_0000218,13925,In vivo,10116.0,1,Intermediate,1,CHEMBL625643,,948.0
14807,N,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,Rattus norvegicus,A,,BAO_0000218,13925,In vivo,10116.0,1,Intermediate,1,CHEMBL625644,,2113.0
14808,N,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,Rattus norvegicus,A,,BAO_0000218,13925,In vivo,10116.0,1,Intermediate,1,CHEMBL625645,,2113.0
14809,N,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,Rattus norvegicus,A,,BAO_0000218,13925,In vivo,10116.0,1,Intermediate,1,CHEMBL625646,,2107.0
14810,N,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,Rattus norvegicus,A,,BAO_0000218,13925,In vivo,10116.0,1,Intermediate,1,CHEMBL625647,,2107.0
14811,N,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,Rattus norvegicus,A,,BAO_0000218,13925,In vivo,10116.0,1,Intermediate,1,CHEMBL625648,,2048.0
14812,N,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,,Rattus norvegicus,A,,BAO_0000218,13925,In vivo,10116.0,1,Intermediate,1,CHEMBL625649,,2048.0
14813,N,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,Rattus norvegicus,A,,BAO_0000218,13925,In vivo,10116.0,1,Intermediate,1,CHEMBL625650,,2385.0
14814,N,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,Rattus norvegicus,A,,BAO_0000218,13925,In vivo,10116.0,1,Intermediate,1,CHEMBL625651,,2385.0
14815,N,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,Rattus norvegicus,A,,BAO_0000218,13925,In vivo,10116.0,1,Intermediate,1,CHEMBL625652,,14.0
14816,N,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,Rattus norvegicus,A,,BAO_0000218,13925,In vivo,10116.0,1,Intermediate,1,CHEMBL625653,,14.0
14817,N,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,Rattus norvegicus,A,,BAO_0000218,13925,In vivo,10116.0,1,Intermediate,1,CHEMBL625654,,2106.0
14818,N,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,Rattus norvegicus,A,,BAO_0000218,13925,In vivo,10116.0,1,Intermediate,1,CHEMBL625655,,2106.0
14819,N,Biodistribution of Compound in rat blood after 15 minutes of administration,,Rattus norvegicus,A,,BAO_0000218,9712,In vivo,10116.0,1,Intermediate,1,CHEMBL625656,,178.0
14820,N,Biodistribution of Compound in rat blood after 2 minutes of administration,,Rattus norvegicus,A,,BAO_0000218,9712,In vivo,10116.0,1,Intermediate,1,CHEMBL625657,,178.0
14821,N,Biodistribution of Compound in rat brain after 15 minutes of administration,,Rattus norvegicus,A,,BAO_0000218,9712,In vivo,10116.0,1,Intermediate,1,CHEMBL625658,,955.0
14822,N,Biodistribution of Compound in rat brain after 2 minutes of administration,,Rattus norvegicus,A,,BAO_0000218,9712,In vivo,10116.0,1,Intermediate,1,CHEMBL625659,,955.0
14823,N,Biodistribution of Compound in rat heart after 15 minutes of administration,,Rattus norvegicus,A,,BAO_0000218,9712,In vivo,10116.0,1,Intermediate,1,CHEMBL625660,,948.0
14824,N,Biodistribution of Compound in rat heart after 2 minutes of administration,,Rattus norvegicus,A,,BAO_0000218,9712,In vivo,10116.0,1,Intermediate,1,CHEMBL625661,,948.0
14825,N,Biodistribution of Compound in rat liver after 15 minutes of administration,,Rattus norvegicus,A,,BAO_0000218,9712,In vivo,10116.0,1,Intermediate,1,CHEMBL625662,,2107.0
14826,N,Biodistribution of Compound in rat liver after 2 minutes of administration,,Rattus norvegicus,A,,BAO_0000218,9712,In vivo,10116.0,1,Intermediate,1,CHEMBL625663,,2107.0
14827,N,Biodistribution of Compound in rat lung after 15 minutes of administration,,Rattus norvegicus,A,,BAO_0000218,9712,In vivo,10116.0,1,Intermediate,1,CHEMBL875621,,2048.0
14828,N,Biodistribution of Compound in rat lung after 2 minutes of administration,,Rattus norvegicus,A,,BAO_0000218,9712,In vivo,10116.0,1,Intermediate,1,CHEMBL628382,,2048.0
14829,N,Biodistribution of Compound in rat muscle after 15 minutes of administration,,Rattus norvegicus,A,,BAO_0000218,9712,In vivo,10116.0,1,Intermediate,1,CHEMBL628383,,2385.0
14830,N,Biodistribution of Compound in rat muscle after 2 minutes of administration,,Rattus norvegicus,A,,BAO_0000218,9712,In vivo,10116.0,1,Intermediate,1,CHEMBL628384,,2385.0
14831,N,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,,Rattus norvegicus,A,,BAO_0000218,13925,,10116.0,1,Intermediate,1,CHEMBL628385,,
14832,N,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,,Rattus norvegicus,A,,BAO_0000218,13925,,10116.0,1,Intermediate,1,CHEMBL875753,,
14833,N,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,,Rattus norvegicus,A,,BAO_0000218,13925,,10116.0,1,Intermediate,1,CHEMBL628386,,
14834,N,Organ distribution in rat blood 2 minutes after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL628387,,
14835,N,Organ distribution in rat blood 2 hr after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL628388,,
14836,N,Organ distribution in rat blood 30 minutes after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL628389,,
14837,N,Organ distribution in rat blood 30 min after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL632756,,
14838,N,Organ distribution in rat brain 2 minutes after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL628390,,
14839,N,Organ distribution in rat brain 2 hr after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL631811,,
14840,N,Organ distribution in rat brain 30 minutes after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL631812,,
14841,N,Organ distribution in rat heart 2 minutes after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL631813,,
14842,N,Organ distribution in rat heart 2 hr after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL631814,,
14843,N,Organ distribution in rat heart 30 minutes after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL631815,,
14844,N,Organ distribution in rat kidney 2 minutes after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL631816,,
14845,N,Organ distribution in rat kidney 2 hr after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL875758,,
14846,N,Organ distribution in rat kidney 30 minutes after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL631817,,
14847,N,Organ distribution in rat liver 2 minutes after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL631818,,2107.0
14848,N,Organ distribution in rat liver 2 hr after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL631819,,2107.0
14849,N,Organ distribution in rat liver 30 minutes after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL631820,,2107.0
14850,N,Organ distribution in rat lung 2 minutes after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL631821,,
14851,N,Organ distribution in rat lung 2 hr after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL631822,,
14852,N,Organ distribution in rat lung 30 minutes after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL631823,,
14853,N,Organ distribution in rat muscle 2 minutes after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL631824,,2385.0
14854,N,Organ distribution in rat muscle 2 hr after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL631825,,2385.0
14855,N,Organ distribution in rat muscle 30 minutes after intravenous injection,,Rattus norvegicus,A,,BAO_0000218,6941,,10116.0,1,Intermediate,1,CHEMBL631826,,2385.0
14856,N,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),,Mus musculus,A,,BAO_0000218,14439,In vivo,10090.0,1,Intermediate,1,CHEMBL631827,,
14857,N,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),,Mus musculus,A,,BAO_0000218,14439,In vivo,10090.0,1,Intermediate,1,CHEMBL631828,,
14858,N,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),,Mus musculus,A,,BAO_0000218,14439,In vivo,10090.0,1,Intermediate,1,CHEMBL631829,,
14859,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL875759,,1088.0
14860,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631830,,1088.0
14861,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631831,,1088.0
14862,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631832,,1088.0
14863,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631833,,1088.0
14864,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631834,,1088.0
14865,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631835,,1088.0
14866,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631836,,1088.0
14867,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631837,,1088.0
14868,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631838,,1088.0
14869,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631839,,1088.0
14870,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631840,,1088.0
14871,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631841,,1088.0
14872,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631842,,1088.0
14873,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631843,,1088.0
14874,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631844,,1088.0
14875,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631845,,1088.0
14876,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631846,,1088.0
14877,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL875760,,1088.0
14878,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL632199,,1088.0
14879,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631847,,1088.0
14880,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL631848,,1088.0
14881,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628707,,1088.0
14882,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628708,,1088.0
14883,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628709,,1088.0
14884,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628710,,1088.0
14885,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628711,,1088.0
14886,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628712,,1088.0
14887,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628713,,1088.0
14888,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,Rattus norvegicus,A,,BAO_0000218,12582,,10116.0,1,Intermediate,1,CHEMBL628714,,1088.0
14889,N,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",,Rattus norvegicus,A,,BAO_0000218,7415,,10116.0,1,Intermediate,1,CHEMBL628715,,
14890,U,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,,,A,,BAO_0000019,7313,,,0,Autocuration,1,CHEMBL629179,,
14891,U,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,,,A,,BAO_0000019,7313,,,0,Autocuration,1,CHEMBL629180,,
14892,U,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,,,A,,BAO_0000019,7313,,,0,Autocuration,1,CHEMBL875108,,
14893,U,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,,A,,BAO_0000019,7570,,,0,Autocuration,1,CHEMBL629181,,1235.0
14894,U,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,,A,,BAO_0000019,7570,,,0,Autocuration,1,CHEMBL629182,,1235.0
14895,U,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,,,A,,BAO_0000019,7570,,,0,Autocuration,1,CHEMBL629183,,
14896,U,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,,,A,,BAO_0000019,7570,,,0,Autocuration,1,CHEMBL629184,,
14897,U,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,,A,,BAO_0000019,7570,,,0,Autocuration,1,CHEMBL629185,,1235.0
14898,U,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,,,A,,BAO_0000019,7570,,,0,Autocuration,1,CHEMBL629186,,1235.0
14899,U,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,,,A,,BAO_0000019,7570,,,0,Autocuration,1,CHEMBL629187,,
14900,U,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,,,A,,BAO_0000019,7570,,,0,Autocuration,1,CHEMBL629887,,
14901,U,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,,,A,,BAO_0000019,7570,,,0,Autocuration,1,CHEMBL629888,,
14902,U,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,,,A,,BAO_0000019,7570,,,0,Autocuration,1,CHEMBL629889,,
14903,U,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,,,A,,BAO_0000019,7570,,,0,Autocuration,1,CHEMBL629890,,1235.0
14904,U,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,,,A,,BAO_0000019,7570,,,0,Autocuration,1,CHEMBL629891,,
14905,U,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,,,A,,BAO_0000019,7570,,,0,Autocuration,1,CHEMBL629892,,
14906,U,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,,A,,BAO_0000019,7570,,,0,Autocuration,1,CHEMBL629893,,1235.0
14907,U,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,,,A,,BAO_0000019,7570,,,0,Autocuration,1,CHEMBL629894,,
14908,U,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,,,A,,BAO_0000019,7570,,,0,Autocuration,1,CHEMBL629895,,
14909,U,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",,Canis lupus familiaris,A,,BAO_0000218,14122,In vivo,9615.0,0,Autocuration,1,CHEMBL875109,,
14910,U,Absolute bioavailability in male cynomolgus monkeys,,Macaca fascicularis,A,,BAO_0000218,16449,In vivo,9541.0,0,Autocuration,1,CHEMBL629896,,
14911,U,Absolute bioavailability in maleSprague-Dawley rats,,Rattus norvegicus,A,,BAO_0000218,16449,In vivo,10116.0,0,Autocuration,1,CHEMBL629897,,
14912,N,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL629898,,2107.0
14913,N,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630057,,2107.0
14914,N,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630058,,2107.0
14915,N,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630059,,2048.0
14916,N,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630060,,2048.0
14917,N,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630061,,2048.0
14918,N,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630062,,2048.0
14919,N,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630063,,2048.0
14920,N,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630064,,2048.0
14921,N,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630065,,2048.0
14922,N,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630066,,2048.0
14923,N,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630067,,2048.0
14924,N,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630068,,2048.0
14925,N,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631113,,2385.0
14926,N,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631114,,2385.0
14927,N,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631115,,2385.0
14928,N,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL631116,,2385.0
14929,N,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630528,,2385.0
14930,N,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630529,,2385.0
14931,N,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630530,,2385.0
14932,N,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630531,,2385.0
14933,N,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630532,,2385.0
14934,N,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630533,,2385.0
14935,N,Biodistribution in normal mice blood after 120 hr,,Mus musculus,A,,BAO_0000218,15045,In vivo,10090.0,1,Intermediate,1,CHEMBL630534,,178.0
14936,N,Biodistribution in normal mice blood after 24 hr,,Mus musculus,A,,BAO_0000218,15045,In vivo,10090.0,1,Intermediate,1,CHEMBL630535,,178.0
14937,N,Biodistribution in normal mice blood after 4 hr,,Mus musculus,A,,BAO_0000218,15045,In vivo,10090.0,1,Intermediate,1,CHEMBL630536,,178.0
14938,N,Biodistribution in normal mice bone after 120 hr,,Mus musculus,A,,BAO_0000218,15045,In vivo,10090.0,1,Intermediate,1,CHEMBL630537,,10000001.0
14939,N,Biodistribution in normal mice bone after 24 hr,,Mus musculus,A,,BAO_0000218,15045,In vivo,10090.0,1,Intermediate,1,CHEMBL630538,,10000001.0
14940,N,Biodistribution in normal mice bone after 4 hr,,Mus musculus,A,,BAO_0000218,15045,In vivo,10090.0,1,Intermediate,1,CHEMBL630539,,10000001.0
14941,N,Biodistribution in normal mice heart after 120 hr,,Mus musculus,A,,BAO_0000218,15045,In vivo,10090.0,1,Intermediate,1,CHEMBL630540,,948.0
14942,N,Biodistribution in normal mice heart after 24 hr,,Mus musculus,A,,BAO_0000218,15045,In vivo,10090.0,1,Intermediate,1,CHEMBL630541,,948.0
14943,N,Biodistribution in normal mice heart after 4 hr,,Mus musculus,A,,BAO_0000218,15045,In vivo,10090.0,1,Intermediate,1,CHEMBL630542,,948.0
14944,N,Biodistribution in normal mice kidney after 120 hr,,Mus musculus,A,,BAO_0000218,15045,In vivo,10090.0,1,Intermediate,1,CHEMBL630543,,2113.0
14945,N,Biodistribution in normal mice kidney after 24 hr,,Mus musculus,A,,BAO_0000218,15045,In vivo,10090.0,1,Intermediate,1,CHEMBL630544,,2113.0
14946,N,Biodistribution in normal mice kidney after 4 hr,,Mus musculus,A,,BAO_0000218,15045,In vivo,10090.0,1,Intermediate,1,CHEMBL630545,,2113.0
14947,N,Biodistribution in normal mice liver after 120 hr,,Mus musculus,A,,BAO_0000218,15045,In vivo,10090.0,1,Intermediate,1,CHEMBL630546,,2107.0
14948,N,Biodistribution in normal mice liver after 24 hr,,Mus musculus,A,,BAO_0000218,15045,In vivo,10090.0,1,Intermediate,1,CHEMBL630547,,2107.0
14949,N,Biodistribution in normal mice liver after 4 hr,,Mus musculus,A,,BAO_0000218,15045,In vivo,10090.0,1,Intermediate,1,CHEMBL630548,,2107.0
14950,N,Biodistribution in normal mice spleen after 120 hr,,Mus musculus,A,,BAO_0000218,15045,In vivo,10090.0,1,Intermediate,1,CHEMBL630549,,2106.0
14951,N,Biodistribution in normal mice spleen after 24 hr,,Mus musculus,A,,BAO_0000218,15045,In vivo,10090.0,1,Intermediate,1,CHEMBL630550,,2106.0
14952,N,Biodistribution in normal mice spleen after 4 hr,,Mus musculus,A,,BAO_0000218,15045,In vivo,10090.0,1,Intermediate,1,CHEMBL876426,,2106.0
14953,N,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630551,,2106.0
14954,N,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630552,,2106.0
14955,N,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630553,,2106.0
14956,N,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630554,,2106.0
14957,N,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630555,,2106.0
14958,N,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630556,,2106.0
14959,N,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630557,,2106.0
14960,N,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630558,,2106.0
14961,N,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630559,,2106.0
14962,N,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL630560,,2106.0
14963,N,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,A,,BAO_0000218,12017,In vivo,10116.0,1,Intermediate,1,CHEMBL876427,,2046.0
14964,N,The Kel values in female wistar rats.,,Rattus norvegicus,A,,BAO_0000218,14941,,10116.0,1,Intermediate,1,CHEMBL630561,,
14965,U,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,,,A,,BAO_0000019,4646,,,0,Autocuration,1,CHEMBL630562,,
14966,U,Hydrolysis rate constant of the compound,,,A,,BAO_0000019,8847,,,0,Autocuration,1,CHEMBL630563,,
14967,U,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,,,P,,BAO_0000100,11778,,,0,Autocuration,1,CHEMBL629673,,
14968,U,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",,,A,,BAO_0000019,2363,,,0,Autocuration,1,CHEMBL629674,,
14969,U,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",,,A,,BAO_0000019,2363,,,0,Autocuration,1,CHEMBL629675,,
14970,U,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",,,A,,BAO_0000019,2363,,,0,Autocuration,1,CHEMBL629676,,
14971,U,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",,,A,,BAO_0000019,2363,,,0,Autocuration,1,CHEMBL629677,,
14972,U,Apparent inactivation rate constant was evaluated,,,A,,BAO_0000019,8371,,,0,Autocuration,1,CHEMBL629678,,
14973,U,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,,,A,,BAO_0000019,14883,,,0,Autocuration,1,CHEMBL629679,,
14974,U,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,,,A,,BAO_0000019,14883,,,0,Autocuration,1,CHEMBL629680,,
14975,U,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,,,A,,BAO_0000019,4643,,,0,Autocuration,1,CHEMBL629681,,
14976,U,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,,,A,,BAO_0000019,3519,,,0,Autocuration,1,CHEMBL629682,,
14977,U,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,,,A,,BAO_0000019,10600,,,0,Autocuration,1,CHEMBL629683,,
14978,U,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,,,F,,BAO_0000019,8501,,,0,Autocuration,1,CHEMBL629684,,
14979,U,Dissociation constant was determined,,,P,,BAO_0000100,8505,,,0,Autocuration,1,CHEMBL629685,,
14980,U,Dissociation constant was determined,,,P,,BAO_0000100,9778,,,0,Autocuration,1,CHEMBL629686,,
14981,U,Dissociation constant at pH 7.4,,,P,,BAO_0000100,9778,,,0,Autocuration,1,CHEMBL872932,,
14982,U,Dissociation constant in presence of 1 mM dithiothreitol,,,P,,BAO_0000100,9778,,,0,Autocuration,1,CHEMBL629687,,
14983,U,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,,A,,BAO_0000019,13007,,,0,Autocuration,1,CHEMBL872931,,
14984,U,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,,A,,BAO_0000019,13007,,,0,Autocuration,1,CHEMBL628151,,
14985,U,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,,A,,BAO_0000019,13007,,,0,Autocuration,1,CHEMBL628152,,
14986,U,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,,A,,BAO_0000019,13007,,,0,Autocuration,1,CHEMBL628153,,
14987,U,Kinetic constant for aromatization of androstenedione,,,A,,BAO_0000019,11482,,,0,Autocuration,1,CHEMBL628154,,
14988,U,Kinetic constant for aromatization of testosterone,,,A,,BAO_0000019,11482,,,0,Autocuration,1,CHEMBL628155,,
14989,U,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,,,A,,BAO_0000019,2303,,,0,Autocuration,1,CHEMBL628156,,
14990,U,Local inhibition constant was determined,,,A,,BAO_0000019,11964,,,0,Autocuration,1,CHEMBL628157,,
14991,N,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,,Saccharomyces cerevisiae,A,,BAO_0000218,3140,,4932.0,1,Intermediate,1,CHEMBL857533,,
14992,U,Dissociation constant value of the compound,,,P,,BAO_0000100,10650,,,0,Autocuration,1,CHEMBL628158,,
14993,U,In vitro permeability through cornea without epithelium,,,A,,BAO_0000019,4667,,,0,Autocuration,1,CHEMBL628159,,964.0
14994,U,In vitro permeability through intact cornea,,,A,,BAO_0000019,4667,,,0,Autocuration,1,CHEMBL875616,,964.0
14995,N,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,,Oryctolagus cuniculus,A,,BAO_0000218,9199,,9986.0,1,Intermediate,1,CHEMBL628160,,964.0
14996,U,Rate of enzyme inactivation for the compound was determined,,,A,,BAO_0000019,11966,,,0,Autocuration,1,CHEMBL628161,,
14997,U,In vitro permeability through cornea without epithelium,,,A,,BAO_0000019,4667,,,0,Autocuration,1,CHEMBL628162,,964.0
14998,U,In vitro permeability through intact cornea,,,A,,BAO_0000019,4667,,,0,Autocuration,1,CHEMBL628163,,964.0
14999,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL628164,,
15000,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL628165,,
15001,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL628166,,
15002,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL628167,,
15003,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL628168,,
15004,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL628169,,
15005,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL628170,,
15006,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL628171,,
15007,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL627434,,
15008,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL627435,,
15009,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL628110,,
15010,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL628111,,
15011,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL628112,,
15012,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL628260,,
15013,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,A,,BAO_0000019,8354,,,0,Autocuration,1,CHEMBL628261,,
15014,N,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),,Mus musculus,A,,BAO_0000218,14439,In vivo,10090.0,1,Intermediate,1,CHEMBL628262,,
15015,N,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,,Homo sapiens,A,,BAO_0000218,14439,In vivo,9606.0,1,Intermediate,1,CHEMBL628263,,
15016,N,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),,Mus musculus,A,,BAO_0000218,14439,In vivo,10090.0,1,Intermediate,1,CHEMBL628264,,
15017,N,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),,Mus musculus,A,,BAO_0000218,14439,In vivo,10090.0,1,Intermediate,1,CHEMBL628265,,
15018,N,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),,Mus musculus,A,,BAO_0000218,14439,In vivo,10090.0,1,Intermediate,1,CHEMBL628266,,
15019,N,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),,Mus musculus,A,,BAO_0000218,14439,In vivo,10090.0,1,Intermediate,1,CHEMBL628267,,
15020,N,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,,Mus musculus,A,,BAO_0000218,14439,In vivo,10090.0,1,Intermediate,1,CHEMBL628268,,
15021,N,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),,Mus musculus,A,,BAO_0000218,14439,In vivo,10090.0,1,Intermediate,1,CHEMBL628269,,
15022,N,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),,Mus musculus,A,,BAO_0000218,14439,In vivo,10090.0,1,Intermediate,1,CHEMBL628270,,
15023,N,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),,Mus musculus,A,,BAO_0000218,14439,In vivo,10090.0,1,Intermediate,1,CHEMBL628271,,
15024,N,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),,Mus musculus,A,,BAO_0000218,14439,In vivo,10090.0,1,Intermediate,1,CHEMBL628272,,
1,H,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,,B,,BAO_0000019,11087,,,8,Autocuration,1,CHEMBL615117,,
2,U,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,,F,,BAO_0000219,684,,,0,Autocuration,1,CHEMBL615118,,
3,U,,,,B,,BAO_0000019,15453,,,0,Autocuration,1,CHEMBL615119,,
4,H,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,Bos taurus,B,,BAO_0000249,17841,,9913.0,4,Autocuration,1,CHEMBL615120,,
5,N,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,Homo sapiens,F,,BAO_0000219,17430,,9606.0,1,Intermediate,1,CHEMBL615121,163.0,
6,N,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,Homo sapiens,F,,BAO_0000219,17430,,9606.0,1,Intermediate,1,CHEMBL615122,163.0,
7,N,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,Mus musculus,F,,BAO_0000219,13799,,10090.0,1,Intermediate,1,CHEMBL615123,163.0,
8,N,In vitro cell cytotoxicity was determined against 143B cell line,,Homo sapiens,F,,BAO_0000219,17774,,9606.0,1,Expert,1,CHEMBL615124,163.0,
9,N,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,Homo sapiens,F,,BAO_0000219,3801,,9606.0,1,Intermediate,1,CHEMBL615125,163.0,
10,N,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,Homo sapiens,F,,BAO_0000219,17430,,9606.0,1,Intermediate,1,CHEMBL615126,163.0,
11,N,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,Homo sapiens,F,,BAO_0000219,17430,,9606.0,1,Intermediate,1,CHEMBL615127,163.0,
12,N,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,Homo sapiens,F,,BAO_0000219,17774,,9606.0,1,Expert,1,CHEMBL615128,163.0,
13,N,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Staphylococcus aureus,F,,BAO_0000218,11324,,1280.0,1,Intermediate,1,CHEMBL857900,,
14,N,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Staphylococcus aureus,F,,BAO_0000218,11324,,1280.0,1,Intermediate,1,CHEMBL615129,,
15,N,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Staphylococcus aureus,F,,BAO_0000218,11324,,1280.0,1,Intermediate,1,CHEMBL615130,,
16,N,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Staphylococcus aureus,F,,BAO_0000218,11324,,1280.0,1,Intermediate,1,CHEMBL615131,,
17,D,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,Rattus norvegicus,A,,BAO_0000357,11347,,10116.0,9,Expert,1,CHEMBL884521,,
18,H,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,,B,,BAO_0000357,16474,,,8,Autocuration,1,CHEMBL615132,,
19,H,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,,B,,BAO_0000019,10091,,,8,Autocuration,1,CHEMBL615133,,
20,H,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,B,,BAO_0000357,16474,,,8,Autocuration,1,CHEMBL615134,,
21,H,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,,B,,BAO_0000357,16474,,,8,Autocuration,1,CHEMBL615135,,
22,H,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,B,,BAO_0000357,16474,,,8,Autocuration,1,CHEMBL615136,,
23,H,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,B,,BAO_0000357,16474,,,8,Autocuration,1,CHEMBL615137,,
24,H,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,B,,BAO_0000357,16474,,,8,Autocuration,1,CHEMBL615138,,
25,U,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,,B,,BAO_0000219,14352,,,0,Autocuration,1,CHEMBL836324,,
26,H,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,Oryctolagus cuniculus,B,,BAO_0000357,5646,,9986.0,8,Autocuration,1,CHEMBL615139,,
27,H,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,Oryctolagus cuniculus,B,,BAO_0000357,5646,,9986.0,8,Autocuration,1,CHEMBL615140,,
28,H,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,,B,,BAO_0000219,10997,,,8,Autocuration,1,CHEMBL615141,,
29,H,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,soya bean,B,,BAO_0000357,6309,,3847.0,8,Autocuration,1,CHEMBL615142,,
30,H,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,Glycine max,B,,BAO_0000357,167,,3847.0,8,Autocuration,1,CHEMBL615143,,
31,H,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,Glycine max,B,,BAO_0000357,167,,3847.0,8,Autocuration,1,CHEMBL615144,,
32,H,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,Glycine max,B,,BAO_0000357,11087,,3847.0,8,Autocuration,1,CHEMBL872867,,
33,H,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,Glycine max,B,,BAO_0000357,11087,,3847.0,8,Autocuration,1,CHEMBL615145,,
34,H,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,Glycine max,B,,BAO_0000357,13622,,3847.0,8,Autocuration,1,CHEMBL615146,,
35,H,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,Glycine max,B,,BAO_0000357,13622,,3847.0,8,Autocuration,1,CHEMBL615147,,
36,U,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,Rattus norvegicus,A,,BAO_0000019,11347,,10116.0,0,Autocuration,1,CHEMBL615148,,
37,U,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,Escherichia coli,B,,BAO_0000019,5926,,562.0,0,Autocuration,1,CHEMBL615149,,
38,U,Dissociation constant with dimeric 16S rRNA RNA construct B,,,B,,BAO_0000019,4567,,,0,Autocuration,1,CHEMBL615150,,
39,M,Dissociation constant towards 16S rRNA construct A,,,B,,BAO_0000225,3782,,,3,Intermediate,1,CHEMBL615151,,
40,M,Dissociation constant towards 16S rRNA construct B,,,B,,BAO_0000225,3782,,,3,Intermediate,1,CHEMBL615152,,
41,M,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,Escherichia coli,B,,BAO_0000225,4466,,562.0,3,Expert,1,CHEMBL615153,,
42,M,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,Escherichia coli,B,,BAO_0000225,6592,,562.0,3,Expert,1,CHEMBL615154,,
43,H,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,B,,BAO_0000019,898,,,8,Autocuration,1,CHEMBL615155,,
44,H,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,B,,BAO_0000019,898,,,8,Autocuration,1,CHEMBL615156,,
45,H,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,Homo sapiens,B,,BAO_0000019,13163,,9606.0,8,Autocuration,1,CHEMBL615157,,
46,H,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,Homo sapiens,B,,BAO_0000019,13163,,9606.0,8,Autocuration,1,CHEMBL615158,,
47,D,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,Rattus norvegicus,B,,BAO_0000019,10691,,10116.0,9,Expert,1,CHEMBL615159,,
48,D,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,Rattus norvegicus,B,,BAO_0000019,10691,,10116.0,9,Expert,1,CHEMBL615172,,
49,D,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,Rattus norvegicus,B,,BAO_0000019,10691,,10116.0,9,Expert,1,CHEMBL615173,,
50,D,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,Rattus norvegicus,B,,BAO_0000019,10691,,10116.0,9,Expert,1,CHEMBL615174,,
51,H,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,B,,BAO_0000019,898,,,8,Autocuration,1,CHEMBL884518,,
52,H,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,,B,,BAO_0000357,912,,,8,Autocuration,1,CHEMBL615175,,
53,H,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,,B,,BAO_0000357,912,,,8,Autocuration,1,CHEMBL615176,,
54,H,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,,B,,BAO_0000357,912,,,8,Autocuration,1,CHEMBL615177,,
55,D,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,Rattus norvegicus,B,,BAO_0000249,15103,,10116.0,5,Autocuration,1,CHEMBL615178,,
56,N,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,Homo sapiens,F,,BAO_0000219,5116,,9606.0,1,Intermediate,1,CHEMBL615179,506.0,
57,D,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,Rattus norvegicus,F,,BAO_0000219,14578,,10116.0,7,Autocuration,1,CHEMBL615180,,
58,D,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,Rattus norvegicus,F,,BAO_0000219,14578,,10116.0,7,Autocuration,1,CHEMBL615181,,
59,D,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,Rattus norvegicus,F,,BAO_0000219,14578,,10116.0,7,Autocuration,1,CHEMBL615182,,
60,N,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,Homo sapiens,F,,BAO_0000219,4787,,9606.0,1,Expert,1,CHEMBL615183,506.0,
61,N,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,Homo sapiens,F,,BAO_0000219,4787,,9606.0,1,Intermediate,1,CHEMBL615184,506.0,
62,N,Cytotoxic activity against human ovarian cancer (1A9) cell line,,Homo sapiens,F,,BAO_0000219,3547,,9606.0,1,Intermediate,1,CHEMBL615185,506.0,
63,N,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,Homo sapiens,F,,BAO_0000219,3547,,9606.0,1,Intermediate,1,CHEMBL615186,506.0,
64,N,Effective dose of compound against replication of 1A9 cell line was evaluated,,Homo sapiens,F,,BAO_0000219,6726,,9606.0,1,Intermediate,1,CHEMBL615187,506.0,
65,N,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,Homo sapiens,F,,BAO_0000219,3455,,9606.0,1,Expert,1,CHEMBL885343,506.0,
66,N,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,Homo sapiens,F,,BAO_0000219,5726,,9606.0,1,Intermediate,1,CHEMBL615188,506.0,
67,N,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,Homo sapiens,F,,BAO_0000219,5726,,9606.0,1,Intermediate,1,CHEMBL615189,506.0,
68,N,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,Homo sapiens,F,,BAO_0000219,5726,,9606.0,1,Intermediate,1,CHEMBL615190,506.0,
69,N,Inhibitory activity against Taxol resistant 1A9 cell lines,,Homo sapiens,F,,BAO_0000219,3395,,9606.0,1,Intermediate,1,CHEMBL615191,506.0,
70,N,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,Homo sapiens,F,,BAO_0000219,3415,,9606.0,1,Expert,1,CHEMBL615192,506.0,
71,N,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,Homo sapiens,F,,BAO_0000219,3415,,9606.0,1,Expert,1,CHEMBL827083,506.0,
72,N,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,Homo sapiens,F,,BAO_0000219,17099,,9606.0,1,Expert,1,CHEMBL615193,506.0,
73,N,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,Homo sapiens,F,,BAO_0000219,17099,,9606.0,1,Intermediate,1,CHEMBL615194,506.0,
74,N,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,Homo sapiens,F,,BAO_0000219,17099,,9606.0,1,Intermediate,1,CHEMBL615195,506.0,
75,N,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,Homo sapiens,F,,BAO_0000219,17099,,9606.0,1,Intermediate,1,CHEMBL615196,506.0,
76,N,Inhibitory concentration against Jurkat cells,,Homo sapiens,F,,BAO_0000219,17721,,9606.0,1,Intermediate,1,CHEMBL615197,503.0,
77,U,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,,F,,BAO_0000019,1229,,,0,Intermediate,1,CHEMBL615198,,
78,D,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,Rattus norvegicus,A,,BAO_0000357,11347,,10116.0,9,Expert,1,CHEMBL615199,,
79,H,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,B,,BAO_0000357,17117,,,8,Expert,1,CHEMBL615200,,
80,H,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,B,,BAO_0000357,17117,,,8,Expert,1,CHEMBL615201,,
81,H,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,,B,,BAO_0000357,17117,,,8,Expert,1,CHEMBL615202,,
82,H,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,Candida albicans,B,,BAO_0000251,11375,,5476.0,8,Autocuration,1,CHEMBL615203,,
83,H,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,Candida albicans,B,,BAO_0000251,11375,,5476.0,8,Autocuration,1,CHEMBL615204,,
84,H,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,Saccharomyces cerevisiae,B,,BAO_0000251,11375,,4932.0,8,Autocuration,1,CHEMBL615205,,
85,H,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,Saccharomyces cerevisiae,B,,BAO_0000251,11375,,4932.0,8,Autocuration,1,CHEMBL615206,,
86,H,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,Sus scrofa,B,,BAO_0000251,11375,,9823.0,8,Autocuration,1,CHEMBL615207,,2107.0
87,H,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,Rattus norvegicus,B,,BAO_0000019,791,,10116.0,8,Autocuration,1,CHEMBL827084,,
88,H,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,Rattus norvegicus,B,,BAO_0000019,791,,10116.0,8,Autocuration,1,CHEMBL615208,,
89,H,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,Rattus norvegicus,B,,BAO_0000019,791,,10116.0,8,Autocuration,1,CHEMBL615209,,
90,D,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,Rattus norvegicus,B,,BAO_0000251,11375,,10116.0,9,Autocuration,1,CHEMBL615210,,2107.0
91,D,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,Rattus norvegicus,B,,BAO_0000251,11375,,10116.0,9,Autocuration,1,CHEMBL615211,,2107.0
92,D,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,Rattus norvegicus,B,,BAO_0000251,153,,10116.0,9,Autocuration,1,CHEMBL615212,,2107.0
93,H,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,,B,,BAO_0000357,8269,,,8,Expert,1,CHEMBL615213,,
94,H,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,,B,,BAO_0000357,8269,,,8,Expert,1,CHEMBL615273,,
95,N,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,Homo sapiens,F,,BAO_0000219,17653,,9606.0,1,Expert,1,CHEMBL615274,726.0,
96,N,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,Homo sapiens,F,,BAO_0000219,14277,,9606.0,1,Intermediate,1,CHEMBL615275,726.0,
97,N,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,Homo sapiens,F,,BAO_0000219,1717,,9606.0,1,Intermediate,1,CHEMBL615276,726.0,
98,N,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,Homo sapiens,F,,BAO_0000219,14091,,9606.0,1,Intermediate,1,CHEMBL615277,726.0,
99,N,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,Homo sapiens,F,,BAO_0000219,14091,,9606.0,1,Intermediate,1,CHEMBL615326,726.0,
100,N,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,Hepatitis B virus,F,,BAO_0000218,17653,,10407.0,1,Expert,1,CHEMBL883130,,
101,N,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,Homo sapiens,F,,BAO_0000219,13105,,9606.0,1,Intermediate,1,CHEMBL884519,726.0,
102,N,Concentration required to inhibit 50% of 2.2.15 cell line,,Homo sapiens,F,,BAO_0000219,1717,,9606.0,1,Intermediate,1,CHEMBL615327,726.0,
103,N,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,Homo sapiens,A,,BAO_0000219,13105,,9606.0,1,Intermediate,1,CHEMBL615328,726.0,
104,N,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,Homo sapiens,F,,BAO_0000218,13600,,9606.0,1,Intermediate,1,CHEMBL615329,,
105,N,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,Homo sapiens,F,,BAO_0000218,13467,,9606.0,1,Intermediate,1,CHEMBL615330,,
106,N,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,Hepatitis B virus,F,,BAO_0000218,17477,,10407.0,1,Expert,1,CHEMBL615331,,
107,N,In vitro anti-HBV activity in 2.2.15 cells,,Homo sapiens,F,,BAO_0000218,1593,,9606.0,1,Intermediate,1,CHEMBL615332,,
108,N,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,Homo sapiens,F,,BAO_0000218,1593,,9606.0,1,Intermediate,1,CHEMBL615333,,
109,N,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,Homo sapiens,F,,BAO_0000218,15089,,9606.0,1,Intermediate,1,CHEMBL615334,,
110,N,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,Homo sapiens,F,,BAO_0000218,15089,,9606.0,1,Intermediate,1,CHEMBL615335,,
111,N,Cytotoxicity in 2.2.15 cells,,Homo sapiens,F,,BAO_0000218,1593,,9606.0,1,Intermediate,1,CHEMBL615336,,
112,N,Cytotoxicity in 2.2.15 cells; Not determined,,Homo sapiens,F,,BAO_0000218,1593,,9606.0,1,Intermediate,1,CHEMBL615337,,
113,N,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,Homo sapiens,F,,BAO_0000218,13600,,9606.0,1,Intermediate,1,CHEMBL615338,,
114,N,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,Homo sapiens,F,,BAO_0000218,13467,,9606.0,1,Intermediate,1,CHEMBL615339,,
115,N,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,Homo sapiens,F,,BAO_0000218,13467,,9606.0,1,Intermediate,1,CHEMBL615340,,
116,N,Antiviral activity against HBV was determined in 2.215 cell line,,Homo sapiens,F,,BAO_0000219,14764,,9606.0,1,Intermediate,1,CHEMBL615341,726.0,
117,U,Inhibition of 20-HETE synthesis in human renal microsomes,,Homo sapiens,B,,BAO_0000251,6531,,9606.0,0,Autocuration,1,CHEMBL615342,,
118,U,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,,B,,BAO_0000019,17322,,,0,Autocuration,1,CHEMBL615343,,
119,N,Inhibitory concentration against 2008 (ovarian) cells,,Homo sapiens,F,,BAO_0000219,17072,,9606.0,1,Intermediate,1,CHEMBL615344,388.0,
120,N,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,Homo sapiens,F,,BAO_0000219,16936,,9606.0,1,Intermediate,1,CHEMBL615345,388.0,
121,N,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,Homo sapiens,F,,BAO_0000219,16936,,9606.0,1,Intermediate,1,CHEMBL615346,388.0,
122,N,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,Homo sapiens,F,,BAO_0000219,17146,,9606.0,1,Intermediate,1,CHEMBL615347,388.0,
123,N,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,Homo sapiens,F,,BAO_0000219,17146,,9606.0,1,Intermediate,1,CHEMBL615348,388.0,
124,N,In vitro inhibition of 2008/R ovarian cancer cell line,,Homo sapiens,F,,BAO_0000219,10797,,9606.0,1,Intermediate,1,CHEMBL827085,561.0,
125,N,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,Homo sapiens,F,,BAO_0000219,10797,,9606.0,1,Intermediate,1,CHEMBL615349,561.0,
126,N,In vitro inhibition of 2008/S ovarian cancer cell line,,Homo sapiens,F,,BAO_0000219,10797,,9606.0,1,Intermediate,1,CHEMBL615350,389.0,
127,N,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,Homo sapiens,F,,BAO_0000219,10797,,9606.0,1,Intermediate,1,CHEMBL615351,389.0,
128,S,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,Homo sapiens,B,,BAO_0000220,4823,,9606.0,2,Expert,1,CHEMBL615352,,
129,S,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,Homo sapiens,B,,BAO_0000220,12912,,9606.0,2,Intermediate,1,CHEMBL615353,,
130,S,Inhibition of chymotrypsin-like activity of 20S proteasome,,,B,,BAO_0000220,2957,,,2,Expert,1,CHEMBL615354,,
131,S,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,,B,,BAO_0000220,2957,,,2,Expert,1,CHEMBL615355,,
132,S,Inhibitory activity against 20S proteosome,,,B,,BAO_0000220,3260,,,2,Intermediate,1,CHEMBL615356,,
133,U,Compound was tested for inhibitory activity against tryptase,,Homo sapiens,B,,BAO_0000019,3451,,9606.0,0,Autocuration,1,CHEMBL615357,,
134,N,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,Homo sapiens,F,,BAO_0000219,13885,,9606.0,1,Intermediate,1,CHEMBL615358,726.0,
135,N,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,Homo sapiens,F,,BAO_0000219,13885,,9606.0,1,Intermediate,1,CHEMBL827086,726.0,
136,U,Compound was tested for the inhibition of Alpha-glucosidase,,,B,,BAO_0000019,3676,,,0,Autocuration,1,CHEMBL615359,,
137,H,Inhibitory concentration against human neutrophil elastase (HNE),,,B,,BAO_0000357,6043,,,8,Autocuration,1,CHEMBL615360,,
138,U,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,Rattus norvegicus,F,,BAO_0000218,11140,,10116.0,0,Autocuration,1,CHEMBL615361,,948.0
139,H,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,F,,BAO_0000019,10543,,,8,Autocuration,1,CHEMBL615362,,
140,H,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,F,,BAO_0000019,10543,,,8,Expert,1,CHEMBL615363,,
141,H,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,B,,BAO_0000357,10543,,,8,Autocuration,1,CHEMBL615364,,
142,H,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,F,,BAO_0000019,10543,,,8,Expert,1,CHEMBL615365,,
143,N,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,Mus musculus,F,,BAO_0000219,11365,,10090.0,1,Intermediate,1,CHEMBL615366,524.0,
144,N,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,Mus musculus,F,,BAO_0000219,11365,,10090.0,1,Intermediate,1,CHEMBL615367,524.0,
145,N,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,Homo sapiens,F,,BAO_0000219,11803,,9606.0,1,Intermediate,1,CHEMBL615368,554.0,
146,U,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,Ovis aries,F,,BAO_0000019,11803,,9940.0,0,Autocuration,1,CHEMBL615369,,
147,U,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,Ovis aries,F,,BAO_0000019,11803,,9940.0,0,Autocuration,1,CHEMBL615370,,
148,H,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,,B,,BAO_0000357,12278,,,8,Autocuration,1,CHEMBL615673,,
149,U,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,Homo sapiens,F,,BAO_0000019,8249,,9606.0,0,Autocuration,1,CHEMBL615674,,
150,U,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,Homo sapiens,F,,BAO_0000019,8249,,9606.0,0,Autocuration,1,CHEMBL615675,,
151,U,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,Homo sapiens,F,,BAO_0000219,8249,,9606.0,0,Autocuration,1,CHEMBL615676,635.0,
152,U,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,Homo sapiens,F,,BAO_0000219,8249,,9606.0,0,Autocuration,1,CHEMBL615677,635.0,
153,U,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,Homo sapiens,F,,BAO_0000219,8249,,9606.0,0,Autocuration,1,CHEMBL615678,635.0,
154,U,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,Homo sapiens,F,,BAO_0000219,8249,,9606.0,0,Autocuration,1,CHEMBL615679,635.0,
155,U,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,Homo sapiens,F,,BAO_0000019,8249,,9606.0,0,Autocuration,1,CHEMBL615680,,
156,U,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,Homo sapiens,F,,BAO_0000019,8249,,9606.0,0,Autocuration,1,CHEMBL615681,,
157,H,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,,B,,BAO_0000249,16992,,,6,Autocuration,1,CHEMBL857972,,
158,N,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,Streptococcus pyogenes,F,,BAO_0000218,10543,,1314.0,1,Intermediate,1,CHEMBL857899,,
159,N,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,Human herpesvirus 3,F,,BAO_0000218,17833,,10335.0,1,Intermediate,1,CHEMBL615371,,
160,N,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,vericilla zoster virus,F,,BAO_0000218,17290,,10335.0,1,Expert,1,CHEMBL615372,468.0,
161,N,Antiviral activity against 07/1 strain of VZV; ND: No data,,vericilla zoster virus,F,,BAO_0000218,17290,,10335.0,1,Intermediate,1,CHEMBL615373,,
162,N,Antiviral activity against 07/1 strain of VZV; ND=No data,,vericilla zoster virus,F,,BAO_0000218,17290,,10335.0,1,Intermediate,1,CHEMBL615374,,
163,N,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,escherichia cloac,F,,BAO_0000218,10932,,561.0,1,Intermediate,1,CHEMBL615375,,
164,U,Ratio of Ki at A2 to Ki at A1 receptors,,,B,,BAO_0000019,9707,,,0,Autocuration,1,CHEMBL615376,,
165,H,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,Candida albicans,B,,BAO_0000249,2346,,5476.0,8,Expert,1,CHEMBL615377,,
166,H,"Inhibition of 1,3-beta-glucan synthase",,Candida glabrata CBS 138,B,,BAO_0000357,2205,,284593.0,8,Expert,1,CHEMBL615378,,
167,N,Inhibition of growth of 1-87 human tumor cell line,,Homo sapiens,F,,BAO_0000219,11900,,9606.0,1,Intermediate,1,CHEMBL615379,832.0,
168,D,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,Rattus norvegicus,B,,BAO_0000219,14864,,10116.0,9,Expert,1,CHEMBL615380,,
169,D,Inhibitory activity against soybean 1-lipoxygenase (SLO),,Glycine max,B,,BAO_0000357,16474,,3847.0,9,Autocuration,1,CHEMBL615381,,
170,D,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,Glycine max,B,,BAO_0000357,16474,,3847.0,9,Autocuration,1,CHEMBL615382,,
171,D,% inhibition against soybean 1-lipoxygenase (SLO),,Glycine max,B,,BAO_0000357,16474,,3847.0,9,Autocuration,1,CHEMBL615383,,
172,D,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,Glycine max,B,,BAO_0000357,16474,,3847.0,9,Autocuration,1,CHEMBL615384,,
173,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,Glycine max,B,,BAO_0000357,3094,,3847.0,9,Autocuration,1,CHEMBL615385,,
174,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,Glycine max,B,,BAO_0000357,3094,,3847.0,9,Autocuration,1,CHEMBL615386,,
175,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,Glycine max,B,,BAO_0000357,3094,,3847.0,9,Autocuration,1,CHEMBL615387,,
176,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,Glycine max,B,,BAO_0000357,3094,,3847.0,9,Autocuration,1,CHEMBL615388,,
177,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,Glycine max,B,,BAO_0000357,3094,,3847.0,9,Autocuration,1,CHEMBL615214,,
178,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,Glycine max,B,,BAO_0000357,3094,,3847.0,9,Autocuration,1,CHEMBL827087,,
179,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,Glycine max,B,,BAO_0000357,3094,,3847.0,9,Autocuration,1,CHEMBL615215,,
180,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,Glycine max,B,,BAO_0000357,3094,,3847.0,9,Autocuration,1,CHEMBL615216,,
181,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,Glycine max,B,,BAO_0000357,3094,,3847.0,9,Autocuration,1,CHEMBL615217,,
182,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,Glycine max,B,,BAO_0000357,3094,,3847.0,9,Autocuration,1,CHEMBL615218,,
183,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,Glycine max,B,,BAO_0000357,3094,,3847.0,9,Autocuration,1,CHEMBL615219,,
184,U,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,Mus musculus,B,,BAO_0000019,10413,,10090.0,0,Autocuration,1,CHEMBL615220,,
185,N,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,Mus musculus,F,,BAO_0000219,16929,,10090.0,1,Intermediate,1,CHEMBL615221,294.0,
186,U,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,,F,,BAO_0000019,1229,,,0,Intermediate,1,CHEMBL615222,,
187,H,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,B,,BAO_0000357,16587,,,8,Autocuration,1,CHEMBL615223,,
188,H,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,B,,BAO_0000357,16587,,,8,Autocuration,1,CHEMBL615224,,
189,H,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,,B,,BAO_0000357,16587,,,8,Autocuration,1,CHEMBL615225,,
190,H,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,,B,,BAO_0000357,16587,,,8,Autocuration,1,CHEMBL615226,,
191,H,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,,B,,BAO_0000357,16587,,,8,Autocuration,1,CHEMBL615227,,
192,D,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,Bos taurus,F,,BAO_0000019,8058,,9913.0,9,Expert,1,CHEMBL615228,,
193,D,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,Rattus norvegicus,B,,BAO_0000357,9065,,10116.0,9,Expert,1,CHEMBL615229,,
194,D,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,Rattus norvegicus,B,,BAO_0000357,8865,,10116.0,9,Expert,1,CHEMBL615230,,2369.0
195,D,Inhibition of rat adrenal 11-beta-hydroxylase,,Rattus norvegicus,B,,BAO_0000357,9066,,10116.0,9,Expert,1,CHEMBL615231,,
196,D,Inhibition of rat adrenal 11-beta-hydroxylase,,Rattus norvegicus,B,,BAO_0000357,8394,,10116.0,9,Expert,1,CHEMBL884520,,
197,D,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,Rattus norvegicus,B,,BAO_0000357,8394,,10116.0,9,Expert,1,CHEMBL615232,,
198,H,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,,B,,BAO_0000019,6431,,,8,Autocuration,1,CHEMBL615233,,
199,H,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,B,,BAO_0000357,6431,,,8,Autocuration,1,CHEMBL827088,,
200,H,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,B,,BAO_0000357,6431,,,8,Autocuration,1,CHEMBL615234,,
201,H,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,,F,,BAO_0000019,9295,,,8,Autocuration,1,CHEMBL615235,,
202,H,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,B,,BAO_0000019,10193,,,8,Autocuration,1,CHEMBL615236,,
203,H,Compound was tested in vitro for inhibition of 12-LO human platelet,,,B,,BAO_0000019,13622,,,8,Autocuration,1,CHEMBL615237,,
204,H,Inhibitory concentration against human platelet 12-lipoxygenase,,,F,,BAO_0000019,12079,,,8,Autocuration,1,CHEMBL615238,,
205,H,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,,B,,BAO_0000019,13622,,,8,Autocuration,1,CHEMBL615239,,
206,D,Inhibitory concentration against human platelet 12-lipoxygenase,,Homo sapiens,F,,BAO_0000019,12079,,9606.0,9,Autocuration,1,CHEMBL615240,,
207,H,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,,B,,BAO_0000019,13500,,,8,Expert,1,CHEMBL615241,,
208,H,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,,B,,BAO_0000357,13723,,,8,Expert,1,CHEMBL615242,,
209,H,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,,B,,BAO_0000019,16474,,,8,Autocuration,1,CHEMBL615243,,
210,H,Inhibitory activity against human platelet 12-lipoxygenase,,,B,,BAO_0000019,1630,,,8,Autocuration,1,CHEMBL615244,,
211,H,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,,B,,BAO_0000019,167,,,8,Autocuration,1,CHEMBL615245,,
212,H,% inhibition against human platelet 12-lipoxygenase (12-HLO),,,B,,BAO_0000019,16474,,,8,Autocuration,1,CHEMBL615246,,
213,H,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,,B,,BAO_0000019,167,,,8,Autocuration,1,CHEMBL615247,,
214,H,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,,B,,BAO_0000019,16474,,,8,Autocuration,1,CHEMBL615248,,
215,H,Inhibitory activity towards porcine 12-lipoxygenase,,,B,,BAO_0000357,10091,,,8,Autocuration,1,CHEMBL615249,,
216,H,Tested for inhibition against porcine 12-LO,,,B,,BAO_0000357,11966,,,8,Autocuration,1,CHEMBL615250,,
217,H,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,,B,,BAO_0000019,951,,,8,Autocuration,1,CHEMBL615251,,
218,H,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,,B,,BAO_0000019,10997,,,8,Autocuration,1,CHEMBL615252,,
219,H,In vitro inhibition of rat platelet 12-lipoxygenase,,,B,,BAO_0000019,10193,,,8,Expert,1,CHEMBL828340,,
220,H,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,B,,BAO_0000019,10193,,,8,Autocuration,1,CHEMBL615253,,
221,H,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,,B,,BAO_0000019,10193,,,8,Autocuration,1,CHEMBL615254,,
222,H,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,,B,,BAO_0000019,10193,,,8,Autocuration,1,CHEMBL615255,,
223,H,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,B,,BAO_0000019,10193,,,8,Autocuration,1,CHEMBL615256,,
224,H,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,,B,,BAO_0000019,10193,,,8,Autocuration,1,CHEMBL615257,,
225,H,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,,B,,BAO_0000019,11087,,,8,Autocuration,1,CHEMBL615258,,
226,N,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,Homo sapiens,F,,BAO_0000219,15569,,9606.0,1,Intermediate,1,CHEMBL615259,621.0,
227,N,In vitro antitumor activity against 41M cell line.,,Homo sapiens,F,,BAO_0000219,12989,,9606.0,1,Expert,1,CHEMBL615260,621.0,
228,N,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,Homo sapiens,F,,BAO_0000219,16745,,9606.0,1,Intermediate,1,CHEMBL615261,621.0,
229,N,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,Homo sapiens,F,,BAO_0000219,15569,,9606.0,1,Intermediate,1,CHEMBL615262,621.0,
230,N,In vitro antitumor activity against 41McisR cell line.,,Homo sapiens,F,,BAO_0000219,12989,,9606.0,1,Expert,1,CHEMBL615263,621.0,
231,N,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,Homo sapiens,F,,BAO_0000219,12989,,9606.0,1,Expert,1,CHEMBL838393,621.0,
232,N,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,Homo sapiens,F,,BAO_0000219,16745,,9606.0,1,Intermediate,1,CHEMBL615264,621.0,
233,D,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,Homo sapiens,B,,BAO_0000357,6210,,9606.0,9,Expert,1,CHEMBL615265,,
234,D,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,Homo sapiens,B,,BAO_0000357,6210,,9606.0,9,Expert,1,CHEMBL615266,,
235,H,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,B,,BAO_0000357,6226,,,8,Expert,1,CHEMBL615267,,
236,H,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,B,,BAO_0000357,17855,,,8,Expert,1,CHEMBL615268,,
237,H,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,,B,,BAO_0000357,17855,,,8,Expert,1,CHEMBL615269,,
238,H,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,B,,BAO_0000357,17855,,,8,Expert,1,CHEMBL615270,,
239,H,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,B,,BAO_0000357,10413,,,8,Autocuration,1,CHEMBL615271,,
240,H,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,Escherichia coli,B,,BAO_0000357,10413,,562.0,8,Autocuration,1,CHEMBL615272,,
241,H,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,Escherichia coli,B,,BAO_0000357,10413,,562.0,8,Autocuration,1,CHEMBL615103,,
242,H,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,Escherichia coli,B,,BAO_0000357,10413,,562.0,8,Autocuration,1,CHEMBL615104,,
243,H,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,B,,BAO_0000357,10413,,,8,Autocuration,1,CHEMBL615105,,
244,H,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,,B,,BAO_0000357,10413,,,8,Autocuration,1,CHEMBL872866,,
245,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,Sus scrofa,B,,BAO_0000357,7587,,9823.0,8,Autocuration,1,CHEMBL615106,,
246,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,Sus scrofa,B,,BAO_0000019,7587,,9823.0,8,Autocuration,1,CHEMBL615107,,
247,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,Sus scrofa,B,,BAO_0000357,7587,,9823.0,8,Autocuration,1,CHEMBL615108,,
248,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,Sus scrofa,B,,BAO_0000357,7587,,9823.0,8,Autocuration,1,CHEMBL615109,,
249,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,Sus scrofa,B,,BAO_0000357,7587,,9823.0,8,Autocuration,1,CHEMBL615110,,
250,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,Sus scrofa,B,,BAO_0000019,7587,,9823.0,8,Autocuration,1,CHEMBL840105,,
251,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,Sus scrofa,B,,BAO_0000019,7587,,9823.0,8,Autocuration,1,CHEMBL615111,,
252,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,Sus scrofa,B,,BAO_0000019,7587,,9823.0,8,Autocuration,1,CHEMBL615112,,
253,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,Sus scrofa,B,,BAO_0000019,7587,,9823.0,8,Autocuration,1,CHEMBL615113,,
254,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,Sus scrofa,B,,BAO_0000019,7587,,9823.0,8,Autocuration,1,CHEMBL615114,,
255,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,Sus scrofa,B,,BAO_0000357,7587,,9823.0,8,Autocuration,1,CHEMBL615115,,
256,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,Sus scrofa,B,,BAO_0000019,7587,,9823.0,8,Autocuration,1,CHEMBL615116,,
257,H,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,,B,,BAO_0000357,7323,,,8,Autocuration,1,CHEMBL615698,,
258,U,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,Sus scrofa,B,,BAO_0000019,7587,,9823.0,0,Autocuration,1,CHEMBL615699,,
259,U,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,Sus scrofa,B,,BAO_0000019,7587,,9823.0,0,Autocuration,1,CHEMBL615700,,
260,H,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,Saccharomyces cerevisiae,B,,BAO_0000357,13750,,4932.0,8,Expert,1,CHEMBL615701,,
261,U,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,Rattus norvegicus,B,,BAO_0000019,7662,,10116.0,0,Autocuration,1,CHEMBL615702,,
262,U,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,Rattus norvegicus,B,,BAO_0000019,7662,,10116.0,0,Autocuration,1,CHEMBL615703,,
263,U,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,Rattus norvegicus,B,,BAO_0000019,7662,,10116.0,0,Autocuration,1,CHEMBL615704,,
264,H,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,F,,BAO_0000019,12211,,,6,Autocuration,1,CHEMBL615705,,
265,H,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,F,,BAO_0000019,12211,,,6,Autocuration,1,CHEMBL615706,,
266,D,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,Cavia porcellus,F,,BAO_0000221,12211,,10141.0,9,Intermediate,1,CHEMBL615707,,2116.0
267,H,Stimulatory activity of intragastric pressure was tested in the rat,,,F,,BAO_0000019,12211,,,8,Expert,1,CHEMBL615708,,
268,H,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,,B,,BAO_0000357,15453,,,8,Autocuration,1,CHEMBL615709,,
269,U,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,Rattus norvegicus,F,,BAO_0000218,11884,,10116.0,0,Autocuration,1,CHEMBL615710,,
270,H,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,F,,BAO_0000019,7185,,,8,Autocuration,1,CHEMBL615711,,
271,D,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,Homo sapiens,B,,BAO_0000357,6876,,9606.0,9,Expert,1,CHEMBL615712,,
272,D,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,Homo sapiens,B,,BAO_0000357,6876,,9606.0,9,Expert,1,CHEMBL836325,,
273,H,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,,F,,BAO_0000019,11863,,,8,Autocuration,1,CHEMBL615713,,
274,H,Inhibition constant of high-affinity 5-HT uptake,,,B,,BAO_0000357,11863,,,8,Autocuration,1,CHEMBL615714,,
275,H,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,,F,,BAO_0000019,11863,,,8,Autocuration,1,CHEMBL615715,,
276,H,Maximum rate was determined for high affinity transport of 5-HT,,,F,,BAO_0000019,11863,,,8,Autocuration,1,CHEMBL615716,,
277,H,Compound was tested for agonistic activity against 5-HT uptake,,,F,,BAO_0000019,4639,,,4,Autocuration,1,CHEMBL615717,,
278,H,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,,B,,BAO_0000019,15796,,,8,Expert,1,CHEMBL881818,,
279,H,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,Bos taurus,B,,BAO_0000357,15796,,9913.0,8,Expert,1,CHEMBL884540,,
280,D,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,Rattus norvegicus,B,,BAO_0000224,12801,,10116.0,5,Autocuration,1,CHEMBL615718,,
281,H,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,,B,,BAO_0000224,12801,,,4,Autocuration,1,CHEMBL615719,,
282,H,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,,B,,BAO_0000249,12120,,,4,Autocuration,1,CHEMBL615720,,
283,H,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,,B,,BAO_0000249,12120,,,4,Autocuration,1,CHEMBL615721,,
284,H,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,B,,BAO_0000019,11963,,,4,Autocuration,1,CHEMBL615722,,
285,H,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,,F,,BAO_0000019,11701,,,8,Autocuration,1,CHEMBL615723,,
286,H,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,B,,BAO_0000221,9995,,,8,Autocuration,1,CHEMBL615724,,10000000.0
287,H,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,B,,BAO_0000221,9995,,,8,Autocuration,1,CHEMBL615725,,10000000.0
288,H,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,B,,BAO_0000221,9995,,,8,Autocuration,1,CHEMBL615726,,10000000.0
289,H,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,,F,,BAO_0000218,16394,In vivo,,8,Autocuration,1,CHEMBL615727,,
290,D,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,Cavia porcellus,F,,BAO_0000019,11574,,10141.0,9,Intermediate,1,CHEMBL615728,,
291,H,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL857971,449.0,
292,H,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,15363,,,8,Autocuration,1,CHEMBL615729,,
293,D,Efficacy against 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,F,,BAO_0000019,15363,,10116.0,9,Expert,1,CHEMBL615730,,
294,H,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,,F,,BAO_0000019,15329,,,8,Expert,1,CHEMBL615731,,
295,H,Relative potency towards 5-HT2A receptor of rat tail artery,,,F,,BAO_0000019,15329,,,8,Expert,1,CHEMBL615732,,
296,H,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,F,,BAO_0000019,15329,,,8,Expert,1,CHEMBL615733,,
297,H,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,,F,,BAO_0000019,15329,,,8,Expert,1,CHEMBL615734,,
298,H,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,,F,,BAO_0000019,15329,,,8,Autocuration,1,CHEMBL615735,,
299,H,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,F,,BAO_0000019,15329,,,8,Expert,1,CHEMBL615736,,
300,D,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,Cavia porcellus,F,,BAO_0000221,273,,10141.0,9,Intermediate,1,CHEMBL615737,,2116.0
301,D,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,Cavia porcellus,F,,BAO_0000221,273,,10141.0,9,Intermediate,1,CHEMBL615738,,2116.0
302,D,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,Cavia porcellus,F,,BAO_0000221,273,,10141.0,9,Intermediate,1,CHEMBL615739,,2116.0
303,H,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,,B,,BAO_0000357,12092,,,8,Autocuration,1,CHEMBL615278,,
304,D,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,Rattus norvegicus,F,,BAO_0000019,1317,,10116.0,9,Expert,1,CHEMBL615279,,
305,H,Binding affinity against 5-hydroxytryptamine 4 receptor,,,B,,BAO_0000357,12409,,,8,Expert,1,CHEMBL615280,,
306,U,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,Gallus gallus,B,,BAO_0000019,11126,,9031.0,0,Autocuration,1,CHEMBL615281,,
307,U,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,Homo sapiens,F,,BAO_0000019,11126,,9606.0,0,Autocuration,1,CHEMBL615282,,
308,U,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,Homo sapiens,F,,BAO_0000019,11126,,9606.0,0,Autocuration,1,CHEMBL615283,,
309,N,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,Homo sapiens,B,,BAO_0000219,11126,,9606.0,1,Autocuration,1,CHEMBL615284,649.0,
310,U,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,Homo sapiens,B,,BAO_0000019,11126,,9606.0,0,Autocuration,1,CHEMBL615285,,
311,U,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,Homo sapiens,B,,BAO_0000019,11126,,9606.0,0,Autocuration,1,CHEMBL615286,,
312,D,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,Homo sapiens,B,,BAO_0000219,17807,,9606.0,7,Autocuration,1,CHEMBL615287,,
313,S,Chymotryptic inhibitory activity against 26S proteasome,,,F,,BAO_0000220,16575,,,2,Intermediate,1,CHEMBL615288,,
314,S,Inhibitory activity against 26S proteasome degradation of IkB,,,B,,BAO_0000220,15407,,,2,Intermediate,1,CHEMBL615289,,
315,N,In vitro inhibition of 2780/DOX ovarian cancer cell line,,Homo sapiens,F,,BAO_0000219,10797,,9606.0,1,Intermediate,1,CHEMBL615290,478.0,
316,N,In vitro inhibition of 2780/S ovarian cancer cell line,,Homo sapiens,F,,BAO_0000219,10797,,9606.0,1,Intermediate,1,CHEMBL884522,478.0,
317,U,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,Homo sapiens,F,,BAO_0000019,3469,,9606.0,0,Autocuration,1,CHEMBL615291,,
318,M,Association constant for binding to AATT 28-mer AATT hairpin,,,B,,BAO_0000225,16037,,,3,Intermediate,1,CHEMBL615292,,
319,M,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,,B,,BAO_0000225,16037,,,3,Intermediate,1,CHEMBL615293,,
320,M,Reaction Rate Parameter for 28-mer AATT hairpin,,,B,,BAO_0000225,16037,,,3,Intermediate,1,CHEMBL615294,,
321,M,Reaction Rate Parameter for 28-mer AATT hairpin,,,B,,BAO_0000225,16037,,,3,Intermediate,1,CHEMBL615295,,
322,U,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,Homo sapiens,F,,BAO_0000019,16524,,9606.0,0,Autocuration,1,CHEMBL825021,,
323,U,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,Homo sapiens,F,,BAO_0000019,16524,,9606.0,0,Autocuration,1,CHEMBL615296,,
324,U,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,Homo sapiens,F,,BAO_0000019,16524,,9606.0,0,Autocuration,1,CHEMBL615297,,
325,U,Cytotoxicity against cell line 2SC/20 determined by MTT test,,Cricetulus griseus,F,,BAO_0000019,16758,,10029.0,0,Autocuration,1,CHEMBL615298,,
326,U,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,Cricetulus griseus,F,,BAO_0000019,16758,,10029.0,0,Autocuration,1,CHEMBL615299,,
327,U,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,Cricetulus griseus,F,,BAO_0000019,16758,,10029.0,0,Autocuration,1,CHEMBL615300,,
328,H,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,,B,,BAO_0000357,14360,,,8,Autocuration,1,CHEMBL615301,,
329,D,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,Homo sapiens,B,,BAO_0000357,14360,,9606.0,9,Expert,1,CHEMBL615302,,
330,U,Selectivity ratio of ID50 in liver and heart,,Rattus norvegicus,B,,BAO_0000019,9964,,10116.0,0,Autocuration,1,CHEMBL615303,,
331,H,"Selectivity, ratio of relative ID50 in liver and heart",,,B,,BAO_0000019,9964,,,8,Autocuration,1,CHEMBL615304,,
332,H,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,,B,,BAO_0000019,9964,,,8,Autocuration,1,CHEMBL615305,,
333,H,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,B,,BAO_0000218,9964,,,8,Autocuration,1,CHEMBL615306,,
334,H,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,B,,BAO_0000218,9964,,,8,Autocuration,1,CHEMBL615307,,
335,H,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,B,,BAO_0000218,9964,In vivo,,8,Autocuration,1,CHEMBL615308,,
336,H,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,F,,BAO_0000218,9964,In vivo,,8,Autocuration,1,CHEMBL615309,,
337,U,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,,B,,BAO_0000019,9964,,,0,Autocuration,1,CHEMBL615310,,
338,H,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,,B,,BAO_0000019,9964,,,8,Autocuration,1,CHEMBL615311,,
339,U,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,Homo sapiens,B,,BAO_0000019,9964,,9606.0,0,Autocuration,1,CHEMBL615312,,
340,H,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,B,,BAO_0000019,9964,,,8,Autocuration,1,CHEMBL615313,,
341,H,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,F,,BAO_0000019,9964,,,8,Autocuration,1,CHEMBL615314,,
342,H,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,,B,,BAO_0000019,9964,,,8,Autocuration,1,CHEMBL615315,,
343,U,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,Rattus norvegicus,B,,BAO_0000218,9964,,10116.0,0,Autocuration,1,CHEMBL615316,,
344,H,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,,B,,BAO_0000218,9964,In vivo,,8,Autocuration,1,CHEMBL615317,,
345,H,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,B,,BAO_0000218,9964,,,8,Autocuration,1,CHEMBL615318,,
346,U,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,Rattus norvegicus,B,,BAO_0000218,9964,,10116.0,0,Autocuration,1,CHEMBL615319,,
347,H,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,B,,BAO_0000019,9964,,,8,Autocuration,1,CHEMBL615320,,
348,H,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,F,,BAO_0000019,9964,,,8,Autocuration,1,CHEMBL615321,,
349,U,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,Rattus norvegicus,B,,BAO_0000019,3796,,10116.0,0,Autocuration,1,CHEMBL615322,,
350,H,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,Escherichia coli,B,,BAO_0000357,4251,,562.0,8,Autocuration,1,CHEMBL615323,,
351,H,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,Escherichia coli,B,,BAO_0000357,4251,,562.0,8,Autocuration,1,CHEMBL615407,,
352,H,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,Escherichia coli,B,,BAO_0000357,4251,,562.0,8,Autocuration,1,CHEMBL857267,,
353,H,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,Escherichia coli,B,,BAO_0000357,4251,,562.0,8,Autocuration,1,CHEMBL615408,,
354,H,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,,B,,BAO_0000357,166,,,8,Autocuration,1,CHEMBL615409,,
355,H,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,,B,,BAO_0000357,17861,,,8,Autocuration,1,CHEMBL615410,,
356,H,Inhibition constant against 3-dehydroquinate synthase,,,B,,BAO_0000357,166,,,8,Autocuration,1,CHEMBL615411,,
357,H,Association rate constant against 3-dehydroquinate synthase,,,B,,BAO_0000357,166,,,8,Autocuration,1,CHEMBL615412,,
358,H,Rate constant against 3-dehydroquinate synthase,,,B,,BAO_0000357,166,,,8,Autocuration,1,CHEMBL615413,,
359,U,Inhibitory activity against fuc-TVII,,,B,,BAO_0000019,3548,,,0,Autocuration,1,CHEMBL615414,,
360,D,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,Rattus norvegicus,B,,BAO_0000251,9877,,10116.0,9,Autocuration,1,CHEMBL615415,,2107.0
361,D,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,Rattus norvegicus,B,,BAO_0000251,9877,,10116.0,9,Autocuration,1,CHEMBL615416,,2107.0
362,D,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,Rattus norvegicus,B,,BAO_0000251,9877,,10116.0,9,Autocuration,1,CHEMBL615417,,2107.0
363,D,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,Rattus norvegicus,B,,BAO_0000251,9877,,10116.0,9,Autocuration,1,CHEMBL615418,,2107.0
364,D,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,Rattus norvegicus,B,,BAO_0000251,9877,,10116.0,9,Autocuration,1,CHEMBL615419,,2107.0
365,D,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,Rattus norvegicus,B,,BAO_0000251,9877,,10116.0,9,Autocuration,1,CHEMBL615420,,2107.0
366,D,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,Rattus norvegicus,B,,BAO_0000251,9877,,10116.0,9,Autocuration,1,CHEMBL615421,,2107.0
367,D,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,Rattus norvegicus,B,,BAO_0000251,9877,,10116.0,9,Autocuration,1,CHEMBL615422,,2107.0
368,D,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,Rattus norvegicus,B,,BAO_0000251,9877,,10116.0,9,Autocuration,1,CHEMBL615423,,2107.0
369,D,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,Rattus norvegicus,B,,BAO_0000251,9877,,10116.0,9,Autocuration,1,CHEMBL872868,,2107.0
370,D,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,Rattus norvegicus,B,,BAO_0000251,9877,,10116.0,9,Autocuration,1,CHEMBL615424,,2107.0
371,H,Inhibitory activity against 3-phosphoglycerate kinase.,,,B,,BAO_0000224,3003,,,4,Autocuration,1,CHEMBL825022,,
372,H,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,,B,,BAO_0000224,3003,,,4,Autocuration,1,CHEMBL615425,,
373,H,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,,B,,BAO_0000224,3003,,,4,Autocuration,1,CHEMBL615426,,
374,D,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,Homo sapiens,B,,BAO_0000357,17185,,9606.0,9,Expert,1,CHEMBL615427,,
375,N,Cytotoxicity on 3677 melanoma cells,,Homo sapiens,F,,BAO_0000219,6072,,9606.0,1,Intermediate,1,CHEMBL615428,844.0,
376,N,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,Homo sapiens,F,,BAO_0000219,6072,,9606.0,1,Intermediate,1,CHEMBL615429,844.0,
377,N,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,Mus musculus,F,,BAO_0000219,5018,,10090.0,1,Intermediate,1,CHEMBL615430,700.0,
378,U,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,Homo sapiens,F,,BAO_0000019,2852,,9606.0,0,Intermediate,1,CHEMBL615431,,
379,U,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,,F,,BAO_0000218,8663,,,0,Autocuration,1,CHEMBL615432,798.0,
380,U,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,,F,,BAO_0000218,8663,,,0,Autocuration,1,CHEMBL615433,798.0,
381,D,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,Human rhinovirus 14,F,,BAO_0000019,3245,,12131.0,9,Expert,1,CHEMBL615434,,
382,N,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,Human rhinovirus sp.,F,,BAO_0000218,3245,,169066.0,1,Intermediate,1,CHEMBL615435,,
383,N,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,human rhinovirus type 14,F,,BAO_0000218,3877,,169066.0,1,Intermediate,1,CHEMBL615436,,
384,N,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,human rhinovirus type 14,F,,BAO_0000218,3877,,169066.0,1,Intermediate,1,CHEMBL615437,,
385,D,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,Human rhinovirus 14,F,,BAO_0000019,5861,,12131.0,9,Expert,1,CHEMBL615438,,
386,D,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,Human rhinovirus 14,F,,BAO_0000019,5861,,12131.0,9,Expert,1,CHEMBL615439,,
387,D,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,Human rhinovirus 14,F,,BAO_0000019,5861,,12131.0,9,Expert,1,CHEMBL615440,,
388,D,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,Human rhinovirus 14,F,,BAO_0000019,5861,,12131.0,9,Expert,1,CHEMBL615441,,
389,N,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,Enterovirus,F,,BAO_0000218,13748,,12059.0,1,Intermediate,1,CHEMBL615641,,
390,N,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,Enterovirus,F,,BAO_0000218,13748,,12059.0,1,Intermediate,1,CHEMBL872065,,
391,N,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,Enterovirus,F,,BAO_0000218,13748,,12059.0,1,Intermediate,1,CHEMBL825023,,
392,N,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,Enterovirus,F,,BAO_0000218,13748,,12059.0,1,Intermediate,1,CHEMBL615642,,
393,H,Inhibition of human rhinovirus 3C protease,,Human rhinovirus B,B,,BAO_0000357,13748,,147712.0,8,Expert,1,CHEMBL615643,,
394,U,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,Homo sapiens,B,,BAO_0000019,17699,,9606.0,0,Autocuration,1,CHEMBL615644,,
395,N,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,Mus musculus,F,,BAO_0000218,7145,,10090.0,1,Intermediate,1,CHEMBL615645,833.0,
396,N,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,Mus musculus,F,,BAO_0000218,7145,,10090.0,1,Intermediate,1,CHEMBL615646,833.0,
397,N,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,Mus musculus,F,,BAO_0000218,7145,,10090.0,1,Intermediate,1,CHEMBL615647,833.0,
398,N,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,Mus musculus,F,,BAO_0000218,7145,,10090.0,1,Intermediate,1,CHEMBL615648,833.0,
399,N,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,Mus musculus,F,,BAO_0000218,7145,,10090.0,1,Intermediate,1,CHEMBL615649,833.0,
400,N,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,Mus musculus,F,,BAO_0000218,7145,,10090.0,1,Intermediate,1,CHEMBL615650,833.0,
401,N,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,Mus musculus,F,,BAO_0000218,5325,,10090.0,1,Intermediate,1,CHEMBL615651,847.0,
402,N,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,Mus musculus,F,,BAO_0000218,5325,,10090.0,1,Intermediate,1,CHEMBL615652,847.0,
403,N,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,Mus musculus,F,,BAO_0000218,5325,,10090.0,1,Expert,1,CHEMBL615653,847.0,
404,N,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615654,847.0,
405,N,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615655,847.0,
406,N,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL825024,847.0,
407,N,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615656,847.0,
408,N,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615657,847.0,
409,N,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615658,847.0,
410,N,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615659,847.0,
411,N,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615660,847.0,
412,N,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615661,847.0,
413,N,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615662,847.0,
414,N,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615663,847.0,
415,N,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615664,847.0,
416,N,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615665,847.0,
417,N,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615666,847.0,
418,N,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615667,847.0,
419,N,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615668,847.0,
420,N,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615669,847.0,
421,N,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615670,847.0,
422,N,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL836739,847.0,
423,N,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615671,847.0,
424,N,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615672,847.0,
425,N,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615791,847.0,
426,N,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615792,847.0,
427,N,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615793,847.0,
428,N,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615794,847.0,
429,N,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,Mus musculus,F,,BAO_0000219,16169,,10090.0,1,Intermediate,1,CHEMBL615795,847.0,
430,N,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,Homo sapiens,F,,BAO_0000219,15547,,9606.0,1,Intermediate,1,CHEMBL615590,971.0,
431,U,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,,F,,BAO_0000218,8663,,,0,Autocuration,1,CHEMBL615591,,
432,U,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,,F,,BAO_0000218,8663,,,0,Autocuration,1,CHEMBL615592,,
433,U,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,,F,,BAO_0000218,8663,,,0,Autocuration,1,CHEMBL615593,,
434,U,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,,F,,BAO_0000218,8663,,,0,Autocuration,1,CHEMBL615594,,
435,N,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,Mus musculus,F,,BAO_0000219,4504,,10090.0,1,Intermediate,1,CHEMBL615595,723.0,
436,N,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,Mus musculus,F,,BAO_0000219,4504,,10090.0,1,Intermediate,1,CHEMBL615596,723.0,
437,H,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,,F,,BAO_0000219,12695,,,8,Expert,1,CHEMBL615597,723.0,
438,N,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,Mus musculus,F,,BAO_0000219,12695,,10090.0,1,Intermediate,1,CHEMBL615598,723.0,
439,N,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,Mus musculus,F,,BAO_0000219,12695,,10090.0,1,Intermediate,1,CHEMBL615599,723.0,
440,N,Effective dose against murine 3T3 fibroblasts cells,,Mus musculus,F,,BAO_0000219,17642,,10090.0,1,Expert,1,CHEMBL615600,723.0,
441,N,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,Mus musculus,F,,BAO_0000219,17642,,10090.0,1,Expert,1,CHEMBL615601,723.0,
442,N,Cytotoxic effect on 3T3 cells,,Mus musculus,F,,BAO_0000219,12340,,10090.0,1,Expert,1,CHEMBL615602,723.0,
443,N,Cytotoxic effect on 3T3 cells,,Mus musculus,F,,BAO_0000219,12340,,10090.0,1,Expert,1,CHEMBL615603,723.0,
444,N,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,Mus musculus,F,,BAO_0000219,12716,,10090.0,1,Intermediate,1,CHEMBL615604,723.0,
445,N,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,Mus musculus,F,,BAO_0000219,6277,,10090.0,1,Intermediate,1,CHEMBL615605,723.0,
446,N,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,Mus musculus,F,,BAO_0000219,6277,,10090.0,1,Intermediate,1,CHEMBL615606,723.0,
447,N,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,Mus musculus,F,,BAO_0000219,6277,,10090.0,1,Expert,1,CHEMBL884526,723.0,
448,N,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,Mus musculus,F,,BAO_0000219,6277,,10090.0,1,Expert,1,CHEMBL615607,723.0,
449,N,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,Mus musculus,F,,BAO_0000219,6277,,10090.0,1,Intermediate,1,CHEMBL615608,723.0,
450,N,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,Mus musculus,F,,BAO_0000219,6277,,10090.0,1,Expert,1,CHEMBL615609,723.0,
451,N,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,Mus musculus,F,,BAO_0000219,6277,,10090.0,1,Expert,1,CHEMBL615682,723.0,
452,N,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,Mus musculus,F,,BAO_0000219,6277,,10090.0,1,Intermediate,1,CHEMBL615683,723.0,
453,N,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,Mus musculus,F,,BAO_0000218,17780,,10090.0,1,Expert,1,CHEMBL615684,723.0,
454,D,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,Mus musculus,F,,BAO_0000219,12751,,10090.0,7,Autocuration,1,CHEMBL615685,,
455,N,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,Mus musculus,F,,BAO_0000219,12380,,10090.0,1,Expert,1,CHEMBL615686,723.0,
456,N,Inhibitory activity against 3T3 cell line,,Mus musculus,F,,BAO_0000219,14892,,10090.0,1,Intermediate,1,CHEMBL615687,723.0,
457,N,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,Mus musculus,F,,BAO_0000219,12695,,10090.0,1,Intermediate,1,CHEMBL884523,723.0,
458,H,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,,F,,BAO_0000019,12695,,,8,Expert,1,CHEMBL615688,,
459,N,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,Mus musculus,F,,BAO_0000219,12695,,10090.0,1,Intermediate,1,CHEMBL615689,723.0,
460,N,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,Mus musculus,F,,BAO_0000219,12695,,10090.0,1,Intermediate,1,CHEMBL615690,723.0,
461,H,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,,F,,BAO_0000019,12695,,,8,Expert,1,CHEMBL615691,,
462,H,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,,F,,BAO_0000019,12695,,,8,Expert,1,CHEMBL615692,,
463,N,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,Mus musculus,F,,BAO_0000219,6277,,10090.0,1,Intermediate,1,CHEMBL615693,723.0,
464,N,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,Mus musculus,F,,BAO_0000219,6277,,10090.0,1,Expert,1,CHEMBL615324,723.0,
465,D,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,Homo sapiens,F,,BAO_0000219,4959,,9606.0,9,Expert,1,CHEMBL615325,723.0,
466,D,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,Homo sapiens,F,,BAO_0000219,4959,,9606.0,9,Expert,1,CHEMBL615490,723.0,
467,D,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,Homo sapiens,F,,BAO_0000219,4959,,9606.0,9,Expert,1,CHEMBL615491,723.0,
468,D,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,Homo sapiens,F,,BAO_0000219,4959,,9606.0,9,Expert,1,CHEMBL615492,723.0,
469,N,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,Mus musculus,F,,BAO_0000219,12082,,10090.0,1,Intermediate,1,CHEMBL615493,723.0,
470,N,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,Mus musculus,F,,BAO_0000219,12082,,10090.0,1,Intermediate,1,CHEMBL615494,723.0,
471,N,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,Mus musculus,F,,BAO_0000219,12082,,10090.0,1,Intermediate,1,CHEMBL615495,723.0,
472,N,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,Mus musculus,F,,BAO_0000219,12082,,10090.0,1,Intermediate,1,CHEMBL615496,723.0,
473,N,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,Mus musculus,F,,BAO_0000219,2643,,10090.0,1,Intermediate,1,CHEMBL615497,723.0,
474,N,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,Mus musculus,F,,BAO_0000219,11926,,10090.0,1,Expert,1,CHEMBL615498,723.0,
475,N,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,Mus musculus,A,,BAO_0000219,15204,,10090.0,1,Intermediate,1,CHEMBL615499,723.0,
476,N,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,Mus musculus,F,,BAO_0000219,15992,,10090.0,1,Expert,1,CHEMBL835522,723.0,
477,N,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,Mus musculus,F,,BAO_0000219,16279,,10090.0,1,Intermediate,1,CHEMBL615500,723.0,
478,N,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Mus musculus,F,,BAO_0000219,16279,,10090.0,1,Intermediate,1,CHEMBL615501,723.0,
479,N,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Mus musculus,F,,BAO_0000219,16279,,10090.0,1,Intermediate,1,CHEMBL615502,723.0,
480,N,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Mus musculus,F,,BAO_0000219,16279,,10090.0,1,Intermediate,1,CHEMBL615503,723.0,
481,N,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Mus musculus,F,,BAO_0000219,16279,,10090.0,1,Intermediate,1,CHEMBL615504,723.0,
482,N,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Mus musculus,F,,BAO_0000219,16279,,10090.0,1,Intermediate,1,CHEMBL615505,723.0,
483,N,Inhibition of swiss 3T3 mouse fibroblast proliferation,,Mus musculus,F,,BAO_0000219,12831,,10090.0,1,Expert,1,CHEMBL615506,723.0,
484,N,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,Mus musculus,F,,BAO_0000219,13497,,10090.0,1,Intermediate,1,CHEMBL615507,723.0,
485,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,F,,BAO_0000218,13715,,,1,Intermediate,1,CHEMBL615508,620.0,
486,N,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,Mus musculus,F,,BAO_0000219,13618,,10090.0,1,Intermediate,1,CHEMBL615509,620.0,
487,N,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,Mus musculus,F,,BAO_0000219,11902,,10090.0,1,Intermediate,1,CHEMBL615510,620.0,
488,N,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,Mus musculus,F,,BAO_0000219,11902,,10090.0,1,Intermediate,1,CHEMBL615511,620.0,
489,N,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,Mus musculus,F,,BAO_0000219,11902,,10090.0,1,Intermediate,1,CHEMBL615512,620.0,
490,N,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,Mus musculus,F,,BAO_0000218,14840,,10090.0,1,Intermediate,1,CHEMBL615513,620.0,
491,N,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,Mus musculus,F,,BAO_0000218,14840,,10090.0,1,Intermediate,1,CHEMBL615514,620.0,
492,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,,F,,BAO_0000219,13715,,,1,Intermediate,1,CHEMBL615515,620.0,
493,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,F,,BAO_0000219,13715,,,1,Intermediate,1,CHEMBL615516,620.0,
494,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,F,,BAO_0000219,13715,,,1,Intermediate,1,CHEMBL615517,620.0,
495,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,F,,BAO_0000219,13715,,,1,Intermediate,1,CHEMBL615518,620.0,
496,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,F,,BAO_0000219,13715,,,1,Intermediate,1,CHEMBL615519,620.0,
497,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,,F,,BAO_0000218,13715,,,1,Intermediate,1,CHEMBL615520,620.0,
498,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,,F,,BAO_0000218,13715,,,1,Intermediate,1,CHEMBL615521,620.0,
499,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,F,,BAO_0000218,13715,,,1,Intermediate,1,CHEMBL615522,620.0,
500,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,F,,BAO_0000218,13715,,,1,Intermediate,1,CHEMBL615523,620.0,
501,N,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,F,,BAO_0000218,13715,,,1,Expert,1,CHEMBL615524,620.0,
502,N,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,F,,BAO_0000218,13715,,,1,Expert,1,CHEMBL615525,620.0,
503,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,F,,BAO_0000218,13715,,,1,Intermediate,1,CHEMBL615526,620.0,
504,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,F,,BAO_0000218,13715,,,1,Intermediate,1,CHEMBL615527,620.0,
505,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,,F,,BAO_0000218,13715,,,1,Intermediate,1,CHEMBL615528,620.0,
506,N,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,F,,BAO_0000218,13715,,,1,Expert,1,CHEMBL615529,620.0,
507,N,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,F,,BAO_0000218,13715,,,1,Expert,1,CHEMBL615530,620.0,
508,N,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,F,,BAO_0000218,13715,,,1,Expert,1,CHEMBL615531,620.0,
509,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,F,,BAO_0000219,13715,,,1,Intermediate,1,CHEMBL615532,620.0,
510,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,F,,BAO_0000219,13715,,,1,Intermediate,1,CHEMBL615533,620.0,
511,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,F,,BAO_0000219,13715,,,1,Intermediate,1,CHEMBL615534,620.0,
512,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,F,,BAO_0000218,13715,,,1,Intermediate,1,CHEMBL615535,620.0,
513,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,F,,BAO_0000218,13715,,,1,Intermediate,1,CHEMBL615536,620.0,
514,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,F,,BAO_0000218,13715,,,1,Intermediate,1,CHEMBL615537,620.0,
515,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,F,,BAO_0000218,13715,,,1,Intermediate,1,CHEMBL615538,620.0,
516,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,F,,BAO_0000218,13715,,,1,Intermediate,1,CHEMBL836166,620.0,
517,H,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,,F,,BAO_0000219,6411,,,8,Expert,1,CHEMBL615539,620.0,
518,N,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,Mus musculus,F,,BAO_0000219,6411,,10090.0,1,Intermediate,1,CHEMBL615540,620.0,
519,H,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,,F,,BAO_0000219,6411,,,8,Expert,1,CHEMBL615541,620.0,
520,N,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,Mus musculus,F,,BAO_0000219,3966,,10090.0,1,Expert,1,CHEMBL615542,620.0,
521,N,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,Mus musculus,F,,BAO_0000219,3966,,10090.0,1,Intermediate,1,CHEMBL615543,620.0,
522,N,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,Mus musculus,F,,BAO_0000219,15556,,10090.0,1,Expert,1,CHEMBL615544,620.0,
523,N,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,Mus musculus,F,,BAO_0000219,5845,,10090.0,1,Expert,1,CHEMBL615545,620.0,
524,N,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,Mus musculus,F,,BAO_0000219,14422,,10090.0,1,Expert,1,CHEMBL615546,620.0,
525,N,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,Mus musculus,F,,BAO_0000219,5845,,10090.0,1,Expert,1,CHEMBL615547,620.0,
526,N,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,Mus musculus,F,,BAO_0000219,14508,,10090.0,1,Expert,1,CHEMBL615548,620.0,
527,N,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,Mus musculus,F,,BAO_0000219,14508,,10090.0,1,Expert,1,CHEMBL615549,620.0,
528,N,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,Mus musculus,F,,BAO_0000219,14508,,10090.0,1,Expert,1,CHEMBL615550,620.0,
529,N,Inhibitory activity against rat fibroblast (3Y1) cell line,,Rattus norvegicus,F,,BAO_0000219,6349,,10116.0,1,Intermediate,1,CHEMBL615551,1118.0,
530,N,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,Rattus norvegicus,F,,BAO_0000219,15899,,10116.0,1,Expert,1,CHEMBL615552,1118.0,
531,N,Cytotoxicity in 3Y1 cells.,,Rattus norvegicus,F,,BAO_0000219,15899,,10116.0,1,Expert,1,CHEMBL615553,1118.0,
532,N,Cytostatic effect in 3Y1 cells.,,Rattus norvegicus,F,,BAO_0000219,15899,,10116.0,1,Expert,1,CHEMBL615554,1118.0,
533,N,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,Rattus norvegicus,F,,BAO_0000219,15899,,10116.0,1,Intermediate,1,CHEMBL615555,1118.0,
534,N,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,Rattus norvegicus,F,,BAO_0000219,17038,,10116.0,1,Expert,1,CHEMBL615556,1118.0,
535,U,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,,B,,BAO_0000019,12421,,,0,Autocuration,1,CHEMBL615557,,
536,U,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,B,,BAO_0000019,12947,,,0,Autocuration,1,CHEMBL615558,,
537,U,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,B,,BAO_0000019,12947,,,0,Autocuration,1,CHEMBL872066,,
538,D,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,Sus scrofa,B,,BAO_0000019,4896,,9823.0,9,Expert,1,CHEMBL615559,,
539,H,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,,B,,BAO_0000019,6148,,,8,Autocuration,1,CHEMBL615560,,
540,H,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,,B,,BAO_0000019,16432,,,8,Autocuration,1,CHEMBL615561,,
541,H,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,,B,,BAO_0000019,4978,,,8,Expert,1,CHEMBL857062,,
542,H,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,,B,,BAO_0000019,4978,,,8,Expert,1,CHEMBL615562,,
543,H,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,,B,,BAO_0000019,3723,,,8,Autocuration,1,CHEMBL615563,,
544,H,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,,B,,BAO_0000357,3518,,,8,Autocuration,1,CHEMBL615564,,
545,H,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,,B,,BAO_0000019,4164,,,8,Autocuration,1,CHEMBL615565,,
546,H,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,,B,,BAO_0000019,3518,,,8,Autocuration,1,CHEMBL615566,,
547,D,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,Sus scrofa,B,,BAO_0000019,4164,,9823.0,9,Expert,1,CHEMBL615567,,
548,H,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,,B,,BAO_0000019,3518,,,8,Autocuration,1,CHEMBL615568,,
549,H,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,,B,,BAO_0000357,3518,,,8,Autocuration,1,CHEMBL615569,,
550,H,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,,B,,BAO_0000019,4978,,,8,Autocuration,1,CHEMBL615570,,
551,H,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,,B,,BAO_0000019,4978,,,8,Autocuration,1,CHEMBL615571,,
552,H,Binding affinity against melatonin (MT1) receptor (pC1),,,B,,BAO_0000224,6455,,,4,Autocuration,1,CHEMBL615572,,
553,U,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,,B,,BAO_0000019,2222,,,0,Autocuration,1,CHEMBL615573,,
554,U,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,,B,,BAO_0000019,13020,,,0,Autocuration,1,CHEMBL615574,,
555,U,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,,B,,BAO_0000019,13021,,,0,Autocuration,1,CHEMBL615575,,
556,H,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,,B,,BAO_0000357,14532,,,8,Autocuration,1,CHEMBL615576,,
557,H,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,B,,BAO_0000357,14118,,,8,Autocuration,1,CHEMBL615577,,
558,H,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,,B,,BAO_0000221,11884,,,8,Autocuration,1,CHEMBL615578,,10000000.0
559,H,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,13969,,,8,Expert,1,CHEMBL615579,,
560,H,Binding affinity for 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,13392,,,8,Expert,1,CHEMBL615580,,
561,H,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,,B,,BAO_0000019,14430,,,8,Expert,1,CHEMBL615581,,
562,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,B,,BAO_0000221,12248,,,8,Autocuration,1,CHEMBL615582,,10000000.0
563,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,B,,BAO_0000221,12249,,,8,Autocuration,1,CHEMBL615583,,10000000.0
564,H,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,B,,BAO_0000221,9995,,,8,Autocuration,1,CHEMBL615584,,10000000.0
565,H,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,B,,BAO_0000221,9995,,,8,Autocuration,1,CHEMBL833691,,10000000.0
566,H,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,B,,BAO_0000221,9995,,,8,Autocuration,1,CHEMBL615585,,10000000.0
567,H,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,B,,BAO_0000221,9995,,,8,Autocuration,1,CHEMBL615586,,10000000.0
568,H,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,B,,BAO_0000221,9995,,,8,Autocuration,1,CHEMBL884524,,10000000.0
569,H,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,B,,BAO_0000221,12249,,,8,Autocuration,1,CHEMBL615587,,10000000.0
570,H,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,B,,BAO_0000221,11799,,,8,Autocuration,1,CHEMBL615588,,10000000.0
571,D,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,Rattus norvegicus,B,,BAO_0000249,14331,,10116.0,9,Expert,1,CHEMBL615589,,
572,H,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,Bos taurus,B,,BAO_0000221,11884,,9913.0,8,Expert,1,CHEMBL615442,,10000000.0
573,H,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,,B,,BAO_0000221,14331,,,8,Autocuration,1,CHEMBL615443,,10000000.0
574,H,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,,B,,BAO_0000221,11701,,,8,Autocuration,1,CHEMBL615444,,10000000.0
575,H,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,,B,,BAO_0000221,11701,,,8,Expert,1,CHEMBL615445,,10000000.0
576,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,,B,,BAO_0000221,12248,,,8,Autocuration,1,CHEMBL615446,,10000000.0
577,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,,B,,BAO_0000219,12248,,,8,Autocuration,1,CHEMBL615447,449.0,
578,H,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,B,,BAO_0000221,12248,,,8,Expert,1,CHEMBL615448,,10000000.0
579,H,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,B,,BAO_0000221,12249,,,8,Expert,1,CHEMBL615449,,10000000.0
580,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,B,,BAO_0000219,12248,,,8,Autocuration,1,CHEMBL615450,449.0,
581,H,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,B,,BAO_0000221,11799,,,8,Expert,1,CHEMBL615451,,10000000.0
582,H,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,B,,BAO_0000357,634,,,8,Autocuration,1,CHEMBL615452,,
583,H,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,B,,BAO_0000221,9995,,,8,Autocuration,1,CHEMBL615453,,10000000.0
584,H,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,B,,BAO_0000221,9995,,,8,Autocuration,1,CHEMBL615454,,10000000.0
585,H,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,B,,BAO_0000221,9995,,,8,Autocuration,1,CHEMBL615455,,10000000.0
586,H,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,B,,BAO_0000221,9995,,,8,Autocuration,1,CHEMBL615456,,10000000.0
587,H,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,B,,BAO_0000221,9995,,,8,Autocuration,1,CHEMBL615457,,10000000.0
588,H,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,,B,,BAO_0000218,12210,,,8,Expert,1,CHEMBL615458,,10000000.0
589,H,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,B,,BAO_0000221,13311,,,8,Expert,1,CHEMBL615459,,10000000.0
590,D,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,Homo sapiens,B,,BAO_0000219,2331,,9606.0,9,Expert,1,CHEMBL615460,449.0,
591,H,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,Cavia porcellus,F,,BAO_0000019,1375,,10141.0,8,Autocuration,1,CHEMBL615461,,
592,H,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,Cavia porcellus,F,,BAO_0000019,1375,,10141.0,8,Autocuration,1,CHEMBL615462,,
593,H,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,Cavia porcellus,F,,BAO_0000221,11574,,10141.0,8,Autocuration,1,CHEMBL615463,,10000000.0
594,H,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,Cavia porcellus,B,,BAO_0000221,12867,,10141.0,8,Autocuration,1,CHEMBL615464,,2116.0
595,H,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,Cavia porcellus,B,,BAO_0000221,12867,,10141.0,8,Autocuration,1,CHEMBL615465,,2116.0
596,H,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,Cavia porcellus,B,,BAO_0000221,12867,,10141.0,8,Autocuration,1,CHEMBL615466,,2116.0
597,H,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,Cavia porcellus,B,,BAO_0000221,12867,,10141.0,8,Autocuration,1,CHEMBL615467,,2116.0
598,H,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,Cavia porcellus,B,,BAO_0000221,12867,,10141.0,8,Autocuration,1,CHEMBL615468,,2116.0
599,H,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,Cavia porcellus,B,,BAO_0000221,12867,,10141.0,8,Autocuration,1,CHEMBL615469,,2116.0
600,H,Binding affinity against 5-hydroxytryptamine 1A receptor,,Cavia porcellus,B,,BAO_0000357,11574,,10141.0,8,Autocuration,1,CHEMBL615470,,
601,H,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,Cavia porcellus,B,,BAO_0000357,13114,,10141.0,8,Autocuration,1,CHEMBL615471,,
602,H,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,Cavia porcellus,B,,BAO_0000357,13181,,10141.0,8,Autocuration,1,CHEMBL615472,,
603,H,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,Cavia porcellus,B,,BAO_0000221,10639,,10141.0,8,Autocuration,1,CHEMBL883242,,10000000.0
604,H,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,Cavia porcellus,F,,BAO_0000221,10639,,10141.0,8,Autocuration,1,CHEMBL615473,,10000000.0
605,H,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,Cricetulus griseus,B,,BAO_0000218,11883,,10029.0,8,Autocuration,1,CHEMBL615474,449.0,
606,H,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,17785,,,8,Autocuration,1,CHEMBL615475,,
607,H,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,,F,,BAO_0000219,1558,,,8,Autocuration,1,CHEMBL615476,308.0,
608,H,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,,F,,BAO_0000219,1558,,,8,Autocuration,1,CHEMBL615477,308.0,
609,H,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,F,,BAO_0000019,15740,,,8,Autocuration,1,CHEMBL615478,,
610,H,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,F,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL615160,449.0,
611,H,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,F,,BAO_0000219,17624,,,8,Expert,1,CHEMBL615161,449.0,
612,H,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,,F,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL615162,449.0,
613,H,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,,F,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL615163,449.0,
614,H,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,B,,BAO_0000219,17624,,,8,Expert,1,CHEMBL615164,449.0,
615,H,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,B,,BAO_0000219,17624,,,8,Expert,1,CHEMBL615165,449.0,
616,H,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,,B,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL615166,449.0,
617,H,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,,F,,BAO_0000219,14256,,,8,Autocuration,1,CHEMBL615167,,
618,D,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,Homo sapiens,B,,BAO_0000219,3445,,9606.0,9,Expert,1,CHEMBL615168,308.0,
619,D,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,Homo sapiens,B,,BAO_0000219,3445,,9606.0,9,Expert,1,CHEMBL615169,308.0,
620,D,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,Homo sapiens,B,,BAO_0000219,17200,,9606.0,9,Expert,1,CHEMBL615170,449.0,
621,D,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,Homo sapiens,B,,BAO_0000219,17200,,9606.0,9,Expert,1,CHEMBL615171,449.0,
622,H,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,F,,BAO_0000019,15180,,,8,Autocuration,1,CHEMBL615694,,
623,H,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,F,,BAO_0000019,15180,,,8,Autocuration,1,CHEMBL615695,,
624,H,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,F,,BAO_0000019,16026,,,8,Autocuration,1,CHEMBL615696,,
625,H,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,F,,BAO_0000219,2759,,,8,Autocuration,1,CHEMBL615697,449.0,
626,D,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,Homo sapiens,F,,BAO_0000219,2759,,9606.0,9,Expert,1,CHEMBL859410,449.0,
627,H,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,F,,BAO_0000219,2759,,,8,Autocuration,1,CHEMBL615841,449.0,
628,D,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,Homo sapiens,F,,BAO_0000219,2759,,9606.0,9,Expert,1,CHEMBL615842,449.0,
629,H,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,F,,BAO_0000219,2759,,,8,Autocuration,1,CHEMBL835003,449.0,
630,H,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,,F,,BAO_0000219,2759,,,8,Autocuration,1,CHEMBL615843,449.0,
631,D,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,Homo sapiens,F,,BAO_0000219,2759,,9606.0,9,Expert,1,CHEMBL615979,449.0,
632,H,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,F,,BAO_0000219,2759,,,8,Autocuration,1,CHEMBL615980,449.0,
633,D,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,Homo sapiens,F,,BAO_0000219,2759,,9606.0,9,Expert,1,CHEMBL615981,449.0,
634,D,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,Homo sapiens,F,,BAO_0000019,3445,,9606.0,9,Expert,1,CHEMBL615982,,
635,D,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,Homo sapiens,F,,BAO_0000019,5272,,9606.0,9,Expert,1,CHEMBL615983,,
636,D,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,Homo sapiens,F,,BAO_0000019,5272,,9606.0,9,Expert,1,CHEMBL615984,,
637,D,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,Homo sapiens,F,,BAO_0000019,5272,,9606.0,9,Expert,1,CHEMBL615985,,
638,H,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,F,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL615986,449.0,
639,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,F,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL615987,449.0,
640,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,F,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL615988,449.0,
641,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,F,,BAO_0000219,17624,,,8,Expert,1,CHEMBL615989,449.0,
642,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,F,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL615990,449.0,
643,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,,F,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL615991,449.0,
644,H,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,F,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL615992,449.0,
645,H,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,F,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL615993,449.0,
646,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,F,,BAO_0000219,17624,,,8,Expert,1,CHEMBL615994,449.0,
647,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,,F,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL615995,449.0,
648,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,F,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL615996,449.0,
649,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,F,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL615997,449.0,
650,H,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,F,,BAO_0000019,6563,,,8,Autocuration,1,CHEMBL615998,,
651,H,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,F,,BAO_0000019,6563,,,8,Autocuration,1,CHEMBL615999,,
652,H,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,F,,BAO_0000019,6563,,,8,Autocuration,1,CHEMBL616000,,
653,H,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,F,,BAO_0000219,17296,,,8,Autocuration,1,CHEMBL616001,722.0,
654,D,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,Homo sapiens,F,,BAO_0000019,6876,,9606.0,9,Expert,1,CHEMBL616002,,
655,H,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,,F,,BAO_0000019,6876,,,8,Expert,1,CHEMBL616003,,
656,D,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,Homo sapiens,F,,BAO_0000019,5272,,9606.0,9,Expert,1,CHEMBL616004,,
657,D,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,Homo sapiens,F,,BAO_0000019,5272,,9606.0,9,Expert,1,CHEMBL616005,,
658,H,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,F,,BAO_0000019,5548,,,8,Autocuration,1,CHEMBL616006,,
659,H,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,,F,,BAO_0000019,5548,,,8,Expert,1,CHEMBL616007,,
660,H,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,F,,BAO_0000019,5548,,,8,Autocuration,1,CHEMBL616008,,
661,H,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,F,,BAO_0000019,5548,,,8,Autocuration,1,CHEMBL616009,,
662,H,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,,F,,BAO_0000019,5929,,,8,Expert,1,CHEMBL616010,,
663,D,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,Homo sapiens,F,,BAO_0000019,5929,,9606.0,9,Expert,1,CHEMBL616011,,
664,D,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,Homo sapiens,F,,BAO_0000019,5929,,9606.0,9,Expert,1,CHEMBL615740,,
665,H,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,,F,,BAO_0000019,16245,,,8,Autocuration,1,CHEMBL615741,,
666,H,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,F,,BAO_0000019,5640,,,8,Expert,1,CHEMBL615742,,
667,H,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,,F,,BAO_0000019,5640,,,8,Autocuration,1,CHEMBL615743,,
668,H,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,,F,,BAO_0000219,14509,,,8,Autocuration,1,CHEMBL615744,449.0,
669,H,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,,F,,BAO_0000219,14509,,,8,Expert,1,CHEMBL615745,449.0,
670,H,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,B,,BAO_0000357,15331,,,8,Autocuration,1,CHEMBL615746,,
671,H,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,B,,BAO_0000357,15331,,,8,Autocuration,1,CHEMBL615747,,
672,H,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,F,,BAO_0000019,6563,,,8,Autocuration,1,CHEMBL615748,,
673,H,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,,F,,BAO_0000019,6563,,,8,Autocuration,1,CHEMBL615749,,
674,H,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,F,,BAO_0000019,6563,,,8,Autocuration,1,CHEMBL615750,,
675,D,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,Homo sapiens,F,,BAO_0000019,6563,,9606.0,9,Expert,1,CHEMBL616259,,
676,H,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,F,,BAO_0000019,6563,,,8,Autocuration,1,CHEMBL616260,,
677,D,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,Homo sapiens,F,,BAO_0000019,5272,,9606.0,9,Expert,1,CHEMBL616261,,
678,D,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,Homo sapiens,F,,BAO_0000019,5272,,9606.0,9,Expert,1,CHEMBL616262,,
679,D,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,Homo sapiens,F,,BAO_0000019,5272,,9606.0,9,Expert,1,CHEMBL616263,,
680,D,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,Homo sapiens,F,,BAO_0000019,5272,,9606.0,9,Expert,1,CHEMBL616264,,
681,D,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,Homo sapiens,F,,BAO_0000019,5272,,9606.0,9,Expert,1,CHEMBL616265,,
682,D,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,Homo sapiens,F,,BAO_0000019,5272,,9606.0,9,Expert,1,CHEMBL616266,,
683,D,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,Homo sapiens,F,,BAO_0000019,5272,,9606.0,9,Expert,1,CHEMBL616267,,
684,D,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,Homo sapiens,F,,BAO_0000019,5272,,9606.0,9,Expert,1,CHEMBL616268,,
685,D,Inhibition of human 5-hydroxytryptamine 1A receptor,,Homo sapiens,B,,BAO_0000357,16146,,9606.0,9,Expert,1,CHEMBL616269,,
686,H,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,B,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL884528,449.0,
687,D,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,,B,,BAO_0000219,13706,,,9,Expert,1,CHEMBL616270,722.0,
688,H,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,,B,,BAO_0000219,15250,,,8,Autocuration,1,CHEMBL616271,449.0,
689,H,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,F,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL616272,449.0,
690,H,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,,B,,BAO_0000357,6861,,,8,Expert,1,CHEMBL616273,,
691,D,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,Homo sapiens,B,,BAO_0000357,17200,,9606.0,9,Expert,1,CHEMBL616274,,
692,H,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,,B,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL616275,449.0,
693,H,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,B,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL616276,449.0,
694,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,Rattus norvegicus,F,,BAO_0000218,12058,In vivo,10116.0,0,Autocuration,1,CHEMBL616277,,
695,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,Rattus norvegicus,F,,BAO_0000218,12058,In vivo,10116.0,0,Autocuration,1,CHEMBL616278,,
696,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,Rattus norvegicus,F,,BAO_0000218,12058,In vivo,10116.0,0,Autocuration,1,CHEMBL616279,,
697,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,Rattus norvegicus,F,,BAO_0000218,12058,In vivo,10116.0,0,Autocuration,1,CHEMBL616280,,
698,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,Rattus norvegicus,F,,BAO_0000218,12058,In vivo,10116.0,0,Autocuration,1,CHEMBL616281,,
699,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,Rattus norvegicus,F,,BAO_0000218,12058,In vivo,10116.0,0,Autocuration,1,CHEMBL616282,,
700,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,Rattus norvegicus,F,,BAO_0000218,12058,In vivo,10116.0,0,Autocuration,1,CHEMBL616283,,
701,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,Rattus norvegicus,F,,BAO_0000218,12058,In vivo,10116.0,0,Autocuration,1,CHEMBL616284,,
702,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,Rattus norvegicus,F,,BAO_0000218,12058,In vivo,10116.0,0,Autocuration,1,CHEMBL616285,,
703,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,Rattus norvegicus,F,,BAO_0000218,12058,In vivo,10116.0,0,Autocuration,1,CHEMBL616286,,
704,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,Rattus norvegicus,F,,BAO_0000218,12058,In vivo,10116.0,0,Autocuration,1,CHEMBL616287,,
705,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,Rattus norvegicus,F,,BAO_0000218,12058,In vivo,10116.0,0,Autocuration,1,CHEMBL616288,,
706,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,Rattus norvegicus,F,,BAO_0000218,12058,In vivo,10116.0,0,Autocuration,1,CHEMBL616289,,
707,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,Rattus norvegicus,F,,BAO_0000218,12058,In vivo,10116.0,0,Autocuration,1,CHEMBL615610,,
708,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,Rattus norvegicus,F,,BAO_0000218,12058,In vivo,10116.0,0,Autocuration,1,CHEMBL615611,,
709,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,Rattus norvegicus,F,,BAO_0000218,12058,In vivo,10116.0,0,Autocuration,1,CHEMBL615612,,
710,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,Rattus norvegicus,F,,BAO_0000218,12058,In vivo,10116.0,0,Autocuration,1,CHEMBL615613,,
711,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,Rattus norvegicus,F,,BAO_0000218,12058,In vivo,10116.0,0,Autocuration,1,CHEMBL615614,,
712,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,Rattus norvegicus,F,,BAO_0000218,12058,In vivo,10116.0,0,Autocuration,1,CHEMBL615615,,
713,H,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,,B,,BAO_0000019,11440,,,4,Autocuration,1,CHEMBL615616,,
714,H,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,,B,,BAO_0000249,6238,,,8,Autocuration,1,CHEMBL615617,,1898.0
715,H,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,,B,,BAO_0000019,10046,,,8,Autocuration,1,CHEMBL615618,,
716,H,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,,B,,BAO_0000019,10046,,,8,Autocuration,1,CHEMBL615619,,
717,H,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,B,,BAO_0000019,10046,,,8,Expert,1,CHEMBL615620,,
718,H,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,,B,,BAO_0000357,167,,,8,Autocuration,1,CHEMBL615621,,
719,H,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,,B,,BAO_0000357,167,,,8,Autocuration,1,CHEMBL615622,,
720,H,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,,F,,BAO_0000019,11520,,,8,Autocuration,1,CHEMBL615623,,
721,H,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,F,,BAO_0000019,11520,,,8,Autocuration,1,CHEMBL615624,,
722,H,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,F,,BAO_0000019,11520,,,8,Autocuration,1,CHEMBL615625,,
723,H,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,F,,BAO_0000019,11520,,,8,Autocuration,1,CHEMBL767045,,
724,H,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,Cavia porcellus,F,,BAO_0000019,135,,10141.0,8,Autocuration,1,CHEMBL615626,,
725,H,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,Cavia porcellus,F,,BAO_0000019,135,,10141.0,8,Autocuration,1,CHEMBL615627,,
726,H,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,Cavia porcellus,B,,BAO_0000019,11311,,10141.0,8,Autocuration,1,CHEMBL615628,,
727,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,Cavia porcellus,B,,BAO_0000357,10193,,10141.0,8,Autocuration,1,CHEMBL615629,,
728,D,Inhibitory concentration against 5-lipoxygenase from human whole blood,,Homo sapiens,B,,BAO_0000357,12281,,9606.0,9,Expert,1,CHEMBL615630,,
729,H,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,B,,BAO_0000219,11311,,,8,Autocuration,1,CHEMBL615631,,
730,H,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,F,,BAO_0000218,12576,,,8,Autocuration,1,CHEMBL615632,,
731,H,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,,B,,BAO_0000357,12281,,,8,Autocuration,1,CHEMBL615633,,
732,H,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,F,,BAO_0000218,12576,,,8,Autocuration,1,CHEMBL615634,,
733,H,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,Sus scrofa,B,,BAO_0000019,11089,,9823.0,8,Expert,1,CHEMBL615635,,
734,H,In vitro inhibition of rat 5-Lipoxygenase,,,B,,BAO_0000357,11006,,,8,Expert,1,CHEMBL615636,,
735,D,Inhibitory activity against 5-Lipoxygenase,,Rattus norvegicus,B,,BAO_0000357,11481,,10116.0,9,Expert,1,CHEMBL615637,,
736,H,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,,B,,BAO_0000219,10864,,,8,Expert,1,CHEMBL615638,702.0,
737,H,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,B,,BAO_0000219,3595,,,8,Autocuration,1,CHEMBL615639,702.0,
738,H,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,,B,,BAO_0000219,11311,,,8,Autocuration,1,CHEMBL615640,702.0,
739,H,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,,B,,BAO_0000019,11311,,,8,Autocuration,1,CHEMBL615796,,
740,H,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,,B,,BAO_0000219,11311,,,8,Autocuration,1,CHEMBL615845,,
741,H,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,B,,BAO_0000357,11006,,,8,Autocuration,1,CHEMBL615846,,
742,H,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,,B,,BAO_0000219,3595,,,8,Autocuration,1,CHEMBL615847,702.0,
743,H,The compound was tested for inhibition of isolated 5-Lipoxygenase,,,B,,BAO_0000357,11311,,,8,Autocuration,1,CHEMBL615848,,
744,U,Ratio of IC50 against 5-LO and COX,,Rattus norvegicus,B,,BAO_0000019,11481,,10116.0,0,Autocuration,1,CHEMBL615849,,
745,H,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,B,,BAO_0000357,11006,,,8,Autocuration,1,CHEMBL615850,,
746,H,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,,B,,BAO_0000357,11006,,,8,Autocuration,1,CHEMBL615851,,
747,H,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,,B,,BAO_0000219,11311,,,8,Autocuration,1,CHEMBL615852,,
748,H,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,,F,,BAO_0000019,11006,,,8,Autocuration,1,CHEMBL615853,,
749,H,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,,B,,BAO_0000357,4288,,,8,Autocuration,1,CHEMBL884527,,2367.0
750,U,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,Columba livia,B,,BAO_0000019,7587,,8932.0,0,Autocuration,1,CHEMBL872871,,
751,U,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,Columba livia,B,,BAO_0000019,7587,,8932.0,0,Autocuration,1,CHEMBL615854,,
752,U,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,Columba livia,B,,BAO_0000019,7587,,8932.0,0,Autocuration,1,CHEMBL767046,,
753,H,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,,B,,BAO_0000357,11249,,,8,Autocuration,1,CHEMBL615855,,
754,D,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,Rattus norvegicus,F,,BAO_0000019,8003,,10116.0,9,Expert,1,CHEMBL615856,,
755,D,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,Rattus norvegicus,F,,BAO_0000019,8003,,10116.0,9,Expert,1,CHEMBL615857,,
756,D,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,Rattus norvegicus,F,,BAO_0000019,8003,,10116.0,9,Expert,1,CHEMBL615858,,
757,H,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,B,,BAO_0000221,12416,,,8,Expert,1,CHEMBL615859,,10000000.0
758,H,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,,B,,BAO_0000357,16293,,,8,Autocuration,1,CHEMBL615860,,
759,U,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,B,,BAO_0000019,13047,,9986.0,0,Autocuration,1,CHEMBL615861,,
760,U,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,B,,BAO_0000019,13047,,9986.0,0,Autocuration,1,CHEMBL615862,,
761,U,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,B,,BAO_0000019,13047,,9986.0,0,Autocuration,1,CHEMBL615863,,
762,U,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,B,,BAO_0000019,13047,,9986.0,0,Autocuration,1,CHEMBL615864,,
763,H,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,B,,BAO_0000221,10085,,,4,Autocuration,1,CHEMBL615865,,10000000.0
764,H,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,B,,BAO_0000221,10085,,,4,Autocuration,1,CHEMBL615866,,10000000.0
765,H,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,B,,BAO_0000221,10085,,,4,Autocuration,1,CHEMBL615867,,10000000.0
766,H,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,,B,,BAO_0000249,9841,,,4,Autocuration,1,CHEMBL615868,,
767,D,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,Rattus norvegicus,B,,BAO_0000249,8822,,10116.0,5,Autocuration,1,CHEMBL615869,,
768,D,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,Rattus norvegicus,B,,BAO_0000019,9806,,10116.0,5,Autocuration,1,CHEMBL615870,,
769,D,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,Rattus norvegicus,B,,BAO_0000019,9806,,10116.0,5,Autocuration,1,CHEMBL615871,,
770,H,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,,B,,BAO_0000224,8868,,,4,Autocuration,1,CHEMBL615872,,
771,H,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,,B,,BAO_0000221,9036,,,4,Autocuration,1,CHEMBL833492,,10000000.0
772,H,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,,B,,BAO_0000221,11374,,,4,Autocuration,1,CHEMBL615873,,10000000.0
773,H,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,,B,,BAO_0000224,10881,,,4,Autocuration,1,CHEMBL615479,,
774,H,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,,B,,BAO_0000019,8822,,,4,Autocuration,1,CHEMBL615480,,
775,D,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,Rattus norvegicus,B,,BAO_0000249,9806,,10116.0,5,Autocuration,1,CHEMBL615481,,
776,H,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,B,,BAO_0000019,15463,,,4,Autocuration,1,CHEMBL872869,,
777,H,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,B,,BAO_0000019,15463,,,4,Autocuration,1,CHEMBL615482,,
778,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,B,,BAO_0000221,14542,,,4,Autocuration,1,CHEMBL615483,,955.0
779,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,B,,BAO_0000221,14542,,,4,Autocuration,1,CHEMBL615484,,955.0
780,H,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,,B,,BAO_0000019,8569,,,4,Autocuration,1,CHEMBL615485,,
781,D,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,Rattus norvegicus,B,,BAO_0000224,10062,,10116.0,5,Autocuration,1,CHEMBL615486,,
782,H,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,,B,,BAO_0000224,4771,,,4,Autocuration,1,CHEMBL615487,,
783,H,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,B,,BAO_0000224,10062,,,4,Autocuration,1,CHEMBL615488,,
784,H,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,B,,BAO_0000224,10062,,,4,Autocuration,1,CHEMBL615489,,
785,H,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,B,,BAO_0000224,10062,,,4,Autocuration,1,CHEMBL615389,,
786,H,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,B,,BAO_0000019,15463,,,4,Autocuration,1,CHEMBL615390,,
787,H,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,B,,BAO_0000019,15463,,,4,Autocuration,1,CHEMBL615391,,
788,H,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,,B,,BAO_0000224,9098,,,4,Autocuration,1,CHEMBL615392,,
789,U,Affinity for 5-hydroxytryptamine 1 receptor,,Rattus norvegicus,B,,BAO_0000019,3070,,10116.0,0,Autocuration,1,CHEMBL615393,,
790,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,,B,,BAO_0000221,14542,,,4,Autocuration,1,CHEMBL615394,,955.0
791,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,B,,BAO_0000221,14542,,,4,Autocuration,1,CHEMBL615395,,955.0
792,H,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,,B,,BAO_0000224,6398,,,4,Autocuration,1,CHEMBL615396,,
793,H,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,,B,,BAO_0000221,1344,,,4,Autocuration,1,CHEMBL615397,,955.0
794,H,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,B,,BAO_0000019,11963,,,4,Autocuration,1,CHEMBL615398,,
795,U,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,Rattus norvegicus,B,,BAO_0000019,8908,,10116.0,0,Autocuration,1,CHEMBL615399,,
796,H,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,,B,,BAO_0000019,9098,,,4,Autocuration,1,CHEMBL615400,,
797,D,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,Rattus norvegicus,B,,BAO_0000019,8841,,10116.0,5,Autocuration,1,CHEMBL615401,,
798,U,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,Rattus norvegicus,B,,BAO_0000019,8814,,10116.0,0,Autocuration,1,CHEMBL615402,,
799,H,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,,B,,BAO_0000019,11752,,,4,Autocuration,1,CHEMBL615403,,
800,H,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,,B,,BAO_0000221,11642,,,4,Autocuration,1,CHEMBL615404,,955.0
801,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,,B,,BAO_0000019,11642,,,4,Autocuration,1,CHEMBL615781,,
802,H,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,,B,,BAO_0000220,9231,,,4,Autocuration,1,CHEMBL615782,,955.0
803,H,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,,B,,BAO_0000221,11351,,,4,Autocuration,1,CHEMBL615783,,955.0
804,U,Compound was tested for binding affinity against 5-HT1 receptor,,,B,,BAO_0000019,4639,,,0,Autocuration,1,CHEMBL873481,,
805,U,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,,B,,BAO_0000019,1205,,,0,Autocuration,1,CHEMBL615784,,
806,H,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,B,,BAO_0000357,10025,,,8,Expert,1,CHEMBL615785,,
807,H,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,F,,BAO_0000249,13241,,,8,Autocuration,1,CHEMBL615786,,
808,H,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,F,,BAO_0000218,16245,In vivo,,8,Autocuration,1,CHEMBL615787,,
809,H,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,F,,BAO_0000218,16245,In vivo,,8,Autocuration,1,CHEMBL615788,,
810,H,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,,F,,BAO_0000019,12438,,,8,Autocuration,1,CHEMBL767044,,
811,H,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,F,,BAO_0000218,16245,In vivo,,8,Autocuration,1,CHEMBL615789,,
812,H,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,F,,BAO_0000218,16245,In vivo,,8,Autocuration,1,CHEMBL615790,,
813,H,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,,F,,BAO_0000019,15740,,,8,Autocuration,1,CHEMBL615813,,
814,H,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,,F,,BAO_0000219,15535,,,8,Autocuration,1,CHEMBL615814,,
815,H,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,,F,,BAO_0000219,15535,,,8,Expert,1,CHEMBL615815,,
816,H,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,,F,,BAO_0000219,15535,,,8,Autocuration,1,CHEMBL615816,,
817,H,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,,B,,BAO_0000249,9888,,,8,Expert,1,CHEMBL615817,,
818,H,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,,B,,BAO_0000221,10085,,,8,Autocuration,1,CHEMBL615818,,10000000.0
819,H,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,,B,,BAO_0000221,10085,,,8,Autocuration,1,CHEMBL615819,,10000000.0
820,H,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,,B,,BAO_0000249,17331,,,8,Expert,1,CHEMBL615820,,
821,D,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,Rattus norvegicus,B,,BAO_0000221,10845,,10116.0,9,Expert,1,CHEMBL615821,,10000000.0
822,D,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,Rattus norvegicus,B,,BAO_0000221,10845,,10116.0,9,Expert,1,CHEMBL615822,,10000000.0
823,H,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000221,10845,,,8,Expert,1,CHEMBL615823,,10000000.0
824,D,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,Rattus norvegicus,B,,BAO_0000221,10845,,10116.0,9,Expert,1,CHEMBL615824,,10000000.0
825,D,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,Rattus norvegicus,B,,BAO_0000221,10845,,10116.0,9,Expert,1,CHEMBL615825,,10000000.0
826,H,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,13730,,,8,Expert,1,CHEMBL615826,,
827,H,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000249,13508,,,8,Expert,1,CHEMBL615827,,
828,H,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000249,13508,,,8,Expert,1,CHEMBL615828,,10000000.0
829,H,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,B,,BAO_0000221,12073,,,8,Expert,1,CHEMBL615829,,10000000.0
830,H,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000221,4671,,,8,Autocuration,1,CHEMBL615830,,10000000.0
831,H,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,,B,,BAO_0000221,13631,,,8,Expert,1,CHEMBL615831,,10000000.0
832,H,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,12438,,,8,Autocuration,1,CHEMBL615832,,
833,H,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,,B,,BAO_0000019,10483,,,8,Autocuration,1,CHEMBL615833,,
834,H,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,,B,,BAO_0000221,10483,,,8,Autocuration,1,CHEMBL615834,,10000000.0
835,H,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,,B,,BAO_0000249,12352,,,8,Intermediate,1,CHEMBL615835,,
836,H,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,,B,,BAO_0000249,14732,,,8,Autocuration,1,CHEMBL615836,,10000000.0
837,D,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,Rattus norvegicus,B,,BAO_0000019,11049,,10116.0,9,Expert,1,CHEMBL615837,,
838,D,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,Rattus norvegicus,B,,BAO_0000019,11049,,10116.0,9,Expert,1,CHEMBL615838,,
839,H,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,,B,,BAO_0000249,13657,,,8,Expert,1,CHEMBL615839,,
840,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,,B,,BAO_0000019,11473,,,8,Autocuration,1,CHEMBL884525,,
841,H,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,B,,BAO_0000249,2014,,,8,Autocuration,1,CHEMBL615840,,
842,H,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,B,,BAO_0000221,3086,,,8,Expert,1,CHEMBL615405,,10000000.0
843,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,B,,BAO_0000019,15854,,,8,Expert,1,CHEMBL615406,,
844,H,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,B,,BAO_0000221,10922,,,8,Expert,1,CHEMBL615900,,10000000.0
845,H,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,,B,,BAO_0000221,13346,,,8,Expert,1,CHEMBL615901,,10000000.0
846,H,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,,B,,BAO_0000357,15311,,,8,Expert,1,CHEMBL615902,,
847,H,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,B,,BAO_0000221,10922,,,8,Autocuration,1,CHEMBL615903,,10000000.0
848,H,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,,B,,BAO_0000357,10025,,,8,Autocuration,1,CHEMBL615904,,
849,H,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,B,,BAO_0000357,10025,,,8,Expert,1,CHEMBL615905,,
850,H,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,B,,BAO_0000019,9742,,,8,Autocuration,1,CHEMBL615906,,
851,H,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,F,,BAO_0000019,9742,,,8,Autocuration,1,CHEMBL615907,,
852,H,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,B,,BAO_0000019,12304,,,8,Expert,1,CHEMBL615908,,
853,H,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,,B,,BAO_0000221,15789,,,8,Autocuration,1,CHEMBL615909,,10000000.0
854,H,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,,B,,BAO_0000019,9912,,,8,Autocuration,1,CHEMBL615910,,
855,H,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,,B,,BAO_0000019,9912,,,8,Autocuration,1,CHEMBL615911,,
856,H,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,,B,,BAO_0000019,9912,,,8,Autocuration,1,CHEMBL615912,,
857,H,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000019,16693,,,8,Expert,1,CHEMBL615913,,
858,H,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,B,,BAO_0000357,13276,,,8,Expert,1,CHEMBL615914,,
859,H,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,B,,BAO_0000221,12678,,,8,Autocuration,1,CHEMBL615915,,10000000.0
860,H,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,,B,,BAO_0000357,11825,,,8,Autocuration,1,CHEMBL615916,,
861,H,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,,B,,BAO_0000357,12443,,,8,Expert,1,CHEMBL615917,,
862,H,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,13830,,,8,Expert,1,CHEMBL615918,,
863,H,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,,B,,BAO_0000249,14286,,,8,Expert,1,CHEMBL615919,,10000000.0
864,D,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,Rattus norvegicus,B,,BAO_0000221,14356,,10116.0,9,Expert,1,CHEMBL615920,,10000000.0
865,H,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,15306,,,8,Autocuration,1,CHEMBL615921,,
866,H,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,,B,,BAO_0000357,15306,,,8,Expert,1,CHEMBL615922,,
867,D,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,Rattus norvegicus,F,,BAO_0000249,16616,,10116.0,9,Expert,1,CHEMBL881290,,
868,H,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,,B,,BAO_0000221,3651,,,8,Autocuration,1,CHEMBL615923,,10000000.0
869,H,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,F,,BAO_0000221,14331,,,8,Autocuration,1,CHEMBL615924,,10000000.0
870,H,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,F,,BAO_0000221,14331,,,8,Autocuration,1,CHEMBL615925,,10000000.0
871,D,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,B,,BAO_0000357,14178,,10116.0,9,Expert,1,CHEMBL615926,,
872,D,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,B,,BAO_0000019,10639,,10116.0,9,Expert,1,CHEMBL615927,,
873,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,B,,BAO_0000221,12306,,,8,Autocuration,1,CHEMBL615928,,10000000.0
874,D,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,Rattus norvegicus,B,,BAO_0000357,1348,,10116.0,9,Expert,1,CHEMBL615929,,
875,H,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,,B,,BAO_0000221,13605,,,8,Autocuration,1,CHEMBL615930,,10000000.0
876,H,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,B,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL615931,449.0,
877,H,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,F,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL615932,449.0,
878,H,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,F,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL615933,449.0,
879,H,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,15267,,,8,Autocuration,1,CHEMBL615934,,
880,H,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,,B,,BAO_0000357,16532,,,8,Autocuration,1,CHEMBL615935,,
881,H,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,F,,BAO_0000019,6563,,,8,Autocuration,1,CHEMBL615936,,
882,H,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,,B,,BAO_0000219,4751,,,8,Autocuration,1,CHEMBL615937,449.0,
883,H,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,15463,,,8,Autocuration,1,CHEMBL615938,,
884,H,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,,B,,BAO_0000357,3805,,,8,Autocuration,1,CHEMBL615797,,
885,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,5640,,,8,Autocuration,1,CHEMBL615798,,
886,H,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,,B,,BAO_0000357,6563,,,8,Autocuration,1,CHEMBL872870,,
887,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,,B,,BAO_0000357,5548,,,8,Autocuration,1,CHEMBL615799,,
888,H,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,6347,,,8,Autocuration,1,CHEMBL615800,,
889,H,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,F,,BAO_0000219,17296,,,8,Autocuration,1,CHEMBL615801,722.0,
890,H,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,,B,,BAO_0000019,13047,,,8,Autocuration,1,CHEMBL615802,,
891,H,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,,B,,BAO_0000357,15740,,,8,Autocuration,1,CHEMBL615803,,
892,H,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,F,,BAO_0000019,5640,,,8,Expert,1,CHEMBL835002,,
893,H,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,,F,,BAO_0000019,5640,,,8,Autocuration,1,CHEMBL615804,,
894,H,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000219,17211,,,8,Expert,1,CHEMBL615805,308.0,
895,H,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000219,4751,,,8,Autocuration,1,CHEMBL615806,449.0,
896,D,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,Homo sapiens,B,,BAO_0000357,6491,,9606.0,9,Expert,1,CHEMBL615807,,
897,H,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,,B,,BAO_0000357,4707,,,8,Autocuration,1,CHEMBL615808,,
898,D,Binding affinity against 5-hydroxytryptamine 1A receptor,,Homo sapiens,B,,BAO_0000357,13910,,9606.0,9,Expert,1,CHEMBL615809,,
899,H,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,,B,,BAO_0000219,16190,,,8,Autocuration,1,CHEMBL615810,308.0,
900,H,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,16633,,,8,Autocuration,1,CHEMBL615811,,
901,H,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,,B,,BAO_0000219,11898,,,8,Autocuration,1,CHEMBL615812,449.0,
902,H,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,B,,BAO_0000219,11898,,,8,Autocuration,1,CHEMBL615751,449.0,
903,H,Binding affinity against human 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,14331,,,8,Autocuration,1,CHEMBL615752,,
904,H,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,,B,,BAO_0000219,17624,,,8,Expert,1,CHEMBL615753,449.0,
905,H,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,,B,,BAO_0000219,17624,,,8,Autocuration,1,CHEMBL615754,449.0,
906,H,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,3307,,,8,Autocuration,1,CHEMBL615755,,
907,D,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,Homo sapiens,B,,BAO_0000219,6563,,9606.0,9,Expert,1,CHEMBL615756,449.0,
908,H,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000019,14165,,,8,Autocuration,1,CHEMBL615757,,
909,H,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,B,,BAO_0000357,5732,,,8,Autocuration,1,CHEMBL615758,,
910,H,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,B,,BAO_0000357,13366,,,8,Expert,1,CHEMBL615759,,
911,H,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,17626,,,8,Autocuration,1,CHEMBL615760,,
912,H,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,,B,,BAO_0000219,6588,,,8,Expert,1,CHEMBL615761,308.0,
913,H,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,,B,,BAO_0000357,16209,,,8,Autocuration,1,CHEMBL872104,,
914,H,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,15463,,,8,Autocuration,1,CHEMBL615762,,
915,H,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,15463,,,8,Autocuration,1,CHEMBL615763,,
916,H,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,,B,,BAO_0000357,14770,,,8,Autocuration,1,CHEMBL615764,,
917,H,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,,B,,BAO_0000219,16245,,,8,Autocuration,1,CHEMBL615765,1167.0,
918,H,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,,B,,BAO_0000019,16245,,,8,Autocuration,1,CHEMBL615766,,
919,H,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,5548,,,8,Autocuration,1,CHEMBL615767,,
920,H,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,5548,,,8,Expert,1,CHEMBL615768,,
921,H,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,5548,,,8,Autocuration,1,CHEMBL615769,,
922,H,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,,B,,BAO_0000357,6876,,,8,Expert,1,CHEMBL615770,,
923,H,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,2598,,,8,Autocuration,1,CHEMBL615771,,
924,H,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,,B,,BAO_0000357,17785,,,8,Expert,1,CHEMBL615772,,
925,H,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,6013,,,8,Autocuration,1,CHEMBL615773,,
926,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,5929,,,8,Expert,1,CHEMBL615774,,
927,H,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,16633,,,8,Autocuration,1,CHEMBL615775,,
928,H,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,B,,BAO_0000357,1558,,,8,Autocuration,1,CHEMBL615776,,
929,H,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,16026,,,8,Expert,1,CHEMBL615777,,
930,H,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,,B,,BAO_0000219,12469,,,8,Autocuration,1,CHEMBL615778,,
931,D,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,Homo sapiens,B,,BAO_0000357,15874,,9606.0,9,Expert,1,CHEMBL615779,,
932,H,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,B,,BAO_0000357,15874,,,8,Autocuration,1,CHEMBL615780,,
933,H,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,3935,,,8,Autocuration,1,CHEMBL616298,,
934,H,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,15818,,,8,Autocuration,1,CHEMBL616299,,
935,H,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,,B,,BAO_0000219,13706,,,8,Autocuration,1,CHEMBL616300,485.0,
936,H,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,,F,,BAO_0000219,13729,,,8,Expert,1,CHEMBL616301,485.0,
937,H,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000019,15413,,,8,Autocuration,1,CHEMBL616302,,
938,H,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,,B,,BAO_0000019,15413,,,8,Autocuration,1,CHEMBL616117,,
939,H,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,,B,,BAO_0000019,15413,,,8,Autocuration,1,CHEMBL616118,,
940,H,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,,B,,BAO_0000019,15413,,,8,Autocuration,1,CHEMBL616119,,
941,D,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,Homo sapiens,B,,BAO_0000219,3445,,9606.0,9,Expert,1,CHEMBL616120,308.0,
942,H,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,15740,,,8,Autocuration,1,CHEMBL616121,,
943,H,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,,B,,BAO_0000357,15740,,,8,Autocuration,1,CHEMBL616122,,
944,H,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,17626,,,8,Autocuration,1,CHEMBL616123,,
945,D,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,Homo sapiens,B,,BAO_0000357,4234,,9606.0,9,Expert,1,CHEMBL616124,,
946,H,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,B,,BAO_0000357,5640,,,8,Expert,1,CHEMBL616125,,
947,H,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,Rattus norvegicus,B,,BAO_0000357,5272,,10116.0,8,Expert,1,CHEMBL616126,,
948,H,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000219,4622,,,8,Autocuration,1,CHEMBL616127,449.0,
949,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000019,17085,,,8,Expert,1,CHEMBL616128,,
950,H,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,B,,BAO_0000357,3025,,,8,Autocuration,1,CHEMBL616129,,
951,H,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,15315,,,8,Expert,1,CHEMBL616130,,
952,H,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,,B,,BAO_0000357,15267,,,8,Autocuration,1,CHEMBL616131,,
953,H,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,,B,,BAO_0000219,17158,,,8,Autocuration,1,CHEMBL616132,308.0,
954,D,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,Homo sapiens,B,,BAO_0000219,14214,,9606.0,9,Expert,1,CHEMBL616133,308.0,
955,H,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,17133,,,8,Autocuration,1,CHEMBL616134,,
956,H,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,,B,,BAO_0000357,16532,,,8,Autocuration,1,CHEMBL616135,,
957,D,Affinity for 5-hydroxytryptamine 1A receptor subtype,,Homo sapiens,B,,BAO_0000357,2391,,9606.0,9,Expert,1,CHEMBL616136,,
958,H,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,,B,,BAO_0000019,14447,,,8,Autocuration,1,CHEMBL616137,,
959,H,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,,B,,BAO_0000019,14447,,,8,Autocuration,1,CHEMBL872105,,
960,H,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,,B,,BAO_0000357,15086,,,8,Autocuration,1,CHEMBL616138,,
961,D,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,Homo sapiens,B,,BAO_0000357,13051,,9606.0,9,Expert,1,CHEMBL616139,,
962,H,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,,F,,BAO_0000019,16026,,,8,Autocuration,1,CHEMBL616140,,
963,H,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,,B,,BAO_0000019,17085,,,8,Expert,1,CHEMBL616141,,
964,H,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,17133,,,8,Autocuration,1,CHEMBL616142,,
965,H,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,,B,,BAO_0000357,17133,,,8,Autocuration,1,CHEMBL616143,,
966,H,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,B,,BAO_0000219,17211,,,8,Autocuration,1,CHEMBL616144,308.0,
967,H,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,,B,,BAO_0000219,17211,,,8,Autocuration,1,CHEMBL616145,308.0,
968,H,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,B,,BAO_0000219,17211,,,8,Autocuration,1,CHEMBL616012,308.0,
969,H,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,B,,BAO_0000219,17211,,,8,Autocuration,1,CHEMBL616013,308.0,
970,H,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,F,,BAO_0000019,16394,,,8,Autocuration,1,CHEMBL616014,,
971,H,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,F,,BAO_0000019,16394,,,8,Autocuration,1,CHEMBL616015,,
972,H,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,F,,BAO_0000019,16394,,,8,Autocuration,1,CHEMBL616016,,
973,H,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,,F,,BAO_0000218,16394,In vivo,,8,Autocuration,1,CHEMBL616017,,
974,H,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,,B,,BAO_0000019,16394,,,8,Autocuration,1,CHEMBL616018,,
975,H,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,,F,,BAO_0000019,15740,,,8,Autocuration,1,CHEMBL616019,,
976,H,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,,F,,BAO_0000019,15740,,,8,Autocuration,1,CHEMBL616020,,
977,H,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,15740,,,8,Autocuration,1,CHEMBL858018,,
978,H,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,F,,BAO_0000219,17296,,,8,Autocuration,1,CHEMBL616021,722.0,
979,H,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,,F,,BAO_0000019,5640,,,8,Expert,1,CHEMBL616022,,
980,H,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,,F,,BAO_0000019,5640,,,8,Autocuration,1,CHEMBL616023,,
981,H,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,,F,,BAO_0000019,5640,,,8,Autocuration,1,CHEMBL616024,,
982,H,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,,F,,BAO_0000019,5640,,,8,Autocuration,1,CHEMBL616025,,
983,H,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,F,,BAO_0000219,2759,,,8,Autocuration,1,CHEMBL616026,449.0,
984,H,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,,F,,BAO_0000019,16394,,,8,Autocuration,1,CHEMBL616027,,
985,D,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,Homo sapiens,F,,BAO_0000019,16394,,9606.0,9,Expert,1,CHEMBL616028,,
986,D,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,Homo sapiens,F,,BAO_0000019,3445,,9606.0,9,Expert,1,CHEMBL616029,,
987,H,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,,B,,BAO_0000219,4316,,,8,Expert,1,CHEMBL616030,449.0,
988,H,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,,B,,BAO_0000019,4316,,,8,Expert,1,CHEMBL616031,,
989,D,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,Homo sapiens,F,,BAO_0000019,15180,,9606.0,9,Expert,1,CHEMBL616032,,
990,D,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,Homo sapiens,F,,BAO_0000019,15180,,9606.0,9,Expert,1,CHEMBL616033,,
991,H,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,F,,BAO_0000019,15042,,,8,Autocuration,1,CHEMBL616034,,
992,H,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,F,,BAO_0000019,15042,,,8,Autocuration,1,CHEMBL616035,,
993,H,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,F,,BAO_0000019,15042,,,8,Autocuration,1,CHEMBL616036,,
994,H,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,F,,BAO_0000019,15042,,,8,Autocuration,1,CHEMBL616037,,
995,H,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,F,,BAO_0000019,15042,,,8,Autocuration,1,CHEMBL616038,,
996,H,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,F,,BAO_0000019,15042,,,8,Autocuration,1,CHEMBL616039,,
997,H,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,F,,BAO_0000019,15042,,,8,Autocuration,1,CHEMBL616040,,
998,D,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,Homo sapiens,F,,BAO_0000219,15180,,9606.0,9,Expert,1,CHEMBL616041,308.0,
999,D,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,Homo sapiens,F,,BAO_0000219,15180,,9606.0,9,Expert,1,CHEMBL616042,308.0,
1000,D,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,Homo sapiens,F,,BAO_0000219,15180,,9606.0,9,Expert,1,CHEMBL616043,308.0,
1001,H,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,,F,,BAO_0000019,16245,,,8,Autocuration,1,CHEMBL616044,,
1002,H,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,F,,BAO_0000019,16026,,,8,Autocuration,1,CHEMBL616045,,
1003,H,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,F,,BAO_0000219,17296,,,8,Autocuration,1,CHEMBL616046,722.0,
1004,H,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,F,,BAO_0000219,2759,,,8,Autocuration,1,CHEMBL616047,449.0,
1005,H,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,F,,BAO_0000219,2759,,,8,Autocuration,1,CHEMBL616048,449.0,
1006,D,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,Homo sapiens,F,,BAO_0000219,2759,,9606.0,9,Expert,1,CHEMBL616049,449.0,
1007,H,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,F,,BAO_0000219,2759,,,8,Autocuration,1,CHEMBL616050,449.0,
1008,H,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,,F,,BAO_0000219,15419,,,8,Expert,1,CHEMBL616051,,
1009,H,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,,F,,BAO_0000219,15419,,,8,Autocuration,1,CHEMBL616212,,
1010,H,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,F,,BAO_0000019,16026,,,8,Autocuration,1,CHEMBL616213,,
1011,H,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,,B,,BAO_0000219,1414,In vitro,,8,Expert,1,CHEMBL616214,,
1012,H,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,,B,,BAO_0000219,1414,In vitro,,8,Expert,1,CHEMBL616215,,
1013,H,Binding activity radioligand.,,,B,,BAO_0000357,12861,,,8,Autocuration,1,CHEMBL616216,,
1014,H,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,B,,BAO_0000019,12861,,,8,Autocuration,1,CHEMBL616217,,
1015,H,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,5104,,,8,Autocuration,1,CHEMBL616218,,
1016,H,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,5105,,,8,Autocuration,1,CHEMBL616219,,
1017,H,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,16312,,,8,Autocuration,1,CHEMBL616220,,
1018,D,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,Homo sapiens,B,,BAO_0000357,15180,,9606.0,9,Expert,1,CHEMBL833493,,
1019,H,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,5033,,,8,Autocuration,1,CHEMBL616221,,
1020,D,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,Homo sapiens,B,,BAO_0000219,16909,,9606.0,9,Expert,1,CHEMBL616222,449.0,
1021,H,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,,F,,BAO_0000019,2590,,,8,Autocuration,1,CHEMBL616223,,
1022,H,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,F,,BAO_0000019,2590,,,8,Autocuration,1,CHEMBL616224,,
1023,H,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,,B,,BAO_0000019,16394,,,8,Expert,1,CHEMBL616225,,
1024,D,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,Homo sapiens,B,,BAO_0000219,4540,,9606.0,9,Expert,1,CHEMBL616226,722.0,
1025,H,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,,B,,BAO_0000219,17296,,,8,Autocuration,1,CHEMBL616227,722.0,
1026,H,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000219,17296,,,8,Autocuration,1,CHEMBL616228,722.0,
1027,H,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL616229,722.0,
1028,H,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL616230,722.0,
1029,H,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL616231,722.0,
1030,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,6166,,,8,Autocuration,1,CHEMBL616232,,
1031,H,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL616233,722.0,
1032,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,,B,,BAO_0000219,4199,,,8,Autocuration,1,CHEMBL857973,722.0,
1033,H,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,,B,,BAO_0000219,15316,,,8,Autocuration,1,CHEMBL616234,,
1034,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,14875,,,8,Autocuration,1,CHEMBL616235,,
1035,H,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,B,,BAO_0000219,14727,,,8,Expert,1,CHEMBL616236,308.0,
1036,H,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,B,,BAO_0000019,14727,,,8,Expert,1,CHEMBL616237,,
1037,H,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,,B,,BAO_0000219,15146,,,8,Autocuration,1,CHEMBL616238,722.0,
1038,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,,B,,BAO_0000219,5213,,,8,Autocuration,1,CHEMBL616239,722.0,
1039,H,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,,B,,BAO_0000219,16429,,,8,Autocuration,1,CHEMBL616240,,
1040,D,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,Homo sapiens,B,,BAO_0000219,15042,,9606.0,9,Expert,1,CHEMBL616241,308.0,
1041,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,,B,,BAO_0000219,14818,,,8,Autocuration,1,CHEMBL616242,722.0,
1042,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,,B,,BAO_0000219,4829,,,8,Autocuration,1,CHEMBL616243,722.0,
1043,D,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,17200,,,9,Expert,1,CHEMBL616244,,
1044,D,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,Homo sapiens,B,,BAO_0000357,13051,,9606.0,9,Autocuration,1,CHEMBL616245,,
1045,H,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,B,,BAO_0000357,5486,,,8,Autocuration,1,CHEMBL616246,,
1046,H,Binding affinity against 5-HT1D receptor,,,B,,BAO_0000357,5254,,,8,Autocuration,1,CHEMBL616247,,
1047,H,Binding affinity against 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,5254,,,8,Autocuration,1,CHEMBL616248,,
1048,H,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,B,,BAO_0000357,15331,,,8,Autocuration,1,CHEMBL616249,,
1049,H,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,Homo sapiens,B,,BAO_0000357,13506,,9606.0,8,Autocuration,1,CHEMBL616250,,
1050,H,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,15267,,,8,Autocuration,1,CHEMBL616251,,
1051,H,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,,F,,BAO_0000218,16616,In vivo,,8,Autocuration,1,CHEMBL616252,,
1052,H,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,,F,,BAO_0000218,16616,In vivo,,8,Autocuration,1,CHEMBL616253,,
1053,H,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,,F,,BAO_0000218,16616,In vivo,,8,Autocuration,1,CHEMBL616254,,
1054,D,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,Mus musculus,F,,BAO_0000218,16616,,10090.0,9,Expert,1,CHEMBL616255,,
1055,D,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,Mus musculus,F,,BAO_0000218,16616,,10090.0,9,Expert,1,CHEMBL832872,,
1056,D,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,Mus musculus,F,,BAO_0000218,16616,,10090.0,9,Expert,1,CHEMBL616256,,
1057,D,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,Mus musculus,F,,BAO_0000218,16616,,10090.0,9,Expert,1,CHEMBL616257,,
1058,D,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,Mus musculus,F,,BAO_0000218,16616,,10090.0,9,Expert,1,CHEMBL616258,,
1059,D,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,Mus musculus,F,,BAO_0000218,16616,,10090.0,9,Expert,1,CHEMBL616384,,
1060,H,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,B,,BAO_0000221,10297,,,8,Autocuration,1,CHEMBL616385,,10000000.0
1061,H,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,,B,,BAO_0000357,13704,,,8,Expert,1,CHEMBL616386,,
1062,D,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,Mus musculus,B,,BAO_0000221,10297,,10090.0,9,Expert,1,CHEMBL616387,,10000000.0
1063,H,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,B,,BAO_0000221,10297,,,8,Autocuration,1,CHEMBL616388,,10000000.0
1064,D,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,Mus musculus,B,,BAO_0000221,10297,,10090.0,9,Expert,1,CHEMBL616389,,10000000.0
1065,H,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,B,,BAO_0000221,10297,,,8,Autocuration,1,CHEMBL616390,,10000000.0
1066,H,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,,B,,BAO_0000357,217,,,8,Autocuration,1,CHEMBL616391,,
1067,D,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,Mus musculus,B,,BAO_0000221,10297,,10090.0,9,Expert,1,CHEMBL616392,,10000000.0
1068,H,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,Sus scrofa,B,,BAO_0000357,4921,,9823.0,8,Autocuration,1,CHEMBL616393,,
1069,H,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,Sus scrofa,B,,BAO_0000357,4921,,9823.0,8,Autocuration,1,CHEMBL616394,,
1070,H,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,Sus scrofa,B,,BAO_0000019,4996,,9823.0,8,Autocuration,1,CHEMBL616395,,
1071,H,Compound was evaluated for the binding affinity at 5- HT1A receptor,,Sus scrofa,B,,BAO_0000357,12918,,9823.0,8,Autocuration,1,CHEMBL616396,,
1072,H,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,Sus scrofa,B,,BAO_0000019,5333,,9823.0,8,Autocuration,1,CHEMBL872907,,
1073,H,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,Sus scrofa,B,,BAO_0000019,4437,,9823.0,8,Autocuration,1,CHEMBL616397,,
1074,H,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,Sus scrofa,B,,BAO_0000019,1742,,9823.0,8,Autocuration,1,CHEMBL616398,,
1075,H,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,Sus scrofa,B,,BAO_0000357,16688,,9823.0,8,Expert,1,CHEMBL616399,,
1076,H,Binding activity radioligand.,,Sus scrofa,B,,BAO_0000357,12861,,9823.0,8,Autocuration,1,CHEMBL857065,,
1077,H,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,Sus scrofa,B,,BAO_0000019,12861,,9823.0,8,Expert,1,CHEMBL616400,,
1078,H,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,Sus scrofa,B,,BAO_0000019,12861,,9823.0,8,Autocuration,1,CHEMBL616401,,
1079,H,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,,B,,BAO_0000019,12490,,,8,Expert,1,CHEMBL616402,,
1080,H,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,Sus scrofa,B,,BAO_0000019,11828,,9823.0,8,Expert,1,CHEMBL616403,,
1081,H,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,Sus scrofa,B,,BAO_0000221,11866,,9823.0,8,Autocuration,1,CHEMBL616404,,10000000.0
1082,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,Sus scrofa,B,,BAO_0000249,12827,,9823.0,8,Autocuration,1,CHEMBL616405,,
1083,H,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,Sus scrofa,B,,BAO_0000019,12918,,9823.0,8,Autocuration,1,CHEMBL616406,,
1084,H,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,Sus scrofa,F,,BAO_0000019,12919,,9823.0,8,Expert,1,CHEMBL616407,,
1085,H,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,Oryctolagus cuniculus,B,,BAO_0000019,13047,,9986.0,8,Autocuration,1,CHEMBL616408,,
1086,D,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,Rattus norvegicus,B,,BAO_0000249,15796,,10116.0,9,Expert,1,CHEMBL616409,,
1087,D,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,Rattus norvegicus,B,,BAO_0000221,3651,,10116.0,9,Expert,1,CHEMBL616410,,10000000.0
1088,H,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,,B,,BAO_0000357,188,,,8,Autocuration,1,CHEMBL616411,,
1089,D,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,Rattus norvegicus,F,,BAO_0000249,16616,,10116.0,9,Expert,1,CHEMBL616412,,
1090,D,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,Rattus norvegicus,F,,BAO_0000249,16616,,10116.0,9,Expert,1,CHEMBL616413,,10000000.0
1091,H,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,B,,BAO_0000221,12306,,,8,Autocuration,1,CHEMBL616414,,10000000.0
1092,D,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,Rattus norvegicus,B,,BAO_0000221,17167,,10116.0,9,Expert,1,CHEMBL616415,,10000000.0
1093,H,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,,B,,BAO_0000019,14776,,,8,Autocuration,1,CHEMBL616416,,
1094,H,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,,B,,BAO_0000357,12158,,,8,Expert,1,CHEMBL616417,,
1095,H,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,B,,BAO_0000357,13481,,,8,Autocuration,1,CHEMBL616418,,
1096,H,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,B,,BAO_0000219,13427,In vitro,,8,Autocuration,1,CHEMBL616419,,
1097,H,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,,B,,BAO_0000357,10210,,,8,Autocuration,1,CHEMBL616420,,
1098,H,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,B,,BAO_0000249,10205,,,8,Autocuration,1,CHEMBL616421,,
1099,H,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,B,,BAO_0000249,10205,,,8,Autocuration,1,CHEMBL616422,,
1100,H,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,,B,,BAO_0000249,10205,,,8,Expert,1,CHEMBL616423,,
1101,D,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,Rattus norvegicus,B,,BAO_0000357,12280,,10116.0,9,Expert,1,CHEMBL616424,,
1102,H,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,17386,,,8,Expert,1,CHEMBL616425,,
1103,H,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,,B,,BAO_0000357,13654,,,8,Expert,1,CHEMBL616426,,
1104,H,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,,B,,BAO_0000221,14423,,,8,Autocuration,1,CHEMBL616427,,10000000.0
1105,H,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,,B,,BAO_0000221,15412,,,8,Autocuration,1,CHEMBL616428,,10000000.0
1106,H,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,B,,BAO_0000221,12073,,,8,Autocuration,1,CHEMBL616290,,10000000.0
1107,D,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,B,,BAO_0000357,4101,,10116.0,9,Expert,1,CHEMBL616052,,
1108,H,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,10062,,,8,Autocuration,1,CHEMBL616053,,
1109,H,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000249,6238,,,8,Autocuration,1,CHEMBL616054,,
1110,H,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,16273,,,8,Autocuration,1,CHEMBL616055,,
1111,H,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,,B,,BAO_0000357,11139,,,8,Autocuration,1,CHEMBL616056,,
1112,H,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,B,,BAO_0000019,16796,,,8,Expert,1,CHEMBL616057,,
1113,D,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,Rattus norvegicus,B,,BAO_0000221,9548,,10116.0,9,Expert,1,CHEMBL616058,,955.0
1114,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,B,,BAO_0000221,10381,,,8,Autocuration,1,CHEMBL616059,,955.0
1115,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000249,13408,,,8,Autocuration,1,CHEMBL616060,,
1116,D,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,Rattus norvegicus,B,,BAO_0000221,13825,,10116.0,9,Expert,1,CHEMBL616061,,10000000.0
1117,H,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,,B,,BAO_0000221,11147,,,8,Expert,1,CHEMBL616062,,10000000.0
1118,H,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000249,10552,,,8,Autocuration,1,CHEMBL616063,,
1119,H,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,B,,BAO_0000249,10552,,,8,Autocuration,1,CHEMBL616064,,2435.0
1120,D,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,Rattus norvegicus,B,,BAO_0000249,17136,,10116.0,9,Expert,1,CHEMBL616065,,
1121,D,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,Rattus norvegicus,B,,BAO_0000249,5778,,10116.0,9,Expert,1,CHEMBL616066,,
1122,H,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000221,13481,,,8,Autocuration,1,CHEMBL616067,,10000000.0
1123,H,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,,B,,BAO_0000221,13481,,,8,Autocuration,1,CHEMBL616068,,10000000.0
1124,H,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000221,13630,,,8,Intermediate,1,CHEMBL616069,,10000000.0
1125,H,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,B,,BAO_0000249,16245,,,8,Expert,1,CHEMBL616070,,
1126,H,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000221,14509,,,8,Autocuration,1,CHEMBL616071,,10000000.0
1127,H,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,B,,BAO_0000221,14509,,,8,Expert,1,CHEMBL616072,,10000000.0
1128,H,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,,B,,BAO_0000221,14509,,,8,Autocuration,1,CHEMBL616073,,10000000.0
1129,H,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,,B,,BAO_0000221,14509,,,8,Autocuration,1,CHEMBL616074,,10000000.0
1130,H,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,,B,,BAO_0000019,14256,,,8,Expert,1,CHEMBL616075,,
1131,H,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,11139,,,8,Autocuration,1,CHEMBL616076,,
1132,D,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,Rattus norvegicus,B,,BAO_0000019,11047,,10116.0,9,Expert,1,CHEMBL616077,,
1133,D,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,Rattus norvegicus,B,,BAO_0000019,11047,,10116.0,9,Expert,1,CHEMBL616078,,
1134,D,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,Rattus norvegicus,B,,BAO_0000019,11047,,10116.0,9,Expert,1,CHEMBL616079,,
1135,D,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,Rattus norvegicus,B,,BAO_0000219,2395,,10116.0,9,Expert,1,CHEMBL616080,485.0,
1136,H,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,9699,,,8,Autocuration,1,CHEMBL616081,,
1137,D,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,Rattus norvegicus,B,,BAO_0000221,12028,,10116.0,9,Expert,1,CHEMBL616082,,10000000.0
1138,H,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,,B,,BAO_0000221,12028,,,8,Autocuration,1,CHEMBL616083,,10000000.0
1139,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,B,,BAO_0000019,5815,,,8,Autocuration,1,CHEMBL616084,,
1140,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,,B,,BAO_0000019,16616,,,8,Expert,1,CHEMBL616085,,
1141,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,,B,,BAO_0000019,5815,,,8,Autocuration,1,CHEMBL616086,,
1142,H,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,,B,,BAO_0000221,2761,,,8,Autocuration,1,CHEMBL616087,,10000000.0
1143,H,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,,B,,BAO_0000357,13133,,,8,Expert,1,CHEMBL616088,,
1144,H,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,,B,,BAO_0000019,10444,,,8,Autocuration,1,CHEMBL616089,,
1145,D,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,Rattus norvegicus,B,,BAO_0000357,13278,,10116.0,9,Expert,1,CHEMBL616090,,
1146,H,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,B,,BAO_0000357,15874,,,8,Autocuration,1,CHEMBL616091,,
1147,H,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,B,,BAO_0000249,10552,,,8,Autocuration,1,CHEMBL616092,,2435.0
1148,H,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,,B,,BAO_0000357,11130,,,8,Autocuration,1,CHEMBL616093,,
1149,H,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,,B,,BAO_0000218,11130,In vivo,,8,Autocuration,1,CHEMBL616094,,
1150,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,,B,,BAO_0000221,14542,,,8,Autocuration,1,CHEMBL616095,,955.0
1151,D,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,B,,BAO_0000357,13670,,10116.0,9,Expert,1,CHEMBL616096,,
1152,H,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,,B,,BAO_0000249,9888,,,8,Expert,1,CHEMBL616097,,
1153,D,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,Rattus norvegicus,B,,BAO_0000249,3678,,10116.0,9,Expert,1,CHEMBL616098,,
1154,H,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000221,11332,,,8,Autocuration,1,CHEMBL616099,,10000000.0
1155,H,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000221,11332,,,8,Autocuration,1,CHEMBL616100,,10000000.0
1156,H,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,1185,,,8,Expert,1,CHEMBL616101,,
1157,H,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,,B,,BAO_0000249,2014,,,8,Expert,1,CHEMBL616102,,
1158,H,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,1185,,,8,Autocuration,1,CHEMBL616103,,
1159,H,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,,B,,BAO_0000019,14429,,,8,Expert,1,CHEMBL616104,,
1160,H,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,,B,,BAO_0000019,16288,,,8,Expert,1,CHEMBL616105,,
1161,D,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,B,,BAO_0000019,5432,,10116.0,9,Expert,1,CHEMBL616106,,
1162,H,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,,B,,BAO_0000019,14429,,,8,Autocuration,1,CHEMBL616107,,
1163,H,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,,B,,BAO_0000357,13672,,,8,Expert,1,CHEMBL616108,,
1164,H,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,B,,BAO_0000221,11296,,,8,Expert,1,CHEMBL616109,,10000000.0
1165,H,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,,B,,BAO_0000357,11296,,,8,Autocuration,1,CHEMBL616110,,
1166,H,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,,B,,BAO_0000219,14749,,,8,Expert,1,CHEMBL616111,449.0,
1167,H,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,,B,,BAO_0000019,15086,,,8,Expert,1,CHEMBL616112,,
1168,H,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,,B,,BAO_0000221,13462,,,8,Autocuration,1,CHEMBL616113,,10000000.0
1169,H,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000019,15363,,,8,Autocuration,1,CHEMBL616114,,
1170,H,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000019,15363,,,8,Autocuration,1,CHEMBL616115,,
1171,H,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,10796,,,8,Autocuration,1,CHEMBL616116,,
1172,H,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000221,12816,,,8,Expert,1,CHEMBL615844,,955.0
1173,H,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000221,13542,,,8,Expert,1,CHEMBL615939,,10000000.0
1174,H,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,,B,,BAO_0000019,13308,,,8,Expert,1,CHEMBL615940,,
1175,H,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,,B,,BAO_0000221,13541,,,8,Expert,1,CHEMBL615941,,10000000.0
1176,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,,B,,BAO_0000221,10058,,,8,Autocuration,1,CHEMBL615942,,10000000.0
1177,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,B,,BAO_0000221,10058,,,8,Autocuration,1,CHEMBL615943,,10000000.0
1178,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,,B,,BAO_0000221,10058,,,8,Autocuration,1,CHEMBL615944,,10000000.0
1179,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,,B,,BAO_0000221,10058,,,8,Autocuration,1,CHEMBL615945,,10000000.0
1180,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,,B,,BAO_0000221,10058,,,8,Autocuration,1,CHEMBL615946,,10000000.0
1181,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,,B,,BAO_0000221,10058,,,8,Autocuration,1,CHEMBL615947,,10000000.0
1182,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,,B,,BAO_0000221,10058,,,8,Autocuration,1,CHEMBL615948,,10000000.0
1183,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,,B,,BAO_0000221,10058,,,8,Autocuration,1,CHEMBL615949,,10000000.0
1184,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,,B,,BAO_0000221,10058,,,8,Autocuration,1,CHEMBL615950,,10000000.0
1185,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,,B,,BAO_0000221,10058,,,8,Autocuration,1,CHEMBL615951,,10000000.0
1186,H,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,,B,,BAO_0000221,10058,,,8,Autocuration,1,CHEMBL615952,,10000000.0
1187,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,,B,,BAO_0000221,10058,,,8,Autocuration,1,CHEMBL615953,,10000000.0
1188,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,,B,,BAO_0000221,10058,,,8,Autocuration,1,CHEMBL615954,,10000000.0
1189,D,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,Rattus norvegicus,B,,BAO_0000221,10058,,10116.0,9,Expert,1,CHEMBL615955,,10000000.0
1190,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,,B,,BAO_0000221,10058,,,8,Autocuration,1,CHEMBL615956,,10000000.0
1191,H,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,,B,,BAO_0000221,10058,,,8,Autocuration,1,CHEMBL615957,,10000000.0
1192,H,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,,B,,BAO_0000019,12879,,,8,Expert,1,CHEMBL615958,,
1193,H,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,,B,,BAO_0000019,11964,,,8,Expert,1,CHEMBL615959,,
1194,H,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,,B,,BAO_0000019,11964,,,8,Autocuration,1,CHEMBL615960,,
1195,H,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,,B,,BAO_0000019,11964,,,8,Autocuration,1,CHEMBL615961,,
1196,H,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,B,,BAO_0000221,9548,,,8,Expert,1,CHEMBL615962,,955.0
1197,H,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,,B,,BAO_0000019,9098,,,8,Expert,1,CHEMBL615963,,
1198,H,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,,B,,BAO_0000019,9098,,,8,Autocuration,1,CHEMBL615964,,
1199,H,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,,B,,BAO_0000019,9098,,,8,Autocuration,1,CHEMBL615965,,
1200,H,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,,B,,BAO_0000219,13248,,,8,Expert,1,CHEMBL615966,449.0,
1201,H,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,,B,,BAO_0000249,3147,,,8,Expert,1,CHEMBL615967,,
1202,H,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,B,,BAO_0000019,13949,,,8,Expert,1,CHEMBL615968,,
1203,H,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,,B,,BAO_0000218,11883,,,8,Autocuration,1,CHEMBL615969,449.0,
1204,H,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,,B,,BAO_0000218,11883,,,8,Autocuration,1,CHEMBL615970,,
1205,D,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,Rattus norvegicus,B,,BAO_0000357,11883,,10116.0,9,Expert,1,CHEMBL615971,,
1206,H,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,B,,BAO_0000249,15535,,,8,Expert,1,CHEMBL615972,,
1207,H,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,,B,,BAO_0000249,15535,,,8,Autocuration,1,CHEMBL615973,,
1208,H,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,,B,,BAO_0000249,15535,,,8,Autocuration,1,CHEMBL615974,,
1209,D,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,Homo sapiens,B,,BAO_0000219,16372,,9606.0,9,Expert,1,CHEMBL615975,449.0,
1210,H,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,,B,,BAO_0000249,14608,,,8,Expert,1,CHEMBL615976,,
1211,D,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,Rattus norvegicus,B,,BAO_0000221,4795,,10116.0,9,Expert,1,CHEMBL872106,,10000000.0
1212,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL615977,,
1213,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL615978,,
1214,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL616166,,
1215,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL616167,,
1216,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL616168,,
1217,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL616169,,
1218,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL616170,,
1219,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL616171,,
1220,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL616172,,
1221,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL616173,,
1222,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL616174,,
1223,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL616175,,
1224,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL616176,,
1225,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL616177,,
1226,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL616178,,
1227,H,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,,B,,BAO_0000019,9742,,,8,Autocuration,1,CHEMBL616179,,
1228,H,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,12073,,,8,Autocuration,1,CHEMBL616180,,
1229,H,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,,B,,BAO_0000357,4101,,,8,Autocuration,1,CHEMBL616181,,
1230,H,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,,B,,BAO_0000019,15360,,,8,Autocuration,1,CHEMBL616182,,
1231,H,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000221,11576,,,8,Autocuration,1,CHEMBL616183,,10000000.0
1232,H,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,,B,,BAO_0000019,5834,,,8,Expert,1,CHEMBL615874,,
1233,D,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,Rattus norvegicus,B,,BAO_0000219,2395,,10116.0,9,Expert,1,CHEMBL615875,485.0,
1234,H,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,,B,,BAO_0000019,1375,,,8,Autocuration,1,CHEMBL615876,,
1235,H,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,,B,,BAO_0000019,1375,,,8,Autocuration,1,CHEMBL615877,,
1236,H,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,,B,,BAO_0000357,3967,,,8,Autocuration,1,CHEMBL615878,,
1237,H,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,,B,,BAO_0000357,12884,,,8,Expert,1,CHEMBL615879,,
1238,H,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,,B,,BAO_0000357,2343,,,8,Expert,1,CHEMBL615880,,
1239,H,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,B,,BAO_0000019,11511,,,8,Autocuration,1,CHEMBL615881,,
1240,D,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,Rattus norvegicus,B,,BAO_0000019,11511,,10116.0,9,Expert,1,CHEMBL615882,,
1241,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,,F,,BAO_0000218,16394,In vivo,,8,Autocuration,1,CHEMBL615883,,
1242,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,,F,,BAO_0000218,16394,In vivo,,8,Autocuration,1,CHEMBL615884,,
1243,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,,F,,BAO_0000218,16394,In vivo,,8,Autocuration,1,CHEMBL615885,,
1244,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,,F,,BAO_0000218,16394,In vivo,,8,Autocuration,1,CHEMBL615886,,
1245,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,,F,,BAO_0000218,16394,In vivo,,8,Autocuration,1,CHEMBL615887,,
1246,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,,F,,BAO_0000218,16394,In vivo,,8,Autocuration,1,CHEMBL615888,,
1247,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,,F,,BAO_0000218,16394,In vivo,,8,Autocuration,1,CHEMBL615889,,
1248,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,,F,,BAO_0000218,16394,In vivo,,8,Autocuration,1,CHEMBL615890,,
1249,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,,F,,BAO_0000218,16394,In vivo,,8,Autocuration,1,CHEMBL615891,,
1250,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,,F,,BAO_0000218,16394,In vivo,,8,Autocuration,1,CHEMBL615892,,
1251,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,,F,,BAO_0000218,16394,In vivo,,8,Autocuration,1,CHEMBL615893,,
1252,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,,F,,BAO_0000218,16394,In vivo,,8,Autocuration,1,CHEMBL615894,,
1253,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,,F,,BAO_0000218,16394,In vivo,,8,Autocuration,1,CHEMBL615895,,
1254,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,,F,,BAO_0000218,16394,In vivo,,8,Autocuration,1,CHEMBL615896,,
1255,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,,F,,BAO_0000218,16394,In vivo,,8,Autocuration,1,CHEMBL615897,,
1256,D,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,Rattus norvegicus,F,,BAO_0000249,16616,,10116.0,9,Expert,1,CHEMBL615898,,
1257,H,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,,B,,BAO_0000019,16796,,,8,Autocuration,1,CHEMBL615899,,
1258,H,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,B,,BAO_0000019,16796,,,8,Autocuration,1,CHEMBL616291,,
1259,H,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,,B,,BAO_0000357,15629,,,8,Autocuration,1,CHEMBL616292,,
1260,H,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,F,,BAO_0000249,13241,,,8,Autocuration,1,CHEMBL616293,,
1261,H,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,B,,BAO_0000221,12073,,,8,Expert,1,CHEMBL616294,,10000000.0
1262,H,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,,B,,BAO_0000249,14286,,,8,Autocuration,1,CHEMBL616295,,10000000.0
1263,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,,B,,BAO_0000221,14542,,,8,Autocuration,1,CHEMBL616296,,955.0
1264,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,F,,BAO_0000019,13630,,,8,Autocuration,1,CHEMBL616297,,
1265,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,,F,,BAO_0000019,13630,,,8,Autocuration,1,CHEMBL616605,,
1266,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,,F,,BAO_0000019,13630,,,8,Autocuration,1,CHEMBL616606,,
1267,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,F,,BAO_0000019,13630,,,8,Autocuration,1,CHEMBL616607,,
1268,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,F,,BAO_0000019,13630,,,8,Expert,1,CHEMBL616608,,
1269,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,,F,,BAO_0000019,13630,,,8,Autocuration,1,CHEMBL616609,,
1270,D,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,Rattus norvegicus,F,,BAO_0000019,13630,,10116.0,9,Expert,1,CHEMBL616610,,
1271,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,F,,BAO_0000019,13630,,,8,Autocuration,1,CHEMBL616611,,
1272,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,,F,,BAO_0000019,13630,,,8,Expert,1,CHEMBL616612,,
1273,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,,F,,BAO_0000019,13630,,,8,Autocuration,1,CHEMBL616613,,
1274,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,,F,,BAO_0000019,13630,,,8,Expert,1,CHEMBL616614,,
1275,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,,F,,BAO_0000019,13630,,,8,Autocuration,1,CHEMBL616615,,
1276,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,F,,BAO_0000019,13630,,,8,Expert,1,CHEMBL616616,,
1277,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,,F,,BAO_0000019,13630,,,8,Autocuration,1,CHEMBL616617,,
1278,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,F,,BAO_0000019,13630,,,8,Autocuration,1,CHEMBL616618,,
1279,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,,F,,BAO_0000019,13630,,,8,Autocuration,1,CHEMBL616619,,
1280,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,,F,,BAO_0000019,13630,,,8,Expert,1,CHEMBL616620,,
1281,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,F,,BAO_0000019,13630,,,8,Expert,1,CHEMBL616621,,
1282,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,,F,,BAO_0000019,13630,,,8,Autocuration,1,CHEMBL616622,,
1283,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,,F,,BAO_0000019,13630,,,8,Expert,1,CHEMBL616146,,
1284,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,,F,,BAO_0000019,13630,,,8,Autocuration,1,CHEMBL832873,,
1285,H,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,,F,,BAO_0000019,13630,,,8,Autocuration,1,CHEMBL616147,,
1286,H,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,F,,BAO_0000019,13630,,,8,Autocuration,1,CHEMBL872872,,
1287,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,F,,BAO_0000019,13630,,,8,Autocuration,1,CHEMBL616148,,
1288,H,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,,B,,BAO_0000221,9783,,,8,Autocuration,1,CHEMBL616149,,10000000.0
1289,H,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,,B,,BAO_0000221,9783,,,8,Expert,1,CHEMBL616150,,10000000.0
1290,D,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,Rattus norvegicus,B,,BAO_0000249,14331,,10116.0,9,Expert,1,CHEMBL616151,,
1291,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,,B,,BAO_0000221,15260,,,8,Expert,1,CHEMBL872873,,10000000.0
1292,H,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,,B,,BAO_0000221,15260,,,8,Autocuration,1,CHEMBL616670,,10000000.0
1293,H,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,,B,,BAO_0000221,15260,,,8,Autocuration,1,CHEMBL616671,,10000000.0
1294,D,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,Rattus norvegicus,F,,BAO_0000249,16616,,10116.0,9,Expert,1,CHEMBL884861,,
1295,H,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,,B,,BAO_0000357,15629,,,8,Autocuration,1,CHEMBL616672,,
1296,H,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,B,,BAO_0000019,15086,,,8,Autocuration,1,CHEMBL616673,,
1297,H,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,F,,BAO_0000019,5717,,,8,Expert,1,CHEMBL616674,,
1298,H,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,B,,BAO_0000357,12652,,,8,Autocuration,1,CHEMBL616675,,
1299,H,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,,B,,BAO_0000221,14608,,,8,Autocuration,1,CHEMBL616676,,10000000.0
1300,H,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,B,,BAO_0000221,12306,,,8,Autocuration,1,CHEMBL616677,,10000000.0
1301,H,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,B,,BAO_0000221,12306,,,8,Autocuration,1,CHEMBL616678,,10000000.0
1302,D,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,B,,BAO_0000357,15247,,10116.0,9,Expert,1,CHEMBL616679,,
1303,H,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,,B,,BAO_0000221,17529,,,8,Expert,1,CHEMBL616680,,10000000.0
1304,H,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,B,,BAO_0000221,14826,,,8,Autocuration,1,CHEMBL616681,,10000000.0
1305,H,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,B,,BAO_0000221,14826,,,8,Autocuration,1,CHEMBL616682,,10000000.0
1306,H,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000221,13241,,,8,Autocuration,1,CHEMBL616683,,10000000.0
1307,H,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000221,14093,,,8,Autocuration,1,CHEMBL616684,,10000000.0
1308,H,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,,B,,BAO_0000221,14093,,,8,Autocuration,1,CHEMBL616685,,10000000.0
1309,H,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,,B,,BAO_0000221,14442,,,8,Autocuration,1,CHEMBL616686,,955.0
1310,H,Affinity for 5-hydroxytryptamine 1A receptor site,,,B,,BAO_0000357,9919,,,8,Autocuration,1,CHEMBL616687,,
1311,H,Affinity for 5-hydroxytryptamine 1A receptor site,,,B,,BAO_0000357,9919,,,8,Autocuration,1,CHEMBL616688,,
1312,H,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,,B,,BAO_0000221,11440,,,8,Autocuration,1,CHEMBL616689,,10000000.0
1313,H,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,,B,,BAO_0000357,11257,,,8,Autocuration,1,CHEMBL616690,,
1314,H,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,,B,,BAO_0000357,10330,,,8,Expert,1,CHEMBL616691,,
1315,D,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,Rattus norvegicus,B,,BAO_0000221,17331,,10116.0,9,Expert,1,CHEMBL616692,,10000000.0
1316,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,,B,,BAO_0000249,16567,,,8,Expert,1,CHEMBL616693,,
1317,D,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,Rattus norvegicus,B,,BAO_0000019,12058,,10116.0,9,Expert,1,CHEMBL616694,,
1318,H,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,,B,,BAO_0000221,9699,,,8,Autocuration,1,CHEMBL616695,,10000000.0
1319,H,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,,B,,BAO_0000357,9547,,,8,Autocuration,1,CHEMBL616696,,
1320,H,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,,B,,BAO_0000357,10330,,,8,Autocuration,1,CHEMBL616697,,
1321,H,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,14331,,,8,Autocuration,1,CHEMBL616698,,
1322,D,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,B,,BAO_0000019,14060,,10116.0,9,Expert,1,CHEMBL616949,,
1323,H,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,,B,,BAO_0000221,14744,,,8,Autocuration,1,CHEMBL616950,,10000000.0
1324,H,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,B,,BAO_0000357,13506,,,8,Autocuration,1,CHEMBL832875,,
1325,H,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,B,,BAO_0000221,10862,,,8,Expert,1,CHEMBL616951,,955.0
1326,H,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,B,,BAO_0000221,10862,,,8,Expert,1,CHEMBL616952,,955.0
1327,H,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,,B,,BAO_0000357,10062,,,8,Expert,1,CHEMBL616953,,
1328,H,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,,B,,BAO_0000357,12073,,,8,Autocuration,1,CHEMBL616954,,
1329,H,GTPgammaS radioligand binding assay,,,B,,BAO_0000357,14875,,,8,Autocuration,1,CHEMBL616955,,
1330,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,B,,BAO_0000357,2391,,,8,Autocuration,1,CHEMBL616956,,
1331,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,,F,,BAO_0000019,2391,,,8,Autocuration,1,CHEMBL616957,,
1332,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,,F,,BAO_0000019,2391,,,8,Autocuration,1,CHEMBL616958,,
1333,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,2391,,,8,Autocuration,1,CHEMBL616959,,
1334,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,B,,BAO_0000357,2391,,,8,Autocuration,1,CHEMBL616960,,
1335,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,,F,,BAO_0000019,2391,,,8,Autocuration,1,CHEMBL616961,,
1336,H,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000219,17211,,,8,Expert,1,CHEMBL616962,308.0,
1337,H,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,,B,,BAO_0000219,17211,,,8,Autocuration,1,CHEMBL616963,308.0,
1338,D,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,Homo sapiens,B,,BAO_0000357,6491,,9606.0,9,Expert,1,CHEMBL616524,,
1339,H,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,,B,,BAO_0000219,16190,,,8,Autocuration,1,CHEMBL616525,449.0,
1340,H,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,,B,,BAO_0000019,14165,,,8,Autocuration,1,CHEMBL872908,,
1341,H,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,,B,,BAO_0000019,14165,,,8,Autocuration,1,CHEMBL616526,,
1342,D,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,Homo sapiens,B,,BAO_0000357,4234,,9606.0,9,Expert,1,CHEMBL616527,,
1343,H,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,B,,BAO_0000219,6328,,,8,Expert,1,CHEMBL616528,,
1344,H,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,B,,BAO_0000357,14770,,,8,Autocuration,1,CHEMBL616529,,
1345,H,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,,B,,BAO_0000357,2598,,,8,Autocuration,1,CHEMBL616530,,
1346,H,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,6897,,,8,Expert,1,CHEMBL616531,,
1347,H,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,6897,,,8,Autocuration,1,CHEMBL616532,,
1348,H,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,6013,,,8,Autocuration,1,CHEMBL616533,,
1349,H,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,5843,,,8,Expert,1,CHEMBL616534,,
1350,H,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,,B,,BAO_0000357,14454,,,8,Expert,1,CHEMBL616535,,
1351,H,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,,B,,BAO_0000357,16209,,,8,Autocuration,1,CHEMBL616536,,
1352,H,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,3935,,,8,Autocuration,1,CHEMBL616537,,
1353,H,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,,F,,BAO_0000219,13729,,,8,Expert,1,CHEMBL616538,485.0,
1354,H,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,,F,,BAO_0000019,14251,,,8,Expert,1,CHEMBL616539,,
1355,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000019,17085,,,8,Expert,1,CHEMBL616540,,
1356,H,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,B,,BAO_0000357,3025,,,8,Autocuration,1,CHEMBL616429,,
1357,H,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,15315,,,8,Expert,1,CHEMBL616430,,
1358,D,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,Homo sapiens,B,,BAO_0000219,14214,,9606.0,9,Expert,1,CHEMBL616431,,
1359,D,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,Homo sapiens,B,,BAO_0000357,3804,,9606.0,9,Expert,1,CHEMBL616432,,
1360,D,Affinity for 5-hydroxytryptamine 1B receptor subtype,,Homo sapiens,B,,BAO_0000357,2391,,9606.0,9,Expert,1,CHEMBL616433,,
1361,D,Binding affinity for human 5-hydroxytryptamine 1B receptor,,Homo sapiens,B,,BAO_0000357,4175,,9606.0,9,Expert,1,CHEMBL616434,,
1362,H,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,,B,,BAO_0000219,17296,,,8,Autocuration,1,CHEMBL616435,449.0,
1363,H,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,,B,,BAO_0000019,17085,,,8,Expert,1,CHEMBL616436,,
1364,H,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,B,,BAO_0000219,17211,,,8,Autocuration,1,CHEMBL616437,308.0,
1365,H,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,,B,,BAO_0000219,17211,,,8,Autocuration,1,CHEMBL616438,308.0,
1366,H,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,B,,BAO_0000219,17211,,,8,Autocuration,1,CHEMBL616439,308.0,
1367,D,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,Homo sapiens,B,,BAO_0000357,15926,,9606.0,9,Expert,1,CHEMBL616440,,
1368,H,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,,B,,BAO_0000219,16312,,,8,Autocuration,1,CHEMBL616441,485.0,
1369,H,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,,B,,BAO_0000357,5843,,,8,Expert,1,CHEMBL616442,,
1370,H,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,5843,,,8,Autocuration,1,CHEMBL616443,,
1371,H,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000219,16312,,,8,Expert,1,CHEMBL616444,485.0,
1372,D,Binding activity against human 5-hydroxytryptamine 1B receptor,,Homo sapiens,B,,BAO_0000357,15926,,9606.0,9,Expert,1,CHEMBL616445,,
1373,D,Binding activity against human 5-hydroxytryptamine 1B receptor,,Homo sapiens,B,,BAO_0000357,15926,,9606.0,9,Expert,1,CHEMBL616446,,
1374,D,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,Homo sapiens,B,,BAO_0000219,4540,,9606.0,9,Expert,1,CHEMBL616447,449.0,
1375,H,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,,B,,BAO_0000357,6166,,,8,Autocuration,1,CHEMBL616448,,
1376,H,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,,B,,BAO_0000219,17296,,,8,Autocuration,1,CHEMBL616449,449.0,
1377,H,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,,B,,BAO_0000219,17296,,,8,Autocuration,1,CHEMBL616450,449.0,
1378,H,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,,B,,BAO_0000219,17296,,,8,Autocuration,1,CHEMBL857974,449.0,
1379,H,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL616451,449.0,
1380,H,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL616452,449.0,
1381,H,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL616453,449.0,
1382,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,,B,,BAO_0000219,4199,,,8,Autocuration,1,CHEMBL616454,449.0,
1383,D,Binding affinity for human 5-hydroxytryptamine 1B receptor,,Homo sapiens,B,,BAO_0000357,14875,,9606.0,9,Expert,1,CHEMBL616455,,
1384,H,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,B,,BAO_0000219,15146,,,8,Autocuration,1,CHEMBL616456,449.0,
1385,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,,B,,BAO_0000357,5213,,,8,Autocuration,1,CHEMBL616457,,
1386,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,B,,BAO_0000219,14818,,,8,Autocuration,1,CHEMBL616458,449.0,
1387,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,,B,,BAO_0000219,4829,,,8,Autocuration,1,CHEMBL616459,449.0,
1388,H,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,,F,,BAO_0000019,14454,,,8,Expert,1,CHEMBL616460,,
1389,H,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,,F,,BAO_0000019,14454,,,8,Expert,1,CHEMBL616461,,
1390,H,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,F,,BAO_0000219,14875,,,8,Autocuration,1,CHEMBL616462,449.0,
1391,H,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,F,,BAO_0000219,14875,,,8,Autocuration,1,CHEMBL616463,449.0,
1392,H,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,,F,,BAO_0000019,15250,,,8,Autocuration,1,CHEMBL616464,,
1393,H,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,,B,,BAO_0000219,15250,,,8,Autocuration,1,CHEMBL616465,449.0,
1394,H,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,15086,,,8,Autocuration,1,CHEMBL832874,,
1395,H,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,Oryctolagus cuniculus,F,,BAO_0000019,3025,,9986.0,8,Autocuration,1,CHEMBL616184,,
1396,H,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,Oryctolagus cuniculus,B,,BAO_0000019,14998,,9986.0,8,Autocuration,1,CHEMBL616185,,
1397,H,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,Oryctolagus cuniculus,B,,BAO_0000019,14998,,9986.0,8,Intermediate,1,CHEMBL616186,,
1398,H,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,Oryctolagus cuniculus,B,,BAO_0000019,14998,,9986.0,8,Autocuration,1,CHEMBL616187,,
1399,H,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,,B,,BAO_0000357,13969,,,8,Expert,1,CHEMBL616188,,
1400,D,Binding affinity for 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,13392,,,9,Intermediate,1,CHEMBL873475,,
1401,D,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,Rattus norvegicus,B,,BAO_0000019,3651,,10116.0,9,Expert,1,CHEMBL616189,,2435.0
1402,H,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,B,,BAO_0000357,10025,,,8,Expert,1,CHEMBL616190,,
1403,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL616191,,
1404,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL616192,,
1405,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL616193,,
1406,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL616194,,
1407,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL616195,,
1408,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,,B,,BAO_0000357,13863,,,8,Autocuration,1,CHEMBL616196,,
1409,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,,B,,BAO_0000249,4622,,,8,Autocuration,1,CHEMBL616197,,10000000.0
1410,H,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000019,14911,,,8,Intermediate,1,CHEMBL616198,,
1411,H,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,B,,BAO_0000221,12678,,,8,Autocuration,1,CHEMBL616199,,10000000.0
1412,H,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,,B,,BAO_0000221,12678,,,8,Expert,1,CHEMBL616200,,10000000.0
1413,H,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000221,14235,,,8,Expert,1,CHEMBL616201,,10000000.0
1414,H,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,B,,BAO_0000221,14949,,,8,Expert,1,CHEMBL616202,,10000000.0
1415,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,B,,BAO_0000221,14949,,,8,Expert,1,CHEMBL616203,,10000000.0
1416,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,,B,,BAO_0000221,14949,,,8,Expert,1,CHEMBL616204,,10000000.0
1417,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,,B,,BAO_0000221,14949,,,8,Expert,1,CHEMBL616205,,10000000.0
1418,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,,B,,BAO_0000221,14949,,,8,Expert,1,CHEMBL616206,,10000000.0
1419,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,B,,BAO_0000249,16118,,,8,Expert,1,CHEMBL616207,,
1420,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,,B,,BAO_0000249,3268,,,8,Autocuration,1,CHEMBL616208,,
1421,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,,B,,BAO_0000249,3268,,,8,Autocuration,1,CHEMBL616209,,
1422,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,,B,,BAO_0000357,16117,,,8,Expert,1,CHEMBL616210,,
1423,H,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,,B,,BAO_0000221,9783,,,8,Expert,1,CHEMBL616211,,10000000.0
1424,H,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,,B,,BAO_0000221,9783,,,8,Autocuration,1,CHEMBL616504,,10000000.0
1425,D,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,B,,BAO_0000221,14356,,10116.0,9,Expert,1,CHEMBL616505,,10000000.0
1426,H,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,F,,BAO_0000019,15740,,,8,Autocuration,1,CHEMBL616506,,
1427,H,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,B,,BAO_0000221,12306,,,8,Autocuration,1,CHEMBL872107,,10000000.0
1428,D,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,Rattus norvegicus,B,,BAO_0000221,13348,,10116.0,9,Expert,1,CHEMBL616507,,10000000.0
1429,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,,B,,BAO_0000249,10394,,,8,Autocuration,1,CHEMBL616303,,
1430,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,,B,,BAO_0000221,15260,,,8,Autocuration,1,CHEMBL616304,,10000000.0
1431,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,B,,BAO_0000221,10046,,,8,Expert,1,CHEMBL616305,,10000000.0
1432,H,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,,F,,BAO_0000221,15260,,,8,Intermediate,1,CHEMBL616306,,10000000.0
1433,H,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,12851,,,8,Autocuration,1,CHEMBL616307,,
1434,D,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,Rattus norvegicus,B,,BAO_0000221,2148,,10116.0,9,Expert,1,CHEMBL881829,,10000000.0
1435,H,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,,B,,BAO_0000357,13134,,,8,Expert,1,CHEMBL616308,,
1436,H,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,,B,,BAO_0000019,12462,,,8,Autocuration,1,CHEMBL616309,,
1437,H,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,,B,,BAO_0000019,12462,,,8,Expert,1,CHEMBL616310,,
1438,H,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,,B,,BAO_0000219,12462,,,8,Autocuration,1,CHEMBL616311,449.0,
1439,H,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,11933,,,8,Expert,1,CHEMBL616312,,
1440,H,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,,B,,BAO_0000357,11933,,,8,Autocuration,1,CHEMBL616313,,
1441,D,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,B,,BAO_0000221,403,,10116.0,9,Expert,1,CHEMBL616314,,10000000.0
1442,H,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,,B,,BAO_0000221,15538,,,8,Autocuration,1,CHEMBL616315,,10000000.0
1443,H,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,,B,,BAO_0000221,15538,,,8,Autocuration,1,CHEMBL616567,,10000000.0
1444,H,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,,B,,BAO_0000221,15538,,,8,Autocuration,1,CHEMBL616568,,10000000.0
1445,H,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,,B,,BAO_0000019,12464,,,8,Intermediate,1,CHEMBL616569,,
1446,H,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,,B,,BAO_0000357,1455,,,8,Expert,1,CHEMBL616570,,
1447,H,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,B,,BAO_0000357,12652,,,8,Autocuration,1,CHEMBL616571,,
1448,H,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,,B,,BAO_0000221,12639,,,8,Autocuration,1,CHEMBL616572,,10000000.0
1449,H,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,,B,,BAO_0000249,13949,,,8,Expert,1,CHEMBL616573,,
1450,D,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,Rattus norvegicus,B,,BAO_0000357,12463,,10116.0,9,Expert,1,CHEMBL616574,,
1451,H,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,,B,,BAO_0000221,14829,,,8,Expert,1,CHEMBL616575,,10000000.0
1452,H,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,,B,,BAO_0000221,14829,,,8,Autocuration,1,CHEMBL872108,,10000000.0
1453,H,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,,B,,BAO_0000357,12092,,,8,Autocuration,1,CHEMBL616576,,
1454,H,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,,B,,BAO_0000249,403,,,8,Autocuration,1,CHEMBL616577,,
1455,H,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,,B,,BAO_0000249,403,,,8,Autocuration,1,CHEMBL616578,,
1456,H,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,,B,,BAO_0000357,3967,,,8,Expert,1,CHEMBL616579,,
1457,D,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,Rattus norvegicus,B,,BAO_0000019,12771,,10116.0,9,Expert,1,CHEMBL616580,,
1458,H,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,B,,BAO_0000019,15086,,,8,Autocuration,1,CHEMBL616581,,
1459,H,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,B,,BAO_0000221,14909,,,8,Autocuration,1,CHEMBL616582,,10000000.0
1460,H,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,B,,BAO_0000221,14949,,,8,Expert,1,CHEMBL616583,,10000000.0
1461,D,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,Rattus norvegicus,B,,BAO_0000221,2309,,10116.0,9,Expert,1,CHEMBL616584,,10000000.0
1462,H,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,4170,,,8,Expert,1,CHEMBL616585,,
1463,D,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,Rattus norvegicus,B,,BAO_0000221,11642,,10116.0,9,Expert,1,CHEMBL616586,,10000000.0
1464,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,,B,,BAO_0000221,11642,,,8,Autocuration,1,CHEMBL616587,,10000000.0
1465,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,,B,,BAO_0000221,12953,,,8,Autocuration,1,CHEMBL616588,,10000000.0
1466,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,B,,BAO_0000221,12953,,,8,Autocuration,1,CHEMBL616589,,10000000.0
1467,H,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000221,12953,,,8,Expert,1,CHEMBL616590,,10000000.0
1468,H,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,,B,,BAO_0000219,12903,,,8,Expert,1,CHEMBL616591,449.0,
1469,H,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,12536,,,8,Expert,1,CHEMBL616592,,
1470,H,The inhibition activity of 5-HT1A at 1 uM,,,B,,BAO_0000357,10058,,,8,Autocuration,1,CHEMBL616593,,
1471,H,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,,B,,BAO_0000219,12902,,,8,Expert,1,CHEMBL616594,485.0,
1472,H,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,,B,,BAO_0000249,14057,,,8,Expert,1,CHEMBL616595,,
1473,H,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,,B,,BAO_0000357,11296,,,8,Autocuration,1,CHEMBL616596,,
1474,H,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,B,,BAO_0000221,11296,,,8,Autocuration,1,CHEMBL616597,,10000000.0
1475,H,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,B,,BAO_0000221,11296,,,8,Expert,1,CHEMBL616598,,10000000.0
1476,D,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,Rattus norvegicus,F,,BAO_0000249,16616,,10116.0,9,Expert,1,CHEMBL616599,,
1477,D,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,Rattus norvegicus,F,,BAO_0000249,16616,,10116.0,9,Expert,1,CHEMBL616600,,10000000.0
1478,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,,B,,BAO_0000019,16567,,,8,Autocuration,1,CHEMBL616601,,
1479,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,,B,,BAO_0000019,16567,,,8,Autocuration,1,CHEMBL616602,,
1480,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,,B,,BAO_0000019,16567,,,8,Autocuration,1,CHEMBL616603,,
1481,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,,B,,BAO_0000019,16567,,,8,Autocuration,1,CHEMBL616604,,
1482,H,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,,B,,BAO_0000249,17136,,,8,Autocuration,1,CHEMBL616316,,
1483,H,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,,B,,BAO_0000249,17136,,,8,Autocuration,1,CHEMBL616317,,
1484,D,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,Rattus norvegicus,B,,BAO_0000019,16616,,10116.0,9,Expert,1,CHEMBL616318,,
1485,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,,B,,BAO_0000221,17331,,,8,Autocuration,1,CHEMBL616319,,10000000.0
1486,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,,B,,BAO_0000221,17331,,,8,Autocuration,1,CHEMBL616320,,10000000.0
1487,D,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,Rattus norvegicus,B,,BAO_0000221,17167,,10116.0,9,Expert,1,CHEMBL616321,,10000000.0
1488,H,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,F,,BAO_0000019,15740,,,8,Autocuration,1,CHEMBL616322,,
1489,H,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,,F,,BAO_0000019,15740,,,8,Autocuration,1,CHEMBL616323,,
1490,H,Ratio of binding affinity to 5-HT 1A and D2 receptor,,,B,,BAO_0000357,4671,,,8,Autocuration,1,CHEMBL616324,,
1491,H,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,B,,BAO_0000221,10058,,,8,Autocuration,1,CHEMBL616325,,10000000.0
1492,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,B,,BAO_0000221,10058,,,8,Autocuration,1,CHEMBL616326,,10000000.0
1493,H,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,,B,,BAO_0000221,10058,,,8,Autocuration,1,CHEMBL616327,,10000000.0
1494,H,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,12073,,,8,Autocuration,1,CHEMBL616328,,
1495,H,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,B,,BAO_0000249,2759,,,8,Autocuration,1,CHEMBL858110,,
1496,H,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,F,,BAO_0000249,2759,,,8,Autocuration,1,CHEMBL616329,,
1497,H,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,B,,BAO_0000249,2759,,,8,Autocuration,1,CHEMBL616330,,
1498,H,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,F,,BAO_0000249,2759,,,8,Autocuration,1,CHEMBL616331,,
1499,H,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,F,,BAO_0000249,2759,,,8,Autocuration,1,CHEMBL616332,,
1500,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,B,,BAO_0000249,9737,,,8,Autocuration,1,CHEMBL857063,,955.0
1501,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,,B,,BAO_0000019,9737,,,8,Autocuration,1,CHEMBL616333,,
1502,H,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,,F,,BAO_0000019,5717,,,8,Expert,1,CHEMBL616334,,
1503,H,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,B,,BAO_0000221,12253,,,8,Autocuration,1,CHEMBL616335,,10000000.0
1504,H,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,,B,,BAO_0000019,14025,,,8,Autocuration,1,CHEMBL616336,,
1505,H,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,,B,,BAO_0000249,10425,,,8,Expert,1,CHEMBL616337,,
1506,H,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,,B,,BAO_0000019,14998,,,8,Autocuration,1,CHEMBL616338,,
1507,H,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,,B,,BAO_0000221,13694,,,8,Autocuration,1,CHEMBL616339,,10000000.0
1508,H,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,,B,,BAO_0000221,13694,,,8,Autocuration,1,CHEMBL616340,,10000000.0
1509,H,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,,B,,BAO_0000357,4342,,,8,Autocuration,1,CHEMBL616341,,
1510,D,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,B,,BAO_0000357,12936,,10116.0,9,Expert,1,CHEMBL616342,,
1511,D,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,Rattus norvegicus,B,,BAO_0000019,13144,,10116.0,9,Expert,1,CHEMBL616343,,
1512,H,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,,B,,BAO_0000019,13343,,,8,Expert,1,CHEMBL616344,,
1513,H,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,B,,BAO_0000357,12132,,,8,Expert,1,CHEMBL616345,,
1514,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,,B,,BAO_0000019,15419,,,8,Expert,1,CHEMBL616346,,
1515,H,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,B,,BAO_0000221,1479,,,8,Autocuration,1,CHEMBL616347,,10000000.0
1516,H,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,,B,,BAO_0000019,14287,,,8,Expert,1,CHEMBL616348,,
1517,H,Binding affinity at 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,13116,,,8,Expert,1,CHEMBL616349,,
1518,D,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,Rattus norvegicus,B,,BAO_0000249,2759,,10116.0,9,Expert,1,CHEMBL616152,,
1519,H,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,B,,BAO_0000249,2759,,,8,Autocuration,1,CHEMBL616153,,
1520,H,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,,B,,BAO_0000019,14748,,,8,Expert,1,CHEMBL616154,,
1521,H,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,B,,BAO_0000019,12304,,,8,Autocuration,1,CHEMBL616155,,
1522,D,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,Rattus norvegicus,B,,BAO_0000221,12409,,10116.0,9,Expert,1,CHEMBL616156,,10000000.0
1523,D,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,Rattus norvegicus,B,,BAO_0000221,12409,,10116.0,9,Expert,1,CHEMBL616157,,10000000.0
1524,H,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,,B,,BAO_0000221,13267,,,8,Autocuration,1,CHEMBL616158,,10000000.0
1525,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,B,,BAO_0000357,15194,,,8,Autocuration,1,CHEMBL616159,,
1526,H,pKi value against rat 5-hydroxytryptamine 1A receptor.,,,B,,BAO_0000357,14256,,,8,Expert,1,CHEMBL616160,,
1527,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,,B,,BAO_0000019,16567,,,8,Autocuration,1,CHEMBL616161,,
1528,H,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,F,,BAO_0000019,15740,,,8,Autocuration,1,CHEMBL616162,,
1529,D,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,Rattus norvegicus,B,,BAO_0000357,13278,,10116.0,9,Expert,1,CHEMBL616163,,
1530,H,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,B,,BAO_0000249,1970,,,8,Expert,1,CHEMBL616164,,
1531,H,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,,B,,BAO_0000221,10034,,,8,Autocuration,1,CHEMBL616165,,955.0
1532,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,Rattus norvegicus,B,,BAO_0000019,13348,,10116.0,8,Autocuration,1,CHEMBL616355,,
1533,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,F,,BAO_0000019,13630,,,8,Autocuration,1,CHEMBL616356,,
1534,H,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,B,,BAO_0000221,10862,,,8,Autocuration,1,CHEMBL616357,,955.0
1535,H,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,B,,BAO_0000019,12058,,,8,Autocuration,1,CHEMBL616358,,
1536,H,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,4639,,,8,Autocuration,1,CHEMBL616359,,
1537,H,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,,B,,BAO_0000357,15453,,,8,Expert,1,CHEMBL616360,,
1538,H,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,4820,,,8,Expert,1,CHEMBL616361,,
1539,H,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,1089,,,8,Autocuration,1,CHEMBL616362,,
1540,H,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,,B,,BAO_0000249,386,,,8,Autocuration,1,CHEMBL616363,,
1541,H,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,,B,,BAO_0000357,6011,,,8,Autocuration,1,CHEMBL616364,,
1542,H,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,5014,,,8,Autocuration,1,CHEMBL616365,,
1543,H,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,4402,,,8,Expert,1,CHEMBL616366,,
1544,H,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,17066,,,8,Expert,1,CHEMBL872906,,
1545,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,,B,,BAO_0000357,17515,,,8,Autocuration,1,CHEMBL616367,,
1546,H,Binding affinity against 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,2474,,,8,Autocuration,1,CHEMBL616368,,
1547,H,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,,B,,BAO_0000357,4775,,,8,Autocuration,1,CHEMBL616369,,
1548,D,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,Homo sapiens,B,,BAO_0000357,14294,,9606.0,9,Expert,1,CHEMBL616370,,
1549,D,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,Homo sapiens,B,,BAO_0000357,14294,,9606.0,9,Expert,1,CHEMBL616371,,
1550,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,B,,BAO_0000219,12249,,,8,Autocuration,1,CHEMBL616372,449.0,
1551,H,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,,B,,BAO_0000219,11376,,,8,Expert,1,CHEMBL616373,,
1552,H,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000218,2474,In vivo,,8,Autocuration,1,CHEMBL616374,,
1553,H,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,B,,BAO_0000221,13311,,,8,Autocuration,1,CHEMBL616375,,10000000.0
1554,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,,B,,BAO_0000357,4373,,,8,Autocuration,1,CHEMBL616376,,
1555,H,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,,B,,BAO_0000357,1633,,,8,Expert,1,CHEMBL857064,,
1556,H,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,B,,BAO_0000357,11866,,,8,Autocuration,1,CHEMBL616377,,
1557,H,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,B,,BAO_0000357,4373,,,8,Autocuration,1,CHEMBL616378,,
1558,H,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,4687,,,8,Autocuration,1,CHEMBL616379,,
1559,H,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,16946,,,8,Autocuration,1,CHEMBL616380,,
1560,H,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,,B,,BAO_0000357,13291,,,8,Autocuration,1,CHEMBL616381,,
1561,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,14159,,,8,Autocuration,1,CHEMBL616382,,
1562,H,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,,B,,BAO_0000357,10812,,,8,Autocuration,1,CHEMBL616383,,
1563,D,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,Mus musculus,B,,BAO_0000219,3032,,10090.0,9,Expert,1,CHEMBL616350,449.0,
1564,H,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,16655,,,8,Autocuration,1,CHEMBL616351,,
1565,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,,B,,BAO_0000357,14532,,,8,Autocuration,1,CHEMBL616352,,
1566,H,Binding affinity against 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,13944,,,8,Autocuration,1,CHEMBL616353,,
1567,H,Binding affinity against serotonergic 5-HT1a receptor,,,B,,BAO_0000357,13033,,,8,Autocuration,1,CHEMBL616354,,
1568,H,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,10321,,,8,Autocuration,1,CHEMBL616508,,
1569,D,Binding affinity for 5-hydroxytryptamine 1A receptor,,Mus musculus,B,,BAO_0000357,2968,,10090.0,9,Expert,1,CHEMBL616559,,
1570,H,Binding affinity at 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,13964,,,8,Autocuration,1,CHEMBL616560,,
1571,H,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,,B,,BAO_0000357,15527,,,8,Autocuration,1,CHEMBL616561,,
1572,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,B,,BAO_0000219,12248,,,8,Autocuration,1,CHEMBL616562,449.0,
1573,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,B,,BAO_0000219,12249,,,8,Autocuration,1,CHEMBL616563,449.0,
1574,H,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,15120,,,8,Autocuration,1,CHEMBL616564,,
1575,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,,B,,BAO_0000357,13313,,,8,Autocuration,1,CHEMBL616565,,
1576,H,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000218,2613,,,8,Autocuration,1,CHEMBL616566,,
1577,H,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,,B,,BAO_0000357,16700,,,8,Autocuration,1,CHEMBL616989,,
1578,H,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,2201,,,8,Autocuration,1,CHEMBL857975,,
1579,D,Binding affinity against 5-hydroxytryptamine 1A receptor,,Mus musculus,B,,BAO_0000357,1274,,10090.0,9,Expert,1,CHEMBL616990,,
1580,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,B,,BAO_0000357,1317,,,8,Autocuration,1,CHEMBL616991,,
1581,H,Tested against 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,12146,,,8,Autocuration,1,CHEMBL616992,,
1582,H,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,14059,,,8,Autocuration,1,CHEMBL616993,,
1583,H,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,Oryctolagus cuniculus,B,,BAO_0000019,14025,,9986.0,8,Expert,1,CHEMBL616994,,
1584,H,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,Oryctolagus cuniculus,B,,BAO_0000019,14025,,9986.0,8,Autocuration,1,CHEMBL616995,,
1585,D,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,Gorilla gorilla,B,,BAO_0000219,14447,,9593.0,9,Intermediate,1,CHEMBL616996,722.0,
1586,H,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,Cavia porcellus,F,,BAO_0000218,3025,In vivo,10141.0,8,Autocuration,1,CHEMBL616997,,
1587,H,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,Cavia porcellus,F,,BAO_0000218,3025,In vivo,10141.0,8,Autocuration,1,CHEMBL616998,,
1588,H,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,Cavia porcellus,F,,BAO_0000019,15329,,10141.0,8,Autocuration,1,CHEMBL616999,,
1589,H,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,Cavia porcellus,F,,BAO_0000019,15329,,10141.0,8,Autocuration,1,CHEMBL617000,,
1590,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,Cavia porcellus,F,,BAO_0000019,15847,,10141.0,8,Autocuration,1,CHEMBL617001,,
1591,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,Cavia porcellus,F,,BAO_0000019,15847,,10141.0,8,Autocuration,1,CHEMBL858111,,
1592,H,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,,F,,BAO_0000019,14165,,,8,Autocuration,1,CHEMBL617002,,
1593,H,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,,F,,BAO_0000019,14214,,,8,Autocuration,1,CHEMBL617003,,
1594,H,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,,F,,BAO_0000019,14214,,,8,Autocuration,1,CHEMBL617004,,
1595,D,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,Homo sapiens,F,,BAO_0000019,14214,,9606.0,9,Expert,1,CHEMBL617005,,
1596,D,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,Homo sapiens,F,,BAO_0000219,13729,,9606.0,9,Expert,1,CHEMBL616623,485.0,
1597,H,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,,F,,BAO_0000219,3025,,,8,Autocuration,1,CHEMBL616624,449.0,
1598,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,2391,,,8,Autocuration,1,CHEMBL883243,,
1599,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,,F,,BAO_0000019,2391,,,8,Autocuration,1,CHEMBL616625,,
1600,H,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,,F,,BAO_0000219,14956,,,8,Expert,1,CHEMBL616626,449.0,
1601,H,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,,F,,BAO_0000219,2598,,,8,Autocuration,1,CHEMBL616627,449.0,
1602,H,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,,F,,BAO_0000219,2598,,,8,Autocuration,1,CHEMBL616628,449.0,
1603,H,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,,F,,BAO_0000219,2598,,,8,Autocuration,1,CHEMBL616629,449.0,
1604,H,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,,F,,BAO_0000219,2598,,,8,Autocuration,1,CHEMBL616630,449.0,
1605,H,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,,F,,BAO_0000019,14956,,,8,Expert,1,CHEMBL616631,,
1606,H,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,,F,,BAO_0000019,14956,,,8,Autocuration,1,CHEMBL616632,,
1607,D,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,Homo sapiens,B,,BAO_0000357,14214,,9606.0,9,Expert,1,CHEMBL616633,,
1608,H,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,,B,,BAO_0000219,3463,,,8,Expert,1,CHEMBL616634,449.0,
1609,H,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,,B,,BAO_0000357,15331,,,8,Autocuration,1,CHEMBL616635,,
1610,D,Binding affinity against 5-hydroxytryptamine 1B receptor,,Homo sapiens,B,,BAO_0000357,16146,,9606.0,9,Expert,1,CHEMBL885358,,
1611,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,Homo sapiens,B,,BAO_0000219,14159,,9606.0,9,Expert,1,CHEMBL616636,449.0,
1612,H,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,,B,,BAO_0000219,14158,,,8,Expert,1,CHEMBL616637,449.0,
1613,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,14159,,,8,Autocuration,1,CHEMBL616638,,
1614,H,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,B,,BAO_0000219,15250,,,8,Expert,1,CHEMBL616639,449.0,
1615,H,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,B,,BAO_0000219,15250,,,8,Expert,1,CHEMBL616640,449.0,
1616,H,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,B,,BAO_0000219,15331,,,8,Expert,1,CHEMBL616641,449.0,
1617,H,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,,B,,BAO_0000219,15332,,,8,Expert,1,CHEMBL616642,449.0,
1618,H,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,,B,,BAO_0000219,14956,,,8,Expert,1,CHEMBL616643,449.0,
1619,H,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,,B,,BAO_0000357,3805,,,8,Autocuration,1,CHEMBL616644,,
1620,H,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,,B,,BAO_0000357,14875,,,8,Autocuration,1,CHEMBL616645,,
1621,H,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,Oryctolagus cuniculus,F,,BAO_0000019,14454,,9986.0,8,Autocuration,1,CHEMBL616646,,
1622,H,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,Oryctolagus cuniculus,F,,BAO_0000019,14454,,9986.0,8,Expert,1,CHEMBL616647,,
1623,H,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,,B,,BAO_0000357,16288,,,8,Autocuration,1,CHEMBL616509,,
1624,H,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,,B,,BAO_0000357,16288,,,8,Autocuration,1,CHEMBL616510,,
1625,H,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,16312,,,8,Autocuration,1,CHEMBL616511,,
1626,H,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,Bos taurus,B,,BAO_0000357,1348,,9913.0,8,Expert,1,CHEMBL616512,,
1627,H,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,Bos taurus,B,,BAO_0000357,5834,,9913.0,8,Autocuration,1,CHEMBL616513,,
1628,H,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,Bos taurus,B,,BAO_0000019,13366,,9913.0,8,Autocuration,1,CHEMBL616514,,2435.0
1629,H,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,Bos taurus,B,,BAO_0000357,1414,,9913.0,8,Expert,1,CHEMBL616515,,
1630,H,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,Bos taurus,B,,BAO_0000019,14998,,9913.0,8,Autocuration,1,CHEMBL616516,,
1631,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,Bos taurus,B,,BAO_0000357,11473,,9913.0,8,Autocuration,1,CHEMBL616517,,
1632,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,Bos taurus,B,,BAO_0000357,11473,,9913.0,8,Autocuration,1,CHEMBL616518,,
1633,H,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,Bos taurus,B,,BAO_0000357,10639,,9913.0,8,Autocuration,1,CHEMBL616519,,
1634,H,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,Bos taurus,B,,BAO_0000357,10639,,9913.0,8,Autocuration,1,CHEMBL616520,,
1635,H,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,Bos taurus,B,,BAO_0000357,1375,,9913.0,8,Autocuration,1,CHEMBL616521,,
1636,H,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,Bos taurus,B,,BAO_0000357,1375,,9913.0,8,Autocuration,1,CHEMBL616522,,
1637,H,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,Bos taurus,B,,BAO_0000357,16532,,9913.0,8,Autocuration,1,CHEMBL884531,,
1638,H,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,Bos taurus,B,,BAO_0000357,11147,,9913.0,8,Autocuration,1,CHEMBL616523,,
1639,H,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,Bos taurus,B,,BAO_0000019,13366,,9913.0,8,Autocuration,1,CHEMBL616731,,2435.0
1640,H,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,Bos taurus,B,,BAO_0000019,10444,,9913.0,8,Autocuration,1,CHEMBL616732,,
1641,H,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,Bos taurus,B,,BAO_0000357,16532,,9913.0,8,Autocuration,1,CHEMBL616733,,
1642,H,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,Bos taurus,B,,BAO_0000357,16532,,9913.0,8,Autocuration,1,CHEMBL616734,,
1643,H,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,Bos taurus,B,,BAO_0000249,12827,,9913.0,8,Autocuration,1,CHEMBL616735,,
1644,H,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,Bos taurus,B,,BAO_0000249,12827,,9913.0,8,Autocuration,1,CHEMBL616736,,
1645,H,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Bos taurus,F,,BAO_0000019,12919,,9913.0,8,Expert,1,CHEMBL616737,,
1646,H,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,Bos taurus,B,,BAO_0000019,14025,,9913.0,8,Autocuration,1,CHEMBL616738,,
1647,H,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Bos taurus,F,,BAO_0000019,12919,,9913.0,8,Expert,1,CHEMBL616739,,
1648,H,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Bos taurus,F,,BAO_0000019,12919,,9913.0,8,Expert,1,CHEMBL616740,,
1649,H,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Bos taurus,F,,BAO_0000019,12919,,9913.0,8,Expert,1,CHEMBL616741,,
1650,H,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,Gorilla gorilla,B,,BAO_0000219,14447,,9593.0,8,Autocuration,1,CHEMBL616742,722.0,
1651,D,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,Cavia porcellus,B,,BAO_0000019,1375,,10141.0,9,Intermediate,1,CHEMBL616743,,
1652,D,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,Cavia porcellus,B,,BAO_0000019,1375,,10141.0,9,Intermediate,1,CHEMBL616744,,
1653,D,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,Cavia porcellus,F,,BAO_0000019,12409,,10141.0,9,Intermediate,1,CHEMBL616745,,
1654,D,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Cavia porcellus,F,,BAO_0000019,12409,,10141.0,9,Intermediate,1,CHEMBL616746,,
1655,D,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,Cavia porcellus,F,,BAO_0000019,12409,,10141.0,9,Intermediate,1,CHEMBL616747,,
1656,D,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,Cavia porcellus,F,,BAO_0000019,12409,,10141.0,9,Intermediate,1,CHEMBL616748,,
1657,D,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,Cavia porcellus,F,,BAO_0000019,12409,,10141.0,9,Intermediate,1,CHEMBL616648,,
1658,D,Binding affinity against 5-hydroxytryptamine 1D receptor,,Cavia porcellus,B,,BAO_0000357,11574,,10141.0,9,Intermediate,1,CHEMBL616649,,
1659,D,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,Cavia porcellus,B,,BAO_0000357,1558,,10141.0,9,Intermediate,1,CHEMBL616650,,
1660,D,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Cavia porcellus,F,,BAO_0000218,12409,,10141.0,9,Intermediate,1,CHEMBL616651,,
1661,D,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Cavia porcellus,F,,BAO_0000218,12409,,10141.0,9,Intermediate,1,CHEMBL616652,,
1662,D,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Cavia porcellus,F,,BAO_0000218,12409,,10141.0,9,Intermediate,1,CHEMBL616653,,
1663,D,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,Cavia porcellus,F,,BAO_0000218,12409,,10141.0,9,Intermediate,1,CHEMBL616654,,
1664,D,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,Cavia porcellus,B,,BAO_0000019,12253,,10141.0,9,Intermediate,1,CHEMBL616655,,
1665,D,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,Cavia porcellus,B,,BAO_0000357,12936,,10141.0,9,Intermediate,1,CHEMBL616656,,
1666,H,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,Cavia porcellus,B,,BAO_0000019,13181,,10141.0,8,Autocuration,1,CHEMBL616657,,
1667,D,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,Cavia porcellus,B,,BAO_0000357,12409,,10141.0,9,Intermediate,1,CHEMBL616658,,2435.0
1668,D,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,Cavia porcellus,B,,BAO_0000357,10639,,10141.0,9,Intermediate,1,CHEMBL616659,,
1669,H,Binding affinity against 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,5254,,,8,Autocuration,1,CHEMBL616660,,
1670,H,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,,B,,BAO_0000357,13051,,,8,Autocuration,1,CHEMBL616661,,
1671,H,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,,F,,BAO_0000019,3463,,,8,Expert,1,CHEMBL616662,,
1672,H,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,,F,,BAO_0000019,15315,,,8,Autocuration,1,CHEMBL616663,,
1673,H,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,,F,,BAO_0000019,6011,,,8,Autocuration,1,CHEMBL616664,,
1674,D,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,Homo sapiens,F,,BAO_0000219,14159,,9606.0,9,Expert,1,CHEMBL881820,449.0,
1675,H,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,,F,,BAO_0000219,14159,,,8,Autocuration,1,CHEMBL616665,449.0,
1676,H,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000219,15250,,,8,Expert,1,CHEMBL616666,449.0,
1677,H,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000219,15250,,,8,Autocuration,1,CHEMBL616667,449.0,
1678,H,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,,F,,BAO_0000219,15331,,,8,Expert,1,CHEMBL616668,449.0,
1679,D,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,Homo sapiens,F,,BAO_0000219,15332,,9606.0,9,Expert,1,CHEMBL616669,449.0,
1680,H,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,,F,,BAO_0000219,15332,,,8,Expert,1,CHEMBL617040,449.0,
1681,H,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,,F,,BAO_0000219,3294,,,8,Autocuration,1,CHEMBL617041,449.0,
1682,H,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,,F,,BAO_0000219,14158,,,8,Expert,1,CHEMBL617042,449.0,
1683,H,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,,F,,BAO_0000219,14956,,,8,Expert,1,CHEMBL617043,449.0,
1684,H,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,,F,,BAO_0000019,12469,,,8,Autocuration,1,CHEMBL617044,,
1685,H,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,F,,BAO_0000219,3463,,,8,Expert,1,CHEMBL617045,449.0,
1686,D,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,Homo sapiens,F,,BAO_0000219,15250,,9606.0,9,Expert,1,CHEMBL617046,449.0,
1687,D,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,Homo sapiens,F,,BAO_0000219,15250,,9606.0,9,Expert,1,CHEMBL617047,449.0,
1688,H,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,,F,,BAO_0000019,14956,,,8,Expert,1,CHEMBL617048,,
1689,H,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,,F,,BAO_0000019,14159,,,8,Autocuration,1,CHEMBL616897,,
1690,D,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,Homo sapiens,F,,BAO_0000019,14159,,9606.0,9,Expert,1,CHEMBL616898,,
1691,D,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,Homo sapiens,F,,BAO_0000219,14499,,9606.0,9,Expert,1,CHEMBL858201,449.0,
1692,H,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,,F,,BAO_0000019,15315,,,8,Autocuration,1,CHEMBL616899,,
1693,H,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,,B,,BAO_0000219,3294,In vitro,,8,Autocuration,1,CHEMBL616900,,
1694,H,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,,B,,BAO_0000219,3463,,,8,Expert,1,CHEMBL616901,449.0,
1695,H,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,,B,,BAO_0000357,15331,,,8,Autocuration,1,CHEMBL616902,,
1696,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,Homo sapiens,B,,BAO_0000219,14159,,9606.0,9,Expert,1,CHEMBL616903,449.0,
1697,H,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,,B,,BAO_0000219,14158,,,8,Expert,1,CHEMBL616904,449.0,
1698,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,14159,,,8,Autocuration,1,CHEMBL616905,,
1699,H,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,B,,BAO_0000219,15250,,,8,Expert,1,CHEMBL616906,449.0,
1700,H,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,B,,BAO_0000219,15250,,,8,Expert,1,CHEMBL616907,449.0,
1701,H,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,B,,BAO_0000219,15331,,,8,Expert,1,CHEMBL616908,449.0,
1702,D,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,Homo sapiens,B,,BAO_0000219,15332,,9606.0,9,Expert,1,CHEMBL616909,449.0,
1703,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,Homo sapiens,B,,BAO_0000219,14499,,9606.0,9,Expert,1,CHEMBL616910,449.0,
1704,H,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,B,,BAO_0000219,15332,,,8,Expert,1,CHEMBL616911,449.0,
1705,H,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,B,,BAO_0000219,14956,,,8,Expert,1,CHEMBL616912,449.0,
1706,H,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,,B,,BAO_0000357,3805,,,8,Autocuration,1,CHEMBL616913,,
1707,D,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,Homo sapiens,B,,BAO_0000219,6011,,9606.0,9,Expert,1,CHEMBL616914,449.0,
1708,H,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,,B,,BAO_0000219,16190,,,8,Autocuration,1,CHEMBL616915,449.0,
1709,H,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,,B,,BAO_0000019,14165,,,8,Autocuration,1,CHEMBL616916,,
1710,D,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,Homo sapiens,B,,BAO_0000357,4234,,9606.0,9,Expert,1,CHEMBL616917,,
1711,H,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,,B,,BAO_0000357,15527,,,8,Autocuration,1,CHEMBL616918,,
1712,H,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,B,,BAO_0000219,6328,,,8,Expert,1,CHEMBL616919,,
1713,H,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,,B,,BAO_0000357,16209,,,8,Autocuration,1,CHEMBL616920,,
1714,H,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,,B,,BAO_0000357,14770,,,8,Autocuration,1,CHEMBL872914,,
1715,H,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,,B,,BAO_0000357,2598,,,8,Autocuration,1,CHEMBL616921,,
1716,H,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,6897,,,8,Expert,1,CHEMBL616922,,
1717,H,Binding affinity towards 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,6013,,,8,Autocuration,1,CHEMBL616923,,
1718,H,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,5843,,,8,Expert,1,CHEMBL616924,,
1719,H,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,,B,,BAO_0000357,14454,,,8,Expert,1,CHEMBL875909,,
1720,H,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,,B,,BAO_0000357,14454,,,8,Autocuration,1,CHEMBL616925,,
1721,H,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,,B,,BAO_0000357,14454,,,8,Autocuration,1,CHEMBL616926,,
1722,H,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,15818,,,8,Autocuration,1,CHEMBL616927,,
1723,H,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,,F,,BAO_0000219,13729,,,8,Expert,1,CHEMBL616928,485.0,
1724,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,Homo sapiens,B,,BAO_0000219,6011,In vitro,9606.0,9,Expert,1,CHEMBL616929,,
1725,D,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,Homo sapiens,B,,BAO_0000357,4234,,9606.0,9,Expert,1,CHEMBL616930,,
1726,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000019,17085,,,8,Expert,1,CHEMBL616931,,
1727,H,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,B,,BAO_0000357,3025,,,8,Autocuration,1,CHEMBL616932,,
1728,H,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,15315,,,8,Expert,1,CHEMBL616933,,
1729,D,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,Homo sapiens,B,,BAO_0000219,14214,,9606.0,9,Expert,1,CHEMBL616934,,
1730,D,Binding affinity for human 5-hydroxytryptamine 1D receptor,,Homo sapiens,B,,BAO_0000357,3804,,9606.0,9,Expert,1,CHEMBL616935,,
1731,H,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,,B,,BAO_0000357,16700,,,8,Autocuration,1,CHEMBL616936,,
1732,D,Affinity for 5-hydroxytryptamine 1D receptor subtype,,Homo sapiens,B,,BAO_0000357,2391,,9606.0,9,Expert,1,CHEMBL616937,,
1733,D,Binding affinity for human 5-hydroxytryptamine 1D receptor,,Homo sapiens,B,,BAO_0000357,4175,,9606.0,9,Expert,1,CHEMBL616938,,
1734,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000019,17085,,,8,Autocuration,1,CHEMBL616939,,
1735,H,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,,B,,BAO_0000019,17085,,,8,Expert,1,CHEMBL616940,,
1736,D,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,Homo sapiens,B,,BAO_0000357,15926,,9606.0,9,Expert,1,CHEMBL616941,,
1737,H,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,,B,,BAO_0000219,16312,,,8,Autocuration,1,CHEMBL616942,485.0,
1738,H,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,,B,,BAO_0000219,16312,,,8,Autocuration,1,CHEMBL616943,485.0,
1739,H,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,,B,,BAO_0000219,14956,,,4,Autocuration,1,CHEMBL616944,449.0,
1740,H,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,,F,,BAO_0000019,3294,,,8,Autocuration,1,CHEMBL616945,,
1741,H,Binding activity radioligand.,,,B,,BAO_0000357,12861,,,8,Autocuration,1,CHEMBL616946,,
1742,H,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,B,,BAO_0000019,12861,,,8,Autocuration,1,CHEMBL616947,,
1743,H,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000219,16312,,,8,Expert,1,CHEMBL616948,485.0,
1744,H,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,5104,,,8,Autocuration,1,CHEMBL616851,,
1745,H,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,5105,,,8,Autocuration,1,CHEMBL616852,,
1746,H,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,14499,,,8,Autocuration,1,CHEMBL616853,,
1747,D,Binding activity against human 5-hydroxytryptamine 1D receptor,,Homo sapiens,B,,BAO_0000357,15926,,9606.0,9,Expert,1,CHEMBL616854,,
1748,D,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,Homo sapiens,B,,BAO_0000219,4540,,9606.0,9,Expert,1,CHEMBL616855,449.0,
1749,H,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL616856,449.0,
1750,H,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL616857,449.0,
1751,H,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,6166,,,8,Autocuration,1,CHEMBL616858,,
1752,H,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL616859,449.0,
1753,H,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL616860,449.0,
1754,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,B,,BAO_0000219,17451,,,8,Autocuration,1,CHEMBL616861,722.0,
1755,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,B,,BAO_0000219,17451,,,8,Autocuration,1,CHEMBL616541,722.0,
1756,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,,B,,BAO_0000219,17451,,,8,Autocuration,1,CHEMBL616542,722.0,
1757,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,,B,,BAO_0000219,4199,,,8,Autocuration,1,CHEMBL616543,449.0,
1758,D,Binding affinity for human 5-hydroxytryptamine 1D receptor,,Homo sapiens,B,,BAO_0000357,14875,,9606.0,9,Expert,1,CHEMBL616544,,
1759,H,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,,B,,BAO_0000219,15146,,,8,Autocuration,1,CHEMBL616545,449.0,
1760,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,,B,,BAO_0000357,5213,,,8,Autocuration,1,CHEMBL616546,,
1761,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,,B,,BAO_0000219,14818,,,8,Autocuration,1,CHEMBL616547,449.0,
1762,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,,B,,BAO_0000219,4829,,,8,Autocuration,1,CHEMBL616548,449.0,
1763,H,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,,F,,BAO_0000019,14454,,,8,Expert,1,CHEMBL616549,,
1764,H,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,,F,,BAO_0000019,14454,,,8,Expert,1,CHEMBL616550,,
1765,H,Binding affinity against 5-HT2C receptor,,,B,,BAO_0000357,5254,,,8,Autocuration,1,CHEMBL857066,,
1766,H,Binding affinity against 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,5254,,,8,Autocuration,1,CHEMBL616551,,
1767,H,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,B,,BAO_0000357,10639,,,8,Autocuration,1,CHEMBL616552,,
1768,H,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,F,,BAO_0000019,10639,,,8,Autocuration,1,CHEMBL832876,,
1769,H,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,,B,,BAO_0000019,12352,,,8,Expert,1,CHEMBL616553,,
1770,H,Binding affinity towards 5-HT1B was determined,,,B,,BAO_0000357,9098,,,8,Autocuration,1,CHEMBL616554,,
1771,H,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,,B,,BAO_0000019,14430,,,8,Expert,1,CHEMBL616555,,
1772,H,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,,B,,BAO_0000019,13657,,,8,Expert,1,CHEMBL616556,,
1773,H,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,,B,,BAO_0000019,13657,,,8,Autocuration,1,CHEMBL616557,,
1774,H,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,B,,BAO_0000019,15854,,,8,Expert,1,CHEMBL616558,,
1775,D,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,Rattus norvegicus,B,,BAO_0000019,10639,,10116.0,9,Expert,1,CHEMBL616749,,
1776,H,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,B,,BAO_0000357,10025,,,8,Autocuration,1,CHEMBL616750,,
1777,H,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,,B,,BAO_0000357,10025,,,8,Autocuration,1,CHEMBL616751,,
1778,H,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,B,,BAO_0000249,14286,,,8,Autocuration,1,CHEMBL616752,,
1779,H,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,,B,,BAO_0000019,3651,,,8,Autocuration,1,CHEMBL616753,,2435.0
1780,D,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,Rattus norvegicus,B,,BAO_0000357,14178,,10116.0,9,Expert,1,CHEMBL616754,,
1781,H,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,,B,,BAO_0000019,10639,,,8,Autocuration,1,CHEMBL616755,,
1782,H,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,,B,,BAO_0000019,13605,,,8,Autocuration,1,CHEMBL616756,,2435.0
1783,H,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,,B,,BAO_0000019,5834,,,8,Autocuration,1,CHEMBL616757,,2435.0
1784,H,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,,B,,BAO_0000357,10922,,,8,Autocuration,1,CHEMBL616758,,2435.0
1785,H,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,B,,BAO_0000249,14286,,,8,Autocuration,1,CHEMBL616759,,
1786,H,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,,B,,BAO_0000357,11825,,,8,Autocuration,1,CHEMBL616760,,
1787,H,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,,B,,BAO_0000019,14826,,,8,Autocuration,1,CHEMBL616761,,2435.0
1788,H,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,,B,,BAO_0000019,9699,,,8,Autocuration,1,CHEMBL616762,,2435.0
1789,H,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,,B,,BAO_0000019,14423,,,8,Autocuration,1,CHEMBL616763,,
1790,H,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,,B,,BAO_0000357,10062,,,8,Expert,1,CHEMBL872909,,
1791,H,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,10062,,,8,Autocuration,1,CHEMBL616764,,
1792,D,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,Rattus norvegicus,B,,BAO_0000357,12280,,10116.0,9,Expert,1,CHEMBL616765,,
1793,H,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,,B,,BAO_0000357,15412,,,8,Autocuration,1,CHEMBL616766,,2435.0
1794,H,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,,B,,BAO_0000357,15412,,,8,Autocuration,1,CHEMBL616767,,2435.0
1795,H,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,10062,,,8,Autocuration,1,CHEMBL616768,,
1796,H,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,B,,BAO_0000357,11147,,,8,Autocuration,1,CHEMBL616769,,
1797,H,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,,B,,BAO_0000019,9547,,,8,Autocuration,1,CHEMBL616770,,
1798,H,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,,B,,BAO_0000019,10444,,,8,Autocuration,1,CHEMBL616771,,
1799,H,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,,B,,BAO_0000019,12469,,,8,Autocuration,1,CHEMBL616772,,2435.0
1800,H,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,,B,,BAO_0000019,9098,,,8,Expert,1,CHEMBL616773,,
1801,H,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,,B,,BAO_0000019,9098,,,8,Autocuration,1,CHEMBL616774,,
1802,H,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,9699,,,8,Autocuration,1,CHEMBL616775,,
1803,H,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,B,,BAO_0000249,10394,,,8,Autocuration,1,CHEMBL616776,,
1804,H,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,,B,,BAO_0000357,12092,,,8,Autocuration,1,CHEMBL616777,,
1805,H,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,,B,,BAO_0000357,16700,,,8,Autocuration,1,CHEMBL616778,,
1806,D,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,Rattus norvegicus,B,,BAO_0000249,403,,10116.0,9,Expert,1,CHEMBL616779,,
1807,D,Binding affinity towards 5-hydroxytryptamine 1B receptor,,Rattus norvegicus,B,,BAO_0000357,12771,,10116.0,9,Expert,1,CHEMBL616780,,
1808,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,,B,,BAO_0000019,11642,,,8,Autocuration,1,CHEMBL616781,,
1809,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,,B,,BAO_0000357,12953,,,8,Autocuration,1,CHEMBL616782,,
1810,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,,B,,BAO_0000357,12953,,,8,Autocuration,1,CHEMBL616783,,
1811,H,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,,B,,BAO_0000019,12953,,,8,Expert,1,CHEMBL616784,,2435.0
1812,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,,B,,BAO_0000357,12953,,,8,Autocuration,1,CHEMBL616785,,
1813,H,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,B,,BAO_0000249,9737,,,8,Autocuration,1,CHEMBL857067,,955.0
1814,H,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,,B,,BAO_0000019,9737,,,8,Autocuration,1,CHEMBL616786,,
1815,H,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,B,,BAO_0000249,9737,,,8,Autocuration,1,CHEMBL616787,,955.0
1816,H,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,,B,,BAO_0000357,12827,,,8,Autocuration,1,CHEMBL616788,,
1817,H,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,5033,,,8,Autocuration,1,CHEMBL616789,,
1818,D,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,Rattus norvegicus,B,,BAO_0000019,9786,,10116.0,9,Expert,1,CHEMBL616790,,
1819,H,Binding affinity at 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,13116,,,8,Expert,1,CHEMBL616791,,
1820,H,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,,B,,BAO_0000019,16429,,,8,Autocuration,1,CHEMBL616792,,
1821,D,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,Rattus norvegicus,B,,BAO_0000249,12409,,10116.0,9,Expert,1,CHEMBL616793,,
1822,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,B,,BAO_0000357,15194,,,8,Autocuration,1,CHEMBL616794,,
1823,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,B,,BAO_0000357,15194,,,8,Autocuration,1,CHEMBL616795,,
1824,H,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,,B,,BAO_0000019,5486,,,4,Autocuration,1,CHEMBL616796,,
1825,H,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,4639,,,8,Autocuration,1,CHEMBL616797,,
1826,H,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,,B,,BAO_0000249,386,,,8,Autocuration,1,CHEMBL616798,,
1827,H,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,,B,,BAO_0000357,2474,,,8,Autocuration,1,CHEMBL616799,,
1828,H,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,,B,,BAO_0000357,6011,,,8,Autocuration,1,CHEMBL616800,,
1829,H,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,5014,,,8,Autocuration,1,CHEMBL616801,,
1830,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,,B,,BAO_0000357,17515,,,8,Autocuration,1,CHEMBL616802,,
1831,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,,B,,BAO_0000357,4373,,,8,Autocuration,1,CHEMBL616803,,
1832,H,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,,B,,BAO_0000357,1633,,,8,Expert,1,CHEMBL857068,,
1833,H,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,,B,,BAO_0000357,1633,,,8,Autocuration,1,CHEMBL616804,,
1834,H,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,,B,,BAO_0000357,4373,,,8,Autocuration,1,CHEMBL616805,,
1835,H,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,4687,,,8,Autocuration,1,CHEMBL616806,,
1836,H,Binding affinity against 5-hydroxytryptamine 1B receptor,,,B,,BAO_0000357,11574,,,8,Autocuration,1,CHEMBL616807,,
1837,H,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,,B,,BAO_0000357,10321,,,8,Autocuration,1,CHEMBL616808,,
1838,H,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,B,,BAO_0000357,15527,,,8,Autocuration,1,CHEMBL616809,,
1839,H,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,,B,,BAO_0000357,17200,,,8,Autocuration,1,CHEMBL616810,,
1840,H,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,,B,,BAO_0000224,14423,,,4,Autocuration,1,CHEMBL616811,,
1841,H,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,Bos taurus,B,,BAO_0000357,5834,,9913.0,8,Autocuration,1,CHEMBL616812,,
1842,H,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,Sus scrofa,B,,BAO_0000357,11473,,9823.0,8,Autocuration,1,CHEMBL616813,,
1843,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,Sus scrofa,B,,BAO_0000357,11473,,9823.0,8,Autocuration,1,CHEMBL616814,,
1844,H,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,Sus scrofa,B,,BAO_0000357,10639,,9823.0,8,Autocuration,1,CHEMBL616815,,
1845,H,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,Sus scrofa,B,,BAO_0000357,10639,,9823.0,8,Autocuration,1,CHEMBL616816,,
1846,H,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,Sus scrofa,B,,BAO_0000357,14331,,9823.0,8,Autocuration,1,CHEMBL616817,,
1847,H,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,Sus scrofa,B,,BAO_0000357,10796,,9823.0,8,Autocuration,1,CHEMBL616818,,
1848,H,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,Sus scrofa,B,,BAO_0000357,9098,,9823.0,8,Expert,1,CHEMBL616819,,
1849,H,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,Sus scrofa,B,,BAO_0000357,14331,,9823.0,8,Expert,1,CHEMBL616820,,
1850,H,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,Sus scrofa,B,,BAO_0000019,11828,,9823.0,8,Expert,1,CHEMBL616821,,
1851,H,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,Sus scrofa,B,,BAO_0000357,11866,,9823.0,8,Autocuration,1,CHEMBL616822,,
1852,H,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,Oryctolagus cuniculus,B,,BAO_0000019,13047,,9986.0,8,Autocuration,1,CHEMBL616823,,
1853,D,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,Rattus norvegicus,B,,BAO_0000357,188,,10116.0,9,Autocuration,1,CHEMBL616824,,
1854,D,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,Rattus norvegicus,B,,BAO_0000357,11825,,10116.0,9,Autocuration,1,CHEMBL616825,,
1855,D,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,Rattus norvegicus,B,,BAO_0000357,11825,,10116.0,9,Autocuration,1,CHEMBL616826,,
1856,D,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,Rattus norvegicus,B,,BAO_0000019,11624,,10116.0,9,Expert,1,CHEMBL616827,,
1857,D,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,Rattus norvegicus,B,,BAO_0000357,11139,,10116.0,9,Autocuration,1,CHEMBL616828,,
1858,D,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,Rattus norvegicus,B,,BAO_0000357,11147,,10116.0,9,Autocuration,1,CHEMBL616829,,
1859,D,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,Rattus norvegicus,B,,BAO_0000019,10444,,10116.0,9,Autocuration,1,CHEMBL616830,,
1860,D,Binding affinity against 5-hydroxytryptamine 1C receptor,,Rattus norvegicus,B,,BAO_0000357,11624,,10116.0,9,Expert,1,CHEMBL616831,,
1861,D,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Rattus norvegicus,B,,BAO_0000019,11662,,10116.0,9,Autocuration,1,CHEMBL616832,,
1862,D,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Rattus norvegicus,B,,BAO_0000019,11662,,10116.0,9,Autocuration,1,CHEMBL616833,,
1863,D,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Rattus norvegicus,B,,BAO_0000019,11662,,10116.0,9,Expert,1,CHEMBL616834,,
1864,D,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Rattus norvegicus,B,,BAO_0000019,11662,,10116.0,9,Autocuration,1,CHEMBL829595,,
1865,D,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,Rattus norvegicus,B,,BAO_0000357,9098,,10116.0,9,Autocuration,1,CHEMBL616835,,
1866,D,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,Rattus norvegicus,B,,BAO_0000249,10394,,10116.0,9,Autocuration,1,CHEMBL872910,,
1867,H,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,,B,,BAO_0000357,11933,,,8,Expert,1,CHEMBL616836,,
1868,D,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,Rattus norvegicus,B,,BAO_0000357,12092,,10116.0,9,Autocuration,1,CHEMBL616837,,
1869,D,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,Rattus norvegicus,B,,BAO_0000019,12253,,10116.0,9,Autocuration,1,CHEMBL616466,,
1870,D,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,Rattus norvegicus,B,,BAO_0000219,12253,,10116.0,9,Autocuration,1,CHEMBL616467,722.0,
1871,H,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,B,,BAO_0000357,1558,,,8,Autocuration,1,CHEMBL616468,,
1872,H,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,B,,BAO_0000357,2474,,,8,Autocuration,1,CHEMBL616469,,
1873,H,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,B,,BAO_0000357,2474,,,8,Autocuration,1,CHEMBL616470,,
1874,H,Binding affinity against 5-hydroxytryptamine 1C receptor,,,B,,BAO_0000357,11574,,,8,Autocuration,1,CHEMBL616471,,
1875,H,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,B,,BAO_0000357,1558,,,8,Autocuration,1,CHEMBL616472,,
1876,H,Binding affinity against 5-hydroxytryptamine 1C receptor,,,B,,BAO_0000357,13944,,,8,Autocuration,1,CHEMBL616473,,
1877,H,Binding affinity against serotonergic 5-HT1c receptor,,,B,,BAO_0000357,13033,,,8,Autocuration,1,CHEMBL616474,,
1878,H,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,,B,,BAO_0000357,10321,,,8,Autocuration,1,CHEMBL616475,,
1879,H,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,,B,,BAO_0000357,11866,,,8,Autocuration,1,CHEMBL616476,,
1880,H,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,Oryctolagus cuniculus,B,,BAO_0000019,14454,,9986.0,8,Autocuration,1,CHEMBL616477,,
1881,H,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,,B,,BAO_0000224,11574,,,4,Autocuration,1,CHEMBL616478,,
1882,H,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,,B,,BAO_0000224,11574,,,4,Autocuration,1,CHEMBL616479,,
1883,H,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,,B,,BAO_0000019,13631,,,4,Autocuration,1,CHEMBL616480,,
1884,D,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,Rattus norvegicus,B,,BAO_0000019,9630,,10116.0,5,Autocuration,1,CHEMBL616481,,
1885,D,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,Rattus norvegicus,B,,BAO_0000249,8822,,10116.0,5,Autocuration,1,CHEMBL616482,,
1886,D,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,Rattus norvegicus,B,,BAO_0000221,9064,,10116.0,5,Autocuration,1,CHEMBL884713,,955.0
1887,H,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,,B,,BAO_0000224,8868,,,4,Autocuration,1,CHEMBL616483,,
1888,H,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,,B,,BAO_0000224,9064,,,4,Autocuration,1,CHEMBL616484,,
1889,H,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,,B,,BAO_0000019,9806,,,4,Autocuration,1,CHEMBL616485,,
1890,H,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,B,,BAO_0000224,9098,,,4,Autocuration,1,CHEMBL616486,,
1891,H,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,,B,,BAO_0000224,8868,,,4,Autocuration,1,CHEMBL616487,,
1892,H,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,B,,BAO_0000224,12765,,,4,Autocuration,1,CHEMBL616488,,
1893,H,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,B,,BAO_0000019,11049,,,4,Autocuration,1,CHEMBL616489,,
1894,H,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,B,,BAO_0000019,11049,,,4,Autocuration,1,CHEMBL616490,,
1895,H,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,,B,,BAO_0000019,11049,,,4,Autocuration,1,CHEMBL616491,,
1896,H,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,,B,,BAO_0000019,11049,,,4,Autocuration,1,CHEMBL616492,,
1897,H,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,B,,BAO_0000019,11049,,,4,Autocuration,1,CHEMBL616493,,
1898,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,,B,,BAO_0000019,11473,,,4,Autocuration,1,CHEMBL616494,,
1899,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,,B,,BAO_0000019,11473,,,4,Autocuration,1,CHEMBL616495,,
1900,H,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,,B,,BAO_0000019,3086,,,4,Autocuration,1,CHEMBL616496,,
1901,H,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,B,,BAO_0000019,11049,,,4,Autocuration,1,CHEMBL616497,,
1902,H,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,B,,BAO_0000019,11049,,,4,Autocuration,1,CHEMBL616498,,
1903,H,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,,B,,BAO_0000019,10639,,,4,Autocuration,1,CHEMBL616499,,
1904,H,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,,B,,BAO_0000019,10922,,,4,Autocuration,1,CHEMBL616500,,
1905,D,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,Rattus norvegicus,B,,BAO_0000221,9064,,10116.0,5,Autocuration,1,CHEMBL616501,,955.0
1906,H,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,,B,,BAO_0000221,10748,,,4,Autocuration,1,CHEMBL616502,,955.0
1907,H,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,B,,BAO_0000249,11614,,,4,Autocuration,1,CHEMBL884529,,
1908,H,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,B,,BAO_0000249,11615,,,4,Autocuration,1,CHEMBL616503,,
1909,H,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,11615,,,4,Autocuration,1,CHEMBL616964,,
1910,H,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,B,,BAO_0000249,11614,,,4,Autocuration,1,CHEMBL616965,,
1911,H,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,,B,,BAO_0000224,11702,,,4,Autocuration,1,CHEMBL616966,,
1912,H,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,,B,,BAO_0000224,11702,,,4,Autocuration,1,CHEMBL616967,,
1913,D,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,B,,BAO_0000224,11702,,10116.0,5,Autocuration,1,CHEMBL616968,,
1914,H,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,,B,,BAO_0000224,11702,,,4,Autocuration,1,CHEMBL616969,,
1915,H,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,,B,,BAO_0000019,13346,,,4,Autocuration,1,CHEMBL884530,,
1916,H,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,10025,,,4,Autocuration,1,CHEMBL616970,,
1917,H,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,B,,BAO_0000224,10025,,,4,Autocuration,1,CHEMBL616971,,
1918,H,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,B,,BAO_0000224,10025,,,4,Autocuration,1,CHEMBL616972,,
1919,H,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,,B,,BAO_0000224,9036,,,4,Autocuration,1,CHEMBL616973,,
1920,H,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,,B,,BAO_0000224,9036,,,4,Autocuration,1,CHEMBL616974,,
1921,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,,B,,BAO_0000019,9161,,,4,Autocuration,1,CHEMBL616975,,
1922,H,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,,B,,BAO_0000019,12304,,,4,Autocuration,1,CHEMBL616976,,
1923,H,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,,B,,BAO_0000224,13276,,,4,Autocuration,1,CHEMBL616977,,
1924,H,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,B,,BAO_0000224,11825,,,4,Autocuration,1,CHEMBL616978,,
1925,H,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,,B,,BAO_0000224,12443,,,4,Autocuration,1,CHEMBL616979,,
1926,H,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,13830,,,4,Autocuration,1,CHEMBL616980,,
1927,H,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,,B,,BAO_0000249,9592,,,4,Autocuration,1,CHEMBL616981,,
1928,H,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,,B,,BAO_0000249,9592,,,4,Autocuration,1,CHEMBL616982,,
1929,H,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,,B,,BAO_0000224,10881,,,4,Autocuration,1,CHEMBL616983,,
1930,H,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,,B,,BAO_0000019,13605,,,4,Autocuration,1,CHEMBL616984,,
1931,D,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,B,,BAO_0000224,11624,,10116.0,5,Autocuration,1,CHEMBL616985,,
1932,H,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,B,,BAO_0000224,4101,,,4,Autocuration,1,CHEMBL616986,,
1933,H,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,B,,BAO_0000224,4101,,,4,Autocuration,1,CHEMBL616987,,
1934,H,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,,B,,BAO_0000019,15360,,,4,Autocuration,1,CHEMBL616988,,
1935,H,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,,B,,BAO_0000019,11576,,,4,Autocuration,1,CHEMBL617243,,
1936,H,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,,B,,BAO_0000019,5834,,,4,Autocuration,1,CHEMBL617244,,
1937,D,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,Rattus norvegicus,B,,BAO_0000219,2395,,10116.0,5,Autocuration,1,CHEMBL617245,485.0,
1938,H,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,B,,BAO_0000249,11965,,,4,Autocuration,1,CHEMBL617246,,
1939,H,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,,B,,BAO_0000224,3967,,,4,Autocuration,1,CHEMBL617546,,
1940,H,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,,B,,BAO_0000249,11130,,,4,Autocuration,1,CHEMBL617547,,
1941,H,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,B,,BAO_0000219,13427,In vitro,,4,Autocuration,1,CHEMBL617548,,
1942,H,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,9443,,,4,Autocuration,1,CHEMBL617549,,
1943,H,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,B,,BAO_0000224,9443,,,4,Autocuration,1,CHEMBL617550,,
1944,H,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,B,,BAO_0000224,11825,,,4,Autocuration,1,CHEMBL617551,,
1945,H,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,,B,,BAO_0000249,12120,,,4,Autocuration,1,CHEMBL617552,,
1946,H,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,,B,,BAO_0000249,12120,,,4,Autocuration,1,CHEMBL617553,,
1947,H,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,,F,,BAO_0000019,11963,,,4,Autocuration,1,CHEMBL617554,,1515.0
1948,H,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000019,9069,,,4,Autocuration,1,CHEMBL617555,,
1949,H,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,B,,BAO_0000224,8868,,,4,Autocuration,1,CHEMBL617556,,
1950,H,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,B,,BAO_0000357,17200,,,8,Autocuration,1,CHEMBL617557,,
1951,H,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,B,,BAO_0000357,17200,,,8,Autocuration,1,CHEMBL617558,,
1952,H,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,,B,,BAO_0000357,13969,,,8,Expert,1,CHEMBL617559,,
1953,D,Binding affinity for 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,13392,,,9,Expert,1,CHEMBL617560,,
1954,H,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,B,,BAO_0000249,1742,,,8,Autocuration,1,CHEMBL617561,,
1955,H,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,B,,BAO_0000249,1742,,,8,Autocuration,1,CHEMBL617562,,
1956,H,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,,B,,BAO_0000357,14331,,,8,Autocuration,1,CHEMBL617563,,2435.0
1957,H,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,,F,,BAO_0000019,12861,,,8,Autocuration,1,CHEMBL617564,,
1958,H,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,,B,,BAO_0000019,12861,,,8,Expert,1,CHEMBL617565,,
1959,H,Binding activity radioligand.,,,B,,BAO_0000357,12861,,,8,Autocuration,1,CHEMBL856076,,
1960,H,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,B,,BAO_0000019,12861,,,8,Autocuration,1,CHEMBL617566,,
1961,H,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,B,,BAO_0000019,12861,,,8,Expert,1,CHEMBL875911,,
1962,H,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,B,,BAO_0000019,12861,,,8,Autocuration,1,CHEMBL617567,,
1963,H,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,B,,BAO_0000249,675,,,8,Autocuration,1,CHEMBL617568,,
1964,H,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,,B,,BAO_0000019,12490,,,8,Expert,1,CHEMBL617569,,
1965,H,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,,B,,BAO_0000249,11828,,,8,Expert,1,CHEMBL617570,,
1966,H,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,,B,,BAO_0000357,11866,,,8,Autocuration,1,CHEMBL617571,,
1967,H,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,Sus scrofa,B,,BAO_0000357,773,,9823.0,8,Autocuration,1,CHEMBL617572,,
1968,H,The compound was tested for intrinsic activity against 5-HT1D receptor,,Oryctolagus cuniculus,B,,BAO_0000357,13047,,9986.0,8,Expert,1,CHEMBL617573,,
1969,H,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,B,,BAO_0000019,13047,,9986.0,8,Autocuration,1,CHEMBL617574,,
1970,H,The compound was tested for binding affinity against 5-HT1D receptor,,Oryctolagus cuniculus,B,,BAO_0000357,13047,,9986.0,8,Expert,1,CHEMBL617575,,
1971,H,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,,B,,BAO_0000357,188,,,8,Autocuration,1,CHEMBL617576,,
1972,H,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,,F,,BAO_0000019,10639,,,8,Autocuration,1,CHEMBL617577,,
1973,H,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,,F,,BAO_0000019,12438,,,8,Autocuration,1,CHEMBL617578,,
1974,H,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,12438,,,8,Autocuration,1,CHEMBL617579,,
1975,H,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,B,,BAO_0000019,15854,,,8,Expert,1,CHEMBL617580,,
1976,H,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,B,,BAO_0000249,10394,,,8,Autocuration,1,CHEMBL617581,,
1977,H,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,,B,,BAO_0000357,12092,,,8,Autocuration,1,CHEMBL617582,,
1978,H,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,,B,,BAO_0000019,3389,,,8,Expert,1,CHEMBL617583,,
1979,H,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,,B,,BAO_0000357,6011,,,8,Autocuration,1,CHEMBL617584,,
1980,H,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,4639,,,8,Autocuration,1,CHEMBL617585,,
1981,H,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,,B,,BAO_0000357,2474,,,8,Autocuration,1,CHEMBL875912,,
1982,H,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,5014,,,8,Autocuration,1,CHEMBL617586,,
1983,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,,B,,BAO_0000357,17515,,,8,Autocuration,1,CHEMBL617587,,
1984,H,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,,B,,BAO_0000357,11866,,,8,Autocuration,1,CHEMBL617588,,
1985,H,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,4687,,,8,Autocuration,1,CHEMBL857980,,
1986,H,Tested against 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,12146,,,8,Autocuration,1,CHEMBL617589,,
1987,H,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,,B,,BAO_0000357,10321,,,8,Autocuration,1,CHEMBL617590,,
1988,H,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,B,,BAO_0000219,13267,,,8,Autocuration,1,CHEMBL617591,722.0,
1989,D,Binding affinity against 5-Hydroxytryptamine 1D receptor,,Homo sapiens,B,,BAO_0000357,1274,,9606.0,9,Expert,1,CHEMBL617592,,
1990,H,,,,B,,BAO_0000357,15250,,,8,Autocuration,1,CHEMBL617593,,
1991,H,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,B,,BAO_0000219,13706,,,8,Autocuration,1,CHEMBL617594,485.0,
1992,H,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,B,,BAO_0000219,13706,,,8,Autocuration,1,CHEMBL617595,485.0,
1993,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,,B,,BAO_0000219,13706,,,8,Autocuration,1,CHEMBL617596,722.0,
1994,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,B,,BAO_0000219,13706,,,8,Autocuration,1,CHEMBL617597,722.0,
1995,H,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,B,,BAO_0000019,13047,,,8,Autocuration,1,CHEMBL617598,,
1996,H,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,,B,,BAO_0000357,13366,,,8,Autocuration,1,CHEMBL872916,,
1997,H,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,,B,,BAO_0000357,13366,,,8,Expert,1,CHEMBL617599,,
1998,H,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,,B,,BAO_0000357,1558,,,8,Autocuration,1,CHEMBL617091,,
1999,H,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,,B,,BAO_0000219,12902,,,8,Expert,1,CHEMBL617092,485.0,
2000,H,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,B,,BAO_0000219,13706,,,8,Autocuration,1,CHEMBL617093,485.0,
2001,H,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,,F,,BAO_0000019,13706,,,8,Autocuration,1,CHEMBL617094,,
2002,H,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,F,,BAO_0000019,13706,,,8,Autocuration,1,CHEMBL617095,,
2003,H,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,F,,BAO_0000019,14251,,,8,Autocuration,1,CHEMBL617096,,
2004,H,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,F,,BAO_0000019,14251,,,8,Autocuration,1,CHEMBL617097,,
2005,H,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,F,,BAO_0000019,14251,,,8,Autocuration,1,CHEMBL617098,,
2006,H,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,,B,,BAO_0000357,13313,,,8,Autocuration,1,CHEMBL617301,,
2007,H,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,,B,,BAO_0000357,13313,,,8,Autocuration,1,CHEMBL617302,,
2008,H,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,,B,,BAO_0000357,13366,,,8,Autocuration,1,CHEMBL617303,,
2009,H,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,,B,,BAO_0000357,13051,,,8,Expert,1,CHEMBL617304,,
2010,H,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,,B,,BAO_0000219,12903,,,8,Expert,1,CHEMBL617305,449.0,
2011,D,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,Homo sapiens,B,,BAO_0000219,12469,,9606.0,9,Autocuration,1,CHEMBL617306,,
2012,H,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,,B,,BAO_0000357,5619,,,8,Autocuration,1,CHEMBL617307,,
2013,H,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,B,,BAO_0000019,13047,,9986.0,8,Autocuration,1,CHEMBL617308,,
2014,H,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,,B,,BAO_0000357,16633,,,8,Autocuration,1,CHEMBL617309,,
2015,H,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,B,,BAO_0000357,16633,,,8,Autocuration,1,CHEMBL617310,,
2016,H,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,B,,BAO_0000357,16633,,,8,Autocuration,1,CHEMBL617311,,
2017,H,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,16633,,,8,Autocuration,1,CHEMBL617312,,
2018,H,Affinity against 5-hydroxytryptamine 1D receptor alpha,,,B,,BAO_0000357,3269,,,8,Autocuration,1,CHEMBL617313,,
2019,H,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,,B,,BAO_0000357,12409,,,8,Expert,1,CHEMBL617314,,
2020,H,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,F,,BAO_0000019,13706,,,8,Autocuration,1,CHEMBL617315,,
2021,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,,B,,BAO_0000219,13706,,,8,Autocuration,1,CHEMBL617316,722.0,
2022,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,B,,BAO_0000219,13706,,,8,Autocuration,1,CHEMBL617317,722.0,
2023,H,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,B,,BAO_0000219,12903,,,8,Autocuration,1,CHEMBL617318,449.0,
2024,H,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,B,,BAO_0000019,13047,,,8,Autocuration,1,CHEMBL617319,,
2025,D,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,B,,BAO_0000357,13366,,,9,Expert,1,CHEMBL617320,,
2026,D,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,B,,BAO_0000357,13366,,,9,Expert,1,CHEMBL617321,,
2027,D,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,B,,BAO_0000357,13366,,,9,Expert,1,CHEMBL617322,,
2028,H,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,13366,,,8,Autocuration,1,CHEMBL616862,,
2029,H,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000357,13366,,,8,Autocuration,1,CHEMBL616863,,
2030,H,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,,B,,BAO_0000219,12469,,,8,Autocuration,1,CHEMBL616864,449.0,
2031,H,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,,B,,BAO_0000219,13706,,,8,Autocuration,1,CHEMBL616865,485.0,
2032,H,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,,B,,BAO_0000219,13706,,,8,Autocuration,1,CHEMBL616866,485.0,
2033,H,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,F,,BAO_0000019,13706,,,8,Autocuration,1,CHEMBL616867,,
2034,H,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,,B,,BAO_0000219,12902,,,8,Expert,1,CHEMBL616868,485.0,
2035,H,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,,B,,BAO_0000357,13051,,,8,Expert,1,CHEMBL616869,,
2036,H,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,B,,BAO_0000219,12903,,,8,Expert,1,CHEMBL616870,449.0,
2037,H,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,,F,,BAO_0000219,1558,,,8,Autocuration,1,CHEMBL616871,485.0,
2038,H,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,,F,,BAO_0000219,1558,,,8,Autocuration,1,CHEMBL616872,485.0,
2039,H,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,,F,,BAO_0000219,1558,,,8,Autocuration,1,CHEMBL616873,485.0,
2040,H,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,,F,,BAO_0000219,1558,,,8,Autocuration,1,CHEMBL616838,485.0,
2041,H,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,,B,,BAO_0000357,1558,,,8,Autocuration,1,CHEMBL616839,,
2042,H,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,B,,BAO_0000019,13047,,9986.0,8,Autocuration,1,CHEMBL616840,,
2043,H,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,,B,,BAO_0000357,13313,,,8,Autocuration,1,CHEMBL616841,,
2044,H,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,,B,,BAO_0000357,13313,,,8,Autocuration,1,CHEMBL616842,,
2045,H,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,,B,,BAO_0000357,12409,,,8,Expert,1,CHEMBL857976,,
2046,H,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,,B,,BAO_0000219,15250,,,8,Autocuration,1,CHEMBL616843,449.0,
2047,D,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,Homo sapiens,B,,BAO_0000357,1348,,9606.0,9,Expert,1,CHEMBL616844,,
2048,H,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,,B,,BAO_0000357,1348,,,8,Autocuration,1,CHEMBL616845,,
2049,D,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,Homo sapiens,B,,BAO_0000357,4234,,9606.0,9,Expert,1,CHEMBL616846,,
2050,H,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,,B,,BAO_0000357,16209,,,8,Autocuration,1,CHEMBL616847,,
2051,H,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,,B,,BAO_0000019,10444,,,8,Autocuration,1,CHEMBL616848,,
2052,H,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,,B,,BAO_0000357,3935,,,8,Autocuration,1,CHEMBL616849,,
2053,H,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,,B,,BAO_0000357,15818,,,8,Autocuration,1,CHEMBL872911,,
2054,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,,B,,BAO_0000019,17085,,,8,Autocuration,1,CHEMBL616850,,
2055,D,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,Homo sapiens,B,,BAO_0000219,12936,,9606.0,9,Expert,1,CHEMBL616699,449.0,
2056,H,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,,B,,BAO_0000357,6166,,,8,Autocuration,1,CHEMBL616700,,
2057,H,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL616701,449.0,
2058,H,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL616702,449.0,
2059,H,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL616703,449.0,
2060,H,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,,B,,BAO_0000357,13181,,,8,Autocuration,1,CHEMBL616704,,
2061,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,,B,,BAO_0000219,4199,,,8,Autocuration,1,CHEMBL616705,449.0,
2062,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,,B,,BAO_0000357,14875,,,8,Autocuration,1,CHEMBL616706,,
2063,H,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,,B,,BAO_0000219,15146,,,8,Autocuration,1,CHEMBL616707,449.0,
2064,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,,B,,BAO_0000357,5213,,,8,Autocuration,1,CHEMBL616708,,
2065,H,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,,B,,BAO_0000357,12146,,,8,Autocuration,1,CHEMBL616709,,
2066,H,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,,B,,BAO_0000219,13267,,,8,Autocuration,1,CHEMBL616710,449.0,
2067,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,,B,,BAO_0000219,14818,,,8,Autocuration,1,CHEMBL616711,449.0,
2068,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,,B,,BAO_0000219,4829,,,8,Autocuration,1,CHEMBL616712,449.0,
2069,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,,B,,BAO_0000357,4373,,,8,Autocuration,1,CHEMBL616713,,
2070,H,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,,B,,BAO_0000357,4373,,,8,Autocuration,1,CHEMBL616714,,
2071,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,,B,,BAO_0000357,14159,,,8,Autocuration,1,CHEMBL616715,,
2072,H,Binding affinity towards 5-hydroxytryptamine 1E receptor,,,B,,BAO_0000357,16633,,,8,Autocuration,1,CHEMBL616716,,
2073,H,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,,F,,BAO_0000019,17085,,,8,Autocuration,1,CHEMBL616717,,
2074,H,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,,F,,BAO_0000019,17085,,,8,Expert,1,CHEMBL616718,,
2075,H,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,,F,,BAO_0000019,16209,,,8,Autocuration,1,CHEMBL875905,,
2076,H,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,,F,,BAO_0000019,16209,,,8,Autocuration,1,CHEMBL616719,,
2077,H,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,,F,,BAO_0000019,17085,,,8,Expert,1,CHEMBL616720,,
2078,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,,B,,BAO_0000357,14159,,,8,Autocuration,1,CHEMBL616721,,
2079,H,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,,B,,BAO_0000219,15250,,,8,Autocuration,1,CHEMBL616722,449.0,
2080,H,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,,B,,BAO_0000357,3805,,,8,Autocuration,1,CHEMBL616723,,
2081,H,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,,B,,BAO_0000219,16190,,,8,Autocuration,1,CHEMBL616724,449.0,
2082,H,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,,B,,BAO_0000357,16190,,,8,Autocuration,1,CHEMBL616725,,
2083,H,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,,B,,BAO_0000357,16209,,,8,Autocuration,1,CHEMBL616726,,
2084,H,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,,B,,BAO_0000357,16209,,,8,Autocuration,1,CHEMBL616727,,
2085,H,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,,B,,BAO_0000357,16209,,,8,Autocuration,1,CHEMBL616728,,
2086,H,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,,B,,BAO_0000357,6866,,,8,Autocuration,1,CHEMBL616729,,
2087,H,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,,B,,BAO_0000019,17085,,,8,Expert,1,CHEMBL616730,,
2088,H,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,,B,,BAO_0000357,16312,,,8,Autocuration,1,CHEMBL617125,,
2089,H,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,,B,,BAO_0000357,6166,,,8,Autocuration,1,CHEMBL857977,,
2090,H,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL617126,449.0,
2091,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,,B,,BAO_0000219,4199,,,8,Autocuration,1,CHEMBL617127,449.0,
2092,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,,B,,BAO_0000357,14875,,,8,Autocuration,1,CHEMBL617128,,
2093,H,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,,B,,BAO_0000219,15146,,,8,Autocuration,1,CHEMBL617129,449.0,
2094,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,,B,,BAO_0000357,5213,,,8,Autocuration,1,CHEMBL617130,,
2095,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,,B,,BAO_0000219,14818,,,8,Autocuration,1,CHEMBL617131,449.0,
2096,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,B,,BAO_0000219,4829,,,8,Autocuration,1,CHEMBL617132,449.0,
2097,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,B,,BAO_0000219,4829,,,8,Autocuration,1,CHEMBL617133,449.0,
2098,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,,B,,BAO_0000357,4373,,,8,Autocuration,1,CHEMBL617134,,
2099,H,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,,B,,BAO_0000357,4373,,,8,Autocuration,1,CHEMBL617135,,
2100,H,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,,B,,BAO_0000357,5014,,,8,Autocuration,1,CHEMBL617136,,
2101,H,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,,B,,BAO_0000019,11662,,,4,Autocuration,1,CHEMBL617137,,
2102,H,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,B,,BAO_0000019,11662,,,4,Autocuration,1,CHEMBL617138,,
2103,H,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,B,,BAO_0000019,11662,,,4,Autocuration,1,CHEMBL617139,,
2104,H,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000019,14093,,,8,Autocuration,1,CHEMBL617140,,
2105,H,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,,F,,BAO_0000218,11200,In vivo,,4,Autocuration,1,CHEMBL617141,,
2106,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,F,,BAO_0000019,11200,,,4,Autocuration,1,CHEMBL858112,,
2107,H,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,,B,,BAO_0000019,12352,,,8,Intermediate,1,CHEMBL617142,,
2108,U,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,Bos taurus,B,,BAO_0000019,13657,,9913.0,0,Autocuration,1,CHEMBL617143,,
2109,U,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,Bos taurus,B,,BAO_0000019,14331,,9913.0,0,Autocuration,1,CHEMBL617144,,
2110,U,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,Bos taurus,B,,BAO_0000019,14331,,9913.0,0,Autocuration,1,CHEMBL617145,,
2111,U,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,,B,,BAO_0000019,14331,,,0,Autocuration,1,CHEMBL617146,,
2112,H,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,Cavia porcellus,B,,BAO_0000019,12685,,10141.0,4,Autocuration,1,CHEMBL617147,,
2113,H,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,Cavia porcellus,B,,BAO_0000019,14389,,10141.0,4,Autocuration,1,CHEMBL617148,,
2114,H,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,Cavia porcellus,B,,BAO_0000019,14386,,10141.0,4,Autocuration,1,CHEMBL617149,,
2115,H,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,,B,,BAO_0000224,5732,,,4,Autocuration,1,CHEMBL617150,,
2116,H,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,B,,BAO_0000224,16293,,,4,Autocuration,1,CHEMBL617151,,
2117,H,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,2078,,,4,Autocuration,1,CHEMBL617201,,
2118,H,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,B,,BAO_0000357,5486,,,8,Autocuration,1,CHEMBL617202,,
2119,H,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,B,,BAO_0000218,11820,In vivo,,4,Autocuration,1,CHEMBL617203,,
2120,H,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,B,,BAO_0000019,10297,,,4,Autocuration,1,CHEMBL617204,,
2121,H,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,,B,,BAO_0000224,13704,,,4,Autocuration,1,CHEMBL617205,,
2122,D,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,Mus musculus,B,,BAO_0000019,10297,,10090.0,5,Autocuration,1,CHEMBL617206,,
2123,H,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,B,,BAO_0000218,11820,In vivo,,4,Autocuration,1,CHEMBL617207,,
2124,D,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,Mus musculus,B,,BAO_0000019,10297,,10090.0,5,Autocuration,1,CHEMBL617208,,
2125,H,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,11555,,,4,Autocuration,1,CHEMBL617209,,
2126,H,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,,B,,BAO_0000224,11555,,,4,Autocuration,1,CHEMBL617210,,
2127,H,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,,B,,BAO_0000224,11555,,,4,Autocuration,1,CHEMBL617211,,
2128,D,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,Mus musculus,B,,BAO_0000019,10297,,10090.0,5,Autocuration,1,CHEMBL617212,,
2129,H,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,Sus scrofa,B,,BAO_0000224,16688,,9823.0,4,Autocuration,1,CHEMBL617213,,
2130,H,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,Sus scrofa,B,,BAO_0000224,16688,,9823.0,4,Autocuration,1,CHEMBL617214,,
2131,U,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,B,,BAO_0000221,5333,,,0,Autocuration,1,CHEMBL617215,,
2132,U,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,B,,BAO_0000221,4437,,,0,Autocuration,1,CHEMBL617216,,
2133,H,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,Sus scrofa,B,,BAO_0000357,5033,,9823.0,8,Autocuration,1,CHEMBL617217,,
2134,H,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000019,15267,,,4,Autocuration,1,CHEMBL617218,,
2135,H,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000019,15267,,,4,Autocuration,1,CHEMBL872913,,
2136,H,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,,B,,BAO_0000019,11820,,,4,Autocuration,1,CHEMBL617219,,
2137,H,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,9069,,,4,Autocuration,1,CHEMBL873482,,
2138,D,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,Rattus norvegicus,B,,BAO_0000019,9162,,10116.0,5,Autocuration,1,CHEMBL617220,,
2139,H,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,,B,,BAO_0000019,9162,,,4,Autocuration,1,CHEMBL617221,,
2140,H,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,,B,,BAO_0000019,9162,,,4,Autocuration,1,CHEMBL617222,,
2141,H,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,,F,,BAO_0000019,10428,,,4,Autocuration,1,CHEMBL875906,,
2142,H,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,,B,,BAO_0000019,9628,,,4,Autocuration,1,CHEMBL617223,,
2143,H,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,12704,,,4,Autocuration,1,CHEMBL617224,,
2144,D,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,Rattus norvegicus,B,,BAO_0000224,15453,,10116.0,5,Autocuration,1,CHEMBL617225,,
2145,H,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,,B,,BAO_0000224,188,,,4,Autocuration,1,CHEMBL617226,,
2146,H,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,,B,,BAO_0000224,10349,,,4,Autocuration,1,CHEMBL617227,,
2147,H,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,,B,,BAO_0000224,10349,,,4,Autocuration,1,CHEMBL617228,,
2148,H,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,B,,BAO_0000224,8868,,,4,Autocuration,1,CHEMBL617229,,
2149,H,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,B,,BAO_0000224,10025,,,4,Autocuration,1,CHEMBL617230,,
2150,H,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,B,,BAO_0000224,10025,,,4,Autocuration,1,CHEMBL617231,,
2151,H,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,,B,,BAO_0000224,11702,,,4,Autocuration,1,CHEMBL617232,,
2152,H,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,11702,,,4,Autocuration,1,CHEMBL617233,,
2153,H,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,,B,,BAO_0000224,11702,,,4,Autocuration,1,CHEMBL617234,,
2154,H,Compound was tested for the inhibition of quipazine induced head twitches in rats,,,F,,BAO_0000019,11702,,,4,Autocuration,1,CHEMBL617235,,
2155,H,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,,F,,BAO_0000019,11702,,,4,Autocuration,1,CHEMBL617236,,
2156,H,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,,B,,BAO_0000221,10085,,,4,Autocuration,1,CHEMBL617237,,10000000.0
2157,H,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,,B,,BAO_0000221,10085,,,4,Autocuration,1,CHEMBL617238,,10000000.0
2158,D,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,Rattus norvegicus,B,,BAO_0000221,9630,,10116.0,5,Autocuration,1,CHEMBL617239,,955.0
2159,H,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,,B,,BAO_0000019,11070,,,4,Autocuration,1,CHEMBL617240,,
2160,H,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,B,,BAO_0000249,9841,,,4,Autocuration,1,CHEMBL617241,,
2161,H,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,B,,BAO_0000249,9841,,,4,Autocuration,1,CHEMBL875907,,
2162,H,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,,B,,BAO_0000019,13291,,,4,Autocuration,1,CHEMBL617242,,
2163,H,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,,F,,BAO_0000019,10590,,,4,Autocuration,1,CHEMBL617152,,
2164,D,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,Rattus norvegicus,B,,BAO_0000221,9064,,10116.0,5,Autocuration,1,CHEMBL617153,,955.0
2165,D,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,Rattus norvegicus,B,,BAO_0000249,12268,,10116.0,5,Autocuration,1,CHEMBL617154,,
2166,H,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,,B,,BAO_0000221,13508,,,4,Autocuration,1,CHEMBL617155,,955.0
2167,H,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,F,,BAO_0000019,11279,,,4,Autocuration,1,CHEMBL617156,,
2168,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,,F,,BAO_0000019,11200,,,4,Autocuration,1,CHEMBL617157,,
2169,H,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,F,,BAO_0000019,11200,,,4,Autocuration,1,CHEMBL617158,,
2170,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,F,,BAO_0000019,11200,,,4,Autocuration,1,CHEMBL617159,,
2171,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,F,,BAO_0000019,11200,,,4,Autocuration,1,CHEMBL617160,,
2172,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,F,,BAO_0000019,11200,,,4,Autocuration,1,CHEMBL858113,,
2173,H,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,,B,,BAO_0000220,9231,,,4,Autocuration,1,CHEMBL617247,,955.0
2174,H,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,B,,BAO_0000019,9737,,,4,Autocuration,1,CHEMBL617248,,
2175,H,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,B,,BAO_0000249,9737,,,4,Autocuration,1,CHEMBL617249,,955.0
2176,H,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,,B,,BAO_0000019,9737,,,4,Autocuration,1,CHEMBL617250,,
2177,H,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,B,,BAO_0000019,9737,,,4,Autocuration,1,CHEMBL617251,,
2178,D,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,B,,BAO_0000019,11828,,10116.0,5,Autocuration,1,CHEMBL617252,,
2179,H,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,,B,,BAO_0000019,12253,,,4,Autocuration,1,CHEMBL617006,,
2180,H,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,,B,,BAO_0000019,12253,,,4,Autocuration,1,CHEMBL617007,,
2181,H,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,,F,,BAO_0000019,11279,,,4,Autocuration,1,CHEMBL617008,,
2182,H,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,,B,,BAO_0000019,11866,,,4,Autocuration,1,CHEMBL617009,,
2183,D,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,Rattus norvegicus,B,,BAO_0000224,14424,,10116.0,5,Autocuration,1,CHEMBL617010,,
2184,D,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,B,,BAO_0000019,15180,,10116.0,5,Autocuration,1,CHEMBL857978,,
2185,D,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,B,,BAO_0000019,15180,,10116.0,5,Autocuration,1,CHEMBL617011,,
2186,D,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,Rattus norvegicus,B,,BAO_0000019,9786,,10116.0,5,Autocuration,1,CHEMBL617012,,
2187,H,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,,B,,BAO_0000224,12132,,,4,Autocuration,1,CHEMBL617013,,
2188,H,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,,B,,BAO_0000249,5486,,,4,Autocuration,1,CHEMBL617014,,
2189,H,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000019,15316,,,4,Autocuration,1,CHEMBL617015,,
2190,H,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,,B,,BAO_0000019,16429,,,4,Autocuration,1,CHEMBL617016,,
2191,H,pKi value for 5-hydroxytryptamine 2 receptor binding site,,,B,,BAO_0000224,14617,,,4,Autocuration,1,CHEMBL617017,,
2192,H,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,,B,,BAO_0000221,11351,,,4,Autocuration,1,CHEMBL617018,,955.0
2193,H,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,F,,BAO_0000019,11279,,,4,Autocuration,1,CHEMBL617019,,
2194,H,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,B,,BAO_0000019,9523,,,4,Autocuration,1,CHEMBL617020,,
2195,H,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,B,,BAO_0000019,9523,,,4,Autocuration,1,CHEMBL617021,,
2196,H,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,B,,BAO_0000019,9523,,,4,Autocuration,1,CHEMBL617022,,
2197,H,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,B,,BAO_0000019,9523,,,4,Autocuration,1,CHEMBL617023,,
2198,H,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,B,,BAO_0000019,9523,,,4,Autocuration,1,CHEMBL617024,,
2199,H,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,B,,BAO_0000019,9523,,,4,Autocuration,1,CHEMBL617025,,
2200,H,Hill coefficient of compound was determined,,,B,,BAO_0000224,9523,,,4,Autocuration,1,CHEMBL617026,,
2201,U,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000019,4771,,,0,Autocuration,1,CHEMBL617027,,
2202,D,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,Rattus norvegicus,B,,BAO_0000019,5033,,10116.0,5,Autocuration,1,CHEMBL617028,,
2203,H,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,,B,,BAO_0000019,10845,,,8,Expert,1,CHEMBL617029,,
2204,H,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,,B,,BAO_0000019,10845,,,8,Expert,1,CHEMBL875908,,
2205,H,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,,B,,BAO_0000357,16288,,,8,Autocuration,1,CHEMBL617030,,
2206,H,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,,B,,BAO_0000019,16288,,,8,Autocuration,1,CHEMBL617031,,
2207,H,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,,B,,BAO_0000019,16190,,,8,Autocuration,1,CHEMBL617032,,
2208,D,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,Rattus norvegicus,B,,BAO_0000224,12463,,10116.0,5,Autocuration,1,CHEMBL617033,,
2209,H,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,,B,,BAO_0000224,9699,,,4,Autocuration,1,CHEMBL617034,,
2210,H,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,,B,,BAO_0000224,9699,,,4,Autocuration,1,CHEMBL617035,,
2211,H,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,B,,BAO_0000019,11662,,,4,Autocuration,1,CHEMBL617036,,
2212,H,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,1205,,,4,Autocuration,1,CHEMBL617037,,
2213,U,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,,B,,BAO_0000219,11376,,,0,Autocuration,1,CHEMBL617038,,
2214,H,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,,B,,BAO_0000219,11376,,,4,Autocuration,1,CHEMBL617039,,
2215,H,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,4639,,,4,Autocuration,1,CHEMBL617161,,
2216,H,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,2222,,,4,Autocuration,1,CHEMBL617162,,
2217,H,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,1558,,,4,Autocuration,1,CHEMBL617163,,
2218,H,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,1089,,,4,Autocuration,1,CHEMBL617164,,
2219,H,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,,B,,BAO_0000249,386,,,4,Autocuration,1,CHEMBL617165,,
2220,H,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,,B,,BAO_0000224,2474,,,4,Autocuration,1,CHEMBL617166,,
2221,H,Binding affinity towards 5-HT2 receptor,,,B,,BAO_0000224,17066,,,4,Autocuration,1,CHEMBL617167,,
2222,H,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,959,,,4,Autocuration,1,CHEMBL872912,,
2223,H,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,,B,,BAO_0000224,6398,,,4,Autocuration,1,CHEMBL617168,,
2224,H,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,,B,,BAO_0000224,11889,,,4,Autocuration,1,CHEMBL617169,,
2225,H,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,4221,,,4,Autocuration,1,CHEMBL617170,,
2226,H,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,,B,,BAO_0000224,11026,,,4,Autocuration,1,CHEMBL617171,,
2227,H,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,,B,,BAO_0000224,11866,,,4,Autocuration,1,CHEMBL617172,,
2228,H,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,4221,,,4,Autocuration,1,CHEMBL617173,,
2229,U,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000019,13950,,,0,Autocuration,1,CHEMBL617174,,
2230,H,5-hydroxytryptamine 2 receptor binding affinity,,,B,,BAO_0000224,1263,,,4,Autocuration,1,CHEMBL617175,,
2231,H,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,,B,,BAO_0000357,13291,,,8,Autocuration,1,CHEMBL617176,,
2232,H,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,,B,,BAO_0000357,10812,,,8,Autocuration,1,CHEMBL617177,,
2233,H,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,B,,BAO_0000224,13020,,,4,Autocuration,1,CHEMBL617178,,
2234,H,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,,B,,BAO_0000224,13021,,,4,Autocuration,1,CHEMBL617179,,
2235,H,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,B,,BAO_0000224,13020,,,4,Autocuration,1,CHEMBL617180,,
2236,H,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,,B,,BAO_0000357,14532,,,8,Autocuration,1,CHEMBL617181,,
2237,H,Binding affinity against 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000357,13944,,,8,Autocuration,1,CHEMBL617182,,
2238,H,Binding affinity against 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000357,14331,,,8,Autocuration,1,CHEMBL617183,,
2239,H,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,B,,BAO_0000357,14118,,,8,Autocuration,1,CHEMBL617184,,
2240,H,Binding affinity against serotonergic 5-HT2 receptor,,,B,,BAO_0000357,13033,,,8,Autocuration,1,CHEMBL617185,,
2241,H,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,,B,,BAO_0000357,10321,,,8,Autocuration,1,CHEMBL617186,,
2242,H,Compound was evaluated for the binding affinity at 5- HT2 receptor,,,B,,BAO_0000357,12918,,,8,Autocuration,1,CHEMBL617187,,
2243,H,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000357,15120,,,8,Autocuration,1,CHEMBL617188,,
2244,H,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000218,2613,,,8,Autocuration,1,CHEMBL617189,,
2245,D,Inhibitory activity against cloned human 5-HT2 receptor,,Homo sapiens,B,,BAO_0000224,13378,,9606.0,5,Autocuration,1,CHEMBL617190,,
2246,D,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,Homo sapiens,B,,BAO_0000219,2331,,9606.0,5,Autocuration,1,CHEMBL617191,449.0,
2247,D,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,Homo sapiens,B,,BAO_0000219,2331,,9606.0,5,Autocuration,1,CHEMBL617192,449.0,
2248,D,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,Homo sapiens,B,,BAO_0000219,2331,,9606.0,5,Autocuration,1,CHEMBL617193,449.0,
2249,D,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,Homo sapiens,B,,BAO_0000219,2331,,9606.0,5,Autocuration,1,CHEMBL617194,449.0,
2250,H,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,4170,,,4,Autocuration,1,CHEMBL617195,,
2251,H,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,B,,BAO_0000224,15453,,,4,Autocuration,1,CHEMBL881830,,
2252,H,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000357,1479,,,8,Autocuration,1,CHEMBL617196,,
2253,H,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,,B,,BAO_0000224,11139,,,4,Autocuration,1,CHEMBL617197,,
2254,H,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,,B,,BAO_0000357,13969,,,8,Expert,1,CHEMBL617198,,
2255,H,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,13392,,,8,Expert,1,CHEMBL873476,,
2256,H,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,,B,,BAO_0000019,14430,,,8,Expert,1,CHEMBL617199,,
2257,H,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,Cavia porcellus,B,,BAO_0000357,13181,,10141.0,8,Autocuration,1,CHEMBL617200,,
2258,H,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,B,,BAO_0000357,17200,,,8,Autocuration,1,CHEMBL617484,,
2259,H,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,B,,BAO_0000357,17200,,,8,Autocuration,1,CHEMBL617485,,
2260,H,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,B,,BAO_0000357,17200,,,8,Autocuration,1,CHEMBL617486,,
2261,H,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,,B,,BAO_0000357,13463,,,8,Autocuration,1,CHEMBL858022,,
2262,H,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,B,,BAO_0000219,6347,,,8,Autocuration,1,CHEMBL617049,449.0,
2263,D,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,Homo sapiens,F,,BAO_0000219,6857,,9606.0,9,Expert,1,CHEMBL617050,449.0,
2264,H,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,F,,BAO_0000219,4176,,,8,Autocuration,1,CHEMBL617051,,
2265,H,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,,F,,BAO_0000219,4176,,,8,Autocuration,1,CHEMBL617052,,
2266,H,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,F,,BAO_0000219,4176,,,8,Autocuration,1,CHEMBL617053,,
2267,H,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,,B,,BAO_0000219,6347,,,8,Autocuration,1,CHEMBL617054,449.0,
2268,H,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,,B,,BAO_0000219,6347,,,8,Autocuration,1,CHEMBL617055,449.0,
2269,H,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,,B,,BAO_0000357,15331,,,8,Autocuration,1,CHEMBL882924,,
2270,D,Inhibition of human 5-hydroxytryptamine 2A receptor,,Homo sapiens,B,,BAO_0000357,16146,,9606.0,9,Expert,1,CHEMBL617056,,
2271,H,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,B,,BAO_0000219,15250,,,8,Autocuration,1,CHEMBL617057,449.0,
2272,H,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,,B,,BAO_0000219,13631,,,8,Expert,1,CHEMBL617058,,
2273,H,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,,B,,BAO_0000357,3805,,,8,Autocuration,1,CHEMBL617059,,
2274,H,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,,B,,BAO_0000219,4011,,,8,Autocuration,1,CHEMBL617060,449.0,
2275,H,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,,B,,BAO_0000219,4012,,,8,Expert,1,CHEMBL617061,449.0,
2276,H,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,,B,,BAO_0000219,6366,,,8,Expert,1,CHEMBL617062,307.0,
2277,H,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,B,,BAO_0000219,15949,,,8,Expert,1,CHEMBL617063,449.0,
2278,H,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,,F,,BAO_0000019,14093,,,8,Autocuration,1,CHEMBL617064,,
2279,H,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,F,,BAO_0000019,13481,,,8,Autocuration,1,CHEMBL617065,,
2280,H,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,B,,BAO_0000219,6347,,,8,Autocuration,1,CHEMBL617066,449.0,
2281,H,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,,B,,BAO_0000219,6347,,,8,Autocuration,1,CHEMBL617067,449.0,
2282,H,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,,F,,BAO_0000019,14093,,,8,Autocuration,1,CHEMBL617068,,
2283,H,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,,F,,BAO_0000019,14093,,,8,Autocuration,1,CHEMBL617069,,
2284,H,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,F,,BAO_0000019,13481,,,8,Autocuration,1,CHEMBL617070,,
2285,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,,B,,BAO_0000357,14442,,,8,Autocuration,1,CHEMBL617071,,
2286,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,B,,BAO_0000357,14442,,,8,Autocuration,1,CHEMBL872915,,
2287,H,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,,B,,BAO_0000357,14755,,,8,Autocuration,1,CHEMBL617072,,
2288,H,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,,B,,BAO_0000357,16441,,,8,Autocuration,1,CHEMBL617073,,
2289,H,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,,B,,BAO_0000357,14744,,,8,Autocuration,1,CHEMBL617074,,
2290,H,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,B,,BAO_0000219,16659,,,8,Expert,1,CHEMBL617075,449.0,
2291,H,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,3307,,,8,Autocuration,1,CHEMBL617076,,
2292,D,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,Homo sapiens,B,,BAO_0000019,6857,,9606.0,9,Expert,1,CHEMBL617077,,
2293,H,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,,B,,BAO_0000357,5635,,,8,Expert,1,CHEMBL617078,,
2294,D,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,Homo sapiens,B,,BAO_0000357,4234,,9606.0,9,Expert,1,CHEMBL617079,,
2295,H,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,B,,BAO_0000357,15527,,,8,Autocuration,1,CHEMBL617080,,
2296,H,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,,B,,BAO_0000219,6588,,,8,Expert,1,CHEMBL617081,449.0,
2297,H,Binding affinity towards human 5-HT2A receptor in BEK cells,,,B,,BAO_0000219,13631,,,8,Expert,1,CHEMBL617082,,
2298,H,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,17723,,,8,Autocuration,1,CHEMBL617083,,
2299,H,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,B,,BAO_0000357,14770,,,8,Autocuration,1,CHEMBL617084,,
2300,D,Binding affinity for human 5-hydroxytryptamine 2A receptor,,Homo sapiens,B,,BAO_0000357,16293,,9606.0,9,Expert,1,CHEMBL617085,,
2301,H,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,B,,BAO_0000357,16209,,,8,Autocuration,1,CHEMBL617086,,
2302,H,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,,B,,BAO_0000219,12469,,,8,Autocuration,1,CHEMBL617087,,
2303,H,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,15363,,,8,Autocuration,1,CHEMBL617088,,
2304,H,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,15363,,,8,Autocuration,1,CHEMBL617089,,
2305,H,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,,B,,BAO_0000019,16441,,,8,Expert,1,CHEMBL617090,,
2306,H,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,,B,,BAO_0000357,8,,,8,Autocuration,1,CHEMBL617513,,
2307,H,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,,B,,BAO_0000219,4176,,,8,Autocuration,1,CHEMBL617514,722.0,
2308,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000019,17085,,,8,Autocuration,1,CHEMBL617515,,
2309,H,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,B,,BAO_0000357,17200,,,8,Autocuration,1,CHEMBL617516,,
2310,D,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,Homo sapiens,B,,BAO_0000357,17200,,9606.0,9,Expert,1,CHEMBL617517,,
2311,D,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,Homo sapiens,B,,BAO_0000219,4013,,9606.0,9,Expert,1,CHEMBL617518,449.0,
2312,H,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,5088,,,8,Autocuration,1,CHEMBL617519,,
2313,D,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,Homo sapiens,B,,BAO_0000357,5088,,9606.0,9,Expert,1,CHEMBL617520,,
2314,H,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,,B,,BAO_0000357,5088,,,8,Autocuration,1,CHEMBL617521,,
2315,D,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,Homo sapiens,B,,BAO_0000357,5088,,9606.0,9,Expert,1,CHEMBL617522,,
2316,H,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,,B,,BAO_0000357,5088,,,8,Autocuration,1,CHEMBL617523,,
2317,H,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,B,,BAO_0000357,5088,,,8,Autocuration,1,CHEMBL617524,,
2318,H,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,,B,,BAO_0000019,9786,,,4,Autocuration,1,CHEMBL617525,,
2319,D,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,Rattus norvegicus,B,,BAO_0000019,9205,,10116.0,5,Autocuration,1,CHEMBL617526,,
2320,H,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,,B,,BAO_0000224,11257,,,4,Autocuration,1,CHEMBL617527,,
2321,H,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,B,,BAO_0000019,9362,,,4,Autocuration,1,CHEMBL617528,,
2322,H,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,B,,BAO_0000019,9362,,,4,Autocuration,1,CHEMBL617529,,
2323,H,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,,B,,BAO_0000224,10590,,,4,Autocuration,1,CHEMBL617530,,
2324,H,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,B,,BAO_0000019,10468,,,4,Autocuration,1,CHEMBL617531,,
2325,H,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,,B,,BAO_0000019,13050,,,4,Autocuration,1,CHEMBL617532,,
2326,H,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,,B,,BAO_0000019,11624,,,4,Autocuration,1,CHEMBL617533,,
2327,H,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,B,,BAO_0000019,10468,,,4,Autocuration,1,CHEMBL617534,,
2328,H,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,B,,BAO_0000224,10330,,,4,Autocuration,1,CHEMBL617535,,
2329,H,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,B,,BAO_0000224,10062,,,4,Autocuration,1,CHEMBL617536,,
2330,H,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,11642,,,4,Autocuration,1,CHEMBL617537,,
2331,H,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,10062,,,4,Autocuration,1,CHEMBL617538,,
2332,H,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,B,,BAO_0000219,13427,In vitro,,4,Autocuration,1,CHEMBL617539,,
2333,D,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,B,,BAO_0000224,12280,,10116.0,5,Autocuration,1,CHEMBL617540,,
2334,D,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,Rattus norvegicus,B,,BAO_0000224,4101,,10116.0,5,Autocuration,1,CHEMBL617541,,
2335,H,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,10062,,,4,Autocuration,1,CHEMBL617542,,
2336,H,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,,B,,BAO_0000224,11147,,,4,Autocuration,1,CHEMBL617543,,
2337,D,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,Rattus norvegicus,B,,BAO_0000219,2395,,10116.0,5,Autocuration,1,CHEMBL617544,485.0,
2338,D,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,Rattus norvegicus,B,,BAO_0000219,2395,,10116.0,5,Autocuration,1,CHEMBL617545,485.0,
2339,D,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,Rattus norvegicus,B,,BAO_0000019,9098,,10116.0,5,Autocuration,1,CHEMBL617413,,
2340,H,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,,B,,BAO_0000019,9098,,,4,Autocuration,1,CHEMBL617414,,
2341,D,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,Rattus norvegicus,B,,BAO_0000019,9098,,10116.0,5,Autocuration,1,CHEMBL617415,,
2342,H,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,9443,,,4,Autocuration,1,CHEMBL617416,,
2343,H,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,B,,BAO_0000224,9443,,,4,Autocuration,1,CHEMBL617417,,
2344,H,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,,B,,BAO_0000019,9699,,,4,Autocuration,1,CHEMBL617418,,
2345,H,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,,B,,BAO_0000019,9699,,,4,Autocuration,1,CHEMBL617419,,
2346,H,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,B,,BAO_0000224,9098,,,4,Autocuration,1,CHEMBL617420,,
2347,D,Affinity for 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,B,,BAO_0000224,3070,,10116.0,5,Autocuration,1,CHEMBL617421,,
2348,H,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,,B,,BAO_0000224,9547,,,4,Autocuration,1,CHEMBL617422,,
2349,H,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,,B,,BAO_0000019,10444,,,4,Autocuration,1,CHEMBL617423,,
2350,H,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,,B,,BAO_0000019,14617,,,4,Autocuration,1,CHEMBL617424,,
2351,H,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,,B,,BAO_0000019,14617,,,4,Autocuration,1,CHEMBL617425,,
2352,H,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,,B,,BAO_0000224,11130,,,4,Autocuration,1,CHEMBL617426,,
2353,H,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,,B,,BAO_0000218,11130,In vivo,,4,Autocuration,1,CHEMBL617427,,
2354,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,,B,,BAO_0000221,14542,,,4,Autocuration,1,CHEMBL617428,,955.0
2355,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,,B,,BAO_0000224,2797,,,4,Autocuration,1,CHEMBL617429,,
2356,H,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,B,,BAO_0000019,11332,,,4,Autocuration,1,CHEMBL617430,,
2357,H,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,B,,BAO_0000019,11332,,,4,Autocuration,1,CHEMBL617431,,
2358,H,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,,B,,BAO_0000019,10752,,,4,Autocuration,1,CHEMBL617432,,1870.0
2359,H,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,1185,,,4,Autocuration,1,CHEMBL617433,,
2360,H,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,1185,,,4,Autocuration,1,CHEMBL617434,,
2361,D,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,Rattus norvegicus,B,,BAO_0000224,11624,,10116.0,5,Autocuration,1,CHEMBL617435,,
2362,H,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,,B,,BAO_0000019,1344,,,4,Autocuration,1,CHEMBL617436,,
2363,D,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,Rattus norvegicus,B,,BAO_0000019,15453,,10116.0,5,Autocuration,1,CHEMBL617437,,2435.0
2364,H,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,B,,BAO_0000019,11662,,,4,Autocuration,1,CHEMBL617438,,
2365,H,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,B,,BAO_0000019,11662,,,4,Autocuration,1,CHEMBL617439,,
2366,H,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,10796,,,4,Autocuration,1,CHEMBL617440,,
2367,H,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,9069,,,4,Autocuration,1,CHEMBL617441,,
2368,D,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,Rattus norvegicus,B,,BAO_0000019,8814,,10116.0,5,Autocuration,1,CHEMBL872918,,
2369,D,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,Rattus norvegicus,B,,BAO_0000019,8908,,10116.0,5,Autocuration,1,CHEMBL617442,,
2370,H,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,B,,BAO_0000019,9098,,,4,Autocuration,1,CHEMBL617443,,
2371,H,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,,B,,BAO_0000019,9098,,,4,Autocuration,1,CHEMBL617444,,
2372,H,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,B,,BAO_0000019,9098,,,4,Autocuration,1,CHEMBL617445,,
2373,H,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,,B,,BAO_0000019,9098,,,4,Autocuration,1,CHEMBL617446,,
2374,H,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,,B,,BAO_0000249,9098,,,4,Autocuration,1,CHEMBL617447,,
2375,H,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,,B,,BAO_0000019,9098,,,4,Autocuration,1,CHEMBL617448,,
2376,H,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,,B,,BAO_0000019,9098,,,4,Autocuration,1,CHEMBL617449,,
2377,H,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,,B,,BAO_0000019,9161,,,4,Autocuration,1,CHEMBL617450,,
2378,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,,B,,BAO_0000019,9161,,,4,Autocuration,1,CHEMBL617451,,
2379,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,,B,,BAO_0000019,9161,,,4,Autocuration,1,CHEMBL617452,,
2380,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,,B,,BAO_0000019,9161,,,4,Autocuration,1,CHEMBL617453,,
2381,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,,B,,BAO_0000019,9161,,,4,Autocuration,1,CHEMBL617660,,
2382,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,,B,,BAO_0000019,9161,,,4,Autocuration,1,CHEMBL617661,,
2383,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,,B,,BAO_0000019,9161,,,4,Autocuration,1,CHEMBL617662,,
2384,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,,B,,BAO_0000019,9161,,,4,Autocuration,1,CHEMBL872919,,
2385,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,,B,,BAO_0000019,9161,,,4,Autocuration,1,CHEMBL617663,,
2386,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,,B,,BAO_0000019,9161,,,4,Autocuration,1,CHEMBL617664,,
2387,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,,B,,BAO_0000019,9161,,,4,Autocuration,1,CHEMBL617665,,
2388,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,,B,,BAO_0000019,9161,,,4,Autocuration,1,CHEMBL617666,,
2389,H,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,,B,,BAO_0000019,12094,,,4,Autocuration,1,CHEMBL617667,,
2390,H,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,,B,,BAO_0000249,12018,,,4,Autocuration,1,CHEMBL617668,,
2391,H,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,,B,,BAO_0000249,10394,,,4,Autocuration,1,CHEMBL617669,,
2392,H,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,15260,,,4,Autocuration,1,CHEMBL617670,,
2393,D,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,B,,BAO_0000224,11624,,10116.0,5,Autocuration,1,CHEMBL617671,,
2394,H,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,13654,,,4,Autocuration,1,CHEMBL617672,,
2395,H,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,,B,,BAO_0000019,9541,,,4,Autocuration,1,CHEMBL617673,,
2396,H,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,,B,,BAO_0000224,11933,,,4,Autocuration,1,CHEMBL617674,,
2397,H,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,,B,,BAO_0000019,15538,,,4,Autocuration,1,CHEMBL617675,,
2398,H,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,,B,,BAO_0000019,15538,,,4,Autocuration,1,CHEMBL617676,,
2399,H,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,,B,,BAO_0000019,15538,,,4,Autocuration,1,CHEMBL617677,,
2400,D,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000019,8841,,,5,Autocuration,1,CHEMBL617678,,
2401,H,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,,B,,BAO_0000224,1455,,,4,Autocuration,1,CHEMBL617679,,
2402,H,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,,B,,BAO_0000224,1455,,,4,Autocuration,1,CHEMBL617680,,
2403,H,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,,B,,BAO_0000019,11752,,,4,Autocuration,1,CHEMBL617681,,
2404,H,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,,B,,BAO_0000221,11642,,,4,Autocuration,1,CHEMBL617682,,955.0
2405,H,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,,B,,BAO_0000224,12092,,,4,Autocuration,1,CHEMBL617683,,
2406,H,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,,B,,BAO_0000224,3967,,,4,Autocuration,1,CHEMBL617684,,
2407,D,Binding affinity towards 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,B,,BAO_0000224,12771,,10116.0,5,Autocuration,1,CHEMBL617685,,
2408,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,,B,,BAO_0000019,11642,,,4,Autocuration,1,CHEMBL617686,,
2409,H,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,,B,,BAO_0000224,11628,,,4,Autocuration,1,CHEMBL617687,,
2410,H,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,B,,BAO_0000224,13654,,,4,Autocuration,1,CHEMBL617688,,
2411,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,F,,BAO_0000019,11200,,,4,Autocuration,1,CHEMBL617689,,
2412,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,F,,BAO_0000019,11200,,,4,Autocuration,1,CHEMBL617690,,
2413,H,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,F,,BAO_0000218,11200,In vivo,,4,Autocuration,1,CHEMBL617691,,
2414,H,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,F,,BAO_0000218,11200,In vivo,,4,Autocuration,1,CHEMBL617692,,
2415,H,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,F,,BAO_0000218,11200,In vivo,,4,Autocuration,1,CHEMBL617693,,
2416,H,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,F,,BAO_0000218,11200,In vivo,,4,Autocuration,1,CHEMBL617694,,
2417,H,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,,B,,BAO_0000221,15436,,,8,Expert,1,CHEMBL857985,,955.0
2418,D,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,Rattus norvegicus,B,,BAO_0000019,15436,,10116.0,9,Expert,1,CHEMBL617695,,
2419,H,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,,B,,BAO_0000019,14025,,,8,Autocuration,1,CHEMBL617696,,
2420,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,,B,,BAO_0000357,4342,,,8,Autocuration,1,CHEMBL617697,,
2421,D,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,Rattus norvegicus,B,,BAO_0000019,13735,,10116.0,9,Expert,1,CHEMBL617257,,
2422,D,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,Rattus norvegicus,B,,BAO_0000357,5816,,10116.0,9,Expert,1,CHEMBL617258,,
2423,H,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,,B,,BAO_0000019,14287,,,8,Expert,1,CHEMBL617259,,
2424,H,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,,B,,BAO_0000357,15738,,,8,Autocuration,1,CHEMBL617260,,
2425,D,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,B,,BAO_0000357,15738,,10116.0,9,Expert,1,CHEMBL617261,,
2426,H,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,,B,,BAO_0000019,15026,,,8,Autocuration,1,CHEMBL617262,,
2427,H,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,B,,BAO_0000019,16647,,,8,Expert,1,CHEMBL617263,,
2428,H,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,,B,,BAO_0000019,16647,,,8,Autocuration,1,CHEMBL617264,,
2429,D,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,B,,BAO_0000019,13345,,10116.0,9,Expert,1,CHEMBL617265,,
2430,H,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000249,1543,,,8,Autocuration,1,CHEMBL617266,,
2431,H,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,,B,,BAO_0000019,12444,,,8,Autocuration,1,CHEMBL617267,,
2432,H,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,,B,,BAO_0000019,16404,,,8,Expert,1,CHEMBL617268,,
2433,H,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,,B,,BAO_0000219,16404,,,8,Autocuration,1,CHEMBL617269,449.0,
2434,H,Kinetic inhibition constant evaluated by measuring serotonergic activity,,,B,,BAO_0000357,15577,,,8,Expert,1,CHEMBL617323,,
2435,H,Serotonergic activity of the compound.,,,B,,BAO_0000357,15577,,,8,Autocuration,1,CHEMBL617324,,
2436,H,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,,B,,BAO_0000249,2495,,,8,Autocuration,1,CHEMBL617325,,
2437,D,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,Rattus norvegicus,B,,BAO_0000019,15042,,10116.0,9,Expert,1,CHEMBL617326,,
2438,H,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,,B,,BAO_0000249,15026,,,8,Expert,1,CHEMBL617327,,
2439,D,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Rattus norvegicus,F,,BAO_0000019,12919,,10116.0,9,Expert,1,CHEMBL617328,,
2440,D,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Rattus norvegicus,F,,BAO_0000019,12919,,10116.0,9,Expert,1,CHEMBL617329,,
2441,D,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Rattus norvegicus,F,,BAO_0000019,12919,,10116.0,9,Expert,1,CHEMBL617330,,
2442,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,B,,BAO_0000357,15194,,,8,Autocuration,1,CHEMBL617331,,
2443,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,,B,,BAO_0000357,15194,,,8,Autocuration,1,CHEMBL617332,,
2444,H,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,4820,,,8,Expert,1,CHEMBL617333,,
2445,H,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,,B,,BAO_0000357,6736,,,8,Autocuration,1,CHEMBL617334,,
2446,H,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,,B,,BAO_0000357,5163,,,8,Autocuration,1,CHEMBL617335,,
2447,H,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,,B,,BAO_0000357,5163,,,8,Autocuration,1,CHEMBL617336,,
2448,H,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,,B,,BAO_0000357,6011,,,8,Autocuration,1,CHEMBL617337,,
2449,D,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,Homo sapiens,B,,BAO_0000357,14294,,9606.0,9,Expert,1,CHEMBL617338,,
2450,H,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,5014,,,8,Autocuration,1,CHEMBL617339,,
2451,H,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,17066,,,8,Expert,1,CHEMBL617340,,
2452,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,,B,,BAO_0000357,17515,,,8,Autocuration,1,CHEMBL617341,,
2453,H,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,6736,,,8,Expert,1,CHEMBL617342,,
2454,H,Affinity for 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,5163,,,8,Expert,1,CHEMBL617343,,
2455,H,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,,B,,BAO_0000219,16911,,,8,Expert,1,CHEMBL617344,723.0,
2456,H,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,B,,BAO_0000357,6841,,,8,Expert,1,CHEMBL617345,,
2457,H,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,,B,,BAO_0000357,6119,,,8,Expert,1,CHEMBL617346,,
2458,H,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,3962,,,8,Autocuration,1,CHEMBL617347,,
2459,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,,B,,BAO_0000357,4373,,,8,Autocuration,1,CHEMBL617348,,
2460,H,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,,B,,BAO_0000357,4373,,,8,Autocuration,1,CHEMBL617349,,
2461,H,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,,F,,BAO_0000019,3962,,,8,Autocuration,1,CHEMBL617350,,
2462,H,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,B,,BAO_0000357,1633,,,8,Expert,1,CHEMBL872339,,
2463,H,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,,B,,BAO_0000357,4373,,,8,Autocuration,1,CHEMBL617351,,
2464,H,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,6576,,,8,Expert,1,CHEMBL617352,,
2465,H,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,4687,,,8,Autocuration,1,CHEMBL617353,,
2466,H,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,16946,,,8,Autocuration,1,CHEMBL617354,,
2467,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,14159,,,8,Autocuration,1,CHEMBL617355,,
2468,H,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,Mus musculus,B,,BAO_0000219,3032,,10090.0,8,Expert,1,CHEMBL617356,449.0,
2469,H,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,16655,,,8,Autocuration,1,CHEMBL617357,,
2470,H,Binding affinity at 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,13964,,,8,Autocuration,1,CHEMBL617358,,
2471,H,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,16989,,,8,Expert,1,CHEMBL617359,,
2472,H,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,,B,,BAO_0000357,16117,,,8,Autocuration,1,CHEMBL617360,,
2473,H,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,,B,,BAO_0000357,16700,,,8,Autocuration,1,CHEMBL875913,,
2474,H,Affinity against 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,3269,,,8,Autocuration,1,CHEMBL617361,,
2475,D,Binding affinity against 5-Hydroxytryptamine 2A receptor,,Homo sapiens,B,,BAO_0000357,1274,,9606.0,9,Expert,1,CHEMBL617362,,
2476,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,B,,BAO_0000357,1317,,,8,Autocuration,1,CHEMBL617363,,
2477,H,Tested against 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,12146,,,8,Autocuration,1,CHEMBL617364,,
2478,H,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,B,,BAO_0000224,12652,,,4,Autocuration,1,CHEMBL617365,,
2479,H,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,,B,,BAO_0000224,12652,,,4,Autocuration,1,CHEMBL617366,,
2480,H,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,,B,,BAO_0000224,12652,,,4,Autocuration,1,CHEMBL617367,,
2481,H,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,B,,BAO_0000224,12652,,,4,Autocuration,1,CHEMBL617368,,
2482,H,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,,B,,BAO_0000357,16647,,,8,Autocuration,1,CHEMBL617369,,
2483,D,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,Homo sapiens,B,,BAO_0000219,15851,,9606.0,9,Expert,1,CHEMBL617370,722.0,
2484,D,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,Homo sapiens,F,,BAO_0000219,6857,,9606.0,9,Expert,1,CHEMBL617371,449.0,
2485,H,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,,B,,BAO_0000357,3805,,,8,Autocuration,1,CHEMBL617372,,
2486,D,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,Homo sapiens,B,,BAO_0000357,6491,,9606.0,9,Expert,1,CHEMBL617373,,
2487,H,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,,F,,BAO_0000019,14093,,,8,Autocuration,1,CHEMBL617374,,
2488,H,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,,F,,BAO_0000019,13481,,,8,Autocuration,1,CHEMBL617375,,
2489,H,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,,F,,BAO_0000019,14093,,,8,Autocuration,1,CHEMBL617376,,
2490,H,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,,F,,BAO_0000019,14093,,,8,Autocuration,1,CHEMBL617377,,
2491,H,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,,F,,BAO_0000019,14093,,,8,Autocuration,1,CHEMBL617378,,
2492,H,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,F,,BAO_0000019,13481,,,8,Autocuration,1,CHEMBL617379,,
2493,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,,B,,BAO_0000357,14442,,,8,Autocuration,1,CHEMBL617380,,
2494,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,,B,,BAO_0000357,14442,,,8,Autocuration,1,CHEMBL617381,,
2495,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,B,,BAO_0000357,14442,,,8,Autocuration,1,CHEMBL617382,,
2496,H,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,12369,,,8,Autocuration,1,CHEMBL617383,,
2497,H,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,,B,,BAO_0000357,12369,,,8,Expert,1,CHEMBL617384,,
2498,H,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,,B,,BAO_0000357,12369,,,8,Expert,1,CHEMBL617385,,
2499,H,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,,B,,BAO_0000019,14447,,,8,Autocuration,1,CHEMBL617386,,
2500,H,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,,B,,BAO_0000019,14447,,,8,Autocuration,1,CHEMBL617387,,
2501,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,B,,BAO_0000219,17451,,,8,Autocuration,1,CHEMBL617388,723.0,
2502,H,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,F,,BAO_0000219,6857,,,8,Autocuration,1,CHEMBL617389,449.0,
2503,D,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Homo sapiens,F,,BAO_0000219,6857,,9606.0,9,Expert,1,CHEMBL617390,449.0,
2504,H,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,,B,,BAO_0000224,5635,,,4,Autocuration,1,CHEMBL617391,,
2505,H,Binding activity radioligand.,,,B,,BAO_0000357,12861,,,8,Autocuration,1,CHEMBL617392,,
2506,H,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,B,,BAO_0000019,12861,,,8,Autocuration,1,CHEMBL617393,,
2507,H,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,B,,BAO_0000219,5105,,,8,Autocuration,1,CHEMBL617394,307.0,
2508,H,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,B,,BAO_0000219,5104,,,8,Expert,1,CHEMBL617395,307.0,
2509,H,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,,B,,BAO_0000219,5105,,,8,Expert,1,CHEMBL617396,307.0,
2510,H,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,,B,,BAO_0000219,5105,,,8,Autocuration,1,CHEMBL617397,307.0,
2511,H,Binding affinity against 5-HT2A receptor,,,B,,BAO_0000357,5254,,,8,Autocuration,1,CHEMBL617398,,
2512,H,Binding affinity against 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,5254,,,8,Autocuration,1,CHEMBL617399,,
2513,H,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,B,,BAO_0000219,13267,,,8,Autocuration,1,CHEMBL617400,722.0,
2514,H,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,B,,BAO_0000219,13267,,,8,Autocuration,1,CHEMBL617401,722.0,
2515,D,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,Homo sapiens,B,,BAO_0000219,14157,,9606.0,9,Expert,1,CHEMBL617402,722.0,
2516,D,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Homo sapiens,B,,BAO_0000219,12936,,9606.0,9,Expert,1,CHEMBL617403,722.0,
2517,H,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,,B,,BAO_0000357,14068,,,8,Expert,1,CHEMBL617404,,
2518,D,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Homo sapiens,B,,BAO_0000219,12936,,9606.0,9,Expert,1,CHEMBL857981,722.0,
2519,D,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Homo sapiens,B,,BAO_0000219,12936,,9606.0,9,Expert,1,CHEMBL617405,722.0,
2520,D,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,Homo sapiens,B,,BAO_0000219,4540,,9606.0,9,Expert,1,CHEMBL617253,722.0,
2521,H,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,,B,,BAO_0000357,6166,,,8,Expert,1,CHEMBL617254,,
2522,H,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,B,,BAO_0000219,17296,,,8,Autocuration,1,CHEMBL617255,722.0,
2523,H,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,B,,BAO_0000219,17296,,,8,Autocuration,1,CHEMBL617256,722.0,
2524,H,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,,B,,BAO_0000219,17296,,,8,Autocuration,1,CHEMBL616874,722.0,
2525,D,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,Homo sapiens,B,,BAO_0000219,15779,,9606.0,9,Expert,1,CHEMBL616875,722.0,
2526,H,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,,B,,BAO_0000219,14391,,,8,Expert,1,CHEMBL616876,722.0,
2527,H,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,,B,,BAO_0000219,15851,,,8,Expert,1,CHEMBL616877,722.0,
2528,D,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,Homo sapiens,B,,BAO_0000219,15851,,9606.0,9,Expert,1,CHEMBL616878,722.0,
2529,H,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,,B,,BAO_0000219,3832,,,8,Expert,1,CHEMBL616879,722.0,
2530,H,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,,B,,BAO_0000219,3833,,,8,Expert,1,CHEMBL616880,722.0,
2531,D,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Homo sapiens,B,,BAO_0000219,12936,,9606.0,9,Expert,1,CHEMBL616881,722.0,
2532,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,B,,BAO_0000219,17451,,,8,Autocuration,1,CHEMBL616882,723.0,
2533,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,B,,BAO_0000219,17451,,,8,Autocuration,1,CHEMBL616883,723.0,
2534,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,B,,BAO_0000219,17451,,,8,Autocuration,1,CHEMBL616884,723.0,
2535,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,,B,,BAO_0000219,4199,,,8,Autocuration,1,CHEMBL616885,722.0,
2536,H,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,,B,,BAO_0000219,1883,,,8,Autocuration,1,CHEMBL616886,485.0,
2537,H,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,,B,,BAO_0000219,1883,,,8,Expert,1,CHEMBL616887,485.0,
2538,D,Binding affinity for human 5-hydroxytryptamine 2A receptor,,Homo sapiens,B,,BAO_0000357,14875,,9606.0,9,Expert,1,CHEMBL616888,,
2539,H,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,,B,,BAO_0000219,15146,,,8,Autocuration,1,CHEMBL616889,722.0,
2540,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,,B,,BAO_0000219,5213,,,8,Autocuration,1,CHEMBL616890,722.0,
2541,D,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,Homo sapiens,B,,BAO_0000219,16404,,9606.0,9,Expert,1,CHEMBL616891,449.0,
2542,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,,B,,BAO_0000219,14818,,,8,Autocuration,1,CHEMBL616892,722.0,
2543,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,,B,,BAO_0000219,4829,,,8,Autocuration,1,CHEMBL616893,722.0,
2544,H,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,,F,,BAO_0000219,12652,,,8,Autocuration,1,CHEMBL616894,723.0,
2545,H,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,,B,,BAO_0000219,4682,,,8,Expert,1,CHEMBL616895,723.0,
2546,H,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,,F,,BAO_0000019,12652,,,8,Autocuration,1,CHEMBL616896,,
2547,H,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,4921,,,8,Autocuration,1,CHEMBL617099,,
2548,H,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,,B,,BAO_0000357,4921,,,8,Autocuration,1,CHEMBL617100,,
2549,H,Binding affinity against rabbit aorta 5-HT2A receptor,,Oryctolagus cuniculus,B,,BAO_0000357,16312,,9986.0,8,Autocuration,1,CHEMBL884532,,
2550,H,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,Oryctolagus cuniculus,B,,BAO_0000357,14998,,9986.0,8,Expert,1,CHEMBL617101,,
2551,H,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,Oryctolagus cuniculus,B,,BAO_0000357,14025,,9986.0,8,Expert,1,CHEMBL617102,,
2552,H,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,Oryctolagus cuniculus,B,,BAO_0000019,13047,,9986.0,8,Autocuration,1,CHEMBL617103,,
2553,H,The compound was tested for binding affinity against 5-HT2A receptor,,Oryctolagus cuniculus,B,,BAO_0000357,13047,,9986.0,8,Expert,1,CHEMBL617104,,
2554,H,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,,B,,BAO_0000219,1883,,,8,Autocuration,1,CHEMBL857979,485.0,
2555,H,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,,B,,BAO_0000019,13463,,,8,Autocuration,1,CHEMBL857502,,
2556,H,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,B,,BAO_0000019,13463,,,8,Autocuration,1,CHEMBL617105,,
2557,H,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,,B,,BAO_0000019,13463,,,8,Autocuration,1,CHEMBL858021,,945.0
2558,D,Binding affinity for 5-HT 2A in rat stomach fundus,,Rattus norvegicus,B,,BAO_0000019,13463,,10116.0,9,Expert,1,CHEMBL875910,,945.0
2559,H,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,B,,BAO_0000019,13463,,,8,Autocuration,1,CHEMBL617106,,
2560,H,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000219,16326,,,8,Expert,1,CHEMBL617107,723.0,
2561,H,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,,F,,BAO_0000019,14093,,,8,Autocuration,1,CHEMBL617108,,
2562,H,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,,F,,BAO_0000019,14093,,,8,Autocuration,1,CHEMBL617109,,
2563,H,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,15740,,,8,Autocuration,1,CHEMBL617110,,
2564,H,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,,B,,BAO_0000357,16633,,,8,Autocuration,1,CHEMBL617111,,
2565,D,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,Rattus norvegicus,F,,BAO_0000019,17200,,10116.0,9,Expert,1,CHEMBL617112,,
2566,H,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,17133,,,8,Autocuration,1,CHEMBL617113,,
2567,H,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,17133,,,8,Autocuration,1,CHEMBL617114,,
2568,H,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,17133,,,8,Autocuration,1,CHEMBL617115,,
2569,H,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,F,,BAO_0000219,17200,,,8,Autocuration,1,CHEMBL617116,,
2570,H,Efficacy at 5-hydroxytryptamine 2A receptor,,,F,,BAO_0000019,15363,,,8,Autocuration,1,CHEMBL617117,,
2571,H,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,B,,BAO_0000357,17200,,,8,Autocuration,1,CHEMBL617118,,
2572,D,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,Rattus norvegicus,B,,BAO_0000357,17200,,10116.0,9,Expert,1,CHEMBL617119,,
2573,D,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,Rattus norvegicus,B,,BAO_0000357,17200,,10116.0,9,Expert,1,CHEMBL617120,,
2574,D,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,Rattus norvegicus,F,,BAO_0000219,17200,,10116.0,9,Expert,1,CHEMBL617121,,
2575,H,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,F,,BAO_0000219,17200,,,8,Autocuration,1,CHEMBL617122,,
2576,H,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000019,17211,,,8,Autocuration,1,CHEMBL617123,,
2577,H,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,,B,,BAO_0000019,17331,,,8,Expert,1,CHEMBL617124,,
2578,H,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,,B,,BAO_0000249,13565,,,8,Expert,1,CHEMBL617600,,
2579,H,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,,B,,BAO_0000357,13730,,,8,Expert,1,CHEMBL617601,,
2580,H,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,,B,,BAO_0000019,12416,,,8,Expert,1,CHEMBL882923,,
2581,H,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,15295,,,8,Autocuration,1,CHEMBL617602,,
2582,H,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,,B,,BAO_0000019,1742,,,8,Autocuration,1,CHEMBL617603,,
2583,H,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,15295,,,8,Autocuration,1,CHEMBL617604,,
2584,H,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,,B,,BAO_0000019,14970,,,8,Expert,1,CHEMBL617605,,
2585,H,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,,B,,BAO_0000019,16693,,,8,Expert,1,CHEMBL617606,,
2586,D,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,B,,BAO_0000019,14776,,10116.0,9,Expert,1,CHEMBL617607,,
2587,H,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,B,,BAO_0000249,14286,,,8,Autocuration,1,CHEMBL617455,,
2588,D,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,Rattus norvegicus,B,,BAO_0000019,17200,,10116.0,9,Expert,1,CHEMBL617456,,
2589,H,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,,B,,BAO_0000357,15306,,,8,Expert,1,CHEMBL617457,,
2590,D,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,B,,BAO_0000357,14178,,10116.0,9,Expert,1,CHEMBL617458,,
2591,D,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,Rattus norvegicus,B,,BAO_0000019,14229,,10116.0,9,Expert,1,CHEMBL617459,,
2592,H,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,,B,,BAO_0000357,12884,,,8,Expert,1,CHEMBL617460,,
2593,H,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,,B,,BAO_0000357,13149,,,8,Expert,1,CHEMBL617461,,
2594,D,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,Rattus norvegicus,B,,BAO_0000019,15295,,10116.0,9,Expert,1,CHEMBL617462,,
2595,H,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,,B,,BAO_0000357,15740,,,8,Autocuration,1,CHEMBL617463,,
2596,H,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,,B,,BAO_0000019,15185,,,8,Autocuration,1,CHEMBL617464,,
2597,H,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,,B,,BAO_0000019,15185,,,8,Autocuration,1,CHEMBL617465,,
2598,H,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,,B,,BAO_0000019,17529,,,8,Expert,1,CHEMBL617466,,
2599,H,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,B,,BAO_0000019,14826,,,8,Autocuration,1,CHEMBL617467,,
2600,H,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,,B,,BAO_0000019,17211,,,8,Expert,1,CHEMBL617468,,
2601,H,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,B,,BAO_0000019,14826,,,8,Autocuration,1,CHEMBL617469,,
2602,H,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000019,14093,,,8,Autocuration,1,CHEMBL617470,,
2603,H,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,,B,,BAO_0000019,14093,,,8,Autocuration,1,CHEMBL617471,,
2604,H,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,,B,,BAO_0000219,13246,,,8,Expert,1,CHEMBL617472,723.0,
2605,H,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,,B,,BAO_0000357,13246,,,8,Expert,1,CHEMBL617473,,
2606,D,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,Rattus norvegicus,B,,BAO_0000019,15436,,10116.0,9,Expert,1,CHEMBL617474,,
2607,D,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,Rattus norvegicus,B,,BAO_0000019,15436,,10116.0,9,Expert,1,CHEMBL617475,,
2608,H,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,,B,,BAO_0000221,14442,,,8,Autocuration,1,CHEMBL617476,,955.0
2609,H,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,12457,,,8,Expert,1,CHEMBL617477,,
2610,H,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000219,12457,,,8,Expert,1,CHEMBL617478,723.0,
2611,H,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,,F,,BAO_0000221,14755,,,8,Autocuration,1,CHEMBL617479,,
2612,H,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,,B,,BAO_0000357,4707,,,8,Autocuration,1,CHEMBL617480,,
2613,H,Binding affinity against 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,13297,,,8,Expert,1,CHEMBL617481,,
2614,H,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,,B,,BAO_0000019,17331,,,8,Expert,1,CHEMBL617482,,
2615,H,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,,B,,BAO_0000019,4664,,,8,Autocuration,1,CHEMBL617483,,
2616,H,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,B,,BAO_0000357,16633,,,8,Autocuration,1,CHEMBL621528,,
2617,D,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,Rattus norvegicus,B,,BAO_0000219,4664,,10116.0,9,Expert,1,CHEMBL621529,723.0,
2618,H,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,B,,BAO_0000357,16133,,,8,Expert,1,CHEMBL621530,,
2619,H,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,B,,BAO_0000357,16133,,,8,Expert,1,CHEMBL621531,,
2620,D,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,B,,BAO_0000019,14060,,10116.0,9,Expert,1,CHEMBL621532,,
2621,H,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,B,,BAO_0000357,16326,,,8,Expert,1,CHEMBL621533,,
2622,H,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,B,,BAO_0000219,16659,,,8,Expert,1,CHEMBL621534,449.0,
2623,H,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,,B,,BAO_0000019,14776,,,8,Autocuration,1,CHEMBL621535,,
2624,H,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,B,,BAO_0000357,13481,,,8,Autocuration,1,CHEMBL621536,,
2625,H,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,17386,,,8,Autocuration,1,CHEMBL621537,,
2626,D,Binding affinity for 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,B,,BAO_0000357,6611,,10116.0,9,Expert,1,CHEMBL621538,,
2627,H,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,,B,,BAO_0000019,14423,,,8,Autocuration,1,CHEMBL621539,,
2628,H,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,,B,,BAO_0000019,15412,,,8,Autocuration,1,CHEMBL621540,,
2629,H,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,,B,,BAO_0000019,15412,,,8,Autocuration,1,CHEMBL621541,,
2630,H,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,,B,,BAO_0000019,6238,,,8,Autocuration,1,CHEMBL621542,,
2631,H,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,,B,,BAO_0000357,6648,,,8,Expert,1,CHEMBL621543,,
2632,H,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,,B,,BAO_0000357,5667,,,8,Expert,1,CHEMBL621544,,
2633,D,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,Rattus norvegicus,B,,BAO_0000357,6611,,10116.0,9,Expert,1,CHEMBL621545,,
2634,H,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,B,,BAO_0000357,13481,,,8,Autocuration,1,CHEMBL621546,,
2635,H,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,,B,,BAO_0000357,13481,,,8,Autocuration,1,CHEMBL621547,,
2636,H,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000219,15558,,,8,Expert,1,CHEMBL618692,723.0,
2637,H,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,6013,,,8,Autocuration,1,CHEMBL618693,,
2638,H,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,B,,BAO_0000357,16633,,,8,Autocuration,1,CHEMBL872922,,
2639,H,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,,B,,BAO_0000357,6013,,,8,Autocuration,1,CHEMBL618694,,
2640,D,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,Rattus norvegicus,B,,BAO_0000357,6013,,10116.0,9,Expert,1,CHEMBL618695,,
2641,H,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,,B,,BAO_0000357,6013,,,8,Autocuration,1,CHEMBL618696,,
2642,H,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,,B,,BAO_0000357,6013,,,8,Expert,1,CHEMBL618697,,
2643,H,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,,B,,BAO_0000357,6013,,,8,Autocuration,1,CHEMBL618892,,
2644,H,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,,B,,BAO_0000357,6013,,,8,Autocuration,1,CHEMBL618893,,
2645,H,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,16293,,,8,Autocuration,1,CHEMBL618894,,
2646,H,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,,B,,BAO_0000219,17175,,,8,Expert,1,CHEMBL618895,723.0,
2647,D,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,Rattus norvegicus,B,,BAO_0000357,13278,,10116.0,9,Expert,1,CHEMBL618896,,
2648,H,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,,B,,BAO_0000019,3682,,,8,Autocuration,1,CHEMBL618897,,5383.0
2649,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,,B,,BAO_0000357,2014,,,8,Autocuration,1,CHEMBL618898,,
2650,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,,B,,BAO_0000357,2014,,,8,Autocuration,1,CHEMBL618899,,
2651,H,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,,B,,BAO_0000357,4932,,,8,Autocuration,1,CHEMBL618900,,
2652,H,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,,B,,BAO_0000019,4932,,,8,Autocuration,1,CHEMBL618901,,
2653,H,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,3935,,,8,Autocuration,1,CHEMBL618902,,
2654,D,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,B,,BAO_0000221,5432,,10116.0,9,Expert,1,CHEMBL618903,,10000000.0
2655,H,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,15818,,,8,Autocuration,1,CHEMBL618904,,
2656,H,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,,B,,BAO_0000357,13672,,,8,Autocuration,1,CHEMBL618905,,
2657,H,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,,B,,BAO_0000357,13672,,,8,Autocuration,1,CHEMBL618906,,
2658,H,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,,B,,BAO_0000219,14749,,,8,Expert,1,CHEMBL618907,723.0,
2659,H,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,,B,,BAO_0000019,13462,,,8,Autocuration,1,CHEMBL618908,,
2660,H,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,15740,,,8,Autocuration,1,CHEMBL617909,,
2661,H,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,B,,BAO_0000019,16647,,,8,Expert,1,CHEMBL617910,,
2662,H,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,,B,,BAO_0000221,13345,,,8,Autocuration,1,CHEMBL617911,,955.0
2663,H,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,B,,BAO_0000249,16740,,,8,Autocuration,1,CHEMBL872923,,
2664,H,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,B,,BAO_0000249,16740,,,8,Autocuration,1,CHEMBL617912,,
2665,D,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,Rattus norvegicus,B,,BAO_0000019,15535,,10116.0,9,Expert,1,CHEMBL617913,,
2666,H,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,B,,BAO_0000249,16740,,,8,Expert,1,CHEMBL617914,,
2667,H,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,B,,BAO_0000249,16740,,,8,Autocuration,1,CHEMBL617915,,
2668,H,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,B,,BAO_0000249,16740,,,8,Autocuration,1,CHEMBL617916,,
2669,D,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,B,,BAO_0000019,4795,,10116.0,9,Expert,1,CHEMBL617917,,
2670,H,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,,B,,BAO_0000019,8,,,8,Expert,1,CHEMBL617918,,
2671,H,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,,B,,BAO_0000019,8,,,8,Autocuration,1,CHEMBL617919,,
2672,D,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,Rattus norvegicus,B,,BAO_0000019,17200,,10116.0,9,Expert,1,CHEMBL617920,,
2673,D,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,Rattus norvegicus,B,,BAO_0000019,2148,,10116.0,9,Expert,1,CHEMBL617921,,
2674,D,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,Rattus norvegicus,B,,BAO_0000224,13345,,10116.0,5,Expert,1,CHEMBL617922,,
2675,H,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,B,,BAO_0000357,5088,,,8,Autocuration,1,CHEMBL617923,,
2676,H,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,B,,BAO_0000357,5088,,,8,Autocuration,1,CHEMBL617924,,
2677,H,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,,B,,BAO_0000357,17133,,,8,Autocuration,1,CHEMBL617925,,
2678,D,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,Rattus norvegicus,B,,BAO_0000357,17133,,10116.0,9,Expert,1,CHEMBL617926,,
2679,H,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,,B,,BAO_0000357,16532,,,8,Autocuration,1,CHEMBL617927,,
2680,H,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,,B,,BAO_0000357,15086,,,8,Autocuration,1,CHEMBL617928,,
2681,D,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Rattus norvegicus,B,,BAO_0000019,2309,,10116.0,9,Expert,1,CHEMBL617929,,
2682,H,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,,B,,BAO_0000019,12953,,,8,Expert,1,CHEMBL617930,,
2683,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,,B,,BAO_0000019,12953,,,8,Autocuration,1,CHEMBL617931,,
2684,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,,B,,BAO_0000019,12953,,,8,Autocuration,1,CHEMBL617932,,
2685,H,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,,B,,BAO_0000219,16659,,,8,Autocuration,1,CHEMBL617933,449.0,
2686,H,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,B,,BAO_0000019,16740,,,8,Autocuration,1,CHEMBL617934,,
2687,H,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,B,,BAO_0000019,16740,,,8,Autocuration,1,CHEMBL617935,,
2688,H,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,,B,,BAO_0000357,17133,,,8,Autocuration,1,CHEMBL617936,,
2689,H,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,,B,,BAO_0000019,17211,,,8,Autocuration,1,CHEMBL617937,,
2690,H,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,,B,,BAO_0000019,17331,,,8,Autocuration,1,CHEMBL617938,,
2691,H,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,,B,,BAO_0000218,16633,,,8,Autocuration,1,CHEMBL617939,,
2692,H,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,,B,,BAO_0000218,16633,,,8,Autocuration,1,CHEMBL617940,,
2693,H,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,,B,,BAO_0000218,16633,,,8,Autocuration,1,CHEMBL617941,,
2694,H,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,,B,,BAO_0000357,15026,,,8,Expert,1,CHEMBL617942,,
2695,H,Ratio of pKi of 5-HT2A to that of D2 receptor,,,B,,BAO_0000357,15026,,,8,Expert,1,CHEMBL617943,,
2696,H,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,B,,BAO_0000224,16404,,,4,Expert,1,CHEMBL617944,,
2697,H,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,B,,BAO_0000224,16404,,,4,Expert,1,CHEMBL617945,,
2698,H,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000224,16404,,,4,Expert,1,CHEMBL617946,,
2699,H,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,,B,,BAO_0000357,16404,,,8,Autocuration,1,CHEMBL617947,,
2700,H,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,,B,,BAO_0000357,16326,,,8,Expert,1,CHEMBL617948,,
2701,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,,F,,BAO_0000019,15847,,,8,Autocuration,1,CHEMBL858116,,
2702,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,,F,,BAO_0000019,15847,,,8,Autocuration,1,CHEMBL617949,,
2703,H,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,,F,,BAO_0000019,15329,,,8,Autocuration,1,CHEMBL617950,,
2704,H,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,,F,,BAO_0000019,16404,,,8,Expert,1,CHEMBL617951,,1515.0
2705,H,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,,F,,BAO_0000019,16404,,,8,Expert,1,CHEMBL617952,,1515.0
2706,H,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,,F,,BAO_0000019,16404,,,8,Autocuration,1,CHEMBL617953,,1515.0
2707,H,Binding activity radioligand.,,,B,,BAO_0000357,12861,,,8,Autocuration,1,CHEMBL617954,,
2708,H,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,B,,BAO_0000019,12861,,,8,Expert,1,CHEMBL617955,,
2709,H,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,B,,BAO_0000019,12861,,,8,Autocuration,1,CHEMBL857071,,
2710,H,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,,B,,BAO_0000019,12490,,,8,Expert,1,CHEMBL617270,,
2711,H,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,,B,,BAO_0000219,12827,,,8,Autocuration,1,CHEMBL617271,339.0,
2712,H,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,,B,,BAO_0000219,12827,,,8,Autocuration,1,CHEMBL617272,339.0,
2713,H,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,,B,,BAO_0000019,12918,,,8,Autocuration,1,CHEMBL617273,,
2714,D,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,Rattus norvegicus,F,,BAO_0000019,12919,,10116.0,9,Expert,1,CHEMBL617274,,
2715,H,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,17723,,,8,Autocuration,1,CHEMBL617275,,
2716,H,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,6013,,,8,Autocuration,1,CHEMBL617276,,
2717,H,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,16293,,,8,Autocuration,1,CHEMBL617277,,
2718,H,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000019,3857,,,8,Expert,1,CHEMBL617278,,
2719,H,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,,B,,BAO_0000019,3857,,,8,Expert,1,CHEMBL617279,,
2720,H,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000019,3857,,,8,Expert,1,CHEMBL617280,,
2721,H,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,15363,,,8,Autocuration,1,CHEMBL617281,,
2722,H,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,15363,,,8,Autocuration,1,CHEMBL617282,,
2723,H,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,,B,,BAO_0000019,16441,,,8,Expert,1,CHEMBL617283,,
2724,H,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,,B,,BAO_0000019,16441,,,8,Expert,1,CHEMBL617284,,
2725,H,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,,B,,BAO_0000219,4176,,,8,Autocuration,1,CHEMBL617285,722.0,
2726,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000019,17085,,,8,Autocuration,1,CHEMBL617286,,
2727,D,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,Homo sapiens,B,,BAO_0000357,17200,,9606.0,9,Expert,1,CHEMBL617287,,
2728,H,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,,B,,BAO_0000357,5088,,,8,Expert,1,CHEMBL617288,,
2729,H,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,,B,,BAO_0000357,5088,,,8,Autocuration,1,CHEMBL617289,,
2730,H,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,B,,BAO_0000357,5088,,,8,Autocuration,1,CHEMBL872917,,
2731,H,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,B,,BAO_0000357,5088,,,8,Autocuration,1,CHEMBL617290,,
2732,H,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,B,,BAO_0000219,16659,,,8,Autocuration,1,CHEMBL617291,449.0,
2733,H,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,,B,,BAO_0000219,16659,,,8,Autocuration,1,CHEMBL617292,449.0,
2734,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,B,,BAO_0000219,17451,,,8,Autocuration,1,CHEMBL617293,723.0,
2735,D,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Homo sapiens,F,,BAO_0000219,6857,,9606.0,9,Expert,1,CHEMBL617294,449.0,
2736,H,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,B,,BAO_0000019,3857,,,8,Expert,1,CHEMBL617295,,
2737,H,Binding activity radioligand.,,,B,,BAO_0000357,12861,,,8,Autocuration,1,CHEMBL617296,,
2738,H,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,B,,BAO_0000019,12861,,,8,Autocuration,1,CHEMBL617297,,
2739,H,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,,B,,BAO_0000219,5104,,,8,Expert,1,CHEMBL617298,449.0,
2740,H,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,,B,,BAO_0000219,5105,,,8,Expert,1,CHEMBL617299,449.0,
2741,H,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,,B,,BAO_0000219,5105,,,8,Autocuration,1,CHEMBL617300,449.0,
2742,H,Binding affinity against 5-HT2C receptor,,,B,,BAO_0000357,5254,,,8,Autocuration,1,CHEMBL617454,,
2743,H,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,B,,BAO_0000219,13267,,,8,Autocuration,1,CHEMBL617505,722.0,
2744,D,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,Homo sapiens,B,,BAO_0000219,14157,,9606.0,9,Expert,1,CHEMBL617506,722.0,
2745,D,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,Homo sapiens,B,,BAO_0000219,12936,,9606.0,9,Expert,1,CHEMBL617507,722.0,
2746,H,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,,B,,BAO_0000357,14068,,,8,Expert,1,CHEMBL617508,,
2747,D,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,Homo sapiens,B,,BAO_0000219,12936,,9606.0,9,Expert,1,CHEMBL857982,722.0,
2748,D,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,Homo sapiens,B,,BAO_0000219,4540,,9606.0,9,Expert,1,CHEMBL617509,722.0,
2749,D,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,Homo sapiens,B,,BAO_0000219,4540,,9606.0,9,Expert,1,CHEMBL617510,722.0,
2750,H,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,,B,,BAO_0000357,6166,,,8,Autocuration,1,CHEMBL617511,,
2751,H,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,,B,,BAO_0000219,17296,,,8,Autocuration,1,CHEMBL617512,722.0,
2752,H,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,,B,,BAO_0000219,17296,,,8,Autocuration,1,CHEMBL617749,722.0,
2753,H,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL617750,722.0,
2754,H,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL617751,722.0,
2755,H,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,,B,,BAO_0000219,14391,,,8,Expert,1,CHEMBL617752,722.0,
2756,H,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL617753,722.0,
2757,H,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,,B,,BAO_0000219,15851,,,8,Expert,1,CHEMBL617754,722.0,
2758,D,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,Homo sapiens,B,,BAO_0000219,15851,,9606.0,9,Expert,1,CHEMBL617755,722.0,
2759,H,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL617756,722.0,
2760,H,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,,B,,BAO_0000219,3832,,,8,Expert,1,CHEMBL617757,722.0,
2761,H,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,,B,,BAO_0000219,3833,,,8,Expert,1,CHEMBL617758,722.0,
2762,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,B,,BAO_0000219,17451,,,8,Autocuration,1,CHEMBL617759,723.0,
2763,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,,B,,BAO_0000219,4199,,,8,Autocuration,1,CHEMBL617760,722.0,
2764,H,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,,B,,BAO_0000219,1883,,,8,Expert,1,CHEMBL617761,485.0,
2765,D,Binding affinity against 5-hydroxytryptamine 2C receptor,,Homo sapiens,B,,BAO_0000357,4321,,9606.0,9,Expert,1,CHEMBL617762,,
2766,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,14875,,,8,Autocuration,1,CHEMBL617763,,
2767,H,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,,B,,BAO_0000219,15146,,,8,Autocuration,1,CHEMBL857983,722.0,
2768,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,,B,,BAO_0000219,5213,,,8,Autocuration,1,CHEMBL617764,722.0,
2769,H,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,,B,,BAO_0000219,16404,,,8,Autocuration,1,CHEMBL617765,308.0,
2770,H,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,,F,,BAO_0000019,13267,,,8,Autocuration,1,CHEMBL617766,,
2771,H,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,,F,,BAO_0000221,13267,,,8,Autocuration,1,CHEMBL617767,,10000000.0
2772,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,,B,,BAO_0000219,14818,,,8,Autocuration,1,CHEMBL617768,722.0,
2773,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,,B,,BAO_0000219,4829,,,8,Autocuration,1,CHEMBL617769,722.0,
2774,H,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,,B,,BAO_0000357,13463,,,8,Autocuration,1,CHEMBL858023,,
2775,H,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,,B,,BAO_0000019,13463,,,8,Autocuration,1,CHEMBL617770,,945.0
2776,H,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,,B,,BAO_0000019,13463,,,8,Autocuration,1,CHEMBL617771,,945.0
2777,H,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,,F,,BAO_0000219,12652,,,8,Autocuration,1,CHEMBL617772,625.0,
2778,H,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,B,,BAO_0000219,4682,,,8,Autocuration,1,CHEMBL617773,723.0,
2779,H,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,,B,,BAO_0000219,4682,,,8,Autocuration,1,CHEMBL617850,723.0,
2780,H,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,B,,BAO_0000219,4682,,,8,Autocuration,1,CHEMBL617851,723.0,
2781,H,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,,F,,BAO_0000019,12652,,,8,Autocuration,1,CHEMBL617852,,
2782,H,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,Mus musculus,B,,BAO_0000019,13463,,10090.0,8,Autocuration,1,CHEMBL858024,,945.0
2783,D,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,Rattus norvegicus,B,,BAO_0000019,13463,,10116.0,9,Expert,1,CHEMBL617853,,945.0
2784,H,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,,B,,BAO_0000357,13969,,,8,Expert,1,CHEMBL617854,,
2785,H,Binding affinity for 5-hydroxytryptamine 2C receptor,,Sus scrofa,B,,BAO_0000357,13392,,9823.0,8,Expert,1,CHEMBL873477,,
2786,H,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,13392,,,8,Expert,1,CHEMBL617855,,
2787,H,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,,B,,BAO_0000019,14430,,,8,Expert,1,CHEMBL617856,,
2788,H,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,,B,,BAO_0000019,1742,,,8,Autocuration,1,CHEMBL617857,,
2789,H,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,,B,,BAO_0000249,14286,,,8,Autocuration,1,CHEMBL617858,,
2790,H,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,5619,,,8,Autocuration,1,CHEMBL617859,,
2791,H,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,15086,,,8,Autocuration,1,CHEMBL617860,,
2792,H,Binding activity radioligand.,,,B,,BAO_0000357,12861,,,8,Autocuration,1,CHEMBL617861,,
2793,H,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,B,,BAO_0000019,12861,,,8,Expert,1,CHEMBL617862,,
2794,H,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,B,,BAO_0000019,12861,,,8,Autocuration,1,CHEMBL617863,,
2795,H,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,,B,,BAO_0000249,12827,,,8,Autocuration,1,CHEMBL617864,,
2796,H,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,,B,,BAO_0000249,12827,,,8,Autocuration,1,CHEMBL617649,,
2797,H,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,Sus scrofa,F,,BAO_0000019,12919,,9823.0,8,Expert,1,CHEMBL617650,,
2798,H,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,Sus scrofa,F,,BAO_0000019,12919,,9823.0,8,Expert,1,CHEMBL617651,,
2799,H,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,Sus scrofa,B,,BAO_0000357,16429,,9823.0,8,Autocuration,1,CHEMBL617652,,
2800,H,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,Sus scrofa,B,,BAO_0000019,773,,9823.0,8,Autocuration,1,CHEMBL857072,,
2801,H,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,Sus scrofa,B,,BAO_0000357,5033,,9823.0,8,Autocuration,1,CHEMBL617653,,
2802,H,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,B,,BAO_0000019,12861,,,8,Autocuration,1,CHEMBL617654,,
2803,H,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,,F,,BAO_0000019,14093,,,8,Autocuration,1,CHEMBL617655,,
2804,H,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,,B,,BAO_0000357,14970,,,8,Expert,1,CHEMBL617656,,
2805,H,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,,B,,BAO_0000357,14970,,,8,Autocuration,1,CHEMBL617657,,
2806,H,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,,B,,BAO_0000357,14970,,,8,Autocuration,1,CHEMBL617658,,
2807,D,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,Rattus norvegicus,B,,BAO_0000357,14178,,10116.0,9,Expert,1,CHEMBL617659,,
2808,D,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,Rattus norvegicus,B,,BAO_0000357,14178,,10116.0,9,Expert,1,CHEMBL617838,,
2809,D,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,Rattus norvegicus,B,,BAO_0000249,14229,,10116.0,9,Expert,1,CHEMBL617839,,
2810,H,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,,B,,BAO_0000357,16532,,,8,Autocuration,1,CHEMBL617840,,
2811,H,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,,B,,BAO_0000019,14826,,,8,Autocuration,1,CHEMBL617841,,
2812,H,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,,B,,BAO_0000019,17211,,,8,Autocuration,1,CHEMBL875915,,
2813,H,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,,B,,BAO_0000219,17211,In vitro,,8,Expert,1,CHEMBL617842,,
2814,H,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,,B,,BAO_0000219,13246,,,8,Expert,1,CHEMBL617843,723.0,
2815,H,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,,B,,BAO_0000357,13246,,,8,Expert,1,CHEMBL617844,,
2816,H,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,12457,,,8,Expert,1,CHEMBL617845,,
2817,H,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000219,12457,,,8,Expert,1,CHEMBL617846,723.0,
2818,H,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,,B,,BAO_0000357,4707,,,8,Autocuration,1,CHEMBL617847,,
2819,H,Binding affinity against 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,13297,,,8,Expert,1,CHEMBL617848,,
2820,H,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,B,,BAO_0000357,16633,,,8,Autocuration,1,CHEMBL617849,,
2821,H,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,B,,BAO_0000357,16133,,,8,Expert,1,CHEMBL621507,,
2822,H,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,,B,,BAO_0000357,16326,,,8,Expert,1,CHEMBL621508,,
2823,H,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,,B,,BAO_0000019,14423,,,8,Autocuration,1,CHEMBL621509,,
2824,H,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,,B,,BAO_0000019,15412,,,8,Autocuration,1,CHEMBL621510,,
2825,H,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,,B,,BAO_0000019,15412,,,8,Autocuration,1,CHEMBL621511,,
2826,H,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000219,15558,,,8,Expert,1,CHEMBL621512,625.0,
2827,H,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,B,,BAO_0000357,16633,,,8,Autocuration,1,CHEMBL621513,,
2828,H,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,,B,,BAO_0000357,6013,,,8,Expert,1,CHEMBL621514,,
2829,H,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,,B,,BAO_0000219,17175,In vitro,,8,Expert,1,CHEMBL621515,,
2830,H,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,,B,,BAO_0000219,12469,,,8,Autocuration,1,CHEMBL621516,,
2831,H,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,,B,,BAO_0000019,3682,,,8,Autocuration,1,CHEMBL621517,,5383.0
2832,H,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,,B,,BAO_0000357,4932,,,8,Autocuration,1,CHEMBL621518,,
2833,H,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,,B,,BAO_0000019,4932,,,8,Autocuration,1,CHEMBL621519,,
2834,H,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,3935,,,8,Autocuration,1,CHEMBL621520,,
2835,H,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,15818,,,8,Autocuration,1,CHEMBL621521,,
2836,H,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,15818,,,8,Autocuration,1,CHEMBL621522,,
2837,H,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,,B,,BAO_0000219,14749,,,8,Expert,1,CHEMBL621523,,
2838,H,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,15740,,,8,Autocuration,1,CHEMBL621524,,
2839,D,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,Rattus norvegicus,B,,BAO_0000357,17133,,10116.0,9,Expert,1,CHEMBL621525,,
2840,H,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,,B,,BAO_0000357,16532,,,8,Autocuration,1,CHEMBL872921,,
2841,H,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,12369,,,8,Autocuration,1,CHEMBL621526,,
2842,H,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,,B,,BAO_0000219,12369,,,8,Expert,1,CHEMBL621527,,
2843,D,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,Rattus norvegicus,B,,BAO_0000019,2309,,10116.0,9,Expert,1,CHEMBL617865,,
2844,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,12953,,,8,Autocuration,1,CHEMBL617866,,
2845,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,,B,,BAO_0000019,12953,,,8,Autocuration,1,CHEMBL617867,,
2846,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,,B,,BAO_0000357,12953,,,8,Autocuration,1,CHEMBL617487,,
2847,H,Binding affinity for 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,12953,,,8,Expert,1,CHEMBL617488,,
2848,H,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,,B,,BAO_0000357,17133,,,8,Autocuration,1,CHEMBL617489,,
2849,H,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,,B,,BAO_0000019,17211,,,8,Autocuration,1,CHEMBL617490,,
2850,H,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,,B,,BAO_0000019,17211,,,8,Autocuration,1,CHEMBL617491,,
2851,H,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,,B,,BAO_0000019,14025,,,8,Autocuration,1,CHEMBL617492,,
2852,H,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,,B,,BAO_0000019,14998,,,8,Autocuration,1,CHEMBL617493,,
2853,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,,B,,BAO_0000357,4342,,,8,Autocuration,1,CHEMBL617494,,
2854,D,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,Rattus norvegicus,B,,BAO_0000019,13735,,10116.0,9,Expert,1,CHEMBL617495,,
2855,H,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,B,,BAO_0000357,13181,,,8,Autocuration,1,CHEMBL617496,,
2856,H,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,,B,,BAO_0000219,1883,,,8,Autocuration,1,CHEMBL617497,485.0,
2857,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,B,,BAO_0000357,15194,,,8,Autocuration,1,CHEMBL617498,,
2858,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,,B,,BAO_0000357,15194,,,8,Autocuration,1,CHEMBL617499,,
2859,H,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,,F,,BAO_0000019,14579,,,8,Autocuration,1,CHEMBL617500,,
2860,H,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,4639,,,8,Autocuration,1,CHEMBL617501,,
2861,H,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,4820,,,8,Expert,1,CHEMBL617502,,
2862,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,,B,,BAO_0000357,14442,,,8,Autocuration,1,CHEMBL617503,,
2863,H,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,,B,,BAO_0000357,14755,,,8,Autocuration,1,CHEMBL617504,,
2864,H,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,,B,,BAO_0000357,14744,,,8,Autocuration,1,CHEMBL617406,,
2865,D,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,Homo sapiens,B,,BAO_0000019,6857,,9606.0,9,Expert,1,CHEMBL617407,,
2866,H,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,,B,,BAO_0000357,16209,,,8,Autocuration,1,CHEMBL617408,,
2867,H,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,B,,BAO_0000357,15363,,,8,Autocuration,1,CHEMBL617409,,
2868,H,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,B,,BAO_0000357,15363,,,8,Autocuration,1,CHEMBL617410,,
2869,H,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,,B,,BAO_0000357,15363,,,8,Autocuration,1,CHEMBL617411,,
2870,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,,B,,BAO_0000019,17085,,,8,Autocuration,1,CHEMBL617412,,
2871,D,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,Homo sapiens,B,,BAO_0000357,17200,,9606.0,9,Expert,1,CHEMBL617774,,
2872,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,Homo sapiens,B,,BAO_0000219,15851,,9606.0,9,Expert,1,CHEMBL617775,722.0,
2873,D,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,Homo sapiens,B,,BAO_0000219,15851,,9606.0,9,Expert,1,CHEMBL617776,722.0,
2874,D,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Homo sapiens,F,,BAO_0000219,6857,,9606.0,9,Expert,1,CHEMBL617777,449.0,
2875,D,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Homo sapiens,F,,BAO_0000219,6857,,9606.0,9,Expert,1,CHEMBL617778,449.0,
2876,H,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL617779,722.0,
2877,H,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,,B,,BAO_0000219,15851,,,8,Expert,1,CHEMBL617780,722.0,
2878,H,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL617781,722.0,
2879,D,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,Homo sapiens,B,,BAO_0000219,14157,,9606.0,9,Expert,1,CHEMBL617782,722.0,
2880,D,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,Homo sapiens,B,,BAO_0000219,4540,,9606.0,9,Expert,1,CHEMBL617783,722.0,
2881,H,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,,B,,BAO_0000357,6166,,,8,Autocuration,1,CHEMBL617784,,
2882,H,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL617785,722.0,
2883,H,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,,B,,BAO_0000219,14391,,,8,Expert,1,CHEMBL857984,722.0,
2884,H,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,,B,,BAO_0000219,3832,,,8,Expert,1,CHEMBL617786,722.0,
2885,H,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,,B,,BAO_0000219,3833,,,8,Expert,1,CHEMBL617787,722.0,
2886,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,Homo sapiens,B,,BAO_0000219,15851,,9606.0,9,Expert,1,CHEMBL617788,722.0,
2887,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,Homo sapiens,B,,BAO_0000219,15851,,9606.0,9,Expert,1,CHEMBL617789,722.0,
2888,H,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,,B,,BAO_0000219,4199,,,8,Autocuration,1,CHEMBL617790,722.0,
2889,H,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,,B,,BAO_0000219,1883,,,8,Expert,1,CHEMBL617791,485.0,
2890,H,Binding affinity against 5-hydroxytryptamine 2B receptor,,,B,,BAO_0000357,4321,,,8,Expert,1,CHEMBL617608,,
2891,H,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,,B,,BAO_0000219,15146,,,8,Autocuration,1,CHEMBL617609,722.0,
2892,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,,B,,BAO_0000219,5213,,,8,Autocuration,1,CHEMBL617610,722.0,
2893,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,,B,,BAO_0000219,14818,,,8,Autocuration,1,CHEMBL617611,722.0,
2894,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,B,,BAO_0000219,4829,,,8,Autocuration,1,CHEMBL617612,722.0,
2895,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,B,,BAO_0000219,4829,,,8,Autocuration,1,CHEMBL617613,722.0,
2896,H,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,Oryctolagus cuniculus,B,,BAO_0000019,14025,,9986.0,8,Autocuration,1,CHEMBL617614,,
2897,H,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,,B,,BAO_0000019,13463,,,8,Expert,1,CHEMBL617615,,945.0
2898,H,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,,B,,BAO_0000357,7259,,,8,Expert,1,CHEMBL858114,,945.0
2899,H,Affinity against serotonergic receptor in the isolated rat stomach fundus,,,B,,BAO_0000357,7259,,,8,Autocuration,1,CHEMBL617616,,945.0
2900,D,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,Rattus norvegicus,F,,BAO_0000019,7185,,10116.0,9,Expert,1,CHEMBL617617,,945.0
2901,D,Antagonistic against 5-hydroxytryptamine 2B receptor,,Rattus norvegicus,F,,BAO_0000019,7185,,10116.0,9,Expert,1,CHEMBL875914,,
2902,H,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,,F,,BAO_0000019,13267,,,8,Autocuration,1,CHEMBL617618,,945.0
2903,D,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,Rattus norvegicus,B,,BAO_0000357,13735,,10116.0,9,Expert,1,CHEMBL617619,,945.0
2904,H,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,,F,,BAO_0000019,15738,,,8,Autocuration,1,CHEMBL617620,,
2905,H,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,,F,,BAO_0000019,15738,,,8,Autocuration,1,CHEMBL617621,,
2906,H,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,,F,,BAO_0000019,15738,,,8,Autocuration,1,CHEMBL617622,,
2907,D,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,Rattus norvegicus,B,,BAO_0000357,12936,,10116.0,9,Expert,1,CHEMBL617623,,945.0
2908,D,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,Rattus norvegicus,B,,BAO_0000357,12936,,10116.0,9,Expert,1,CHEMBL617624,,945.0
2909,D,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,Rattus norvegicus,B,,BAO_0000357,12936,,10116.0,9,Expert,1,CHEMBL617625,,945.0
2910,D,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,Rattus norvegicus,B,,BAO_0000357,12936,,10116.0,9,Expert,1,CHEMBL617626,,945.0
2911,H,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,F,,BAO_0000019,16404,,,8,Autocuration,1,CHEMBL617627,,945.0
2912,H,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,F,,BAO_0000019,16404,,,8,Expert,1,CHEMBL617628,,945.0
2913,H,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,,F,,BAO_0000019,16404,,,8,Autocuration,1,CHEMBL617629,,945.0
2914,H,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,,F,,BAO_0000019,16404,,,8,Autocuration,1,CHEMBL858115,,945.0
2915,D,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,Rattus norvegicus,F,,BAO_0000019,16404,,10116.0,9,Expert,1,CHEMBL617630,,945.0
2916,H,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,,F,,BAO_0000019,16404,,,8,Autocuration,1,CHEMBL617631,,1515.0
2917,H,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,B,,BAO_0000357,7483,,,8,Autocuration,1,CHEMBL617632,,
2918,H,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,,B,,BAO_0000357,7483,,,8,Expert,1,CHEMBL617633,,
2919,H,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,B,,BAO_0000357,7483,,,8,Autocuration,1,CHEMBL617634,,
2920,H,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,,B,,BAO_0000357,7483,,,8,Autocuration,1,CHEMBL617635,,
2922,D,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,Rattus norvegicus,F,,BAO_0000019,16404,,10116.0,9,Autocuration,1,CHEMBL617637,,945.0
2923,H,Binding affinity against 5-hydroxytryptamine 1A receptor,,,B,,BAO_0000357,6347,,,8,Autocuration,1,CHEMBL617638,,
2924,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,,B,,BAO_0000357,4373,,,8,Autocuration,1,CHEMBL617639,,
2925,H,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,,B,,BAO_0000357,4373,,,8,Autocuration,1,CHEMBL617640,,
2926,H,Evaluated for the binding affinity to 5-HT 2B receptor,,,B,,BAO_0000357,4687,,,8,Autocuration,1,CHEMBL617641,,
2927,H,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,,B,,BAO_0000357,16946,,,8,Autocuration,1,CHEMBL617642,,
2928,H,Binding affinities against 5-hydroxytryptamine 2B receptor,,,B,,BAO_0000357,16633,,,8,Autocuration,1,CHEMBL617643,,
2929,H,Binding affinities towards 5-hydroxytryptamine 2B receptor,,,B,,BAO_0000357,16633,,,8,Autocuration,1,CHEMBL617644,,
2930,H,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,,B,,BAO_0000357,16633,,,8,Autocuration,1,CHEMBL617645,,
2931,H,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,B,,BAO_0000357,15026,,,8,Expert,1,CHEMBL617646,,
2932,H,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,Bos taurus,B,,BAO_0000357,15738,,9913.0,8,Autocuration,1,CHEMBL617647,,
2933,H,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,Bos taurus,B,,BAO_0000357,15738,,9913.0,8,Autocuration,1,CHEMBL617648,,
2934,H,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,Bos taurus,B,,BAO_0000357,15738,,9913.0,8,Autocuration,1,CHEMBL617875,,
2935,H,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,Bos taurus,B,,BAO_0000357,15738,,9913.0,8,Autocuration,1,CHEMBL617876,,
2936,H,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,Bos taurus,B,,BAO_0000357,16404,,9913.0,8,Expert,1,CHEMBL617877,,
2937,H,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,Bos taurus,B,,BAO_0000357,15026,,9913.0,8,Expert,1,CHEMBL617878,,
2938,H,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,Bos taurus,B,,BAO_0000357,15738,,9913.0,8,Autocuration,1,CHEMBL617879,,
2939,H,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,Cavia porcellus,B,,BAO_0000019,16312,,10141.0,8,Autocuration,1,CHEMBL617880,,
2940,D,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,Cavia porcellus,B,,BAO_0000357,5486,,10141.0,9,Intermediate,1,CHEMBL617881,,2435.0
2941,H,Binding affinity against 5-HT1A receptor,,,B,,BAO_0000357,5254,,,8,Autocuration,1,CHEMBL857073,,
2942,H,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,,F,,BAO_0000219,3857,,,8,Expert,1,CHEMBL617882,449.0,
2943,D,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,Homo sapiens,F,,BAO_0000219,6857,,9606.0,9,Expert,1,CHEMBL617883,449.0,
2944,H,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,,F,,BAO_0000219,4176,,,8,Autocuration,1,CHEMBL617884,,
2945,H,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,,B,,BAO_0000219,6347,,,8,Autocuration,1,CHEMBL617885,449.0,
2946,H,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,,B,,BAO_0000219,6347,,,8,Autocuration,1,CHEMBL617886,449.0,
2947,D,Inhibition of human 5-hydroxytryptamine 2C receptor,,Homo sapiens,B,,BAO_0000357,16146,,9606.0,9,Expert,1,CHEMBL617887,,
2948,H,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,,B,,BAO_0000357,3805,,,8,Autocuration,1,CHEMBL617888,,
2949,H,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,B,,BAO_0000019,3857,,,8,Autocuration,1,CHEMBL617889,,
2950,H,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,5635,,,8,Autocuration,1,CHEMBL617890,,
2951,H,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,B,,BAO_0000357,5635,,,8,Autocuration,1,CHEMBL617891,,
2952,H,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,B,,BAO_0000357,5635,,,8,Autocuration,1,CHEMBL617892,,
2953,H,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,,B,,BAO_0000219,4012,,,8,Expert,1,CHEMBL617893,449.0,
2954,H,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,,B,,BAO_0000219,6366,,,8,Expert,1,CHEMBL617894,449.0,
2955,H,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,B,,BAO_0000219,15949,,,8,Expert,1,CHEMBL617895,449.0,
2956,H,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000219,17211,,,8,Autocuration,1,CHEMBL617896,449.0,
2957,D,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,Homo sapiens,B,,BAO_0000357,6491,,9606.0,9,Expert,1,CHEMBL617897,,
2958,H,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,,F,,BAO_0000019,14093,,,8,Autocuration,1,CHEMBL617898,,
2959,H,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,F,,BAO_0000019,13481,,,8,Autocuration,1,CHEMBL617899,,
2960,H,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,Rattus norvegicus,B,,BAO_0000219,6347,,10116.0,8,Expert,1,CHEMBL617900,449.0,
2961,H,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,,F,,BAO_0000019,14093,,,8,Autocuration,1,CHEMBL617901,,
2962,H,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,,F,,BAO_0000019,14093,,,8,Autocuration,1,CHEMBL617902,,
2963,H,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,F,,BAO_0000019,13481,,,8,Autocuration,1,CHEMBL617903,,
2964,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,,B,,BAO_0000357,14442,,,8,Autocuration,1,CHEMBL617904,,
2965,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,,B,,BAO_0000357,14442,,,8,Autocuration,1,CHEMBL617905,,
2966,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,,B,,BAO_0000357,14442,,,8,Autocuration,1,CHEMBL617906,,
2967,H,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,,B,,BAO_0000357,14755,,,8,Autocuration,1,CHEMBL617907,,
2968,H,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,,B,,BAO_0000357,14744,,,8,Autocuration,1,CHEMBL617908,,
2969,H,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,B,,BAO_0000219,16659,,,8,Expert,1,CHEMBL620617,449.0,
2970,D,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,Homo sapiens,B,,BAO_0000019,6857,,9606.0,9,Expert,1,CHEMBL620618,,
2971,H,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,,B,,BAO_0000357,5635,,,8,Expert,1,CHEMBL620619,,
2972,D,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,Homo sapiens,B,,BAO_0000357,4234,,9606.0,9,Expert,1,CHEMBL620620,,
2973,H,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,,B,,BAO_0000357,16209,,,8,Autocuration,1,CHEMBL620621,,
2974,D,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,Rattus norvegicus,B,,BAO_0000249,5778,,10116.0,7,Autocuration,1,CHEMBL872920,,
2975,H,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,,B,,BAO_0000223,5094,,,6,Autocuration,1,CHEMBL620622,,
2976,D,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,Rattus norvegicus,B,,BAO_0000019,809,,10116.0,7,Autocuration,1,CHEMBL620623,,
2977,H,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,,B,,BAO_0000019,1578,,,6,Autocuration,1,CHEMBL620624,,
2978,H,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,,B,,BAO_0000019,809,,,6,Autocuration,1,CHEMBL620625,,
2979,H,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,,B,,BAO_0000219,12469,,,6,Autocuration,1,CHEMBL620626,,
2980,H,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,,B,,BAO_0000019,14290,,,6,Autocuration,1,CHEMBL621307,,
2981,H,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,,B,,BAO_0000019,14290,,,6,Autocuration,1,CHEMBL621308,,
2982,H,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,,B,,BAO_0000223,10609,,,6,Autocuration,1,CHEMBL621309,,
2983,H,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,,B,,BAO_0000223,10609,,,6,Autocuration,1,CHEMBL621310,,
2984,H,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,,B,,BAO_0000223,10609,,,6,Autocuration,1,CHEMBL621311,,
2985,H,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,B,,BAO_0000249,15253,,,6,Autocuration,1,CHEMBL621502,,
2986,H,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,B,,BAO_0000249,15253,,,6,Autocuration,1,CHEMBL621503,,
2987,H,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,,B,,BAO_0000249,11683,,,6,Autocuration,1,CHEMBL621504,,
2988,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000223,12092,,,6,Autocuration,1,CHEMBL621505,,
2989,H,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,B,,BAO_0000019,1946,,,6,Autocuration,1,CHEMBL621506,,
2990,H,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,,B,,BAO_0000223,11623,,,6,Autocuration,1,CHEMBL619781,,
2991,H,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,,B,,BAO_0000223,11623,,,6,Autocuration,1,CHEMBL619782,,
2992,H,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,,B,,BAO_0000019,14788,,,6,Autocuration,1,CHEMBL619783,,
2993,D,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,Rattus norvegicus,B,,BAO_0000019,5432,,10116.0,7,Autocuration,1,CHEMBL619784,,
2994,H,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,B,,BAO_0000249,14826,,,6,Autocuration,1,CHEMBL619785,,
2995,H,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000223,2222,,,6,Autocuration,1,CHEMBL619786,,
2996,H,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,,B,,BAO_0000019,11963,,,6,Autocuration,1,CHEMBL619787,,
2997,H,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,,B,,BAO_0000019,14145,,,6,Autocuration,1,CHEMBL872925,,
2998,H,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,,B,,BAO_0000019,17819,,,6,Autocuration,1,CHEMBL619788,,
2999,H,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,B,,BAO_0000249,10394,,,6,Autocuration,1,CHEMBL619789,,
3000,H,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,B,,BAO_0000249,10394,,,6,Autocuration,1,CHEMBL619790,,
3001,H,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,B,,BAO_0000019,15034,,,6,Autocuration,1,CHEMBL619791,,
3002,H,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,B,,BAO_0000019,691,,,6,Autocuration,1,CHEMBL619792,,
3003,H,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,,B,,BAO_0000249,12092,,,6,Autocuration,1,CHEMBL619793,,
3004,D,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,B,,BAO_0000223,11752,,10116.0,7,Autocuration,1,CHEMBL619794,,
3005,H,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,,B,,BAO_0000221,11752,,,6,Autocuration,1,CHEMBL619795,,955.0
3006,H,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,,B,,BAO_0000019,301,,,6,Autocuration,1,CHEMBL619796,,
3007,H,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,,B,,BAO_0000223,16532,,,6,Autocuration,1,CHEMBL620448,,
3008,H,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,B,,BAO_0000223,16532,,,6,Autocuration,1,CHEMBL620449,,
3009,H,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,,B,,BAO_0000223,12092,,,6,Autocuration,1,CHEMBL620450,,
3010,H,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,,B,,BAO_0000223,11684,,,6,Autocuration,1,CHEMBL620451,,
3011,H,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,,B,,BAO_0000223,11684,,,6,Autocuration,1,CHEMBL620631,,
3012,H,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,,B,,BAO_0000019,12953,,,6,Autocuration,1,CHEMBL620632,,
3013,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,,B,,BAO_0000019,12953,,,6,Autocuration,1,CHEMBL620633,,
3014,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,,B,,BAO_0000223,12953,,,6,Autocuration,1,CHEMBL620634,,
3015,H,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,B,,BAO_0000019,12861,,,6,Autocuration,1,CHEMBL620635,,
3016,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL620636,,
3017,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL620637,,
3018,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL620638,,
3019,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL620639,,
3020,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL620640,,
3021,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL620641,,
3022,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL620642,,
3023,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL620643,,
3024,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL620644,,
3025,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL620645,,
3026,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL620646,,
3027,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL620647,,
3028,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL620648,,
3029,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL620649,,
3030,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL620650,,
3031,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL620651,,
3032,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL872875,,
3033,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL620652,,
3034,H,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,,F,,BAO_0000019,10609,,,6,Autocuration,1,CHEMBL620653,,
3035,H,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,,B,,BAO_0000019,12861,,,6,Autocuration,1,CHEMBL857076,,
3036,D,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,B,,BAO_0000019,12861,,10116.0,7,Autocuration,1,CHEMBL620654,,
3037,H,Binding activity radioligand.,,,B,,BAO_0000223,12861,,,6,Autocuration,1,CHEMBL620655,,
3038,H,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,,B,,BAO_0000249,10728,,,6,Autocuration,1,CHEMBL620656,,
3039,H,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,,B,,BAO_0000249,10728,,,6,Autocuration,1,CHEMBL620657,,
3040,H,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,,B,,BAO_0000357,5163,,,8,Autocuration,1,CHEMBL620658,,
3041,H,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,,B,,BAO_0000357,5163,,,8,Autocuration,1,CHEMBL620659,,
3042,H,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,,B,,BAO_0000357,6011,,,8,Autocuration,1,CHEMBL620660,,
3043,H,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,5014,,,8,Autocuration,1,CHEMBL620661,,
3044,H,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,5635,,,8,Autocuration,1,CHEMBL620662,,
3045,H,Affinity for 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,5163,,,8,Expert,1,CHEMBL620663,,
3046,H,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,B,,BAO_0000357,6841,,,8,Autocuration,1,CHEMBL620664,,
3047,H,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,,B,,BAO_0000357,6119,,,8,Expert,1,CHEMBL620665,,
3048,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,,B,,BAO_0000357,4373,,,8,Autocuration,1,CHEMBL620666,,
3049,H,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,,B,,BAO_0000357,1633,,,8,Autocuration,1,CHEMBL620667,,
3050,H,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,,B,,BAO_0000357,1633,,,8,Expert,1,CHEMBL620668,,
3051,H,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,,B,,BAO_0000357,4373,,,8,Autocuration,1,CHEMBL620669,,
3052,H,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,6576,,,8,Expert,1,CHEMBL620670,,
3053,H,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,4687,,,8,Autocuration,1,CHEMBL620671,,
3054,H,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,,B,,BAO_0000357,12146,,,8,Autocuration,1,CHEMBL620672,,
3055,H,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,,B,,BAO_0000357,12146,,,8,Autocuration,1,CHEMBL620673,,
3056,H,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,16946,,,8,Autocuration,1,CHEMBL620674,,
3057,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,14159,,,8,Autocuration,1,CHEMBL620675,,
3058,H,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,,B,,BAO_0000357,16700,,,8,Autocuration,1,CHEMBL620676,,
3059,H,Affinity against 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,3269,,,8,Autocuration,1,CHEMBL621382,,
3060,D,Binding affinity against 5-hydroxytryptamine 2C receptor,,Homo sapiens,B,,BAO_0000357,1274,,9606.0,9,Expert,1,CHEMBL621383,,
3061,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,,B,,BAO_0000357,1317,,,8,Autocuration,1,CHEMBL621384,,
3062,H,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,Bos taurus,B,,BAO_0000357,5834,,9913.0,8,Autocuration,1,CHEMBL621385,,
3063,H,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,Bos taurus,B,,BAO_0000357,11147,,9913.0,8,Autocuration,1,CHEMBL617989,,
3064,H,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,Cavia porcellus,F,,BAO_0000019,14145,,10141.0,4,Expert,1,CHEMBL617990,,
3065,H,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,Cavia porcellus,B,,BAO_0000221,10561,,10141.0,4,Autocuration,1,CHEMBL875085,,2116.0
3066,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,Cavia porcellus,F,,BAO_0000019,15847,,10141.0,4,Autocuration,1,CHEMBL617991,,
3067,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,Cavia porcellus,F,,BAO_0000019,15847,,10141.0,4,Autocuration,1,CHEMBL617992,,
3068,H,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,Cavia porcellus,B,,BAO_0000221,10561,,10141.0,4,Autocuration,1,CHEMBL617993,,2116.0
3069,H,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,Cavia porcellus,B,,BAO_0000221,11454,,10141.0,4,Autocuration,1,CHEMBL617994,,2116.0
3070,H,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,Cavia porcellus,F,,BAO_0000019,4639,,10141.0,4,Autocuration,1,CHEMBL617995,,
3071,H,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,Cavia porcellus,F,,BAO_0000019,4639,,10141.0,4,Autocuration,1,CHEMBL617996,,
3072,H,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,Cavia porcellus,F,,BAO_0000019,4639,,10141.0,4,Autocuration,1,CHEMBL617997,,
3073,H,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,Cavia porcellus,F,,BAO_0000019,4639,,10141.0,4,Autocuration,1,CHEMBL617998,,
3074,H,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,Cavia porcellus,F,,BAO_0000019,4639,,10141.0,4,Autocuration,1,CHEMBL617999,,
3075,H,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,Cavia porcellus,F,,BAO_0000019,4639,,10141.0,4,Autocuration,1,CHEMBL618000,,
3076,H,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,Cavia porcellus,F,,BAO_0000221,15253,,10141.0,4,Autocuration,1,CHEMBL617815,,2116.0
3077,H,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,Cavia porcellus,F,,BAO_0000221,15253,,10141.0,4,Autocuration,1,CHEMBL617816,,2116.0
3078,H,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,Cavia porcellus,F,,BAO_0000221,11963,,10141.0,4,Autocuration,1,CHEMBL617817,,2116.0
3079,H,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,Cavia porcellus,B,,BAO_0000221,1946,,10141.0,4,Autocuration,1,CHEMBL617818,,2116.0
3080,H,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,Cavia porcellus,B,,BAO_0000221,1946,,10141.0,4,Autocuration,1,CHEMBL617819,,2116.0
3081,H,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,Cavia porcellus,B,,BAO_0000223,12045,,10141.0,4,Autocuration,1,CHEMBL617820,,
3082,H,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,Cavia porcellus,B,,BAO_0000221,1559,,10141.0,4,Autocuration,1,CHEMBL617821,,2116.0
3083,H,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,Cavia porcellus,F,,BAO_0000221,273,,10141.0,4,Autocuration,1,CHEMBL617822,,2116.0
3084,H,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,Cavia porcellus,F,,BAO_0000221,273,,10141.0,4,Autocuration,1,CHEMBL617823,,2116.0
3085,H,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,Cavia porcellus,F,,BAO_0000221,188,,10141.0,4,Autocuration,1,CHEMBL617824,,2116.0
3086,H,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,Cavia porcellus,F,,BAO_0000221,12919,,10141.0,4,Autocuration,1,CHEMBL617825,,2116.0
3087,H,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,Cavia porcellus,F,,BAO_0000221,12918,,10141.0,4,Autocuration,1,CHEMBL617826,,2116.0
3088,H,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,Cavia porcellus,B,,BAO_0000221,1559,,10141.0,4,Autocuration,1,CHEMBL617827,,2116.0
3089,H,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,Cavia porcellus,F,,BAO_0000221,273,,10141.0,4,Autocuration,1,CHEMBL617828,,2116.0
3090,H,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,Cavia porcellus,B,,BAO_0000221,1559,,10141.0,4,Autocuration,1,CHEMBL617829,,2116.0
3091,H,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,Cavia porcellus,B,,BAO_0000221,1559,,10141.0,4,Autocuration,1,CHEMBL617830,,2116.0
3092,H,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,Cavia porcellus,B,,BAO_0000221,1559,,10141.0,4,Autocuration,1,CHEMBL617831,,2116.0
3093,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,Cavia porcellus,B,,BAO_0000221,14424,,10141.0,4,Autocuration,1,CHEMBL617832,,2116.0
3094,U,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,Cavia porcellus,B,,BAO_0000019,13181,,10141.0,0,Autocuration,1,CHEMBL617833,,
3095,H,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,,B,,BAO_0000357,5486,,,8,Autocuration,1,CHEMBL617834,,
3096,D,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,Homo sapiens,B,,BAO_0000223,6491,,9606.0,5,Expert,1,CHEMBL617835,,
3097,H,Binding affinity towards 5-HT3 receptor,,,B,,BAO_0000223,6013,,,4,Autocuration,1,CHEMBL617836,,
3098,H,Binding activity radioligand.,,,B,,BAO_0000223,12861,,,4,Autocuration,1,CHEMBL617837,,
3099,H,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,,B,,BAO_0000019,12861,,,4,Autocuration,1,CHEMBL620392,,
3100,H,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000223,5104,,,4,Autocuration,1,CHEMBL620393,,
3101,H,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000223,5105,,,4,Autocuration,1,CHEMBL620394,,
3102,H,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,,B,,BAO_0000223,5104,,,4,Autocuration,1,CHEMBL620395,,
3103,U,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000019,3935,,,0,Autocuration,1,CHEMBL620396,,
3104,H,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,,B,,BAO_0000219,13657,,,4,Expert,1,CHEMBL620582,433.0,
3105,H,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,,B,,BAO_0000218,10369,In vivo,,4,Autocuration,1,CHEMBL620583,,
3106,H,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,B,,BAO_0000019,10369,,,4,Autocuration,1,CHEMBL620584,,
3107,H,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,,B,,BAO_0000224,12918,,,4,Autocuration,1,CHEMBL620585,,
3108,H,Compound was evaluated for the binding affinity at 5- HT3 receptor,,,B,,BAO_0000224,12918,,,4,Autocuration,1,CHEMBL620586,,
3109,H,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,B,,BAO_0000019,10369,,,4,Autocuration,1,CHEMBL620587,,
3110,H,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,B,,BAO_0000019,773,,,4,Autocuration,1,CHEMBL620588,,
3111,H,5-hydroxytryptamine 3 receptor agonism in mouse,,,F,,BAO_0000218,12918,,,4,Autocuration,1,CHEMBL620589,,
3112,H,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,,B,,BAO_0000219,10561,,,4,Autocuration,1,CHEMBL620590,,
3113,H,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,B,,BAO_0000019,12827,,,4,Autocuration,1,CHEMBL617956,,
3114,H,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,B,,BAO_0000019,12827,,,4,Autocuration,1,CHEMBL617957,,
3115,H,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,,B,,BAO_0000224,12918,,,4,Autocuration,1,CHEMBL617958,,
3116,H,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,B,,BAO_0000219,273,,,4,Autocuration,1,CHEMBL617959,,
3117,H,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,B,,BAO_0000219,273,,,4,Autocuration,1,CHEMBL617960,,
3118,H,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,B,,BAO_0000224,10561,,,4,Autocuration,1,CHEMBL617961,,
3119,H,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,,B,,BAO_0000219,5033,In vitro,,4,Autocuration,1,CHEMBL617962,,
3120,H,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,,B,,BAO_0000219,16429,,,4,Autocuration,1,CHEMBL617963,339.0,
3121,H,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,B,,BAO_0000019,10322,,,8,Autocuration,1,CHEMBL617964,,
3122,H,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,,B,,BAO_0000219,14331,,,8,Autocuration,1,CHEMBL617965,,
3123,D,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,Mus musculus,B,,BAO_0000357,13462,,10090.0,9,Autocuration,1,CHEMBL617966,,
3124,H,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,B,,BAO_0000019,12861,,,8,Autocuration,1,CHEMBL857074,,
3125,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,Sus scrofa,B,,BAO_0000357,15086,,9823.0,8,Autocuration,1,CHEMBL617967,,
3126,H,Binding activity radioligand.,,Sus scrofa,B,,BAO_0000357,12861,,9823.0,8,Autocuration,1,CHEMBL617968,,
3127,H,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,Oryctolagus cuniculus,B,,BAO_0000223,10561,,9986.0,4,Autocuration,1,CHEMBL617969,,
3128,H,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,Oryctolagus cuniculus,B,,BAO_0000223,10561,,9986.0,4,Autocuration,1,CHEMBL617970,,
3129,H,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,Oryctolagus cuniculus,B,,BAO_0000223,10561,,9986.0,4,Autocuration,1,CHEMBL617971,,
3130,H,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,Oryctolagus cuniculus,B,,BAO_0000019,10561,,9986.0,4,Autocuration,1,CHEMBL617972,,
3131,H,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,Oryctolagus cuniculus,F,,BAO_0000019,273,,9986.0,4,Autocuration,1,CHEMBL617973,,
3132,H,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,Oryctolagus cuniculus,F,,BAO_0000019,273,,9986.0,4,Autocuration,1,CHEMBL617974,,
3133,H,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,Oryctolagus cuniculus,F,,BAO_0000221,273,,9986.0,4,Autocuration,1,CHEMBL617975,,2116.0
3134,H,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,Oryctolagus cuniculus,F,,BAO_0000019,273,,9986.0,4,Autocuration,1,CHEMBL617976,,
3135,H,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,Oryctolagus cuniculus,F,,BAO_0000019,273,,9986.0,4,Autocuration,1,CHEMBL617977,,
3136,H,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,Oryctolagus cuniculus,F,,BAO_0000019,273,,9986.0,4,Autocuration,1,CHEMBL617978,,
3137,H,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,Oryctolagus cuniculus,F,,BAO_0000019,273,,9986.0,4,Autocuration,1,CHEMBL617979,,
3138,H,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,Oryctolagus cuniculus,B,,BAO_0000219,13047,,9986.0,4,Autocuration,1,CHEMBL617980,449.0,
3139,D,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,B,,BAO_0000019,1650,,10116.0,7,Autocuration,1,CHEMBL617981,,
3140,H,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,,B,,BAO_0000019,16288,,,8,Autocuration,1,CHEMBL617982,,
3141,H,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,,B,,BAO_0000357,16288,,,8,Autocuration,1,CHEMBL617983,,
3142,D,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,Rattus norvegicus,B,,BAO_0000019,10254,,10116.0,7,Autocuration,1,CHEMBL617984,,
3143,H,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,,B,,BAO_0000019,14532,,,6,Autocuration,1,CHEMBL617985,,
3144,H,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,F,,BAO_0000218,13392,In vivo,,6,Autocuration,1,CHEMBL617986,,948.0
3145,H,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,F,,BAO_0000019,13392,,,6,Autocuration,1,CHEMBL617987,,948.0
3146,H,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,F,,BAO_0000019,13392,,,6,Autocuration,1,CHEMBL617988,,948.0
3147,H,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,,F,,BAO_0000019,13392,,,6,Autocuration,1,CHEMBL617792,,948.0
3148,H,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,F,,BAO_0000019,13392,,,6,Autocuration,1,CHEMBL617793,,948.0
3149,H,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,,F,,BAO_0000019,13392,,,6,Autocuration,1,CHEMBL617794,,
3150,H,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,F,,BAO_0000019,13392,,,6,Autocuration,1,CHEMBL617795,,
3151,H,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,F,,BAO_0000019,13392,,,6,Autocuration,1,CHEMBL617796,,
3152,H,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,,F,,BAO_0000019,13392,,,6,Autocuration,1,CHEMBL617797,,
3153,D,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,Rattus norvegicus,F,,BAO_0000218,1089,In vivo,10116.0,7,Autocuration,1,CHEMBL617798,,
3154,H,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,,F,,BAO_0000218,1089,In vivo,,6,Autocuration,1,CHEMBL617799,,
3155,D,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,Rattus norvegicus,F,,BAO_0000218,11454,In vivo,10116.0,7,Autocuration,1,CHEMBL617800,,
3156,D,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,Rattus norvegicus,F,,BAO_0000019,11454,,10116.0,7,Autocuration,1,CHEMBL617801,,
3157,D,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,Rattus norvegicus,F,,BAO_0000218,12205,In vivo,10116.0,7,Autocuration,1,CHEMBL617802,,
3158,D,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,Rattus norvegicus,F,,BAO_0000019,1089,,10116.0,7,Autocuration,1,CHEMBL617803,,
3159,H,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,B,,BAO_0000019,5094,,,6,Autocuration,1,CHEMBL617804,,
3160,D,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,B,,BAO_0000019,2622,,10116.0,7,Autocuration,1,CHEMBL617805,,
3161,H,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000223,245,,,6,Autocuration,1,CHEMBL617806,,
3162,H,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,,B,,BAO_0000019,14788,,,6,Autocuration,1,CHEMBL617807,,
3163,H,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,,B,,BAO_0000019,14788,,,6,Autocuration,1,CHEMBL617808,,
3164,H,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,,B,,BAO_0000249,3020,,,6,Autocuration,1,CHEMBL617809,,
3165,H,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,,B,,BAO_0000019,1742,,,6,Autocuration,1,CHEMBL617810,,
3166,H,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,,B,,BAO_0000249,17394,,,6,Autocuration,1,CHEMBL617811,,955.0
3167,H,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,,B,,BAO_0000221,17394,,,6,Autocuration,1,CHEMBL617812,,955.0
3168,H,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,B,,BAO_0000249,17394,,,6,Autocuration,1,CHEMBL617813,,
3169,H,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,B,,BAO_0000249,14286,,,6,Autocuration,1,CHEMBL617814,,
3170,H,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,,B,,BAO_0000019,14178,,,6,Autocuration,1,CHEMBL617698,,
3171,D,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,Rattus norvegicus,B,,BAO_0000019,14178,,10116.0,7,Autocuration,1,CHEMBL617699,,
3172,D,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,Rattus norvegicus,B,,BAO_0000019,14178,,10116.0,7,Autocuration,1,CHEMBL617700,,
3173,D,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,B,,BAO_0000223,14178,,10116.0,7,Autocuration,1,CHEMBL617701,,
3174,H,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,B,,BAO_0000019,15034,,,6,Autocuration,1,CHEMBL617702,,
3175,H,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,,B,,BAO_0000249,1089,,,6,Autocuration,1,CHEMBL617703,,
3176,D,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,Rattus norvegicus,B,,BAO_0000019,1089,,10116.0,7,Autocuration,1,CHEMBL617704,,
3177,H,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,B,,BAO_0000223,16532,,,6,Autocuration,1,CHEMBL617705,,
3178,D,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,B,,BAO_0000223,12801,,10116.0,7,Autocuration,1,CHEMBL617706,,
3179,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,,B,,BAO_0000219,15194,,,6,Autocuration,1,CHEMBL617707,433.0,
3180,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,,B,,BAO_0000219,15194,,,6,Autocuration,1,CHEMBL617708,433.0,
3181,H,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,,B,,BAO_0000019,15194,,,6,Autocuration,1,CHEMBL617709,,
3182,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,,B,,BAO_0000019,15194,,,6,Autocuration,1,CHEMBL617710,,
3183,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,,B,,BAO_0000019,15194,,,6,Autocuration,1,CHEMBL882925,,
3184,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,,B,,BAO_0000019,15194,,,6,Autocuration,1,CHEMBL617711,,
3185,H,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,,F,,BAO_0000019,10610,,,6,Autocuration,1,CHEMBL617712,,
3186,D,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,Rattus norvegicus,F,,BAO_0000019,10355,,10116.0,7,Autocuration,1,CHEMBL617713,,
3187,H,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,,F,,BAO_0000019,691,,,6,Autocuration,1,CHEMBL617714,,
3188,H,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,,F,,BAO_0000218,10611,,,6,Autocuration,1,CHEMBL617715,,
3189,H,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,,F,,BAO_0000218,12801,In vivo,,6,Autocuration,1,CHEMBL617716,,
3190,H,Inhibition of 5-HT evoked reflex bradycardia in rat.,,,F,,BAO_0000218,10609,,,6,Autocuration,1,CHEMBL617717,,
3191,H,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617718,,
3192,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617719,,
3193,H,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617720,,
3194,D,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,Rattus norvegicus,F,,BAO_0000218,11454,In vivo,10116.0,7,Autocuration,1,CHEMBL617721,,
3195,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617722,,
3196,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617723,,
3197,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617724,,
3198,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617725,,
3199,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617726,,
3200,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617727,,
3201,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617728,,
3202,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617729,,
3203,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617730,,
3204,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617731,,
3205,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617732,,
3206,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617733,,
3207,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617734,,
3208,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL872874,,
3209,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617735,,
3210,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617736,,
3211,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617737,,
3212,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617738,,
3213,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617739,,
3214,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617740,,
3215,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617741,,
3216,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617742,,
3217,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617743,,
3218,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617744,,
3219,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,,F,,BAO_0000218,11454,In vivo,,6,Autocuration,1,CHEMBL617745,,
3220,H,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,,F,,BAO_0000218,670,,,6,Autocuration,1,CHEMBL617746,,
3221,H,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,,F,,BAO_0000218,670,,,6,Autocuration,1,CHEMBL617747,,
3222,H,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,,F,,BAO_0000218,10321,In vivo,,6,Autocuration,1,CHEMBL617748,,
3223,H,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,,F,,BAO_0000218,10321,In vivo,,6,Autocuration,1,CHEMBL618909,,
3224,H,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,,F,,BAO_0000218,10321,In vivo,,6,Autocuration,1,CHEMBL618910,,
3225,H,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,,F,,BAO_0000218,10321,In vivo,,6,Autocuration,1,CHEMBL618911,,
3226,H,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,,F,,BAO_0000218,10321,In vivo,,6,Autocuration,1,CHEMBL618912,,
3227,H,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,,F,,BAO_0000218,10322,In vivo,,6,Autocuration,1,CHEMBL618913,,
3228,H,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,F,,BAO_0000019,15412,,,6,Autocuration,1,CHEMBL618914,,
3229,H,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,F,,BAO_0000019,15412,,,6,Autocuration,1,CHEMBL618915,,
3230,D,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,B,,BAO_0000223,15412,,10116.0,7,Autocuration,1,CHEMBL618916,,
3231,H,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,,F,,BAO_0000019,15412,,,6,Autocuration,1,CHEMBL618917,,
3232,D,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,,B,,BAO_0000221,15412,,,7,Intermediate,1,CHEMBL618918,,10000000.0
3233,D,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,Rattus norvegicus,B,,BAO_0000019,15412,,10116.0,7,Autocuration,1,CHEMBL618919,,
3234,D,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,B,,BAO_0000019,17394,,10116.0,7,Autocuration,1,CHEMBL618920,,
3235,H,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000223,12457,,,6,Autocuration,1,CHEMBL618921,,
3236,H,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000019,12457,,,6,Autocuration,1,CHEMBL618922,,
3237,H,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,,B,,BAO_0000019,12205,,,6,Autocuration,1,CHEMBL618923,,
3238,H,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,,B,,BAO_0000019,14532,,,6,Autocuration,1,CHEMBL618924,,
3239,H,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,,B,,BAO_0000019,1122,,,6,Autocuration,1,CHEMBL618925,,
3240,H,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,B,,BAO_0000019,5094,,,6,Autocuration,1,CHEMBL618926,,
3241,D,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,Cavia porcellus,F,,BAO_0000221,809,,10141.0,9,Intermediate,1,CHEMBL618927,,2116.0
3242,D,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,Cavia porcellus,F,,BAO_0000221,809,,10141.0,9,Intermediate,1,CHEMBL618928,,2116.0
3243,D,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,Cavia porcellus,F,,BAO_0000221,14290,,10141.0,9,Intermediate,1,CHEMBL618929,,2116.0
3244,D,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,Cavia porcellus,F,,BAO_0000221,14290,,10141.0,9,Intermediate,1,CHEMBL618930,,2116.0
3245,D,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,Cavia porcellus,F,,BAO_0000221,14290,,10141.0,9,Intermediate,1,CHEMBL618931,,2116.0
3246,D,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,Cavia porcellus,F,,BAO_0000221,14290,,10141.0,9,Intermediate,1,CHEMBL619594,,2116.0
3247,D,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,Cavia porcellus,F,,BAO_0000221,14290,,10141.0,9,Intermediate,1,CHEMBL619595,,2116.0
3248,D,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,Cavia porcellus,F,,BAO_0000221,13961,,10141.0,9,Intermediate,1,CHEMBL619596,,2116.0
3249,D,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,Cavia porcellus,F,,BAO_0000221,13961,,10141.0,9,Intermediate,1,CHEMBL619755,,2116.0
3250,D,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,Cavia porcellus,F,,BAO_0000221,809,,10141.0,9,Intermediate,1,CHEMBL619756,,2116.0
3251,D,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,Cavia porcellus,F,,BAO_0000221,809,,10141.0,9,Intermediate,1,CHEMBL619757,,2116.0
3252,D,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,Cavia porcellus,F,,BAO_0000221,809,,10141.0,9,Intermediate,1,CHEMBL619758,,2116.0
3253,D,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,Cavia porcellus,F,,BAO_0000221,14290,,10141.0,9,Intermediate,1,CHEMBL619759,,2116.0
3254,D,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,Cavia porcellus,F,,BAO_0000221,14290,,10141.0,9,Intermediate,1,CHEMBL619760,,2116.0
3255,D,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,Cavia porcellus,F,,BAO_0000221,14290,,10141.0,9,Intermediate,1,CHEMBL619761,,2116.0
3256,D,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,Cavia porcellus,F,,BAO_0000221,14290,,10141.0,9,Intermediate,1,CHEMBL619762,,2116.0
3257,D,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,Cavia porcellus,F,,BAO_0000221,14290,,10141.0,9,Intermediate,1,CHEMBL619763,,2116.0
3258,D,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,Cavia porcellus,F,,BAO_0000221,14290,,10141.0,9,Intermediate,1,CHEMBL617868,,2116.0
3259,D,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,Cavia porcellus,B,,BAO_0000357,15034,,10141.0,9,Intermediate,1,CHEMBL617869,,
3260,D,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,Cavia porcellus,B,,BAO_0000249,5094,,10141.0,9,Intermediate,1,CHEMBL882926,,2435.0
3261,D,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,Cavia porcellus,B,,BAO_0000249,5094,,10141.0,9,Intermediate,1,CHEMBL617870,,2435.0
3262,D,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,Cavia porcellus,B,,BAO_0000357,5399,,10141.0,9,Intermediate,1,CHEMBL617871,,2435.0
3263,D,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,Cavia porcellus,B,,BAO_0000357,17394,,10141.0,9,Intermediate,1,CHEMBL617872,,2435.0
3264,D,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,Cavia porcellus,B,,BAO_0000357,17394,,10141.0,9,Intermediate,1,CHEMBL617873,,2435.0
3265,D,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,Cavia porcellus,B,,BAO_0000357,17394,,10141.0,9,Intermediate,1,CHEMBL617874,,2435.0
3266,D,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,Cavia porcellus,F,,BAO_0000221,13961,,10141.0,9,Intermediate,1,CHEMBL619067,,2116.0
3267,D,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,Cavia porcellus,F,,BAO_0000221,13961,,10141.0,9,Intermediate,1,CHEMBL619068,,2116.0
3268,D,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,Cavia porcellus,F,,BAO_0000221,13961,,10141.0,9,Intermediate,1,CHEMBL619069,,2116.0
3269,D,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,Cavia porcellus,B,,BAO_0000357,16946,,10141.0,9,Intermediate,1,CHEMBL619070,,
3270,D,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,Cavia porcellus,B,,BAO_0000357,16946,,10141.0,9,Intermediate,1,CHEMBL619071,,
3271,D,Agonistic activity against 5-hydroxytryptamine 4 receptor,,Cavia porcellus,F,,BAO_0000019,15034,,10141.0,9,Intermediate,1,CHEMBL619072,,
3272,D,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,Cavia porcellus,F,,BAO_0000019,15034,,10141.0,9,Intermediate,1,CHEMBL619073,,
3273,D,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,Cavia porcellus,F,,BAO_0000019,12918,,10141.0,9,Intermediate,1,CHEMBL619074,,
3274,D,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,Cavia porcellus,B,,BAO_0000357,16946,,10141.0,9,Intermediate,1,CHEMBL619075,,
3275,D,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,Cavia porcellus,B,,BAO_0000357,17394,,10141.0,9,Intermediate,1,CHEMBL619076,,2435.0
3276,D,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,Cavia porcellus,B,,BAO_0000357,15034,,10141.0,9,Intermediate,1,CHEMBL619077,,2435.0
3277,D,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,Cavia porcellus,B,,BAO_0000249,5094,,10141.0,9,Intermediate,1,CHEMBL619078,,2435.0
3278,D,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,Cavia porcellus,B,,BAO_0000249,5094,,10141.0,9,Intermediate,1,CHEMBL619079,,2435.0
3279,D,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,Cavia porcellus,B,,BAO_0000221,17358,,10141.0,9,Intermediate,1,CHEMBL619080,,2116.0
3280,D,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,Cavia porcellus,B,,BAO_0000357,12953,,10141.0,9,Expert,1,CHEMBL619081,,
3281,D,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,Cavia porcellus,B,,BAO_0000357,12953,,10141.0,9,Intermediate,1,CHEMBL619082,,
3282,D,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,Cavia porcellus,B,,BAO_0000357,12953,,10141.0,9,Intermediate,1,CHEMBL619083,,
3283,D,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,Cavia porcellus,B,,BAO_0000357,12953,,10141.0,9,Intermediate,1,CHEMBL619084,,
3284,D,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,Cavia porcellus,F,,BAO_0000221,273,,10141.0,9,Intermediate,1,CHEMBL859397,,2116.0
3285,D,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,Cavia porcellus,F,,BAO_0000221,12918,,10141.0,9,Intermediate,1,CHEMBL619085,,2116.0
3286,D,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,Cavia porcellus,F,,BAO_0000221,12919,,10141.0,9,Intermediate,1,CHEMBL619086,,2116.0
3287,D,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,Cavia porcellus,F,,BAO_0000221,273,,10141.0,9,Intermediate,1,CHEMBL619087,,2116.0
3288,D,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,Cavia porcellus,F,,BAO_0000221,273,,10141.0,9,Intermediate,1,CHEMBL619088,,2116.0
3289,D,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,Cavia porcellus,B,,BAO_0000357,13181,,10141.0,9,Intermediate,1,CHEMBL619089,,
3290,H,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,Cavia porcellus,B,,BAO_0000357,13181,,10141.0,8,Autocuration,1,CHEMBL619090,,
3291,D,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,Cavia porcellus,F,,BAO_0000019,15034,,10141.0,9,Intermediate,1,CHEMBL619091,,
3292,D,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,Cavia porcellus,B,,BAO_0000357,5033,,10141.0,9,Intermediate,1,CHEMBL619092,,
3293,D,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,Cavia porcellus,B,,BAO_0000019,1980,,10141.0,9,Intermediate,1,CHEMBL619093,,
3294,H,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,Cavia porcellus,B,,BAO_0000219,13181,,10141.0,8,Autocuration,1,CHEMBL619094,722.0,
3295,D,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,Cavia porcellus,B,,BAO_0000019,14287,,10141.0,9,Intermediate,1,CHEMBL619095,,
3296,D,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,Cavia porcellus,B,,BAO_0000357,1317,,10141.0,9,Intermediate,1,CHEMBL857988,,
3297,D,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,Cavia porcellus,B,,BAO_0000357,15316,,10141.0,9,Intermediate,1,CHEMBL619096,,
3298,D,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,Cavia porcellus,B,,BAO_0000357,16429,,10141.0,9,Intermediate,1,CHEMBL619097,,2435.0
3299,D,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,Cavia porcellus,B,,BAO_0000221,14818,,10141.0,9,Intermediate,1,CHEMBL619098,,10000000.0
3300,D,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,Cavia porcellus,B,,BAO_0000357,15194,,10141.0,9,Intermediate,1,CHEMBL619751,,
3301,D,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,Cavia porcellus,B,,BAO_0000357,15194,,10141.0,9,Intermediate,1,CHEMBL619752,,
3302,D,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,Cavia porcellus,F,,BAO_0000221,13961,,10141.0,9,Intermediate,1,CHEMBL875096,,2116.0
3303,H,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,,B,,BAO_0000357,5486,,,8,Autocuration,1,CHEMBL619004,,
3304,H,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,,B,,BAO_0000357,16209,,,8,Autocuration,1,CHEMBL619005,,
3305,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,,B,,BAO_0000019,17085,,,8,Autocuration,1,CHEMBL619006,,
3306,H,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,,B,,BAO_0000219,4199,,,8,Autocuration,1,CHEMBL619007,308.0,
3307,H,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,,B,,BAO_0000357,15146,,,8,Autocuration,1,CHEMBL619008,,
3308,H,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,,B,,BAO_0000357,5213,,,8,Autocuration,1,CHEMBL619009,,
3309,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,,B,,BAO_0000219,4829,,,8,Autocuration,1,CHEMBL619010,308.0,
3310,H,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,,B,,BAO_0000357,17358,,,8,Autocuration,1,CHEMBL619011,,
3311,H,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,,B,,BAO_0000357,17358,,,8,Autocuration,1,CHEMBL619012,,
3312,H,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,,B,,BAO_0000219,16946,,,8,Autocuration,1,CHEMBL619013,,
3313,H,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,,B,,BAO_0000357,17358,,,8,Autocuration,1,CHEMBL619014,,
3314,H,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,,F,,BAO_0000019,268,,,8,Autocuration,1,CHEMBL857503,,2081.0
3315,H,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,,F,,BAO_0000019,268,,,8,Autocuration,1,CHEMBL619015,,2081.0
3316,H,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,,B,,BAO_0000357,15086,,,8,Autocuration,1,CHEMBL619016,,
3317,H,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,,B,,BAO_0000221,14875,,,8,Autocuration,1,CHEMBL619017,,10000000.0
3318,H,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,Sus scrofa,B,,BAO_0000221,13267,,9823.0,8,Autocuration,1,CHEMBL619018,,10000000.0
3319,H,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,B,,BAO_0000019,13047,,9986.0,8,Autocuration,1,CHEMBL619019,,
3320,D,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,Rattus norvegicus,B,,BAO_0000357,1650,,10116.0,9,Expert,1,CHEMBL619020,,
3321,H,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,F,,BAO_0000019,567,,,8,Autocuration,1,CHEMBL619021,,
3322,H,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,,B,,BAO_0000357,17358,,,8,Autocuration,1,CHEMBL619022,,
3323,H,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,,B,,BAO_0000357,188,,,8,Autocuration,1,CHEMBL619023,,
3324,H,lntrinsic activity relative to 5-HT receptor,,,F,,BAO_0000019,670,,,8,Autocuration,1,CHEMBL619024,,
3325,H,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,,F,,BAO_0000019,204,,,8,Autocuration,1,CHEMBL619025,,
3326,H,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,,F,,BAO_0000019,1946,,,8,Expert,1,CHEMBL619026,,
3327,H,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,,F,,BAO_0000019,6398,,,8,Autocuration,1,CHEMBL619027,,
3328,H,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,,F,,BAO_0000019,6398,,,8,Autocuration,1,CHEMBL619028,,
3329,H,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,,F,,BAO_0000019,17358,,,8,Autocuration,1,CHEMBL619029,,
3330,H,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,,F,,BAO_0000019,6398,,,8,Autocuration,1,CHEMBL619030,,
3331,H,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,,B,,BAO_0000357,11752,,,8,Expert,1,CHEMBL619031,,
3332,H,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,,F,,BAO_0000019,809,,,8,Autocuration,1,CHEMBL619032,,
3333,D,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,Rattus norvegicus,B,,BAO_0000357,14178,,10116.0,9,Expert,1,CHEMBL619033,,
3334,H,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,B,,BAO_0000357,567,,,8,Autocuration,1,CHEMBL619034,,
3335,H,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,,B,,BAO_0000357,1946,,,8,Autocuration,1,CHEMBL619035,,
3336,H,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,,B,,BAO_0000357,1946,,,8,Autocuration,1,CHEMBL619036,,
3337,D,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,Rattus norvegicus,B,,BAO_0000019,13961,,10116.0,9,Expert,1,CHEMBL619037,,
3338,H,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,,B,,BAO_0000249,6238,,,8,Autocuration,1,CHEMBL619038,,2435.0
3339,H,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,,B,,BAO_0000249,14290,,,8,Autocuration,1,CHEMBL619039,,
3340,H,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,,B,,BAO_0000249,14290,,,8,Expert,1,CHEMBL619040,,
3341,D,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,Rattus norvegicus,B,,BAO_0000019,809,,10116.0,9,Expert,1,CHEMBL619041,,2435.0
3342,H,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,B,,BAO_0000019,1578,,,8,Autocuration,1,CHEMBL619042,,2435.0
3343,H,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,,B,,BAO_0000249,16709,,,8,Expert,1,CHEMBL619043,,2435.0
3344,H,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,,B,,BAO_0000019,1946,,,8,Expert,1,CHEMBL619044,,2435.0
3345,H,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,,B,,BAO_0000249,15253,,,8,Expert,1,CHEMBL619045,,2435.0
3346,H,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,B,,BAO_0000249,4535,,,8,Expert,1,CHEMBL619046,,2435.0
3347,H,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,,B,,BAO_0000249,13961,,,8,Expert,1,CHEMBL619047,,
3348,H,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,,F,,BAO_0000221,17358,,,8,Autocuration,1,CHEMBL619048,,955.0
3349,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,,F,,BAO_0000019,15847,,,8,Autocuration,1,CHEMBL859398,,
3350,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,,F,,BAO_0000019,15847,,,8,Autocuration,1,CHEMBL619049,,
3351,H,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,,F,,BAO_0000019,670,,,8,Autocuration,1,CHEMBL857886,,
3352,H,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,,F,,BAO_0000019,670,,,8,Autocuration,1,CHEMBL619050,,
3353,H,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,F,,BAO_0000019,1317,,,8,Autocuration,1,CHEMBL620591,,
3354,D,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,Rattus norvegicus,B,,BAO_0000357,12936,,10116.0,9,Expert,1,CHEMBL620592,,
3355,H,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,B,,BAO_0000249,4535,,,8,Expert,1,CHEMBL620593,,2435.0
3356,D,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,Rattus norvegicus,F,,BAO_0000019,14424,,10116.0,9,Expert,1,CHEMBL620594,,
3357,H,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,,F,,BAO_0000019,14424,,,8,Expert,1,CHEMBL875079,,
3358,H,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,F,,BAO_0000019,14424,,,8,Expert,1,CHEMBL620595,,
3359,D,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,Rattus norvegicus,F,,BAO_0000019,14424,,10116.0,9,Expert,1,CHEMBL620596,,
3360,H,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,,F,,BAO_0000019,14424,,,8,Autocuration,1,CHEMBL620597,,
3361,H,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,,F,,BAO_0000019,14424,,,8,Expert,1,CHEMBL620598,,
3362,H,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,,F,,BAO_0000218,14424,,,8,Expert,1,CHEMBL620599,,
3363,H,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,F,,BAO_0000019,14424,,,8,Autocuration,1,CHEMBL620600,,
3364,H,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,Rattus norvegicus,F,,BAO_0000019,1980,,10116.0,8,Autocuration,1,CHEMBL620601,,
3365,H,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,,F,,BAO_0000019,4639,,,8,Autocuration,1,CHEMBL620602,,
3366,H,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,,B,,BAO_0000357,17358,,,8,Autocuration,1,CHEMBL620603,,
3367,H,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,,B,,BAO_0000357,17358,,,8,Autocuration,1,CHEMBL620604,,
3368,H,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,,B,,BAO_0000357,17358,,,8,Autocuration,1,CHEMBL620605,,
3369,H,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,,B,,BAO_0000357,1558,,,8,Autocuration,1,CHEMBL620606,,
3370,H,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,F,,BAO_0000019,17358,,,8,Autocuration,1,CHEMBL620607,,
3371,H,In vitro binding affinity towards 5-HT4 receptor was determined,,,B,,BAO_0000357,16117,,,8,Autocuration,1,CHEMBL620608,,
3372,H,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,F,,BAO_0000019,17358,,,8,Autocuration,1,CHEMBL620609,,
3373,H,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,,F,,BAO_0000019,17358,,,8,Autocuration,1,CHEMBL620610,,
3374,H,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,,B,,BAO_0000357,17358,,,8,Autocuration,1,CHEMBL620611,,
3375,H,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,,B,,BAO_0000357,17358,,,8,Autocuration,1,CHEMBL620612,,
3376,H,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,,B,,BAO_0000357,17358,,,8,Autocuration,1,CHEMBL620613,,
3377,H,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,,B,,BAO_0000357,17358,,,8,Autocuration,1,CHEMBL620614,,
3378,H,Binding affinity against 5-Hydroxytryptamine 4 receptor,,,B,,BAO_0000357,1274,,,8,Expert,1,CHEMBL620615,,
3379,H,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,,B,,BAO_0000249,10728,,,6,Autocuration,1,CHEMBL857075,,
3380,H,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,,B,,BAO_0000249,11695,,,6,Autocuration,1,CHEMBL620616,,
3381,H,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,,B,,BAO_0000249,11695,,,6,Autocuration,1,CHEMBL619411,,
3382,H,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,,B,,BAO_0000019,12490,,,6,Autocuration,1,CHEMBL619412,,
3383,D,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,B,,BAO_0000019,11828,,10116.0,7,Autocuration,1,CHEMBL619413,,
3384,H,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,,B,,BAO_0000221,12253,,,6,Autocuration,1,CHEMBL619414,,10000000.0
3385,H,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,B,,BAO_0000019,10561,,,6,Autocuration,1,CHEMBL619415,,
3386,H,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,,B,,BAO_0000019,10561,,,6,Autocuration,1,CHEMBL619416,,
3387,H,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,,F,,BAO_0000019,14432,,,6,Autocuration,1,CHEMBL619417,,
3388,D,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,B,,BAO_0000223,12936,,10116.0,7,Autocuration,1,CHEMBL619418,,
3389,D,Binding affinity against 5-Hydroxytryptamine 3 receptor,,Rattus norvegicus,B,,BAO_0000223,1274,,10116.0,7,Autocuration,1,CHEMBL619419,,
3390,H,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,,B,,BAO_0000019,1980,,,6,Autocuration,1,CHEMBL619420,,
3391,H,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,,B,,BAO_0000249,670,,,6,Autocuration,1,CHEMBL619421,,
3392,D,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,Rattus norvegicus,B,,BAO_0000019,968,,10116.0,7,Autocuration,1,CHEMBL619422,,
3393,H,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,,B,,BAO_0000019,14287,,,6,Autocuration,1,CHEMBL619423,,
3394,H,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,,B,,BAO_0000019,567,,,6,Autocuration,1,CHEMBL875080,,
3395,H,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,,B,,BAO_0000019,13267,,,6,Autocuration,1,CHEMBL619424,,
3396,H,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,,B,,BAO_0000249,14826,,,6,Autocuration,1,CHEMBL619425,,
3397,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,,B,,BAO_0000223,15194,,,6,Autocuration,1,CHEMBL619426,,
3398,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,,B,,BAO_0000223,15194,,,6,Autocuration,1,CHEMBL619427,,
3399,D,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,B,,BAO_0000223,10394,,10116.0,7,Autocuration,1,CHEMBL619645,,
3400,D,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,,B,,BAO_0000249,13657,,,9,Expert,1,CHEMBL619646,,
3401,H,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,,F,,BAO_0000221,1879,,,8,Autocuration,1,CHEMBL619647,,955.0
3402,H,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,,F,,BAO_0000019,1879,,,8,Autocuration,1,CHEMBL619648,,
3403,H,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,,F,,BAO_0000019,1879,,,8,Autocuration,1,CHEMBL619165,,
3404,H,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,,F,,BAO_0000218,204,In vivo,,8,Autocuration,1,CHEMBL620719,,
3405,H,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,B,,BAO_0000019,1879,,,8,Autocuration,1,CHEMBL872924,,
3406,H,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000357,1879,,,8,Autocuration,1,CHEMBL620720,,
3407,H,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,B,,BAO_0000019,1879,,,8,Autocuration,1,CHEMBL620721,,
3408,H,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,,B,,BAO_0000019,1879,,,8,Autocuration,1,CHEMBL620722,,
3409,H,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,,B,,BAO_0000019,10641,,,6,Autocuration,1,CHEMBL620723,,
3410,H,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,B,,BAO_0000019,773,,,8,Autocuration,1,CHEMBL620724,,
3411,H,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,,B,,BAO_0000249,11952,,,6,Autocuration,1,CHEMBL620725,,
3412,D,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,Rattus norvegicus,F,,BAO_0000019,14145,,10116.0,9,Autocuration,1,CHEMBL620726,,
3413,H,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000357,17066,,,8,Expert,1,CHEMBL620727,,
3414,H,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,,B,,BAO_0000223,6398,,,4,Autocuration,1,CHEMBL620728,,
3415,U,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,B,,BAO_0000019,10321,,,0,Autocuration,1,CHEMBL620729,,
3416,H,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,,F,,BAO_0000019,511,,,4,Autocuration,1,CHEMBL858288,,
3417,H,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000223,4639,,,4,Autocuration,1,CHEMBL620730,,
3418,H,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000223,4639,,,4,Autocuration,1,CHEMBL620731,,
3419,H,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,Cavia porcellus,F,,BAO_0000019,4639,,10141.0,4,Autocuration,1,CHEMBL620732,,
3420,H,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,Cavia porcellus,F,,BAO_0000019,4639,,10141.0,4,Autocuration,1,CHEMBL618042,,
3421,H,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,Cavia porcellus,F,,BAO_0000019,4639,,10141.0,4,Autocuration,1,CHEMBL618043,,
3422,H,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000223,1558,,,4,Autocuration,1,CHEMBL618044,,
3423,H,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,,F,,BAO_0000019,268,,,4,Autocuration,1,CHEMBL618045,,
3424,H,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,,B,,BAO_0000223,2474,,,4,Autocuration,1,CHEMBL618046,,
3425,H,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,,F,,BAO_0000019,5067,,,4,Autocuration,1,CHEMBL618047,,
3426,H,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,,F,,BAO_0000019,5067,,,4,Autocuration,1,CHEMBL875084,,
3427,H,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,,F,,BAO_0000019,5067,,,4,Autocuration,1,CHEMBL618048,,
3428,H,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,,B,,BAO_0000223,5067,,,4,Autocuration,1,CHEMBL618049,,
3429,H,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,,F,,BAO_0000019,5067,,,4,Autocuration,1,CHEMBL619764,,
3430,H,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,,F,,BAO_0000019,5067,,,4,Autocuration,1,CHEMBL619765,,
3431,H,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,,F,,BAO_0000019,5067,,,4,Autocuration,1,CHEMBL619766,,
3432,H,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,,B,,BAO_0000223,5067,,,4,Autocuration,1,CHEMBL619767,,
3433,H,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,,B,,BAO_0000223,5067,,,4,Autocuration,1,CHEMBL619768,,
3434,H,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,,F,,BAO_0000019,5067,,,4,Autocuration,1,CHEMBL619769,,
3435,H,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,,B,,BAO_0000223,5067,,,4,Autocuration,1,CHEMBL619770,,
3436,H,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000223,5067,,,4,Autocuration,1,CHEMBL619771,,
3437,H,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,,B,,BAO_0000219,14331,,,4,Autocuration,1,CHEMBL619772,,
3438,H,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,,B,,BAO_0000223,5067,,,4,Autocuration,1,CHEMBL619773,,
3439,H,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,,B,,BAO_0000219,6179,,,4,Autocuration,1,CHEMBL619774,433.0,
3440,H,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,,B,,BAO_0000019,4265,,,4,Autocuration,1,CHEMBL875083,,
3441,H,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,,B,,BAO_0000219,4265,,,4,Autocuration,1,CHEMBL620718,433.0,
3442,H,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,B,,BAO_0000223,17358,,,4,Autocuration,1,CHEMBL618127,,
3443,H,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,,B,,BAO_0000223,17358,,,4,Autocuration,1,CHEMBL618128,,
3444,H,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,,B,,BAO_0000219,13628,In vitro,,4,Autocuration,1,CHEMBL618129,,
3445,H,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,B,,BAO_0000223,4612,,,4,Autocuration,1,CHEMBL618130,,
3446,H,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,,F,,BAO_0000019,17358,,,4,Autocuration,1,CHEMBL618131,,
3447,H,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,Cavia porcellus,F,,BAO_0000019,4639,,10141.0,4,Autocuration,1,CHEMBL618132,,
3448,H,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,Cavia porcellus,F,,BAO_0000019,4639,,10141.0,4,Autocuration,1,CHEMBL618133,,
3449,H,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,Cavia porcellus,F,,BAO_0000019,4639,,10141.0,4,Autocuration,1,CHEMBL618134,,
3450,H,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,Cavia porcellus,F,,BAO_0000019,4639,,10141.0,4,Autocuration,1,CHEMBL618135,,
3451,H,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,,B,,BAO_0000223,511,,,4,Autocuration,1,CHEMBL618136,,
3452,H,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000223,1479,,,4,Autocuration,1,CHEMBL618137,,
3453,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,,B,,BAO_0000223,1317,,,4,Autocuration,1,CHEMBL618138,,
3454,H,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,,B,,BAO_0000223,12146,,,4,Autocuration,1,CHEMBL618139,,
3455,H,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,,B,,BAO_0000223,12146,,,4,Autocuration,1,CHEMBL618140,,
3456,H,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,,B,,BAO_0000223,13969,,,4,Autocuration,1,CHEMBL618141,,
3457,H,Binding affinity for 5-hydroxytryptamine 2C receptor,,,B,,BAO_0000357,13392,,,8,Expert,1,CHEMBL873478,,
3458,H,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000223,13392,,,6,Autocuration,1,CHEMBL618142,,
3459,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000357,14159,,,8,Autocuration,1,CHEMBL618143,,
3460,H,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000357,1558,,,8,Autocuration,1,CHEMBL618144,,
3461,H,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000357,16655,,,8,Autocuration,1,CHEMBL618145,,
3462,H,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,B,,BAO_0000223,13020,,,4,Autocuration,1,CHEMBL618146,,
3463,H,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,,B,,BAO_0000223,13021,,,4,Autocuration,1,CHEMBL618147,,
3464,H,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,B,,BAO_0000223,13020,,,4,Autocuration,1,CHEMBL618148,,
3465,H,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,B,,BAO_0000019,10321,,,8,Autocuration,1,CHEMBL618149,,
3466,H,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000357,15818,,,8,Autocuration,1,CHEMBL872927,,
3467,H,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000357,15818,,,8,Autocuration,1,CHEMBL618150,,
3468,H,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,B,,BAO_0000357,17358,,,8,Autocuration,1,CHEMBL618151,,
3469,H,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000357,2222,,,8,Autocuration,1,CHEMBL875094,,
3470,H,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,B,,BAO_0000019,10322,,,8,Autocuration,1,CHEMBL618152,,
3471,H,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,B,,BAO_0000357,16117,,,8,Autocuration,1,CHEMBL618153,,
3472,H,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,,B,,BAO_0000357,17200,,,8,Autocuration,1,CHEMBL618888,,
3473,H,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,,F,,BAO_0000019,17358,,,8,Autocuration,1,CHEMBL618889,,
3474,H,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,,B,,BAO_0000357,16700,,,8,Autocuration,1,CHEMBL618890,,
3475,H,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,,B,,BAO_0000019,1980,,,8,Autocuration,1,CHEMBL618891,,
3476,H,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,,B,,BAO_0000019,1980,,,8,Autocuration,1,CHEMBL619054,,
3477,H,Binding affinity against the 5-hydroxytryptamine 3 receptor,,,B,,BAO_0000223,12409,,,4,Autocuration,1,CHEMBL619055,,
3478,H,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,B,,BAO_0000357,4365,,,8,Autocuration,1,CHEMBL619056,,
3479,H,Percent efficacy against 5-hydroxytryptamine 3A receptor,,,F,,BAO_0000019,4365,,,8,Autocuration,1,CHEMBL619057,,
3480,H,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,B,,BAO_0000357,4365,,,8,Autocuration,1,CHEMBL619058,,
3481,D,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,Rattus norvegicus,F,,BAO_0000219,6769,,10116.0,9,Expert,1,CHEMBL619059,,
3482,D,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,Rattus norvegicus,F,,BAO_0000219,6769,,10116.0,9,Expert,1,CHEMBL619060,,
3483,D,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,Rattus norvegicus,F,,BAO_0000219,6769,,10116.0,9,Expert,1,CHEMBL875095,,
3484,D,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,Cavia porcellus,F,,BAO_0000221,809,,10141.0,9,Intermediate,1,CHEMBL619061,,2116.0
3485,D,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,Cavia porcellus,F,,BAO_0000221,809,,10141.0,9,Intermediate,1,CHEMBL619062,,2116.0
3486,D,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,Cavia porcellus,F,,BAO_0000019,14290,,10141.0,9,Intermediate,1,CHEMBL619063,,
3487,D,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,Cavia porcellus,B,,BAO_0000221,17358,,10141.0,9,Intermediate,1,CHEMBL619064,,2116.0
3488,D,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,Cavia porcellus,B,,BAO_0000357,17358,,10141.0,9,Intermediate,1,CHEMBL619065,,
3489,D,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,Cavia porcellus,B,,BAO_0000221,17358,,10141.0,9,Intermediate,1,CHEMBL619066,,2116.0
3490,H,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,B,,BAO_0000221,17386,,,8,Autocuration,1,CHEMBL619775,,2116.0
3491,H,Affinity against 5-hydroxytryptamine 7 receptor,,,B,,BAO_0000357,3269,,,8,Autocuration,1,CHEMBL619776,,
3492,H,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,Cavia porcellus,B,,BAO_0000224,7721,,10141.0,4,Autocuration,1,CHEMBL619777,,
3493,H,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,Cavia porcellus,B,,BAO_0000224,7721,,10141.0,4,Autocuration,1,CHEMBL619778,,
3494,H,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,Cavia porcellus,B,,BAO_0000221,9117,,10141.0,4,Autocuration,1,CHEMBL619779,,2116.0
3495,H,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,Cavia porcellus,B,,BAO_0000224,7721,,10141.0,4,Autocuration,1,CHEMBL619780,,
3496,H,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,Cavia porcellus,B,,BAO_0000224,7721,,10141.0,4,Autocuration,1,CHEMBL619166,,
3497,H,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,Cavia porcellus,F,,BAO_0000019,15796,,10141.0,4,Autocuration,1,CHEMBL619167,,
3498,H,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,Cavia porcellus,F,,BAO_0000019,15796,,10141.0,4,Autocuration,1,CHEMBL619168,,
3499,D,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,Homo sapiens,B,,BAO_0000219,15650,,9606.0,9,Expert,1,CHEMBL619169,,2081.0
3500,D,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,Homo sapiens,B,,BAO_0000219,15650,,9606.0,9,Expert,1,CHEMBL619170,,2081.0
3501,D,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,Homo sapiens,F,,BAO_0000019,6866,,9606.0,5,Autocuration,1,CHEMBL619171,,
3502,D,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,Homo sapiens,F,,BAO_0000219,15650,,9606.0,9,Expert,1,CHEMBL619172,,2081.0
3503,U,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,Mus musculus,B,,BAO_0000019,10063,,10090.0,0,Autocuration,1,CHEMBL619173,,
3504,U,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,Mus musculus,B,,BAO_0000019,12665,,10090.0,0,Autocuration,1,CHEMBL619174,,
3505,H,5-hydroxytryptamine receptor binding affinity was determined in rats,,,B,,BAO_0000019,7504,,,4,Autocuration,1,CHEMBL619175,,
3506,H,Binding affinity at rat 5-hydroxytryptamine receptor.,,,B,,BAO_0000224,7504,,,4,Autocuration,1,CHEMBL619176,,
3507,H,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,,B,,BAO_0000019,7038,,,4,Autocuration,1,CHEMBL619177,,
3508,H,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,,B,,BAO_0000224,7626,,,4,Autocuration,1,CHEMBL619178,,
3509,H,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,,B,,BAO_0000224,7626,,,4,Autocuration,1,CHEMBL619179,,
3510,H,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,,F,,BAO_0000019,7185,,,4,Autocuration,1,CHEMBL619180,,945.0
3511,H,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,,F,,BAO_0000019,7185,,,4,Autocuration,1,CHEMBL619181,,945.0
3512,H,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,F,,BAO_0000019,7185,,,4,Autocuration,1,CHEMBL619182,,
3513,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,,B,,BAO_0000224,6960,,,4,Autocuration,1,CHEMBL619183,,
3514,H,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,,B,,BAO_0000224,6960,,,4,Autocuration,1,CHEMBL619184,,
3515,H,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,B,,BAO_0000221,12416,,,8,Autocuration,1,CHEMBL619185,,10000000.0
3516,H,Binding affinity for rat 5-hydroxytryptamine transporter.,,,B,,BAO_0000357,15753,,,8,Expert,1,CHEMBL619186,,
3517,H,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,,B,,BAO_0000019,8062,,,4,Autocuration,1,CHEMBL619187,,
3518,D,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,Rattus norvegicus,B,,BAO_0000019,9036,,10116.0,5,Autocuration,1,CHEMBL619188,,
3519,D,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,Rattus norvegicus,B,,BAO_0000224,15067,,10116.0,5,Autocuration,1,CHEMBL619189,,
3520,D,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,Rattus norvegicus,F,,BAO_0000019,15753,,10116.0,9,Expert,1,CHEMBL619190,,955.0
3521,D,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,Rattus norvegicus,F,,BAO_0000221,15753,,10116.0,9,Expert,1,CHEMBL619191,,2037.0
3522,D,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,Rattus norvegicus,B,,BAO_0000019,15295,,10116.0,5,Autocuration,1,CHEMBL619192,,
3523,D,Percent binding affinity against 5-hydroxytryptamine receptor,,Rattus norvegicus,B,,BAO_0000224,6347,,10116.0,5,Autocuration,1,CHEMBL619193,,
3524,U,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,,B,,BAO_0000019,6763,,,0,Autocuration,1,CHEMBL619194,,
3525,D,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,Rattus norvegicus,B,,BAO_0000224,12092,,10116.0,5,Autocuration,1,CHEMBL619195,,
3526,D,Affinity against 5-hydroxytryptamine receptor was determined,,Rattus norvegicus,B,,BAO_0000224,1579,,10116.0,5,Autocuration,1,CHEMBL619196,,
3527,D,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,Rattus norvegicus,B,,BAO_0000019,1579,,10116.0,5,Autocuration,1,CHEMBL619197,,945.0
3528,D,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,Homo sapiens,B,,BAO_0000219,5963,In vitro,9606.0,9,Expert,1,CHEMBL619198,,
3529,D,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,Homo sapiens,B,,BAO_0000219,5963,In vitro,9606.0,9,Expert,1,CHEMBL875081,,
3530,H,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,,B,,BAO_0000357,5030,,,8,Autocuration,1,CHEMBL884712,,
3531,H,Inhibition of 5-hydroxytryptamine reuptake,,,B,,BAO_0000357,15796,,,8,Expert,1,CHEMBL884710,,
3532,H,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,,F,,BAO_0000019,15413,,,8,Autocuration,1,CHEMBL619199,,
3533,H,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,,F,,BAO_0000019,15413,,,8,Autocuration,1,CHEMBL619200,,
3534,H,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,,F,,BAO_0000019,15413,,,8,Autocuration,1,CHEMBL619201,,
3535,H,Tested for 5-hydroxytryptamine receptor uptake,,,F,,BAO_0000019,12409,,,8,Autocuration,1,CHEMBL619202,,
3536,D,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,Homo sapiens,B,,BAO_0000219,16909,,9606.0,9,Expert,1,CHEMBL619203,449.0,
3537,D,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,Homo sapiens,F,,BAO_0000019,16909,,9606.0,9,Expert,1,CHEMBL619204,,
3538,H,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,Homo sapiens,B,,BAO_0000249,15629,,9606.0,8,Autocuration,1,CHEMBL619205,,
3539,H,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,,B,,BAO_0000357,15629,,,8,Autocuration,1,CHEMBL619206,,
3540,H,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,,B,,BAO_0000249,15629,,,8,Expert,1,CHEMBL619207,,
3541,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,,F,,BAO_0000019,10034,,,8,Autocuration,1,CHEMBL619208,,2435.0
3542,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,,F,,BAO_0000019,10034,,,8,Autocuration,1,CHEMBL619209,,2435.0
3543,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,,F,,BAO_0000019,10034,,,8,Autocuration,1,CHEMBL619210,,2435.0
3544,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,,F,,BAO_0000019,10034,,,8,Autocuration,1,CHEMBL619211,,2435.0
3545,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,,F,,BAO_0000019,10034,,,8,Autocuration,1,CHEMBL619212,,2435.0
3546,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,,F,,BAO_0000019,10034,,,8,Autocuration,1,CHEMBL620681,,2435.0
3547,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,,F,,BAO_0000019,10034,,,8,Autocuration,1,CHEMBL620682,,2435.0
3548,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,,F,,BAO_0000019,10034,,,8,Autocuration,1,CHEMBL620683,,2435.0
3549,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,,F,,BAO_0000019,10034,,,8,Autocuration,1,CHEMBL620684,,2435.0
3550,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,,F,,BAO_0000019,10034,,,8,Autocuration,1,CHEMBL620685,,2435.0
3551,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,,F,,BAO_0000019,10034,,,8,Autocuration,1,CHEMBL620686,,2435.0
3552,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,,F,,BAO_0000019,10034,,,8,Autocuration,1,CHEMBL620687,,349.0
3553,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,F,,BAO_0000019,10034,,,8,Autocuration,1,CHEMBL620688,,349.0
3554,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,,F,,BAO_0000019,10034,,,8,Autocuration,1,CHEMBL620689,,349.0
3555,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,,F,,BAO_0000019,10034,,,8,Autocuration,1,CHEMBL620690,,349.0
3556,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,,F,,BAO_0000019,10034,,,8,Autocuration,1,CHEMBL620691,,349.0
3557,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,,F,,BAO_0000019,10034,,,8,Autocuration,1,CHEMBL620692,,349.0
3558,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,,F,,BAO_0000019,10034,,,8,Autocuration,1,CHEMBL620693,,349.0
3559,H,Binding affinity against 5-hydroxytryptamine 4 receptor,,,B,,BAO_0000357,1274,,,8,Expert,1,CHEMBL620694,,
3560,H,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,F,,BAO_0000019,17358,,,8,Autocuration,1,CHEMBL857986,,
3561,H,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,,B,,BAO_0000357,14532,,,8,Autocuration,1,CHEMBL620695,,
3562,H,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,,B,,BAO_0000357,16989,,,8,Expert,1,CHEMBL620696,,
3563,H,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,,B,,BAO_0000357,17200,,,8,Autocuration,1,CHEMBL620697,,
3564,H,Binding affinity towards 5-hydroxytryptamine 4 receptor,,,B,,BAO_0000357,15779,,,8,Autocuration,1,CHEMBL620698,,
3565,H,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,B,,BAO_0000357,15779,,,8,Autocuration,1,CHEMBL620699,,
3566,H,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,B,,BAO_0000357,15779,,,8,Autocuration,1,CHEMBL620700,,
3567,H,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,,B,,BAO_0000219,15650,,,8,Autocuration,1,CHEMBL620701,643.0,
3568,H,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,,B,,BAO_0000219,15650,,,8,Autocuration,1,CHEMBL875082,643.0,
3569,H,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,,B,,BAO_0000219,15650,,,8,Autocuration,1,CHEMBL620702,643.0,
3570,H,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,,B,,BAO_0000219,15650,,,8,Autocuration,1,CHEMBL620703,643.0,
3571,H,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,B,,BAO_0000219,17046,,,8,Autocuration,1,CHEMBL620704,673.0,
3572,H,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,B,,BAO_0000219,17046,,,8,Expert,1,CHEMBL620705,673.0,
3573,H,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,,B,,BAO_0000219,15650,,,8,Expert,1,CHEMBL620706,673.0,
3574,H,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,,B,,BAO_0000219,17046,,,8,Expert,1,CHEMBL620707,673.0,
3575,H,Binding affinity towards 5-hydroxytryptamine 5 receptor,,,B,,BAO_0000357,17066,,,8,Expert,1,CHEMBL620708,,
3576,H,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,,B,,BAO_0000357,17200,,,8,Autocuration,1,CHEMBL620709,,
3577,D,Binding affinity against 5-hydroxytryptamine 5A receptor,,Homo sapiens,B,,BAO_0000357,16146,,9606.0,9,Expert,1,CHEMBL620710,,
3578,H,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,,B,,BAO_0000219,15250,,,8,Autocuration,1,CHEMBL620711,449.0,
3579,D,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,Homo sapiens,B,,BAO_0000357,6491,,9606.0,9,Expert,1,CHEMBL620712,,
3580,D,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,Homo sapiens,B,,BAO_0000357,17066,,9606.0,9,Expert,1,CHEMBL620713,,
3581,D,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,Homo sapiens,B,,BAO_0000357,17066,,9606.0,9,Expert,1,CHEMBL620714,,
3582,D,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,Homo sapiens,B,,BAO_0000357,4234,,9606.0,9,Expert,1,CHEMBL620715,,
3583,H,Binding affinity towards 5-HT5A receptor,,,B,,BAO_0000357,6013,,,8,Autocuration,1,CHEMBL620716,,
3584,H,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,B,,BAO_0000357,17175,,,8,Expert,1,CHEMBL620717,,
3585,H,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,,B,,BAO_0000357,15818,,,8,Autocuration,1,CHEMBL618072,,
3586,H,Binding affinity towards cloned human 5-HT5A receptor was determined,,,B,,BAO_0000357,6166,,,8,Autocuration,1,CHEMBL857987,,
3587,H,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL618073,722.0,
3588,H,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL618074,722.0,
3589,H,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,,B,,BAO_0000219,5213,,,8,Autocuration,1,CHEMBL618075,722.0,
3590,D,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,Mus musculus,B,,BAO_0000357,17066,,10090.0,9,Expert,1,CHEMBL618076,,
3591,D,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,Mus musculus,B,,BAO_0000357,17066,,10090.0,9,Expert,1,CHEMBL618077,,
3592,D,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,Mus musculus,B,,BAO_0000357,17066,,10090.0,9,Expert,1,CHEMBL618078,,
3593,D,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,Mus musculus,B,,BAO_0000357,17066,,10090.0,9,Expert,1,CHEMBL881821,,
3594,D,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,Mus musculus,B,,BAO_0000357,17066,,10090.0,9,Expert,1,CHEMBL618079,,
3595,H,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,B,,BAO_0000357,17175,,,8,Expert,1,CHEMBL618080,,
3596,H,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,B,,BAO_0000219,16190,,,8,Autocuration,1,CHEMBL618081,722.0,
3597,H,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,B,,BAO_0000219,16190,,,8,Autocuration,1,CHEMBL618082,722.0,
3598,H,Binding affinity towards 5-HT5a receptor,,,B,,BAO_0000357,4820,,,8,Expert,1,CHEMBL618083,,
3599,D,Binding affinity towards 5-hydroxytryptamine 5A receptor,,Homo sapiens,B,,BAO_0000357,17066,,9606.0,9,Expert,1,CHEMBL618084,,
3600,H,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,,B,,BAO_0000357,17066,,,8,Expert,1,CHEMBL618085,,
3601,H,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,,B,,BAO_0000357,17175,,,8,Expert,1,CHEMBL618086,,
3602,H,Binding affinities against 5-hydroxytryptamine 5A receptor,,,B,,BAO_0000357,16633,,,8,Autocuration,1,CHEMBL875092,,
3603,H,Binding affinities towards 5-hydroxytryptamine 5A receptor,,,B,,BAO_0000357,16633,,,8,Autocuration,1,CHEMBL618087,,
3604,H,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,,B,,BAO_0000357,16700,,,8,Autocuration,1,CHEMBL872926,,
3605,H,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,Cavia porcellus,F,,BAO_0000019,4639,,10141.0,4,Autocuration,1,CHEMBL618088,,
3606,H,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,,B,,BAO_0000223,5486,,,4,Autocuration,1,CHEMBL618089,,
3607,D,Inhibition of human 5-hydroxytryptamine 6 receptor,,Homo sapiens,B,,BAO_0000357,16146,,9606.0,9,Expert,1,CHEMBL618090,,
3608,D,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,Homo sapiens,B,,BAO_0000357,17273,,9606.0,9,Expert,1,CHEMBL618091,,
3609,H,Inhibition against human 5-hydroxytryptamine 6 receptor,,,B,,BAO_0000357,17687,,,8,Autocuration,1,CHEMBL618092,,
3610,D,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,Homo sapiens,B,,BAO_0000357,6491,,9606.0,9,Expert,1,CHEMBL618093,,
3611,H,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,,B,,BAO_0000219,16190,,,8,Expert,1,CHEMBL618094,308.0,
3612,D,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,Homo sapiens,B,,BAO_0000357,17066,,9606.0,9,Expert,1,CHEMBL618095,,
3613,D,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,Homo sapiens,B,,BAO_0000357,17066,,9606.0,9,Expert,1,CHEMBL875093,,
3614,D,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,Homo sapiens,B,,BAO_0000357,17066,,9606.0,9,Expert,1,CHEMBL618096,,
3615,D,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,Homo sapiens,B,,BAO_0000357,17066,,9606.0,9,Expert,1,CHEMBL618118,,
3616,D,Binding affinity against 5-hydroxytryptamine 6 receptor,,Homo sapiens,B,,BAO_0000357,3555,,9606.0,9,Expert,1,CHEMBL618119,,
3617,H,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,B,,BAO_0000357,5808,,,8,Expert,1,CHEMBL618120,,
3618,H,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,B,,BAO_0000357,6013,,,8,Autocuration,1,CHEMBL618121,,
3619,H,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,,B,,BAO_0000219,15818,,,8,Expert,1,CHEMBL618122,722.0,
3620,H,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,,B,,BAO_0000357,16209,,,8,Autocuration,1,CHEMBL618123,,
3621,H,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,,B,,BAO_0000219,3935,,,8,Expert,1,CHEMBL618124,722.0,
3622,H,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,,B,,BAO_0000357,15818,,,8,Autocuration,1,CHEMBL618125,,
3623,D,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,Homo sapiens,B,,BAO_0000219,3805,,9606.0,9,Expert,1,CHEMBL618126,722.0,
3624,H,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,,B,,BAO_0000019,16441,,,8,Expert,1,CHEMBL618236,,
3625,H,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,B,,BAO_0000019,16441,,,8,Expert,1,CHEMBL618237,,
3626,H,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,,B,,BAO_0000219,6786,,,8,Expert,1,CHEMBL618238,643.0,
3627,D,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,Homo sapiens,B,,BAO_0000357,4234,,9606.0,9,Expert,1,CHEMBL618239,,
3628,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,,B,,BAO_0000019,17085,,,8,Autocuration,1,CHEMBL618240,,
3629,H,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,,B,,BAO_0000357,17200,,,8,Autocuration,1,CHEMBL618241,,
3630,H,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,,B,,BAO_0000219,17451,,,8,Autocuration,1,CHEMBL859399,722.0,
3631,H,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,,F,,BAO_0000019,3935,,,8,Autocuration,1,CHEMBL618242,,
3632,H,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,,B,,BAO_0000357,5033,,,8,Autocuration,1,CHEMBL857991,,
3633,H,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,B,,BAO_0000357,4540,,,8,Expert,1,CHEMBL619951,,
3634,D,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,Homo sapiens,B,,BAO_0000219,4540,,9606.0,9,Expert,1,CHEMBL619952,308.0,
3635,D,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,Homo sapiens,B,,BAO_0000219,4540,,9606.0,9,Expert,1,CHEMBL619953,308.0,
3636,H,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,,B,,BAO_0000219,17296,,,8,Autocuration,1,CHEMBL619954,308.0,
3637,H,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,B,,BAO_0000219,17296,,,8,Autocuration,1,CHEMBL619955,308.0,
3638,H,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,B,,BAO_0000219,17296,,,8,Autocuration,1,CHEMBL619956,308.0,
3639,H,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL619957,449.0,
3640,H,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL619958,722.0,
3641,H,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL620627,722.0,
3642,H,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL620628,722.0,
3643,H,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL620629,308.0,
3644,H,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,B,,BAO_0000357,6166,,,8,Autocuration,1,CHEMBL620630,,
3645,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,,B,,BAO_0000219,17451,,,8,Autocuration,1,CHEMBL620782,308.0,
3646,H,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,,B,,BAO_0000357,15316,,,8,Autocuration,1,CHEMBL620783,,
3647,H,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,B,,BAO_0000357,4199,,,8,Expert,1,CHEMBL620784,,
3648,H,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,,B,,BAO_0000219,15146,,,8,Expert,1,CHEMBL620785,308.0,
3649,H,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,,B,,BAO_0000357,5213,,,8,Autocuration,1,CHEMBL857992,,
3650,H,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,,B,,BAO_0000219,16429,,,8,Autocuration,1,CHEMBL620786,,
3651,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,,B,,BAO_0000219,14818,,,8,Autocuration,1,CHEMBL620787,308.0,
3652,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,,B,,BAO_0000219,4829,,,8,Autocuration,1,CHEMBL620788,308.0,
3653,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,,B,,BAO_0000219,4829,,,8,Autocuration,1,CHEMBL620789,308.0,
3654,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,,B,,BAO_0000219,4829,,,8,Autocuration,1,CHEMBL620790,308.0,
3655,H,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,,B,,BAO_0000219,15250,,,8,Autocuration,1,CHEMBL620791,449.0,
3656,H,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,,B,,BAO_0000019,14423,,,8,Autocuration,1,CHEMBL620792,,
3657,H,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,,B,,BAO_0000357,15086,,,8,Autocuration,1,CHEMBL620793,,
3658,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,,B,,BAO_0000357,4342,,,8,Autocuration,1,CHEMBL620794,,
3659,D,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,Homo sapiens,B,,BAO_0000219,16190,,9606.0,9,Autocuration,1,CHEMBL620795,308.0,
3660,H,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,B,,BAO_0000357,4820,,,8,Expert,1,CHEMBL620796,,
3661,H,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,,B,,BAO_0000357,4639,,,8,Autocuration,1,CHEMBL620797,,
3662,D,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,Homo sapiens,F,,BAO_0000019,17066,,9606.0,9,Expert,1,CHEMBL620798,,
3663,H,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,,B,,BAO_0000357,6011,,,8,Autocuration,1,CHEMBL620799,,
3664,H,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,B,,BAO_0000357,17066,,,8,Expert,1,CHEMBL620800,,
3665,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,,B,,BAO_0000357,17515,,,8,Autocuration,1,CHEMBL620801,,
3666,H,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,,B,,BAO_0000357,5014,,,8,Autocuration,1,CHEMBL875100,,
3667,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,,B,,BAO_0000357,4373,,,8,Autocuration,1,CHEMBL620802,,
3668,H,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,,F,,BAO_0000019,17066,,,8,Expert,1,CHEMBL620803,,
3669,H,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,F,,BAO_0000019,17066,,,8,Expert,1,CHEMBL620804,,
3670,H,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,,B,,BAO_0000357,4373,,,8,Autocuration,1,CHEMBL620805,,
3671,H,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,,B,,BAO_0000357,4687,,,8,Autocuration,1,CHEMBL620806,,
3672,H,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,,B,,BAO_0000357,16946,,,8,Autocuration,1,CHEMBL620807,,
3673,H,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,,B,,BAO_0000357,16946,,,8,Autocuration,1,CHEMBL620808,,
3674,H,Binding affinities against 5-hydroxytryptamine 6 receptor,,,B,,BAO_0000357,16633,,,8,Autocuration,1,CHEMBL620809,,
3675,H,Binding affinities towards 5-hydroxytryptamine 6 receptor,,,B,,BAO_0000357,16633,,,8,Autocuration,1,CHEMBL620810,,
3676,D,Binding affinity towards 5-hydroxytryptamine 6 receptor,,Homo sapiens,B,,BAO_0000357,17066,,9606.0,9,Expert,1,CHEMBL620811,,
3677,H,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,,B,,BAO_0000357,16700,,,8,Autocuration,1,CHEMBL620812,,
3678,H,Affinity against 5-hydroxytryptamine 6 receptor,,,B,,BAO_0000357,3269,,,8,Autocuration,1,CHEMBL620813,,
3679,H,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,,B,,BAO_0000357,5486,,,8,Autocuration,1,CHEMBL620814,,
3680,D,Inhibition of human 5-hydroxytryptamine 7 receptor,,Homo sapiens,B,,BAO_0000357,16146,,9606.0,9,Expert,1,CHEMBL620815,,
3681,H,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,,B,,BAO_0000219,5014,,,8,Autocuration,1,CHEMBL620816,722.0,
3682,H,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,,B,,BAO_0000357,15463,,,8,Autocuration,1,CHEMBL620817,,
3683,H,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,,B,,BAO_0000357,3805,,,8,Autocuration,1,CHEMBL620818,,
3684,H,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,,B,,BAO_0000219,5014,,,8,Expert,1,CHEMBL620819,722.0,
3685,D,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,Homo sapiens,B,,BAO_0000357,6491,,9606.0,9,Expert,1,CHEMBL620820,,
3686,H,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,,B,,BAO_0000219,16190,,,8,Autocuration,1,CHEMBL620821,449.0,
3687,D,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,Homo sapiens,B,,BAO_0000357,17066,,9606.0,9,Expert,1,CHEMBL620822,,
3688,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,Homo sapiens,B,,BAO_0000357,17066,,9606.0,9,Expert,1,CHEMBL620823,,
3689,D,Binding affinity against 5-hydroxytryptamine 7 receptor,,Homo sapiens,B,,BAO_0000357,3555,,9606.0,9,Expert,1,CHEMBL620824,,
3690,H,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,,B,,BAO_0000219,6588,,,8,Expert,1,CHEMBL620825,449.0,
3691,H,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,,B,,BAO_0000357,15463,,,8,Autocuration,1,CHEMBL872930,,
3692,H,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,B,,BAO_0000357,6013,,,8,Autocuration,1,CHEMBL620826,,
3693,H,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,B,,BAO_0000357,16209,,,8,Autocuration,1,CHEMBL620827,,
3694,H,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,,B,,BAO_0000357,3935,,,8,Autocuration,1,CHEMBL620828,,
3695,H,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,,B,,BAO_0000357,15818,,,8,Autocuration,1,CHEMBL620829,,
3696,H,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,,B,,BAO_0000219,5014,,,8,Expert,1,CHEMBL620830,722.0,
3697,H,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,,B,,BAO_0000019,16441,,,8,Expert,1,CHEMBL620831,,
3698,H,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,B,,BAO_0000019,16441,,,8,Expert,1,CHEMBL620832,,
3699,D,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,Homo sapiens,B,,BAO_0000357,4234,,9606.0,9,Expert,1,CHEMBL621548,,
3700,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,,B,,BAO_0000019,17085,,,8,Autocuration,1,CHEMBL621549,,
3701,H,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,,B,,BAO_0000357,17200,,,8,Autocuration,1,CHEMBL621550,,
3702,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,,B,,BAO_0000219,17451,,,8,Autocuration,1,CHEMBL621551,449.0,
3703,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,,B,,BAO_0000019,17085,,,8,Autocuration,1,CHEMBL621552,,
3704,H,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,,B,,BAO_0000357,5104,,,8,Autocuration,1,CHEMBL857077,,
3705,H,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,,B,,BAO_0000357,5104,,,8,Autocuration,1,CHEMBL618158,,
3706,D,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,Homo sapiens,B,,BAO_0000219,5033,,9606.0,9,Expert,1,CHEMBL618159,643.0,
3707,H,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,,B,,BAO_0000219,5486,,,8,Autocuration,1,CHEMBL875101,643.0,
3708,D,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,Homo sapiens,B,,BAO_0000219,4540,,9606.0,9,Expert,1,CHEMBL618160,722.0,
3709,H,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,,B,,BAO_0000357,6166,,,8,Expert,1,CHEMBL618161,,
3710,H,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,,B,,BAO_0000219,17342,,,8,Expert,1,CHEMBL618162,722.0,
3711,H,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,,B,,BAO_0000357,17342,,,8,Expert,1,CHEMBL618163,,
3712,H,Binding affinity against 5-hydroxytryptamine 7 human receptors,,,B,,BAO_0000357,17296,,,8,Autocuration,1,CHEMBL618164,,
3713,H,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,,B,,BAO_0000219,16429,,,8,Expert,1,CHEMBL618165,,
3714,H,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL618166,722.0,
3715,H,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL857989,722.0,
3716,H,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL619888,722.0,
3717,H,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL619889,722.0,
3718,H,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,,B,,BAO_0000219,15779,,,8,Autocuration,1,CHEMBL619890,722.0,
3719,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,,B,,BAO_0000219,17451,,,8,Autocuration,1,CHEMBL619891,449.0,
3720,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,,B,,BAO_0000219,4199,,,8,Autocuration,1,CHEMBL619892,722.0,
3721,D,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,,B,,BAO_0000219,4199,,,9,Expert,1,CHEMBL619893,722.0,
3722,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,,B,,BAO_0000219,4199,,,8,Autocuration,1,CHEMBL619894,722.0,
3723,D,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,,B,,BAO_0000219,3680,,,9,Intermediate,1,CHEMBL619895,722.0,
3724,D,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,,B,,BAO_0000357,3680,,,9,Intermediate,1,CHEMBL619896,,
3725,H,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,,B,,BAO_0000219,15316,,,8,Autocuration,1,CHEMBL619897,643.0,
3726,H,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,,B,,BAO_0000219,15146,,,8,Autocuration,1,CHEMBL619898,722.0,
3727,H,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,,B,,BAO_0000219,5213,,,8,Expert,1,CHEMBL619899,722.0,
3728,H,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,,B,,BAO_0000219,5213,,,8,Autocuration,1,CHEMBL619900,722.0,
3729,D,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,Homo sapiens,B,,BAO_0000219,14818,,9606.0,9,Expert,1,CHEMBL619901,722.0,
3730,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,,B,,BAO_0000219,14818,,,8,Autocuration,1,CHEMBL620580,722.0,
3731,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,,B,,BAO_0000219,14818,,,8,Autocuration,1,CHEMBL620581,722.0,
3732,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,,B,,BAO_0000219,4829,,,8,Autocuration,1,CHEMBL620733,722.0,
3733,D,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,Homo sapiens,B,,BAO_0000357,17200,,9606.0,9,Autocuration,1,CHEMBL620734,,
3734,D,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,Mus musculus,B,,BAO_0000357,17066,,10090.0,9,Expert,1,CHEMBL620735,,
3735,H,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,Oryctolagus cuniculus,B,,BAO_0000019,14025,,9986.0,8,Autocuration,1,CHEMBL620736,,
3736,H,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,,B,,BAO_0000219,15250,,,8,Autocuration,1,CHEMBL620737,449.0,
3737,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,,B,,BAO_0000219,16372,,,8,Autocuration,1,CHEMBL620738,449.0,
3738,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,,B,,BAO_0000219,16372,,,8,Autocuration,1,CHEMBL620739,449.0,
3739,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,,B,,BAO_0000219,16372,,,8,Autocuration,1,CHEMBL620740,449.0,
3740,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,,B,,BAO_0000219,16372,,,8,Autocuration,1,CHEMBL620741,449.0,
3741,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,,B,,BAO_0000219,16372,,,8,Autocuration,1,CHEMBL620742,449.0,
3742,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,,B,,BAO_0000219,16372,,,8,Autocuration,1,CHEMBL620743,449.0,
3743,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,,B,,BAO_0000219,16372,,,8,Autocuration,1,CHEMBL620744,449.0,
3744,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,,B,,BAO_0000219,16372,,,8,Autocuration,1,CHEMBL620745,449.0,
3745,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,,B,,BAO_0000219,16372,,,8,Autocuration,1,CHEMBL620746,449.0,
3746,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,,B,,BAO_0000219,16372,,,8,Autocuration,1,CHEMBL620747,449.0,
3747,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,,B,,BAO_0000219,16372,,,8,Autocuration,1,CHEMBL620748,449.0,
3748,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,,B,,BAO_0000219,16372,,,8,Autocuration,1,CHEMBL620749,449.0,
3749,H,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,,B,,BAO_0000357,17066,,,8,Expert,1,CHEMBL620750,,
3750,D,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,Rattus norvegicus,B,,BAO_0000357,17066,,10116.0,9,Expert,1,CHEMBL620751,,
3751,H,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,,B,,BAO_0000357,17386,,,8,Expert,1,CHEMBL620752,,
